<SEC-DOCUMENT>0001013762-24-002657.txt : 20240730
<SEC-HEADER>0001013762-24-002657.hdr.sgml : 20240730
<ACCEPTANCE-DATETIME>20240730160557
ACCESSION NUMBER:		0001013762-24-002657
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240730
DATE AS OF CHANGE:		20240730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China Jo-Jo Drugstores, Inc.
		CENTRAL INDEX KEY:			0001856084
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40724
		FILM NUMBER:		241157349

	BUSINESS ADDRESS:	
		STREET 1:		4TH FLOOR, BUILDING 5, RENXIN YAJU
		STREET 2:		GONG SHU DISTRICT
		CITY:			HANGZHOU CITY
		STATE:			F4
		ZIP:			310014
		BUSINESS PHONE:		8657188219579

	MAIL ADDRESS:	
		STREET 1:		4TH FLOOR, BUILDING 5, RENXIN YAJU
		STREET 2:		GONG SHU DISTRICT
		CITY:			HANGZHOU CITY
		STATE:			F4
		ZIP:			310014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	China Jo-Jo Drugstores Holdings, Inc.
		DATE OF NAME CHANGE:	20210408
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0209917-20f_chinajojo.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 30 06:45:37 UTC 2024 -->
<html xmlns:cjjd="http://chinajojodrugstores.com/20240331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON,
D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-23752">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-23753">&#9744;</ix:nonNumeric>
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-23754">&#9746;</ix:nonNumeric>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-23755"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-23756">March&#160;31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-23757">2024</ix:nonNumeric></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-23758">&#9744;</ix:nonNumeric>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from __________ to __________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-23759">&#9744;</ix:nonNumeric>
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of event requiring this shell company report ________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-93"><span style="text-decoration:underline">001-40724</span></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-100"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>China
Jo-Jo Drugstores, Inc.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of Registrant&#8217;s name into English)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-122"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; border-bottom: black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-23760">Renxin Yaju</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-23761">Building 5 Floor 4</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine3" id="ixv-23762">Gong Shu District</ix:nonNumeric></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-23763">Hangzhou City</ix:nonNumeric>, Zhejiang Province</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">People&#8217;s Republic of <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-23764">China</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-23765">310008</ix:nonNumeric></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction of incorporation or organization)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-145"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei
Liu</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-23766">Renxin
Yaju</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-23767">Building 5 Floor 4</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine3" id="ixv-23768">Gong Shu District</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-23769">Hangzhou
City</ix:nonNumeric>, Zhejiang Province</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">People&#8217;s
Republic of <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-23770">China</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-23771">310008</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-23772">+86</ix:nonNumeric>-<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-23773">571-88219579</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
telephone, Email and/or facsimile number and address of company contact person)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-186"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares, par value $0.24 per share</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-191"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CJJD</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-23774">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">none</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Class)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or ordinary shares as of the close of the period covered
by the annual report. <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23775">1,743,362</ix:nonFraction> Ordinary Shares and 0 Preferred Shares outstanding as of March&#160;31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744; Yes &#9746; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-23776">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934. &#9744; Yes &#9746; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-23777">No</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746; <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-23778">Yes</ix:nonNumeric> &#9744; No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). &#9746; <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-23779">Yes</ix:nonNumeric> &#9744; No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an &#8220;emerging
growth company.&#8221; See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-291"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-301"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under&#160;Section 404(b) of the Sarbanes-Oxley Act&#160;(15 U.S.C. 7262(b)) by the
registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-23780">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-23781">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-0">U.S. GAAP</span> &#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 54%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards as issued</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by the International Accounting Standards Board &#9744;</span></p></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow. Item 17 &#9744; Item 18 &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). &#9744; Yes <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-23782">&#9746;</ix:nonNumeric> No</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
this annual report:</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
    to the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and &#8220;us&#8221; are to China Jo-Jo Drugstores, Inc., a Cayman
    Islands company, and its predecessor China Jo-Jo Drugstores, Inc., a Nevada corporation, and its consolidated subsidiaries, subsidiaries
    controlled by contract and therefore deemed as variable interest entities under U.S. GAAP;</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
    to &#8220;China&#8221; or the &#8220;PRC&#8221; refers to the People&#8217;s Republic of China, excluding, for the purposes of this
    annual report only, Hong Kong, Macau and Taiwan;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
    to &#8220;RMB&#8221; and &#8220;Renminbi&#8221; refer to the legal currency of China;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;US$,&#8221;
    &#8220;U.S. dollars,&#8221; &#8220;$,&#8221; and &#8220;dollars&#8221; refer to the legal currency of the United States;&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
    to &#8220;variable interest entit[y][ies]&#8221; or &#8220;VIE[s]&#8221; refer to Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service,
    as well as the subsidiaries of Jiuzhou Pharmacy, collectively as &#8220;HJ Group&#8221;</i>.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Special
Note Regarding Forward-looking Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report contains forward-looking statements. All forward-looking statements are inherently uncertain as they are based on current expectations
and assumptions concerning future events or future performance of the registrant. Readers are cautioned not to place undue reliance on
these forward-looking statements, which are only predictions and speak only as of the date hereof. Forward-looking statements usually
contain the words &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; or similar expressions,
and are subject to numerous known and unknown risks and uncertainties. In evaluating such statements, prospective investors should carefully
review various risks and uncertainties identified in this report, including the matters set forth under the captions &#8220;Risk Factors&#8221;
and in the registrant&#8217;s other SEC filings. These risks and uncertainties could cause the registrant&#8217;s actual results to differ
materially from those indicated in the forward-looking statements. The registrant undertakes no obligation to update or publicly announce
revisions to any forward-looking statements to reflect future events or developments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts
and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual
results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements.
Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed
under the heading &#8220;<i>Risks Relating to Our Business</i>&#8221; below, as well as those discussed elsewhere in this report. Readers
are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We file reports
with the Securities and Exchange Commission (the &#8220;SEC&#8221;). You can read and copy any materials we file with the SEC at our
internet address at www.jiuzhou360.com. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and
information statements, and other information regarding issuers that file electronically with the SEC, including the registrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise
after the date of this report. Readers are urged to carefully review and consider the various disclosures made throughout the entirety
of this report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition,
results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_001"><span style="font-size: 10pt">Part
    I</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_002"><span style="font-size: 10pt">Identity
    of Directors, Senior Management and Advisers</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_003"><span style="font-size: 10pt">Offer
    Statistics and Expected Timetable</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_004"><span style="font-size: 10pt">Key
    Information</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_005"><span style="font-size: 10pt">[Reserved]</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_006"><span style="font-size: 10pt">Capitalization
    and Indebtedness</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_007"><span style="font-size: 10pt">Reasons
    for the Offer and Use of Proceeds</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_008"><span style="font-size: 10pt">Risk
    Factors</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_009"><span style="font-size: 10pt">Information
    on the Company</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_010"><span style="font-size: 10pt">History
    and Development of the Company</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_011"><span style="font-size: 10pt">Business
    Overview</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_012"><span style="font-size: 10pt">Organizational
    Structure</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">43</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_013"><span style="font-size: 10pt">Property,
    Plants and Equipment</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_014"><span style="font-size: 10pt">Unresolved
    Staff Comments</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_015"><span style="font-size: 10pt">Operating
    and Financial Review and Prospects</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="padding-left: -0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-left: -0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="padding-left: -0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_016"><span style="font-size: 10pt">Operating
    Results</span></a></span></td>
    <td style="padding-left: -0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_017"><span style="font-size: 10pt">Liquidity
    and Capital Resources</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_018"><span style="font-size: 10pt">Research
    and Development, Patents and Licenses, etc.</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_019"><span style="font-size: 10pt">Trend
    Information</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_020"><span style="font-size: 10pt">Critical
    Accounting Estimates</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_021"><span style="font-size: 10pt">Directors,
    Senior Management and Employees</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_022"><span style="font-size: 10pt">Directors
    and Senior Management</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_023"><span style="font-size: 10pt">Compensation</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_024"><span style="font-size: 10pt">Board
    Practices</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_025"><span style="font-size: 10pt">Employees</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_026"><span style="font-size: 10pt">Share
    Ownership</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_027"><span style="font-size: 10pt">Disclosure
    of a registrant&#8217;s action to recover erroneously awarded compensation</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_028"><span style="font-size: 10pt">Major
    Shareholders and Related Party Transactions</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_029"><span style="font-size: 10pt">Major
    Shareholders</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_030"><span style="font-size: 10pt">Related
    Party Transactions</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_031"><span style="font-size: 10pt">Interests
    of Experts and Counsel</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_032"><span style="font-size: 10pt">Financial
    Information</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_033"><span style="font-size: 10pt">Consolidated
    Statements and Other Financial Information</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_034"><span style="font-size: 10pt">Significant
    Changes</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_035"><span style="font-size: 10pt">The
    Offer and Listing</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_036"><span style="font-size: 10pt">Offer
    and Listing Details</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_037"><span style="font-size: 10pt">Plan
    of Distribution</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_038"><span style="font-size: 10pt">Markets</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_039"><span style="font-size: 10pt">Selling
    shareholders</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_040"><span style="font-size: 10pt">Dilution</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_041"><span style="font-size: 10pt">Expenses
    of the issue</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_042"><span style="font-size: 10pt">Additional
    Information</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_043"><span style="font-size: 10pt">Share
    Capital</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_044"><span style="font-size: 10pt">Memorandum
    and Articles of Association</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_045"><span style="font-size: 10pt">Material
    Contracts</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">74</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_046"><span style="font-size: 10pt">Exchange
    Controls</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">74</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_047"><span style="font-size: 10pt">Taxation</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_048"><span style="font-size: 10pt">Dividends
    and Paying Agents</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_049"><span style="font-size: 10pt">Statement
    by Experts</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_050"><span style="font-size: 10pt">Documents
    on Display</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_051"><span style="font-size: 10pt">Subsidiary
    Information</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_052"><span style="font-size: 10pt">Annual
    Report to Security Holders</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="padding-left: -0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 78%; padding-left: 0in; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_053"><span style="font-size: 10pt">Quantitative
    and Qualitative Disclosures about Market Risk</span></a></span></td>
    <td style="padding-left: -0.125in; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_054"><span style="font-size: 10pt">Description
    of Securities Other than Equity Securities</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_055"><span style="font-size: 10pt">Debt
    Securities</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_056"><span style="font-size: 10pt">Warrants
    and Rights</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_057"><span style="font-size: 10pt">Other
    Securities</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_058"><span style="font-size: 10pt">American
    Depositary Shares</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_059">Part
    II</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_060"><span style="font-size: 10pt">Defaults,
    Dividend Arrearages and Delinquencies</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_061"><span style="font-size: 10pt">Material
    Modifications to the Rights of Security Holders and Use of Proceeds</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_062"><span style="font-size: 10pt">Controls
    and Procedures</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_063"><span style="font-size: 10pt">[Reserved]</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_064"><span style="font-size: 10pt">Audit
    Committee Financial Expert</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_065"><span style="font-size: 10pt">Code
    of Ethics</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_066"><span style="font-size: 10pt">Principal
    Accountant Fees and Services</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">81</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_067"><span style="font-size: 10pt">Exemptions
    from the Listing Standards for Audit Committees</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">81</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16E.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_068"><span style="font-size: 10pt">Purchases
    of Equity Securities by the Issuer and Affiliated Purchasers</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16F.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_069"><span style="font-size: 10pt">Change
    in Registrant&#8217;s Certifying Accountant</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16G.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_070"><span style="font-size: 10pt">Corporate
    Governance</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16H.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_071"><span style="font-size: 10pt">Mine
    Safety Disclosure</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16I</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_072"><span style="font-size: 10pt">Disclosure
    Regarding Foreign Jurisdictions That Prevent Inspections</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16J</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_073"><span style="font-size: 10pt">Insider
    trading policies</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_074"><span style="font-size: 10pt">Cybersecurity</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_075"><span style="font-size: 10pt">Part
    III</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    17.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_076"><span style="font-size: 10pt">Financial
    Statements</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    18.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_077"><span style="font-size: 10pt">Financial
    Statements</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    19.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_078"><span style="font-size: 10pt">Exhibits</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_079"><span style="font-size: 10pt">Index
    to Consolidated Financial Statements</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. KEY INFORMATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">China Jo-Jo Drugstores, Inc.
(&#8220;CJJD&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, or &#8220;us&#8221;) is not a Chinese operating
company but a holding company incorporated in the Cayman Islands. The Cayman Islands holding company has no material operations of its
own. The operations are conducted through our operating entities established in the PRC, including the VIEs. We do not have any equity
ownership in the business of the VIEs. Instead, we receive the economic benefits of the VIEs, are the primary beneficiary for accounting
purposes, and consolidate VIEs&#8217; financial statements through the VIE Agreements to the extent we have satisfied the conditions
for consolidation of the VIEs under U.S. GAAP.. The VIE structure is used to provide contractual exposure to foreign investment in Chinese-based
companies where Chinese law prohibits direct foreign investment in the operating companies, and that investors may never directly hold
equity interests in the Chinese operating entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are subject to certain legal
and operational risks associated with the VIEs&#8217; operations in China. PRC laws and regulations governing our current business operations
are sometimes vague and uncertain, and therefore, these risks may result in a material change in the VIEs&#8217; operations, significant
depreciation of the value of our ordinary shares, or a complete hindrance of our ability to offer or continue to offer our securities
to investors. Rules and regulations in China can change quickly with little advance notice. Recently, the PRC government initiated a
series of regulatory actions and statements to regulate business operations in China, including cracking down on illegal activities in
the securities market, enhancing supervision over China-based companies listed overseas using variable interest entity structure, adopting
new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. Since these statements
and regulatory actions are new, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and
what existing or new laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and
the potential impact of such modified or new laws and regulations will have on our daily business operation, the ability to accept foreign
investments and list on an U.S. or other foreign exchange. The Chinese regulatory authorities could disallow our structure, which could
result in a material change in our operations and the value of our securities could decline or become worthless. Our current corporate
structure and business operations and the market price of our ordinary shares may be affected by the newly enacted PRC Foreign Investment
Law which does not explicitly classify whether VIEs that we have contractual arrangements with would be deemed as foreign-invested enterprises
if they are ultimately &#8220;controlled&#8221; by foreign investors. Because we do not have ownership of the VIEs, we must rely on the
shareholders of these VIEs to comply with their contractual obligations. The approval of PRC regulatory agencies may be required in connection
with this offering under a PRC regulation or any new laws, rules or regulations to be enacted, and if required, we may not be able to
obtain such approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Adverse regulatory developments
in China may subject us to additional regulatory review, and additional disclosure requirements and regulatory scrutiny to be adopted
by the SEC in response to risks related to recent regulatory developments in China may impose additional compliance requirements for
companies like us with significant China-based operations, all of which could increase our compliance costs, subject us to additional
disclosure requirements. In addition, uncertainties with respect to the PRC legal system could adversely affect us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The recent regulatory developments
in China, in particular with respect to restrictions on China-based companies raising capital offshore, may lead to additional regulatory
review in China over our financing and capital raising activities in the United States. In addition, we may be subject to industry-wide
regulations that may be adopted by the relevant PRC authorities, which may have the effect of limiting our service offerings, restricting
the scope of our operations in China, or causing the suspension or termination of our business operations in China entirely, all of which
will materially and adversely affect our business, financial condition and results of operations. We may have to adjust, modify, or completely
change our business operations in response to adverse regulatory changes or policy developments, and we cannot assure you that any remedial
action adopted by us can be completed in a timely, cost-efficient, or liability-free manner or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On July 30, 2021, in response
to the recent regulatory developments in China and actions adopted by the PRC government, the Chairman of the SEC issued a statement
asking the SEC staff to seek additional disclosures from offshore issuers associated with China-based operating companies before their
registration statements will be declared effective. On August 1, 2021, the China Securities Regulatory Commission (the &#8220;CSRC&#8221;)
stated in a statement that it had taken note of the new disclosure requirements announced by the SEC regarding the listings of Chinese
companies and the recent regulatory development in China, and that both countries should strengthen communications on regulating China-related
issuers. To the best knowledge of this Company, as of the date of this annual report, current Chinese laws and regulations do not forbid
us from issuing securities overseas. On February 17, 2023, the CSRC promulgated the Trial Administrative Measures of Overseas Securities
Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;), which took effect on March 31, 2023. The Company will
need to file accordingly with the CSRC within 3 working days after any future offering is completed. &#8220;Item 3. Key Information -
D. Risk Factor &#8211; <b><i>Adverse regulatory developments in China may subject us to additional regulatory review, and additional
disclosure requirements and regulatory scrutiny to be adopted by the SEC in response to risks related to recent regulatory developments
in China may impose additional compliance requirements for companies like us with significant China-based operations, all of which could
increase our compliance costs, subject us to additional disclosure requirements. In addition, uncertainties with respect to the PRC legal
system could adversely affect us</i></b>&#8221; for more details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 20, 2020 and on December
2, 2020, the U.S. Senate passed and the U.S. House of Representatives approved the Holding Foreign Companies Accountable Act (&#8220;HFCAA&#8221;)
requiring a foreign company to certify it is not owned or controlled by a foreign government if the Public Company Accounting Oversight
Board (the &#8220;PCAOB&#8221;) is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB
inspection. If the PCAOB is unable to inspect the Company&#8217;s auditors for three consecutive years, the issuer&#8217;s securities
are prohibited to trade on a U.S. stock exchange. On December 18, 2020, the Holding Foreign Companies Accountable Act was signed into
law. The PCAOB issued a Determination Report on December 16, 2021 which found that the PCAOB is unable to inspect or investigate completely
registered public accounting firms headquartered in: (1) mainland China of the PRC because of a position taken by one or more authorities
in mainland China; and (2) Hong Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or
more authorities in Hong Kong. On June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act (&#8220;AHFCAA&#8221;)
which, if passed by the U.S. House of Representatives and signed into law, would reduce the number of consecutive non-inspection years
required for triggering the prohibitions under the HFCAA from three years to two, and that as a result, the time before our securities
may be prohibited from trading or delisted would be reduced. On August 26, 2022, the PCAOB announced and signed a Statement of Protocol
(the &#8220;Protocol&#8221;) with the China Securities Regulatory Commission and the Ministry of Finance of the People&#8217;s Republic
of China. The Protocol provides the PCAOB with: (1) sole discretion to select the firms, audit engagements and potential violations it
inspects and investigates, without any involvement of Chinese authorities; (2) procedures for PCAOB inspectors and investigators to view
complete audit work papers with all information included and for the PCAOB to retain information as needed; (3) direct access to interview
and take testimony from all personnel associated with the audits the PCAOB inspects or investigates. On December 15, 2022, the PCAOB
issued a new Determination Report which: (1) vacated the December 16, 2021 Determination Report; and (2) concluded that the PCAOB has
been able to conduct inspections and investigations completely in the PRC in 2022. The December 15, 2022 Determination Report cautions,
however, that authorities in the PRC might take positions at any time that would prevent the PCAOB from continuing to inspect or investigate
completely. As required by the HFCAA, if in the future the PCAOB determines it no longer can inspect or investigate completely because
of a position taken by an authority in the PRC, the PCAOB will act expeditiously to consider whether it should issue a new determination.
Our auditor is headquartered in Irvine, California and will be inspected by the PCAOB on a regular basis. Our auditor is subject to laws
in the United States pursuant to which the PCAOB conducts regular inspections to assess our auditor&#8217;s compliance with the applicable
professional standards. Please see &#8220;Item 3. Key Information - D. Risk Factor &#8211; <b><i>Our auditor, YCM CPA Inc., is headquartered
in California, and is subject to inspection by the PCAOB on a regular basis. To the extent that our independent registered public accounting
firm&#8217;s audit documentation related to their audit reports for our company become located in China, the PCAOB may not be able inspect
such audit documentation and, as such, you may be deprived of the benefits of such inspection and our ordinary shares could be delisted
from the stock exchange pursuant to the Holding Foreign Companies Accountable Act</i></b>&#8221; for more details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">The
following diagram illustrates our current corporate structure as of July 30, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; "><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Cash Transfer </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">Our
holding company, subsidiaries and the consolidated VIEs usually operate independently and transfer funds upon capital raising. We raised
capital of $17.5 million in our IPO in April 2010. In addition, we raised capital for a total amount of $39.863 million from 2015 to
2024 through various financings. Renovation Investment (HK) Co., Ltd. (&#8220;Renovation&#8221;), our Hong Kong intermediate holding
subsidiary, received funds from our investors in these financings. After receiving the proceeds, Renovation typically invested these
funds into Jiuxin Management, a WFOE, which then exchanged the currency of the proceeds from U.S. dollar into Chinese Yuan (&#8220;RMB&#8221;)
upon the approval from local banks. Additionally, Renovation lent funds to Jiuxin Management. As of the date of this annual report, the
total amount invested in and lent to Jiuxin Management is approximately $27.5 million and $8.7 million, respectively. Jiuxin Management
then distributed the RMB as loans to the operating entities including Jiuzhou Pharmacy, Jiuxin Medicine, Jiuzhou Service and Jiuzhou
Clinic, which are the consolidated VIEs. As of the date of this annual report, Jiuxin Management has distributed a loan of approximately
$18.58 million to Jiuzhou Pharmacy, a loan of approximately $1.03 million to Jiuzhou Service, a loan of approximately $0.20 million to
Jiuzhou Clinic, a loan of approximately $1.01 million to Linjia Medical, a loan of approximately $0.14 to Shouantang Bio.<span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;
</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">Additionally,
Jiuxin Medicine is the major supplier to Jiuzhou Pharmacy and Jiuzhou Pharmacy transfers funds to pay off the debts owed to Jiuxin Medicine
as a result of merchandise purchases. In the last three fiscal years, the annual amount of purchases by Jiuxin Medicine from Jiuzhou
Pharmacy ranges from approximately $60 million to $80 million. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;
</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">All
the sales and purchases between Jiuxin Medicine and Jiuzhou Pharmacy are eliminated as internal transactions. Furthermore, the ending
balances owed to/from the VIEs are eliminated in the balance sheets. Below are the sales and purchases between Jiuxin Medicine and Jiuzhou
Pharmacy in last three fiscal years: </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Fiscal 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">80,712,044</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fiscal 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">87,124,074</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fiscal 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76,989,329</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">Additional
transfers between other VIEs and subsidiaries are as below: </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Transfer from</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Transfer to</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 33%">Renovation</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: left">Jiuxin Management</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuxin Management</td><td>&#160;</td>
    <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">582,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,809,289</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">692,414</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jiuxin Management</td><td>&#160;</td>
    <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">779,059</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,853,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(131</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuxin Management</td><td>&#160;</td>
    <td style="text-align: left">Qianhong Agriculture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,627</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,907</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jiuxin Management</td><td>&#160;</td>
    <td style="text-align: left">Shouantang Technology</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">821,706</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,877,272</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td>
    <td style="text-align: left">Jiuzhou Service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">342,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(591,606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,545</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The PRC government imposes
controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of China. The majority
of the VIEs&#8217; and their subsidiaries&#8217; income is received in RMB and shortages in foreign currencies may restrict our ability
to pay dividends or other payments, or otherwise satisfy our foreign currency denominated obligations, if any. Under existing PRC foreign
exchange regulations, payments of current account items, including profit distributions, interest payments and expenditures from trade-related&#160;transactions,
can be made in foreign currencies without prior approval from The State Administration of the Foreign Exchange (&#8220;SAFE&#8221;) in
the PRC as long as certain procedural requirements are met. Approval from appropriate government authorities is required if Renminbi
is converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign
currencies. The PRC government may, at its discretion, impose restrictions on access to foreign currencies for current account transactions
and if this occurs in the future, we may not be able to pay dividends in foreign currencies to our shareholders. To the extent cash or
assets in the business is in the PRC/Hong Kong or a PRC/Hong Kong entity, the funds or assets may not be available to fund operations
or for other use outside of the PRC/Hong Kong due to interventions in or the imposition of restrictions and limitations on the ability
of such entities, their subsidiaries, or the consolidated VIEs by the PRC government to transfer cash or assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Supplemental Financial Information Related to the VIEs&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following tables present
supplemental information provided in the form of condensed consolidated statements of operations, condensed consolidated balance sheets
and condensed consolidated cash flows for China Jo-Jo Drugstores, Inc., the primary beneficiaries of the VIEs, the VIEs, and other subsidiaries
for the periods as of and for the dates presented.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Condensed Consolidated Statements of Operations&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">123,994,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">107,536,353</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(76,989,329</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,541,077</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,779,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,642,435</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,989,329</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,432,529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,214,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,893,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,108,548</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,769,364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,057,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,189,060</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,643,111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,676</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,163,213</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,534,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(808</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,194,566</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">558,557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(636,817</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,363</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,862</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,484</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(707,937</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,708,881</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,234,242</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235,936,050</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(87,124,074</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">148,811,976</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,739</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,729,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,195,959</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,531,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,206,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,280,464</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,534,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,200,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,798,397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(327,313</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,205,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,534,233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,198,791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,591,557</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,925,383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,261,118</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,442,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,147</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,541</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,541</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10,534,880</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,459,909</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,543,186</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,138,777</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">181,179</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">244,933,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(80,722,148</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,392,555</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,169,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,478,391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,873,515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,553</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,764,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(243,757</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,519,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,479,243</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,583,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,212,930</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,042</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,480,796</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(819,438</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(350,614</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,693,890</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,931</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">617,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">595,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,099,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,099,726</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(43,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,502,974</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,301,478</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(350,614</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,198,366</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Condensed Consolidated Balance Sheets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,718,328</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64,561,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(48,278,463</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">95,057,090</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(58,302,810</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,398,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,268,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,399,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,763,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,931,574</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,313,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,618,235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,682,362</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(58,302,810</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,398,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,268,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,995,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,360,095</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,358,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,466,953</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,955,205</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,613,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,677,733</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,677,819</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,005,227</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,755,517</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,068,683</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,507,246</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,358,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,319,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,707,005</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59,677,805</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,293,137</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,820</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,799,950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,392,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(36,233,569</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90,970,602</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,763,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,027,715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,103,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,935,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,303,450</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,296,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,064,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,890,096</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,482,790</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,763,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,027,715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,103,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,535,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,775,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,730,804</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,039,408</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,057,262</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,052,444</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,671,335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,095,498</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,993,830</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,512,355</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69,273,018</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,775,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,772,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,711,162</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,168,951</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,667,152</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">46,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,796,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90,528,406</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(39,987,233</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">106,384,209</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,578,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,576,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,864,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,782,980</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,645,423</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,676,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,423,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,694,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,451,894</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,578,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,576,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,864,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,414,047</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,448,396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,624,910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,899,305</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,441,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,280,741</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,003,498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,136,455</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,669,391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,496,890</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(831,757</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,134,493</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,624,910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,220,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,336,149</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,770,213</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,738,786</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Condensed Consolidated Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,596,084</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,966,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,644,328</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,118,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,155,439</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,156</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,031,694</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,039,850</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,639,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,113,399</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,974,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,503,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,004,291</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,264</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,174,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,622,297</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,505,475</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,516</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,212,606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,472,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,303,527</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,359,880</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,882,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,892,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,065,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,283,513</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(311,719</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,378</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(316,097</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,325,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,320,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,223,285</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,529</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,366,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(948,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,646,017</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,535,478</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,880</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,151,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,768,932</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended March 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(43,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,283,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,638,849</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,012,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,385,973</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63,291</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(242,847</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(306,138</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,256,428</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,810,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,807,397</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,836,898</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,499,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(205,577</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,522,146</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,537,168</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,157,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">666,933</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Enforceability Of Civil Liabilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are an exempted company
incorporated in the Cayman Islands because of certain benefits associated with being a Cayman Islands exempted company, such as political
and economic stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency restrictions
and the availability of professional and support services. However, the Cayman Islands has a less developed body of securities laws as
compared to the United States and provides less protection for investors. In addition, Cayman Islands companies do not have standing
to sue before the federal courts of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Substantially all of our assets
are located outside the United States. In addition, a majority of our directors and officers, namely, Lei Liu, Chief Executive Officer
and Chairman of the Board of Directors; Ming Zhao, Chief Financial Officer of the Company; Li Qi, Caroline Wang, Jiangliang He, Genghua
Gu, Pingfan Wu, all of whom are directors of the Company, are nationals or residents of jurisdictions other than the United States and
all or a substantial portion of their assets are located outside the United States. As a result, it may be difficult for investors to
effect service of process within the United States upon our company or these persons, or to bring an action against our company or against
these persons in the United States, in the event that you believe that your rights have been infringed under the securities laws of the
United States or any state in the United States. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S.
courts based on the civil liability provisions of the U.S. federal securities laws against our company and its officers and directors.
We have appointed Pryor Cashman LLP as our agent to receive service of process in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">There is uncertainty as to
whether the courts of the Cayman Islands would (1) recognize or enforce judgments of U.S. courts obtained against our company or its
directors or officers, predicated upon the civil liability provisions of the securities laws of the United States or any state in the
United States, or (2) entertain original actions brought in the Cayman Islands against our company or its directors or officers, predicated
upon the securities laws of the United States or any state in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Although there is no statutory
enforcement in the Cayman Islands of judgments obtained in the federal or state courts of the United States (and the Cayman Islands are
not a party to any treaties for the reciprocal enforcement or recognition of such judgments), a judgment obtained in such jurisdiction
will be recognized and enforced in the courts of the Cayman Islands at common law, without any re-examination of the merits of the underlying
dispute, by an action commenced on the foreign judgment debt in the Grand Court of the Cayman Islands, provided such judgment (a) is
given by a foreign court of competent jurisdiction, (b) imposes on the judgment debtor a liability to pay a liquidated sum for which
the judgment has been given, (c) is final, (d) is not in respect of taxes, a fine or a penalty, &#8364; is not inconsistent with a Cayman
Islands judgement of the same matter, (f) is not impeachable on grounds of fraud, and (g) was not obtained in a manner and is not of
a kind the enforcement of which is contrary to natural justice or the public policy of the Cayman Islands. However, the Cayman Islands
courts are unlikely to enforce a judgment obtained from the U.S. courts under civil liability provisions of the U.S. federal securities
law if such judgment is determined by the courts of the Cayman Islands to give rise to obligations to make payments that are penal or
punitive in nature. Because such a determination has not yet been made by a court of the Cayman Islands, it is uncertain whether such
civil liability judgments from U.S. courts would be enforceable in the Cayman Islands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">It is our understanding that
the PRC does not have treaties with the United States and many other countries providing for the reciprocal recognition and enforcement
of judgments of courts and that there is uncertainty as to whether the courts of the PRC would recognize or enforce judgments of United
States courts against our company or the directors or officers of our company predicated upon the civil liability provisions of the securities
laws of the United States or any state in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Additionally, it is our understanding
that it may be difficult for you to bring an original action against us or against our directors and officers who are nationals or residents
of countries other than the United States in a PRC court in the event that you believe that your rights have been infringed under the
U.S. federal securities laws, PRC laws, Cayman Islands laws or otherwise because we are incorporated under the laws of the Cayman Islands
and it may be difficult for U.S. shareholders, by virtue only of holding our ordinary shares, to establish a connection to the PRC as
required by the PRC Civil Procedures Law in order for a PRC court to have jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
[Reserved.]</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
CAPITALIZATION AND INDEBTEDNESS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
REASONS FOR THE OFFER AND USE OF PROCEEDS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
RISK FACTORS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should carefully consider the risks described below together with all of the other information included in this report before making
an investment decision with regard to our securities. The statements contained in or incorporated into this report that are not historic
facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially
from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial
condition or results of operations could be harmed. In that case, the trading price of our ordinary shares could decline, and you may
lose all or part of your investment.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business in General</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face significant competition, and if we do not compete successfully against existing and new competitors, our revenue and profitability
    could be materially and adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    continued penetration of counterfeit products into the pharmaceutical market in China may damage our reputation and have a material
    adverse effect on our business, financial condition, results of operations and prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have significant cash deposits with our suppliers and landlords, which we may not be able to recover in the event of bankruptcy by
    our suppliers or landlords or other events beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to optimize management of our procurement and distribution activities, we may be unable to meet customer demand while
    increasing the burden on managing our supply chain.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend substantially on the continuing efforts of the Key Personnel, and our business and prospects may be disrupted if we lose their
    services.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    retail and wholesale operations require a number of permits and licenses in order to carry on their business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Pharmacy Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to grow our pharmacy business may be constrained by our inability to find suitable new store locations at acceptable prices
    or by the expiration of our current leases.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a distributor of pharmaceutical and other healthcare products, we are exposed to inherent risks relating to product liability and
    personal injury claims.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to fines and penalties if we fail to comply with the applicable PRC laws and regulations governing sales of medicines
    under China&#8217;s National Medical Insurance Program.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Wholesale Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not able to effectively grow our&#160;&#160;wholesale business organically and growing through acquisitions may prove challenging.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be competitive in the wholesale business, we need to continue to invest heavily in building new platforms, attracting new customers
    and recruiting experiences management personnel and there is no guarantee that such efforts would be successful.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Online Sales</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on computer software and hardware systems in managing our online sales, the capacity of which may restrict our growth and the
    failure of which could adversely affect our business, financial condition and results of operations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our online business fails to obtain and maintain the requisite assets, licenses, qualified personnel and approvals required under
    the complex regulatory environment for Internet-based businesses in China, the business prospects for such business may be materially
    and adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    operation results of our online business fluctuates and we cannot assure our efforts for alternative vendors will result in the stable
    increase in revenues from online pharmacy in the coming years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    IT system may not perform as anticipated and is vulnerable to damage and interruption, which may lead to leakage of personal data
    of the employees of our end-users and our seconded employees.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to comply with privacy, data protection and cyber security laws and regulations could have a materially adverse effect on our reputation,
    results of operations or financial condition, or have other adverse consequences.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relating
to Our Medical Services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not attract and retain qualified physicians and other medical personnel, our ability to provide medical services would be adversely
    affected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a provider of medical services, we are exposed to inherent risks relating to malpractice claims.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Corporate Structure</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the PRC government deems that the VIE Agreements do not comply with PRC regulatory restrictions on foreign investment in the relevant
    industries or other laws or regulations of the PRC, or if these regulations or the interpretation of existing regulations change
    in the future, we could be subject to severe penalties or be forced to relinquish our interests in those operations, which may therefore
    materially reduce the value of our ordinary shares or cause them to become worthless.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
    we rely on contractual arrangements to manage and operate&#160;&#160;HJ Group and for substantially all of our revenue, the termination
    of such agreements will severely and detrimentally affect our continuing business viability under our current corporate structure.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current corporate structure and business operations and the market price of our ordinary shares may be affected by the newly enacted
    Foreign Investment Law which does not explicitly classify whether VIEs that are controlled through contractual arrangements would
    be deemed as foreign-invested enterprises if they are ultimately &#8220;controlled&#8221; by foreign investors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely principally on dividends paid by our consolidated operating entities to fund any cash and financing requirements we may have,
    and any limitation on the ability of our consolidated PRC entities to pay dividends to us could have a material adverse effect on
    our ability to conduct our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    management members of HJ Group have potential conflicts of interest with us, which may adversely affect our business and your ability
    for recourse.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Doing Business in China</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial
    uncertainties and restrictions with respect to the political and economic policies of the PRC government and PRC laws and regulations
    could have a significant impact upon the business that we may be able to conduct in the PRC and accordingly on the results of our
    operations and financial condition.&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be adversely affected by complexity, uncertainties and changes in Chinese regulation of drugstores and the practice of medicine.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    with China&#8217;s new Data Security Law, Measures on Cybersecurity Review, Personal Information Protection Law (second draft for
    consultation), regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations
    may entail significant expenses and could materially affect our business.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
    regulatory developments in China may subject us to additional regulatory review, and additional disclosure requirements and regulatory
    scrutiny to be adopted by the SEC in response to risks related to recent regulatory developments in China may impose additional compliance
    requirements for companies like us with significant China-based operations, all of which could increase our compliance costs, subject
    us to additional disclosure requirements. In addition, uncertainties with respect to the PRC legal system could adversely affect
    us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    may be difficult for U.S. regulators, such as the Department of Justice, the SEC, and other authorities, to conduct investigation
    or collect evidence within China.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing original actions in China
    against us or our management based on United States or other foreign laws.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    advent of recent healthcare reform directives from China&#8217;s central government may increase both competition and our cost of
    doing business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    management will have broad discretion over the use of the proceeds we receive from our financing activities and might not apply the
    proceeds in ways that increase the value of your investment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HJ
    Group is subject to restrictions on making payments to us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
    we receive from our subsidiaries located in the PRC may be subject to PRC withholding tax.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face risks related to disease epidemics and other outbreaks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to comply with the U.S. Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    relations between the United States and China worsen, investors may be unwilling to hold or buy our stock and our stock price may
    decrease.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    auditor, YCM CPA Inc., is headquartered in California, and is subject to inspection by the PCAOB on a regular basis. To the extent
    that our independent registered public accounting firm&#8217;s audit documentation related to their audit reports for our company
    become located in China, the PCAOB may not be able inspect such audit documentation and, as such, you may be deprived of the benefits
    of such inspection and our ordinary shares could be delisted from the stock exchange pursuant to the Holding Foreign Companies Accountable
    Act.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to an Investment in Our Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our ordinary shares has fluctuated and may continue to fluctuate in the future, and we may not pay dividends on our
    ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    officers and directors own a substantial portion of our outstanding ordinary shares, which will enable them to influence many significant
    corporate actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
General Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in economic conditions and consumer confidence in China may influence the drugstore industry, consumer preferences and spending patterns.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainties
    with respect to the Chinese legal system could adversely affect us.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Techniques
    employed by manipulative short sellers in Chinese small-cap stocks may drive down the market price of our ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business in General</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition, and if we do not compete successfully against existing and new competitors, our revenue and profitability
could be materially and adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the drugstore, online pharmacy and wholesale pharmaceutical distribution industries in China are highly competitive, and we expect competition
to intensify in the future. Our primary drugstore competitors include other drugstore chains and independent drugstores. Increasingly,
we also face competition from discount stores, convenience stores and supermarkets as we expand our offering of non-drug convenience
products and services. We compete for customers and revenue primarily on the basis of store location, merchandise selection, price, services
offered, and our brand name. Our online pharmacy competitors include other online pharmaceutical vendors. As larger traditional drugstore
chain companies entered into the online sales, we face competition ranging from prices to service. Our primary wholesale competitors
include regional and national players. In addition, we may be subject to additional competition from new entrants to both industries
in China. We could also face increased competition from foreign companies if the Chinese government removes the restrictions on the entry
of foreign companies into these industries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our larger competitors may enjoy competitive advantages, such as:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    financial and other resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">larger
    variety of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
    extensive and advanced supply chain management systems;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    pricing flexibility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">larger
    economies of scale and purchasing power;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">more
    extensive advertising and marketing efforts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    knowledge of local market conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stronger
    brand recognition; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">larger
    sales and distribution networks.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the aforementioned advantages, we may be unable to offer products similar to, or more desirable than, those offered by our
competitors, market our products as effectively as our competitors, or otherwise respond successfully to competitive pressures. As competition
increases in the markets in which we operate, a significant increase in general pricing pressures could occur, which could require us
to reevaluate our pricing structures to remain competitive. Our competitors may be able to offer larger discounts on competing products,
and we may not be able to profitably match those discounts. Furthermore, our competitors may offer products that are more attractive
to our customers or that render our products uncompetitive. In addition, the timing of the introduction of competing products into the
market could affect the market acceptance and market share of our products. Our failure to successfully compete could materially and
adversely affect our business, financial condition, results of operation, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
continued penetration of counterfeit products into the pharmaceutical market in China may damage our reputation and have a material adverse
effect on our business, financial condition, results of operations and prospects.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterfeit
products have continued to make their way into the Chinese pharmaceutical market. Counterfeit products are generally sold at lower prices
compared to their authentic counterparts due to their low production costs, and in some cases may be very similar in appearance to their
authentic counterparts. Counterfeit pharmaceuticals may or may not have the same chemical content as their authentic counterparts, and
are typically manufactured without proper licenses or approvals as well as fraudulently mislabeled with respect to their content and/or
manufacturer. Although China&#8217;s central government has been increasingly active in combating counterfeit pharmaceutical and other
products, China does not yet have effective regulatory control or an enforcement system over counterfeit pharmaceutical products. Although
we have implemented a series of quality control procedures in our procurement process, we cannot provide assurance that we may not be
inadvertently selling counterfeit pharmaceutical products. Any unintentional sale of counterfeit products may subject us to negative
publicity, fines and/or other administrative penalties, or may even result in litigation against us. Moreover, the increased distribution
of counterfeit products and other products in recent years may reinforce the negative image of drug distributors among consumers in China.
The continued proliferation of counterfeit products in China could have a material adverse effect on our business financial condition,
and results of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have significant cash deposits with our suppliers and landlords in order to obtain and maintain our inventory and maintain and establish
store locations, which we may not be able to recover in the event of bankruptcy by our suppliers or landlords or other events beyond
our control.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain products and maintain inventory at, and to establish and maintain leases for, our pharmacies, is dependent upon our
ability to post and maintain significant cash deposits with our suppliers and landlords. Many vendors in China are unwilling to ship
merchandise on credit and instead require cash deposits, and landlords may require security deposits consisting of the equivalent of
twelve (12) months of rent. As of March 31, 2024, we had approximately $0.91 million deposited with suppliers and approximately $1.63
million deposited with landlords for our pharmacies. If we are unable or unwilling to establish such advances and deposits, our ability
to generate sales and expand our business could be adversely affected. In general, we expect the amounts required for advances and deposits
to increase as we undertake our expansion plans, complete store openings and expand our business through acquisitions or otherwise. We
do not generally receive interest on the deposits made to suppliers or landlords, and such deposits are subject to the risk of loss as
a result of the creditworthiness or bankruptcy of the party who holds our funds, as well as the risk from any illegal acts associated
with the third party, such as conversion, fraud, theft or dishonesty. If these circumstances were to arise, we could find it difficult
or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with our
vendors or landlords.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to optimize management of our procurement and distribution activities, we may be unable to meet customer demand while increasing
the burden on managing our supply chain.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
May 2011, we have been using Jiuxin Medicine&#8217;s facility as our distribution center for both our retail and wholesale businesses.
Starting from March 31, 2018, we outsourced our logistic service to Astro Boy Cloud Pan (Hangzhou) Storage and Logistic Co. Ltd (&#8220;Astro
Boy Logistic&#8221;). As a result, Jiuxin Medicine&#8217;s warehouse lease has been terminated. Astro Boy Logistic provides us with a
facility with approximately 14,000 square meters located approximately eighteen (18) miles from our headquarters, which served as our
central distribution center. Astro Boy Logistic&#8217;s staff and vehicles make regular deliveries to our pharmacies and wholesale customers.
Our ability to meet customer demand may be significantly limited if we do not successfully and efficiently conduct our distribution activities,
or if Astro Boy Logistic&#8217;s facility is destroyed or shut down for any reason, including as the result of natural disasters. Any
disruption in the operation of our distribution activities could result in higher costs or longer lead times associated with distributing
our products. Since it is difficult to predict accurate sales volume in our industry, we may be unable to optimize our distribution activities,
which may result in excess or insufficient inventory, warehousing, fulfillment or distribution capacity. Furthermore, failure to effectively
control product damage during the distribution process could decrease our operating margins and reduce our profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
product procurements are handled through our corporate headquarters. Such centralization is intended to reduce the cost of goods sold
as a result of volume purchase benefits. However, we may be less successful than anticipated in achieving these volume purchase benefits.
In addition, such centralization is expected to increase the complexity of tracking inventory and could place additional burdens on the
management of our supply chain. If we cannot successfully reduce our costs through centralizing procurement, our profitability and prospects
could be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend substantially on the continuing efforts of the Key Personnel, and our business and prospects may be severely disrupted if we lose
their services.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success is dependent on the continued services of Mr. Lei Liu and Ms. Li Qi (the &#8220;Key Personnel&#8221;) but we do not maintain
key-man insurance. If we lose the services of either of the Key Personnel, we may not be able to locate suitable or qualified replacements,
which could severely disrupt our business and prospects. Each of the Key Personnel has entered into confidentiality and non-competition
agreements with us. However, if any disputes arise between us and the Key Personnel, we cannot provide assurance, in light of uncertainties
associated with the PRC legal system, that any of these agreements can be enforced in China, the jurisdiction in which the Key Personnel
reside and hold some of their assets. See &#8220;<i>Risks Related to Doing Business in China - You may experience difficulties in effecting
service of legal process, enforcing foreign judgments or bringing original actions in China based on United States or other foreign laws
against us or our management.</i>&#160;&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
retail and wholesale operations require a number of permits and licenses in order to carry on their business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to obtain certain permits and licenses from various PRC governmental authorities, including a Drug Distribution Permit and
a GSP certification. We are also required to obtain food hygiene certificates for the distribution of nutritional supplements and food
products. We cannot provide any assurance that we can maintain all required licenses, permits and certifications to carry on our business
at all times, and from time to time we may have not been in the past, or may not be in the future, in compliance with all such required
licenses, permits and certifications. Moreover, these licenses, permits and certifications are subject to periodic renewal and/or reassessment
by the relevant PRC governmental authorities and the standards of such renewal or reassessment may change from time to time. We intend
to apply for renewal of these licenses, permits and certifications when required by applicable laws and regulations. Any failure by us
to obtain and maintain all licenses, permits and certifications necessary to carry on our business at any time could have a material
adverse effect on our business, financial condition and results of operations. In addition, any inability to renew any of these licenses,
permits and certifications could severely disrupt our business, and prevent us from continuing to carry on our business. Any changes
in the standards used by governmental authorities in considering whether to renew or reassess our business licenses, permits and certifications,
as well as any enactment of new regulations that may restrict the conduct of our business, may also decrease our revenue and/or increase
our costs, materially reducing our profitability and prospects. Furthermore, if the interpretation or implementation of existing laws
and regulations changes or if new regulations come into effect requiring us to obtain any additional licenses, permits or certifications
that were previously not required to operate our existing businesses, we cannot provide assurance that we can successfully obtain such
licenses, permits or certifications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Pharmacy Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to grow our pharmacy business may be constrained by our inability to find suitable new store locations at acceptable prices or
by the expiration of our current leases.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to grow our pharmacy business may be constrained if suitable new store locations cannot be identified with lease terms or purchase
prices that are acceptable to us. We compete with other retailers and businesses for suitable locations for our stores. Local land use
regulations and other regulations applicable to the kinds of stores we seek to construct may impact our ability to find suitable locations
and influence the cost of constructing our stores. The expiration of leases at existing store locations may adversely affect us if the
renewal terms of those leases are unacceptable to us and we are forced to close or relocate stores. Furthermore, changing local demographics
at existing store locations could materially and adversely affect revenue and profitability levels at those stores, and overall our business,
financial condition, results of operation, and prospects. In fact, our growth of the pharmacy business through new store opening has
slowed down significantly in recent years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a distributor of pharmaceutical and other healthcare products, we are exposed to inherent risks relating to product liability and personal
injury claims.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributors
of pharmaceutical and other healthcare products are exposed to risks inherent in the packaging and distribution of such products. Such
risks include unintentional distribution of counterfeit, mislabeled or contaminated drugs, and, with respect to our pharmacies, improper
filling of prescriptions, labeling of prescriptions and adequacy of warnings. Errors in the packaging or dispensing of pharmaceuticals
could lead to serious injury or death. Furthermore, the applicable PRC laws, rules and regulations require our in-store pharmacists to
offer counseling to our customers, without additional charge, about medication, dosage, delivery systems, common side effects, and other
information the in-store pharmacists deem significant. Our in-store pharmacists sometimes also have a duty to warn customers regarding
any potential negative effects of a prescription drug if the warning could reduce or negate these effects, and we may be liable for claims
arising from any advice given by our in-store pharmacists. Product liability or personal injury claims may be asserted against us with
respect to any of the products or pharmaceuticals we sell or services we provide, and we may be required to pay for substantial monetary
damages for any successful product liability or personal injury claim against us. We may, however, in product liability claims, have
the right under applicable PRC laws, rules and regulations to recover from the relevant manufacturer any compensation we paid to our
customers in connection with such claim. However, even if we successfully defend ourselves against this type of claim, we could be required
to spend significant management, financial and other resources in the process, which could disrupt our business. Our reputation and our
brand names may also suffer as a result of any product liability or personal injury claims against us. Like many other similar companies
in China, we do not carry product liability insurance. A product recall or damage to our reputation in the event of a product liability
or personal injury claim or judgment against us could have a material adverse effect on our business, financial condition and results
of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to fines and penalties if we fail to comply with the applicable PRC laws and regulations governing sales of medicines
under China&#8217;s National Medical Insurance Program.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligible
participants in China&#8217;s national medical insurance program, mainly consisting of urban residents in China, are entitled to buy
medicines using their medical insurance cards from an authorized pharmacy, provided that the medicines they purchase have been included
in the national or provincial medical insurance catalogs. The pharmacy, in turn, obtains reimbursement from the relevant government social
security bureaus. Moreover, the applicable PRC laws, rules and regulations prohibit pharmacies from selling goods other than pre-approved
medicines when purchases are made with medical insurance cards. We have established procedures to prohibit our drugstores from selling
unauthorized goods to customers who make purchases with medical insurance cards. However, we cannot provide assurance that those procedures
will be strictly followed by all of our employees in all of our stores.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Wholesale Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not able to effectively grow our wholesale business organically and growing through acquisitions may prove challenging.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholesale business has experienced significant growth in recent years compared with other businesses; however, to maintain our position
in this very competitive market, we need to grow even faster and grab more market share. We may decide that we need to grow wholesale
business through acquisitions, which can be expensive and time consuming. There is no assurance that a suitable target can be found or
a deal can be reached with a suitable target. If we failed to execute an acquisition, our growth in the wholesale business may be stalled.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
remain competitive in the wholesale business, we need to continue to invest heavily in building new platforms, attracting new customers
and recruiting experiences management personnel and there is no guarantee that such efforts would be successful.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to remain competitive in the wholesale business, we need to continue to invest heavily in building new platforms, which we believe
will play a critical role in the wholesale industry going forward. Currently, supplying to our own retain business is a significant part
of our wholesale business; however, to grow the business further, we need to attract and retain more outside customers. The wholesale
business is relevant new to us and most of our senior management personnel including the founders, Mr. Liu and Mr. Qi, are less experienced
in the whole agreement than the pharmacy retain business, where they originally started. Therefore, it is very important for us to recruit
and retain highly experienced management personnel for our wholesale business. All these efforts require heavy investment in funding,
resources and time of the senior management and there is no guarantee that such efforts would be successful. If these efforts are not
successful, our wholesale business may suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
wholesale business has a lower gross margin compared with our pharmacy business and continued growth of the wholesale business may reduce
the overall gross margin of our company at least in the short run.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholesale business currently has a lower gross margin than our pharmacy business and as we will continue to focus on growing the wholesale
business, we don&#8217;t expect this to change in the near term. With wholesale business growing at a faster pace than other businesses,
our overall gross margin may decline at least in the short run&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Online Sales</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on computer software and hardware systems in managing our online sales, the capacity of which may restrict our growth and the failure
of which could adversely affect our business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent upon our electronic commerce system to carry out our online sales. Any system failure which causes interruptions to the
input, retrieval and transmission of data, or increases in service time could disrupt our normal operations. Although we believe our
existing disaster recovery plan that can handle the failure of our computer software and hardware systems, we cannot provide assurance
that we can effectively carry out this disaster recovery plan and that we will be able to restore our operation within a sufficiently
short time frame to avoid disruption to our business. Any failure in our computer software and/or hardware systems could have a material
adverse effect on our business, financial condition and results of operations. In addition, if the capacity of our computer software
and hardware systems fails to meet the increasing needs of our operations, our ability to grow may be constrained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our online business fails to obtain and maintain the requisite assets, licenses, qualified personnel and approvals required under the
complex regulatory environment for Internet-based businesses in China, the business prospects for such business may be materially and
adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internet-based
businesses in China are highly regulated by China&#8217;s central government, and numerous regulatory authorities are empowered to issue
and implement regulations governing various aspects of these businesses. Our online business is operated by one of the VIEs, Jiuzhou
Pharmacy, which is required to obtain and maintain certain assets relevant to its business, such as computers and other electrical equipment,
as well as applicable licenses or approvals from different regulatory authorities. These assets and licenses are essential to the operation
of an e-commerce business and are generally subject to annual review by the relevant governmental authorities. Furthermore, we may be
required to obtain additional licenses. If we fail to obtain or maintain any of the required assets, licenses or approvals, our Internet
business may be subject to various penalties, such as confiscation of income, fines, and/or the discontinuation or restriction of its
operations. Any such disruption may materially and adversely affect the prospects of our online business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
operation results of our online business fluctuates and we cannot assure our efforts for alternative vendors will result in the stable
increase in revenues from online pharmacy in the coming years</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
online pharmacy sales decreased by approximately $527,206, or 1.6% for the year ended March 31, 2024, as compared to the year ended March
31, 2023. The decrease was primarily caused by a decrease in sales via e-commerce platforms such as JD and Pinduoduo. Because the online
prices are transparent, to be competitive in online sales, we have to keep low prices. More competitors came into the online retail sales
market. As we do not have dominating power such as lowest prices or exclusive products, we may not be able to improve our sales significantly
in the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
IT system may not perform as anticipated and is vulnerable to damage and interruption, which may lead to leakage of personal data of
the employees of our end-users and our seconded employees</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
online sales is dependent on our IT system. We have in our possession a substantial amount of personal data related to the employees
of our end users and our seconded employees. We are obliged to keep all the personal data in our possession in such manner required by
the laws and regulations relating to personal data protection implemented in the PRC. If our IT system experiences any functional problems
or there is any failure of our IT system due to power outages, hacker attacks, computer viruses, security breaches and errors in usage
by our internal employees causing any breach of confidentiality by us or any failure to comply with the protection, collection, use and
disclosure of personal data as prescribed under the relevant laws and regulations, resulting in personal data related to the employees
of the end-users of our payroll outsourcing services or our seconded employees being leaked to or obtained by third parties, our reputation
will be in jeopardy which could lead to loss of our major customers. The employees of the end-users of our payroll outsourcing services
or our seconded employees may also take legal actions against us for damages and/or compensation for the loss that may have arisen or
been incurred therefrom, in addition to the penalties prescribed under the relevant laws and regulations in the PRC we are subject to.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
internal control procedures we have implemented to safeguard the security and confidentiality of our customer database may not effectively
prevent leakage of personal data or unauthorized access to our customer database under all circumstances. If such incident happens, we
may be subject to investigation, litigation, arbitration and other forms of legal proceedings and/or dispute for breach of personal data
privacy laws and regulations in the PRC, and our management team will have to divert substantial time, effort and resources to handle
the legal procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with privacy, data protection and cyber security laws and regulations could have a materially adverse effect on our reputation,
results of operations or financial condition, or have other adverse consequences</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
collection, storage, hosting, transfer, processing, disclosure, use, security and retention and destruction of personal information required
to provide our services is subject to national and foreign privacy, data protection and cyber security laws. These laws, which are not
uniform, generally do one or more of the following: regulate the collection, storage, hosting, transfer (including in some cases, the
transfer outside the country of collection), processing, disclosure, use, security and retention and destruction of personal information;
require notice to individuals of privacy practices; give individuals certain access and correction rights with respect to their personal
information; and regulate the use or disclosure of personal information for secondary purposes such as marketing. Under certain circumstances,
some of these laws require us to provide notification to affected individuals, clients, data protection authorities and/or other regulators
in the event of a data breach. In many cases, these laws apply not only to third-party transactions, but also to transfers of information
among the Company and its subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that providing insights from data, including artificial intelligence and machine learning, will become increasingly important
to the value that our solutions and services deliver to our customers. However, the ability to provide data-driven insights may be constrained
by current or future regulatory requirements or ethical considerations that could restrict or impose burdensome and costly requirements
on our ability to leverage data in innovative ways.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complying
with privacy, data protection and cyber security laws and requirements may result in significant costs to our business and require us
to amend certain of our business practices. Further, enforcement actions and investigations by regulatory authorities related to data
security incidents and privacy violations continue to increase. The future enactment of more restrictive laws, rules or regulations and/or
future enforcement actions or investigations could have a materially adverse impact on us through increased costs or restrictions on
our businesses and noncompliance could result in significant regulatory penalties and legal liability and damage our reputation. In addition,
data security events and concerns about privacy abuses by other companies are changing consumer and social expectations for enhanced
privacy and data protection. As a result, even the perception of noncompliance, whether or not valid, may damage our reputation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Medical Services</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not attract and retain qualified physicians and other medical personnel, our ability to provide medical services would be adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our medical services will, in part, be dependent upon the number and quality of doctors, nurses and other medical support
personnel that we employ and our ability to maintain good relationships with them. Our medical staff may terminate their employment with
us at any time. If we are unable to successfully maintain good relationships with them, our ability to provide medical services may be
adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a provider of medical services, we are exposed to inherent risks relating to malpractice claims.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a provider of medical services, any misdiagnosis or improper treatment may result in negative publicity regarding us or our services,
which would harm our reputation. If we are found liable for malpractice, we may be required to pay substantial monetary damages. Furthermore,
even if we successfully defend ourselves against a malpractice claim, we could be required to spend significant management, financial
and other resources in the process, which could disrupt our business, and our reputation and brand name may also suffer. Since malpractice
claims are not common in China, we do not carry malpractice insurance. As a result, any imposition of malpractice liability could materially
harm our business, financial condition and results of operations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Corporate Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the PRC government deems that the VIE Agreements do not comply with PRC regulatory restrictions on foreign investment in the relevant
industries or other laws or regulations of the PRC, or if these regulations or the interpretation of existing regulations change in the
future, we could be subject to severe penalties or be forced to relinquish our interests in those operations, which may therefore materially
reduce the value of our ordinary shares or cause them to become worthless.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a holding company incorporated in the Cayman Islands. As a holding company with no material operations of our own, we conduct a substantial
majority of our operations through the VIEs in the PRC, Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou
Clinic and Jiuzhou Service, in which we have no equity ownership interest and must rely on contractual arrangements to operate and manage
the businesses. These contractual arrangements are not as effective in management and operations as direct ownership. For example, the
VIEs may be unwilling or unable to perform its contractual obligations under our commercial agreements. Consequently, we would not be
able to conduct our operations in the manner currently planned, we cannot provide assurance that the Key Personnel will act in our best
interests. Under such circumstances, we may have to rely on legal remedies under Chinese law, which may not be effective in providing
us any relief. In addition, the VIEs may seek to renew its agreements on terms that are disadvantageous to us. Although we have entered
into a series of agreements that provide us with substantial ability to operates and manage the VIEs, we may not succeed in enforcing
our rights under them insofar as our contractual rights and legal remedies under PRC law are inadequate. In addition, if we are unable
to renew these agreements on favorable terms when these agreements expire or enter into similar agreements with other parties, our business
may not be able to operate or expand, and our operating expenses may significantly increase.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Since
we rely on contractual arrangements to manage and operate HJ Group and for substantially all of our revenue, the termination of such
agreements will severely and detrimentally affect our continuing business viability under our current corporate structure.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we do not own equity interests of HJ Group, the termination of our contractual arrangements with them would sever our ability to continue
receiving payments from them under our current holding company structure. We cannot provide assurance that there will not be any event
or reason that may cause the contractual arrangements to terminate. In the event that the contractual arrangements terminate, we will
lose our management over them and their business operations and, as a result, over our primary sources of revenue. This may have a severe
and detrimental effect on our continuing business viability under our current corporate structure, which in turn may affect the value
of your investment. Should this occur, we may seek to acquire control of HJ Group through other means, although we cannot guarantee that
we will do so, nor can we guarantee that we will be successful if we do.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our holding company is an exempted company incorporated in the Cayman Islands with limited liability, it is classified as a foreign enterprise
under PRC laws and regulations, and our wholly foreign-owned enterprises in the PRC will be foreign-invested enterprises. As a result
of these contractual arrangements, we have management over and are the primary beneficiary of the consolidated VIEs and hence consolidate
its financial results as the consolidated VIEs under U.S. GAAP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chinese
regulations limit foreign ownership of any pharmacy operator with thirty (30) or more stores, and limit foreign ownership of medical
clinics to Sino-foreign joint venture. The entities that operate our pharmacies and clinics are controlled by us through contractual
arrangements. The validity of such contractual arrangements is uncertain. If the Chinese government determines that these contractual
arrangements do not comply with applicable regulations, we could be subject to severe penalties and our business could be adversely affected.
In addition, changes in the relevant Chinese laws and regulations may materially and adversely affect our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
PRC regulations limit foreign ownership of a pharmacy operator to forty nine percent (49%) if such operator owns interests in thirty
(30) or more drugstores in China that sell a variety of branded pharmaceutical products sourced from different suppliers. Since we do
not own any equity interests in Jiuzhou Pharmacy, but instead manage and operate it through contractual arrangements, we do not believe
that the regulations limiting foreign ownership apply to us even if Jiuzhou Pharmacy or Jiuxin Medicine expands beyond thirty (30) stores.
In fact, Jiuzhou Pharmacy has expended to one hundred and twenty-seven (127) stores as of March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
PRC regulations restrict foreign ownership of medical practices in China to Sino-foreign joint ventures. Since we do not have any actual
equity interest in Jiuzhou Clinic or Jiuzhou Service, but manage and operate these entities through contractual arrangements, we do not
believe that such PRC regulations are applicable to us or our structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are, however, uncertainties regarding the interpretation and application of PRC laws, rules and regulations, including but not limited
to the laws, rules and regulations governing the validity and enforcement of our contractual arrangements. Although the structures for
operating our business in China (including our corporate structure and contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic,
Jiuzhou Service and the Key Personnel) comply with all applicable PRC laws, rules and regulations, and do not violate, breach, contravene
or otherwise conflict with any applicable PRC laws, rules or regulations, we cannot provide assurance that a regulatory authority will
not determine that our corporate structure and contractual arrangements violate PRC laws, rules or regulations. If any such authority
determines that our contractual arrangements are in violation of applicable PRC laws, rules or regulations, our contractual arrangements
may become invalid or unenforceable, and we may not be able to consolidate the operations of HJ Group with our results of operations.
In addition, new PRC laws, rules and regulations may be introduced from time to time to impose additional requirements that may be applicable
to our contractual arrangements. For example, pursuant to the new Civil Code in China promulgated in May 2020, the pledge of any equity
interests of a PRC private entity shall become effective once it is duly registered with the local branches of the SAIC. The SAIC issued
the&#160;<i>Administrative Measures for Registrations of Share Pledge</i>&#160;on September 1, 2008, further amended to its current version
on April 29, 2016, which has failed to provide detailed procedural guidance for the local SAIC offices to handle the registrations of
pledged shares. In accordance with the Foreign Investment Law, the State Council promulgated and approved in 2021 a list of special administrative
measures for market access of foreign investments, or the Negative List. The Negative List contains no limits or restrictions on foreign
investment holdings in the pharmaceutical or retail industries. The Equity Pledge Agreement that forms a part of the contractual arrangements
creates a legally binding obligation on the parties upon the execution date; however, the pledge established under such agreement does
not become effective until due registration with the local SAIC office. On May 18, 2010, registration of the pledged equity interests
in Jiuzhou Pharmacy was completed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese government has broad discretion in dealing with violations of laws and regulations, including levying fines, revoking business
and other licenses, and requiring actions necessary for compliance. In particular, licenses and permits issued or granted to us by the
relevant governmental bodies may be revoked at a later time by higher regulatory bodies. We cannot predict the effect of the interpretation
of existing or new Chinese laws or regulations on our businesses. We cannot provide assurance that our current ownership and operating
structure will not be found in violation of any current or future Chinese laws or regulations. As a result, we may be subject to sanctions,
including fines, and could be required to restructure our operations or cease the provision of certain services. Any of these or similar
actions could significantly disrupt our business operations or restrict us from conducting a substantial portion of our business operations,
which could materially and adversely affect our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are determined to be in violation of any existing or future PRC laws, rules or regulations, or fail to obtain or maintain any of the
required governmental permits or approvals, the relevant PRC regulatory authorities would have broad discretion in dealing with such
violations, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revoking
    the business and operating licenses of the HJ Group entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discontinuing
    or restricting the operations of the HJ Group entities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing
    conditions or requirements with which we or the HJ Group entities may not be able to comply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    us or the HJ Group entities to restructure the relevant ownership structure or operations; and/or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing
    fines.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
imposition of any of these penalties would severely disrupt our ability to conduct business and have a material adverse effect on our
financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, new PRC laws, rules and regulations may be introduced to impose additional requirements that may be applicable to our corporate
structure and contractual arrangements. Occurrence of any of these events could materially and adversely affect our business, financial
condition and results of operations and the market price of our ordinary shares. In addition, if the imposition of any of these penalties
or requirement to restructure our corporate structure causes us to lose the ability to direct the activities of the consolidated VIEs
or to receive their economic benefits, we would no longer be able to consolidate the financial results of such VIEs in our consolidated
financial statements, which may cause the value of our securities to materially decline. Moreover, if the PRC government determines that
the contractual arrangements constituting part of the VIE structure do not comply with PRC regulations, or if these regulations change
or are interpreted differently in the future, our securities may decline in value or become worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current corporate structure and business operations and the market price of our ordinary shares may be affected by the newly enacted
Foreign Investment Law which does not explicitly classify whether VIEs that are controlled through contractual arrangements would be
deemed as foreign-invested enterprises if they are ultimately &#8220;controlled&#8221; by foreign investors.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
VIE structure has been adopted by many Chinese-based companies, including us, to obtain necessary licenses and permits in the industries
that are currently subject to foreign investment restrictions in China. On March&#160;15, 2019, the National People&#8217;s Congress,
China&#8217;s national legislative body (the &#8220;NPC&#8221;) approved the Foreign Investment Law, which took effect on January&#160;1,
2020. On December 26, 2019, the PRC State Council approved the Implementation Rules of the Foreign Investment Law, which came into effect
on January 1, 2020. The interpretations to these laws are still uncertain. The Foreign Investment Law does not explicitly classify whether
variable interest entities that are managed and operated through contractual arrangements by foreign investors would be deemed as foreign-invested&#160;enterprises.
However, it has a catch-all&#160;provision under definition of &#8220;foreign investment&#8221; that includes investments made by foreign
investors in China through other means as provided by laws, administrative regulations or the State Council. Therefore, it still leaves
leeway for future laws, administrative regulations or provisions of the State Council to provide for contractual arrangements being viewed
as a form of foreign investment. Therefore, there can be no assurance that our management and operation over the consolidated VIEs through
contractual arrangements will not be deemed as foreign investment in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Foreign Investment Law, the State Council promulgated and approved in 2021 a list of special administrative measures
for market access of foreign investments, or the Negative List. The Foreign Investment Law grants national treatment to foreign-invested&#160;entities,
except for those foreign-invested&#160;entities that operate in industries specified as either &#8220;restricted&#8221; or &#8220;prohibited&#8221;
from foreign investment in the Negative List. The Foreign Investment Law provides that foreign-invested&#160;entities operating in &#8220;restricted&#8221;
or &#8220;prohibited&#8221; industries will require market entry clearance and other approvals from relevant PRC government authorities.
Pursuant to the Negative List, the Company&#8217;s four business segments ((1) retail drugstores, (2) online pharmacy, (3) wholesale
of products similar to those that the Company carries in its pharmacies, and (4) farming and selling herbs used for traditional Chinese
medicine) do not fall within the &#8220;prohibited&#8221; category. However, since the Negative List has been adjusted and updated from
time to time with little advance notice, we cannot assure you that the aforementioned business segments will continuously be beyond the
&#8220;prohibited&#8221; category. If the management and operations to the consolidated VIEs through contractual arrangements are deemed
as foreign investment in the future, and any business of the consolidated VIEs is &#8220;restricted&#8221; or &#8220;prohibited&#8221;
from foreign investment under the &#8220;Negative List&#8221; effective at the time, we may be deemed to be in violation of the Foreign
Investment Law, the contractual arrangements that allow us to manage and operate the consolidated VIEs may be deemed as invalid and illegal,
and we may be required to unwind such contractual arrangements and/or restructure our business operations, any of which may have a material
adverse effect on our business operation and the market price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if future laws, administrative regulations or provisions mandate further actions to be taken by companies with respect to existing contractual
arrangements, we may face substantial uncertainties as to whether we can complete such actions in a timely manner, or at all. Failure
to take timely and appropriate measures to cope with any of these or similar regulatory compliance challenges could materially and adversely
affect our current corporate structure and business operations and the market price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely principally on dividends paid by our consolidated operating entities to fund any cash and financing requirements we may have, and
any limitation on the ability of our consolidated PRC entities to pay dividends to us could have a material adverse effect on our ability
to conduct our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a holding company and rely principally on dividends paid by the consolidated PRC operating entities for cash requirements, including
the funds required to service any debt we may incur, which are passed on to us through Jiuxin Management. If any of the consolidated
operating entities incurs debt in its own name in the future, the instruments governing the debt may restrict dividends or other distributions
on our equity interest to us. In addition, the PRC tax authorities may require us to adjust our taxable income under the contractual
arrangements in a manner that would materially and adversely affect our ability to pay dividends and other distributions on our equity
interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
applicable PRC laws, rules and regulations permit payment of dividends by our consolidated PRC entities only out of their retained earnings,
if any, determined in accordance with PRC accounting standards. Under PRC laws, rules and regulations, our consolidated PRC entities
are required to set aside at least ten percent (10%) of their after-tax profit each year, based on PRC accounting standards, into their
statutory surplus reserve funds until the accumulative amount of such reserves reaches fifty percent (50%) of their respective registered
capital. Also, dividends cannot be distributed before any previous year&#8217;s loss has been offset. As a result, our consolidated PRC
entities are restricted in their ability to transfer a portion of their net income to us whether in the form of dividends, loans or advances.
As of March 31, 2024, our restricted reserves totaled $1,309,109 (RMB 9,513,278). Our restricted reserves are not distributable as cash
dividends. Any limitation on the ability of our consolidated operating entities to pay dividends to us could materially and adversely
limit our ability to grow, make investments or acquisitions that could be beneficial to our businesses, pay dividends, or otherwise fund
and conduct our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
management members of HJ Group have potential conflicts of interest with us, which may adversely affect our business and your ability
for recourse.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Lei Liu, our Chief Executive Officer and Chairman of our Board of Directors, is also the executive director of Jiuzhou Pharmacy, a general
partner of Jiuzhou Clinic, and the supervising director of Jiuzhou Service. In addition, Mr. Liu has also lent us money out of his personal
funds to help facilitate our payments of expenses in the U.S., as well as to purchase a land use right. Ms. Li Qi, a member of our Board
of Directors, is the general manager of each of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and a general partner of Jiuzhou
Clinic. Conflicts of interests between their respective duties to our company and HJ Group may arise. As our directors and executive
officers, they have a duty of loyalty and care to us under U.S. and Hong Kong law when there are any potential conflicts of interests
between our company and HJ Group. We cannot provide assurance, however, that when any conflicts of interest arise, both of them will
act completely in our interests or that conflicts of interests will be resolved in our favor. For example, they may determine that it
is in HJ Group&#8217;s interests to sever the contractual arrangements with Jiuxin Management, irrespective of the effect such action
may have on us. In addition, either one of them could violate his or her legal duties by diverting business opportunities from us to
others, thereby affecting the amount of payment that HJ Group is obligated to remit to us under the Consulting Services Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that you believe that your rights have been infringed under securities laws or otherwise as a result of any one of the circumstances
described above, it may be difficult or impossible for you to bring an action against HJ Group, or our officers or directors who are
members of the management, all of whom reside within China. Even if you are successful in bringing an action, the laws of China may render
you unable to enforce a judgment against the assets of HJ Group and its management, all of which are located in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Doing Business in China</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Substantial
uncertainties and restrictions with respect to the political and economic policies of the PRC government and PRC laws and regulations
could have a significant impact upon the business that we may be able to conduct in the PRC and accordingly on the results of our operations
and financial condition.</i></b><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business operations conducted through our PRC operating entities may be adversely affected by the current and future political environment
in the PRC. Recently, the PRC government initiated a series of regulatory actions and statements to regulate business operations in China
with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over China-based
companies listed overseas using variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews,
and expanding the efforts in anti-monopoly enforcement. The Chinese government exerts substantial influence and control over the manner
in which we must conduct our business activities. Our ability to operate in China may be adversely affected by changes in Chinese laws
and regulations. Under the current government leadership, the government of the PRC has been pursuing reform policies which have adversely
affected China-based operating companies whose securities are listed in the United States, with significant policies changes being made
from time to time without notice. There are substantial uncertainties regarding the interpretation and application of PRC laws and regulations,
including, but not limited to, the laws and regulations governing our business, or the enforcement and performance of our contractual
arrangements. Only after 1979 did the Chinese government begin to promulgate a comprehensive system of laws that regulate economic affairs
in general, deal with economic matters such as foreign investment, corporate organization and governance, commerce, taxation and trade,
as well as encourage foreign investment in China. Although the influence of the law has been increasing, China has not developed a fully
integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects of economic activities in China.
Also, because these laws and regulations are relatively new, and because of the limited volume of published cases and their lack of force
as precedents, interpretation and enforcement of these laws and regulations involve significant uncertainties. New laws and regulations
that affect existing and proposed future businesses may also be applied retroactively. In addition, there have been constant changes
and amendments of laws and regulations over the past 30 years in order to keep up with the rapidly changing society and economy in China.
Because government agencies and courts provide interpretations of laws and regulations and decide contractual disputes and issues, their
inexperience in adjudicating new business and new polices or regulations in certain less developed areas causes uncertainty and may affect
our business. Consequently, we cannot predict the future direction of Chinese legislative activities with respect to either businesses
with foreign investment or the effectiveness on enforcement of laws and regulations in China. The uncertainties, including new laws and
regulations and changes of existing laws, as well as judicial interpretation by inexperienced officials in the agencies and courts in
certain areas, may cause possible problems to foreign investors. Although the PRC government has been pursuing economic reform policies
for more than two decades, the PRC government continues to exercise significant control over economic growth in the PRC through the allocation
of resources, controlling payments of foreign currency, setting monetary policy and imposing policies that impact particular industries
in different ways. We cannot assure you that the PRC government will continue to pursue policies favoring a market oriented economy or
that existing policies will not be significantly altered, especially in the event of a change in leadership, social or political disruption,
or other circumstances affecting political, economic and social life in the PRC. The Chinese government may intervene or influence our
operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers,
which could result in a material change in our operations and/or the value of the securities being offered. Any adverse changes in Chinese
laws and regulations and the Chinese government&#8217;s significant oversight and discretion over the conduct of our business could significantly
limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of our securities to
significantly decline or be worthless.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be adversely affected by complexity, uncertainties and changes in Chinese regulation of drugstores and the practice of medicine.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chinese government regulates drugstores and the practice of medicine, including foreign ownership and requirements for licenses and permits.
These laws and regulations are relatively new and evolving, and their interpretation and enforcement involve significant uncertainty.
As a result, in certain circumstances it may be difficult to determine what actions or omissions may be deemed to be a violation of applicable
laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interpretation and application of existing Chinese laws, regulations and policies and possible new laws, regulations or policies have
created substantial uncertainties regarding the legality of existing and future foreign investments in, and the businesses and activities
of, pharmaceutical businesses in China, including our business. We currently only have contractual management power over the HJ Group
entities, and do not own them due to the restrictions on foreign ownership of such companies. However, changes to laws in the PRC may
force us to restructure our ownership structure or our operations, which would severely disrupt our ability to conduct business and have
a material adverse effect on our financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainties
relating to the regulation of drugstores and medical practice in China also extend to evolving licensing practices, which means that
permits, licenses or operations at our company may be subject to challenge. This may disrupt our business or subject us to sanctions,
requirements to increase capital, or other conditions or enforcement. In turn, this could compromise enforceability of related contractual
arrangements, or have other harmful effects on us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compliance
with China&#8217;s new Data Security Law, Measures on Cybersecurity Review, Personal Information Protection Law (second draft for consultation),
regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant
expenses and could materially affect our business.</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
has implemented or will implement rules and is considering a number of additional proposals relating to data protection. China&#8217;s
new Data Security Law took effect in September 2021. The Data Security Law provides that the data processing activities must be conducted
based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities
in China from transferring data stored in China to foreign law enforcement agencies or judicial authorities without prior approval by
the Chinese government.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
China&#8217;s Cyber Security Law requires companies to take certain organizational, technical and administrative measures and other necessary
measures to ensure the security of their networks and data stored on their networks. Specifically, the Cyber Security Law provides that
China adopt a multi-level protection scheme (MLPS), under which network operators are required to perform obligations of security protection
to ensure that the network is free from interference, disruption or unauthorized access, and prevent network data from being disclosed,
stolen or tampered. Under the MLPS, entities operating information systems must have a thorough assessment of the risks and the conditions
of their information and network systems to determine the level to which the entity&#8217;s information and network systems belong-from
the lowest Level&#160;1 to the highest Level&#160;5 pursuant to a series of national standards on the grading and implementation of the
classified protection of cyber security. The grading result will determine the set of security protection obligations that entities must
comply with. Entities classified as Level&#160;2 or above should report the grade to the relevant government authority for examination
and approval.<i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the Cyberspace Administration of China has taken action against several Chinese internet companies in connection with their initial public
offerings on U.S. securities exchanges, for alleged national security risks and improper collection and use of the personal information
of Chinese data subjects. According to the official announcement, the action was initiated based on the National Security Law, the Cyber
Security Law and the Measures on Cybersecurity Review, which are aimed at &#8220;preventing national data security risks, maintaining
national security and safeguarding public interests.&#8221; On July 10, 2021, the Cyberspace Administration of China published a revised
draft of the Measures on Cybersecurity Review, expanding the cybersecurity review to data processing operators in possession of personal
information of over 1 million users if the operators intend to list their securities in a foreign country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is unclear at the present time how widespread the cybersecurity review requirement and the enforcement action will be and what effect
they will have on our business. China&#8217;s regulators may impose penalties for non-compliance ranging from fines or suspension of
operations, and this could lead to us delisting from the U.S. stock market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Personal Information Protection Law released by the National People&#8217;s Congress became effective on November 1, 2021. The law
creates a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands
data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in
China, and the processing of personal information of persons in China outside of China if such processing is for purposes of providing
products and services to, or analyzing and evaluating the behavior of, persons in China. The law also provides that critical information
infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to-be-set
by Chinese cyberspace regulators are also required to store in China personal information generated or collected in China, and to pass
a security assessment administered by Chinese cyberspace regulators for any export of such personal information. Lastly, the draft contains
proposals for significant fines for serious violations of up to RMB 50 million or 5% of annual revenues from the prior year and may also
be ordered to suspend any related activity by competent authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation,
application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through
new legislation, amendments to existing legislation and changes in enforcement. Compliance with the Cyber Security Law and the Data Security
Law could significantly increase the cost to us of providing our service offerings, require significant changes to our operations or
even prevent us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in
the future. Despite our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection
and information security, it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed
on us by the Cyber Security Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with
such law or regulations or any other obligations relating to privacy, data protection or information security, or any compromise of security
that results in unauthorized access, use or release of personally identifiable information or other data, or the perception or allegation
that any of the foregoing types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties
from contracting with us or result in investigations, fines, suspension or other penalties by Chinese government authorities and private
claims or litigation, any of which could materially adversely affect our business, financial condition and results of operations. Even
if our practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation
and brand and adversely affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by
the Data Security Law and the recent Chinese government actions could materially adversely affect our ability, on favorable terms, to
raise capital, including engaging in follow-on offerings of our securities in the U.S. market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
regulatory developments in China may subject us to additional regulatory review, and additional disclosure requirements and regulatory
scrutiny to be adopted by the SEC in response to risks related to recent regulatory developments in China may impose additional compliance
requirements for companies like us with significant China-based operations, all of which could increase our compliance costs, subject
us to additional disclosure requirements. In addition, uncertainties with respect to the PRC legal system could adversely affect us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conduct substantially all of our business through the consolidated VIEs in China. Our operations in China are governed by PRC laws and
regulations. The consolidated VIEs are generally subject to laws and regulations applicable to foreign investments in China and, in particular,
laws and regulations applicable to wholly foreign-owned enterprises. The PRC legal system is based on statutes. Prior court decisions
may be cited for reference but have limited precedential value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
recent regulatory developments in China, in particular with respect to restrictions on China-based companies raising capital offshore,
may lead to additional regulatory review in China over our financing and capital raising activities in the United States. In addition,
we may be subject to industry-wide regulations that may be adopted by the relevant PRC authorities, which may have the effect of limiting
our service offerings, restricting the scope of our operations in China, or causing the suspension or termination of our business operations
in China entirely, all of which will materially and adversely affect our business, financial condition and results of operations. We
may have to adjust, modify, or completely change our business operations in response to adverse regulatory changes or policy developments,
and we cannot assure you that any remedial action adopted by us can be completed in a timely, cost-efficient, or liability-free manner
or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2021, in response to the recent regulatory developments in China and actions adopted by the PRC government, the Chairman of
the SEC issued a statement asking the SEC staff to seek additional disclosures from offshore issuers associated with China-based operating
companies before their registration statements will be declared effective. On August 1, 2021, the China Securities Regulatory Commission
(the &#8220;CSRC&#8221;) stated in a statement that it had taken note of the new disclosure requirements announced by the SEC regarding
the listings of Chinese companies and the recent regulatory development in China, and that both countries should strengthen communications
on regulating China-related issuers. To the best knowledge of this Company, as of the date of this annual report, current Chinese laws
and regulations do not forbid us from issuing securities overseas. On December 24, 2021, the CSRC published the Administration of Overseas
Securities Offering and Listing by Domestic Companies (the &#8220;Draft Administrative Provisions&#8221;) and the Administration Measures
for the Filing of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Draft Filing Measures&#8221;). The Draft
Administrative Provisions and the Draft Filing Measures lay out requirements for filing and include unified regulation management, strengthening
regulatory coordination, and cross-border regulatory cooperation. On February 17, 2023, the CSRC promulgated the Trial Administrative
Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;), which took effect on March
31, 2023. On the same date, the CSRC circulated Supporting Guidance Rules No. 1 through No. 5, Notes on the Trial Measures, Notice on
Administration Arrangements for the Filing of Overseas Listings by Domestic Enterprises and relevant CSRC Answers to Reporter Questions,
or collectively, the Guidance Rules and Notice, on CSRC&#8217;s official website. The Trial Measures, together with the Guidance Rules
and Notice reiterate the basic principles of the Draft Administrative Provisions and Draft Filing Measures and impose substantially the
same requirements for the overseas securities offering and listing by domestic enterprises, and clarified and emphasized several aspects,
which include but are not limited to: (1) criteria to determine whether an issuer will be required to go through the filing procedures
under the Trial Measures; (2) exemptions from immediate filing requirements for issuers including those that have already been listed
in foreign securities markets, including U.S. markets, prior to the effective date of the Trial Measures, but these issuers shall still
be subject to filing procedures if they conduct refinancing or are involved in other circumstances that require filing with the CSRC;
(3) a negative list of types of issuers banned from listing or offering overseas, such as issuers whose affiliates have been recently
convicted of bribery and corruption; (4) issuers&#8217; compliance with web security, data security, and other national security laws
and regulations; (5) issuers&#8217; filing and reporting obligations, such as obligation to file with the CSRC after it submits an application
for initial public offering to overseas regulators, and obligation after offering or listing overseas to file with the CSRC after it
completes subsequent offerings and to report to the CSRC material events including change of control or voluntary or forced delisting
of the issuer; and (6) the CSRC&#8217;s authority to fine both issuers and their relevant shareholders for failure to comply with the
Trial Measures, including failure to comply with filing obligations or committing fraud and misrepresentation. Specifically, pursuant
to the Trial Measures, our future securities offerings in the Nasdaq Capital Market where we have currently offered and listed shall
also be filed with the CSRC within 3 working days after the offering is completed. As the Trial Measures are newly issued, there remain
uncertainties regarding its interpretation and implementation. Therefore, we cannot assure you that we will be able to complete the filings
for our future offering and fully comply with the relevant new rules on a timely basis, if at all. In addition, we cannot guarantee that
we will not be subject to tightened regulatory review and we could be exposed to government interference in China.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
1979, PRC legislation and regulations have significantly enhanced the protections afforded to various forms of foreign investments in
China. However, China has not developed a fully integrated legal system and recently enacted laws and regulations may not sufficiently
cover all aspects of economic activities in China. In particular, because these laws and regulations are relatively new, and because
of the limited volume of published decisions and their nonbinding nature, the interpretation and enforcement of these laws and regulations
involve uncertainties. In addition, the PRC legal system is based in part on government policies and internal rules (some of which are
not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not be aware of our violation of these
policies and rules until some time after the violation. In addition, any litigation in China may be protracted and result in substantial
costs and diversion of resources and management attention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult for U.S. regulators, such as the Department of Justice, the SEC, and other authorities, to conduct investigation or
collect evidence within China.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
claims or regulatory investigation that are common in the United States generally are difficult to pursue as a matter of law or practicality
in China. For example, in China, there are significant legal and other obstacles to providing information needed for regulatory investigations
or litigations initiated outside China. Although the authorities in China may establish a regulatory cooperation mechanism with the securities
regulatory authorities of another country or region to implement cross-border supervision and administration, such cooperation with regulatory
authorities in the Unities States&#8212;including the SEC and the Department of Justice&#8212;may not be efficient in the absence of
mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which became effective in
March 2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the
PRC territory. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, the inability for
an overseas securities regulator to directly conduct investigation or evidence collection activities within China may further increase
the difficulties you face in protecting your interests.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing original actions in China
against us or our management based on United States or other foreign laws.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a holding company and conduct our business through our subsidiaries and controlled companies in the PRC. In addition, all of our
operating assets are located in, and all of our other senior executive officers reside within, China. As a result, it may not be possible
to effect service of process within the United States or elsewhere outside China upon those of our senior executive officers and directors
that do not reside in the United States, including with respect to matters arising under U.S. federal securities laws or applicable state
securities laws. Moreover, our Chinese counsel has advised us that China does not have treaties with the United States or many other
countries providing for the reciprocal recognition and enforcement of judgment of courts. As a result, our public shareholders may face
substantially more difficulty in protecting their interests through actions against our management or directors than would shareholders
of a corporation with assets and management located in the United States.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
advent of recent healthcare reform directives from China&#8217;s central government may increase both competition and our cost of doing
business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the auspices of the Healthy China 2020 program (the &#8220;Program&#8221;), published by China&#8217;s National Development and Reform
Commission in October 2008, the central government has set in motion a series of policies in fairly rapid succession aimed to improve
China&#8217;s healthcare system. Such policies include (1) discouraging hospitals from both prescribing and dispensing medication, (2)
the unveiling in April 2009 of formal healthcare reform guidelines aimed at improving the availability of and subsidies for &#8220;essential&#8221;
drugs, and (3) the announcement in August 2009 of China&#8217;s National Essential Drugs List (&#8220;NEDL&#8221;), initially listing
approximately three hundred (300) medicines to be sold at government-controlled prices. While an underlying goal of these policies is
to make drugs more accessible to China&#8217;s poorer population, these policies also serve to create opportunities that in turn will
intensify business competition in the Chinese retail drugstore industry, as well as competition for skilled labor and retail spaces.
Additionally, we expect the NEDL to result in a rise in the number of government-subsidized community healthcare service centers, which
in turn may erode the convenience and price advantage that our drugstores traditionally enjoy against hospitals.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management will have broad discretion over the use of the proceeds we receive from our financing activities and might not apply the proceeds
in ways that increase the value of your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion to use the net proceeds from any offerings we may conduct from time to time, and the shareholders
will be relying on the judgment of our management regarding the application of these proceeds. Except as described in our offering books,
the net proceeds received by us from our offerings will be added to our general funds and will be used for general corporate purposes.
Our management might not apply the net proceeds from offerings of our securities in ways that increase the value of your investment and
might not be able to yield a significant return, if any, on any investment of such net proceeds. You may not have the opportunity to
influence our decisions on how to use such proceeds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>HJ
Group is subject to restrictions on making payments to us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely substantially on our contractual arrangements with HJ Group for our revenue. The Chinese government also imposes controls on the
conversion of RMB into foreign currencies and the remittance of currencies out of China. We may experience difficulties in completing
the administrative procedures necessary to obtain and remit foreign currency. Furthermore, if these companies incur debt on their own
in the future, the instruments governing the debt may restrict their ability to make payments. If we are unable to receive all of the
revenues from our operations through these contractual arrangements, we may be unable to pay dividends on our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends
we receive from our subsidiaries located in the PRC may be subject to PRC withholding tax.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Enterprise Income Tax Law (&#8220;EIT Law&#8221;) provides that a maximum income tax rate of twenty percent (20%) is applicable to dividends
payable to non-PRC investors that are &#8220;non-resident enterprises,&#8221; to the extent such dividends are derived from sources within
the PRC. However, the State Council has reduced such rate to ten percent (10%) through the implementation regulations. We are a Cayman
Islands holding company and substantially all of our income is derived from our subsidiaries and controlled companies located in the
PRC. Therefore, dividends paid to us from China may be subject to the ten percent (10%) income tax if we are considered a &#8220;non-resident
enterprise&#8221; under the EIT Law. If we are required to pay income tax for any dividends we receive from our PRC subsidiaries under
the EIT Law and its implementation regulations, it may have a material and adverse effect on our net income and materially reduce the
amount of dividends, if any, and we may pay to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face risks related to disease epidemics and other outbreaks.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
economy, infrastructure and livelihood of the people of the PRC or such other jurisdictions may be materially and adversely affected
by acts of God, acts of war and terrorism, natural disasters, riots, epidemics and other disasters which are beyond our control. Our
business, financial condition and results of operations may be adversely affected if these events occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, epidemics threaten people&#8217;s lives and may adversely affect their livelihood as well as their living and consumption patterns.
The occurrence of an epidemic is beyond our control, and we cannot assure you that the outbreak of coronavirus (including COVID-19),
severe acute respiratory syndrome, the H5N1 strain of avian influenza, the H1N1 strain of swine flu, the Zika virus or any other epidemics
or pandemics will not happen. Any epidemic or pandemic occurring, such as the most recent outbreak of COVID-19, in the PRC, or even in
areas outside of the PRC, may severely affect and restrict the level of economic activity as the government may impose regulatory administrative
measures quarantining affected areas or other measures to control the outbreak of the disease, which in turn may adversely affect our
business, financial condition and results of operations. Acts of war and terrorism may cause damage or disruption to us or our employees,
facilities, markets, suppliers or customers, any of which may adversely impact our revenue, cost, financial condition and results of
operations or the trading price of our securities. Potential war or terrorist attacks may also cause uncertainty and cause our business
to suffer in ways that we cannot currently predict.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with the U.S. Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to comply with the United States Foreign Corrupt Practices Act, which generally prohibits United States companies from engaging
in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. Foreign companies, including
some that may compete with us, are not subject to these prohibitions, and therefore may have a competitive advantage over us. Corruption,
extortion, bribery, pay-offs, theft and other fraudulent practices may occur in the PRC. If our competitors engage in these practices,
they may receive preferential treatment in the PRC, giving them an advantage in securing business, which would put us at a disadvantage.
We cannot provide assurance that our employees or other agents will not engage in such conduct for which we might be held responsible.
If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences
that may have a material adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
relations between the United States and China worsen, investors may be unwilling to hold or buy our stock and our stock price may decrease.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
various times in recent years, the United States and China have had significant disagreements over political and economic issues. Controversies
may arise in the future between the two countries. Any political or trade controversies between the United States and China, whether
or not directly related to our business, could reduce the price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
auditor, YCM CPA Inc., is headquartered in California, and is subject to inspection by the PCAOB on a regular basis. To the extent that
our independent registered public accounting firm&#8217;s audit documentation related to their audit reports for our company become located
in China, the PCAOB may not be able inspect such audit documentation and, as such, you may be deprived of the benefits of such inspection
and our ordinary shares could be delisted from the stock exchange pursuant to the Holding Foreign Companies Accountable Act.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holding Foreign Companies Accountable Act, or the HFCAA, was enacted on December 18, 2020. The HFCAA states if the SEC determines that
we have filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for three
consecutive years beginning in 2021, the SEC shall prohibit our shares from being traded on a national securities exchange or in the
over-the-counter trading market in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm issued an audit opinion on the financial statements included in our annual reports filed
with the SEC. Our independent registered public accounting firm&#8217;s audit documentation related to their audit reports included in
our annual reports is located in China, and audit procedures take place within China&#8217;s borders. As auditors of companies that are
traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board, or the PCAOB, our auditor
is required by the laws of the United States to undergo regular inspections by the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2021, the SEC adopted interim final rules relating to the implementation of certain disclosure and documentation requirements
of the HFCAA, which became effective on May 5, 2021. We will be required to comply with these rules if the SEC identifies our auditors
as having a &#8220;non-inspection&#8221; year under a process to be subsequently established by the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2021, the PCAOB proposed a new rule for implementing the HFCAA. Among other things, the proposed rule provides a framework for
the PCAOB to use when determining, under the HFCAA, whether it is unable to inspect or investigate completely registered public accounting
firms located in a foreign jurisdiction because of a position taken by one or more authorities in that jurisdiction. The proposed rule
would also establish the manner of the PCAOB&#8217;s determinations; the factors the PCAOB will evaluate and the documents and information
it will consider when assessing whether a determination is warranted; the form, public availability, effective date, and duration of
such determinations; and the process by which the board of the PCAOB can modify or vacate its determinations. The proposed rule was adopted
by the PCAOB on September 22, 2021 and approved by the SEC on November 5, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2021, the U.S. Senate passed a bill which, if passed by the U.S. House of Representatives and signed into law, would reduce
the number of consecutive non-inspection years required for triggering the prohibitions under the HFCAA from three years to two, thus
reducing the time period before the securities of such foreign companies may be prohibited from trading or delisted. On December 29,
2022, the Accelerating Holding Foreign Companies Accountable Act was signed into law, which officially reduce the number of years that
the auditor is not subject to inspection to two consecutive years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC is assessing how to implement other requirements of the HFCAA, including the listing and trading prohibition requirements described
above. The SEC may propose additional rules or guidance that could impact us if our auditor is not subject to the PCAOB inspection. For
example, on August 6, 2020, the President&#8217;s Working Group on Financial Markets, or the PWG, issued the Report on Protecting United
States Investors from Significant Risks from Chinese Companies to the then President of the United States. This report recommended the
SEC implement five recommendations to address companies from jurisdictions that do not provide the PCAOB with sufficient access to fulfill
its statutory mandate. Some of the concepts of these recommendations were implemented with the enactment of the HFCAA. However, some
of the recommendations were more stringent than the HFCAA. For example, if a company was not subject to the PCAOB inspection, the report
recommended that the transition period before a company would be delisted would end on January 1, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2021, the SEC issued amendments to finalize the interim final rules previously adopted in March 2021, and established procedures
to identify issuers and prohibit the trading of the securities of certain registrants as required by the HFCAA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2022, the PCAOB signed a Statement of Protocol with the CSRC and the Ministry of Finance of the PRC (the &#8220;Statement
of Protocol&#8221;), which is intended to enable the PCAOB to inspect and investigate completely registered public accounting firms in
mainland China and Hong Kong. According to a statement released by the PCAOB, the Statement of Protocol (i) provides the PCAOB with sole
discretion to select the firms, audit engagements and potential violations it inspects and investigates without consultation with, nor
input from, Chinese authorities, (ii) puts procedures in place for PCAOB inspectors and investigators to view complete audit work papers
with all information included and for the PCAOB to retain information as needed and (iii) provides the PCAOB with direct access to interview
and take testimony from all personnel associated with the audits the PCAOB inspects or investigates. While the Chairs of both the PCAOB
and the SEC made statements supporting the Statement of Protocol, both emphasized that this is only the first step in the process. As
such, uncertainties remain regarding how the Statement of Protocol will be implemented and how it will impact China-based issuers and
there is no assurance that the PCAOB will be able to execute, in a timely manner, its future inspections and investigations in a manner
that satisfies the Statement of Protocol. While the Statement of Protocol may lead to resolution of the previously identified issues,
there can be no assurance that this will be the case.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the PCAOB issued a new Determination Report which: (1) vacated the December 16, 2021 Determination Report; and (2)
concluded that the PCAOB has been able to conduct inspections and investigations completely in the PRC in 2022. The December 15, 2022
Determination Report cautions, however, that authorities in the PRC might take positions at any time that would prevent the PCAOB from
continuing to inspect or investigate completely. As required by the HFCAA, if in the future the PCAOB determines it no longer can inspect
or investigate completely because of a position taken by an authority in the PRC, the PCAOB will act expeditiously to consider whether
it should issue a new determination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the HFCAA is not currently applicable to the Company because the Company&#8217;s current auditors are subject to PCAOB review, if this
changes in the future for any reason, the Company may be subject to the HFCAA. The implications of this regulation if the Company were
to become subject to it are uncertain. Such uncertainty could cause the market price of our ordinary shares to be materially and adversely
affected, and our securities could be delisted or prohibited from being traded on Nasdaq earlier than would be required by the HFCAA.
If our ordinary shares is unable to be listed on another securities exchange by then, such a delisting would substantially impair your
ability to sell or purchase the ordinary shares when you wish to do so, and the risk and uncertainty associated with a potential delisting
would have a negative impact on the price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
auditor, the independent registered public accounting firm that issues the audit report for the year ended March 31, 2024 included elsewhere
in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB,
is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable
professional standards. Our auditor is headquartered in Irvine, California and has been inspected by the PCAOB in March 2023. In the
event that, in the future, either there is any regulatory change or step taken by PRC regulators that does not permit YCM CPA Inc. to
provide audit documentations located in China or Hong Kong to the PCAOB for inspection or investigation, or the PCAOB expands the scope
of the determinations so that our PRC operating entities will be subject to the HFCAA, as the same may be amended, you may be deprived
of the benefits of such inspection which could result in limitation or restriction to our access to the U.S. capital markets and trading
of our securities, including &#8220;over-the-counter&#8221; trading, may be prohibited, under the HFCAA. The recent developments would
add uncertainties to our listing and we cannot assure you whether Nasdaq Capital Market or regulatory authorities would apply additional
and more stringent criteria to us after considering the effectiveness of our auditor&#8217;s audit procedures and quality control procedures,
adequacy of personnel and training, or sufficiency of resources, geographic reach, or experience as it relates to our audit.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
new laws and regulations or changes in laws and regulations in both the United States and China could affect our ability to list our
shares on Nasdaq, which could materially impair the market for and market price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to an Investment in Our Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
date, we have not paid any cash dividends and we do not estimate to distribute any cash dividends in the foreseeable future.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying cash dividends on our ordinary shares in the foreseeable future and we may not have sufficient funds legally
available to pay dividends. Even if the funds are legally available for distribution, we may nevertheless decide not to pay any dividends.
We intend to retain all earnings for our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
may delist our ordinary shares from trading on the Nasdaq Capital Market for failing to maintain a minimum bid price of $1.00, which
could limit investors&#8217; ability to effect transactions in our ordinary shares and subject us to additional trading restrictions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2023, the Company was first notified by the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), notifying us our failure to maintain
a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A). The Company
was given its first 180-day extension, or until December 12, 2023 to regain compliance by maintaining a minimum closing bid price of
at least $1.00 for a minimum of 10 consecutive trading days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 13, 2023, the Company was notified by the Nasdaq regarding a second 180-day extension from or until June 10, 2024 to regain
compliance. Effective March 1, 2024, the Company effected a 1-for-20 reverse stock split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2024, the Company received a compliance letter from Nasdaq notifying that as of&#160;March 14, 2024, the Company evidenced
a closing bid price of its ordinary shares at or greater than the&#160;$1.00&#160;per share minimum requirement for the last 10 consecutive
business days, from March 1, 2024 through March 14, 2024. Nasdaq stated that accordingly, Jo-Jo Drugstores has regained compliance with
Nasdaq Marketplace Rule 5550(a)(2).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot provide assurance that we will remain compliant with the Bid Price Rule in the future. If Nasdaq delists our ordinary shares from
trading on its exchange due to incompliance, we could face significant material adverse consequences including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our ordinary shares;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage for our company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Although
publicly traded, the trading market in our ordinary shares may be substantially less liquid than the average stock quoted on the Nasdaq
Capital Market, and such low trading volume may adversely affect the price of our ordinary shares.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our securities has been listed on the Nasdaq Capital Market since April 22, 2010, the historical trading volume of our securities has
generally been low. Limited trading volume will subject our ordinary shares to greater price volatility and may make it difficult for
you to sell your shares at a price that is attractive to you.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price for our stock may be volatile, and such volatility may subject us to securities litigation.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our stock may be volatile and, when compared to seasoned issuers, subject to wide fluctuations in response to various
factors, many of which are beyond our control, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our quarterly operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates by securities research analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    in the retail pharmacy markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of other retail pharmacy operators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of new products, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">addition
    or departure of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    of exchange rates between RMB and the U.S. dollar;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual
    property litigation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic or political conditions in China.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an illustration of such volatility, the closing price of our ordinary shares during the fifty two (52) weeks preceding the date of this
report ranged from a low of $2.65 to a high of $95.40. In addition, the securities market has from time to time experienced significant
price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may
also materially and adversely affect the market price of our stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the
market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial
costs and liabilities and could divert management&#8217;s attention and resources.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Techniques
employed by manipulative short sellers in Chinese small-cap stocks may drive down the market price of our ordinary shares.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention
of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from the difference in
the sale price of the borrowed securities and the purchase price of the replacement shares. As it is therefore in the short seller&#8217;s
best interests for the price of the stock to decline, there have been incidents of short sellers publishing, or arranging to publish
negative opinions in order to create negative market momentum. While traditionally these disclosed shorts have been limited in their
ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological
advancements regarding document creation, videotaping and publication by weblog (&#8220;blogging&#8221;) have allowed many disclosed
shorts to publicly attack a company&#8217;s credibility, strategy and veracity by means of so-called research reports that mimic the
type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the
past, resulted in the selling of shares in the market, on occasion on a large scale and broad base. Issuers with business operations
based in the PRC, that have limited trading volumes and that are susceptible to higher volatility levels than U.S. domestic large-cap
stocks can be particularly vulnerable to such short attacks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S.,
are not subject to the certification requirements imposed by the SEC in Regulation Analyst Certification and, accordingly, the opinions
they express may be based on distortion of the actual facts or, in some cases, fabrication of the facts. In light of the limited risks
involved in publishing such information, and the enormous profit that can be made from running just one successful short attack, unless
the short sellers become subject to significant penalties, it is more likely than not that disclosed shorts will continue to issue such
reports.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to strongly defend our public filings against any such short seller attacks, oftentimes we are constrained, either by principles
of freedom of speech, applicable state law (often called Anti-SLAPP statutes), or issues of commercial confidentiality, in the manner
in which we can proceed against the relevant short seller. You should be aware that in light of the relative freedom to operate that
such persons enjoy &#8211; oftentimes blogging from outside the U.S. with little or no assets or identity requirements &#8211; should
we be targeted for such an attack and the rumors not dismissed by market participants, our stock will likely suffer from a temporary,
or possibly long term, decline in market price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
General Risk Factors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in economic conditions and consumer confidence in China may influence the drugstore industry, consumer preferences and spending patterns.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and revenue growth primarily depend on the size of the pharmaceutical market in China. As a result, our revenue and profitability
may be negatively affected by changes in national, regional or local economic conditions and consumer confidence in China. In particular,
as we focus on our expansion of pharmacies in metropolitan markets, where living standards and consumer purchasing power are relatively
high, we are especially susceptible to changes in economic conditions, consumer confidence and customer preferences of the urban Chinese
population. External factors beyond our control that affect consumer confidence include unemployment rates, levels of personal disposable
income, national, regional or local economic conditions, and acts of war or terrorism. Changes in economic conditions and consumer confidence
could adversely affect consumer preferences, purchasing power and spending patterns. A decrease in overall consumer spending as a result
of changes in economic conditions could adversely affect our front-end and pharmacy sales and negatively impact our profitability. In
addition, acts of war or terrorism may cause damage to our facilities, disrupt the supply of the products and services we offer in our
stores, or adversely impact consumer demand. Any of these factors could have a material adverse effect on our business, financial condition
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to timely identify or otherwise effectively respond to changing customer preferences, and we may fail to optimize our
product offering and inventory position.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry in China is rapidly evolving and is subject to rapidly changing customer preferences that are difficult to predict.
Our success depends on our ability to anticipate and identify customer preferences, and adapt our product selection to meet these preferences.
In particular, we must optimize our product selection and inventory positions based on sales trends. We cannot provide assurance that
our product selection, especially our selection of nutritional supplements and food products, will accurately reflect customer preferences
at any given time. If we fail to accurately anticipate either the market for our products or customers&#8217; purchasing habits or fail
to respond to customers&#8217; changing preferences promptly and effectively, we may not be able to adapt our product selection to customer
preferences or make appropriate adjustments to our inventory positions, which could significantly reduce our revenue and have a material
adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to establish effective advertising, marketing and promotional programs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to establish effective advertising, marketing and promotional programs, including pricing strategies implemented
in response to competitive pressures and/or to drive demand for our products. Our advertisements are designed to promote our brand, our
corporate image and the prices of products available for sale in our stores. Our pricing strategies and value propositions must be appropriate
for our target customers. If we are not able to maintain and increase the awareness of our pharmacy&#8217;s brand and the products and
services we provide, we may not be able to attract and retain customers and our reputation may also suffer. We expect to incur substantial
expenses in our marketing and promotional efforts to both attract and retain customers. However, our marketing and promotional activities
may be less successful than we anticipate, and may not be effective at building our brand awareness and customer base. In addition, the
government may impose restrictions on how marketing and promotional activities can be conducted. We cannot provide assurance that our
current and proposed budget for marketing activities will be adequate to support our future growth. Failure to successfully execute our
advertising, marketing and promotional programs may result in material decreases in our revenue and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to maintain optimal inventory levels could increase our inventory holding costs or cause us to lose sales, either of which could have
a material adverse effect on our business, financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
need to maintain sufficient inventory levels to operate both of our retail and wholesale businesses successfully as well as meet customer
expectations. However, we must also guard against the risk of accumulating excess inventory. We are exposed to inventory risks as a result
of rapid changes in product life cycles, changing consumer preferences, uncertainty of the success of product launches, seasonality,
and manufacturer backorders and other vendor-related problems. We cannot provide assurance that we can accurately predict these trends
and events and avoid over-stocking or under-stocking products. In addition, demand for products could change significantly between the
time product inventory is ordered and the time it is available for sale.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we begin selling a new product, it is particularly difficult to accurately forecast product demand. The purchase of certain types of
inventory may require significant lead-time. As we carry a broad selection of products and maintain significant inventory levels for
a substantial portion of our merchandise, we may be unable to sell such inventory in sufficient quantities or during the relevant selling
seasons. Carrying excess inventory could increase our inventory holding costs, and failure to have inventory in stock when a customer
orders or purchases it could cause us to lose that order or that customer, either of which could have a material adverse effect on our
business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may need additional capital, and the sale of equity securities could result in dilution to our shareholders, while debts may require
us to make covenants restricting how we operate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the aggregate amount of our current cash, anticipated cash flow from operations, available borrowings under our existing
bank facilities, and personal loans from our principal shareholders should be sufficient to meet our anticipated cash needs for the near
future. We may, however, require additional cash resources due to changed business conditions or other future developments. If our resources
are insufficient to satisfy our cash requirements, we may seek to sell additional equity or debt securities or obtain credit facilities.
The sale of additional equity securities could result in the dilution of our existing shareholders. We cannot guarantee that we will
be able to obtain any additional financing on terms that are acceptable to us, or at all. Even if we are able to obtain any requisite
financing, the incurrence of additional indebtedness would result in increased debt service obligations, and could result in further
operating and financing covenants that would restrict our freedom to operate our business, such as conditions that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    our ability to pay dividends or require us to seek consent for the payment of dividends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our vulnerability to general adverse economic and industry conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to dedicate a portion of our cash flow from operations to payments on our debt, thereby reducing the availability of our cash
    flow to fund capital expenditures, working capital and other general corporate purposes; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    our flexibility in planning for, or reacting to, changes in our business and our industry.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
brand names, trade secrets and other intellectual property are valuable assets. If we are unable to protect them from infringement, our
business and prospects may be harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider our pharmacy brand names to be valuable assets. We may be unable to prevent third parties from using such brand names without
authorization, which may adversely affect our business and reputation, including the perceived quality and reliability of our products
and services. We have five registered trademarks. We also own three domain names that we actively use in our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets to protect our know-how and other proprietary information, including pricing, purchasing, promotional strategies,
customer lists and/or suppliers lists. As a result, our employees are required to sign employment agreements that contain confidentiality
provisions as a condition of their employment with us. However, trade secrets are difficult to protect. While we believe we use reasonable
efforts to protect our trade secrets, our employees, consultants, contractors or advisors may unintentionally or willfully disclose our
information to competitors. In addition, confidentiality agreements executed by the aforementioned individuals may not be enforceable
or provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, such efforts could be expensive
and time-consuming, and the outcome unpredictable. Additionally, if our competitors independently develop information that is equivalent
to our trade secrets or other proprietary information, we have little recourse to enforce our rights, and our business and prospects
could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation
may be necessary in the future to enforce our intellectual property rights or to determine the validity and scope of the intellectual
property rights of others. However, since the validity, enforceability and scope of protection of intellectual property rights in the
PRC are uncertain and still evolving, we may not be successful in prosecuting these cases. In addition, any litigation, proceeding or
other efforts to protect our intellectual property rights could result in substantial costs and diversion of our resources, and could
seriously harm our business and operating results. Furthermore, the degree of future protection of our proprietary rights is uncertain
and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we are unable to protect our trade
names, trade secrets and other propriety information from infringement, our business, financial condition and results of operations may
be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be exposed to intellectual property infringement and other claims by third parties which, if successful, could disrupt our business
and have a material adverse effect on our financial condition and results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in large part, on our ability to use our proprietary information and know-how without infringing third party intellectual
property rights. As litigation becomes more common in China, we face a higher risk of being the subject of claims for intellectual property
infringement, invalidity or indemnification relating to other parties&#8217; proprietary rights. Our current or potential competitors,
many of whom have substantial resources, may have or may obtain intellectual property protection that will prevent, limit or interfere
with our ability to conduct our business in China. Moreover, the defense of intellectual property suits, including trademark infringement
suits and related legal and administrative proceedings, can be both costly and time consuming and may significantly divert the efforts
and resources of our management personnel. Furthermore, an adverse determination in any such litigation or proceeding to which we may
become a party could cause us to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
    damage awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    licenses from third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
    ongoing royalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">redesign
    our product offerings; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    restricted by injunctions,</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of which could effectively prevent us from pursuing some or all of our business and result in our customers or potential customers deferring
or limiting their purchase from our stores, which could have a material adverse effect on our financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face competition that could adversely affect our results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinics compete with a large number and variety of healthcare facilities in their respective markets. There are numerous government-run
and private hospitals and clinics available to the general populace. There can be no assurance that these or other clinics, hospitals
or other facilities will not commence or expand such operations, which would increase their competitive position. Furthermore, there
can be no assurance that a healthcare organization that having greater resources in the provision or management of healthcare services
will not decide to engage in operations similar to those being conducted by us in Hangzhou.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may need to obtain additional governmental approvals to open new drugstores. Our inability to obtain such approvals will have a material
adverse effect on our business and growth.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the&#160;<i>Measures on the Administration of Foreign Investment in the Commercial Sector</i>&#160;(the &#8220;Measures&#8221;) promulgated
by China&#8217;s Ministry of Commerce (the &#8220;MOC&#8221;), which became effective on June 1, 2004, a company that is directly owned
by a foreign invested enterprise needs to obtain relevant governmental approvals before it opens new retail stores. However, there are
no specific laws, rules or regulations with respect to whether such approvals are necessary for a company that is contractually controlled
by a foreign invested enterprise. In addition, the Measures state that the MOC will promulgate a detailed implementation regulation to
govern foreign invested enterprises engaging in drug sale. However, such implementation regulation has not yet been promulgated. Therefore,
we cannot provide assurance that the MOC will not require such approvals to be obtained, or as to when any regulation of such requirements
may be implemented. If additional governmental approvals are deemed to be necessary and we are unable to obtain such approvals on a timely
basis or at all, our business, financial condition, results of operations and prospects, as well as the trading price of our ordinary
shares, will be materially and adversely affected.&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
PRC&#8217;s labor law restricts our ability to reduce our workforce in the PRC in the event of an economic downturn and may increase
our production costs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2007, the National People&#8217;s Congress of the PRC enacted new labor law legislation called the Labor Contract Law, which became
effective on January 1, 2008 (the &#8220;LC Law&#8221;). The LC Law formalized workers&#8217; rights concerning overtime hours, pensions,
layoffs, employment contracts and the role of trade unions. Considered one of the strictest labor laws in the world, among other things,
the LC Law provides for specific standards and procedures for the termination of an employment contract and places the burden of proof
on the employer. In addition, the law requires the payment of a statutory severance pay upon the termination of an employment contract
in most cases, including the case of the expiration of a fixed-term employment contract. Further, the LC Law requires an employer to
conclude an &#8220;employment contract without a fixed-term&#8221; with any employee who either has worked for the same employer for
ten (10) consecutive years or more or has had two (2) consecutive fixed-term contracts with the same employer. An &#8220;employment contract
without a fixed term&#8221; can no longer be terminated on the ground of the expiration of the contract, although it can still be terminated
pursuant to the standards and procedures set forth under the new law. Because of the lack of implementing rules for the LC Law and the
precedents for the enforcement of such a law, the standards and procedures set forth under the LC Law in relation to the termination
of an employment contract have raised concerns among foreign investment enterprises in the PRC that such &#8220;employment contract without
a fixed term&#8221; might in fact become a &#8220;lifetime, permanent employment contract.&#8221; Finally, under the LC Law, downsizing
of either more than twenty (20) people or more than ten percent (10%) of the workforce may occur only under specified circumstances,
such as a restructuring undertaken pursuant to the PRC&#8217;s Enterprise Bankruptcy Law, or where a company suffers serious difficulties
in production and/or business operations, or where there has been a material change in the objective economic circumstances relied upon
by the parties at the time of the conclusion of the employment contract, thereby making the performance of such employment contract impossible.
To date, there has been very little guidance and precedent as to how such specified circumstances for downsizing will be interpreted
and enforced by the relevant PRC authorities. All of our employees working for us exclusively within the PRC are covered by the LC Law
and thus, our ability to adjust the size of our operations when necessary in periods of recession or less severe economic downturns may
be curtailed. Accordingly, if we face future periods of decline in business activity generally or adverse economic periods specific to
our business, the LC Law can be expected to exacerbate the adverse effect of the economic environment on our results of operations and
financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
cannot be certain that the Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the Renminbi,
especially with respect to foreign exchange transactions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuations
in the value of the Renminbi may have a material and adverse effect on your investment. The change in value of the Renminbi against the
U.S. dollar is affected by, among other things, changes in PRC&#8217;s political and economic conditions. We receive substantially all
of our revenues in RMB. Under our current structure, our income is primarily derived from payments from the three (3) HJ Group companies.
Shortages in the availability of foreign currency may restrict the ability of our subsidiaries and our PRC affiliated entities to remit
sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign currency denominated obligations.
Under existing Chinese foreign exchange regulations, payments of current account items, including profit distributions, interest payments
and expenditures from trade-related transactions, can be made in foreign currencies without prior approval from SAFE by complying with
certain procedural requirements. However, approval from appropriate government authorities is required where RMB is to be converted into
foreign currency and remitted out of China to pay capital expenses, such as the repayment of bank loans denominated in foreign currencies.
The Chinese government may also, at its discretion, restrict access in the future to foreign currencies for current account transactions.
If the foreign exchange control system prevents us from obtaining sufficient foreign currency to satisfy our currency demands, we may
not be able to pay dividends in foreign currencies to our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi
appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation
halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, the Renminbi has
fluctuated against the U.S. dollar, at times significantly and unpredictably. On November 30, 2015, the Executive Board of the International
Monetary Fund (IMF) completed the regular five-year review of the basket of currencies that make up the Special Drawing Right, or the
SDR, and decided that with effect from October 1, 2016, Renminbi is determined to be a freely usable currency and will be included in
the SDR basket as a fifth currency, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter
of 2016, the Renminbi depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. In
2017, the RMB appreciated approximately 6.3% against the U.S. dollar. In 2018, however, the RMB depreciated approximately 5.7% against
the U.S. dollar, and the trend continued in 2019. In 2020 and 2021, the RMB appreciated approximately 8.7% against the U.S. Dollar, but
the RMB has sharply depreciated against the U.S. Dollar by 7.8% and 2.9%, respectively, in 2022 and 2023.With the development of the
foreign exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in
the future announce further changes to the exchange rate system and we cannot assure you that the Renminbi will not appreciate or depreciate
significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces, international relations especially
the trade tensions between U.S. and China, or government policies of PRC or U.S. may impact the exchange rate between the Renminbi and
the U.S. dollar in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fluctuations
in the value of RMB may have a material adverse effect on your investment.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political
and economic conditions. Our revenues, costs, and financial assets are mostly denominated in RMB, while our reporting currency is the
U.S. dollar. Accordingly, this may result in gains or losses from currency translation on our financial statements. We rely entirely
on fees paid to us by our affiliated entities in China. Therefore, any significant fluctuation in the value of RMB may materially and
adversely affect our cash flows, revenues, earnings, financial position, and the value of, and any dividends payable on, our stock in
U.S. dollars. For example, an appreciation of RMB against the U.S. dollar would, to the extent that we need to convert U.S. dollars into
RMB for such purposes, make any new RMB denominated investments or expenditures more costly to us. An appreciation of RMB against the
U.S. dollar would result in foreign currency translation gains for financial reporting purposes when we translate our RMB denominated
financial assets into U.S. dollars, as the U.S. dollar is our reporting currency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported
in U.S. dollars without giving effect to any underlying change in our business or results of operations. The income statements of our
operations are translated into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens
against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating
expenses and net income for our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies,
the translation of these foreign currency denominated transactions results in increased revenue, operating expenses and net income for
our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our
foreign subsidiaries into U.S. dollars in consolidation. If there is a change in foreign currency exchange rates, the conversion of the
foreign subsidiaries&#8217; financial statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component
of other comprehensive income. Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations.
To date, we have not entered into any hedging transactions. While we may enter into hedging transactions in the future, the availability
and effectiveness of these transactions may be limited, and we may not be able to successfully hedge our exposure at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
economy of China had experienced unprecedented growth. This growth has slowed in the recent years, and if the growth of the economy continues
to slow or if the economy contracts, our financial condition may be materially and adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rapid growth of the Chinese economy had historically resulted in widespread growth opportunities for industries across China. This growth
has slowed in the recent years. As a result of the global financial crisis due to COVID-19, and Ukraine War, and the inability of enterprises
to gain comparable access to the same amounts of capital available in past years, there may be an adverse effect on the business climate
and growth of private enterprises in China. An economic slowdown could have an adverse effect on our sales and may increase our costs.
Further, if economic growth continues to slow, and if, in conjunction, inflation continues unchecked, our costs would be likely to increase,
and there can be no assurance that we would be able to increase our prices to an extent that would offset the increase in our expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a tightened labor markets in our geographic region may result in fewer qualified applicants for job openings in our facilities.
Further, higher wages, related labor costs and other increasing cost trends may negatively impact our results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. INFORMATION ON THE COMPANY.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A<i>.
</i>HISTORY AND DEVELOPMENT OF THE COMPANY.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People&#8217;s Republic of China (&#8220;PRC&#8221;
or &#8220;China&#8221;). Prior to acquiring Zhejiang Jiuxin Medicine Co., Ltd. (&#8220;Jiuxin Medicine&#8221;) in August 2011 (see &#8220;<i>Our
Corporate History and Structure - HJ Group</i>&#8221; below), we were primarily a retail pharmacy operator. As of March 31, 2024, we
have one hundred and twenty-seven (127) store locations under the store brand &#8220;Jiuzhou Grand Pharmacy&#8221; in Hangzhou city.
We acquired four single drugstores in fiscal 2021. After the acquisition, we liquidated them and then opened four new stores with the
four licenses of local government medical insurance reimbursement program. On the other side, we have been concentrating on new stores
within Hangzhou metropolitan area and opened fourteen stores in the fiscal year 2024. As China has been successfully controlling the
spread of COVID-19, and the recurrences of the pandemic have not materially affected our business, the negative impacts are limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently operate in four business segments in China: (1) retail drugstores, (2) online pharmacy, (3) wholesale business selling products
similar to those we carry in our pharmacies, and (4) farming and selling herbs used for traditional Chinese medicine (&#8220;TCM&#8221;).
All of the above business are performed in China with no international sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stores provide customers with a wide variety of pharmaceutical products, including prescription and over-the-counter (&#8220;OTC&#8221;)
drugs, nutritional supplements, TCM, personal and family care products, and medical devices, as well as convenience products, including
consumable, seasonal, and promotional items. Additionally, we have doctors licensed in both western medicine and TCM on site for consultation,
examination and treatment of common ailments at scheduled hours. Four (4) stores have adjacent medical clinics offering urgent care (to
provide treatment for minor ailments such as sprains, minor lacerations, and dizziness that can be treated on an outpatient basis), TCM
(including acupuncture, therapeutic massage, and cupping) and minor outpatient surgical treatments (such as suturing). Our stores vary
in size, but presently average close to 200 square meters per store. We attempt to tailor each store&#8217;s product offerings, physician
access, and operating hours to suit the community where the store is located.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate our pharmacies (including the medical clinics) through the following companies in China that we manage through contractual arrangements
(refer to &#8220;<i>Contractual Arrangements with HJ Group and the Key Personnel&#8221; below in this report regarding the details of
contractual arrangements</i>:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hangzhou
    Jiuzhou Grand Pharmacy Chain Co., Ltd. (&#8220;Jiuzhou Pharmacy&#8221;), which we control contractually, operates our &#8220;Jiuzhou
    Grand Pharmacy&#8221; stores;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hangzhou
    Jiuzhou Clinic of Integrated Traditional and Western Medicine (General Partnership) (&#8220;Jiuzhou Clinic&#8221;), which we control
    contractually, operates one (1) of our three (3) medical clinics; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hangzhou
    Jiuzhou Medical &amp; Public Health Service Co., Ltd. (&#8220;Jiuzhou Service&#8221;), which we control contractually, operates our
    other medical clinics.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also offer OTC drugs and nutritional supplements for sale through a website (www.dada360.com) operated by Jiuzhou Pharmacy. For the fiscal
year ended March 31, 2024, retail revenue, including pharmacies, medical clinics accounted for approximately 49.0% of our total revenue,
while online pharmacy revenue accounted for 20.6% of our total revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
August 2011, we have operated a wholesale business through Jiuxin Medicine, distributing third-party pharmaceutical products (similar
to those carried by our pharmacies) primarily to trading companies throughout China. Jiuxin Medicine is wholly owned by Jiuzhou Pharmacy.
For the fiscal year March 31, 2024, wholesale revenue accounted for approximately 30.4% of our total revenue. In addition, Jiuxin Medicine
supplies 96.8% of the inventory of Jiuzhou Pharmacy worth $77,054,670 in the fiscal year March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have a herb farming business cultivating and wholesaling herbs used for TCM. This business is conducted through Hangzhou Qianhong
Agriculture Development Co., Ltd. (&#8220;Qianhong Agriculture&#8221;), a wholly-owned subsidiary. During the fiscal year ended March
31, 2024, our herb farming business generated approximately 0% of our retail revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this report, we will sometimes refer to Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries of Jiuzhou
Pharmacy, collectively as &#8220;HJ Group.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
History </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to our corporate history is incorporated by reference from our annual report on Form 20-F for the fiscal year March 31, 2023
filed with the SEC on June 15, 2023 (the &#8220;<a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a>&#8221;) under the caption &#8220;Corporate History.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contractual
Arrangements with HJ Group and the Key Personnel</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to the contractual arrangements with HJ Group and the Key Personnel is incorporated by reference from our 2023 Annual Report
under the caption &#8220;Contractual Arrangements with HJ Group and the Key Personnel.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 4th Floor, Building 5, Renxin Yaju, Gong Shu District, Hangzhou City, Zhejiang Province, and
China. Our main telephone number is +86-571-88219579. Our website is www.jiuzhou360.com. We routinely post important information on our
website. The information contained on our website is not a part of this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
transfer agent is Equiniti Trust Company, , LLC, whose address is 48 Wall Street, Floor 23 New York, NY 10005, and whose telephone number
is (800) 468-9716.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC at www.sec.gov.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
BUSINESS OVERVIEW.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmacies</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we currently have one hundred and twenty-seven (127) pharmacies throughout Hangzhou, the provincial capital of Zhejiang
and neighborhood cities. Pharmacy sales accounted for approximately 95.4% of our retail revenue, and 46.7% of our total revenue, for
the fiscal year ended March 31, 2024. We offer primarily third-party products at our pharmacies, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    1,460 prescription drugs (345 of which require a physician&#8217;s prescription and the remainder requiring customer personal information
    registration only), sales of which accounted for approximately 33.4% of our retail revenue for the fiscal year ended March 31, 2024;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    1,722 OTC drugs, sales of which accounted for approximately 41.7% of our retail revenue for the fiscal year ended March 31, 2024;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    916 nutritional supplements, including a variety of healthcare supplements, vitamin, mineral and dietary products, sales of which
    accounted for approximately 13.1% of our retail revenue for the fiscal year ended March 31, 2024;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM,
    including drinkable herbal remedies and pre-packaged herbal mixtures for making soup, sales of which accounted for approximately
    4.5% of our retail revenue for the fiscal year ended March 31, 2024;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sundry
    products (i.e., personal care products such as skin care, hair care and beauty products, convenience products such as soft drinks,
    packaged snacks, and other consumable, cleaning agents, stationeries, and seasonal and promotional items tailored to local consumer
    demand for convenience and quality), sales of which accounted for approximately 1.5% of our retail revenue for the fiscal year ended
    March 31, 2024; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    devices (i.e., family planning and birth control products, early pregnancy test products, portable electronic diagnostic apparatus,
    rehabilitation equipment, and surgical tools such as hemostats, needle forceps and surgical scissors), sales of which accounted for
    approximately 5.9% of our retail revenue for the fiscal year ended March 31, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
favor retail locations in well-established residential communities with relatively concentrated consumer purchasing power or are located
in close proximity to local hospitals, and evaluate potential store sites to assess consumer traffic, visibility and convenience. Depending
on its size, each drugstore has between two (2) to twenty-five (25) pharmacists on staff, all of whom are properly licensed. We only
accept prescriptions from licensed health care providers, and verify the validity, accuracy, and completeness of all prescriptions. We
also ask all prescription customers to disclose their drug allergies, current medical conditions, and current medications. Most pharmacies
also maintain a TCM counter staffed by licensed herbalists.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
opening, a location without SHI (Social Health Insurance) coverage may take up to one year to achieve our projected revenue goals for
that particular location. Various factors influence individual store revenue including, but not limited to: location, nearby competition,
local population demographics, square footage, and government insurance coverage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our one hundred and twenty-seven (127) of our drugstores are located in Hangzhou city.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enhance our customers&#8217; experience, we have licensed physicians available at several of our &#8220;Jiuzhou Grand Pharmacy&#8221;
locations for consultation, examination and treatment of common ailments at scheduled hours. In addition, our Daguan, Wenhua, Xiasha
and Yueming stores have adjoining medical clinics that provide urgent care (for conditions such as sprains, minor lacerations, and dizziness),
TCM treatments (including acupuncture, therapeutic massage, moxibustion, and cupping), and minor outpatient surgical treatments (such
as suturing).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure quality and personal attention for patients, we employ only licensed doctors and certified nurses and technicians. Patient treatment
at our five (5) Jiuzhou Clinics and Jiuzhou Service, follow nationally established clinical practice guidelines from China&#8217;s Ministry
of Health. We currently have seventy-seven (77) physicians and thirty-eight (38) clinic staff. In-store consultations and examinations
by our physicians are provided free-of-charge to ensure that customers are being prescribed and taking the appropriate medication for
their ailments, and to afford customers convenience.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
view our medical services as more consumer-driven than other health care specialties, because consumers requiring the types of medical
services that we provide often seek treatment on their own accord. We have developed our medical services to respond to the public need
for convenient access to medical consultations and/or care and the significant savings that we can provide as compared to a more traditional
medical setting such as a hospital. Many of our patients often need immediate access to medical services, do not have a regular physician,
or may lack suitable alternatives. Patient flow is derived from the physical presence of our drugstores, not from pre-existing doctor-patient
relationships or referrals from other healthcare providers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generate limited revenue directly from our clinics. However, our clinic brings patients into our stores, where they then purchase medical
products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Online
Sales</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
May 2010, we have been retailing OTC drugs and nutritional supplements on the Internet at www.dada360.com. Before November 2015, our
subsidiary Quannuo Technology operated and maintained the website pursuant to the Internet Pharmaceutical Transaction Service Qualification
Certificate issued by the National Medical Products Administration (the &#8220;NMPA&#8221;) of Zhejiang Province, which allows us to
engage in online retail pharmaceutical sales throughout China. As we sold all our equity interests in Quannuo Technology in November
2015, we have transferred our online pharmacy operation function to Jiuzhou Pharmacy. We have established payment methods with banks
and online intermediaries such as Alipay or Wechat Pay, and are cooperating with business-to-consumer online vendors such as Taobao,
JD.com or Pinduoduo. By using Taobao&#8217;s platform in addition to our own website as mentioned above, we can be exposed to a wider
range of customers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Online
sales accounted for approximately 20.6% of our total revenue, for the fiscal year ended March 31, 2024. Online sales accounted for approximately
21.8% of our total revenue, for the fiscal year ended March 31, 2023. Online sales accounted for approximately 18.4% of our total revenue,
for the fiscal year ended March 31, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Wholesale</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
acquiring Jiuxin Medicine in August 2011, we have been distributing third-party products primarily to drug distributors throughout China,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    1,542 prescription drugs, the sales of which accounted for approximately 65.5% of our wholesale revenue for the fiscal year ended
    March 31, 2024 as compared to approximately 1,615 prescription drugs, the sales of which accounted for approximately 65.4% of our
    wholesale revenue for the fiscal year ended March 31, 2023;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    1,793 OTC drugs, the sales of which accounted for approximately 24.1% of our wholesale revenue for the fiscal year ended March 31,
    2024 as compared to approximately 1,886 OTC drugs, the sales of which accounted for approximately 31.1% of our wholesale revenue
    for the fiscal year ended March 31, 2023;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately
    841 nutritional supplements, the sales of which accounted for approximately 1.6% of our wholesale revenue for the fiscal year ended
    March 31, 2024 as compared to approximately 813 nutritional supplements, the sales of which accounted for approximately 0.9% of our
    wholesale revenue for the fiscal year ended March 31, 2023;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
    products, the sales of which accounted for approximately 0.8% of our wholesale revenue for the fiscal year ended March 31, 2024;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sundry
    products, the sales of which accounted for approximately 1.5% of our wholesale revenue for the fiscal year ended March 31, 2024;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    devices, the sales of which accounted for approximately 6.5% of our wholesale revenue for the fiscal year ended March 31, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale
revenue increased primarily as a result of our ability to resell certain products, which our retail stores made large orders on, to other
vendors. As our retail drugstores achieved large quantity sales of certain brand name merchandise, we were able to negotiate for lower
purchase prices than the market level on such merchandise. As a result, certain vendors who were unable to obtain better prices than
ours, will turn to us for such merchandise, leading the wholesale volume to grow. On the other side, we have been trying to act as a
local agent for well-known health products in Zhejiang Province. For example, we kept a strategic cooperation agreement with Dong&#8217;a
Gelatin (DEEJ) and act as its local sale agent in Zhejiang Province.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Herb
Farming</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
2010 to the third quarter of fiscal 2013, we had been cultivating and harvested ten (10) types of herbs, such as fructusrubi (used in
TCM to promote blood circulation), white atractylodes rhizome (used in TCM to treat physical and mental fatigue), atractylodesmacrocephala
(used in TCM to control sweating), ginkgo seeds (used in TCM to treat asthma), and ginkgo trees used for TCM on approximately forty eight
(48) acres of leased land in Lin&#8217;an, approximately thirty (30) miles from Hangzhou.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
ginkgo tree may have a growth period of up to twenty years before it is mature enough to harvest. Typically, the longer the plant grows,
the more valuable it becomes. We plan to continue cultivating the trees in order to maximize their market value in the future. We may
continue growing trees and cultivating other herbs&#160;in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we have not harvested any ginkgo trees, herb farming revenue accounted for no revenue for the fiscal years ended March 31, 2024 and 2023.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Customers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Retail
Customers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended March 31, 2024, our pharmacies collectively served an average of 23,253 customers per day. We periodically conduct
qualitative customer surveys to help us build a stronger understanding of our market position and our customers&#8217; purchasing habits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmacy
customers pay by cash, debit or credit cards, mobile devices or medical insurance cards under Hangzhou and Zhejiang&#8217;s medical insurance
programs. During the fiscal year ended March 31, 2024, approximately 3% of our pharmacy revenue came from cash sales, 39% from Hangzhou&#8217;s
and Zhejiang&#8217;s medical insurance cards (where most of our pharmacies are located), and 58% from debit and credit cards, Alipay
and other charge cards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain strict cash control procedures at our pharmacies. Our integrated information management system records the details of each sale,
which we control from our headquarters. Depending on each location&#8217;s sales activities, cash may be deposited daily or several times
per week in designated bank accounts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
sales made to eligible participants in the national medical insurance program, we generally obtain payments from the relevant government
social security bureaus on a monthly basis. See &#8220;<i>Relevant PRC Regulations - Reimbursement under the National Medical Insurance
Program.</i>&#8221; According to relevant regulations, a drugstore usually needs to operate for at least one (1) year before it can apply
to be licensed to accept Hangzhou&#8217;s medical insurance cards. As of the date of this report, one hundred and twenty-five (125) of
our one hundred and twenty-seven (127) &#8220;Jiuzhou Grand Pharmacy&#8221; stores are licensed to accept medical insurance cards. Those
of our stores that accept medical insurance cards are designated as such by clear signage on their storefront windows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Online
Sales Customers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
online customers consist primarily of consumers between the ages of 20 and 40. While our website is accessible throughout China, approximately
thirty percent (30%) of our online sales during the fiscal year ended March 31, 2024, were from Zhejiang and neighboring Jiangsu and
Shanghai.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Wholesale
Customers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholesale customers are primarily third-party trading companies that purchase from us to resell to pharmacies throughout China. We also
supply some hospitals and pharmacies, although they collectively make up less than 10.0% of our wholesale customers currently.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Herb
Farming Customers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
farming customers primarily include local herb vendors. For the fiscal year ended March, 31, 2024, we had not harvested or sold any herbs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
and Promotion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to our marketing and promotion activities is incorporated by reference from our <a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Marketing
and Promotion.&#8221; The updates relating to our marketing and promotion during the fiscal year of 2024 is as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended March 31, 2024, approximately 39% of our customers used their rewards cards to make purchases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Logistics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to our logistics is incorporated by reference from our <a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Logistics.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Suppliers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently source retail products from approximately 26 suppliers, including trading companies and direct manufacturers. We source wholesale
products from approximately 401 suppliers, including many of those that provide our retail products. For the fiscal year ended March
31, 2024, one supplier, HuaDong Pharmaceutical Co., Ltd. accounted for thirteen point five percent (13.5%) of our total purchases. The
suppliers are neither related to nor affiliated with us. For the fiscal year ended March 31, 2023, one supplier, HuaDong Pharmaceutical
Co., Ltd. accounted for fifteen point eight percent (15.8%) of our total purchases. The suppliers are neither related to nor affiliated
with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that competitive sources are readily available for substantially all of the products we require for our retail and wholesale
businesses. As such, we believe that we can change suppliers without any material interruption to our business. To date, we have not
experienced any significant difficulty in sourcing our suppliers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quality
Control</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to our quality control is incorporated by reference from our <a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Quality Control.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to the competition we face is incorporated by reference from our <a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Competition.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to the our intellectual property is incorporated by reference from our <a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Intellectual
Property.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had 1,003 employees combined in our retail and wholesale operations, consisting of 939 full-time and 64 part-time
employees. The number of employees for each area of operations, and such employees as a percentage of our total workforce, are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of March&#160;31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Employees</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Percentage</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-pharmacist store staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">46.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Pharmacists</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Management - non-pharmacists</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Physicians</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Non-physician clinic staff</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Wholesale - non-warehouse</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Online pharmacy - technicians</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Online pharmacy - non-technicians</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,003</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.00</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
closely monitor the quality of the service provided by our employees at all levels, including in-store pharmacists and store staff who
directly interact with our customers. We provide extensive training for newly recruited employees in the first three months of their
employment. The training is designed to encompass a number of areas, such as knowledge of our products and effective customer service.
In addition, we regularly carry out training programs on medicinal information, nutritional information, and selling skills for our store
staff and in-store pharmacists. We believe these programs have played an important role in strengthening the capabilities of our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
drug manufacturers also pay us to have their representatives in our drugstores, and accordingly, we train them under our store policies
and procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relevant
PRC Regulations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to the relevant PRC Regulations is incorporated by reference from our <a href="http://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Relevant PRC
Regulations.&#8221; Please also refer to the above Risk Factor sections &#8220;Risks Related to Our Corporate Structure&#8221; and &#8220;Risks
Related to Doing Business in China&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Distribution</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, the accumulated balance of our statutory reserve funds reserves amounted to $1.31 million, and the accumulated losses
of our consolidated PRC entities amounted to $40.85 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
relating to the environmental matters is incorporated by reference from our <a href="https://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023_chinajojo.htm">2023 Annual Report</a> under the caption &#8220;Environmental
Matters.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
ORGANIZATIONAL STRUCTURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following diagram illustrates our current corporate structure as of July 30, 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img alt="" src="image_001.jpg"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the status of the registered capital of our PRC subsidiaries and controlled companies as of the date of this report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 45%; text-align: left">Entity Name</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center">Entity <br/>Type</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center">Registered <br/>Capital</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center">Registered <br/>Capital Paid</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: center">Due Date <br/>for&#160;Unpaid <br/>Registered <br/>Capital</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jiutong Medical</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD 2,600,000</td><td>&#160;</td>
    <td style="text-align: center">USD 2,600,000</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuzhou Clinic</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">USD&#160;733,500</td><td>&#160;</td>
    <td style="text-align: center">USD&#160;733,500</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuzhou Service</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">USD 73,350</td><td>&#160;</td>
    <td style="text-align: center">USD 73,350</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jiuxin Management</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD&#160;30,000,000</td><td>&#160;</td>
    <td style="text-align: center">USD&#160;27,500,000</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD 1,564,000</td><td>&#160;</td>
    <td style="text-align: center">USD 1,564,000</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Qianhong Agriculture</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD&#160;1,497,000</td><td>&#160;</td>
    <td style="text-align: center">USD&#160;1,497,000</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Shouantang Technology</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD 11,000,000</td><td>&#160;</td>
    <td style="text-align: center">USD 11,000,000</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shouantang Bio</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD 162,900</td><td>&#160;</td>
    <td style="text-align: center">USD 162,900</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiuyi Technology</td><td>&#160;</td>
    <td style="text-align: center">Subsidiary</td><td>&#160;</td>
    <td style="text-align: center">USD 5,000,000</td><td>&#160;</td>
    <td style="text-align: center">USD 2,500,000</td><td>&#160;</td>
    <td style="text-align: center">September 25, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Linjia Medical</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">USD 2,979,460</td><td>&#160;</td>
    <td style="text-align: center">USD 1,489,730</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Hongtong Service</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">USD 14,615</td><td>&#160;</td>
    <td style="text-align: center">USD 0</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jiuzhen Health</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">USD 14,615</td><td>&#160;</td>
    <td style="text-align: center">USD 14,615</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Shouantang Clinic</td><td>&#160;</td>
    <td style="text-align: center">VIE</td><td>&#160;</td>
    <td style="text-align: center">USD 14,615</td><td>&#160;</td>
    <td style="text-align: center">USD 14,615</td><td>&#160;</td>
    <td style="text-align: center">N/A</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is the tabular form condensed consolidating schedule depicting the financial position, cash flows and results of operations
for the parent, the consolidated variable interest entity, and any consolidation adjustments separately - as of and for the years ending
March 31, 2024, 2023 and 2022.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidating
Statements of Income Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">123,994,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">107,536,353</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(76,989,329</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,541,077</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118,779,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,642,435</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,989,329</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,432,529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,214,630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,893,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,108,548</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,676</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,769,364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,057,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,189,060</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,643,111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,676</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,163,213</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,534,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(808</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,194,566</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">558,557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(636,817</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,363</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,862</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,484</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(707,937</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,708,881</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,234,242</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">235,936,050</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(87,124,074</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">148,811,976</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,739</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,729,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,195,959</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,531,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,206,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,280,464</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,534,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,200,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,798,397</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(327,313</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,205,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,534,233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,198,791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,591,557</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,925,383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,261,118</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,442,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,147</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,541</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394,541</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(10,534,880</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,459,909</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,543,186</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,138,777</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">181,179</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">244,933,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(80,722,148</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,392,555</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,732</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,169,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80,478,391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,873,515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,553</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,764,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(243,757</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,519,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,479,243</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,583,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,212,930</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,042</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,480,796</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(819,438</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(350,614</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,693,890</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,931</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">617,439</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">595,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,099,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,099,726</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(43,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,502,974</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,301,478</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(350,614</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,198,366</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidating
Balance Sheets Information&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,718,328</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64,561,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(48,278,463</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">95,057,090</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(58,302,810</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,398,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,268,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,399,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,763,953</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,931,574</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,313,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,618,235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,682,362</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(58,302,810</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,398,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,268,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,995,486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,360,095</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,358,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,466,953</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,955,205</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,613,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,677,733</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,677,819</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,005,227</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,755,517</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,068,683</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(73,507,246</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,358,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,319,801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,707,005</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(59,677,805</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,293,137</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,820</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,799,950</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77,392,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(36,233,569</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90,970,602</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,763,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,027,715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,103,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,935,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,303,450</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,296,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,064,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,890,096</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,482,790</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,763,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,027,715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,103,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167,166</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,535,234</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,775,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,730,804</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,039,408</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,057,262</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,052,444</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,671,335</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,095,498</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,993,830</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,512,355</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69,273,018</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,775,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,772,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,711,162</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,168,951</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,667,152</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Total assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">46,700</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,796,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">90,528,406</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(39,987,233</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">106,384,209</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,578,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,576,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,864,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,782,980</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,645,423</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,676,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,423,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,694,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,451,894</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,578,210</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,576,098</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,864,555</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,414,047</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,448,396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,624,910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,899,305</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,441,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,280,741</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,003,498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,136,455</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,669,391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,496,890</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(831,757</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,134,493</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,624,910</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,220,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,336,149</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,770,213</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,738,786</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidating
Cash Flows Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,596,084</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,966,213</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,644,328</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,118,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,155,439</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,156</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,031,694</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,039,850</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,639,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,113,399</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,974,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,503,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,004,291</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,264</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,174,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,622,297</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,505,475</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,516</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,212,606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,472,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,303,527</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,359,880</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,882,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,892,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,065,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,283,513</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(311,719</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,378</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(316,097</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,325,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,320,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,223,285</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,529</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,366,156</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(948,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,646,017</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,535,478</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,880</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,151,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,768,932</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">PARENT</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">SUBSIDIARIES</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">VIE</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Eliminations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(43,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,283,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,638,849</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,012,974</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,385,973</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(63,291</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(242,847</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(306,138</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net cash (used in)/provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,256,428</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,810,723</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,807,397</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,836,898</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,499,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(205,577</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,522,146</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,537,168</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,157,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">666,933</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
PROPERTY, PLANTS AND EQUIPMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are headquartered in Hangzhou, China. We own three properties. Additionally, our current leased properties are as follows:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Location</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Size<br/>
    (square meters)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    expiration <br/>
    date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    executive office</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renxin
    Yaju Building 5 Floor 4</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gong
    Shu District,Hangzhou City, Zhejiang Province, China</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">184</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, 2034</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmacies
    (1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
    locations in Hangzhou, Zhejiang Province, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range&#160;from&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79
    to 1,713</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2022 to<br/>
    October 2033</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Farmland
    for herb cultivation (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qianhong
    Township, Hangzhou, Zhejiang Province, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">196,677</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    1, 2040</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land
    (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin&#8217;An
    District, Hangzhou, Zhejiang Province, China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,616</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    1, 2040</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the date of this report, we maintain operating leases in connection with our 127 pharmacies. See Note 11, &#8220;Long Term Deposits&#8221;.
    The leases do not contain any material escalating lease payments or contingent rental payment terms. We must negotiate with the landlords
    for an extension of the current leases or enter into new leases upon their termination, upon which our landlords may request a rent
    increase. Under applicable PRC law, we have priority over other potential lessees with respect to the leased store space on the same
    terms. We also do not expect any significant difficulties in renewing the existing leases upon their expiration, where desired. Our
    community stores are normally relatively small in size and the fixtures inside such stores are easily movable. As a result, we do
    not expect our drugstore operations to be materially and adversely affected by any failure to renew current leases or enter into
    new leases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    lease the land from the People&#8217;s Government of Qianhong Village under a 30-year lease entered in February 2010. The rent for
    the land was prepaid in full in May 2010. See Note 12, &#8220;Other Noncurrent Assets,&#8221; and Note 14, &#8220;Intangible Assets,&#8221;
    to the Financial Statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;&#160;</b></span></p><div>

</div><div><a id="k_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4A. UNRESOLVED STAFF COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;5.
OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A<i>.
</i>OPERATING RESULTS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our results of operations and financial condition for the fiscal years ended March 31, 2024, 2023
and 2022 should be read in conjunction with our financial statements and the notes to those financial statements that are included elsewhere
in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties,
such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the &#8220;Risk Factors,&#8221;
&#8220;Cautionary Notice Regarding Forward-Looking Statements&#8221; and &#8220;Description of Business&#8221; sections and elsewhere
in this report. We use words such as &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;continuing,&#8221;
&#8220;ongoing,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221;
&#8220;could,&#8221; &#8220;predict&#8221; and similar expressions to identify forward-looking statements. Although we believe the expectations
expressed in these forward-looking statements are based on reasonable assumptions within the bound of our knowledge of our business,
our actual results could differ materially from those discussed in these statements. Factors that could contribute to such differences
include, but are not limited to, those discussed in the &#8220;Risk Factors&#8221; section of this report. We undertake no obligation
to update publicly any forward-looking statements for any reason even if new information becomes available or other events occur in the
future other than in compliance with the SEC rules and regulations.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
financial statements are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States.
See &#8220;Exchange Rates&#8221; at the end of this section for information concerning the exchanges rates at which Renminbi (&#8220;RMB&#8221;)
were translated into U.S. Dollars (&#8220;USD&#8221; or &#8220;$&#8221;) at various pertinent dates and for pertinent periods.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently operate in four business segments in China: (1) retail drugstores, (2) online pharmacy, (3) wholesale of products similar to
those that we carry in our pharmacies, and (4) farming and selling herbs used for traditional Chinese medicine (&#8220;TCM&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
drugstores offer customers a wide variety of pharmaceutical products, including prescription and over-the-counter (&#8220;OTC&#8221;)
drugs, nutritional supplements, TCM, personal and family care products, medical devices, and convenience products, including consumable,
seasonal, and promotional items. Additionally, we have licensed doctors of both western medicine and TCM on site for consultation, examination
and treatment of common ailments at scheduled hours. During the year ended March 31, 2021, the Company sold its Lin&#8217;An Jiuzhou
Pharmacy Co., Ltd (&#8220;Lin&#8217;An Jiuzhou&#8221;), which runs ten stores in Linan City, to local investors for total proceeds of
$125,514. On the other side, we have been concentrating on new stores within Hangzhou metropolitan area. As of March 31, 2024, we had
127 pharmacies in Hangzhou city under the store brand of &#8220;Jiuzhou Grand Pharmacy&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
May 2010, we have also been selling certain OTC drugs, medical devices, nutritional supplements and other sundry products online. Our
online pharmacy sells through several third-party platforms such as Alibaba&#8217;s Tmall, JD.com and Amazon.com, and the Company&#8217;s
own platform all over China. In fiscal year 2020, in order to keep competitive in certain third-party platforms such as Tmall, we have
spent reasonable resources on marketing our products through these third-party platforms. Our sales through our own platform are primarily
generated by customers who use their private commercial medical insurances package.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate a wholesale business through Jiuxin Medicine distributing third-party pharmaceutical products (similar to those carried by our
pharmacies) primarily to trading companies and other local drugstores in China. We also farm certain herbs used in TCM but have not made
sales in the year ended March 31, 2024.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the COVID-19 outbreak, we experienced a decline in the number of customer visits at our stores. To avoid face-to-face contact, customers
tended to shop online. In order to keep pace with customers&#8217; change in their ways of shopping, we strengthened our O2O service
team, which takes orders online, i.e. via mobile phone app, and delivers products to local community from our stores. The spread of the
disease has been effectively controlled in China. In December 2022, the local government has eased its control and the demand on medical
products surged therefrom. Currently, COVID-19 has no significant impact on our operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our audited consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America, we are required to make judgments, estimates and assumptions that affect: (i) the reported amounts of our assets and liabilities;
(ii) the disclosure of our contingent assets and liabilities at the end of each reporting period; and (iii) the reported amounts of revenue
and expenses during each reporting period. We continually evaluate these estimates based on our own historical experience, knowledge
and assessment of current business and other conditions, our expectations regarding the future based on available information and reasonable
assumptions, which together form our basis for making judgments about matters that are not readily apparent from other sources. Since
the use of estimates is an integral component of the financial reporting process, our actual results could differ materially from those
estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any reasonable deviation from those judgments and estimates would not have a material impact on our financial condition
or results of operations. To the extent that the estimates used differ from actual results, however, adjustments to the statement of
operations and corresponding balance sheet accounts would be necessary. These adjustments would be made in future financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
reading our financial statements, you should consider: (i) our critical accounting policies; (ii) the judgment and other uncertainties
affecting the application of such policies; and (iii) the sensitivity of reported results to changes in conditions and assumptions.&#160;The
critical accounting policies and related judgments and estimates used to prepare our financial statements are identified in Note 2 to
our audited consolidated financial statements accompanying in this report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
recognition</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued ASU No. 2014-09, which creates Topic 606, Revenue from Contracts with Customers. The new guidance outlines
a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The core principle
of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount
that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. Additionally, the
guidance requires improved disclosure to help users of financial statements better understand the nature, amount, timing, and uncertainty
of revenue that is recognized. The new guidance supersedes most current revenue recognition guidance, including industry-specific guidance.
The standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting
period, and permits early adoption on a limited basis. The update permits the use of either the retrospective or cumulative effect transition
method. On April 1, 2018, we adopted the guidance in ASC 606 and all the related amendments and applied the new revenue standard to all
contracts using the modified retrospective method. Based on the new standard our revenue recognition policies related to membership rewards
programs has changed. Membership rewards, usually membership points, are accumulated by customers based on their historical spending
levels. The Company has determined that there is an additional performance obligation to those customers at the time of the initial transaction.
The customers can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period,
unredeemed membership rewards are reflected as a contract liability. The adoption of the new revenue standard was not material and is
not expected to be material to our net income on an ongoing basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of definite-lived intangible assets</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate that the
carrying value of an asset may not be recoverable. These long-lived assets are grouped and evaluated for impairment at the lowest level
at which individual cash flows can be identified. When evaluating these long-lived assets for potential impairment, the Company first
compares the carrying amount of the asset group to the asset group&#8217;s estimated future cash flows (undiscounted and without interest
charges). If the estimated future cash flows are less than that carrying amount of the asset group, an impairment loss calculation is
prepared. The impairment loss calculation compares the carrying amount of the asset group to the asset group&#8217;s estimated future
cash flows (discounted and with interest charges). If required, an impairment loss is recorded for the portion of the asset group&#8217;s
carrying value that exceeds the asset group&#8217;s estimated future cash flows (discounted and with interest charges).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
long-lived asset impairment loss calculation contains uncertainty since management must use judgment to estimate each asset group&#8217;s
future sales, profitability and cash flows. When preparing these estimates, the Company considers historical results and current operating
trends and consolidated sales, profitability and cash flow results and forecasts. These estimates can be affected by a number of factors
including, but not limited to, general economic and regulatory conditions, efforts of third party organizations to reduce their prescription
drug costs and/or increased member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo
trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060. Based on the evaluation
of the forest land use rights, the Company did not record an impairment for the years ended March 31, 2024 and 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of years ended March 31, 2024, 2023 and 2022</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the years ended March 31, 2024, 2023 and 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="text-align: center; border-bottom: Black 1.5pt solid">Years ended December&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Percentage of<br/> total revenue</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Percentage of <br/> total revenue</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Percentage of <br/> total revenue</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -9pt; padding-left: 9pt">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,541,077</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">148,811,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,392,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">123,432,529</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,531,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,873,515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31,108,548</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,280,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36,519,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27,385,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,177,163</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,876,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,257,524</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,668,684</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,187,176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,360,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">148,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,534,563</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(20,925,383</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,693,890</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other Expense, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(636,817</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">181,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">595,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Income tax expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">394,541</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,099,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,234,242</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21,138,777</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,198,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.9</td><td style="text-align: left">)%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
by Segment</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of years ended March 31, 2024 and 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table breaks down the revenue for our four business segments for the years ended March 31, 2024 and 2023:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">For the years ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">% of <br/> total revenue</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">% of<br/> total revenue</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">Variance by <br/> amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid">% of <br/> change</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from retail drugstores</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,678,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">49.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83,351,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,673,298</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9.2</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from online sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,857,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,385,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(527,206</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from wholesale business</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,004,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,075,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,929,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue from farming business</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,541,077</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,811,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,729,101</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.8</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail
drugstores sales, which accounted for approximately 49.0% of total revenue for the year ended March 31, 2024, decreased by $7,673,298,
or 9.2% compared to the year ended March 31, 2023, to $75,678,470. Same-store sales decreased by approximately $9,071,271 or 10.9%, while
new stores contributed approximately $1,397,972 in revenue in the year ended March 31, 2024. However, after removing the impact of exchange
rate fluctuation, the actual retail drugstores sales decreased 5.0%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decrease in our retail
drugstore sales is primarily due to local consumption cutback, extremely competitive market and the temporary surge of sale in the second
half of fiscal 2023, which is nonrecurring and is due to Chinese government&#8217;s sanction lift on COVID-19.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the economy slowdown, local people tend to be more frugal and spend less. Except for prescription medicines, the sale of other products
such as nutritional supplements and upscale merchandises used as gifts decreased. Unless the economy recovers quickly, the retail sales
may continue to slow down.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
retail drugstore market has become saturated in China. In Hangzhou City, over 4,000 drugstores, including chain stores and single stores,
make the city one of the most competitive drugstore markets in China. The local population per store becomes as low as 2,000. As such,
the sales per store were negatively affected. In order to keep competitive, we have to adjust our product category or lower our prices
continually, therefore, our store sales decreased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the second half of 2023, the government lifted the sanction on Covid 19. People were no longer quarantined and were able to travel, so
we quickly experienced a Covid 19 outbreak. Because people had not prepared enough preventive and therapeutic medicines, they flooded
into local drugstores for medicines. Our retail sales surged in that time period. However, the increase was temporary and we were able
to achieve the same level of sales in fiscal 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
new stores have also contributed additional sales. Our store count is 114 at March 31, 2023 and 127 at March 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
online pharmacy sales decreased by approximately $527,206 or 1.6% for the year ended March 31, 2024, as compared to the year ended March
31, 2023. The decrease was primarily caused by a decrease in sales via e-commerce platforms such as JD and Pinduoduo. Because the online
prices are transparent, to be competitive in online sales, we have to keep low prices. More competitors came into the online retail sales
market. As we do not have dominating power such as lowest prices or exclusive products, we may not be able to improve our sales significantly
in the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale
revenue increased by $13,929,605 or 42.1%. In the year ended March 31, 2024, Online platforms such as Pharmacist Help, Yiyao Help and
Yao Help have become popular ways to transact medical products by bulk. The platforms attract a plenty of buyers and sellers, so both
parties have extended opportunities to expose themselves. We have spent significant efforts in exploring these buyers with certain products
at reasonable prices as a result, we are able to attract more buyers and promote our sales. We believe that selling on the modern wholesale
platform may be a new growth point. Therefore, we are actively looking for potential acquisition targets with trading platform to strengthen
our wholesale business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the years ended March 31, 2024 and 2023, we have not harvested and generated revenue from our farming business. We planted ginkgo trees
during the year ended March 31, 2013. A ginkgo tree may have a growth period of up to twenty years before it is mature enough for harvest.
Usually, the longer it grows the more valuable it becomes. We plan to continue cultivating the trees in order to maximize their market
value in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of years ended March 31, 2023 and 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table breaks down the revenue for our four business segments for the years ended March 31, 2023 and 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid">For the years ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">% of <br/> total <br/> revenue</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">% of<br/> total <br/> revenue</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Variance by <br/> amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">% of <br/> change</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from retail drugstores</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83,351,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">84,228,492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">51.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(876,724</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from online sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,385,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,219,364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,165,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revenue from wholesale business</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,075,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,944,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,869,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33.8</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Revenue from farming business</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,811,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">164,392,555</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(15,580,579</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(9.5</td><td style="padding-bottom: 4pt; text-align: left">)%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail
drugstores sales, which accounted for approximately 56.0% of total revenue for the year ended March 31, 2023, decreased by $876,724 or
1.0% compared to the year ended March 31, 2022, to $83,351,768. Same-store sales decreased by approximately $1,569,549, or 1.9%, while
new stores contributed approximately $692,824 in revenue in the year ended March 31, 2023.However, after removing the impact of exchange
rate fluctuation, the actual retail drugstores sales increased 5.6%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual increase in our retail drugstore sales is primarily due to continuous efforts in promoting non-NHSA covered products, close cooperation
with major suppliers, and contribution from the new store sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to stricter budget control on medical reimbursement program from local National Healthcare Security Administration (&#8220;NHSA&#8221;)
and competitive market condition, we spent significant efforts in selecting and replacing our merchandises at stores. To minimize the
effect from local NHSA&#8217;s budget control, we expand the categories of our merchandises. As a result, we were able to depend less
on the medical reimbursement program and increase our cash sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to fight against our competitors, we have been closely working with our suppliers to conduct a series of market promotions
in local communities. As a major player in local retail pharmaceutical market, our stores are densely located in major communities in
Hangzhou City. As a prime local sales network, we were able to attract large pharmaceutical manufacturers to support us in performing
a series of sale campaigns, in which large manufacturers provide ads, prices cutback and specialist support. As a result, our sales were
able to increase slightly although NHSA tightened its budget.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
new stores have also contributed additional sales. Our store count is 111 at March 31, 2022 and 114 at March 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
online pharmacy sales increased by approximately $2,165,725, or 7.2% for the year ended March 31, 2023, as compared to the year ended
March 31, 2022. The increase was primarily caused by an increase in sales via e-commerce platforms such as Tmall. We maintained a membership
care program targeted at chronic disease customers. We have closely interacted with our members via WeChat by providing healthcare knowledge
and reminding our customers to refill medicine. By implementing a personalized customer care program, we were able to promote our sales.
Additionally, we increasingly cooperate with certain manufacturers to promote their products such as Dendrobium Candidum. These manufacturers
reward us with lower supply prices and more advertising supports. As a result, we are able to better promote our sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription
drugs used to be prohibited from sales online due to safety concern. However, because the nation has lifted the ban order, online prescription
drug sales become popular. As a result, the sale of prescription drugs was $10,606,244 in the year ended March 31, 2023 as compared to
$10,331,652 in the year ended March 31, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale
revenue decreased by $16,869,580 or 33.8%. Hospitals are still the dominant drug distributors in China. Local hospitals usually have
strong ties with their existing suppliers and we have not been able to make significant progress in becoming a major supplier to local
hospitals.&#160;As a relatively small wholesale distributor in pharmaceutical products, our sales are subject to significant variance.
Wholesale business usually carries low gross profit margin. However, we incurred labor, logistic and tax cost for our wholesale business.
As a result, to keep reasonable profitability, we abandoned certain wholesales at low gross profit margin in the year ended March 31,
2023.&#160;As a result, the wholesale revenue declined.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the years ended March 31, 2023 and 2022, we have not harvested and generated revenue from our farming business. We planted ginkgo trees
during the year ended March 31, 2013. A ginkgo tree may have a growth period of up to twenty years before it is mature enough for harvest.
Usually, the longer it grows the more valuable it becomes. We plan to continue cultivating the trees in order to maximize their market
value in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gross
Profit</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
average gross margins for each of our four business segments for the years ended March 31, 2024, 2023 and 2022 are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">Year ended March&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Average gross margin for retail drugstores</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Average gross margin for online sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Average gross margin for wholesale business</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Average gross margin for farming business</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of years ended March 31, 2024 and 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit decreased by $3,171,916&#160;or 9.3% period over period primarily as a result of a decrease in gross profit provided by retail
drugstores, which decreased significantly in the year ended March 31, 2024. At the same time, gross margin decreased from 23.0% to 20.1%
due to lower retail drugstores profit margins.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail
gross margins decreased. In order to control its budget, the local municipal health insurance agency adjusted down certain prices of
drugs reimbursed by it from time to time. We actively negotiated with suppliers to lower the purchase price as well, so we can keep reasonable
profit margin. However, certain pharmaceutical giant companies are not willing to lower their prices. On the other side, as overall drugstore
market becomes more competitive, we had to lower our prices to keep our market shares. Unless the economy quickly recovers, we do not
expect to keep a high retail profit margin.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
margin of online pharmacy sales decreased only slightly primarily due to the competitive market. Although we have spent significant efforts
in promoting our profit margin, due to the competitive market, we have to keep competitive prices as online customers are very sensitive
to prices, which are easily comparable among different website vendors. We do not expect significant increase in gross margin our online
sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale
gross margin slightly decreased primarily due to certain products with low profit margin we carried and sold to certain pharmaceutical
vendors. In the year ended March 31, 2024,we have been actively looking for new buyers in certain emerging new platforms such as . As
we have price advantages in quite a few products, we have attracted quite a few customers such as other local drugstores and clinics
across the country. In order to attract these customers, we offered competitive prices. However, as we accumulate the sale volume by
selling to more customers, we may negotiate and obtain lower purchase prices from our vendors. Eventually, we may be able to increase
our wholesale profit margin.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of years ended March 31, 2023 and 2022</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit decreased by $2,238,576&#160;or 6.1% period over period primarily as a result of a decrease in gross profit provided by wholesale
business, which decreased significantly in the year ended March 31, 2023. At the same time, gross margin increased from 22.2% to 23.0%
due to higher retail drugstores profit margins.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail
gross margins increased slightly primarily reflecting our stable and balanced operation. As described in detail below, in order to increase
the gross margin of our store sales, we have introduced certain popular products with high profit margin and lowered the sale percentile
of DTC (Direct-to-Customer) products. However, extremely high profit margin products may hinder certain customers. As a matter of fact,
certain popular brand products usually do not carry high profit margin but are crucial to retain customers. In other words, extremely
high profit margin may have negative effect on overall sales volume. As a result, we try to balance our sales profit margin and sales
volume.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
margin of online pharmacy sales increased only slightly primarily due to the competitive market. Although we have spent significant efforts
in promoting our profit margin, due to the competitive market, we have to keep competitive prices as online customers are very sensitive
to prices, which are easily comparable among different website vendors. We do not expect significant increase in gross margin our online
sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale
gross margin decreased primarily due to various products with different profit margin we carried and sold to certain pharmaceutical vendors.
Although we have attempted to market our products to major local hospitals and other pharmacies, we have not been able to make significant
progress. We are also actively looking at possible acquisition opportunities to increase our customer base in the wholesale business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Selling
and Marketing Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales and marketing expenses
for the year ended March 31, 2024 decreased by $1,791,576 or 6.1% as compared to the year ended March 31, 2023, primarily due to a decrease
in expense related to Normal Nucleic Acid Testing (&#8220;NNAT&#8221;) requested by local government and a decrease in the sales and marketing
expenses. In fiscal 2023, in response to the local government, we set up NNAT outposts adjacent to our stores. We subsidized our staff
with each test they performed. As a comparison, we incurred no such expense in fiscal 2024. As a result, the expense related to NNAT decreased
by approximately $0.88 million period over period. The sales and marketing expenses decreased by approximately $0.87 million, which primarily
attributable to the decrease in fee charged by distribution channels resulting from the decrease in retail drugstores and online pharmacy
sales. Overall, such expenses as a percentage of our revenue were 17.7% and 19.6% respectively, in the years ended March 31, 2024 and
2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales and marketing expenses
for the year ended March 31, 2023 decreased by $1,699,796 or 5.5% as compared to the year ended March 31, 2022, primarily due to decrease
in rent, offset by increase in the sales and marketing expenses. Because the COVID-19 National Control continued to impose restrictions
in 2022 and impeded the local business significantly, we made significant efforts in renegotiating our rental agreements. As a result,
the rent expense decreased by approximately $3.39 million. The sales and marketing expenses increased by approximately $1.91 million,
which primarily reflects the increase in fee charged by distribution channels such as Tmall and JD as a percentage of online pharmacy
sales. Overall, such expenses as a percentage of our revenue were 19.6% and 18.8% respectively, in the years ended March 31, 2023 and
2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for the year ended March 31, 2024 decreased by $8,411,160 or 53.7% as compared to the year ended March 31,
2023, primarily due to the decrease in bad debt expense.&#160;Such expenses as a percentage of revenue decreased to 4.7% from 10.5% for
the same period a year ago. In the year ended March 31, 2024, we recorded a reduction of $0.22 million in the allowance account for bad
debts as compared to the increase of $7.58 million in the allowance account for bad debts in FY2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for the year ended March 31, 2023 increased by $7,481,508 or 91.4% as compared to the year ended March 31,
2022, primarily due to the increase in bad debt expense.&#160;Such expenses as a percentage of revenue increased to 10.5% from 5.0% for
the same period a year ago. In the year ended March 31, 2023, we recorded an increase in the allowance for bad debts of $7.58 million
as compared to the increase in the allowance for bad debts of $1.32 million in FY2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-based
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded stock-based compensation of $0, $10,360,000 and $0 for the years ended March 31, 2024, 2023 and 2022. In April and December
2022, we issued a total of 3,000,000 shares of ordinary shares and recorded stock-based compensation of approximately $10.36 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-lived Assets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recorded an impairment of long-lived assets of $0, $0 and $148,795 for the year ended March 31, 2024, 2023 and 2022. In the year ended
March 31, 2024, we evaluated the forest land use rights and did not record an impairment. In the year ended March 31, 2023, we evaluated
the forest land use rights and did not record an impairment. In the year ended March 31, 2022, we evaluated the forest land use rights
and recorded an impairment of $148,795.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loss
from Operations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, loss from operations was $3,534,563, $20,925,383 and $2,693,890 for the years ended March 31, 2024, 2023 and 2022,
respectively. Our operating margin for the year ended March 31, 2024, 2023 and 2022 was (2.3) %, (14.1) % and (1.6) %, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
income tax expense for the year ended March 31, 2024 decreased by $331,679 as compared to the year ended March 31, 2023 due to a decrease
in the effective rate resulting from an increase in profits in several business lines.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
income tax expense for the year ended March 31, 2023 decreased by $705,185 as compared to the year ended March 31, 2022 due to an increase
in the effective rate resulting from a decrease in profits in several business lines.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
Loss</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, net loss was $4,234,242, $21,138,777 and $3,198,366 in the years ended March 31, 2024, 2023 and 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts
receivable</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable, which are unsecured, are stated at the amount we expect to collect. We continuously monitor collections and payments from
our customers (our distributors) and maintain a provision for estimated credit losses.&#160;To prepare for potential loss in such accounts,
we made corresponding reserves.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
accounts receivable aging was as follows for the periods described below:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">From date of invoice to customer</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Herb <br/> farming</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total <br/> amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: -9pt; padding-left: 9pt">1- 3 months</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,663,872</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,682,630</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,225,356</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">14,571,858</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">4- 6 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,806</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">909,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">932,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,844,798</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">7- 12 months</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,589</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,657</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Over one year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(704,482</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(112,273</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(106,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(923,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total accounts receivable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,231,014</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,525,147</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,067,942</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,824,103</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable from our retail business mainly consist of reimbursements from local government health insurance bureaus and commercial health
insurance programs.&#160;In the year ended March 31, 2024, we wrote off an approximately $56,170 collectible from provincial and Hangzhou
City government insurance, as such amounts have been determined by the health insurance bureaus to be unqualified for reimbursement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivables from our online pharmacy business mainly consist of receivables from insurance company and a service company handling with
insurance companies. As we continue to expand our business with commercial insurance company, our receivables from them increased. Additionally,
certain receivables are from third-party platforms such as JD.com where we sell products. Usually, the third-party platforms will collect
from customers ordering on their platforms and then reimburse us at a later date, such reimbursement periods times ranging from several
days to a month after orders are placed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable from our drug wholesale business consist of receivables from our customers such as pharmaceutical distributors and local drugstores
primarily in Zhejiang Province. In fiscal 2023, we accelerated collection of certain aged accounts from customers which we no longer
or rarely sold products to. By doing so, we are able to take better use of our cash. As a result, the overall reserve on wholesale accounts
receivables decreased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to March 31, 2024 and through June 30, 2024, we collected approximately $6.1 million in receivables relating to our drugstore business,
approximately $2.9 million in receivables relating to our online pharmacy business, approximately $5.4 million relating to our wholesale
business, and $0 relating to our herb farming business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advances
to suppliers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
to suppliers are mainly prepayments to secure certain products or services at favorable pricing.&#160;Since the acquisition of Jiuxin
Medicine, we have gradually transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only
purchases certain non-medical products such as sundry. As a result, our retail chain made few advances to suppliers as of March 31, 2024.
At the end of 2024 we had outstanding advances to suppliers with which we have ceased doing business. These advances have been fully
reserved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
to suppliers for our drug wholesale business consist of prepayments to our vendors such as pharmaceutical manufacturers and other distributors.&#160;We
typically receive products from vendors within three to nine months after making prepayments.&#160;We continuously monitor delivery from
and payments to our vendors while maintaining a provision for estimated credit losses based upon past experience and any supplier-specific
issues such as the discontinuation of inventory supply that have been identified.&#160;If we are having difficulty receiving products
from a vendor, we take the following steps: cease purchasing products from the vendor, ask for return of our prepayment promptly, and
if necessary, take legal action.&#160;If all of these steps are unsuccessful, management then determines whether or not the prepayments
should be reserved or written off. In fiscal 2024, in order to use our cash more efficiently, we accelerated the collection of deposits
from quite a few suppliers, especially aged accounts. We chose to only leave deposits with critical suppliers who supply large quantities
of merchandise. As a result, the outstanding advances to suppliers decreased dramatically.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Off-Balance Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Contractual
Obligations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual obligations:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="text-align: center; border-bottom: Black 1.5pt solid">Payments due by period</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Contractual obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Less than <br/> 1 year</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">1-3 years</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">3-5 years</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">More than<br/>
5 years</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 9pt">Short-term loan payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">276,997</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">276,997</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,676,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,676,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Long-term loan payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,953,332</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31,953,332</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Off-balance
Sheet Arrangements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any outstanding financial guarantees or commitments to guarantee the payment obligations of any third parties. We have not
entered into any derivative contracts that are indexed to our shares and classified as stockholder&#8217;s equity or that are not reflected
in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an
unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in
any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research
and development services with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
Rates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
subsidiaries, the VIEs and affiliated companies in the PRC maintain their books and records in RMB, the lawful currency of the PRC. In
general, for consolidation purposes, we translate their assets and&#160;liabilities into USD using the applicable exchange rates prevailing
at the balance sheet date, and the statement of income is translated at average exchange rates during the reporting period. Adjustments
resulting from the translation of&#160;their financial statements are recorded as accumulated&#160;other comprehensive income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exchange rates used to translate amounts in RMB into USD for the purposes of preparing the audited consolidated financial statements
or otherwise&#160;disclosed in this&#160;report were as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, <br/>
    2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, <br/>
    2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    31, <br/>
    2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 67%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    sheet items, except for the registered and paid-up capital, as of end of period/year</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD1:&#160;RMB&#160;7.2203</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD1:&#160;RMB&#160;6.8676</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD1:&#160;RMB&#160;6.3393</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    included in the statement of Operations and statement of cash flows for the period/ year ended</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD1:
    RMB 7.1671</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD1:
    RMB 6.8516</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD1:
    RMB&#160;6.4180</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that inflation has not had a material effect on our operations to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
LIQUIDITY AND CAPITAL RESOURCES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash flows for the periods indicated are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash&#160;used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,155,439</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,283,513</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,385,973</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,039,850</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(316,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(306,138</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,004,291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,366,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,836,898</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash&#160;used in operating activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2024 cash used in operating activities amounted to $(3,155,439), as compared to $(3,283,513) a year ago. The
change is primarily attributable to an increase in net income of $16,904,535, an increase in accounts receivable of $727,315, an increase
in cash provided by accounts payable of $4,236,698 and an increase in cash provided by other payables and accrued liabilities of $2,210,422,
offset by a decrease in bad debt direct write-off and provision of $6,789,437, a decrease in inventories and biological assets of $1,177,071
and a decrease in stock compensation of $10,360,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2023 cash used in operating activities amounted to $(3,283,513), as compared to $(5,385,793) a year ago. The
change is primarily attributable to a decrease in cash provided by inventories and biological assets of $2,045,648, a decrease in cash
provided by customer deposits of $1,714,057, a decrease in cash provided by net loss of $17,940,411 offset by an increase of $10,360,000
in stock compensation, an increase in cash provided by accounts payable of $5,323,538.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in investing activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2024, net cash used in investing activities amounted to $(2,039,850), as compared to $(316,097) provided by
investing activities a year ago. The change is primarily attributable to investment in a joint venture and purchases of long-term assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2023, net cash used in investing activities amounted to $(316,097), as compared to $(306,138) provided by investing
activities a year ago. The change is primarily attributable to purchases of long-term assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash provided by financing activities&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2024, net cash provided by financing activities amounted to $8,004,291, as compared to $2,366,156 a year ago.
The change is primarily due to notes payable and proceeds from short-term bank loan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended March 31, 2023, net cash provided by financing activities amounted to $2,366,156, as compared to $4,836,898 a year ago.
The change is primarily due to repayment of notes payable and proceeds from equity and debt financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had cash of approximately $32,874,171. Our total current assets as of March 31, 2024, were $69,682,362 and total
current liabilities were $74,360,095, which resulted in a working capital deficit of $4,677,733.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES, ETC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no research and development policy for the past three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
TREND INFORMATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
and Market Outlook</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for
the year ended March 31, 2024 that are reasonably likely to have a material and adverse effect on our net revenues, income, profitability,
liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results
of operations or financial conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
CRITICAL ACCOUNTING ESTIMATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion and analysis of our financial condition and results of operations are based upon our audited consolidated financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these audited
consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses. We evaluate our estimates on an ongoing basis, including those related to revenue recognition and income taxes.
We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances,
the results of which form the basis for making the judgments we make about the carrying values of our assets and liabilities that are
not readily apparent from other sources. Because these estimates can vary depending on the situation, actual results may differ from
the estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical accounting policies summarized in this section are discussed in further detail in the notes to the audited consolidated financial
statements appearing elsewhere in this annual report. Management believes that the application of these policies on a consistent basis
enables us to provide useful and reliable financial information about our operating results and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;&#160;</b></span></p><div>

</div><div><a id="k_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;6.
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
DIRECTORS AND SENIOR MANAGEMENT.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table identifies our current executive officers and directors as of the date of this report, their respective offices and positions,
and their respective dates of election or appointment:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Age(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    of<br/>
    Appointment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 23%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei
    Liu</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    17, 2009</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ming
    Zhao</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    1, 2011</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Li
    Qi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    23, 2009</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caroline
    Wang (2) (3) (4)</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangliang
    He (2) (3) (4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4, 2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genghua
    Gu (2) (3) (4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    28, 2014</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the date of this report.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Audit Committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Compensation Committee.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Nominating Committee.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Biographical
Information of Our Current Directors and Executive Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lei
Liu</b> has served as our Chief Executive Officer and Chairman of our Board of Directors since September 17, 2009. Mr. Liu is one of
the three founders of Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (&#8220;Jiuzhou Pharmacy&#8221;), Hangzhou Jiuzhou Clinic of Integrated
Traditional and Western Medicine (General Partnership) (&#8220;Jiuzhou Clinic&#8221;) and Hangzhou Jiuzhou Service &amp; Public Health
Service Co., Ltd. (&#8220;Jiuzhou Service&#8221;) (Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries
of Jiuzhou Pharmacy, collectively as &#8220;HJ Group&#8221;), and has been the executive director of Jiuzhou Pharmacy since September
2003 and the supervising director of Jiuzhou Service since November 2005. From December 1997 to August 2003, Mr. Liu worked in Tai He
Drugstore as a general manager. From September 1992 to November 1997, Mr. Liu was an administration official of Hangzhou Medical Junior
College, his alma mater, where he was also a researcher and an anatomy instructor from September 1983 to July 1992. Mr. Liu has been
a licensed researcher in the PRC since September 1988. As the founder and CEO responsible for our strategies and directions, Mr. Liu
has been valuable to us and our Board of Directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ming
Zhao</b> has served as our Chief Financial Officer since August 2011. From September 2010 to July 2011, Mr. Zhao was a senior manager
at CFO Oncall, Inc., a financial consulting firm providing CFO services to U.S.-listed, China-based publicly traded companies. From December
2006 through August 2010, Mr. Zhao was a senior auditor at Sherb &amp; Co., LLP. From January through June 2003, Mr. Zhao worked as a
financial analyst at Microsoft Corporation. Mr. Zhao is a licensed certified public accountant. He graduated with a bachelor&#8217;s
degree in accounting from Central University of Finance and Economic in Beijing in July 1999, and obtained a master&#8217;s degree in
professional accounting from the University of Washington in December 2002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Li
Qi</b> is one of the three founders of HJ Group. Ms. Qi had served as our secretary since October 23, 2009 to September 4, 2018, and
is currently the general manager of both Jiuzhou Pharmacy and Jiuzhou Service. From January 2000 to June 2003, Ms. Qi worked in Zhejiang
Yikang Drugstore as a general manager. From October 1991 to January 2000, Ms. Qi worked in the Branch Hospital of Hangzhou No. 1 People&#8217;s
Hospital as a nurse. Ms. Qi is a licensed TCM pharmacist in the PRC and is a 1991 graduate of Hangzhou Nurse School. As a founder and
general manager of our two subsidiaries overseeing our day-to-day corporate operations, Ms. Qi is qualified to serve on our Board of
Directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Caroline
Wang</b> has been a member of our Board since March 29, 2017. Ms. Wang has been a project manager with JC Group, a comprehensive industrial
financial group which serves the &#8220;city management&#8221;, performing internal audit and projects management for a variety of financial
products since October 2015. Prior to that, Ms. Wang served as a CFO assistant of Kandi Technologies Group, Inc. (Nasdaq: KNDI), a company
engaged in the research, development, manufacturing, and sales of vehicle products. She was mainly responsible for consolidation of financial
reports and internal control audits. From 2012 to 2015, Ms. Wang was an audit department assistant manager with KPMG Huazhen LLP Hangzhou
Branch, conducting financial report audits and internal control audits for listing companies and also providing audit services to pre-IPO
companies. None of these companies are related to or affiliated with the registrant. Ms. Wang holds a master&#8217;s degree in public
administration from the London School of Economics and Political Science, and a bachelor&#8217;s degree in finance from Beijing Language
and Culture University. The Board has determined that Ms. Wang has the qualification to serve as a member of the Board given her extensive
financial, accounting and auditing experience, as well as her English and Chinese bilingual capabilities to facilitate the Board&#8217;s
supervision of the management.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jiangliang
He</b>, has extensive experience as a professional attorney. He has served as a partner in Dentons China, a large law firm with a presence
in approximately 45 cities in China, since August 2008. From July 1997 to July 2008, he was a partner in the Zhejiang Jiuyao law firm.
From July 1984 to June 1997, he was a professor at Hangzhou School of Law. Mr. He received his bachelor&#8217;s degree in law from Beijing
University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Genghua
Gu</b> is a retired physician, professor and published scientific researcher in the field of stomatology. From 2003 to 2013, Dr. Gu was
a member of the Standing Committee of Zhejiang Province Political Consultative Conference. From 2000 to 2009, Dr. Gu was the Vice President
of the Women&#8217;s Hospital of Zhejiang University&#8217;s School of Medicine (the &#8220;School of Medicine&#8221;), where, in addition
to being a chief physician, professor and researcher, he was also in charge of logistics and financial control as part of the hospital&#8217;s
management. From 1998 to 2000, Dr. Gu was the Vice President of the Second Affiliate Hospital of the School of Medicine (the &#8220;Affiliate
Hospital&#8221;), where, in addition to his medical, teaching and research duties, he was also in charge of the hospital&#8217;s logistics.
From 1995 to 1998, Dr. Gu served as the Deputy Magistrate with the Shuichang County Government in Zhejiang Province, in charge of the
county&#8217;s culture, education and hygiene programs. From 1988 to 1995, Dr. Gu was the Head of the Medical Department at the Affiliate
Hospital and was involved in planning and management of the medical department. Dr. Gu served as an oral surgeon from 1977 to 1988 at
the Affiliate Hospital. Dr. Gu graduated from Shanghai Jiaotong University&#8217;s School of Medicine, Department of Stomatology in 1977.
The Board has determined that Dr. Gu should serve as a director given his extensive medical and scientific research experience, as well
as his government and hospital management and logistics experience.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among our officers and directors and those of our subsidiaries and affiliated companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Diversity</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating Committee does not have a formal policy with respect to diversity. However, the Board of Directors and the Nominating Committee
believe that it is essential that the members of the Board of Directors represent diverse viewpoints. In considering candidates for the
Board of Directors, the Board of Directors and the Nominating Committee consider the entirety of each candidate&#8217;s credentials in
the context of the factors mentioned above. The Company is currently in compliance with the diversity requirements of Nasdaq Rule 5605(f)
and 5606, with three female Asian directors and three male Asian directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    Diversity Matrix (as of the date of this annual report)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
    of Principal Executive Offices</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>China</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
    Private Issuer</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Yes</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
    Prohibited under Home Country Law</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
    Number of Directors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    I: Gender Identity</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Female</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-<br/>
    Binary</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not<br/>
    Disclose<br/>
    Gender</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td colspan="17" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    II: Demographic Background</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented
    Individual in Home Country Jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Demographic Background</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="k_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
COMPENSATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors and Executive Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive
officer and principal financial officer during the last two (2) fiscal years. No other executive officer received compensation in excess
of $100,000 during the fiscal year ended March 31, 2024 and 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="36" style="text-align: center; border-bottom: Black 1.5pt solid">Summary Compensation Table</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Name and Principal Position</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Fiscal Year <br/> ended <br/> March&#160;31,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Salary ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Bonus <br/> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Stock <br/> Awards <br/> ($)(1)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Option <br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Non-Equity <br/> Incentive Plan <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Nonqualified <br/> Deferred <br/> Compensation <br/> Earnings <br/> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">All Other <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lei Liu,</td><td style="width: 1%">&#160;</td>
    <td style="width: 6%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-0-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-0-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-0-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-0-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;-0-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">90,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">CEO&#160;(2)</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,691,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,781,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Ming Zhao,</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">CFO</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    the full fair value of stock issued during the applicable fiscal year for financial statement reporting purposes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary
    as reported is based on interbank exchange rate of RMB 6.8516 to $1.00 on March 31, 2023 and RMB 7.1671 to $1.00 on March 31, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements, Termination of Employment and Change-in-Control Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below, we currently have no employment agreements with any of our executive officers, nor any compensatory plans or arrangements
resulting from the resignation, retirement or any other termination of any of our executive officers, from a change-in-control, or from
a change in any executive officer&#8217;s responsibilities following a change-in-control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Agreement
with Ming Zhao</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Mr. Zhao dated as of August 1, 2011, under which Mr. Zhao is serving as our Chief Financial
Officer for a term of two years commencing August 1, 2011, for annual compensation of $100,000, payable in monthly installments, as well
as a one-time grant of 3,333 shares of our ordinary shares (the &#8220;Shares&#8221;) under our 2010 Equity Incentive Plan. The term
of his employment was extended verbally for another two (2) years with an amended annual compensation of $88,000 starting from October
2012. The term of this employment was extended verbally for another one (1) year automatically (unless providing prior notice otherwise)
with an annual compensation of $88,000 starting from October 2015. During his employment, Mr. Zhao is subject to certain restrictive
covenants, including (i) prohibition against engaging in any work that competes with us and our business and soliciting our customers,
potential customers and employees, and (ii) requirement to maintain our confidential information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Zhao&#8217;s employment agreement terminates upon his death or disability. If Mr. Zhao is unable to perform his duties for 60 days during
any 12 month period, we may terminate the employment agreement upon 30-day written notice. We may also terminate the employment agreement
for cause, upon notice if at any time Mr. Zhao commits (a) fraudulent, unlawful or grossly negligent conduct in connection with his employment
duties; (b) willful misconduct; (c) willful and continued failure to perform his duties; (d) any felony or any crime involving moral
turpitude; (e) any violation of any of our material policies; or (f) any material breach of any written agreement with us. Mr. Zhao may
terminate his employment agreement immediately upon written notice if we breach our agreement with him.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year Ended March 31, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="20" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    Awards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Awards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of<br/>
    securities<br/>
    underlying<br/>
    unexercised<br/>
    options<br/>
    exercisable</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity<br/>
    incentive plan <br/>
    awards: <br/>
    number of <br/>
    securities <br/>
    underlying <br/>
    unexercised <br/>
    options <br/>
    unexercisable</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity<br/>
    incentive<br/>
    plan awards:<br/>
 number of <br/>
    securities <br/>
    underlying <br/>
    unexercised <br/>
    unearned <br/>
    options</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    <br/>
    exercise <br/>
    price <br/>
    ($)</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    <br/>
    expiration <br/>
    date</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of<br/>
 shares <br/>
    or units <br/>
    of stock that<br/>
 have <br/>
    not <br/>
    vested</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market<br/>
    value of<br/>
    shares or<br/>
    units of<br/>
    stock that <br/>
    have not <br/>
    vested <br/>
    ($)</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity<br/>
    incentive<br/>
    plan awards:<br/>
    number of<br/>
    unearned<br/>
    shares,&#160;units<br/>
    or other<br/>
    rights that<br/>
    have not<br/>
    vested</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    incentive <br/>
    plan awards: <br/>
    market or<br/>
    payout <br/>
    value of<br/>
 unearned <br/>
    shares, units <br/>
    or other rights <br/>
    that have not<br/>
    vested <br/>
    ($)</span></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei
    Liu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ming&#160;Zhao</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Li
    Qi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Plan Category</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> securities <br/> to be <br/> issued <br/> upon <br/> exercise of <br/> outstanding <br/> options, <br/> warrants <br/> and rights</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- <br/> average <br/> exercise <br/> price of <br/> outstanding <br/> options, <br/> warrants <br/> and rights</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of securities <br/> remaining<br/> available <br/> for future issuance <br/> under equity <br/> compensation<br/> plans</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%; text-align: left; text-indent: -9pt; padding-left: 9pt">Equity compensation plans approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discussion
of Summary Compensation and Grants of Plan-based Awards Tables</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of certain material terms of our existing compensation plans and arrangements is set forth below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 21, 2010, our Board of Directors approved a stock incentive plan for officers, directors, employees, and consultants entitled
&#8220;China Jo-Jo Drugstores, Inc. 2010 Equity Incentive Plan&#8221; (the &#8220;Plan&#8221;). The maximum number of shares that may
be issued under the Plan is 168,750 shares of our ordinary shares. The Plan was approved by our shareholders at our annual meeting held
on November 2, 2010. On February 24, 2015, our Board of Directors adopted and approved Amendment No. 1 to the Plan to increase the number
of shares of the Company&#8217;s ordinary shares available for issuance thereunder from 168,750 share limit to 360,417 shares. Amendment
No. 1 was approved by the stockholders at the annual shareholders meeting on March 23, 2015. On January 27, 2016, our Board of Directors
adopted and approved Amendment No. 2 to the Plan to increase the number of shares of the Company&#8217;s ordinary shares available for
issuance thereunder from 360,417 share limit to 597,917 shares. Amendment No. 2 was approved by the stockholders at the annual shareholders
meeting on March 23, 2016. Under the Plan, the Company may issue ordinary shares and/or options to purchase ordinary shares to our officers,
directors, employees and consultants. The Plan is administered either by our Board of Directors or a committee that it designates comprising
of at least two (2) &#8220;non-employee&#8221; directors. The board (or the committee, if one is designated) has full and complete authority,
in its discretion, but subject to the express provisions of the Plan, to grant awards, to determine the number of awards to be granted
and the time or times at which awards shall be granted; to establish the terms and conditions upon which awards may be exercised; to
remove or adjust any restrictions and conditions upon awards; to specify, at the time of grant, provisions relating to exercisability
of awards and to accelerate or otherwise modify the exercisability of any awards; and to adopt such rules and regulations and to make
all other determinations deemed necessary or desirable for the administration of the Plan. On February 14, 2017, our Board of Directors
adopted and approved Amendment No. 3 to the Plan to increase the number of shares of the Company&#8217;s ordinary shares available for
issuance thereunder from 597,917 share limit to 808,039 shares. Amendment No. 3 was approved by the stockholders at the annual shareholders
meeting on March 29, 2017. On March 26, 2018, the shareholders of the Company approved the Amendment No. 4 to the Plan which increased
the total shares of ordinary shares available for issuance thereunder to 1,016,372. On June 30, 2018, the Compensation Committee of the
Board approved the Amendment No. 5 to the Plan as The Tax Cuts and Jobs Act of 2017 removed the 162(m) qualified performance based compensation
exemption to the $1 million cap on deductions for compensation to covered executives. Section 1.3.2 was in the Plan to permit grants
under the Plan to fit within that exemption. As that exemption no longer applies for grants made in 2018 or thereafter, the Plan had
been amended to remove the provisions intended to comply with that exemption, including the one in Section 1.3.2. of the Plan. On March
5, 2020, the shareholders of the Company approved the Amended and Restated 2010 Equity Incentive Plan, which in addition to the incorporation
of the Amendment No. 4 and Amendment No. 5 to the Plan, clarified the term of the Plan in order to render the Plan being available for
incentive stock options grants in the future and approved the proposal of adding a ten-year term to the Plan. The Plan, effective since
November 2, 2010, shall terminate automatically on January 14, 2030 (the tenth anniversary of the Board&#8217;s approval of this Plan),
unless terminated earlier by the Board, except with respect to Awards then outstanding. The Plan, as amended and restated, has authorized,
with the stockholders&#8217; approval previously obtained, to reserve a total of 1,016,372 shares of our ordinary shares for issuance
under the Plan. As of March 31, 2024, there were 0 ordinary share available for future issuance under the Plan.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides compensation information for our directors during the fiscal year ended March 31, 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="32" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Compensation Table</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fiscal&#160;Year <br/>
    ended <br/>
    March&#160;31,</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    Earned <br/>
    or Paid in <br/>
    Cash <br/>
    ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    <br/>
    Awards <br/>
    ($)(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    <br/>
    Awards <br/>
    ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Equity
    <br/>
    Incentive Plan <br/>
    Compensation <br/>
    ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonqualified
    <br/>
    Deferred<br/>
    Compensation<br/>
    Earnings <br/>
    ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other <br/>
    Compensation <br/>
    ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    <br/>
    ($)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei
    Liu (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Li
    Qi (2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caroline
    Wang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,162</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,162</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genghua&#160;Gu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangliang
    He</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pingfan
    Wu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,757</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-0-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,757</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
    dollar amount expensed by the Company during the applicable fiscal year for financial statement reporting purposes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
    is reflected in the Summary Compensation Table on page 60 above.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 31, 2024, Ms. Pingfan Wu had resigned from her position as a member of the board of directors (the &#8220;Board&#8221;) due to
    personal reasons. The resignation of Ms. Wu did not result from any disagreement with the Company on any matter relating to the Company&#8217;s
    business operations, financial reporting or controls, policies or practices</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have an established policy to provide compensation to members of our Board of Directors for their services in that capacity,
although we have entered into certain agreements with some of our directors as described below. We intend to develop such a policy in
the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Agreement
with Genghua Gu</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2013, we entered into an agreement with Dr. Gu in the form of a director offer letter, pursuant to which we have agreed to
compensate him $6,000 annually for his services, payable in monthly installments on the last day of each month. Additionally, he is entitled
to be included as an insured under our directors and officers insurance policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Agreement
with Caroline Wang</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 29, 2017, we entered into an agreement with Ms. Wang in the form of a director offer letter pursuant to which we agreed to compensate
her $11,162 (RMB80,000) annually for her services. Additionally, she is entitled to be included as an insured under our directors and
officers insurance policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Agreement
with Jiangliang He</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 4, 2018, we entered into an agreement with Mr. He in the form of a director offer letter pursuant to which we agreed to compensate
her $5,023 (RMB36,000) annually for her services. Additionally, she is entitled to be included as an insured under our directors and
officers insurance policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Agreement
with Pingfan Wu</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 26, 2018, we entered into an agreement with Ms. Wu in the form of a director offer letter pursuant to which we agreed to compensate
her $9,349 (RMB60,000) annually for her services. Additionally, she is entitled to be included as an insured under our directors and
officers insurance policy. On May 31, 2024, Ms. Pingfan Wu had resigned from her position as a member of the board of directors (the
&#8220;Board&#8221;) due to personal reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
BOARD PRACTICES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors and Committees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek directors with established strong professional reputations and experience in areas relevant to the strategy and operation of our
businesses. We also seek directors who possess the qualities of integrity and candor, who have strong analytical skills, and who are
willing to engage with the management and each other in a constructive and collaborative fashion. We also seek directors who have the
ability and commitment to devote significant time and energy to service on the board and its committees. We believe that all of our directors
meet the foregoing qualifications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the information submitted by Ms. Caroline Wang, Mr. Jiangliang He, Ms. Pingfan Wu and Dr. Genghua Gu, our Board of Directors has determined
that each of them is independent under Rule 5605(a)(2) of The Nasdaq Listing Rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has three (3) committees. During the fiscal year ended March 31, 2024, our Board of Directors and its committees held
the following number of meetings and took the following number of actions by unanimous written consent:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid">Meetings</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid">Unanimous written <br/> consents</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Board of Directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Audit Committee</td><td>&#160;</td>
    <td style="text-align: center">1</td><td>&#160;</td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation Committee</td><td>&#160;</td>
    <td style="text-align: center">1</td><td>&#160;</td>
    <td style="text-align: center">0</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Nominating Committee</td><td>&#160;</td>
    <td style="text-align: center">1</td><td>&#160;</td>
    <td style="text-align: center">0</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee operates under a written charter, a copy of which is available on our website at http://www.jiuzhou360.com under the
tabs &#8220;Investor&#8221;&#8211;&#8220;Corporate Governance&#8221;&#8211;&#8220;Documents&#8221;, and is composed of our three (3)
independent directors. Our Board of Directors has determined, based on information furnished by Ms. Caroline Wang and other available
information, that she meets the requirements of an &#8220;audit committee financial expert&#8221; as that term is defined in the rules
promulgated under the Securities Act and the Exchange Act, and has accordingly designated her as such. Our Board of Directors has also
appointed her chairperson of the committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
responsibilities of our Audit Committee include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
    with our management periodically to consider the adequacy of our internal control over financial reporting and the objectivity of
    our financial reporting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing
    the independent registered public accounting firm, determining the compensation of the independent registered public accounting firm,
    and pre-approving the engagement of the independent registered public accounting firm for audit and non-audit services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the independent registered public accounting firm, including reviewing its independence and quality control procedures, as well as
    the experience and qualifications of the audit personnel that are providing audit services to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
    with the independent registered public accounting firm and reviewing the scope and significant findings of the audits performed by
    them, and meeting with management and internal financial personnel regarding these matters; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our financing plans, the adequacy and sufficiency of our financial and accounting controls, practices and procedures, the activities
    and recommendations of the auditors and our reporting policies and practices, and reporting recommendations to our full Board of
    Directors for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation Committee operates under a written charter, a copy of which is available on our website at http://www.jiuzhou360.com under
the tabs &#8220;Investor&#8221;&#8211;&#8220;Corporate Governance&#8221;&#8211;&#8220;Documents&#8221;, and is made up of our three (3)
independent directors. Jiangliang He is chairperson of the committee. Our Compensation Committee oversees and, as appropriate, makes
recommendations to the Board of Directors regarding the annual salaries and other compensation of our executive officers and our employees,
and other employee policies; it also provides assistance and recommendations with respect to our compensation policies and practices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating Committee operates under a written charter, a copy of which is available on our website at http://www.jiuzhou360.com under
the tabs &#8220;Investor&#8221;&#8211;&#8220;Corporate Governance&#8221;&#8211;&#8220;Documents&#8221;, and is made up of our four (4)
independent directors. Genghua Gu is chairperson of the committee. Our Nominating Committee assists in the selection of director nominees,
approves director nominations to be presented for stockholder approval at our annual general meeting, fills any vacancies on our Board
of Directors, considers any nominations of director candidates validly made by shareholders, and reviews and considers developments in
corporate governance practices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Code of Ethics, which applies to all officers, directors and employees, was adopted by the Board on March 15, 2010. The
Code of Ethics was filed as Exhibit 14 to the Company&#8217;s Current Report on <span style="text-decoration:underline">Form 8-K</span> filed with the SEC on March 23, 2010,
a copy of which is available on our website at http://www.jiuzhou360.com under the tabs &#8220;Investor&#8221;&#8211;&#8220;Corporate
Governance&#8221;&#8211;&#8220;Documents&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="k_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
EMPLOYEES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2024, we had 1,003 employees combined in our retail and wholesale operations, consisting of 939 full-time and 64 part-time
employees. The number of employees for each area of operations, and such employees as a percentage of our total workforce, are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of March&#160;31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Employees</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Percentage</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-pharmacist store staff</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">464</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">46.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Pharmacists</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Management - non-pharmacists</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Physicians</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Non-physician clinic staff</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Wholesale - non-warehouse</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Online pharmacy - technicians</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Online pharmacy - non-technicians</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,003</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.00</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
SHARE OWNERSHIP.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Security
Ownership of Certain Beneficial Owners and Management</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information regarding our ordinary shares beneficially owned on July 30, 2024 or the latest applicable date prior to that date,
for (i) each stockholder known to be the beneficial owner of five percent (5%) or more of our outstanding ordinary shares, (ii) each executive
officer and director, and (iii) all executive officers and directors as a group. To the best of our knowledge, subject to community and
marital property laws, all persons named have sole voting and investment power with respect to such shares, except as otherwise noted.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares Beneficially Owned</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive officers and directors: <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> Shares <br/> beneficially <br/> owned (2)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> of class<br/> beneficially<br/> owned (3)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei Liu, Chief Executive Officer and Chairman of the Board of Directors <sup>(4)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">511,568</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">7.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Ming Zhao, Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Li Qi, Director <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Caroline Wang, Director <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genghua Gu, Director <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jiangliang, He, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All directors and executive officers as a group (6 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5% Shareholders: <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 0.1%.&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise noted, the address for each of the named beneficial owners is: Renxin Yaju Building 5&#160;&#160;Floor 4 Gong Shu District,
    Hangzhou City, Zhejiang Province, China, 310008.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement,
    understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting
    of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may
    be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose
    of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares
    (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage
    ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person
    (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as
    shown in this table does not necessarily reflect the person&#8217;s actual ownership or voting power with respect to the number of
    shares of ordinary shares actually outstanding.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unless otherwise noted, the number and percentage of outstanding shares
of ordinary shares is based upon&#160;6,654,077&#160;shares outstanding as of July 30, 2024.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    address of Super Marvel Limited (&#8220;Super Marvel&#8221;) is P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola,
    British Virgin Islands. The owners of Super Marvel are Lei Liu (56.7%) and Li Qi (43.3%). They are also its directors. As such, they
    are deemed to have or share investment control over Super Marvel&#8217;s portfolio. According to Rule 13d-5, when two or more persons
    agree to act together for the purpose of acquiring, holding, voting or disposing of equity securities of an issuer, the group formed
    thereby shall be deemed to have acquired beneficial ownership, for purposes of sections 13(d) and (g) of the Exchange Act, as of
    the date of such agreement, of all equity securities of that issuer beneficially owned by any such persons. As a result, 25,125 ordinary
    shares held by Super Marvel reported herein as beneficially owned by each of Mr. Liu and Ms. Qi, which they in turn own indirectly
    through their respective ownership of Super Marvel.&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Wang&#8217;s address is: 3601B The Center, Changle Road, Xuhui District, and Shanghai, China.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Gu&#8217;s address is: No.1, Xueshi Road, Hangzhou, China.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="k_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation.&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="k_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
MAJOR SHAREHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to Item 6.E &#8220;Directors, Senior Management and Employees &#8212; Share Ownership.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, (A)&#160;we are not directly or indirectly owned or controlled by (i)&#160;another corporation or (ii)&#160;any foreign
government and (B)&#160;there are no arrangements (including any announced or expected takeover bid), the operation of which may at a
subsequent date result in a change in our control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
voting rights of our major shareholders do not differ from the voting rights of other holders of the same class of shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
RELATED PARTY TRANSACTIONS.&#160;BUSINESS RELATIONSHIPS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Officers and Directors&#8217; Relationship with Us, Our Subsidiaries and VIE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in &#8220;<i>Business - Our Corporate History and Structure</i>&#8221; above, we control HJ Group through contractual arrangements
between Jiuxin Management, our wholly-owned subsidiary, and each of Jiuzhou Pharmacy, Jiuzhou Service and Jiuzhou Clinic. HJ Group is
owned by Mr. Lei Liu and Mr. Li Qi (the &#8220;Key Personnel&#8221;), whom also hold positions as our executive officers and/or directors.
Because the Key Personnel also collectively own a substantial amount of our issued and outstanding ordinary shares, we believe that our
interests are aligned with those of HJ Group and the Key Personnel. However, see &#8221; <i>Risk Factors - Risks Related to Our Corporate
Structure</i> - <i>Our contractual arrangements with HJ Group and the Key Personnel may not be as effective in providing control over
these entities as direct ownership,&#8221; and &#8220;Management members of HJ Group have potential conflicts of interest with us, which
may adversely affect our business and your ability for recourse.&#8221;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Related Party Transactions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due from related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Hangzhou Kahamadi Biotechnology Co., Ltd</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32,825</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others (the directors of subsidiaries)<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due to related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to a director and CEO <sup>(2)</sup>:</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,580,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">683,560</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup>:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,452</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,833,509</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">683,560</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
    to directors of our subsidiaries.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to foreign exchange restrictions, the Company&#8217;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to
    facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire
    in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March
    31, 2024.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia
    Medical borrowed from its non-controlling shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
INTERESTS OF EXPERTS AND COUNSEL.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;8.
FINANCIAL INFORMATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 18. Financial Statements.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be subject to legal proceedings, investigations and claims during the ordinary course of our business. We know of
no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending
litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder
holding more than five percent of our ordinary shares, is an adverse party or has a material interest adverse to our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are no restrictions that limit our ability to pay dividends, we have not paid, and do not currently intend to pay cash dividends
on our ordinary shares in the foreseeable future. Our policy is to retain all earnings, if any, to provide funds for the operation and
expansion of our business. The declaration of dividends, if any, will be subject to the discretion of our Board of Directors, who may
consider such factors as our results of operations, financial condition, capital needs and acquisition strategy, among others, in making
its determination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to receive dividends from our subsidiaries may limit our ability to pay dividends on our ordinary shares. See Risk Factors&#160;&#8211;&#160;Risks
Related to Doing Business in China&#160;&#8211;&#160;Our holding company structure may limit the payment of dividends&#8221; and &#8220;Item
10. Additional Information &#8211; D. Exchange Controls &#8211; Dividend Distribution&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
SIGNIFICANT CHANGES.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM&#160;9.
THE OFFER AND LISTING</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
OFFER AND LISTING DETAILS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_037"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
PLAN OF DISTRIBUTION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
MARKETS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares trade on the Nasdaq Capital Market under the symbol &#8220;CJJD&#8221;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the records of our
transfer agent, we had 6,654,077 shares of ordinary shares issued and outstanding as of July 30, 2024.&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
SELLING SHAREHOLDERS.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
DILUTION.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_041"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
EXPENSES OF THE ISSUE.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><div><a id="k_042"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;10. ADDITIONAL INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>A. SHARE CAPITAL</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 10. Additional
Information&#160;&#8211;&#160;Memorandum and Articles of Association&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022,&#160;the
Company effected a 1-for-12&#160;reverse stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every
12 shares of the Company&#8217;s issued and outstanding ordinary shares were automatically be converted into one issued and outstanding
ordinary share. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that would have
resulted from the split were rounded up to the next whole number. The reverse stock split affects all shareholders uniformly and will
not alter any shareholder&#8217;s percentage interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that
may result from the treatment of fractional shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 2024, the Company
effected a 1-for-20&#160;reverse stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 20 shares
of the Company&#8217;s issued and outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary
share. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted
from the split were rounded up to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter
any shareholder&#8217;s percentage interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result
from the treatment of fractional shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_044"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>B. MEMORANDUM AND ARTICLES
OF ASSOCIATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an exempted company
incorporated with limited liability under the laws of the Cayman Islands and our affairs are governed by our Memorandum and Articles of
Association, the Companies Law (as amended) of the Caymans Islands, which is referred to as the Companies Law below, and common law of
the Cayman Islands. Our authorized share capital is US$36,010,000 divided into (i) 150,000,000 Ordinary Shares of a par value of US$0.24
each, and (ii) 10,000,000 preferred shares of a par value of US$0.001 each.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have included summaries
of material provisions of our amended and restated memorandum and articles of association insofar as they relate to the material terms
of our share capital. The summaries do not purport to be complete and are qualified in their entirety by reference to our amended and
restated memorandum and articles of association, which is filed as Exhibit 1.1 to this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our outstanding ordinary
shares are fully paid and non-assessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Issuance of Shares and Changes to Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors with
the power for the Company, insofar as is permitted by law, is able to redeem or purchase any of its shares and to increase or reduce the
said share capital subject to the provisions of the Companies Act (Revised) and the Articles of Association of the Company and to issue
any part of its capital, whether original, redeemed or increased, with or without any preference, priority or special privilege or subject
to any postponement of rights or to any conditions or restrictions; and so that, unless the conditions of issue shall otherwise expressly
declare, every issue of shares, whether declared to be preference or otherwise, shall be subject to the power otherwise regulated in our
Second Amend and Restated Memorandum and Articles of the Association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the Law, these
Articles and, where applicable, the rules of the Designated Stock Exchange and without prejudice to any special rights or restrictions
for the time being attached to any shares or any class of shares, the unissued shares of the Company (whether forming part of the original
or any increased capital) shall be at the disposal of the Board, which may offer, allot, grant options over or otherwise dispose of them
to such persons, at such times and for such consideration and upon such terms and conditions as the Board may in its absolute discretion
determine but so that no shares shall be issued at a discount, except in accordance with the provisions of Law. In particular and without
prejudice to the generality of the foregoing, the Board is hereby empowered to authorize by resolution or resolutions from time to time
the issuance of one or more classes or series of preferred shares and to fix the designations, powers, preferences and relative, participating,
optional and other rights, if any, and the qualifications, limitations and restrictions thereof, if any, including, without limitation,
the number of shares constituting each such class or series, dividend rights, conversion rights, redemption privileges, voting powers,
full or limited or no voting powers, and liquidation preferences, and to increase or decrease the size of any such class or series (but
not below the number of shares of any class or series of preferred shares then outstanding) to the extent permitted by Law. Without limiting
the generality of the foregoing, the resolution or resolutions providing for the establishment of any class or series of preferred shares
may, to the extent permitted by law, provide that such class or series shall be superior to, rank equally with or be junior to the preferred
shares of any other class or series. Neither the Company nor the Board shall be obliged, when making or granting any allotment of, offer
of, option over or disposal of shares, to make, or make available, any such allotment, offer, option or shares to Members or others with
registered addresses in any particular territory or territories being a territory or territories where, in the absence of a registration
statement or other special formalities, this would or might, in the opinion of the Board, be unlawful or impracticable. Members affected
as a result of the foregoing sentence shall not be, or be deemed to be, a separate class of members for any purpose whatsoever. The Board
may issue options, warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof to
subscribe for, purchase or receive any class of shares or securities in the capital of the Company on such terms as it may from time to
time determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may in connection
with the issue of any shares exercise all powers of paying commission and brokerage conferred or permitted by the Law. Subject to the
Law, the commission may be satisfied by the payment of cash or by the allotment of fully or partly paid shares or partly in one and partly
in the other.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as required by law,
no person shall be recognized by the Company as holding any share upon any trust and the Company shall not be bound by or required in
any way to recognize (even when having notice thereof) any equitable, contingent, future or partial interest in any share or any fractional
part of a share or (except only as otherwise provided by these Articles or by law) any other rights in respect of any share except an
absolute right to the entirety thereof in the registered holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the Law and these
Articles, the Board may at any time after the allotment of shares but before any person has been entered in the Register as the holder,
recognize a renunciation thereof by the allottee in favor of some other person and may accord to any allottee of a share a right to effect
such renunciation upon and subject to such terms and conditions as the Board considers fit to impose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the Companies Law,
our shareholders may, by resolution passed by a simple majority of the voting rights entitled to vote at the general meeting, declare
dividends (including interim dividends) to be paid to our shareholders but no dividend shall be declared in excess of the amount recommended
by our board of directors. Dividends may be declared and paid out of funds lawfully available to us. Except as otherwise provided by the
rights attached to shares, all dividends shall be declared and paid according to the amounts paid up on the shares on which the dividend
is paid. All dividends shall be paid in proportion to the number of ordinary shares a shareholder holds during any portion or portions
of the period in respect of which the dividend is paid; but, if any share is issued on terms providing that it shall rank for dividend
as from a particular date, that share shall rank for dividend accordingly. Our board of directors may also declare and pay dividends out
of the share premium account or any other fund or account which can be authorized for this purpose in accordance with the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever the Board or the
Company in general meeting has resolved that a dividend be paid or declared, the Board may further resolve that such dividend be satisfied
wholly or in part by the distribution of specific assets of any kind and in particular of paid up shares, debentures or warrants to subscribe
securities of the Company or any other company, or in any one or more of such ways, and where any difficulty arises in regard to the distribution
the Board may settle the same as it thinks expedient, and in particular may issue certificates in respect of fractions of shares, disregard
fractional entitlements or round the same up or down, and may fix the value for distribution of such specific assets, or any part thereof,
and may determine that cash payments shall be made to any Members upon the footing of the value so fixed in order to adjust the rights
of all parties, and may vest any such specific assets in trustees as may seem expedient to the Board and may appoint any person to sign
any requisite instruments of transfer and other documents on behalf of the persons entitled to the dividend, and such appointment shall
be effective and binding on the Members. The Board may resolve that no such assets shall be made available to Members with registered
addresses in any particular territory or territories where, in the absence of a registration statement or other special formalities, such
distribution of assets would or might, in the opinion of the Board, be unlawful or impracticable and in such event the only entitlement
of the Members aforesaid shall be to receive cash payments as aforesaid. Members affected as a result of the foregoing sentence shall
not be or be deemed to be a separate class of Members for any purpose whatsoever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Voting and Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of admission
to a shareholders&#8217; meeting, a shareholder must be duly registered as our shareholder at the applicable record date for that meeting
and all calls or installments then payable by such shareholder to us in respect of our ordinary shares must have been paid. Subject to
any special rights or restrictions as to voting then attached to any shares, at any general meeting every shareholder who is present in
person or by proxy (or, in the case of a shareholder being a corporation, by its duly authorized representative not being himself or herself
a shareholder entitled to vote) shall have one vote per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a Cayman Islands exempted
company, we are not obliged by the Companies Law to call annual general meetings; however, our Second Amended And Restated Memorandum
and Articles of Association provide that in each year we will hold an annual general meeting of shareholders at a time determined by our
board of directors. Also, we may, but are not required to (unless required by the Law), in each year hold any other extraordinary general
meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law of the Cayman
Islands provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right
to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association. Our
Second Amended and Restated Memorandum And Articles of Association provide that upon the requisition of shareholders representing not
less than two-thirds of the voting rights entitled to vote at general meetings, our board will convene an extraordinary general meeting
and put the resolutions so requisitioned to a vote at such meeting. However, shareholders may propose only ordinary resolutions to be
put to a vote at such meeting and shall have no right to propose resolutions with respect to the election, appointment or removal of directors
or with respect to the size of the board. Our amended and restated memorandum and articles of association provide no other right to put
any proposals before annual general meetings or extraordinary general meetings. Subject to regulatory requirements, our annual general
meeting and any extraordinary general meetings must be called by not less than ten (10) clear days&#8217; notice prior to the relevant
shareholders meeting and convened by a notice discussed below. Alternatively, upon the prior consent of all holders entitled to attend
and vote (with regards to an annual general meeting), and the holders of 95% in par value of the shares entitled to attend and vote (with
regard to an extraordinary general meeting), that meeting may be convened by a shorter notice and in a manner deemed appropriate by those
holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will give notice of each
general meeting of shareholders by publication on our website and in any other manner that we may be required to follow in order to comply
with Cayman Islands law, Nasdaq and SEC requirements. The holders of registered shares may be convened for a shareholders&#8217; meeting
by means of letters sent to the addresses of those shareholders as registered in our shareholders&#8217; register, or, subject to certain
statutory requirements, by electronic means. We will observe the statutory minimum convening notice period for a general meeting of shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A quorum for a general meeting
consists of any one or more persons holding or representing by proxy not less than one-third of our issued voting shares entitled to vote
upon the business to be transacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A resolution put to the vote
of the meeting shall be decided on a poll. An ordinary resolution to be passed by the shareholders requires the affirmative vote of a
simple majority of the votes cast by, or on behalf of, the shareholders entitled to vote present in person or by proxy and voting at the
meeting. A special resolution requires the affirmative vote of no less than two-thirds of the votes cast by the shareholders entitled
to vote who are present in person or by proxy at a general meeting (except for certain matters described below which require an affirmative
vote of two-thirds). Both ordinary resolutions and special resolutions may also be passed by a unanimous written resolution signed by
all the shareholders of our company, as permitted by the Companies Law and our amended and restated memorandum and articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Second Amended and Restated
Memorandum and Articles of Association provide that the affirmative vote of no less than two-thirds of votes cast by the shareholders
entitled to vote who are present in person or by proxy at a general meeting shall be required to approve a) to reduce its share capital
or any capital redemption reserve or other undistributable reserve; b) the necessary quorum (whether at a separate general meeting or
at its adjourned meeting) shall be a person or persons or (in the case of a Member being a corporation) its duly authorized representative
together holding or representing by proxy not less than one-third in nominal value of the issued voting shares of that class; c) every
holder of shares of the class shall be entitled on a poll to one vote for every such share held by him; and d) any holder of shares of
the class present in person or by proxy or authorized representative may demand a poll.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfers of Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to these Articles
and the requirements of the Designated Stock Exchange, any Member may transfer all or any of his shares by an instrument of transfer in
the usual or common form or in a form prescribed by the Designated Stock Exchange or in any other form approved by the Board and may be
under hand or, if the transferor or transferee is a clearing house or a central depository house or its nominee(s), by hand or by machine
imprinted signature or by Electronic Signature or by such other manner of execution as the Board may approve from time to time. The Board
may, in its absolute discretion, and without giving any reason therefor, refuse to register a transfer of any share made in accordance
with Article 46 but only where such share is not a fully paid up share (and being transferred to a person of whom it does not approve),
or any share issued under any share incentive scheme for employees or pursuant to any other agreement, contract or other such arrangement,
upon which a restriction on transfer imposed thereby still subsists, and it may also, without prejudice to the foregoing generality, refuse
to register a transfer of any share to more than four joint holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board in so far as permitted
by any applicable law may, in its absolute discretion, at any time and from time to time transfer any share upon the Register to any branch
register or any share on any branch register to the Register or any other branch register. In the event of any such transfer, the shareholder
requesting such transfer shall bear the cost of effecting the transfer unless the Board otherwise determines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the Board otherwise
agrees (which agreement may be on such terms and subject to such conditions as the Board in its absolute discretion may from time to time
determine, and which agreement the Board shall, without giving any reason therefore, be entitled in its absolute discretion to give or
withhold), no shares upon the Register shall be transferred to any branch register nor shall shares on any branch register be transferred
to the Register or any other branch register and all transfers and other documents of title shall be lodged for registration, and registered,
in the case of any shares on a branch register, at the relevant Registration Office, and, in the case of any shares on the Register, at
the Office or such other place at which the Register is kept in accordance with the Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to any special rights,
privileges or restrictions as to the distribution of available surplus assets on liquidation for the time being attached to any class
or classes of shares (i) if the Company shall be wound up and the assets available for distribution amongst the Members of the Company
shall be more than sufficient to repay the whole of the capital paid up at the commencement of the winding up, the excess shall be distributed&#160;<i>pari
passu</i>&#160;amongst such members in proportion to the amount paid up on the shares held by them respectively and (ii) if the Company
shall be wound up and the assets available for distribution amongst the Members as such shall be insufficient to repay the whole of the
paid-up capital such assets shall be distributed so that, a nearly as may be, the losses shall be borne by the Members in proportion to
the capital paid up, or which ought to have been paid up, at the commencement of the winding up on the shares held by them respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company shall be wound
up (whether the liquidation is voluntary or by the court) the liquidator may, with the authority of a special resolution and any other
sanction required by the Law, divide among the Members in specie or kind the whole or any part of the assets of the Company and whether
or not the assets shall consist of properties of one kind or shall consist of properties to be divided as aforesaid of different kinds,
and may for such purpose set such value as he deems fair upon any one or more class or classes of property and may determine how such
division shall be carried out as between the Members or different classes of Members. The liquidator may, with the like authority, vest
any part of the assets in trustees upon such trusts for the benefit of the Members as the liquidator with the like authority shall think
fit, and the liquidation of the Company may be closed and the Company dissolved, but so that no contributory shall be compelled to accept
any shares or other property in respect of which there is a liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Provisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of our Second
Amended And Restated Memorandum and Articles Of Association may discourage, delay or prevent a change of control of our company or management
that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one
or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further
vote or action by our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Inspection of Books and Records</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of ordinary shares
will have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records.
No Member (other than a Director) shall have any right of inspecting any accounting record or book or document of the Company except as
conferred by law or authorized by the Board or the Company in general meeting. Notwithstanding the above, our Second Amended and Restated
Memorandum and Articles of Association provide our shareholders with the right to receive annual audited financial statements. Such right
to receive annual audited financial statements may be satisfied by filing such annual reports as we are required to file with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Register of Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands law,
we must keep a register of shareholders that includes: the names and addresses of the shareholders, a statement of the shares held by
each member, and of the amount paid or agreed to be considered as paid, on the shares of each member; the date on which the name of any
person was entered on the register as a member; and the date on which any person ceased to be a member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exempted Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an exempted company
with limited liability under the Companies Law. The Companies Law distinguishes between ordinary resident companies and exempted companies.
Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered
as an exempted company. An exempted company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to file an annual return of its shareholders with the Registrar of Companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is not required to open its register of members for inspection;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to hold an annual general meeting;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may issue shares with no par value;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may obtain an undertaking against the imposition of any future taxation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a limited duration company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a segregated portfolio company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Limited liability&#8221;
means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the Company (except in
exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose or other
circumstances in which a court may be prepared to pierce or lift the corporate veil).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors is
empowered to designate and issue from time to time one or more classes or series of preferred shares and to fix and determine the relative
rights, preferences, designations, qualifications, privileges, options, conversion rights, limitations and other special or relative
rights of each such class or series so authorized. Such action could adversely affect the voting power and other rights of the holders
of our ordinary shares or could have the effect of discouraging any attempt by a person or group to obtain control of us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>C. MATERIAL CONTRACTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All material contracts concluded
by the Company during the two years preceding the date of this annual report were entered into in the ordinary course of business, except
for those entered into in connection with the recent registered direct financings of the Company prior to the date of this report, a form
of such agreement is listed under the Exhibit Index of this annual report and incorporated by reference from the filings as indicated
thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><div><a id="k_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>D. EXCHANGE CONTROLS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section sets forth a
summary of the most significant regulations or requirements that affect our business activities in China or our shareholders&#8217; right
to receive dividends and other distributions from us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulation of Foreign Exchange in Certain Onshore
and Offshore Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2005, the SAFE
issued the Notice on Issues Relating to the Administration of Foreign Exchange in Fund-raising and Return Investment Activities of Domestic
Residents Conducted via Offshore Special Purpose Companies, or SAFE Notice 75, which became effective as of November 1, 2005, and was
further supplemented by two implementation notices issued by the SAFE on November 24, 2005 and May 29, 2007, respectively. Under Circular
75, prior registration with the local SAFE branch is required for PRC residents to establish or to control an offshore company for the
purposes of financing that offshore company with assets or equity interests in an onshore enterprise located in the PRC. An amendment
to the registration or filing with the local SAFE branch by such PRC resident is also required for the injection of equity interests or
assets of an onshore enterprise in the offshore company or overseas funds raised by such offshore company, or any other material change
with respect to the offshore company in connection with any increase or decrease of capital, transfer of shares, merger, division, equity
investment, debt investment, or creation of any security interest over any assets located in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under SAFE Notice 75, PRC
residents are further required to repatriate into the PRC all of their dividends, profits or capital gains obtained from their shareholdings
in the offshore entity within 180 days of their receipt of such dividends, profits or capital gains. The registration and filing procedures
under SAFE Notice 75 are prerequisites for other approval and registration procedures necessary for capital inflow from the offshore entity,
such as inbound investments or shareholders loans, or capital outflow to the offshore entity, such as the payment of profits or dividends,
liquidating distributions, equity sale proceeds, or the return of funds upon a capital reduction. Therefore, failure to comply with such
registration may subject us to certain restrictions on, including but not limited to, the increase of the registered capital of our PRC
subsidiary, making loans to our PRC subsidiary, and making distributions to us from our on-shore companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividend Distribution</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under current applicable laws
and regulations, each of our consolidated PRC entities, including WFOEs and domestic companies, may pay dividends only out of their accumulated
profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, each of our consolidated PRC entities
is required to deposit at least ten percent (10%) of its after-tax profit based on PRC accounting standards each year into its statutory
surplus reserve fund until the accumulative amount of such reserve reaches fifty percent (50%) of its registered capital. These reserves
are not distributable as cash dividends. As of March 31, 2024 the accumulated balance of our statutory reserve funds reserves amounted
to $1.31 million, and the accumulated losses of our consolidated PRC entities amounted to $40.83 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interim Regulations on Administration of
Sino-Foreign Joint Venture and Cooperative Medical Institutions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As per China&#8217;s commitments
to the World Trade Organization, &#8220;Foreign service suppliers are permitted to establish joint venture hospitals or clinics with
local Chinese partners with quantitative limitations in line with China&#8217;s needs. Foreign majority ownership is permitted.&#8221;
In accordance with the <i>Interim Regulations on Administration of Sino-Foreign Joint Venture and Cooperative Medical Institutions</i>
issued jointly by the Ministry of Health (&#8220;MOH&#8221;) and the Ministry of Commerce (&#8220;MOFCOM&#8221;) in 2000, the Chinese
party of Sino-foreign joint ventures and cooperative medical institutions shall hold no less than thirty percent (30%) of shares and
legal rights or interest, which also mean foreign investors are allowed to hold a maximum stake of seventy percent (70%). Such regulations
also specify that the establishment of Sino-foreign joint venture and cooperative medical institutions should be approved respectively
by MOH and MOFCOM. In other words, foreigners are allowed to run hospitals or clinics in the form of equity or co-operative joint ventures
with an equity interest of up to seventy percent (70%) lasting up to twenty (20) years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_047"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>E. TAXATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current PRC Enterprise
Income Tax Law (the &#8220;EIT Law&#8221;), and the implementation regulations for the EIT Law issued by China&#8217;s State Council,
became effective as of January 1, 2008. Under the EIT Law, enterprises are classified as either resident or non-resident enterprises.
An enterprise established outside of China with its &#8220;de facto management bodies&#8221; located within China is considered a &#8220;resident
enterprise,&#8221; meaning that it can be treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. The
implementing rules of the EIT Law defines a &#8220;de facto management body&#8221; as a managing body that in practice exercises &#8220;substantial
and overall management and control over the production and operations, personnel, accounting, and properties&#8221; of the enterprise;
however, it remains unclear whether the PRC tax authorities would deem our managing body as being located within China. Due to the relatively
short history of the EIT Law and lack of applicable legal precedents, the PRC tax authorities determine the PRC tax resident treatment
of entities organized under the laws of foreign jurisdictions on a case-by-case basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the PRC tax authorities
determine that we are a resident enterprise for PRC enterprise income tax purposes, a number of PRC tax consequences could follow. First,
we may be subject to enterprise income tax at a rate of twenty five percent (25%) on our respective worldwide taxable income, as well
as PRC enterprise income tax reporting obligations. Second, although the EIT Law provides that &#8220;dividends, bonuses and other equity
investment proceeds between qualified resident enterprises&#8221; is exempted income, and the implementing rules of the EIT Law refer
to &#8220;dividends, bonuses and other equity investment proceeds between qualified resident enterprises&#8221; as the investment proceeds
obtained by a resident enterprise from its direct investment in another resident enterprise, it is still unclear whether the dividends
we receive from Jiuxin Management would be classified as &#8220;dividends between qualified resident enterprises&#8221; and therefore
qualify for tax exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are treated as a non-resident
enterprise under the EIT Law, any dividends that we receive from Jiuxin Management (assuming such dividends are deemed to be sourced from
within the PRC) (i) may be subject to a five percent (5%) PRC withholding tax, provided that we own more than twenty five percent (25%)
of the registered capital of Jiuxin Management incessantly within twelve (12) months immediately prior to obtaining such dividends from
Jiuxin Management, and if the <i>Arrangement between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance
of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income</i> (the &#8220;Arrangement&#8221;) is applicable,
or (ii) if the Arrangement does not apply (i.e. the PRC tax authorities may deem us to be a conduit not entitled to treaty benefits),
may be subject to a ten percent (10%) PRC withholding tax. Similarly, if we are treated as a non-resident enterprise, and Renovation is
treated as a resident enterprise, then any dividends that we receive from Renovation (assuming such dividends were considered sourced
within the PRC) may be subject to a ten percent (10%) PRC withholding tax. Any such taxes on dividends could materially reduce the amount
of dividends, if any, that we could pay to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, the new &#8220;resident
enterprise&#8221; classification could result in a situation in which a ten percent (10%) PRC tax is imposed on dividends we pay to our
investors that are non-resident enterprises so long as such non-resident enterprise investors do not have an establishment or place of
business in China or, despite the existence of such establishment of place of business in China, the relevant income is not effectively
connected with such establishment or place of business in China, to the extent that such dividends have their sources within the PRC.
Similarly, any gain realized on the transfer of our shares by such investors is also subject to a ten percent (10%) PRC income tax if
such gain is regarded as income derived from sources within China. In such event, we may be required to withhold a ten percent (10%) PRC
tax on any dividends paid to our investors that are non-resident enterprises. Our investors that are non-resident enterprises also may
be responsible for paying PRC tax at a rate of ten percent (10%) on any gain realized from the sale or transfer of our common shares in
certain circumstances. We would not, however, have an obligation to withhold PRC tax with respect to such gain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the State Administration
of Taxation issued the <i>Notice on Strengthening the Administration of Enterprise Income Tax on Share Transfer Income of Non-Resident
Enterprises No. 698</i> (&#8220;Circular 698&#8221;) on December 10, 2009, which reinforces taxation on transfer of non-listed shares
by non-resident enterprises through overseas holding vehicles. Circular 698 applies retroactively and was deemed to be effective as of
January 2008. Pursuant to Circular 698, where (i) a foreign investor who indirectly holds equity interest in a PRC resident enterprise
through an offshore holding company indirectly transfers equity interests in a PRC resident enterprise by selling the shares of the offshore
holding company, and (ii) the offshore holding company is located in a jurisdiction where the effective tax rate is lower than twelve
and a half percent (12.5%) or where the offshore income of its residents is not taxable, the foreign investor is required to provide
the tax authority in charge of that PRC resident enterprise with certain relevant information within thirty (30) days of the transfer.
The tax authorities in charge will evaluate the offshore transaction for tax purposes. In the event that the tax authorities determine
that such transfer is abusing forms of business organization and there is no reasonable commercial purpose other than avoidance of PRC
enterprise income tax, the tax authorities will have the power to conduct a substance-over-form re-assessment of the nature of the equity
transfer. A reasonable commercial purpose may be established when the overall offshore structure is set up to comply with the requirements
of supervising authorities of international capital markets. If the State Administration of Taxation&#8217;s challenge of a transfer
is successful, they will deny the existence of the offshore holding company that is used for tax planning purposes. Since Circular 698
has a brief history, there is uncertainty as to its application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_048"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>F. DIVIDENDS AND PAYING
AGENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_049"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>G. STATEMENT BY EXPERTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_050"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>H. DOCUMENTS ON DISPLAY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to certain
of the information reporting requirements of the Securities and&#160;Exchange Act of 1934, as amended. As a foreign private issuer we
are exempt from the rules and regulations under the&#160;Securities Exchange Act&#160;prescribing the furnishing and content of proxy
statements, and our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit
recovery provisions contained in Section 16 of the Securities Exchange Act, with respect to their purchase and sale of our shares. In
addition, we are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose
securities are registered under the&#160;Securities Exchange Act. Nasdaq rules generally require that companies send an annual report
to shareholders prior to the annual general meeting, however we rely upon an exception under the Nasdaq rules. Specifically, we file annual
reports on Form 20-F, which contain financial statements audited by an independent accounting firm, electronically with the SEC and post
a copy on our website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC maintains a website
that contains reports, proxy and information statements and other information regarding registrants that file electronically with the
SEC, and our SEC reports can be viewed or downloaded there. The address of this web site is http://www.sec.gov. In addition, information
that we furnish or file with the SEC, including annual reports on Form 20-F, current reports on Form 6-K, proxy and information statements
and any amendments to, or exhibits included in, those reports are available to be viewed or download, free of charge, on our website at
www.jiuzhou360.com as soon as reasonably practicable after such materials are filed or furnished with the SEC. Information contained,
or that can be accessed through, our website does not constitute a part of this annual report and is not incorporated by reference herein,
and we have included our website address in this annual report solely for informational purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_051"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>I. SUBSIDIARY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a listing of our subsidiaries,
see &#8220;Item 4. Information on the Company &#8211; C. Organizational Structure.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_052"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>J. ANNUAL REPORT TO SECURITY
HOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;11. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exchange Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our reporting currency
is the U.S. dollar, the majority of our revenues and costs are denominated in RMB and a significant portion of our assets and liabilities
are denominated in RMB. As a result, we are exposed to foreign exchange risk because our revenues and results of operations may be affected
by fluctuations in the exchange rate between the U.S. dollar and the RMB. To the extent that the Company needs to convert the U.S. dollar
into RMB for capital expenditures and working capital and other business purposes, appreciation of RMB against the U.S. dollar would
have an adverse effect on the RMB amount the Company would receive from the conversion. Conversely, if the Company decides to convert
RMB into the U.S. dollar for the purpose of making payments for dividends on ordinary shares, strategic acquisitions or investments or
other business purposes, appreciation of the U.S. dollar against RMB would have a negative effect on the U.S. dollar amount available
to the Company. In addition, a significant depreciation of the RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent
of the Company&#8217;s earnings or losses. Since 2005, China reformed its exchange rate regime and the RMB is no longer pegged to the
U.S. dollar. In 2010, the People&#8217;s Bank of China decided to move to further reform the RMB exchange rate regime to enhance the
flexibility of the RMB exchange rate. For RMB against U.S. dollar, there was depreciation of approximately&#160;6.8%&#160;and&#160;depreciation
of approximately 5.1%&#160;during the years ended March 31, 2023 and 2024, respectively. It is difficult to predict how market forces
or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future, but the RMB may appreciate
or depreciate more significantly in value against the U.S. dollar or other foreign currencies, depending on the market supply and demand
with reference to a basket of currencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Chinese RMB is freely
convertible under the current account, it remains strictly regulated in the capital account. Chinese authorities have expressed their
willingness to allow the RMB to be fully convertible in the near future.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not entered
into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into
hedging transactions in the future, the effectiveness of these hedges may be limited and we may not be able to successfully hedge our
exposure. Accordingly, we may incur economic losses in the future due to foreign exchange rate fluctuations, which could have a negative
impact on our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had cash, cash equivalents,
restricted cash and certificate of deposit totaling $31.68 million and notes receivable of $0.00 million as of March 31, 2024. Cash and
cash equivalents are held for working capital purposes. We do not enter into investments for trading or speculative purposes. As of March
31, 2024, we had $0 million of short-term bank loans and $0 million of long-term loans outstanding. Our exposure to interest rate risk
primarily relates to the interest income generated from cash held in bank deposits and notes receivable, and interest expenses generated
from short-term bank loans. We believe that we do not have any material exposure to changes in fair value as a result of changes in interest
rates due to the short term nature of our cash equivalents. We have not been exposed nor do we anticipate being exposed to material risks
due to changes in interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Inflation Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Consumer
Price Index (CPI) released by National Bureau of Statistics of China, in 2022, the average annual inflation rate in China ranged at around
2 percent compared to the previous year. Projections by the IMF published in April 2021 expect the average annual inflation rate to reach
about 2.1 percent in the year of 2023. In March 2023, the monthly inflation rate in China ranged at 0.7 percent compared to the same month
in the previous year, up from 1.5 percent in the previous month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Economic and Political Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations in China are
subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These
include risks associated with, among others, the political, economic and legal environment in China and foreign currency exchange. Our
performance may be adversely affected by changes in the political and social conditions in China, and by changes in governmental policies
with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation,
among other things.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Credit risk is one of the
most significant risks for the Company&#8217;s business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that
potentially subject the Company to significant concentrations of credit risk consist primarily of cash and accounts receivable. Cash held
at major financial institutions located in the PRC are not insured by the government. While we believe that these financial institutions
are of high credit quality, it also continually monitors their credit worthiness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accounts receivable are typically
unsecured and derived from revenue earned from customers, thereby exposed to credit risk. Credit risk is controlled by the application
of credit approvals, limits and monitoring procedures. The Company manages credit risk through in-house research and analysis of the Chinese
economy and the underlying obligors and transaction structures. To minimize credit risk, the Company normally require prepayment from
the customers prior to begin production or delivery products. The Company identifies credit risk collectively based on industry, geography
and customer type. This information is monitored regularly by management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_054"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;12. DESCRIPTION OF SECURITIES OTHER
THAN EQUITY SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_055"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>A. DEBT SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>B. WARRANTS AND RIGHTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>C. OTHER SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>D. AMERICAN DEPOSITARY
SHARES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_059"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_060"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;13. DEFAULTS, DIVIDEND ARREARAGES
AND DELINQUENCIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_061"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;14. MATERIAL MODIFICATIONS TO THE
RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;15. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure Controls and Procedures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain disclosure controls
and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;)), that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed,
summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated
and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired
control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2024, the
end of the fiscal year covered by this report, our management, under the supervision and with the participation of our Chief Executive
Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the evaluation, our
Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2024, our disclosure controls and procedures were
ineffective. They reached this conclusion due to the presence of material weaknesses in internal controls over financial reporting as
described below. Management anticipates that our disclosure controls and procedures will remain ineffective until such material weaknesses
are remediated.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management&#8217;s Report on Internal Control
over Financial Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We assessed the effectiveness
of the Company&#8217;s internal control over financial reporting as of March 31, 2024. In making this assessment, we used the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in the Internal Control-Integrated
Framework. We are responsible for establishing and maintaining adequate internal control over financial reporting. Based on our evaluation,
management concluded that our internal control over financial reporting was ineffective as of March 31, 2024 due to the following material
weaknesses:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Accounting and Finance Personnel Weaknesses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management concluded that
in light of the inexperience of our accounting staff with respect to the requirements of U.S. GAAP-based reporting and SEC rules and
regulations, we did not maintain effective controls and did not implement adequate and proper supervisory review to ensure that significant
internal control deficiencies can be detected or prevented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management&#8217;s assessment
of the control deficiency over accounting and finance personnel as of March 31, 2024 considered the same factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of adjustments proposed by our independent auditors during our quarterly review and annual audit processes;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">how adequately we complied with U.S. GAAP on transactions; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">how accurately we prepared supporting information to provide to our independent auditors on a quarterly and annual basis.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the above factors,
management concluded that the lack of timely reconciliation of booking and recording from China GAAP to US GAAP, lack of accounting staff
with sufficient US GAAP experience, and lack of timely reconciliation of revenue and accounts receivable collectability are material weaknesses
as of March 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Remediation of Material Weakness for the year
ended March 31, 2024</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequent to the identification
of the material weakness, we have enhanced existing controls and design and implemented new controls. We have devoted significant time
and attention to remediate the above material weaknesses. For example, we redesigned our system to retrieve data faster, so we are able
to identify and reconcile the GAAP difference more efficiently. In addition, we trained our accounting staff with US GAAP knowledge, so
they can meet the requirement from our auditors more efficiently. Additionally, we plan to more closely monitor the collection of our
accounts receivables. We will check more often about the collectability of their receivables. If we determine that the accounts are uncollectible,
we will quickly seek the potential recovery and recognize any potential loss soon. These improvements to our internal control infrastructure
were implemented, and were in place in connection with the preparation of our financial statements for the year ended March 31, 2024.
As such, we believe that the remediation initiative outlined above will be sufficient to remediate as the changes become operational for
future years the material weakness in internal control over financial reporting as discussed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the year ended March 31,
2024, we linked our SAP system, a leading ERP system from Germany that was installed in 2017 with a series of local banks, so it can provide
a view of overall and instant cash information. In addition, we hired specialized managers who are able to program and develop improved
procedure in the system. Furthermore, we have been training our staff in implementing the management system continually. We expect to
continually improve our internal control system. There have been no other changes in our internal controls over financial reporting identified
in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 or Rule 15d-15 that occurred during the year ended
March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations on Controls</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management does not expect
that our disclosure controls and procedures or internal control over financial reporting will prevent or detect all errors and fraud.
Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute,
assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to
error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>Item 16.&#160;[Reserved]</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16A. AUDIT COMMITTEE FINANCIAL EXPERT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
determined, based on information furnished by Ms. Caroline Wang and other available information, that she meets the requirements of an
&#8220;audit committee financial expert&#8221; as that term is defined in the rules promulgated under the Securities Act and the Exchange
Act, and has accordingly designated her as such. Our Board of Directors has also appointed her chairperson of the committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16B. CODE OF ETHICS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Code
of Ethics, which applies to all officers, directors and employees, was adopted by the Board on March 15, 2010. The Code of Ethics was
filed as Exhibit 14 to the Company&#8217;s Current Report on <span style="text-decoration:underline">Form 8-K</span> filed with the SEC on March 23, 2010, a copy of which is
available on our website at http://www.jiuzhou360.com under the tabs &#8220;Investor&#8221;&#8211;&#8220;Corporate Governance&#8221;&#8211;&#8220;Documents&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="k_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16C. PRINCIPAL ACCOUNTANT FEES AND
SERVICES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current principal independent
auditor is YCM CPA Inc. (&#8220;YCM&#8221;) whom we engaged on May 31, 2022. The following table shows the fees for audit and other services
provided by YCM in relation to our 2024 and 2023 fiscal years:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">For the Fiscal Years ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Audit Fees (1)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">190,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">180,000</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit-Related Fees (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax Fees (3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">All Other Fees (4)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,721</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">190,000</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">220,721</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees: This category includes the audit of our annual financial statements, review of financial statements included in our interim semi-annual report on Form 6-K, and services that are normally provided by independent auditors in connection with statutory and regulatory filings or the engagement for fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees: This category consists of assurance and related services by our independent auditors that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees: This category consists of professional services rendered by our independent auditors for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Fees: This category consists of fees for other miscellaneous items.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Approval Policies and Procedures of the
Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee approves
the engagement of our independent auditors and is also required to pre-approve all audit and non-audit expenses. Prior to engaging its
accountants to perform particular services, the Audit Committee obtains an estimate for the service to be performed. All of the services
described above were approved by the Audit Committee in accordance with its procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16D. EXEMPTIONS FROM THE LISTING
STANDARDS FOR AUDIT COMMITTEES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="k_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16E. PURCHASES OF EQUITY SECURITIES
BY THE ISSUER AND AFFILIATED PURCHASERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16F. CHANGE IN REGISTRANT&#8217;S
CERTIFYING ACCOUNTANT.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;16G. CORPORATE GOVERNANCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares are listed
on Nasdaq. In order to list on Nasdaq, we are required to comply with certain of the Nasdaq Rules. As a foreign private issuer, we may
follow our home country&#8217;s corporate governance practices in lieu of certain of the Nasdaq Rules. Nevertheless, there are no significant
ways in which our corporate governance practices differ from those followed by domestic companies under the listing standards of Nasdaq
other than disclosed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NASDAQ Listing Rule 5620(a)
requires each issuer to hold an annual meeting of shareholders no later than one year after the end of the issuer&#8217;s fiscal year
end. However, NASDAQ Listing Rule 5615(a)(3) permits a foreign private issuer like us to follow home country practices in lieu of certain
requirements of Listing Rule 5600, provided that such foreign private issuer discloses in its annual report filed with the SEC each requirement
of Rule 5600 that it does not follow and describes the home country practice followed in lieu of such requirement. We follow home country
practice with respect to annual meetings and may forgo annual shareholder meetings from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NASDAQ Listing Rule 5635 generally
provides that shareholder approval is required of U.S. domestic companies listed on the NASDAQ Capital Market prior to issuance (or potential
issuance) of securities (i) equaling 20% or more of the company&#8217;s ordinary shares or voting power for less than the greater of market
or book value (ii) resulting in a change of control of the company; and (iii) which is being issued pursuant to a stock option or purchase
plan to be established or materially amended or other equity compensation arrangement made or materially amended. Notwithstanding this
general requirement, NASDAQ Listing Rule 5615(a)(3)(A) permits foreign private issuers to follow their home country practice rather than
these shareholder approval requirements. The Cayman Islands do not require shareholder approval prior to any of the foregoing types of
issuances. The Company, therefore, is not required to obtain such shareholder approval prior to entering into a transaction with the potential
to issue securities as described above. The Board of Directors of the Company has elected to follow the Company&#8217;s home country rules
as to such issuances and will not be required to seek shareholder approval prior to entering into such a transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have considered and <ix:nonNumeric contextRef="c52" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-23783">adopted</ix:nonNumeric> several insider
trading policies under the Company&#8217;s Code of Ethics.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following procedure is an excerpt to the requirements
to the confidentiality of the material non-public information and shall be followed by the Company&#8217;s employees, officers and directors:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;Employees, officers, and directors who have
access to confidential information are not permitted to use or share that information for stock trading purposes or for any other purpose
except the conduct of our business.&#8221;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Employees should take
all appropriate measures to avoid inadvertent disclosure of confidential information. Materials that contain or might contain confidential
information such as presentations, memoranda, working papers, data storage devices or disks, and laptop computers should be stored and
maintained in a secure location. Unauthorized release or posting of information concerning our business via internet is prohibited, including
discussions (anonymous or not) about the Company&#8217;s business in &#8220;web logs&#8221; (also known as &#8220;blogs&#8221;) and &#8220;chat
rooms.&#8221; All Company-related correspondence, e-mail, voicemail, and electronic communications are presumed to be confidential and
should not be disseminated outside of the Company, except for legitimate business purposes.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following procedure is an excerpt to the requirements
to the communications with third parties that are related to insider trading:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8220;INSIDER TRADING; COMMUNICATIONS WITH THIRD
PARTIES</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Employees, officers, and directors who have access
to confidential information are not permitted to use or share that information for stock trading purposes or for any other purpose except
the conduct of our business.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Insider Trading</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Inside information
is material information about a publicly traded company that is not known by the public. Information is deemed &#8220;material&#8221;
if it could affect the market price of a security or if a reasonable investor would attach importance to the information in deciding whether
to buy, sell, or hold a security. Inside information typically relates to financial conditions, such as progress toward achieving revenue
and earnings targets or projections of future earnings or losses of the Company. Inside information also includes changes in strategy
regarding a proposed merger, acquisition or tender offer, new products or services, contract awards, and other similar information. Inside
information is not limited to information about the Company. It also includes material non-public information about others, including
the Company&#8217;s customers, suppliers, and competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insider trading is prohibited
by law. It occurs when an individual with material, non-public information trades securities or communicates such information to others
who trade. The person who trades or &#8220;tips&#8221; information violates the law if he or she has a duty or relationship of trust and
confidence not to use the information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trading or helping others
trade while aware of inside information has serious legal consequences, even if the insider does not receive any personal financial benefit.
Insiders may also have an obligation to take appropriate steps to prevent insider trading by others.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="k_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Risk Management and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have implemented cybersecurity risk assessment procedures to ensure effectiveness in cybersecurity management, strategy and governance
and reporting cybersecurity risks. We have also integrated cybersecurity risk management into our overall enterprise risk management system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
of the date of this Report, we have not experienced any material cybersecurity incidents or identified any material cybersecurity threats
that have affected or are reasonably likely to materially affect us, our business strategy, results of operations or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
Board of Directors is responsible for overseeing the Company&#8217;s cybersecurity risk management and be informed on risks from cybersecurity
threats. The Board shall review, approve and maintain oversight of the disclosure (i) on Form 6-K for material cybersecurity incidents
(if any) and (ii) related to cybersecurity matters in the periodic reports (including annual report on Form 20-F) of the Company. In
addition, our management team, including those with experience in dealing with confidentiality-related cybersecurity issues, oversee
and manage cybersecurity related matters and formulate policies as necessary. Our Board review on an annual basis regarding assessment,
identification and management on material risks from cybersecurity threats happened in the ordinary course of our business operations.
If a cybersecurity incident occurs, our Board will promptly organize relevant personnel for internal assessment and, depending on the
situation, seek the opinions of external experts and legal advisors. If it is determined that the incident could potentially be a material
cybersecurity event, our Board will decide on the relevant response measures and whether any disclosure is necessary. If such disclosure
is determined to be necessary, such disclosure material will be prepared and reviewed by our Board before it is disseminated to the public.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;17. FINANCIAL STATEMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information specified in Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;18. FINANCIAL STATEMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Index to Consolidated
Financial Statements&#8221; for a list of all financial statements filed as part of this annual report.&#160;The Financial Statements
begin on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="k_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM&#160;19. EXHIBITS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the Exhibit Index following
the signature page of this report, which is incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign
this annual report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CHINA JO-JO DRUUGSTORES, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="width: 37%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lei Liu</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei Liu</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 30, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents are
filed as part of this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number</p></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1856084/000121390022010113/ea156304ex99-2_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Second Amended and Restated Memorandum and Articles of Association (24)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Exchange Agreement among Kerrisdale Mining Corporation, certain of its stockholders, Renovation Investment (Hong Kong) Co., Ltd. and its shareholders dated September 17, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023ex2-2_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities (25)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000113705007000236/exh41.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen of Ordinary shares Certificate (1)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390020001478/def14a0120_chinajojodrugs.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated 2010 Equity Incentive Plan (20)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1856084/000121390023049280/f20f2023ex8-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries (25)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Services Agreement between Zhejiang Jiuxin Investment Management Co., Ltd. (&#8220;Jiuxin Management&#8221;) and Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (&#8220;Jiuzhou Pharmacy&#8221;) dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Agreement among Jiuxin Management, Jiuzhou Pharmacy and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Pledge Agreement among Jiuxin Management, Jiuzhou Pharmacy and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Agreement among Jiuxin Management, Jiuzhou Pharmacy and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting Rights Proxy Agreement among Jiuxin Management, Jiuzhou Pharmacy and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Services Agreement between Jiuxin Management and Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (General Partnership) (&#8220;Jiuzhou Clinic&#8221;) dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Agreement among Jiuxin Management, Jiuzhou Clinic and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Pledge Agreement among Jiuxin Management, Jiuzhou Clinic and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-13.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Agreement among Jiuxin Management, Jiuzhou Clinic and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-14.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting Rights Proxy Agreement among Jiuxin Management, Jiuzhou Clinic and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Services Agreement between Jiuxin Management and Hangzhou Jiuzhou Medical &amp; Public Health Service Co., Ltd. (&#8220;Jiuzhou Service&#8221;) dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-16.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Agreement among Jiuxin Management, Jiuzhou Service and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-17.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Pledge Agreement among Jiuxin Management, Jiuzhou Service and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-18.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Agreement among Jiuxin Management, Jiuzhou Service and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409049673/v160849_ex99-19.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting Rights Proxy Agreement among Jiuxin Management, Jiuzhou Service and its owners dated August 1, 2009 (3)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Consulting Services Agreement between Jiuxin Management and Jiuzhou Pharmacy dated October 27, 2009 (4)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Operating Agreement between Jiuxin Management and Jiuzhou Pharmacy dated October 27, 2009 (4)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Option Agreement between Jiuxin Management and Jiuzhou Pharmacy dated October 27, 2009 (4)</span></a></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Voting Rights Proxy Agreement between Jiuxin Management and Jiuzhou Pharmacy dated October 27, 2009 (4)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Consulting Services Agreement between Jiuxin Management and Jiuzhou Clinic dated October 27, 2009 (4)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Operating Agreement between Jiuxin Management and Jiuzhou Clinic dated October 27, 2009 (4)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Option Agreement between Jiuxin Management and Jiuzhou Clinic dated October 27, 2009 (4)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Voting Rights Proxy Agreement between Jiuxin Management and Jiuzhou Clinic dated October 27, 2009 (4)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Consulting Services Agreement between Jiuxin Management and Jiuzhou Service dated October 27, 2009 (4)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Operating Agreement between Jiuxin Management and Jiuzhou Service dated October 27, 2009 (4)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Option Agreement between Jiuxin Management and Jiuzhou Service dated October 27, 2009 (4)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000114420409055556/v164096_ex99-12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Voting Rights Proxy Agreement between Jiuxin Management and Jiuzhou Service dated October 27, 2009 (4)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390017006960/f10k2017ex10xxxiii_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Offer Letter with Caroline Wang dated as of March 29, 2017 (21)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390013007173/f8k120913ex99i_chinajo-jo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Offer Letter with Genghua Gu dated December 9, 2013 (13)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390014008553/f8k111814ex10ii_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of the Non-statutory Stock Option Agreement (16)</span></a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="vertical-align: top; text-align: justify; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390015009220/f8k112715ex10i_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of the Restricted Stock Award Agreement for the issuance on November 27, 2015 (18)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390018012184/f8k090418ex10-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter to Mr. Jiangliang He dated September 4, 2018 (22)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390018014512/f8k102618ex10-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Offer Letter with Ms. Pingfan Wu, dated October 26, 2018 (15)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000121390021026554/ea140940ex2-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger by and between China Jo-Jo Drugstores, Inc. and China Jo-Jo Drugstores Holdings, Inc., dated May 14, 2021 (23)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020991701ex12-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification by the Corporation&#8217;s Chief Executive Officer *</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020991701ex12-2_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 302 Certification by the Corporation&#8217;s Chief Financial Officer *</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020991701ex13-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 906 Certification by the Corporation&#8217;s Chief Executive Officer and Chief Financial Officer *</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000115752310001598/a6216752ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics (5)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020991701ex15-1_chinajojo.htm">Consent of Company&#8217;s current Independent Publicly Registered Accounting Firm, YCM CPA, Inc.*</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020991701ex97-1_chinajojo.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Recovery Policy *</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000115752310003865/a6343246ex994.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Project Agreement between The People&#8217;s Government of Qianhong Village, Lin&#8217;an, Zhejiang Province (the &#8220;Qianhong Local Government&#8221;) and Jiuzhou Pharmacy dated February 27, 2010 (7)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1413263/000115752310003865/a6343246ex995.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Deposit Agreement between the Qianhong Local Government and Jiuzhou Pharmacy dated February 27, 2010 (7)</span></a></td></tr>


<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.INS</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Inline XBRL Instance Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.SCH</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.CAL</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.DEF</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.LAB</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>101.PRE</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>104</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Registration Statement on Form SB-2 filed on November 28, 2007</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on July 15, 2008</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on September 24, 2009</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on October 30, 2009</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on March 16, 2010</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on April 14, 2010</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Annual Report on Form 10-K filed on June 29, 2010</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Quarterly Report on Form 10-Q filed on February 14, 2011</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on May 17, 2012</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on November 30, 2012</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on January 4, 2013</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on December 12, 2013</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on October 26, 2018</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on November 24, 2014</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on December 2, 2015</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Exhibit A to the proxy statement on Schedule 14A filed on January 21, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from Exhibit 10.33 of the predecessor of the registrant&#8217;s Annual Report on Form 10-K filed on June 29, 2017</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on September 6, 2018</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference from the predecessor of the registrant&#8217;s Current Report on Form 8-K filed on May 14, 2021</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.2 on Form 6-K filed with the Securities and Exchange Commission on March 1, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="text-align: justify">Incorporated by reference on Form 20-F filed with the
Securities and Exchange Commission on June 15, 2023</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="k_079"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>China Jo-Jo Drugstores, Inc. and Subsidiaries</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 91%; text-align: justify"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports of Independent Registered Public Accounting Firms</span></a></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of March 31, 2024 and 2023</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended March 31, 2024, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&#8217; Equity for the Years Ended March 31, 2024, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended March 31, 2024, 2023 and 2022</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 93; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img alt="" src="fin_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders of China Jo-Jo Drugstores, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of China Jo-Jo Drugstores, Inc. and subsidiaries (collectively, the &#8220;Company&#8221;) as of March 31, 2024 and 2023,
and the related consolidated statements of operations and comprehensive income (loss), changes in shareholders&#8217; equity, and cash
flows for each of the years in the three-year period ended March 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material
respects, the financial position of the Company as of March 31, 2024 and 2023, and the results of its operations and its cash flows for
each of the years in the three-year period ended March 31, 2024, in conformity with accounting principles generally accepted in the United
States of America.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statement. We believe that our audits provide a reasonable
basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The critical audit matters communicated below are matters arising from
the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee
and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate
opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Valuation
of Accounts Receivable</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
of the Matter</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 2 and Note 4 to the consolidated financial statements, the Company&#8217;s accounts receivable totaled approximately
$15.8 million as of March 31, 2024. Accounts receivable are reported at an amount that management expects to collect, net of estimated
allowances. The valuation of accounts receivable is a critical audit matter due to the significant judgments made by management regarding
the allowance for credit losses, which required a high degree of auditor judgment to design and perform audit procedures and evaluate
the audit evidence obtained in relation to the valuation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
We Addressed the Matter in Our Audit</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address the matter involved, we designed and performed audit procedures and evaluated audit evidence in connection with forming our overall
opinion on the consolidated financial statements. Our audit procedures included the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            reviewed the process and methodologies used by management to develop their valuation approach.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            tested the data used by management to ensure its accuracy and completeness.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            verified the underlying assumptions used in estimating the accounts receivable, ensuring
                                            they are reasonable and based on reliable data.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            compared the historical estimates made by management to the actual amounts collected.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            reviewed the forward-looking information and assumptions used by management and evaluated
                                            the reasonableness of these assumptions in the context of current economic conditions and
                                            industry trends.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b><i>Revenue
Recognition &#8211; Determination of Estimated Reserve for Government Medical Insurance Agency</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
of the Matter</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in Note 2 to the consolidated financial statements, the Company separates its revenues into three segments: drugstore retail
sales, online pharmacy sales and wholesale. Purchases related to drugstore retail sales are mainly paid by cash or government medical
insurance card. The government medical insurance card is funded by local government medical insurance agencies and can only be used for
medical purposes. When a customer makes a purchase with the government medical insurance card, the agency receives a notification at
the checkout to reserve the balance on that card. Each month, the Company files claims with the agencies for reimbursement for the prior
month. However, the agency could deny reimbursement for various reasons, such as sales exceeding limited quantities. While the vast majority
of the balance claimed will be reimbursed within a few months, a small portion may take longer, including up to more than a year. The
determination of the reserve for potential losses from the agency is a critical audit matter due to the significant judgment by management
in estimating the loss on claims, which required a high degree of auditor judgement to design and perform audit procedures and evaluate
the audit evidence obtained in relation to the estimated loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
We Addressed the Matter in Our Audit</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
address the matter involved, we designed and performed audit procedures and evaluated audit evidence in connection with forming our overall
opinion on the consolidated financial statements. Our audit procedures included the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated and tested the process used by management to estimate the loss of the claims. This
                                            involved understanding the methodologies and assumptions applied by management in determining
                                            the reserve.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            compared estimated losses to historically uncollected amounts and assessed the accuracy and
                                            reliability of management&#8217;s past estimates.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            researched and reviewed the government medical insurance policies and any updates throughout
                                            the year to evaluate any significant changes in these policies that could impact the reimbursement
                                            of claims.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            examined reimbursements received in the subsequent period through the filing date to identify
                                            any indications of additional loss.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-23784">YCM CPA, Inc.</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We
have served as the Company&#8217;s auditor since 2022. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">PCAOB
ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-23785">6781</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-16198"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Irvine,
California</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">July
30, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>


</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED BALANCE SHEETS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March&#160;31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March&#160;31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="text-decoration:underline">ASSETS</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CURRENT ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-23786">20,149,806</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-23787">18,807,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-23788">12,724,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-23789">12,762,708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Trade accounts receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-23790">15,824,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-23791">14,119,606</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-23792">16,248,373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-23793">15,309,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other receivables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-23794">2,938,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-23795">2,725,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-23796">914,776</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-23797">142,417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="cjjd:DueFromRelatedsParties" scale="0" unitRef="usd" id="ixv-23798">313,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-23799">569,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-23800">616,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-23801">69,682,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-23802">64,482,790</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-23803">4,906,589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-23804">5,100,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-23805">1,195,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-23806">1,772,072</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Farmland assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:FarmlandAssets" scale="0" unitRef="usd" id="ixv-23807">634,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:FarmlandAssets" scale="0" unitRef="usd" id="ixv-23808">666,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23809">1,119,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23810">1,038,125</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other noncurrent assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23811">682,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23812">790,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-23813">13,827,360</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-23814">13,924,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Intangible assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-23815">3,009,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-23816">3,195,748</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23817">25,374,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-23818">26,487,812</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.5in">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-23819">95,057,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-23820">90,970,602</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Short-term loan payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-23821">276,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-23822">31,630,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-23823">26,990,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-23824">31,676,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-23825">29,255,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLoansPayableCurrent" scale="0" unitRef="usd" id="ixv-23826">2,493,482</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLoansPayableCurrent" scale="0" unitRef="usd" id="ixv-23827">1,314,919</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23828">1,833,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23829">683,560</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CustomerDepositCurrent" scale="0" unitRef="usd" id="ixv-23830">518,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CustomerDepositCurrent" scale="0" unitRef="usd" id="ixv-23831">695,931</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-23832">682,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-23833">1,706,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23834">386,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23835">756,516</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Current portion of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-23836">4,862,766</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-23837">5,131,373</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23838">74,360,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-23839">66,535,234</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-23840">6,403,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-23841">7,768,216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-23842">80,763,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-23843">74,303,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares; $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23844"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23845">0.24</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23846"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23847">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23848"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23849">1,743,362</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23850"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23851">1,184,861</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-23852">418,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-23853">284,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Preferred shares; $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23854"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-23855">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23856"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23857">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <span style="-sec-ix-hidden: hidden-fact-7"><span style="-sec-ix-hidden: hidden-fact-8"><span style="-sec-ix-hidden: hidden-fact-9"><span style="-sec-ix-hidden: hidden-fact-10">nil</span></span></span></span> issued and outstanding as of March&#160;31, 2024 and 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-23858">86,413,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-23859">83,958,418</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Statutory reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StatutoryReserves" scale="0" unitRef="usd" id="ixv-23860">1,309,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StatutoryReserves" scale="0" unitRef="usd" id="ixv-23861">1,309,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-23862">73,507,246</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-23863">69,273,018</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-23864">1,005,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-23865">1,735,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total shareholders&#8217; equity attributed to China Jo-Jo</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-23866">15,640,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-23867">18,014,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Noncontrolling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-23868">1,346,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd" id="ixv-23869">1,346,859</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23870">14,293,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23871">16,667,152</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.5in">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-23872">95,057,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-23873">90,970,602</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">REVENUES, NET</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-23874">154,541,077</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-23875">148,811,976</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-23876">164,392,555</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF GOODS SOLD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-23877">123,432,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-23878">114,531,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-23879">127,873,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">GROSS PROFIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-23880">31,108,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-23881">34,280,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-23882">36,519,040</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">SELLING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-23883">27,385,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-23884">29,177,163</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-23885">30,876,959</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">GENERAL AND ADMINISTRATIVE EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-23886">7,257,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-23887">15,668,684</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-23888">8,187,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">STOCK BASED COMPENSATION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-23889">10,360,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">IMPAIRMENT OF LONG-LIVED ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" unitRef="usd" id="ixv-23890">148,795</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-23891">34,643,111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-23892">55,205,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-23893">39,212,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23894">3,534,563</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23895">20,925,383</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23896">2,693,890</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSES):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">INTEREST INCOME</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-23897">516,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-23898">883,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-23899">401,921</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">INTEREST EXPENSE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-23900">13,604</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-23901">65,854</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-23902">262,218</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">INVESTMENT LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23903">1,607,537</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-23904">2,316,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER INCOME (EXPENSES)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-23905">467,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-23906">1,680,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" unitRef="usd" id="ixv-23907">455,547</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LOSS BEFORE INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23908">4,171,380</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23909">20,744,236</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23910">2,098,640</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23911">62,862</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23912">394,541</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23913">1,099,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23914">4,234,242</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23915">21,138,777</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23916">3,198,366</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23917">14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23918">252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23919">6,247</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23920">4,234,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23921">21,138,525</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-23922">3,192,119</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">FOREIGN CURRENCY TRANSLATION ADJUSTMENTS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23923">729,373</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23924">2,617,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-23925">1,534,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23926">4,963,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23927">23,756,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23928">1,663,559</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">WEIGHTED AVERAGE NUMBER OF SHARES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23929">1,444,263</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23930">509,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23931">173,966</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-23932">1,444,263</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-23933">509,828</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-23934">173,966</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">LOSS PER SHARE:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23935">2.93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23936">41.46</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23937">18.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-23938">2.93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-23939">41.46</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-23940">18.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">Non-</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Number&#160;of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">paid-in</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Statutory</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">comprehensive</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">controlling</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Shareholders&#8217;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">reserves</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">income/(loss)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">BALANCE, March&#160;31, 2021</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23941">173,966</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23942">41,752</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23943">66,516,033</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23944">1,309,109</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23945">44,942,374</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23946">2,818,185</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23947">1,340,360</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 6%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23948">24,402,345</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23949">3,192,119</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23950">6,247</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23951">3,198,366</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign currency translation loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" unitRef="usd" id="ixv-23952">1,534,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" unitRef="usd" id="ixv-23953">1,534,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">BALANCE, March&#160;31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23954">173,966</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23955">41,752</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23956">66,516,033</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23957">1,309,109</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23958">48,134,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23959">4,352,992</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23960">1,346,607</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23961">22,738,786</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fractional shares issued for reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-23962">402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" scale="0" unitRef="usd" id="ixv-23963">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" scale="0" sign="-" unitRef="usd" id="ixv-23964">97</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares and warrants in private placements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodShareSaleOfStockAndWarrants" scale="0" unitRef="shares" id="ixv-23965">297,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" scale="0" unitRef="usd" id="ixv-23966">71,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" scale="0" unitRef="usd" id="ixv-23967">7,253,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" scale="0" unitRef="usd" id="ixv-23968">7,325,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-23969">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-23970">36,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-23971">10,324,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd" id="ixv-23972">10,360,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Cashless exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-23973">562,993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-23974">135,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" sign="-" unitRef="usd" id="ixv-23975">135,118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23976">21,138,525</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23977">252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23978">21,138,777</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign currency translation loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23979">2,617,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23980">2,617,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">BALANCE, March&#160;31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23981">1,184,861</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23982">284,367</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23983">83,958,418</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23984">1,309,109</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23985">69,273,018</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23986">1,735,135</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-23987">1,346,859</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-23988">16,667,152</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Fractional shares issued for reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-23989">60,501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" scale="0" unitRef="usd" id="ixv-23990">14,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" scale="0" sign="-" unitRef="usd" id="ixv-23991">14,520</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares and warrants in private placements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodShareSaleOfStockAndWarrants" scale="0" unitRef="shares" id="ixv-23992">498,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" scale="0" unitRef="usd" id="ixv-23993">119,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" scale="0" unitRef="usd" id="ixv-23994">2,470,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" scale="0" unitRef="usd" id="ixv-23995">2,589,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23996">4,234,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23997">14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-23998">4,234,242</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Foreign currency translation loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-23999">729,373</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-24000">729,373</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">BALANCE, March&#160;31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-24001">1,743,362</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24002">418,407</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24003">86,413,978</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24004">1,309,109</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24005">73,507,246</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24006">1,005,762</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-24007">1,346,873</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-24008">14,293,137</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24009">4,234,242</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24010">21,138,777</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-24011">3,198,366</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-24012">790,449</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-24013">718,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" unitRef="usd" id="ixv-24014">1,256,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Bad debt direct write-off and provision and reversal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" sign="-" unitRef="usd" id="ixv-24015">249,257</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-24016">7,579,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="0" unitRef="usd" id="ixv-24017">939,720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-24018">4,594,172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss from disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-24019">107,251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Impairment of long lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" unitRef="usd" id="ixv-24020">148,795</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-24021">10,360,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Investment loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-24022">1,607,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="0" sign="-" unitRef="usd" id="ixv-24023">2,316,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-24024">1,804,440</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-24025">2,531,755</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-24026">2,657,283</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInNotesReceivables" scale="0" sign="-" unitRef="usd" id="ixv-24027">19,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInNotesReceivables" scale="0" unitRef="usd" id="ixv-24028">20,861</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInNotesReceivables" scale="0" sign="-" unitRef="usd" id="ixv-24029">40,260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Inventories and biological assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-24030">1,699,621</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-24031">522,550</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-24032">1,523,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-24033">672,830</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-24034">958,671</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-24035">1,927,692</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd" id="ixv-24036">839,221</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" sign="-" unitRef="usd" id="ixv-24037">201,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidSupplies" scale="0" unitRef="usd" id="ixv-24038">171,783</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long term deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:IncreaseDecreaseInLongTermDeposit" scale="0" sign="-" unitRef="usd" id="ixv-24039">132,568</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:IncreaseDecreaseInLongTermDeposit" scale="0" unitRef="usd" id="ixv-24040">589,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="cjjd:IncreaseDecreaseInLongTermDeposit" scale="0" sign="-" unitRef="usd" id="ixv-24041">159,508</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-24042">19,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-24043">331,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-24044">376,134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other noncurrent assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-24045">69,539</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd" id="ixv-24046">30,483</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-24047">62,394</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amount due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" unitRef="usd" id="ixv-24048">317,828</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" unitRef="usd" id="ixv-24049">6,002,186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" unitRef="usd" id="ixv-24050">1,765,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="0" sign="-" unitRef="usd" id="ixv-24051">3,558,050</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other payables and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-24052">868,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-24053">1,341,447</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-24054">99,132</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:IncreaseDecreaseInCustomerDeposit" scale="0" sign="-" unitRef="usd" id="ixv-24055">144,761</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:IncreaseDecreaseInCustomerDeposit" scale="0" sign="-" unitRef="usd" id="ixv-24056">1,035,456</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="cjjd:IncreaseDecreaseInCustomerDeposit" scale="0" unitRef="usd" id="ixv-24057">678,601</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="0" sign="-" unitRef="usd" id="ixv-24058">948,277</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="0" unitRef="usd" id="ixv-24059">433,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="0" unitRef="usd" id="ixv-24060">1,162,084</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-24061">6,191,522</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24062">3,155,439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24063">3,283,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24064">5,385,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Acquisition of equipment&#160;and building</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24065">330,677</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24066">118,272</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24067">89,960</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Investment in a joint venture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" unitRef="usd" id="ixv-24068">1,116,212</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInterestInJointVenture" scale="0" unitRef="usd" id="ixv-24069">4,379</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Purchases of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-24070">66,973</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-24071">12,774</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" unitRef="usd" id="ixv-24072">7,012</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Additions to leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AdditionsToLeaseholdImprovements" scale="0" unitRef="usd" id="ixv-24073">525,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AdditionsToLeaseholdImprovements" scale="0" unitRef="usd" id="ixv-24074">180,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AdditionsToLeaseholdImprovements" scale="0" unitRef="usd" id="ixv-24075">209,166</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24076">2,039,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24077">316,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-24078">306,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from short-term bank loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherShortTermDebt" scale="0" unitRef="usd" id="ixv-24079">1,116,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Repayment of short-term bank loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherShortTermDebt" scale="0" unitRef="usd" id="ixv-24080">837,159</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherShortTermDebt" scale="0" unitRef="usd" id="ixv-24081">779,059</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Repayment of third parties loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-24082">1,811,558</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-24083">2,613,965</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-24084">56,875,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-24085">57,965,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-24086">65,370,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Repayment of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd" id="ixv-24087">52,997,171</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd" id="ixv-24088">60,273,598</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd" id="ixv-24089">57,829,269</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from issuance of shares and warrants in private placements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-24090">2,589,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-24091">7,325,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from other payable-related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-24092">1,257,406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-24093">43,785</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-24094">689,010</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Repayment of other payable-related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:RepaymentOfOtherPayablesrelatedParties" scale="0" unitRef="usd" id="ixv-24095">882,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-24096">8,004,291</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-24097">2,366,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-24098">4,836,898</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">EFFECT OF EXCHANGE RATE ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-24099">1,505,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-24100">2,535,479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24101">1,522,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-24102">1,303,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-24103">3,768,933</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-24104">666,933</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24105">31,570,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24106">35,339,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24107">34,672,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24108">32,874,171</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24109">31,570,644</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24110">35,339,577</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-24111">149,023</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-24112">63,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" unitRef="usd" id="ixv-24113">3,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-24114">13,604</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-24115">64,943</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-24116">262,218</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">NON-CASH ACTIVITIES&#65306;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Cashless exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CashlessExerciseOfWarrants" scale="0" unitRef="usd" id="ixv-24117">135,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_006"></a></div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-19094"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 &#8211; DESCRIPTION OF BUSINESS AND
ORGANIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">China Jo-Jo Drugstores, Inc. (&#8220;Jo-Jo Drugstores&#8221;
or the &#8220;Company&#8221;), was incorporated in Nevada on December 19, 2006, originally under the name &#8220;Kerrisdale Mining Corporation&#8221;.
On September 24, 2009, the Company changed its name to &#8220;China Jo-Jo Drugstores, Inc.&#8221; in connection with a share exchange
transaction as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2009, the Company completed a
share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (&#8220;Renovation&#8221;), whereby <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24118">7,900,000</ix:nonFraction> shares of ordinary
shares were issued to the stockholders of Renovation in exchange for <ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-24119">100</ix:nonFraction>% of the capital stock of Renovation. The completion of the share
exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization
and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the
accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date
of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment
Management Co., Ltd. (&#8220;Jiuxin Management&#8221;), Zhejiang Shouantang Medical Technology Co., Ltd. (&#8220;Shouantang Technology&#8221;)
and Hangzhou Jiutong Medical Technology Co., Ltd (&#8220;Jiutong Medical&#8221;), Hangzhou Jiuyi Medical Technology Co. Ltd. (&#8220;Jiuyi
Technology&#8221;), its wholly-owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an online and offline retailer
and wholesale distributor of pharmaceutical and other healthcare products in the People&#8217;s Republic of China (&#8220;China&#8221;
or the &#8220;PRC&#8221;). The Company&#8217;s offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou
Jiuzhou Grand Pharmacy Chain Co., Ltd. (&#8220;Jiuzhou Pharmacy&#8221;), a company that the Company controls through contractual arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s offline retail business also
includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (&#8220;Jiuzhou Clinic&#8221;)
and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (&#8220;Jiuzhou Service&#8221;), both of which are also controlled by
the Company through contractual arrangements. In May 2014, Shouantang Technology established Hangzhou Shouantang Bio-technology Co., Ltd.
(&#8220;Shouantang Bio&#8221;). In May 2016, Shouantang Bio set up and held <ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-24120">49</ix:nonFraction>% of Hangzhou Kahamadi Bio-technology Co., Ltd. (&#8220;Kahamadi
Bio&#8221;), a joint venture specializing in brand name development for nutritional supplements. In 2018, Jiuzhou Pharmacy invested a
total of $<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="0" unitRef="usd" id="ixv-24121">741,540</ix:nonFraction> (RMB<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="0" unitRef="cny" id="ixv-24122">5,100,000</ix:nonFraction>) in and held <ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-24123">51</ix:nonFraction>% of Zhejiang Jiuzhou Linjia Medical Investment and Management Co. Ltd (&#8220;Linjia Medical&#8221;),
which has ceased its operation as of March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently conducts its online retail
pharmacy business through Jiuzhou Pharmacy, which holds the Company&#8217;s online pharmacy license. On September 10, 2015, Renovation
set up Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November
2015, the technical support function was transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s wholesale business is primarily
conducted through Zhejiang Jiuxin Medicine Co., Ltd. (&#8220;Jiuxin Medicine&#8221;), which is licensed to distribute prescription and
non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. On April 20,
2018, <ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-24124">10</ix:nonFraction>% of Jiuxin Medicine shares were sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of $<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-24125">79,625</ix:nonFraction> (RMB <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="cny" id="ixv-24126">507,760</ix:nonFraction>). On
January 29, 2021, The Company bought back the <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="cjjd:SharesRepurchasePercentage" scale="0" unitRef="shares" id="ixv-24127">10</ix:nonFraction>% of Jiuxin Medicine for a total price of $<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="0" unitRef="usd" id="ixv-24128">77,410</ix:nonFraction>(RMB<span style="-sec-ix-hidden: hidden-fact-100">507, 760</span>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s herb farming business is conducted
by Hangzhou Qianhong Agriculture Development Co., Ltd. (&#8220;Qianhong Agriculture&#8221;), a wholly-owned subsidiary of Jiuxin Management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>


</div><div>


</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2021, China Jo-Jo Drugstores, Inc.,
a Nevada corporation (&#8220;CJJD&#8221;), completed a corporate reorganization (the &#8220;Reorganization&#8221; or &#8220;Redomicile
Merger&#8221;), resulting in China Jo-Jo Drugstores Holdings, Inc., a company incorporated under the laws of the Cayman Islands (&#8220;CJJD
Cayman&#8221;), becoming the publicly held parent company of CJJD, with CJJD merged with and into CJJD Cayman, pursuant to the Agreement
and Plan of Merger, dated as of May 14, 2021, by and between CJJD and CJJD Cayman (the &#8220;Merger Agreement&#8221;). Prior to the Reorganization,
shares of CJJD&#8217;s ordinary shares were registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;), and listed on the NASDAQ Capital Market under the symbol &#8220;CJJD.&#8221; As a result of the Reorganization,
each issued and outstanding share of CJJD&#8217;s ordinary shares was converted into the right to receive one CJJD Cayman ordinary share,
which shares were issued by CJJD Cayman as part of the Reorganization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 7, 2022, the Company effected a 1-for-12&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24129"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24130">12</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#8217;s percentage
interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2024, the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24131"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24132">20</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#8217;s percentage
interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-24133">The accompanying consolidated financial statements
reflect the activities of the Company and each of the following entities:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_2" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Name</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></td> <td style="width: 1%">&#160;</td> <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovation</span></td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><ix:nonNumeric contextRef="c75" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19151"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008</span></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24134">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuxin&#160;Management</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c76" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19167"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#8220;WFOE&#8221;) under PRC law &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24135">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Technology</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c77" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19187"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24136">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qianhong Agriculture</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c78" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19209"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24137">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Pharmacy (1)</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c79" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19229"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates the &#8220;Jiuzhou Grand Pharmacy&#8221; stores in Hangzhou</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Clinic (1)</span></td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><ix:nonNumeric contextRef="c80" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19249"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003</span></ix:nonNumeric></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><ix:nonNumeric contextRef="c81" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19264"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores</span></ix:nonNumeric></td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Service (1)</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c82" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19279"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_3" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Name</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></td> <td style="width: 1%">&#160;</td> <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuxin Medicine</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c83" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19319"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiutong Medical</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c84" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19341"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Currently has no operation</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24138">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Bio</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c85" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19361"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24139">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuyi Technology</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c86" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19383"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24140">100</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kahamadi Bio</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c87" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19403"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-24141">49</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical</span></td> <td>&#160;</td> <td> <ix:nonNumeric contextRef="c88" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19425"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics</p></ix:nonNumeric></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_4" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Clinic</span></td> <td style="width: 1%">&#160;</td> <td rowspan="8" style="width: 48%"> <ix:nonNumeric contextRef="c89" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19460"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics</p></ix:nonNumeric></td> <td style="width: 1%">&#160;</td> <td rowspan="8" style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_5" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhen Health</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%"> <ix:nonNumeric contextRef="c90" continuedAt="_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState-c90_cont_1" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19503"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> </ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:continuation id="_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState-c90_cont_1">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million</ix:continuation>&#160;</p></td> <td style="width: 1%">&#160;</td> <td style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_6" id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hongtong Service</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%"> <ix:nonNumeric contextRef="c91" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-19520"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Daily service</p></ix:nonNumeric></td> <td style="width: 1%">&#160;</td> <td style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#8220;Owners&#8221;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#8217;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#8220;VIE&#8221;) under the accounting standards of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.</span></ix:footnote></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Liquidity and capital resources</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, we had cash of approximately
$<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-24143">32.9</ix:nonFraction> million and a working capital deficit of $<ix:nonFraction contextRef="c63" decimals="-5" format="ixt:num-dot-decimal" name="cjjd:WorkingCapitalDeficit" scale="6" unitRef="usd" id="ixv-24144">4.7</ix:nonFraction> million. During the year ended March 31, 2024, we had a net loss of approximately
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="6" sign="-" unitRef="usd" id="ixv-24145">4.2</ix:nonFraction> million and net cash used in operating activities were $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd" id="ixv-24146">2.9</ix:nonFraction> million. However, non-cash expenses such as investment loss accounts
for approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="6" unitRef="usd" id="ixv-24147">1.6</ix:nonFraction> million, respectively. Excluding these non-cash expenses, the net loss is approximately $<ix:nonFraction contextRef="c64" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" unitRef="usd" id="ixv-24148">2.6</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts have been prepared
in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) on a going concern
basis. The going concern basis assumes that assets are realized and liabilities are extinguished in the ordinary course of business at
amounts disclosed in the financial statements. The Company&#8217;s ability to continue as a going concern depends upon aligning its sources
of funding (debt and equity) with its expenditure requirements and repayment of the short-term debts as and when they become due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to meet its capital demand, the Company
strived to raise funds in the capital market, increase its credit line from the local banks, and improve its store performance in the
near future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2023, the Company closed a private
placement of <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24149">498,000</ix:nonFraction> shares of ordinary shares at $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24150">5.20</ix:nonFraction> per share with gross proceeds of $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-24151">2,589,600</ix:nonFraction>. On April 29, 2024, the Company entered
into certain Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant
to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering,
an aggregate of <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24152">900,000</ix:nonFraction> ordinary shares (the &#8220;Shares&#8221;), par value $<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24153">0.24</ix:nonFraction> per share, of the Company (&#8220;Ordinary Shares&#8221;),
at a purchase price of $<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24154">1.70</ix:nonFraction> per Share (the &#8220;Purchase Price&#8221;), for aggregate gross proceeds to the Company of $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-24155">1,530,000</ix:nonFraction>.
On May 10, 2024, the Company entered into certain Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors
(the &#8220;Investors&#8221;) pursuant to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from
the Company, in a registered direct offering, an aggregate of <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24156">1,610,000</ix:nonFraction> ordinary shares (the &#8220;Shares&#8221;), par value $<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24157">0.24</ix:nonFraction> per
share, of the Company (&#8220;Ordinary Shares&#8221;), at a purchase price of $<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24158">1.70</ix:nonFraction> per Share (the &#8220;Purchase Price&#8221;), for
aggregate gross proceeds to the Company of $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-24159">2,737,000</ix:nonFraction>. On June 11, 2024, the Company entered into certain Share Purchase Agreements (the
&#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to sell to
the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an aggregate of <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24160">1,980,000</ix:nonFraction> ordinary
shares (the &#8220;Shares&#8221;), par value $<ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-24161">0.24</ix:nonFraction> per share, of the Company (&#8220;Ordinary Shares&#8221;), at a purchase price of $<ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24162">1.70</ix:nonFraction>
per Share (the &#8220;Purchase Price&#8221;), for an aggregate gross proceeds to the Company of $<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-24163">3,366,000</ix:nonFraction>. The private placements raised
a total gross proceeds of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-24164">10,222,600</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a credit line agreement from a
local bank as described in detail in Note 15 and Note 16. As of March 31, 2024, approximately $<ix:nonFraction contextRef="c73" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-24165">1.55</ix:nonFraction> million of the aforementioned bank
credit line was available for further borrowing. On June 6, 2024, bank credit line increased by $<ix:nonFraction contextRef="c74" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-24166">5.54</ix:nonFraction> million (RMB <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="cny" id="ixv-24167">40,000,000</ix:nonFraction>). As the
economy growth slows down, the national interest continues to decrease. local banks are encouraged to provide low interest rate loans
to local enterprises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also obtained additional government
insurance reimbursement certificates for its stores opened in the last two years. In a mature store, nearly half of the revenue are generated
by customers utilizing the government insurance program. With these certificates, mature stores are able to attract more customers who
are eligible for the insurance program, and its sales may significantly increase in the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the above factors, the Company believes
it can support its operations for at least the next 12 months.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-19598"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="ixv-19602"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of presentation and consolidation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). The
consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant
inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationVariableInterestEntityPolicy-c0_cont_1" escape="true" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="ixv-19609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Consolidation of variable interest entities</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConsolidationVariableInterestEntityPolicy-c0_cont_2" id="_ConsolidationVariableInterestEntityPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with accounting standards regarding
consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without
additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the
Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary
is required to consolidate the VIE for financial reporting purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConsolidationVariableInterestEntityPolicy-c0_cont_3" id="_ConsolidationVariableInterestEntityPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has concluded, based on the contractual
arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each
a VIE and that the Company&#8217;s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities
of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual
returns.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConsolidationVariableInterestEntityPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Control and common control are defined under the
accounting standards as &#8220;an individual, enterprise, or immediate family members who hold more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cjjd:BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" scale="-2" unitRef="pure" id="ixv-24168">50</ix:nonFraction> percent of the voting ownership
interest of each entity.&#8221; Because the Owners collectively own <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-24169">100</ix:nonFraction>% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and
have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting
rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly,
the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin
Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin
Management, in turn, is owned by Renovation, which is owned by the Company. <b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-19637"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with&#160;U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial
statements relate to the assessment of the carrying values of accounts receivable, related allowance for doubtful accounts, losses. Because
of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-19644"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair value measurements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company establishes a three-level valuation
hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the
following:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; Quoted prices in active markets
for identical assets or liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of
the assets or liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; Unobservable inputs that are supported
by little or no market activity and that are significant to the fair value of the assets or liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Classification within the hierarchy is determined
based on the lowest level of input that is significant to the fair value measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value of
the Company&#8217;s financial instruments including cash, restricted cash, accounts receivable, advances to suppliers, other current assets,
accounts payable, due to related parties, other current liabilities, short-term bank loans and bank acceptance notes payable approximate
their recorded values due to their short-term maturities. The fair value of longer term long-term bank loan and operating lease liabilities
approximate their recorded values as their stated interest rates approximate the rates currently available.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-19666"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Long-term investments</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Long-term
investments include equity investments. Equity investments include investments in common stock or in-substance common stock of entities.
For those equity investments over which the Group can exercise significant influence but does not own a majority equity interest or control,
the equity method is applied, and the Group adjusts the carrying amount of an investment and recognizes investment income or loss for
the Group&#8217;s share of the earnings or loss of the investee after the date of investment. For those equity investments accounted for
other than under the equity method, the fair value method is applied. However, for equity investments that do not have readily determinable
fair values, the Group chooses to account for them at cost minus impairment, if any, plus or minus changes resulting from observable price
changes in orderly transactions for the identical or a similar investment of the same issuer. If this measurement alternative is elected,
changes in the carrying value of the equity investments will be required to be made whenever there are observable price changes in transactions
for identical or similar investments of the same issuer. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-19688"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 31, 2018, the Company began recognizing
revenue under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;),
using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company&#8217;s
consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict
the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be
entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 1: Identify the contract with the customer</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 2: Identify the performance obligations in the contract</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 3: Determine the transaction price</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to identify the performance obligations
in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or
service that is distinct. A performance obligation meets ASC 606&#8217;s definition of a &#8220;distinct&#8221; good or service (or bundle
of goods or services) if both of the following criteria are met:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a good or service is not distinct, the good
or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenue is net of value added
tax (&#8220;VAT&#8221;) collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers,
net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant
PRC tax authorities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain contract liabilities primarily represent
the Company&#8217;s obligation to transfer additional goods or services to a customer for which the Company has received consideration,
for example, membership points. The consideration received remains a contract liability until goods or services have been provided to
the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a discussion of the Company&#8217;s
revenue recognition policies by segment under the new revenue recognition accounting standard:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacy retail sales</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The physical pharmacies sell prescription drugs,
over-the-counter (&#8220;OTC&#8221;) drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products.
Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and
pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer
pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after
the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local
government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The
Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made
to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services.
Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal
compared to pharmacy retail sales, it is included as part of the pharmacy retail sales.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company deduct the membership rewards directly
from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification.
Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has
determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers
can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership
rewards are reflected as a&#160;contract&#160;liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_20" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Online pharmacy sales</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_21" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from online pharmacy sales is recognized
when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer&#8217;s
location. Any loss caused in a shipment will be reimbursed by the Company&#8217;s courier company. The Company&#8217;s sales policy allows
for the return of certain merchandises without reason within seven days after a customer&#8217;s receipt of the applicable merchandise.
Historically, sales returns seven days after merchandise receipts have been minimal.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_22" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Wholesale</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_23" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiuxin Medicine purchases medicine in quantity
and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers
is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_24" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenue is net of VAT collected
on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases,
is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_25" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disaggregation of Revenue</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_26" id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="ixv-24170">The following table disaggregates the Company&#8217;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock-c0_cont_1"><ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_26"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>For the year ended March 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Retail drugstores</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24171">25,269,177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24172">27,212,994</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24173">28,503,283</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24174">31,542,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24175">32,358,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24176">35,658,864</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24177">9,890,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24178">8,737,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24179">9,664,071</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24180">3,405,979</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24181">9,719,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24182">5,353,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24183">1,129,647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24184">1,082,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24185">1,544,639</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24186">4,440,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24187">4,241,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24188">3,503,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total retail revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24189">75,678,470</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24190">83,351,768</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24191">84,228,492</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Online pharmacy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24192">9,151,412</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24193">10,606,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24194">10,331,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24195">12,969,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24196">13,870,953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24197">11,473,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24198">4,284,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24199">2,740,253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24200">2,014,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24201">571,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24202">434,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24203">315,231</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24204">1,448,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24205">1,129,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24206">2,271,009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24207">3,432,296</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24208">3,603,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24209">3,814,284</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total online revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24210">31,857,883</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24211">32,385,089</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24212">30,219,364</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Drug wholesale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24213">30,784,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24214">21,617,636</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24215">41,116,991</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24216">11,323,730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24217">10,289,987</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24218">7,903,824</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24219">741,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24220">310,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24221">424,210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24222">388,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24223">458,502</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24224">241,828</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24225">692,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24226">64,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24227">93,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24228">3,073,665</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24229">333,663</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24230">164,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total wholesale revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24231">47,004,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24232">33,075,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24233">49,944,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24234">154,541,077</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24235">148,811,976</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-24236">164,392,555</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>


</div><div>


</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-20228"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted cash</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s restricted cash consists of
cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is
required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in
nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="ixv-24237">The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock-c0_cont_1"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-24238">20,149,806</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-24239">18,807,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-24240">12,724,365</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-24241">12,762,708</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24242">32,874,171</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-24243">31,570,644</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" id="ixv-20282"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ReceivablesPolicyTextBlock-c0_cont_2" id="_ReceivablesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable represents the following:
(1) amounts due from banks relating to retail sales that are paid or settled by the customers&#8217; debit or credit cards, (2) amounts
due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine,
and medical services that are paid or settled by the customers&#8217; medical insurance cards, (3) amounts due from non-bank third party
payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ReceivablesPolicyTextBlock-c0_cont_3" id="_ReceivablesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts, as&#160;necessary. In the Company&#8217;s retail
business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance
programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines
to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated
reserves on related outstanding accounts receivable based on expected credit loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ReceivablesPolicyTextBlock-c0_cont_4" id="_ReceivablesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the Company&#8217;s online pharmacy business,
accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce
platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to
certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month.
Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ReceivablesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In its wholesale business, the Company uses the
expected credit loss method to estimate the allowance for anticipated uncollectible receivable balances. At each reporting period, the
allowance balance is adjusted to reflect the amount computed as a result of the expected credit loss method. When facts subsequently become
available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account
as a change in estimate.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="cjjd_CreditLossRollForwardPolicyTextBlock-c0_cont_1" escape="true" name="cjjd:CreditLossRollForwardPolicyTextBlock" id="ixv-20298"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Credit loss roll forward</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="cjjd_CreditLossRollForwardPolicyTextBlock-c0_cont_2" id="cjjd_CreditLossRollForwardPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the adoption of the current expected credit
loss standard in 2020, the company estimates future expected losses on accounts receivable and other receivables over the remaining collection
period of the instrument. <ix:nonNumeric contextRef="c0" continuedAt="_AccountsReceivableAllowanceForCreditLossTableTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="ixv-24244">The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_AccountsReceivableAllowanceForCreditLossTableTextBlock-c0_cont_1"><ix:continuation id="cjjd_CreditLossRollForwardPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year end March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Account <br/> receivable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Other <br/> receivables</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Allowance for credit losses as of March 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24245">2,313,306</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24246">5,329,440</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24247">7,642,746</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Credit loss reversal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" sign="-" unitRef="usd" id="ixv-24248">1,389,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" sign="-" unitRef="usd" id="ixv-24249">2,446,772</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherCreditLosses" scale="0" sign="-" unitRef="usd" id="ixv-24250">3,836,412</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Ending allowance for credit losses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24251">923,666</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24252">2,882,668</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24253">3,806,334</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>




</div><div>


</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-20383"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventories</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts
on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct
costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such
as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs
costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses
and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities
on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="cjjd_FarmlandAssetsPolicyTextBlock-c0_cont_1" escape="true" name="cjjd:FarmlandAssetsPolicyTextBlock" id="ixv-20390"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Farmland assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="cjjd_FarmlandAssetsPolicyTextBlock-c0_cont_2" id="cjjd_FarmlandAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Herbs that the Company farms are recorded at their
cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland,
and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has
been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cjjd_FarmlandAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All related costs described in the above are accumulated
until the time of harvest and then allocated to harvested herbs when they are sold.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-20400"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost, net
of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of
the assets, taking into consideration the assets&#8217; estimated residual value. <ix:nonNumeric contextRef="c0" continuedAt="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock-c0_cont_1" escape="true" name="cjjd:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="ixv-24254">Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#8217;s property
and equipment:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful&#160;Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c161" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24255">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c162" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24256">10</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Motor vehicles</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c163" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24257">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c164" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24258">5</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office equipment &amp; furniture</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24259">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c166" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24260">5</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Buildings</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c167" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-24261">35</ix:nonNumeric> years</td></tr>
  </table></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maintenance, repairs and minor renewals are charged
to expenses as incurred. Major additions and betterment to property and equipment are capitalized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="ixv-20435"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Intangible assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets are acquired individually or
as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction
is allocated to the individual assets based on their relative fair values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock-c0_cont_1" escape="true" name="cjjd:ScheduleOfEstimatedUsefulLivesTableTextBlock" id="ixv-24262">The estimated useful lives of the Company&#8217;s
intangible assets are as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_4" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c168" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-24263">50</ix:nonNumeric> years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Software</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-24264">3</ix:nonNumeric> years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">license</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c170" name="cjjd:FiniteLivedIntangibleAssetUsefulLifeDescription" id="ixv-24265">Infinite</ix:nonNumeric></td></tr> </table></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates intangible assets for impairment
whenever events or changes in circumstances indicate that the assets might be impaired.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-20483"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates long lived tangible and
intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable
from its estimated future cash flows. Recoverability is measured by comparing the assets&#8217; net book value to the related projected
undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections,
market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset
is considered impaired, and a second test is performed to measure the amount of impairment loss. The forest rights certificate from the
local village extends the life of the lease to January 31, 2060. In the year ended March 31, 2022, we evaluated the use rights of the
forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company recorded
an impairment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLeasehold" scale="0" unitRef="usd" id="ixv-24266">148,795</ix:nonFraction>. In the year ended March 31, 2023, we evaluated the use rights of the forest land, which is currently used to
cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended
March 31, 2024, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation
of the forest land use rights, the Company did not record an impairment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="cjjd_NotesPayablePolicyTextBlock-c0_cont_1" escape="true" name="cjjd:NotesPayablePolicyTextBlock" id="ixv-20490"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes payable</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cjjd_NotesPayablePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the normal course of business, the Company
regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The
Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short
maturity period of six to nine months.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-20497"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income taxes</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows FASB ASC Topic 740, &#8220;Income
Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax
consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each
period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting standards clarify the accounting
and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition
and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition,
classification, interest and penalties, accounting in interim periods, disclosures, and transition.&#160;No significant penalties, uncertain
tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="cjjd_ValueAddedTaxPolicyTextBlock-c0_cont_1" escape="true" name="cjjd:ValueAddedTaxPolicyTextBlock" id="ixv-20507"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Value added tax</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cjjd_ValueAddedTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue represents the invoiced value of
goods, net of VAT. All of the Company&#8217;s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT
rates&#160;range up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cjjd:VATPercentage" scale="-2" unitRef="pure" id="ixv-24267">13</ix:nonFraction>%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials
and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments
in the accompanying financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-20528"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share-based compensation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The Company accounts for share-based payment
awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the
fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest
is recognized as an expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. Share-based
awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option
award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using
the Black-Scholes valuation model as permitted under FASB ASC 718 &#8220;Compensation - Stock Compensation.&#8221; The assumptions used
in calculating the fair value of share-based payment awards represent the Company&#8217;s best estimates. The Company&#8217;s estimates
of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain
variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates
of forfeitures, and the related income tax impact.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_AdvertisingCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="ixv-20536"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Advertising and promotion costs</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_AdvertisingCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising and promotion costs are expensed as
incurred and amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-24268">304,075</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-24269">491,684</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-24270">355,078</ix:nonFraction> for the year ended March 31, 2024, 2023 and 2022, respectively. Such costs
consist primarily of print and promotional materials such as flyers to local communities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-20543"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign currency translation</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the United States dollar (&#8220;U.S.
dollars&#8221; or &#8220;USD&#8221;) for financial reporting purposes. The Company&#8217;s subsidiaries and VIEs maintain their books
and records in their functional currency the Renminbi (&#8220;RMB&#8221;), the currency of the PRC.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, for consolidation purposes, the Company
translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at
the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period.
As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes
in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the
translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The balance sheet amounts, with the exception
of equity, at March 31, 2024 and 2023 were translated at 1 USD to 7.2203 RMB and at 1 USD to 6.8676 RMB, respectively. The average translation
rates applied to income and cash flow statement amounts for years ended March 31, 2024 and 2023 were at 1 USD to 7.1671 RMB and at 1 USD
to 6.8516 RMB, respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-20556"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s management does not believe
that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the
accompanying consolidated financial statements.&#160;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-20576"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Risks and Uncertainties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operations of the Company are located in the
PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#8217;s operations in the PRC are subject
to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include
risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s
results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not
experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization
and structure disclosed in Note 1, this may not be indicative of future results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has significant cash deposits with
suppliers in order to obtain and maintain inventory. The Company&#8217;s ability to obtain products and maintain inventory at existing
and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors
are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest
on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party
who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party.
If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings
in China, to recover all or a portion of the amount on deposit with its suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Members of the current management team own controlling
interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements
which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the
Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the
Company would not retain control of the VIEs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentrations and Credit Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain financial instruments, which subject the
Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions
located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection
Board&#8217;s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered
by insurance up to RMB <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="cny" id="ixv-24271">500,000</ix:nonFraction> (USD <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-24272">79,600</ix:nonFraction>) per bank. As of March 31, 2024 and 2023, the Company had deposits totaling $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="0" unitRef="usd" id="ixv-24273">32,247,552</ix:nonFraction> and
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="0" unitRef="usd" id="ixv-24274">31,558,338</ix:nonFraction> that were covered by such limited insurance, respectively. Any balance over RMB <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashUninsuredAmount" scale="0" unitRef="cny" id="ixv-24275">500,000</ix:nonFraction> (USD79,<span style="-sec-ix-hidden: hidden-fact-101">600</span>) per bank in PRC will not
be covered. To date, the Company has not experienced any losses in such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended March 31, 2024, one
vendor collectively accounted for more than 10% of the Company&#8217;s total purchases and two suppliers accounted for more than 10% of
total advances to suppliers.&#160;For the fiscal year ended March 31, 2023, four vendors collectively accounted for more than 10% of the
Company&#8217;s total purchases and four suppliers accounted for more than 10% of total advances to suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended March 31, 2024, one
customer accounted for more than 10% of the Company&#8217;s total sales but no customer accounted for more than 10% of total accounts
receivable. For the fiscal year ended March 31, 2023, one customer accounted for more than 10% of the Company&#8217;s total sales but
no customer accounted for more than 10% of total accounts receivable.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-20612"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; TRADE RECEIVABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="ixv-24276">Trade receivables consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGross" scale="0" unitRef="usd" id="ixv-24277">16,747,769</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableGross" scale="0" unitRef="usd" id="ixv-24278">16,412,099</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24279">923,666</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="0" unitRef="usd" id="ixv-24280">2,313,306</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-24281">15,824,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-24282">14,098,793</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Note receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesReceivableNet" scale="0" unitRef="usd" id="ixv-24283">20,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Trade receivables</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-24284">15,824,103</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-24285">14,119,606</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended March 31, 2024 and 2023, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" unitRef="usd" id="ixv-24286">56,170</ix:nonFraction>
and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" unitRef="usd" id="ixv-24287">50,275</ix:nonFraction> in accounts receivable were directly written off, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-20686"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 &#8211; OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-24288">Other current assets consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_2" id="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid rental expenses <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:PrepaidRent" scale="0" unitRef="usd">513,170</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:PrepaidRent" scale="0" unitRef="usd">530,611</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24291">56,374</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24292">85,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24293">569,544</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-24294">616,008</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfOtherCurrentAssetsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-20748"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;6 &#8211; PROPERTY AND EQUIPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-24295">Property and equipment consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Building</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24296">5,617,617</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24297">6,072,388</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24298">3,503,702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24299">3,134,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Farmland development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24300">1,656,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24301">1,741,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office equipment and furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24302">5,729,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24303">5,811,887</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24304">421,234</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24305">358,542</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24306">16,928,409</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-24307">17,118,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24308">10,355,233</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-24309">10,266,513</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Impairment*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="cjjd:AccumulatedImpairmentPropertyPlantAndEquipment" scale="0" unitRef="usd">1,666,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="cjjd:AccumulatedImpairmentPropertyPlantAndEquipment" scale="0" unitRef="usd">1,752,178</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-24312">4,906,589</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-24313">5,100,264</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total depreciation expense for property and equipment
was $<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-24314">693,537</ix:nonFraction> and $<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-24315">625,739</ix:nonFraction> for the year ended March 31, 2024 and 2023, respectively. There were no fixed assets impaired in the years ended
March 31, 2024 and March 31, 2023.&#160;&#160;</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-20881"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;7 &#8211; LONG-TERM INVESTMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ixv-24316">Long-term investment consists of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_2" id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kahamadi Bio <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhuoli Life <sup>(2)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,680,337</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Songlu Pharmaceutical <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">83,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">87,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Digital <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">4,155</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">4,368</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,108,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Long-term investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-24323">1,195,261</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd" id="ixv-24324">1,772,072</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_3" id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents <ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="cjjd:InvestmentPercentage" scale="-2" unitRef="pure" id="ixv-24325">49</ix:nonFraction>% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-24326">0</ix:nonFraction> and $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-24327">0</ix:nonFraction> in the year ended March 31, 2024 and 2023.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_4" id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents <ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="cjjd:InvestmentPercentage" scale="-2" unitRef="pure" id="ixv-24328">39</ix:nonFraction>% investment in Zhejiang Zhuoli Life Service Co., LTD (&#8220;Zhuoli Service&#8221;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="cjjd:InjectedFunds" scale="0" unitRef="usd" id="ixv-24329">1,443,752</ix:nonFraction> into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-24330">2,402,376</ix:nonFraction> in the year ended March 31, 2023. An impairment loss of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:LongTermInvestmentImpairmentLoss" scale="0" unitRef="usd" id="ixv-24331">1,607,537</ix:nonFraction> was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was <span style="-sec-ix-hidden: hidden-fact-107">nil</span>.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_5" id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents <ix:nonFraction contextRef="c191" decimals="4" format="ixt:num-dot-decimal" name="cjjd:InvestmentPercentage" scale="-2" unitRef="pure" id="ixv-24332">0.37</ix:nonFraction>% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#8220;Songlu Pharmaceutical&#8221;). The investment is recorded based on cost method.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_6" id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents <ix:nonFraction contextRef="c192" decimals="4" format="ixt:num-dot-decimal" name="cjjd:InvestmentPercentage" scale="-2" unitRef="pure" id="ixv-24333">25.92</ix:nonFraction>% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="cjjd:InjectedFunds" scale="0" unitRef="usd" id="ixv-24334">4,379</ix:nonFraction> into Jiuzhou Digital. The investment is recorded based on equity method.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfDebtInstrumentsTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_8_footnote" xml:lang="en-US">It represents <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="cjjd:InvestmentPercentage" scale="-2" unitRef="pure" id="ixv-24336">8</ix:nonFraction>% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:InjectedFunds" scale="0" unitRef="usd" id="ixv-24337">1,113,650</ix:nonFraction>(RMB <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:InjectedFunds" scale="0" unitRef="cny" id="ixv-24338">8,000,000</ix:nonFraction>) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.</ix:footnote>&#160;</span></td></tr> </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cjjd:AdvancesToSuppliersTextBlock" id="ixv-21021"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;8 &#8211; ADVANCES TO SUPPLIERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers consist of deposits, with
or advances to, outside vendors for future inventory purchases. Most of the Company&#8217;s suppliers require a certain amount of money
to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears
no interest. <ix:nonNumeric contextRef="c0" continuedAt="cjjd_AdvanceToSuppliersTableTextBlock-c0_cont_1" escape="true" name="cjjd:AdvanceToSuppliersTableTextBlock" id="ixv-24339">As of March 31, 2024 and March 31, 2023, advance to suppliers consist of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="cjjd_AdvanceToSuppliersTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AdvancesOnInventoryPurchasesGross" scale="0" unitRef="usd" id="ixv-24340">1,177,399</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AdvancesOnInventoryPurchasesGross" scale="0" unitRef="usd" id="ixv-24341">362,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: reserve for vendor non-performance on advances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AllowanceForAdvancesToSuppliers" scale="0" unitRef="usd" id="ixv-24342">262,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:AllowanceForAdvancesToSuppliers" scale="0" unitRef="usd" id="ixv-24343">219,630</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Advance to suppliers, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-24344">914,776</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="0" unitRef="usd" id="ixv-24345">142,417</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-21083"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9 &#8211; INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consisted of finished goods, valued
at $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-24346">16,248,373</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-24347">15,309,100</ix:nonFraction> as of March 31, 2024 and March 31, 2023, respectively. The Company constantly monitors its potential obsolete
products and is allowed to return products close to their expiration date to its suppliers. Any loss on damaged items is immaterial and
will be recognized immediately. As a result, <span style="-sec-ix-hidden: hidden-fact-108"><span style="-sec-ix-hidden: hidden-fact-109">no</span></span> reserves were made for inventory as of March 31, 2024 and March 31, 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cjjd:FarmlandAssetsTextBlock" id="ixv-21093"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 &#8211; FARMLAND ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="cjjd_ScheduleOfFarmlandAssetsTableTextBlock-c0_cont_1" escape="true" name="cjjd:ScheduleOfFarmlandAssetsTableTextBlock" id="ixv-24348">Farmland assets consist of ginkgo trees planted
in 2012 and expected to be harvested and sold in several years. As of March 31, 2024 and March 31, 2023, farmland assets are valued as
follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="cjjd_ScheduleOfFarmlandAssetsTableTextBlock-c0_cont_2" id="cjjd_ScheduleOfFarmlandAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Farmland assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:FarmlandAssetsGross" scale="0" unitRef="usd" id="ixv-24349">2,176,079</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:FarmlandAssetsGross" scale="0" unitRef="usd" id="ixv-24350">2,287,836</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Impairment*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="cjjd:ImpairmentsOfFarmlandAssets" scale="0" unitRef="usd">1,541,926</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="cjjd:ImpairmentsOfFarmlandAssets" scale="0" unitRef="usd">1,621,115</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Farmland assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Land" scale="0" unitRef="usd" id="ixv-24353">634,153</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Land" scale="0" unitRef="usd" id="ixv-24354">666,721</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="cjjd_ScheduleOfFarmlandAssetsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><ix:footnote id="ix_9_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfRealEstate" scale="0" unitRef="usd" id="ixv-24355">148,795</ix:nonFraction>.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cjjd:LongTermDepositsTextBlock" id="ixv-21159"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;11 &#8211; LONG TERM DEPOSITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024 and March 31, 2023, long
term deposits amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-24356">1,119,006</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-24357">1,038,125</ix:nonFraction>, respectively.&#160;Long term deposits are sums deposited with, or advanced to, landlords
for the purpose of securing retail store leases that the Company does not anticipate applying or being returned within the next twelve
months. Most of the Company&#8217;s landlords require a minimum payment of nine months&#8217; rent, paid up front, plus additional deposits.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" id="ixv-21167"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;12 &#8211; OTHER NONCURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherAssetsNoncurrentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="ixv-24358">Other noncurrent assets consisted of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfOtherAssetsNoncurrentTextBlock-c0_cont_2" id="_ScheduleOfOtherAssetsNoncurrentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Forest land use rights*</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="cjjd:ForestLandUseRights" scale="0" unitRef="usd">639,414</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="cjjd:ForestLandUseRights" scale="0" unitRef="usd">691,537</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="cjjd:Others" scale="0" unitRef="usd" id="ixv-24361">43,023</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="cjjd:Others" scale="0" unitRef="usd" id="ixv-24362">98,519</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-24363">682,437</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-24364">790,056</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfOtherAssetsNoncurrentTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><ix:footnote id="ix_10_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. <ix:nonNumeric contextRef="c0" name="cjjd:DescriptionOfLeasePrepaymentLife" id="ixv-24365">The forest rights certificate from the local village extends the life of the lease to January 31, 2060.</ix:nonNumeric></span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amortization of the prepayment for the lease
of land use right was approximately $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-24366">18,477</ix:nonFraction> and $<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-24367">19,328</ix:nonFraction> for the years ended March 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-24368">The Company&#8217;s amortizations of the prepayment
for lease of land use right for the next five years and thereafter are as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Years ending March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd" id="ixv-24369">18,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd" id="ixv-24370">18,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd" id="ixv-24371">18,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd" id="ixv-24372">18,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd" id="ixv-24373">18,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd" id="ixv-24374">547,029</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-21286"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 13 &#8211; Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases most of its retail stores and
corporate offices under operating leases, typically with initial terms of <ix:nonNumeric contextRef="c203" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-24375">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c204" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-24376">10</ix:nonNumeric> years. Usually within one to three months prior to the
expiration date of a lease, the Company is required to notify the lessor and has a priority to continue renting the lease property if
a lessor intends to lease property. The lease itself does not have restriction or covenants. If both parties agree to continue, a new
lease contract with new lease terms has to been signed by both parties. Usually the rent may increase year by year based on the lease
contract. Sublease is typically not allowed. Any damage, if made by the lessee, to the property and equipment within the property has
to been fixed or reimbursed by the lessee. The Company does not have any leases entered into but which have not yet commenced. The net
lease cost for the year ended March 31, 2024 is $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-24377">7,487,456</ix:nonFraction>. The Company does not have finance lease according to the definition of ASU
2016-02, <i>Leases </i>(Topic 842). <ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-24378">Supplemental cash flow information related to leases for the year ended March 31, 2024 is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_2" id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt">Operating cash flows paid for operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-24379">7,487,456</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_3" id="_LeaseCostTableTextBlock-c0_cont_2">Supplemental balance sheet information related
to leases as of March 31, 2024 is as follows:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Operating leases:</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-24381">13,827,360</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of operating lease liabilities</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-24382">4,862,766</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-24383">6,403,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24384">11,266,624</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average remaining lease term</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-24385">3.93</ix:nonNumeric> years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-24386">4.8</ix:nonFraction></td><td style="text-align: left">%</td></tr> </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-24387">The following table summarizes the maturity of
lease liabilities under operating leases as of March 31, 2024:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Operating</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">For the year ending March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Leases</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-24388">5,294,771</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-24389">2,872,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-24390">1,913,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd" id="ixv-24391">1,107,753</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" unitRef="usd" id="ixv-24392">448,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" unitRef="usd" id="ixv-24393">621,050</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-24394">12,257,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-24395">990,915</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-24396">11,266,624</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="ixv-21467"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;14 &#8211; INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-24397">Net intangible assets consisted of the following
at:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">2,305,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">2,354,534</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,115,192</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,172,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,350,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">1,419,936</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-24404">4,771,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-24405">4,946,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-24406">1,155,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-24407">1,114,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: impairment <sup>(4)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="cjjd:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" scale="0" unitRef="usd">606,035</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="cjjd:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" scale="0" unitRef="usd">637,159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-24410">3,009,922</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-24411">3,195,748</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense of intangibles amounted to
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-24412">96,912</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-24413">92,263</ix:nonFraction> for the years ended March 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_3" id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_11_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#8217; business and liquidate all of the stores&#8217; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_12_footnote" xml:lang="en-US">They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#8217; health.</ix:footnote> </span></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><ix:footnote id="ix_13_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2013, the Company purchased the land use rights of a plot of land in Lin&#8217;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#8217;s farming business in Lin&#8217;an has not grown, the Company does not expect completion of the plant in the near future.</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="ix_14_footnote" xml:lang="en-US">In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020.</ix:footnote> </span></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-21613"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;15 &#8211; NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has credit facilities with Hangzhou
United Bank (&#8220;HUB&#8221;), Bank of Hangzhou (&#8220;BOH&#8221;), and China Merchant Bank (&#8220;CMB&#8221;) that provided working
capital in the form of the following bank acceptance notes. Usually, the Company applies to issue a note, which is guaranteed by the bank,
to its supplier to pay off its debt in a future date. Before the payment date, the bank will ask the Company to inject cash into the bank.
On the payment date, the bank will pay the amount to whoever legally holds the note. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfLineOfCreditFacilitiesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="ixv-24416">As of at March 31, 2024 and March 31, 2023, the balances
of notes payable are as follow:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfLineOfCreditFacilitiesTextBlock-c0_cont_2" id="_ScheduleOfLineOfCreditFacilitiesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">Origination</td><td>&#160;</td> <td style="text-align: center">Maturity</td><td>&#160;</td> <td colspan="2" style="text-align: center">March&#160;31,</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Endorser</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">date</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">date</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Jiuzhou Pharmacy</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c216" id="ix_22_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c216" format="ixt:date-month-day-year" id="ix_23_fact" name="cjjd:DebtInstrumentIOriginationDate">10/19/22</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c216" format="ixt:date-month-day-year" id="ix_24_fact" name="us-gaap:DebtInstrumentMaturityDate">04/19/23</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">3,289,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c219" id="ix_26_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c219" format="ixt:date-month-day-year" id="ix_27_fact" name="cjjd:DebtInstrumentIOriginationDate">10/20/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c219" format="ixt:date-month-day-year" id="ix_28_fact" name="us-gaap:DebtInstrumentMaturityDate">04/19/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">36,403</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c222" id="ix_30_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c222" format="ixt:date-month-day-year" id="ix_31_fact" name="cjjd:DebtInstrumentIOriginationDate">11/17/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c222" format="ixt:date-month-day-year" id="ix_32_fact" name="us-gaap:DebtInstrumentMaturityDate">05/17/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">5,576,213</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c225" id="ix_34_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c225" format="ixt:date-month-day-year" id="ix_35_fact" name="cjjd:DebtInstrumentIOriginationDate">12/16/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c225" format="ixt:date-month-day-year" id="ix_36_fact" name="us-gaap:DebtInstrumentMaturityDate">06/16/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">1,207,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c228" id="ix_38_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c228" format="ixt:date-month-day-year" id="ix_39_fact" name="cjjd:DebtInstrumentIOriginationDate">12/26/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c228" format="ixt:date-month-day-year" id="ix_40_fact" name="us-gaap:DebtInstrumentMaturityDate">06/27/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">659,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c231" id="ix_42_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c231" format="ixt:date-month-day-year" id="ix_43_fact" name="cjjd:DebtInstrumentIOriginationDate">12/28/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c231" format="ixt:date-month-day-year" id="ix_44_fact" name="us-gaap:DebtInstrumentMaturityDate">06/29/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">2,654,696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c234" id="ix_46_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c234" format="ixt:date-month-day-year" id="ix_47_fact" name="cjjd:DebtInstrumentIOriginationDate">01/16/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c234" format="ixt:date-month-day-year" id="ix_48_fact" name="us-gaap:DebtInstrumentMaturityDate">07/16/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" id="ix_49_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">346,545</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c237" id="ix_50_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c237" format="ixt:date-month-day-year" id="ix_51_fact" name="cjjd:DebtInstrumentIOriginationDate">02/27/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c237" format="ixt:date-month-day-year" id="ix_52_fact" name="us-gaap:DebtInstrumentMaturityDate">08/27/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" id="ix_53_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">3,242,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c240" id="ix_54_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c240" format="ixt:date-month-day-year" id="ix_55_fact" name="cjjd:DebtInstrumentIOriginationDate">03/20/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c240" format="ixt:date-month-day-year" id="ix_56_fact" name="us-gaap:DebtInstrumentMaturityDate">09/20/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" id="ix_57_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">4,573,664</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c243" id="ix_58_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c243" format="ixt:date-month-day-year" id="ix_59_fact" name="cjjd:DebtInstrumentIOriginationDate">03/23/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c243" format="ixt:date-month-day-year" id="ix_60_fact" name="us-gaap:DebtInstrumentMaturityDate">09/23/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" id="ix_61_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">440,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c246" id="ix_62_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c246" format="ixt:date-month-day-year" id="ix_63_fact" name="cjjd:DebtInstrumentIOriginationDate">11/17/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c246" format="ixt:date-month-day-year" id="ix_64_fact" name="us-gaap:DebtInstrumentMaturityDate">05/17/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" id="ix_65_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">1,303,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c249" id="ix_66_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c249" format="ixt:date-month-day-year" id="ix_67_fact" name="cjjd:DebtInstrumentIOriginationDate">12/16/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c249" format="ixt:date-month-day-year" id="ix_68_fact" name="us-gaap:DebtInstrumentMaturityDate">06/16/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" id="ix_69_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">3,704,790</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c252" id="ix_70_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c252" format="ixt:date-month-day-year" id="ix_71_fact" name="cjjd:DebtInstrumentIOriginationDate">12/21/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c252" format="ixt:date-month-day-year" id="ix_72_fact" name="us-gaap:DebtInstrumentMaturityDate">06/21/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" id="ix_73_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">200,741</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c255" id="ix_74_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c255" format="ixt:date-month-day-year" id="ix_75_fact" name="cjjd:DebtInstrumentIOriginationDate">12/29/22</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c255" format="ixt:date-month-day-year" id="ix_76_fact" name="us-gaap:DebtInstrumentMaturityDate">06/29/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" id="ix_77_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">1,215,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c258" id="ix_78_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c258" format="ixt:date-month-day-year" id="ix_79_fact" name="cjjd:DebtInstrumentIOriginationDate">03/20/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c258" format="ixt:date-month-day-year" id="ix_80_fact" name="us-gaap:DebtInstrumentMaturityDate">09/20/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" id="ix_81_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">803,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c261" id="ix_82_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c261" format="ixt:date-month-day-year" id="ix_83_fact" name="cjjd:DebtInstrumentIOriginationDate">10/12/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c261" format="ixt:date-month-day-year" id="ix_84_fact" name="us-gaap:DebtInstrumentMaturityDate">04/12/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" id="ix_85_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">5,126,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c264" id="ix_86_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c264" format="ixt:date-month-day-year" id="ix_87_fact" name="cjjd:DebtInstrumentIOriginationDate">11/21/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c264" format="ixt:date-month-day-year" id="ix_88_fact" name="us-gaap:DebtInstrumentMaturityDate">05/21/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" id="ix_89_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">5,703,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#160;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c267" id="ix_90_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c267" format="ixt:date-month-day-year" id="ix_91_fact" name="cjjd:DebtInstrumentIOriginationDate">12/22/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c267" format="ixt:date-month-day-year" id="ix_92_fact" name="us-gaap:DebtInstrumentMaturityDate">06/22/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" id="ix_93_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">6,040,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c270" id="ix_94_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c270" format="ixt:date-month-day-year" id="ix_95_fact" name="cjjd:DebtInstrumentIOriginationDate">12/27/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c270" format="ixt:date-month-day-year" id="ix_96_fact" name="us-gaap:DebtInstrumentMaturityDate">06/27/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" id="ix_97_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">274,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c273" id="ix_98_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c273" format="ixt:date-month-day-year" id="ix_99_fact" name="cjjd:DebtInstrumentIOriginationDate">12/28/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c273" format="ixt:date-month-day-year" id="ix_100_fact" name="us-gaap:DebtInstrumentMaturityDate">06/28/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" id="ix_101_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">151,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c276" id="ix_102_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c276" format="ixt:date-month-day-year" id="ix_103_fact" name="cjjd:DebtInstrumentIOriginationDate">01/03/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c276" format="ixt:date-month-day-year" id="ix_104_fact" name="us-gaap:DebtInstrumentMaturityDate">07/03/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" id="ix_105_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">102,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c279" id="ix_106_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c279" format="ixt:date-month-day-year" id="ix_107_fact" name="cjjd:DebtInstrumentIOriginationDate">01/11/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c279" format="ixt:date-month-day-year" id="ix_108_fact" name="us-gaap:DebtInstrumentMaturityDate">07/11/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" id="ix_109_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">248,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c282" id="ix_110_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c282" format="ixt:date-month-day-year" id="ix_111_fact" name="cjjd:DebtInstrumentIOriginationDate">02/06/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c282" format="ixt:date-month-day-year" id="ix_112_fact" name="us-gaap:DebtInstrumentMaturityDate">08/06/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" id="ix_113_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">3,189,602</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c285" id="ix_114_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c285" format="ixt:date-month-day-year" id="ix_115_fact" name="cjjd:DebtInstrumentIOriginationDate">03/13/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c285" format="ixt:date-month-day-year" id="ix_116_fact" name="us-gaap:DebtInstrumentMaturityDate">09/13/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" id="ix_117_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">3,274,739</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c288" id="ix_118_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c288" format="ixt:date-month-day-year" id="ix_119_fact" name="cjjd:DebtInstrumentIOriginationDate">03/14/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c288" format="ixt:date-month-day-year" id="ix_120_fact" name="us-gaap:DebtInstrumentMaturityDate">09/14/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" id="ix_121_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">969,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c291" id="ix_122_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c291" format="ixt:date-month-day-year" id="ix_123_fact" name="cjjd:DebtInstrumentIOriginationDate">12/27/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c291" format="ixt:date-month-day-year" id="ix_124_fact" name="us-gaap:DebtInstrumentMaturityDate">06/27/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c292" decimals="0" format="ixt:num-dot-decimal" id="ix_125_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">415,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c294" id="ix_126_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c294" format="ixt:date-month-day-year" id="ix_127_fact" name="cjjd:DebtInstrumentIOriginationDate">12/28/23</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c294" format="ixt:date-month-day-year" id="ix_128_fact" name="us-gaap:DebtInstrumentMaturityDate">06/28/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c295" decimals="0" format="ixt:num-dot-decimal" id="ix_129_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">1,689,726</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c297" id="ix_130_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c297" format="ixt:date-month-day-year" id="ix_131_fact" name="cjjd:DebtInstrumentIOriginationDate">01/11/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c297" format="ixt:date-month-day-year" id="ix_132_fact" name="us-gaap:DebtInstrumentMaturityDate">07/11/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c298" decimals="0" format="ixt:num-dot-decimal" id="ix_133_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">3,234,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c300" id="ix_134_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c300" format="ixt:date-month-day-year" id="ix_135_fact" name="cjjd:DebtInstrumentIOriginationDate">02/06/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c300" format="ixt:date-month-day-year" id="ix_136_fact" name="us-gaap:DebtInstrumentMaturityDate">08/06/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" id="ix_137_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">186,973</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c302" id="ix_138_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c302" format="ixt:date-month-day-year" id="ix_139_fact" name="cjjd:DebtInstrumentIOriginationDate">03/15/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c302" format="ixt:date-month-day-year" id="ix_140_fact" name="us-gaap:DebtInstrumentMaturityDate">09/15/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" id="ix_141_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">415,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c304" id="ix_142_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c304" format="ixt:date-month-day-year" id="ix_143_fact" name="cjjd:DebtInstrumentIOriginationDate">03/28/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c304" format="ixt:date-month-day-year" id="ix_144_fact" name="us-gaap:DebtInstrumentMaturityDate">09/28/24</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" id="ix_145_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">293,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Jiuxin Medicine</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c306" id="ix_146_fact" name="us-gaap:DebtInstrumentIssuer">HUB</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c306" format="ixt:date-month-day-year" id="ix_147_fact" name="cjjd:DebtInstrumentIOriginationDate">03/29/24</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c306" format="ixt:date-month-day-year" id="ix_148_fact" name="us-gaap:DebtInstrumentMaturityDate">09/29/24</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" id="ix_149_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">359,179</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_150_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">31,676,335</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_151_fact" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd">29,255,776</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfLineOfCreditFacilitiesTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_15_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-24547">31,676,335</ix:nonFraction> (RMB<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="cny" id="ixv-24548">228,712,642</ix:nonFraction>) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd" id="ixv-24549">12,657,839</ix:nonFraction> (RMB <ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="cny" id="ixv-24550">91,393,395</ix:nonFraction> ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCollateralAmount" scale="0" unitRef="usd" id="ixv-24551">4,501,198</ix:nonFraction> three-year deposit (RMB<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCollateralAmount" scale="0" unitRef="cny" id="ixv-24552">32,500,000</ix:nonFraction>) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-24553">29,255,776</ix:nonFraction> (RMB <ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="cny" id="ixv-24554">200,916,968</ix:nonFraction>) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="usd" id="ixv-24555">12,217,616</ix:nonFraction> (RMB <ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="0" unitRef="cny" id="ixv-24556">83,905,700</ix:nonFraction> ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCollateralAmount" scale="0" unitRef="usd" id="ixv-24557">4,732,366</ix:nonFraction> three-year deposit (RMB<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCollateralAmount" scale="0" unitRef="cny" id="ixv-24558">32,500,000</ix:nonFraction>) deposited into HUB as a collateral for current and future notes payable from HUB.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, the Company had a credit
line of approximately $<ix:nonFraction contextRef="c211" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="usd" id="ixv-24559">19.25</ix:nonFraction> million in the aggregate&#160;from HUB. By putting up a three-year deposit of $<ix:nonFraction contextRef="c212" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="6" unitRef="usd" id="ixv-24560">4.50</ix:nonFraction> million and the restricted
cash of $<ix:nonFraction contextRef="c212" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" unitRef="usd" id="ixv-24561">8.16</ix:nonFraction> million deposited in the banks, the total credit line was $<ix:nonFraction contextRef="c212" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="6" unitRef="usd" id="ixv-24562">31.91</ix:nonFraction> million. As of March 31, 2024, the Company had approximately
$<ix:nonFraction contextRef="c215" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="6" unitRef="usd" id="ixv-24563">31.68</ix:nonFraction> million of bank notes payable and approximately $<ix:nonFraction contextRef="c212" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" unitRef="usd" id="ixv-24564">0.23</ix:nonFraction> million bank credit line was still available for further borrowing. The bank
notes are secured by three shops of Jiuzhou Pharmacy and guaranteed by the Company&#8217;s major shareholders.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cjjd:LoanPayableTextBlock" id="ixv-22233"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 16 &#8211; LOAN PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 4, 2023, Jiuzhou&#160;Service signed
a Maximum Amount Pledge Contract with Industrial and Commercial Bank of China, pledging Mr. Lei Liu&#8217;s land use rights and property
ownership as security, for a loan facility with a maximum principal amount of US$<ix:nonFraction contextRef="c309" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-24565">1.60</ix:nonFraction>(RMB<ix:nonFraction contextRef="c310" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="cny" id="ixv-24566">11.49</ix:nonFraction>) million during the period from August
4, 2023 to August 4, 2028. As of March 31, 2024, the outstanding amount of the short-term bank loan under this pledge contract was US$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd" id="ixv-24567">276,997</ix:nonFraction>(RMB<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="cny" id="ixv-24568">2,000,000</ix:nonFraction>)
..</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-22241"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;17 &#8211; TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax expense includes a provision for federal,
state and foreign taxes based on the annual estimated effective tax rate applicable to the Company and its subsidiaries, adjusted for
items which are considered discrete to the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rates on income before income
taxes for the year ended March 31, 2024 was (<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-24569">1.5</ix:nonFraction>)%. The (<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" sign="-" unitRef="pure" id="ixv-24570">1.5</ix:nonFraction>)% rate adjustments for the year ended March 31, 2024 represent expenses that
primarily include legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rates on income before income
taxes for the year ended March 31, 2023 was (<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-24571">1.9</ix:nonFraction>)%. The (<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" sign="-" unitRef="pure" id="ixv-24572">1.9</ix:nonFraction>)% rate adjustments for the year ended March 31, 2023 represent expenses that
primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC
income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through the rest
of the year as a result of the unpredictable impact of COVID-19 on the Company&#8217;s operating activities.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rates on income before income
taxes for the year ended March 31, 2022 was (<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-24573">52.4</ix:nonFraction>)%. The (<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" sign="-" unitRef="pure" id="ixv-24574">52.4</ix:nonFraction>)% rate adjustments for the year ended March 31, 2022 represent expenses
that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible
for PRC income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through
the rest of the year as a result of the unpredictable impact of COVID-19 on the Company&#8217;s operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-24575">A reconciliation of the income tax provision at
the federal statutory rate and the effective rate is as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year ended <br/> March 31</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">U.S. Statutory rates</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-24576">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-24577">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-24578">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign income not recognized in the U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-24579">21.0</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-24580">21.0</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-24581">21.0</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">China income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" scale="-2" unitRef="pure" id="ixv-24582">25.0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" scale="-2" unitRef="pure" id="ixv-24583">25.0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" scale="-2" unitRef="pure" id="ixv-24584">25.0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-24585">25.0</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-24586">25.0</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-24587">25.0</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-deductible expenses-permanent difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" sign="-" unitRef="pure" id="ixv-24588">1.5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" sign="-" unitRef="pure" id="ixv-24589">1.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" sign="-" unitRef="pure" id="ixv-24590">52.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-24591">1.5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-24592">1.9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" sign="-" unitRef="pure" id="ixv-24593">52.4</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has recorded $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" unitRef="usd" id="ixv-24594">0</ix:nonFraction> unrecognized benefit
as of March 31, 2024. On the information currently available, the Company does not anticipate a significant increase or decrease to its
unrecognized benefit within the next 12 months.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-22366"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 18 &#8211; POSTRETIREMENT BENEFITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulations in the PRC require the Company to
contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage
of the employee&#8217;s current compensation as required by the local government. The Company contributed $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="0" unitRef="usd" id="ixv-24595">1,325,312</ix:nonFraction>, $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="0" unitRef="usd" id="ixv-24596">1,284,218</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="0" unitRef="usd" id="ixv-24597">1,301,315</ix:nonFraction>
in employment benefits and pension for the years ended March 31, 2024, 2023 and 2022, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-22385"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 19 &#8211; RELATED PARTY TRANSACTIONS
AND ARRANGEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-24598">Summary of Balances with Related Parties as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due from related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hangzhou Kahamadi Biotechnology Co., Ltd<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" id="ix_152_fact" name="us-gaap:OtherReceivables" scale="0" unitRef="usd">32,825</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others (the directors of subsidiaries)<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" id="ix_153_fact" name="us-gaap:OtherReceivables" scale="0" unitRef="usd">280,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-24601">313,346</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><ix:footnote id="ix_16_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lend to related parties</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_4" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due to related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to a director and CEO<sup>(2)</sup>:</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c315" decimals="0" format="ixt:num-dot-decimal" id="ix_154_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">1,580,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c316" decimals="0" format="ixt:num-dot-decimal" id="ix_155_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">683,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup>:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" id="ix_156_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">253,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24605">1,833,509</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-24606">683,560</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances to directors of our subsidiaries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_5" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><ix:footnote id="ix_17_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to foreign exchange restrictions, the Company&#8217;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><ix:footnote id="ix_18_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical borrowed from its non-controlling shareholder.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-22524"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 20 &#8211; SHAREHOLDER&#8217;S EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2023, the Company closed a private
placement of <ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24607">498,000</ix:nonFraction> shares of ordinary shares at $<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24608">5.20</ix:nonFraction> per share with gross proceeds of $<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" unitRef="usd" id="ixv-24609">2,589,600</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2024, <ix:nonNumeric contextRef="c0" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-24610">the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares</ix:nonNumeric>. Upon the effectiveness of the reverse stock split, every <ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-24611"><ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-24612">20</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#8217;s percentage
interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the registered direct offering
of common stock that closed on April 15, 2019, the Company issued to several investors in a private placement warrants to purchase up
to <ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-24613">12,501</ix:nonFraction> shares of common stock. In connection with the offering, the Company also issued a warrant to its placement agent of this offering,
pursuant to which the agent may purchase up to <ix:nonFraction contextRef="c319" decimals="2" format="ixt:num-dot-decimal" name="cjjd:AggregateSharePercentage" scale="-2" unitRef="pure" id="ixv-24614">6</ix:nonFraction>% of the aggregate number of shares of common stock sold in the offering, i.e. <ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24615">1,000</ix:nonFraction> shares
at an exercise price of $<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24616">750</ix:nonFraction> per share. The warrant became exercisable on October 11, 2019 and has expired on April 11, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the registered direct offering
of common stock that closed on June 3, 2020, the Company issued to several investors in a private placement warrants to purchase up to
<ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-24617">15,625</ix:nonFraction> shares of common stock. In connection with the offering, the Company also issued warrants to its placement agent of this offering,
pursuant to which the agent may purchase up to <ix:nonFraction contextRef="c322" decimals="3" format="ixt:num-dot-decimal" name="cjjd:AggregateSharePercentage" scale="-2" unitRef="pure" id="ixv-24618">6.5</ix:nonFraction>% of the aggregate number of shares of common stock sold in the offering, i.e. <ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-24619">1,250</ix:nonFraction>
shares at an exercise price of $<ix:nonFraction contextRef="c322" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24620">616.8</ix:nonFraction> per share. The warrant becomes exercisable on December 2, 2020 and will expire on June 2, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the registered direct offering
of ordinary shares that closed on September 26, 2023, the Company issued to several investors warrants to purchase up to <ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-24621">996,000</ix:nonFraction> shares
of ordinary shares at an exercise price of $<ix:nonFraction contextRef="c324" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-24622">5.20</ix:nonFraction>. The warrant became exercisable on September 26, 2023 and valid for three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Statutory reserves</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Statutory reserves represent restricted retained
earnings. Based on their legal formation, the Company is required to set aside <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cjjd:StatutoryAccountsPercentage" scale="-2" unitRef="pure" id="ixv-24623">10</ix:nonFraction>% of its net income as reported in their statutory accounts
on an annual basis to the Statutory Surplus Reserve Fund (the &#8220;Reserve Fund&#8221;). Once the total amount set aside in the Reserve
Fund reaches <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cjjd:ReserveFundPercentage" scale="-2" unitRef="pure" id="ixv-24624">50</ix:nonFraction>% of the entity&#8217;s registered capital, further appropriations become discretionary. The Reserve Fund can be used to
increase the entity&#8217;s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC
GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise,
except in the event of liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Appropriations to the Reserve Fund are accounted
for as a transfer from unrestricted earnings to statutory reserves. During the years ended March 31, 2024 and 2023, the Company did not
make appropriations to statutory reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no legal requirements in the PRC to
fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-22569"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 21 &#8211; NET LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reports earnings per share in accordance
with the provisions of the FASB&#8217;s related accounting standard. This standard requires presentation of basic and diluted earnings
per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes
dilution, but includes vested restricted stocks and is computed by dividing income available to ordinary shareholders by the weighted
average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur
if securities or other contracts to issue ordinary shares were exercised and converted into ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-24625">The following is a reconciliation of the basic
and diluted earnings per share computation:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss attributable to controlling interest</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24626">4,234,228</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24627">21,138,525</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24628">3,192,119</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average shares used in basic computation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24629">1,444,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24630">509,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-24631">173,966</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted effect of stock options and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average shares used in diluted computation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24632">1,444,263</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24633">509,828</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-24634">173,966</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share &#8211; Basic:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss before noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest" scale="0" sign="-" unitRef="usdPershares" id="ixv-24635">2.93</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest" scale="0" sign="-" unitRef="usdPershares" id="ixv-24636">41.46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest" scale="0" sign="-" unitRef="usdPershares" id="ixv-24637">18.35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: Net loss attributable to noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24638">2.93</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24639">41.46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-24640">18.35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share &#8211; Diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net income before noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest" scale="0" sign="-" unitRef="usdPershares" id="ixv-24641">2.93</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest" scale="0" sign="-" unitRef="usdPershares" id="ixv-24642">41.46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest" scale="0" sign="-" unitRef="usdPershares" id="ixv-24643">18.35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: Net loss attributable to noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24644">2.93</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24645">41.46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-24646">18.35</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended March 31, 2024, <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24647">1,024,126</ix:nonFraction> shares
underlying outstanding purchase warrants to several investors, and <ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-24648">2,250</ix:nonFraction> shares underlying outstanding purchase warrants to an investment
placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-22787"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 22 &#8211; SEGMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates within <ix:nonFraction contextRef="c326" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-24649">three</ix:nonFraction> main reportable
segments: retail drugstores, online pharmacy, and drug wholesale. The retail drugstores segment sells prescription and over-the-counter
(&#8220;OTC&#8221;) medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers.&#160;The online pharmacy
sells prescription drugs, OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms
such as Alibaba&#8217;s Tmall, JD.com and Amazon.com, and the Company&#8217;s own platform all over China. The drug wholesale segment
includes supplying the Company&#8217;s own retail&#160;drugstores with prescription and OTC medicines, TCM, dietary supplement, medical
devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors
and hospitals. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable
segments and are included in the retail drugstores segment. The segments&#8217; accounting policies are the same as those described in
the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest
and income taxes not including nonrecurring gains and losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s reportable business segments
are strategic business units that offer different products and services. Each segment is managed separately because they require different
operations and markets to distinct classes of customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-24650">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2024:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24651">75,678,470</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24652">31,857,883</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24653">47,004,724</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24654">154,541,077</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24655">53,056,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24656">28,249,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24657">42,126,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24658">123,432,529</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24659">22,622,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24660">3,608,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24661">4,878,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24662">31,108,548</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24663">21,680,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24664">4,770,855</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24665">934,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24666">27,385,587</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24667">5,195,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24668">466,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24669">1,596,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24670">7,257,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24671">4,253,531</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24672">1,629,006</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-24673">2,347,974</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24674">3,534,563</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24675">754,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24676">36,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24677">790,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24678">855,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24679">1,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24680">856,665</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_3" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_2">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2023:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_4" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24682">83,351,768</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24683">32,385,089</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24684">33,075,119</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24685">148,811,976</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24686">56,551,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24687">28,506,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24688">29,473,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24689">114,531,512</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24690">26,800,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24691">3,878,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24692">3,601,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24693">34,280,464</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24694">23,644,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24695">4,266,799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24696">1,266,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24697">29,177,163</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24698">13,803,165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24699">439,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24700">1,425,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24701">15,668,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-24702">10,360,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-24703">10,360,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24704">21,007,343</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24705">827,605</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-24706">909,565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24707">20,925,383</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24708">686,777</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24709">31,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24710">718,002</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24711">303,312</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24712">704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24713">304,016</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_5" id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_4">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2022:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24715">84,228,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24716">30,219,364</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24717">49,944,699</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24718">164,392,555</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24719">57,290,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24720">26,621,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24721">43,961,351</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-24722">127,873,515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24723">26,937,642</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24724">3,598,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24725">5,983,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-24726">36,519,040</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24727">25,186,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24728">3,972,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24729">1,718,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingExpense" scale="0" unitRef="usd" id="ixv-24730">30,876,959</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24731">6,766,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24732">285,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24733">1,136,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-24734">8,187,176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" unitRef="usd" id="ixv-24735">148,795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" unitRef="usd" id="ixv-24736">148,795</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24737">5,163,433</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24738">659,477</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-24739">3,129,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-24740">2,693,890</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24741">1,234,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24742">22,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-24743">1,256,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24744">296,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24745">2,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="cjjd:CapitalExpenditureContinuedOperations" scale="0" unitRef="usd" id="ixv-24746">299,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>


</div><div>


</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have long-lived assets located
outside the PRC. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="ixv-24747">In accordance with the enterprise-wide disclosure requirements of FASB&#8217;s accounting standard, the Company&#8217;s
net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2024, 2023 and
2022 were as follows:</ix:nonNumeric>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_2" id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24748">25,269,177</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24749">27,212,994</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24750">28,503,283</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24751">31,542,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24752">32,358,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24753">35,658,864</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24754">9,890,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24755">8,737,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24756">9,664,071</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24757">3,405,979</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24758">9,719,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24759">5,353,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24760">1,129,647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24761">1,082,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24762">1,544,639</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24763">4,440,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24764">4,241,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24765">3,503,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24766">75,678,470</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24767">83,351,768</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24768">84,228,492</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_3" id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_2">The Company&#8217;s net revenue from external
customers through online pharmacy by main product category is as follows:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_4" id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years&#160;ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24770">9,151,412</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24771">10,606,244</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24772">10,331,652</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24773">12,969,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24774">13,870,953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24775">11,473,177</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24776">4,284,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24777">2,740,253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24778">2,014,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24779">571,769</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24780">434,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24781">315,231</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24782">1,448,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24783">1,129,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24784">2,271,009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24785">3,432,296</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24786">3,603,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24787">3,814,284</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24788">31,857,883</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24789">32,385,089</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24790">30,219,364</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation continuedAt="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_5" id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_4">The Company&#8217;s net revenue from external
customers through wholesale by main product category is as follows:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years&#160;ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c336" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24792">30,784,949</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24793">21,617,636</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24794">41,116,991</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24795">11,323,730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24796">10,289,987</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c341" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24797">7,903,824</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24798">741,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24799">310,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24800">424,210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24801">388,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c346" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24802">458,502</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24803">241,828</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c348" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24804">692,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24805">64,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24806">93,338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24807">3,073,665</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24808">333,663</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c353" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24809">164,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c354" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24810">47,004,724</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24811">33,075,119</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-24812">49,944,699</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-23727"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 23 &#8211; SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2024, the compensation committee of
our board of directors granted <ix:nonFraction contextRef="c357" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-24813">420,715</ix:nonFraction> ordinary shares (the &#8220;Shares&#8221;) of restricted stock awards (with the vesting conditions
waived) to Lei Liu, Chief Executive Officer and Director. The Shares were granted under the Company&#8217;s Third Amended and Restated
2010 Equity Incentive Plan. The issuance of the Shares is registered under a Registration Statement on Form S-8 filed with the Securities
and Exchange Commission and became effective on March 12, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2024, the Company entered into certain
Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of <ix:nonFraction contextRef="c358" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24814">900,000</ix:nonFraction> ordinary shares (the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Shares&#8221;), par value $<ix:nonFraction contextRef="c359" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24815">0.24</ix:nonFraction> per share,
of the Company (&#8220;Ordinary Shares&#8221;), at a purchase price of $<ix:nonFraction contextRef="c359" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24816">1.70</ix:nonFraction> per Share (the &#8220;Purchase Price&#8221;), for aggregate
gross proceeds to the Company of $<ix:nonFraction contextRef="c358" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-24817">1,530,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2024, the Company entered into certain
Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of <ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24818">1,610,000</ix:nonFraction> ordinary shares (the &#8220;Shares&#8221;), par value $<ix:nonFraction contextRef="c361" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24819">0.24</ix:nonFraction> per share, of the Company (&#8220;Ordinary Shares&#8221;),
at a purchase price of $<ix:nonFraction contextRef="c361" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24820">1.70</ix:nonFraction> per Share (the &#8220;Purchase Price&#8221;), for aggregate gross proceeds to the Company of $<ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-24821">2,737,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 11, 2024, the Company entered into certain
Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of <ix:nonFraction contextRef="c362" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-24822">1,980,000</ix:nonFraction> ordinary shares (the &#8220;Shares&#8221;), par value $<ix:nonFraction contextRef="c363" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24823">0.24</ix:nonFraction> per share, of the Company (&#8220;Ordinary Shares&#8221;),
at a purchase price of $<ix:nonFraction contextRef="c363" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-24824">1.70</ix:nonFraction> per Share (the &#8220;Purchase Price&#8221;), for an aggregate gross proceeds to the Company of $<ix:nonFraction contextRef="c362" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-24825">3,366,000</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-33</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric>
<ix:nonFraction contextRef="c5" id="hidden-fact-1" name="cjjd:DueFromRelatedsParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-10" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-11" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-12" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-13" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-14" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-15" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-16" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-17" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-18" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-19" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-20" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-21" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-22" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-25" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-26" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-27" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-28" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-29" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-31" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-32" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-33" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-43" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-44" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-45" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-46" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-47" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-48" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-49" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-50" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-51" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-52" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-53" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-54" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-55" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="cjjd:StockIssuedDuringPeriodValueForReverseStockSplit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-57" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-58" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-59" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-60" name="cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-61" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-62" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-63" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-64" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-65" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-66" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-67" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-68" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-69" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-70" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-71" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-72" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-73" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-74" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-75" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-76" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-77" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-78" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-79" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-80" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-81" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-82" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-83" name="us-gaap:PaymentsToAcquireInterestInJointVenture" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-84" name="us-gaap:ProceedsFromOtherShortTermDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-85" name="us-gaap:ProceedsFromOtherShortTermDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-86" name="us-gaap:RepaymentsOfOtherShortTermDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-87" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-89" name="cjjd:RepaymentOfOtherPayablesrelatedParties" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-90" name="cjjd:CashlessExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-91" name="cjjd:CashlessExerciseOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c79" id="hidden-fact-92" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c80" id="hidden-fact-93" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c82" id="hidden-fact-94" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c83" id="hidden-fact-95" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c88" id="hidden-fact-96" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c89" id="hidden-fact-97" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c90" id="hidden-fact-98" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c91" id="hidden-fact-99" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c60" decimals="0" id="hidden-fact-100" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" unitRef="cny">507760</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="0" id="hidden-fact-101" name="us-gaap:CashUninsuredAmount" unitRef="usd">79600</ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-102" name="us-gaap:NotesReceivableNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c185" id="hidden-fact-103" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c194" id="hidden-fact-104" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c195" id="hidden-fact-105" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c201" id="hidden-fact-106" name="us-gaap:LongTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-107" name="cjjd:LongTermInvestmentImpairmentLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-108" name="us-gaap:InventoryValuationReserves" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-109" name="us-gaap:InventoryValuationReserves" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-110" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c217" id="hidden-fact-111" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c220" id="hidden-fact-112" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c223" id="hidden-fact-113" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c226" id="hidden-fact-114" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c229" id="hidden-fact-115" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c232" id="hidden-fact-116" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c235" id="hidden-fact-117" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c238" id="hidden-fact-118" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c241" id="hidden-fact-119" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c244" id="hidden-fact-120" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c247" id="hidden-fact-121" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c250" id="hidden-fact-122" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c253" id="hidden-fact-123" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c256" id="hidden-fact-124" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c259" id="hidden-fact-125" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c263" id="hidden-fact-126" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c266" id="hidden-fact-127" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c269" id="hidden-fact-128" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c272" id="hidden-fact-129" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c275" id="hidden-fact-130" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c278" id="hidden-fact-131" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c281" id="hidden-fact-132" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c284" id="hidden-fact-133" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c287" id="hidden-fact-134" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c290" id="hidden-fact-135" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c293" id="hidden-fact-136" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c296" id="hidden-fact-137" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c299" id="hidden-fact-138" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c308" id="hidden-fact-139" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c312" id="hidden-fact-140" name="us-gaap:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c314" id="hidden-fact-141" name="us-gaap:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-142" name="us-gaap:OtherReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-143" name="cjjd:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-144" name="cjjd:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-145" name="cjjd:EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-146" name="cjjd:EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-147" name="cjjd:EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-148" name="cjjd:EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-149" name="cjjd:EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-150" name="cjjd:EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c328" id="hidden-fact-151" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c328" id="hidden-fact-152" name="cjjd:CapitalExpenditureContinuedOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c331" id="hidden-fact-153" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c332" id="hidden-fact-154" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c331" id="hidden-fact-155" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c331" id="hidden-fact-156" name="cjjd:CapitalExpenditureContinuedOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c334" id="hidden-fact-157" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c335" id="hidden-fact-158" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c334" id="hidden-fact-159" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c334" id="hidden-fact-160" name="cjjd:CapitalExpenditureContinuedOperations" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-24989">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-24990">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-24991">0001856084</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="cjjd-20240331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="hidden-fact-92 hidden-fact-93 hidden-fact-94" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-92 hidden-fact-93 hidden-fact-94 hidden-fact-95 hidden-fact-96 hidden-fact-97 hidden-fact-98 hidden-fact-99" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-103 hidden-fact-104" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-105 ix_4_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_5_fact ix_6_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_7_fact ix_8_fact" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_9_fact hidden-fact-106" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact ix_11_fact" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_12_fact ix_13_fact" toRefs="ix_10_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_14_fact ix_15_fact" toRefs="ix_11_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_16_fact ix_17_fact" toRefs="ix_12_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_18_fact ix_19_fact" toRefs="ix_13_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_20_fact ix_21_fact" toRefs="ix_14_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_22_fact ix_23_fact ix_24_fact hidden-fact-111 ix_25_fact ix_26_fact ix_27_fact ix_28_fact hidden-fact-112 ix_29_fact ix_30_fact ix_31_fact ix_32_fact hidden-fact-113 ix_33_fact ix_34_fact ix_35_fact ix_36_fact hidden-fact-114 ix_37_fact ix_38_fact ix_39_fact ix_40_fact hidden-fact-115 ix_41_fact ix_42_fact ix_43_fact ix_44_fact hidden-fact-116 ix_45_fact ix_46_fact ix_47_fact ix_48_fact hidden-fact-117 ix_49_fact ix_50_fact ix_51_fact ix_52_fact hidden-fact-118 ix_53_fact ix_54_fact ix_55_fact ix_56_fact hidden-fact-119 ix_57_fact ix_58_fact ix_59_fact ix_60_fact hidden-fact-120 ix_61_fact ix_62_fact ix_63_fact ix_64_fact hidden-fact-121 ix_65_fact ix_66_fact ix_67_fact ix_68_fact hidden-fact-122 ix_69_fact ix_70_fact ix_71_fact ix_72_fact hidden-fact-123 ix_73_fact ix_74_fact ix_75_fact ix_76_fact hidden-fact-124 ix_77_fact ix_78_fact ix_79_fact ix_80_fact hidden-fact-125 ix_81_fact ix_82_fact ix_83_fact ix_84_fact ix_85_fact hidden-fact-126 ix_86_fact ix_87_fact ix_88_fact ix_89_fact hidden-fact-127 ix_90_fact ix_91_fact ix_92_fact ix_93_fact hidden-fact-128 ix_94_fact ix_95_fact ix_96_fact ix_97_fact hidden-fact-129 ix_98_fact ix_99_fact ix_100_fact ix_101_fact hidden-fact-130 ix_102_fact ix_103_fact ix_104_fact ix_105_fact hidden-fact-131 ix_106_fact ix_107_fact ix_108_fact ix_109_fact hidden-fact-132 ix_110_fact ix_111_fact ix_112_fact ix_113_fact hidden-fact-133 ix_114_fact ix_115_fact ix_116_fact ix_117_fact hidden-fact-134 ix_118_fact ix_119_fact ix_120_fact ix_121_fact hidden-fact-135 ix_122_fact ix_123_fact ix_124_fact ix_125_fact hidden-fact-136 ix_126_fact ix_127_fact ix_128_fact ix_129_fact hidden-fact-137 ix_130_fact ix_131_fact ix_132_fact ix_133_fact hidden-fact-138 ix_134_fact ix_135_fact ix_136_fact ix_137_fact ix_138_fact ix_139_fact ix_140_fact ix_141_fact ix_142_fact ix_143_fact ix_144_fact ix_145_fact ix_146_fact ix_147_fact ix_148_fact ix_149_fact hidden-fact-139 ix_150_fact ix_151_fact" toRefs="ix_15_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_152_fact hidden-fact-140 ix_153_fact hidden-fact-141" toRefs="ix_16_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_154_fact ix_155_fact" toRefs="ix_17_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_156_fact" toRefs="ix_18_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:RenovationInvestmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2009-09-01</xbrli:startDate>
    <xbrli:endDate>2009-09-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:RenovationInvestmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2009-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:ShouantangBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-04-20</xbrli:startDate>
    <xbrli:endDate>2018-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-26</xbrli:startDate>
    <xbrli:endDate>2023-09-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-29</xbrli:startDate>
    <xbrli:endDate>2024-04-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-10</xbrli:startDate>
    <xbrli:endDate>2024-05-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-11</xbrli:startDate>
    <xbrli:endDate>2024-06-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cjjd:BankLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:RenovationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntitySixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:JiuzhouClinicOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntitySevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityNineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:ShouantangBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:JiuyiTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:LinjiaMedicalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:ShouantangClinicMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:JiuzhenHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:HongtongServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cjjd:OtherReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cjjd:OtherReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cjjd:OtherReceivablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:MotorVehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:LandUseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2015-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:FarmlandDevelopmentCostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZfg1f/OyMqeFkW4NxCRgc5zrMfOkODGpvnGwO67GcnxcMLoHh2bQdp9cqh7BBV1bpF2FDoEydlb4/CB4Q1RcA6BkFWukNPnSbNdgcFXy0j51Nyr3MVn75aB0UDm6KdgKWkIDFyVjwW12yAP66X3j7uVH+FbGya9WCnnXOUl4XE3uB1TJeQOH3eK29ryfO2nyLkWQ3FLaRkPF0rpKE9KNRxbNRckj0bSeaIdtTbhitr/aqcfQbNpj16] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:FarmlandDevelopmentCostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhuoliServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhuoliServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:SongluPharmaceuticalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:JiuzhouDigitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhetongMedicalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhetongMedicalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:SongluPharmaceuticalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:JiuzhouDigitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:JiuzhouDigitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:LandUseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:SapSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:SapSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateElevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateElevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateElevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwelveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwelveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwelveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFifteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFifteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFifteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEighteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEighteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEighteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyThreeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySixMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyNineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyNineMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyTwoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cjjd:LandUseRightsAndPropertyOwnershipMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:LandUseRightsAndPropertyOwnershipMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:HangzhouKahamadiBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:HangzhouKahamadiBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:DirectorAndCEOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:DirectorAndCEOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-15</xbrli:startDate>
    <xbrli:endDate>2019-04-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-03</xbrli:startDate>
    <xbrli:endDate>2020-06-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-04-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-29</xbrli:startDate>
    <xbrli:endDate>2024-04-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-10</xbrli:startDate>
    <xbrli:endDate>2024-05-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-11</xbrli:startDate>
    <xbrli:endDate>2024-06-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001856084</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>ea020991701ex12-1_chinajojo.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>I, Lei Liu, certify that:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: 20.7pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of China
Jo-Jo Drugstores, Inc.;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.4pt 0pt 40.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 60%">Date: July 30, 2024</TD>
    <TD STYLE="font-size: 10pt; width: 40%">/s/ Lei Liu</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1.5pt solid; font-size: 10pt">Lei Liu</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><I>(Principal Executive Officer)</I></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>ea020991701ex12-2_chinajojo.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
BY THE PRINCIPAL FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I,
Ming Zhao, certify that:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have reviewed this annual report on Form 20-F of China Jo-Jo Drugstores, Inc.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by
the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over
financial reporting; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the
equivalent functions):</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal
control over financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 40.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 30, 2024</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ming Zhao</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ming
    Zhao</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Accounting Officer
    &amp; Principal Financial Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>ea020991701ex13-1_chinajojo.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual report on Form 20-F for the year ended March 31, 2024 (the &ldquo;Report&rdquo;) of China Jo-Jo Drugstores,
Inc. (the &ldquo;Company&rdquo;) as filed with the Securities and Exchange Commission on the date hereof, we, Lei Liu, Chief Executive
Officer, and Ming Zhao, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lei Liu</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lei Liu</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ming Zhao</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ming Zhao</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Accounting Officer)</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 30, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>5
<FILENAME>ea020991701ex15-1_chinajojo.htm
<DESCRIPTION>CONSENT OF COMPANY'S CURRENT INDEPENDENT PUBLICLY REGISTERED ACCOUNTING FIRM, YCM CPA, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex15-1_001.jpg" ALT="" STYLE="height: 81px; width: 140px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Consent of Independent Registered Public Accounting
Firm</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">China Jo-Jo Drugstores, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference
in the Registration Statements on Form F-3 (No. 333-259692 and No. 269182) and S-8 (No. 268809 and No. 277849) of China Jo-Jo Drugstores,
Inc. of our report dated July 30, 2024, relating to the consolidated financial statements and schedules for the years ended March 31,
2024, 2023 and 2022, which appears in this annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ YCM CPA, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Irvine, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 30, 2024</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>6
<FILENAME>ea020991701ex97-1_chinajojo.htm
<DESCRIPTION>COMPENSATION RECOVERY POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 97.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>China
Jo-Jo Drugstores, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMPENSATION RECOVERY POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Effective December 1, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt">In accordance with Section
10D of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), Exchange Act Rule 10D-1, and rule 5608
of the Nasdaq rules (&ldquo;<B>Nasdaq Rules</B>&rdquo;), the rules where the securities of China Jo-Jo Drugstores, Inc. (the &ldquo;<B>Company</B>&rdquo;)
are listed. The Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;) has adopted this Compensation Recovery Policy (the
&ldquo;<B>Policy</B>&rdquo;). The purpose of this Policy is to recover the erroneously awarded Inventive-Based Compensation (defined below),
if any, in the event that the Company is required to prepare an Accounting Restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Capitalized terms used in
the Policy are defined in <U>Section A</U> below. The application of the Policy to Executive Officers is not discretionary, except to
the limited extent provided in <U>Section G</U> below, and applies without regard to whether an Executive Officer was at fault.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>A.</B></TD><TD STYLE="text-align: justify"><B>Definitions</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Accounting Restatement</B>&rdquo; means
an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities
laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to
the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current
period or left uncorrected in the current period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Accounting Restatement Determination
Date</B>&rdquo; means the date that a Company is required to prepare an Accounting Restatement, which is the earlier of: (a) the date
the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not
required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the
date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Excess Compensation</B>&rdquo; means
the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive-Based Compensation that otherwise would have
been Received had such Incentive-Based Compensation been determined based on the restated amounts (this is referred to in the listings
standards as &ldquo;erroneously awarded incentive-based compensation&rdquo;) and must be computed without regard to any taxes paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Executive Officer</B>&rdquo; means each
individual who is or was ever designated as an &ldquo;officer&rdquo; by the Board in accordance with Exchange Act Rule 16a-1(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Financial Reporting Measures</B>&rdquo;
means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s financial
statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also
Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing
with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Incentive-Based Compensation</B>&rdquo;
means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure
(for the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company&rsquo;s
duty to recover under the Policy has lapsed) and excludes the following: salaries, bonuses paid solely at the discretion of the Committee
or Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure, bonuses paid solely upon
satisfying one or more subjective standards and/or completion of a specified employment period, non-equity incentive plan awards earned
solely upon satisfying one or more strategic measures or operational measures, and equity awards for which the grant is not contingent
upon achieving any Financial Reporting Measure performance goal and vesting upfront, upon the signing of certain agreements, or is contingent
solely upon completion of time requirement (e.g., time-based vesting equity awards) and/or attaining one or more non-Financial Reporting
Measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<B>Received</B>&rdquo; means, with respect
to any Incentive-based Compensation, actual or deemed receipt, and Incentive-Based Compensation is &ldquo;Received&rdquo; under the Policy
in the Company&rsquo;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award
is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of
doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to October
2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>B.</B></TD><TD STYLE="text-align: justify"><B>Persons Covered by the Policy</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Policy is binding and
enforceable against all Executive Officers who received Incentive-Based Compensation covered by this Policy from the Company (See <U>Section
E</U> below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Administration of the Policy</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Compensation Committee
of the Board (the &ldquo;<B>Committee</B>&rdquo;) has full-delegated authority to administer the Policy. The Committee is authorized to
interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy.
In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another
committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer
to such independent members of the Board or such other Board committee. All determinations of the Committee will be final and binding
and will be given the maximum deference permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Accounting Restatements Requiring Application of the Policy</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Company is required
to prepare an Accounting Restatement, then the Committee must determine the Excess Compensation, if any, that must be recovered. The Company&rsquo;s
obligation to recover Excess Compensation is not dependent on if or when the restated financial statements are filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>E.</B></TD><TD STYLE="text-align: justify"><B>Compensation Covered by the Policy</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Policy applies to all
Incentive-Based Compensation Received by an Executive Officer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">after beginning service as an Executive Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">who served as an Executive Officer at any time during the performance period for that Incentive-Based
Compensation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">while the Company has a class of securities listed on the Exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">during the three completed fiscal years immediately preceding the Accounting Restatement Determination
Date. In addition to these last three completed fiscal years, the Policy must apply to any transition period (that results from a change
in the Company&rsquo;s fiscal year) within or immediately following those three completed fiscal years. However, a transition period between
the last day of the Company&rsquo;s previous fiscal year end and the first day of the Company&rsquo;s new fiscal year that comprises a
period of nine to 12 months would be deemed a completed fiscal year; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">on or after October 2, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><B>F.</B></TD><TD STYLE="text-align: justify"><B>Excess Compensation Subject to Recovery of the Policy</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To determine the amount of
Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is&nbsp;not&nbsp;subject
to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate
of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation
was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide the documentation
to the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>G.</B></TD><TD STYLE="text-align: justify"><B>Repayment of Excess Compensation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company must recover
Excess Compensation reasonably promptly and Executive Officers are required to repay Excess Compensation to the Company. Subject to applicable
law, the Company may recover Excess Compensation by requiring the Executive Officer to repay such amount to the Company by direct payment
to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not
need to be identical as to each Executive Officer). These means may include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">requiring reimbursement of cash Incentive-Based Compensation previously paid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition
of any equity-based awards;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company
or any affiliate of the Company to the Executive Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">cancelling outstanding vested or unvested equity awards; and/or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">taking any other remedial and recovery action permitted by law, as determined by the Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The repayment of Excess Compensation
must be made by an Executive Officer notwithstanding any Executive Officer&rsquo;s belief (whether or not legitimate) that the Excess
Compensation had been previously earned under applicable law and therefore is not subject to recovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is prohibited
from indemnifying any Executive Officer or former Executive Officer against the loss of Excess Compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to its rights
to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce
an Executive Officer&rsquo;s obligations to the Company or its affiliate or to discipline an Executive Officer, including (without limitation)
termination of employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction
of future compensation opportunities, or change in role. The decision to take any actions described in the preceding sentence will not
be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of
the Company or of any applicable affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>H.</B></TD><TD STYLE="text-align: justify"><B>Limited Exceptions to the Policy</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company must recover
Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below are met, and
the Committee determines that recovery of the Excess Compensation would be impracticable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to
be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover the Excess Compensation, document
the reasonable attempt(s) taken to so recover, and provide that documentation to the Exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before
reaching this conclusion, the Company must obtain an opinion of home country counsel, acceptable to the Exchange, that recovery would
result in such a violation, and must provide such opinion to the Exchange; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly
available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) (Assignment and alienation) or 26 U.S.C.
411(a) (Minimum vesting standards) and regulations thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>I.</B></TD><TD STYLE="text-align: justify"><B>Other Important Information in the Policy</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding the terms
of any of the Company&rsquo;s organizational documents (including, but not limited to, the Company&rsquo;s Memorandum and Articles of
Association), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company
nor any affiliate of the Company will indemnify or provide advancement for any Executive Officer against any loss of Excess Compensation,
or any claims relating to the Company&rsquo;s enforcement of its rights under the Policy. Neither the Company nor any affiliate of the
Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event
that pursuant to the Policy the Company is required to recover Excess Compensation from an Executive Officer who is no longer an employee,
the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims
or separation agreement such individual may have signed. Neither the Company nor any affiliate of the Company will enter into any agreement
that exempts any Incentive-Based Compensation that is granted, paid, or awarded to an Executive Officer from the application of the Policy
or that waives the Company&rsquo;s right to recovery of any Excess Compensation, and the Policy shall supersede any such agreement (whether
entered into before, on, or after the adoption of the Policy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Committee or Board may
review and modify the Policy from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any provision of the Policy
or the application of any such provision to any Executive Officer is adjudicated to be invalid, illegal, or unenforceable in any respect,
such invalidity, illegality, or unenforceability will not affect any other provisions of the Policy or the application of such provision
to another Executive Officer, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary
to render any such provision or application enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Policy will terminate
and no longer be enforceable when the Company ceases to be a listed issuer within the meaning of Section 10D of the Exchange Act or when
the Exchange Act Rule 10D-1, and the rule 5608 of the Nasdaq Rules are no longer effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (7 HH# 2(  A$! Q$!_\0
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M7^F:=+=LUU+86%UJTMK9R7+-</;Q1M,QD+$^TU\E_L"_\F*?L5_]FE_LX_\
MJG?!M?6E( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ),4_8K_ .S2_P!G'_U3O@VOK2F,**** "BBB@ HHHH **** "BBB@ HHHH
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MS5KO2_"O@KPOX5TB61?A=X;N/".C>$_#WASPIX-9[^RT+P[;:.VGZ9IW<_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBN(^)?B/Q+X.^'7CSQ;X-\&3_$
M;Q;X7\'^)/$/AGX?6NL6OA^[\<:[HVCWFHZ7X1L]<OK:[L=(O/$5[;0Z1::C
M>VTUG9W-W%/=+Y"2$ 'QQ_P3RNK>Z\"_M'?9Y/,^S?MO_M96<_R2Q^7<V_Q3
MU))HB)4C+;&_C0-&X(*.P.:^_J_FO_X-]_\ @IUK?_!0*[_;&T72_P!E;Q]\
M&_!?@?X^?$WXB>(/'WC+QOI6LV\'C[XO>.+O7+#X.P:)!X<T>^E\0^%] MKZ
M_P#%&I_:!!ILD>F036$)URR\O^E"@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\S/@QH7[3W[0V@>+_B
M0/VS_B1\-;9_C%\:O"6E^"?"'PB_9PU+P[X?T+P'\4/%/@W0;+3[[QG\*/$W
MBF\8:1HEG)?7FM:_J5U=ZA)=3J]O!)#:0>N_\,Y?M.?])"?C9_X93]DG_P"<
M72_L$_\ )$/$W_9P_P"T]_ZOOQ_7VK0!\4_\,Y?M.?\ 20GXV?\ AE/V2?\
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MYU&YAA"H%V6UO%%;0[8(HD3V/_AG+]IS_I(3\;/_  RG[)/_ ,XNOFSXJ?\
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M9XM\#>(?&OPE^)6M7P$6H_$+X;>(- UYTM]-O(&@UC2=.U.W]X_X=^?L-?\
M1HW[.W_AI/!/_P IZ/\ AWY^PU_T:-^SM_X:3P3_ /*>BRYZ4_M49*5)W?NN
M,:<$K7M*/+2I1<)<T)*E34E+DBQJ4DI13LI_%MOSRJ*2=GRR52<YJ4>62E.=
MG:<HR]Z\5?"/X9^.;[PQJGC7P5H'BW4?!FF>*M&\,WWB.R36;G2M+\<^'F\)
M^,K**6_,[2P>*/#;R:-KJ7/G?VE8R20W7F"1\^4>&/V,?V6/!?BOPGXW\*_
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MA^F,^_;KB@?\%$? I^[^S)_P4"/IG]A?]HQ.P/\ RT\$)CKWQ@YSC!Q^@-%
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M^"?.OCI][]I;X+CJ.^UFZ=#7W?10!\(?\-#_ +9YZ?\ !/K5Q_O?M-_!L?\
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MK:/^%&_M5?\ 1\'B#_Q'_P"#'_RMK[&HH ^.?^%&_M5?]'P>(/\ Q'_X,?\
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M#'_RMK[&HH ^.?\ A1O[57_1\'B#_P 1_P#@Q_\ *VC_ (4;^U5_T?!X@_\
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M_P#*VOL:B@#XY_X4;^U5_P!'P>(/_$?_ (,?_*VC_A1O[57_ $?!X@_\1_\
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MIM)I-I-ZI-I-KFY+I7YFN?W')1<5.T7*,G&,OYA/^#>O]JWXQ_##]BZ\N?\
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M?CS_ -1;5:\Q_9*T'0I/V4_V9'DT72'8_L]?!;).FV1/_)-_#6!_J. .@ P
M.  * ,W_ (;L_8I_Z.V_9O\ _#T_#S_YH:/^&[/V*?\ H[;]F_\ \/3\//\
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MN\<B?L;_ +3KI)&S(Z.OP3\;E71U(9'5@&5E(96 (((!KNK']DG]E-K*S/\
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M3Q!\!/V7K_Q7XW\-Z_K^O_!]=7T_P7>Z?KNCZV/$]]<ZOHG[3NK>(FU3Q/\
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M=6CUWP?XST/3?$OAG6HK>]M(M5T36+6.]TV_CM=1MK._MTNK6:.98KRUM[A
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M_$3_ ,1]_:"_^=A7W-10!\,_\/'?V3?^AM^(G_B/O[07_P ["O5/@O\ M<?
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M-K[6KXI\1_\ *1CX-?\ 9E/[2_\ ZO3]DVOM:@ HHHH **** "BBB@ HHHH
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M;UWQ5JT@MYKK2WTP:%;:IJ>DV=G?WGZ]U\=?\-P?"K_HF7[8O_B!_P"V;_\
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M*"Y*BJ1<K^WI8AQ4G%.='"5\'"_+9^["NZD9>]*%:*E%.,ZM.:J)5(N,DO\
M=ZV&3Y8MJ%?%4,7-^\GJYX>,&M(NE)Q=I1ISA^9%G^Q_\??B1\.O!?@WXM?#
M?XRW?Q;A_:X^%OCS]I#XK:E^T5XA3PM\4_"/ASXP>+=8O?$GPJL-#^(,)\#:
M/8_#^?1=-M-.\'^'OA]K6E^#[K_A7<23VUM+(>-U[]CG]O.XT3XU1Z?J_P 8
MEOOA1X(^(T'[%5C%^TEXKBT[1?%>A?M?^/\ Q3\$[W6;,^,/LOC/4]$^ <WA
M+0K;4_BXOBTR^$'N/!/B%M2M9[^TE_6G_AN#X5?]$R_;%_\ $#_VS?\ YQ='
M_#<'PJ_Z)E^V+_X@?^V;_P#.+I0C[.5.<7RNG&BDHI1I\]!9?&E55./N0G"&
M7JG%07+&&-S!+7%U&KG+VG-S)-2]NO>;E+DQ$\PJ5*;G+WIQE/,)-N34I?5,
M!S.V%BI?!&H? #]L#5?VG]:\3/IGQ+CU>;]H+XQ:WX@^+-U\79YO@OXO_8LU
M_P""WC'0OA[^S[IWPC3Q.-"M?%5E\0M3\"727<O@*SU;1O$'AG6?&[^-[I=5
MO+'5/$O@7^RC^VE\/[7X'Z!XC\+_ !-TOQY\/W_8_M_AS\1O#7QC:U^$GP;^
M"7@'P7X2LOVB/A-XJ^&FB>([72O%^O\ B36--^(T6HO=^#O&-QX\D\8^$[BW
MU_3D\'Z);Z)^LG_#<'PJ_P"B9?MB_P#B!_[9O_SBZ/\ AN#X5?\ 1,OVQ?\
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M2S:6WQ:BL-9T2XN8&\;^%_$5_<ZN/$6GZ?/<+'^IW_#<'PJ_Z)E^V+_X@?\
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M%EJFK>)_A[X\T'5T\.Z+^Y/_  VO^QI_T=M^S)_X?KX5_P#S5T?\-K_L:?\
M1VW[,G_A^OA7_P#-76D(QI^QC!-4L/B:%:A3E)U/9T<)6IU<)AN>HI.4</"A
M2HQJ2BW54\7B<12KX[$0Q>$QK)UXXA3DU4Q6'Q5&M4@HPYJN,PU7#XFOR1M%
M>U=>I55&+C&C[/"8?#5:.#PSP^)_*'X$_%G]JO3G_90\#>-[OXS_ +-?@2;X
M:^,O%-GI/P<_8FT>[\._%3XSG]I'QUX>7X._&/18O@QKVG?!/P%;_#.V\+^)
M[ ^'C^S[KWBZZ\6ZAXRD^,BV>F7]K/\ .7BKXQ_ML?M"G]H7P#XS\%_M+>+?
MA3=V_P"S!\4/"?ASX@_LXZGX;UOX7?$_P]^W5;>%O&7PU\'ZSX-_9_\ A3#K
M?AJR^%6D>'_B#J^BZOX@_:'U?1=*1/%T/QOO?#E[J.G6'[U_\-K_ +&G_1VW
M[,G_ (?KX5__ #5T?\-K_L:?]';?LR?^'Z^%?_S5TZ/[IT'+]ZZ,8IN=[U9P
MG@*D*U1N4[58RP%)IPY(PY:;I0IM8GZ]K6FZLL1*/[MUYU)^[JZ4:BQRE2IR
MM%^SMCJJ:GSSFI35:I53HO"?3=%?,G_#:_[&G_1VW[,G_A^OA7_\U='_  VO
M^QI_T=M^S)_X?KX5_P#S5T$'">(_^4C'P:_[,I_:7_\ 5Z?LFU]K5^</AWXR
M?"#XP?\ !1'X87/PD^*_PT^*4&@?L6_M$1:]+\.?'GA;QNFAR:I\<_V6SI:Z
MR?#.JZH-+.IC3-3_ +-^W_9QJ!TS4A9^<=/O!!^CU !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\8?LM:WK>K?%3]M6SU76=5U2TT/]HZ'3=$M=1U"
M[O;;1=-/PL^']T=.TF"YEDCTZP-U<7%T;2T6*#[3<3S;/,E=C]BWU]8Z78WF
MIZG>6NG:;IUK<7VH:A?7$-I8V-C:0O<7=Y>7=P\<%K:VL$<D]Q<3R)##"CR2
M.J*S#\ZOV,/BK\+/$WQL_;1TGPS\3_AQXFU;Q#^T*==T+2O#GCSPIKVJ:OHM
MI\)_ANEWJVGZ=I.KWE[=:;:R.(KB]B@:W@E#12R+(CJH!^C]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!X5^T!^T9\-?V9_"WAGQ?\ $X>-YM,\8?$#PS\,O#VG_#OX:^/_ (N>+=5\
M7^+5OWT;3]-\"_##PYXL\:ZJ)(],O9KF32- U V=O!)<W");QR2I2G_:3\%P
MZ[\(_#__  A'[04UU\:--L-5\-7T'[,_Q^?0O#%MJ*EH8?BYX@/PZ71_@GJ4
M(4B_TCXLWG@[5=-8A;^SMV(!D^/+^.$G^!__  A/PV\,_$9'^/W@-/&4GB2P
M-\WP^\#MI_B7^V_B3X>(O[#[%XF\.S#3[73;\B]$$6K7:FPN/,S'[]0!\XVW
M[3?A.[M?C'=0?#7]H['P3DLXM>@N?V;?C3I]UXT>]N]4LT/P<@U'P9:-\98X
M'TJ::\F^&Y\1PV=I=:7=W$D=OJEA)/5G_:A\/0V7P;OU^$7[3%Q%\:I8X])A
M@_9X^)_VWP&)+RWLO,^,EA-H,-W\)HD:X%Q(WC6'2REG%<717RH78?3%% 'S
MG%^TAILWB#XQ^'4^#O[1@F^#.CZCK%YJLOP6\5V_A_XC+IJ[FTWX.:W<116'
MQ*UB\Z:=I^@RO)>L<1-UQS-Y^UE;6O@CX:^-X_V=?VLKZ/XE>(KKP]'X5L_@
M=JW_  F_@8VMU':G6_B5X:NM2M;KPAX=G,GVBUU2YDG6>U22=8L)@_65% '@
M-O\ 'F6X^)OQ!^&B_!'X_1+X!\*7GBE/B%<> ;*#X9>.'LX;&9?#'P^\42>(
MED\0>*[S[=Y-GID^FZ=;RS6=\DE]$( S\&?VK=;;X2^'/BI;_LD?M=7-YXA\
M8OX2D^% \!?#VS^+7AVV2.ZD_P"$Q\1^']4^*UAH=EX.8VRQI?6OB>_U5I+J
MU T;:\C1?75% 'A\'QEUB?XN7'PL/P)^.$.EP>%X?$@^,$^C>!$^$=Q<RZ<E
M^?"EOJJ_$)_&#>*(I'.FS6S^"8]*744>,:PUL!=-\_\ C_XU>,/'/P=T3XA+
M^QI\>)M6\*?&[X?W*?"'X@^%?@Y>?$BYL_#VM6&M_P#"=>#[*T_:%T_P397=
MC*BP>%=9U;QZEY8>)%MY+CPKJ%J-LGWA7RU^V GPOD^$_A]?B[KGB_P_X4_X
M7S^S*=/O_!'V?^V9?':_M"?#4_#72[G[5:WD7_".ZS\0!X;TGQ7B)91X;O-4
M,,UO*$F0 [2/XP>*)?B-X+\"_P##/GQKBT7Q9X87Q%J?Q1F3X5)\/_ =Z^AW
M^L?\(EXQ"_%)_&@\3+=64/A]U\,>#O$N@KK6HV0_MTZ7]JU.VY&#X_?$JX\$
M>/?%:?L@_M"PZUX/\16^AZ#\/;O5OV>X/%OQ)L)F19/%'@VY'QSD\(VNA6H=
MFFC\9^)_">MLL;>1H\S%5;Z?HH \$E^+GQ'7Q7\+= A_9F^+D^B^/= L-8\7
M^-O^$D^!\.@_!G4+R.9[CPSX]L)OBTGBC6-9TUHXX[R;X:Z!X[T61KB,V6K7
M:K,T63'\9/C%+I/Q<OQ^R/\ %J'4/ &HW%EX T2Z\?\ [.R7?QTM8=8N-.CU
M;P/=V_QCNM-\+65U811:]#%\5KOP#J*V%S%;3V,6JI-I\7TC10!\XS_%SXU)
M/\($@_91^(,T/CWRS\1YW^)7P,A/P+#WD5O(/%<7_"Q96\8R16SR7S+\,SXN
MC>*%H$E:Y>.)IH?BG\;I=6^,UB_[+_BFVT[P#92S_"W6YOBA\)6M?CO>))>+
M'8:#9V_B:XU'P&9D@M95N?B':Z'"BWR+)M>WG5/HBB@#YDG^+7[0J>%/A7K-
MM^R=KD_B3QCK%U9?$CP=+\9/A5!<_!_28=06VMM;U#6UU.?1O&RWEB6U)=.\
M(7%W=PHGV6;;<L%KID^('QK?QY\2/#S?L_2Q>"O#'ANYU/X>_$)_BGX.,7Q/
M\0QZ?:7-OX87PM'"^N>#/M-_-<Z:=:UX2V4!LS=O&T$\0KW6B@#Y<^#/Q]\=
M^._'6H_"_P"*7P.U?X-^/M(^'^F_$/4K$>--#^(7AR+3=9\3:OX<TW3+?Q9H
M%E86%WK+C1YM2O+.*#_0K2>V#N[2AJ^HZ\0TW_A9/_#1'BG[9XL\-S_"7_A4
MWA7^Q/!,-Y9-XLT_QW_PE'B'^V_$=[8K9KJ$>AZAHO\ 96GV5U+?26LEY974
M<5M'+')(_M] !1110 4444 %?"FE_P#*3/QS_P!F*?"G_P!7_P#&6ONNOA72
M@3_P4R\=, 2J_L*_"@,P'"E_C_\ &<H&/8N$<J#]X(^,[3@ ^Z'1)$>.1%DC
MD5DDC=0Z.C@JR.K JRLI(92"""000:Y#_A7?P_'3P+X._P#"8T3_ .0:[&B@
M#CO^%=_#_P#Z$7P=_P"$QHG_ ,@T?\*[^'__ $(O@[_PF-$_^0:[&B@#CO\
MA7?P_P#^A%\'?^$QHG_R#1_PKOX?_P#0B^#O_"8T3_Y!KL:* .._X5W\/_\
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MHV[\O)'G4N5IB_\ "S/VW?\ HTWX*?\ B7>L?_0R4?\ "S/VW?\ HTWX*?\
MB7>L?_0R53G_ ."@_P"R+%>?"VQA^+MAJ,_QDO\ P!I'@1M'T+Q/J]O=:U\4
MM>U#POX T/6[K3M&N;;PIK?BC7]'UK2].TGQ/+I-^UWHNK1RP1&QGV_9]4XR
M2YFGR\TH7MISQ492BGLVHSA+1M.,XR4I1E&3FZ4N5NTN15.5Z2Y)2G",^5V:
MBYTZD+M+WX3BTI1E%? WQ,_:)_;"^%/PW^(/Q1\3?LD_".;PY\-? _BWX@:_
M!I/[6NHW.JW&B>#- U#Q'JMOI=O=?LW6-I/J4]CIL\-A#=WUE:R7;PI<WEK
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MGL;B[T#Q3I%IK>CW%Q8W2175E<2Z??6[SV=S''<6LI>">-)8W4=?7RY^P_\
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MP0+P:#J3R.;A[S20UZ9]1T*1DL-3NK+2KB\2633+0Q_1^W_@H+_SV_8W_P#
M;XV?_)= 'V117QOM_P""@O\ SV_8W_\  ;XV?_)=&W_@H+_SV_8W_P# ;XV?
M_)= 'V117P'XI^*G[97PH\0?"*X^)>G?LQZSX+\?_&;P'\*];B\#M\5K+Q38
M6_CBXO;&/5M(DUU[K29;C3[F&"9[6^2.*XMC.JSQS"(/][SRK!#-.^=D,4DK
M[1EML:%VP.YP#@=S0!+17P;X$_:U^-GQ/\(Z)X_\!?L:^.]9\&>*+>XU#PUJ
MUW\6_@_I-SJ6DI?75G:W\^EW.OO<Z<UXEK]I6SN6^T0Q2QK,%DW*.M_X7S^T
MU_T9%XS_ /#U_!G_ .7M 'V+7Y^_M[?ME_!/]ESPOX'TCX@?%[]G7P!XV\7_
M !#^%.I:'X=_:$\8>'/"VEZQ\/M(^+W@:'XK>*M 3Q'J.F07FN> _!-SK/B;
M1);::2YL=?T[2KB"WN+A8+>;O?\ A?/[37_1D7C/_P /7\&?_E[7Y!_\%DOV
M"_BG_P %<O@%\/OA1XG_ &0/%/@3QI\-?B_X)\;^%OB-_P +?^#-QJFC^#+C
M7M+T[XR^&K"1-6N)!/XK^'?]I#18)8S8?\)KI'A&]U,BPL;E7 /Z"?AM\2_
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M_A)J-I9W.H-H#:C]EM[^\2VCNX[=KB26*0T ?H717QS_ ,+ _;B_Z-L^!_\
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MA_\ 'Z]A_P"& ?V%O^C-?V7/_#"_"_\ ^9BC_A@']A;_ *,U_9<_\,+\+_\
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M^(/B;X^;3](\#>.M$\+:I+X.^(/B7P#>I>3WNKZ1X ^*MCK7PAUTR6<%Y/\
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MK.-.$HTX.I)M4Z=-)1O44O"OV'_^3,OV3_\ LW+X+_\ JN_#U?4=?+G[#_\
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MFW>B^(=*\\3^,V__  1_\8GX1>,O@9K7[4'A_P 3^!]?_8>L_P!B/PEK6K_
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M^%-+^(/@C5/%6G:OX"\8ZUKFB:WI'BGP9K/A;Q/!I#1OJVAPZQHVN_/WC/\
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MBN6M6B:>..4L@]EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^-_VC?^2_?L(_\ 9=OB/_ZS/\::]'_:N^.,W[-'[-GQO_: M_#5MXRN
M/A!\-O%'CZ#PM>:]_P (M9:]+X>TV:^CTV]\2#2M=.A6=P\86ZU4:-JAL;?S
M+@6-R8_*;SC]HW_DOW["/_9=OB/_ .LS_&FO;/CY\&?#'[1'P7^)OP,\:W.J
M6?A+XJ^#M9\$^(KK1)K>WU:'2=<M6M+UK":ZM[NV2X\EV53/:SQ$$AXG4D5E
M6525*HJ+Y:KBE"5TK-SI7=W&5K0]M9\LK-JR;Y3;#NBJ]%XA.5!5(NK%)MRI
MI3NDHRBVV^3:4>NJ5S\F?#O_  5WU@?%+P%X'\<_#+P(_A\_$;X[^ ?B7XU_
M9\\9^,OVEO!FJK\+_P!FWP/^T5H^L?!GQ9H7P]\$77B?^RM,\777AWXMZ=K?
M@VP/@?6M$N+2.]NUN+:YD_0;4?VZ/V:M+\?_  0^'-YX\$.L?M&:/X7UKX.:
MB^G7<6@>-H/&EG?7_A>VTC4YUB^UWFJVNGSNL=M!/#92-!:ZE/97<\<#7?'?
M['/PC\<>)?@UXD6WOO"/_"C_  O\:?"OA'1/!<.C>'M GLOCIX&M? /B^YU+
M2[/2EMY+VWTNT2\TJ6T6T2'4F>XN([E"(A\WZ-_P2L^#.@?%+X5?$K2_B#\2
MXH?A7IG[,UO:>%[L>"=5MM;U?]D_P_XE\*_"[4Y_$FK>$;[QCX=TZ?0O%-^O
MBSPCX,UWP[X5U_6H_P#A)6TNUUW5?$M[KVZ:=2G%V5)5ZG/546I3H748_NU.
M7)*:C[6'*YJC)NA.-6->57#<J518>$FU+$_4J*G!V4(XWE@ZCYTE&<%*56G-
MI0C4BH5*;INE&%?H;?\ X*L?L=WO@WP[\0-/\2?$/4?"?B_0/BAXP\*:K8_"
M+XB7">(O _P3N[>R^+OCK2X$T#[1-X.^'L\\@\1>()(HK&-;*^:QDO?(^;K+
MO_@I)^RM9> ?&OQ)N?$_BBV\,_#^_P#"<'B:74? _B/0[RTT;Q[X9E\8^!?&
M26NOV>E;_!GC+PS#+JGAC7VDC@UL)]AL$FU1DL6Y+1?^"8OP+T/X:?#?X6VG
MB?XDOH/PP_9P_:(_9BT*ZGUK3&U*Z\"_M*OI\GCC4]2G71DBF\1Z<VG0?\([
M>0PP6MF"XN;.[X(QOB+_ ,$M?@]X\U_1_%UI\0?B5X7\4Z'I?@+P_9:A;#P9
MXFTO^P?!/P6\7? .6VN/"GC7PIXA\*W>JZMX!\;:U);^(;S2+C5?#GB46NL:
M#-:6[ZGIFIXR]JJ#<.26(]DN52]VFJZPM*2<[2?[N6-C5I347>GAZWMH.I+#
M1I8GJJ+#JNO9.H\/[>KS<R2JK#?6<0J2CHDZWU1X>H^:T95X3IR]FJSG0]IO
M_P!OO]FNV;4)]+\2^)?%NAZ)\,] ^+GB7Q;X*\">+/%7A+PKX+\6^#KKX@>%
M+KQ-KVD:5<6>CZAXC\%VDGB32]*NF6];2Y;.YNHK9;^R\_V[X;?'KX6_%WQ)
MXT\+?#SQ(OB34_A]I7PZU;Q7)9V5ZNG:;#\5?"<7COP5:C4IH([.XU+4O!UW
MI?B2?3K>62ZT_2=<T.ZO8X$U6S\WYK^$7[ W@[X$ZW8/\,_BC\2]+^'UW\/O
MAAX$^(_PGU0>"=>\*?%<?"#X;P_"CPEK?B>]UCPC>:[I5]JG@BSTK2?'-KX7
MO]'TSQ:="T6YN+.TFM[XZE9_X)U_L>O^Q/\ LXV?PMUK6X?%7C_Q!XS\6?$#
MXB>*HK[5-5CU#5-9O(='\&>&[+5=< UJ_P##OPH^$?A[X<_!GP8^I!;F'P7\
M._#]L8X5B$2]+5'VE90=3V4(59T932C.I.6-K4*-)J/-'ECA52Q;J<RG*FI4
MJM.GB*D5#E7M53HN7(ZLJD(5E!MTX4XX2G7J5DY6DY3Q"J814[.,:DX5:<ZE
M&G-SZ?\ ;'_X\/V;/^SP?@#_ .GW4*^N-2_Y!U__ ->5U_Z(DKY'_;'_ ./#
M]FS_ +/!^ /_ *?=0KZXU+_D'7__ %Y77_HB2LC0^4/V"/\ DSK]G_\ [$.V
M_P#3CJ%?7E?(?[ __)G7[/\ _P!B';_IJ.H5]>4 ?)GQC_:BO?A_\6/#_P "
M?AK\'/&?QU^+>K_#_4OBQJGACPMKW@GPC8^%OASI^NP^%XM?UGQ'X]UW0=(-
MWK/B.5])T+0[*6ZU&_DL]0NI$MK&RFN1XAIG_!0_PS:^/OBII7Q+TCP'\(?A
MI\&?&WQQ\.>//''CGXI"SU^R\/?!?X1?!;XK:GXQLO!</@^2&]TZQM_BS<:7
MXXC3Q.D7@U-"L]1CO=?CUP6^G>Q?%_\ 9E\5^*?C=X>_:+^#7Q;'P?\ BI8_
M#/4O@WXJN=0\":/\0/#GC3X>7?B!/%>C6NH:3?W^C7=EKO@_Q(^H:IX<U2TU
M4VVW5]3L-3TZ^M+D+'\M?%W_ ()2>#_C#;?&V/6_C-XQLKOXWVO[2D.O7UMX
M;\.O)877[2WP=^"WPB\27UI;CR;9Y-%M_@U9^(-/@\J&VGOM?OK.2*&TM+45
M%/GO3<[:RQ,:O-M%RQ-&.&E3C3LYT88)U*LN>4:SQ<:D)?N_8IZVI-R3;C'_
M &5QE"[DX*A7>*4W-/DJO%>RC%1C.FL/R2@^9U;?2^F_MK?"OQ?\0OA?X=^'
MOBSX<Z]X.\7W7QHTSQGKWB'QGJ/@CQAX2U;X1^#_  [XU>WT3X?Z[X32Z\4V
M5UH.O1Z[KVJ7NL^&+3P_X6ETGQ':-K]GJR)![I\'OCI\*_C[X>U#Q7\)/%D'
MB_P_IFK?V-=:E!IVL:;";M]-T_6;66U76M/TZ6_TW4=&U;3-6TK5[&.XTK5-
M/OK>ZL;R>-F*_&WCC_@FUX!^(/QV\4?&O7_B'XKQXO?XRQZSX3LM/TNVM6L/
MC1^SOX1_9VUNTM=8&^^MGTO0?"<>O:=<B)W.J7LD$J&UAC!^IOV;OA1X\^"O
MPTTKX=^.OBHGQ8'A>TT7P[X1UA/ ^C>!9-*\&>&/#>B^&M#TF^L]&O+Z/5]6
MD329M7U?6I98$N+_ %.>VL-.T[3K6UMEUARNE#FO&I[&<I1WM5EBU%0=1>[+
MDPT5*$8TX1:JSYJSG0A"MA+G4_=LX\].-U_(L/.4Y\CLXWKR4)2YYN].'+14
M:TY4O?:^&_\ @HU_R:AXC_[*]^RI_P"M7?!.ON2OAO\ X*-?\FH>(_\ LKW[
M*G_K5WP3J2C[DKX=_P""<'_)F_PI_P"PM\7/_5U_$6ON*OAW_@G!_P F;_"G
M_L+?%O\ 7XU_$7% 'J?[5W[2WA']DGX+ZY\:_&^DZGK&@Z-K/A70)(-/O-&T
M>TMKWQAXBT[PSINH^)/$_B2_TKPQX-\)Z??:E!<^(_&'B;4[#0?#NF1SZAJ=
MU%;Q,U9NA_M9?#'^S?APGQ!N3\.?%_Q%L-#OX/"D]W;>-K+0H/%6OR^&?!]]
MK?CSP ?$?@*P\/\ CG5TAM_ OB6^\066D>*S>VD>EW$ERTMM#Z[\4O#'C'Q=
MX/O-$\"^,-,\$Z_/<6<J:KK?@_3O'>B75E#.KWVCZOX;U&[T]+RPU6WWVL\E
MMJ%E>VP836TZNNUOR5^&_P#P1+_9[^&GB;X8^)K?2?@EX]NO"D.G?\)-!\6_
MV6O@]\2;/3+G3_C#XT^-<%O^SE9^);"\M?V8/">E>)/'NNZ'X/\  /P\BE\(
M>"/#-GX9'A_2X->T"+6[IT+.LXUU:A*MAKU8O]Y"CRR6(A3AK%R;_>+$5'*,
M6J>'>':F\2E6;5%RHI2K*CB.6#=HRK)IT7.37PM)4_90Y9/FG659.'L7^@7A
M']N']E'QWJWB31O"OQL\)ZK=>$]*^)&MZ[<!=6L]*MM-^#NJRZ'\5[B#6[_3
M;71]0/PXUB&33O&<.G7UU/H%VIBU".%@V..\,_MV_!63P5<^/_'_ (W^'WA[
MPYK7Q;\0?#;X8S^#?$VN?$>_\=6>F>'8/&5CJ,NA:9X-TW7]%U]?!KW/BGQ7
MX;CTO5;;P9HMM]NU77WMW\Q/%?%/_!+WP/XG_9_^'7P&;XJ>+]-MO!OQ,^.G
MB/Q%XPL=,TZ+7O'WPF_:>^(OC[QA^T%\#M8$=Q&MCX>^)'ASQ_>^#;OQ%93?
MV_IATG2/$MC(NL6HSLZA_P $[FT;Q[X?^+WPG^-&H^ /BGX4^./[0?Q5\/:Q
MJ'@70?%?A>S\*_M+^%_"GAGX@_#:7PC<7NFV\EKII\!^"-;\(>(X+ZUU'2+[
MPXNFW%M?:!K&KZ9=3AVW"@\3>%24<-#$*E%58PE*EA*V*J48N=-VA7J5L'!3
MJ2E"E0KXODKWP]*KK75-3Q$:$N>G&>(GA93O&52$*N+HX:G5?*^652E3H8R;
MC34'*O0PO-1DL14I_86D_M%_!G7?B)%\*](\;6E]XSN)KZRM+2+3M9&D7VM:
M5HL'B36/"UAXH?3E\,7WC'1?#MU;Z]K/A"UUB7Q+I.D2_;]0TNWMXYGC]LK\
MS?A'_P $R?@]\(?VIO%?[36E:#\%M>\1>*_B7X\^,\WB?Q)^S=\*=3^/ND_$
M;XFZ$FD>,ET+]HR?3G^(.D^#;J]EU75-*T&T:/4M(L=9N?!D.O2^"[:RT:#]
M,JNT?9TG=^T<9.K'[,9<_NQBVDVDN9<STJ1C2K*-*5:I0H8Z^UJI+]TG#V,G
M;GDG&\G)+W5KRM16L)2J4VYJE"K5^/O '_)[?[1W_9%OV>O_ $[_ !;KZ^,<
M9))1"2<DE5R3ZDXY-?(/@#_D]O\ :._[(M^SU^/_ !-_BWT]?\<CM7V#4E'G
M,GQ8^$\6I_$/1I/B)X"35_A'I>D:W\5-,/BC0A??#?2-?L=3U/0]2\=6OVWS
MO"EGK&FZ-JNHZ;/KB6*7MAI]U>6YDMXFD'E*?MC?LKSQ?#*XLOC;\/\ 4[3X
MQ>*]3\#_  YO=(U1=7L/$7BO1M1M=&U30Q?:;%=6NEWMCK>H:;HEPFLS:<L>
MLZII>F%OMNH6D,WX\?%G]F/XM^)/C=_P4XT[X0_L9>*_ GA']H+P!^R)JGA3
MQ'!I_P !/ _P_P#CC\0/V<?B9\7_ !O\7[+6V\,_$6Z\2RZU\5](\<Z!IF@^
M*/'/A&S?Q-=+?6GBB^T:QTZ&YEUM0_8C^,/QY^(?QH^,DWPD^(_[/VJ_M&?M
M8> ?%W@6"]\=^$-%UWX%?";X<_ 'X"^#?%?Q(^*7A#P/XL\5^$?$'C[Q7\3_
M ()P>(_A3X2\.:MXC31_$F@_#'XA>+=<MX[/7/"3J@_:*C*HK*5#"5JD(WBW
M*I.I#$4X3JQM"\DJ=%5H*M15&KB,33=.I1A.ZT8TY58QDWRU:].G-14TTHT9
M4I2C3FW>G3G*K6<).E6<HX;#35>,W']V?!?CWP/\1;/7-0\#Z]IGB:P\-^+?
M$W@36KW2RTUI9>+O!FJ3:'XJT(W)C6&>\T#6K:ZTC4_LSS16VIV=Y8O+]IM+
MB*/L?+C_ .>:?]\K_A7YS?\ !,[PQ^TIX#^"6K_#W]H+P!;?#73? >N:9X7^
M%GA=;+P3:7-CH&G>&=(7Q7%977@;Q'XH@\3^#1X\;Q!)X&\>^,M2A^*7CW0Y
MAXJ^).FV'B?4KN-OT<K248Q]FXR4U.CAZJDDXO\ >T*51J4&W*E)2E.]&<I5
M**<*564JL*K,HMMU$XN+A6KTK-J6E*M4@G&:M&I%Q4;58)0JM3J4TJ<J=RBB
MBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^'M& _P"'DWQ'.!G_ (8>^"HS@9Q_POKX^G&>N,\XZ9)]:^X:_GV\.?\
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M.<</*4'!SPL*E>+4E[+$.<5[).23;<?;.<?>=+V%-N3^LQB3T445D;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SU\??@7JGQD?X9:UX
M7^)FN?";QS\)?&M[XU\(^+=%T#PYXI5+C5O!GB?P)K&G:EH'BFTN]*OK.^T+
MQ7J CD*Q7%G>16US#(=CQOY=_P ,_P#[5O\ T??XN_\ #"?!7_Y45]K44 ?%
M/_#/_P"U;_T??XN_\,)\%?\ Y44?\,__ +5O_1]_B[_PPGP5_P#E17VM10!^
M4O[6&A?MA_L]_LV_&GXUZ!^VYKVL:Y\-? 6L>*M(TW5O@#\&I-+O+_3UC:""
M_BM]/MIY+5V8K*D5Q#)M.Y) R@'Z&?X ?M5%V*?MV^+T0L2BM\!O@J[*N> 7
M_L==Q X+;5R>=HZ5F?\ !3/_ ),$_:P_[(YXF_\ 0(:^YZ /BG_AG_\ :M_Z
M/O\ %W_AA/@K_P#*BC_AG_\ :M_Z/O\ %W_AA/@K_P#*BOM:B@#X9D_92^,?
MB?Q+\.-2^*O[7'C#XB>&/AW\1_#'Q/@\'CX3_"SPG#K6O>#VO)M$M[[7-!TI
M-6M].CO+M;FZ@LY(I+K[/%$TJ1EL_<<L:3120R#='+&\<BY(W)(I5AD8(RI(
MR"".U/HH ^&O#7[#R>"=#T_PKX)_:L_:Y\)>$M&6XM] \,Z3XY^&DFEZ#ITU
MW<7<6E:=)JOPAU+4VL;(W#068O\ 4;ZZCMDBBDNI?+#5N?\ #(_B7_H\[]LG
M_P +;X2__.4K[)HH ^-O^&1_$O\ T>=^V3_X6WPE_P#G*4?\,C^)?^CSOVR?
M_"V^$O\ \Y2OLFB@#XV_X9'\2_\ 1YW[9/\ X6WPE_\ G*4?\,C^)?\ H\[]
MLG_PMOA+_P#.4K[)HH ^-O\ AD?Q+_T>=^V3_P"%M\)?_G*5@^(_V&;'QO8V
M&A_$#]J#]J_QYX4M?%G@'Q??>$/$?C?X<#0M>O?ASX\\-?$;0+#63HOPFT?5
MVTF;Q%X4TD:K;Z=JNG7-]IOVO3_M<,5U*:^YZ* "OC'3/V"/V?-!M7TWPU<_
M'GPIHO\ :.M:G;>'O"G[5G[3OAKPYIMUXAUO4?$>KKH^@:-\6[+2=(M+K6M6
MU&_%AIMI;65O)=2);6\,02-?LZB@#Y _X8@^#/\ T-7[3/\ XF/^U?\ _/EH
M_P"&(/@S_P!#5^TS_P")C_M7_P#SY:^OZ* /D#_AB#X,_P#0U?M,_P#B8_[5
M_P#\^6C_ (8@^#/_ $-7[3/_ (F/^U?_ //EKZ_HH ^0/^&(/@S_ -#5^TS_
M .)C_M7_ /SY:/\ AB#X,_\ 0U?M,_\ B8_[5_\ \^6OK^B@#PSX1_LZ?##X
M):KXKU_P1!XUN_$/C:#0K3Q+X@\??%+XF_%77;ZQ\-)?)H6G0ZM\3/%WBR]T
M[3M._M/4'AL=,FL[5YKN:::*24AU]SHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \D^*/Q[^"7P1.AK\8/BQ\/
MOAD_B;^T?^$=B\;^*]&\.3ZXND"S.JOI4&J7=M-?Q:9_:.GB_EMDDCLVO[);
MAXVN[<2>3?\ #>?[%?\ T=1\!_\ PYGA7_Y95ROQ#L+#4/V_/V=X=0L;.^B7
M]E_]IYECO;6"Z1&_X6'^S6-R+/'($8@E2R@$J2I)!(K[ _X17PQ_T+F@_P#@
MGT__ .1Z /FG_AO/]BO_ *.H^ __ (<SPK_\LJ/^&\_V*_\ HZCX#_\ AS/"
MO_RRKV#Q-XA^"/@N;4;?QCKGPK\)SZ1X7OO'&K0^)M3\):#-I?@O3+VVTW4O
M%^HQZI/:O9>%]/U&\M+"^\07*Q:3:7MU;6L]W'//%&S?'GB'X,_"_P !Z]\4
M?B#=>!?"?P[\,:1_;VO^,M8M=*M] TK128@-3NM0%N\*V3>?#LG4LCB5"I(8
M&E=6YKKEYE'FNN7F<U34>;;F<VH*-^9S]Q+FO%/EES*-GS-<RC9\SCR\_,HV
MYG'E][F2:Y?>ORZOR'_AO/\ 8K_Z.H^ _P#X<SPK_P#+*OSRTKP'_P $GM)_
MX*1^(O\ @I[#^TE\"Y/CSK_P$L?@<MA-X^\ 2>']+N(]59]7^)VGN]P^HV_C
M_6?!]MI/P[FU.WN+<0^$8-8L/WX\2:F#^T8\+>%R 1X<T$@C(/\ 8^G\@_\
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M .8#W&BO#O\ AG3X6?\ /IXW_P##O?%[_P";JC_AG3X6?\^GC?\ \.]\7O\
MYNJ/8Y7_ -!^,_\ #6O_ )YA[3,/^@/"_P#APE_\P'N-%?$W[1WP\\#?!S]G
M[XW?%KPWH_B/4O$'PR^$_P 0/'NB:?K?Q;^-$FC7VK>$O"VJ:[I]IJL=E\0K
M2\?3[BZL8HKQ;6ZM[AK=Y!#/%)M=?0O!?P.^&WB3P=X3\17VG^+X+W7_  SH
M.M7D-I\7?C$MK#=:KI=K?7$5LLOCV246\<L[I"))))!&%#NS98GLLK_Z#\9_
MX:X__/,/:9A_T!X7_P .#_\ F ^EZ*\._P"&=/A9_P ^GC?_ ,.]\7O_ )NJ
M/^&=/A9_SZ>-_P#P[WQ>_P#FZH]CE?\ T'XS_P -:_\ GF'M,P_Z \+_ .'"
M7_S >XT5X=_PSI\+/^?3QO\ ^'>^+W_S=4?\,Z?"S_GT\;_^'>^+W_S=4>QR
MO_H/QG_AK7_SS#VF8?\ 0'A?_#A+_P"8#W&BO#O^&=/A9_SZ>-__  [WQ>_^
M;JC_ (9T^%G_ #Z>-_\ P[WQ>_\ FZH]CE?_ $'XS_PUK_YYA[3,/^@/"_\
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M/OV^?V3_ -H+XI_MS_!G]H?P%\')/C/\'_@Y^S?>V'COX67?B;X9Z+X?^/\
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M2_\ #.Z%_P#-_1_PV5>?]&B?MI?^&=T+_P";^@#[2HKXM_X;*O/^C1/VTO\
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MYCAJ=*OAX1G47MJ]/#\S4XUH_O\ 5\?_ +8)(L_V:P"0&_; ^ 08=B!KNH,
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MNA:EI>HZ?/::M<VDQO;6-7F3X'F_X)E>./AUX\\7>-?AKI?PM^)W@VX_:O\
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M;4M-M[F&(34O9>T<:5.HW&K7J.,*6%<<?5PLZE;GE"7LJ="6%Q=2;=.$,/\
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M?\\8O^_:?X4>1!_SQB_[]I_A4M% $7D0?\\8O^_:?X4>1!_SQB_[]I_A4M%
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MW9I_%OP9_P %"_B%^T=\>='TOX:_M 6'P@UWX6_M,?"Y_#^K^+O VO\ PO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOBO_ .&$^-G_ ,P='_#>/[/?_/;XK_\ AA/C9_\ ,'7V310!\;?\-X_L]_\
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M#QM^RK=>$M(LKK59/^)CJ&KVG@;Q9=16]HLI@M]$NY;HP!K;S_T,HH ****
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ME&<J<HMI2C.#IQG!Q;34X2JTE*+2E%U:::3J4U/YI_X:N\6_]&9?M??^$O\
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MX-?_ #[Z/^&KO%O_ $9E^U]_X2_P:_\ GWU]A44 ?'O_  U=XM_Z,R_:^_\
M"7^#7_S[Z/\ AJ[Q;_T9E^U]_P"$O\&O_GWU]A44 ?'O_#5WBW_HS+]K[_PE
M_@U_\^^C_AJ[Q;_T9E^U]_X2_P &O_GWU]A44 ?'O_#5WBW_ *,R_:^_\)?X
M-?\ S[Z/^&KO%O\ T9E^U]_X2_P:_P#GWU]A44 ?'O\ PU=XM_Z,R_:^_P#"
M7^#7_P ^^C_AJ[Q;_P!&9?M??^$O\&O_ )]]?85% 'Q[_P -7>+?^C,OVOO_
M  E_@U_\^^C_ (:N\6_]&9?M??\ A+_!K_Y]]?85% 'Q[_PU=XM_Z,R_:^_\
M)?X-?_/OH_X:N\6_]&9?M??^$O\ !K_Y]]?85% 'Q\/VK?%K$*/V,_VO020
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M<JH4HPIPC%QA2Y?9Q4IM14?J]M9RJ.7^[0NY.4GS56Y\TU.F4445F;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\;_ +!G_)O$G_9P7[9/_K8OQXK[(KXW_8,_Y-XD_P"S@OVR?_6Q?CQ0
M!]D4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2;3H?AS9>$(];U'P0;&WT_K?$?\ P2V^)VC_  L^']I\,- ^ <'Q\T;]J_\
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M2J1E*,)P_#WX ?L7?M%>%_%7P^B_:6\":5\?)G_9M^ ?PNTOXF:M\7[BZ?\
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MTX1EB*>,IRC3C%I0IQCC\5R4U>"]HTXZ*<8HOV"HJ'O>QI8>C'VC=5RAAJV
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MO>%/AU)H>C?$/PWX4TS_ (33^T]0O? W/.JU0KS24*E'"U\2_:\_LZ?L,O\
M:R4_9Q<YTOKU.K252G:K4IU*5.CAZE:%21T.G%8BG3NY4IXREA5*GRRE.%;'
MQI1J1E*4:<*D<#5A5E"?[F,Z5:K5Q-&@UR_N)X4_;;_9'\;>)OAUX'\-_M$?
M"F]\=_%OPKX>\<?#;P!<^+-.TCQ_XP\(>+;34K_PKXCTGP-K,FG^*Y-)\2:?
MI&IZAH-Y-H\,6K6%C<7M@9[6,RU?\>?MB?LR?#GP=X]\>>(OC)X2OO#GPO\
M&;?#KX@/X'DO_B?K?A;Q_%HL'B6Z\$ZGX3^&MCXM\6+XKT[PS<Q^)M6T"'1)
MM4TCPVEQX@U.UM-'M+J]A_+KX8>!/B/XP\3_ +)_Q9_95^%GQN^%.H^+O!?[
M'D_Q=^,.H^-O"6E_LZ^._P!GOX<_#:[C\1^ ?%OPAO\ QI>^.E^(^@#Q#KW@
M#P_I[?#+1=6T_P 0?8?$!\6P:!9SSOF^%?V8/%>H>&O^"A_A+3?V'?%_A/2O
MB3^T%X?^,?[,GA*^\9?#KX,^$=:UB?X._#;X):MK6L^)_@[\2]7\3>"],O\
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M445!04444 %?&_[!G_)O$G_9P7[9/_K8OQXK[(KXW_8,_P"3>)/^S@OVR?\
MUL7X\4 ?9%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\67G_*13P[_ -F6>,__ %>7@.OM.OBR\_Y2*>'?^S+/&?\
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MA\#/V]/CDG[/?[.7@SXX2W_B76_B!?\ [./Q"\(?$OP3\5-7TKQ[KOA_7O\
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MQ'6_\*?$FXO;CPM\/O P^'2WFI:+JNJZE!XLLFUK]13^WG\#]7_:[\ _L>^
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MMJ\GAWQ?K6@6+^"_C9H+Z-X9\6>(-+O97T:]^&7A:V\2V;:)J4%Y8?I*R(^
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M]D5\;_L&?\F\2?\ 9P7[9/\ ZV+\>* /LBBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *^++S_E(IX=_[,L\9_\ J\O
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M (0_]O+_ *+;^SE_X93QK_\ /0HHH /^$/\ V\O^BV_LY?\ AE/&O_ST*/\
MA#_V\O\ HMO[.7_AE/&O_P ]"BB@ _X0_P#;R_Z+;^SE_P"&4\:__/0H_P"$
M/_;R_P"BV_LY?^&4\:__ #T*** #_A#_ -O+_HMO[.7_ (93QK_\]"C_ (0_
M]O+_ *+;^SE_X93QK_\ /0HHH /^$/\ V\O^BV_LY?\ AE/&O_ST*/\ A#_V
M\O\ HMO[.7_AE/&O_P ]"BB@ _X0_P#;R_Z+;^SE_P"&4\:__/0H_P"$/_;R
M_P"BV_LY?^&4\:__ #T*** #_A#_ -O+_HMO[.7_ (93QK_\]"C_ (0_]O+_
M *+;^SE_X93QK_\ /0HHH /^$/\ V\O^BV_LY?\ AE/&O_ST*/\ A#_V\O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M(KF..1Y+C,D:2V\#^7)D?NA[UI?\,=_]54^,G_A2_P#VNC_ACO\ ZJI\9/\
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MELY24QQF1)/*WC]V.OTH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?^K,C]7*8[]*N:*]E$UU#8_9,1W#^>L./W<AP[[\?QG?G\: -6BBB@ KQ_\
M8[_Y$CQ=_P!CYXF_].US7L%>/_L=_P#(D>+O^Q\\3?\ IVN: /8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *XG]I7_DW3Q__ -BWJ'_I-)7;5@?$/P>GC_X?ZYH,DTEN
MFNZ?<:?)/']Z/S(S'O\ PS0!G_ #_D@_@G_L V'_ *3QUU]>)^#_ (._&#P;
MX1TO1K;XG> Y+?2[2.SC=_ EQYA2./8/^8I["M/_ (0+XT?]%,\ ?^$'<?\
MRTH ]9KQ']KJTFN-<^$,SQRR:/:^/K.74C&G&#;W,=OO_P"WV2VK5_X0+XT?
M]%,\ ?\ A!W'_P M*/\ A OC1_T4SP!_X0=Q_P#+2@#Y=\'_ +*_QY\ ^"_"
M#?VUJ6J?V7H5WIMYIFG?8[&]TR"XUG39;BWMKCS/WEQ)917'ER2>6(B/]9&9
M#79:%\)_CDD%CJMYKGC&W30I+.?2]-N-;MYI);8Z]<2217_E_P#'Q/'I/E1R
M8DD&?]7YDO[RO;_^$!^-'_13/A__ .$'<?\ RTH/@3XT#_FIG@'_ ,(.X_\
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M(75O_D>O6** /*?^&N] _P"A9^*7_A":M_\ (])_PUWH?_0K?%;_ ,(/5?\
MY'KU>B@#R7_AKS0_^A5^*W_A!ZK_ /(]+_PU_HO_ $*?Q9_\(+5?_C%>LT4
M>2?\-A:+_P!"G\6?_"#U7_XQ3/\ AL31?^A0^+7_ (0>J_\ QBO7J* /(?\
MAL31?^A0^+7_ (0>J_\ QBC_ (;%T?\ Z$WXM?\ A!ZK_P#&*]>HH ^2_C/^
MU9IM_P#M#_!NX7PC\4HDMK_5=T<G@O44DE_XELOW/W=>K_\ #8FE_P#0D_%O
M_P (C4/_ (W5_P"*7P[U3Q/\</AAKEC!')8>&[R_EU"1I,&-)+&2*/C^/]X]
M>G4 >1?\-?Z5_P!"/\6O_"'U#_XW2?\ #7>G?]"+\6__  B[W_XBO7JA\]/-
M\O?'O_N4 >3_ /#7>G?]"+\6_P#PB[W_ .(I/^&O++_H0_BW_P"$?=_X5Z_1
M0!Y#_P -<6O_ $3_ .+7_A(7-._X:ZM?^B>_%K_PD[BO7** /(O^&N8/^B>_
M%G_PD[BD_P"&MX?^B=_%K_PEY?\ &O7J* /(?^&LX_\ HG?Q:_\ "8D_QH_X
M:R7_ *)O\7/_  FW_P#BZ]>HH \B_P"&L_\ JFWQ:_\ "<_^V4O_  UE_P!4
MS^+7_A/_ /VRO7** /(_^&L&_P"B9_%K_P )_P#^V4W_ (:KD_Z)C\6/_!%'
M_P#':]>HH \A_P"&K+C_ *)?\6O_  21_P#Q^D_X:IN/^B6_%O\ \$\7_P D
M5Z_10!Y'_P -477_ $2KXM?^">W_ /DBC_AJ>\_Z)3\6O_!5;_\ R17KE% '
MD/\ PU)??]$I^+7_ (++/_Y)I/\ AJ;4/^B2_%G_ ,%MG_\ )->OT4 >1_\
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M$B8Y_P!7]* /<O\ AASX,?\ 1*/AW_X3MG_\;H_X8<^#'_1*/AW_ .$[9_\
MQNO5J* /*?\ AASX,?\ 1*/AW_X3MG_\;H_X8<^#'_1*/AW_ .$[9_\ QNO5
MJ* /*?\ AASX,?\ 1*/AW_X3MG_\;H_X8<^#'_1*/AW_ .$[9_\ QNO5J* /
M*?\ AASX,?\ 1*/AW_X3MG_\;H_X8<^#'_1*/AW_ .$[9_\ QNO5J* /*?\
MAASX,?\ 1*/AW_X3MG_\;H_X8<^#'_1*/AW_ .$[9_\ QNO5J* /*?\ AASX
M,?\ 1*/AW_X3MG_\;H_X8<^#'_1*/AW_ .$[9_\ QNO5J* /*?\ AASX,?\
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MQ)O22,&/$5Q!)^\Q_K8^YKU.O ?V>?V1+KX5_'34/'VM:I#JFL7OA'2/#/\
MHD)M;8O;>;]HN?LX_=QO+_H\?[O_ )9VT8KWZJF1#8\9^,7_ ">'\&_^O3Q!
M_P"D]M7LU>,_&+_D\/X-_P#7IX@_])[:O9JDL**** /)OV:/^2@_&S_L>_\
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M^1YM'X_\I]2_\,PZY_T6CXM?]_=)_P#E?0!Z]17D/_#,.N?]%H^+7_?W2?\
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MSTKSL_\ !+_PGK^O^'-4U;Q)XBN;KP[J$.JK!:"W@LI;F&6*2.6.*2.0V_\
MJ(P?+D&] 17!Z)_P5<^R>(OB;?74FGZEX?AS>^# ^GWEC$;.WU&/2KF66X\N
M3[1'YDD=YYEM')_H\OTKI]+_ &^/&>K^"HM8O/">BZ796EEHFJWSV.JRW5U)
M'J.I26]O';P2V\9_>6\7F?O/+_UE9_WP/6_#7[%OA7PQKOAO4+>\UPW7A>TL
M;&T+SIB2.SM[ZWB\S]WS^[U"X!Z?P=,5RMG_ ,$W/!MC9QZ2FM^+O^$?C@C;
M^R3/;?9I+J/2O[*2\\SR/-\T6W\'F>5YGS^7FN"O?^"I<>@^#+?6-:TGPFT6
MI>&)?$M@EEXF$AG/VBRCCL)<Q?N[G9=Y>,>9S'Z52\(?MT^-?!/Q"\40^))/
M!^J>%]+O+>WMW:]^PZE%'<>)[K2C<R#R_*^SV\:)D]3Y?_304_[@3]WWS8_:
MC_X)V:IX_P#%6BZIX(O[.&2UD\V\35M0DCB:6.WL[>#?%';R1W%OY=G'YEO)
MY?FY_P!;'7UQ9^8+2,3-&\@7YRG0FOD/Q!_P4ZOHO"&N>)-%\):;JGA_PY:3
MW-Q/;ZR\LEUC6[S1[?RXTMR?+,EOY\DG_+.+_GH>:]^_9H^*.K?&/X1Z=X@U
MC0YO#U_>2W$<EH9!)%^[F>/S(\<^7)Y?F#S/G DY[5?Q1(4.74Q?BG_R>;\(
M_P#L#^(O_<=7L5>._%/_ )/-^$?_ &!_$7_N.KV*@L**** "BBB@ HHHH \E
M_8[_ .2?^)O^Q[\4?^GJ]KH!^SWX&A\5:EK4?@_P]_;&MR1S7]Y]@C\Z[>.2
M.1/,?J<21QO]8P>M<_\ L=_\D_\ $W_8]^*/_3U>UZU0!PNJ_L]>!M9U[2]8
MN?"/AVXU;0;B2YT^[>PC\RTDDE\V1XSMX<R?/G^_SUYK!NOV*/@_J!U#SOAC
MX$E7599+B[\S1+8_:I)/,WE_W?.?-DZG_EH]>L5\#_M"_#OXI7?[<OB?6?#V
MC^*[S3Y/(-H\"7D=K<6?]C7,<L7VC[1]F\L7/ER?9_LWF22_\M*S ^QM2^!_
M@_5M-GL+OPOX=FL;J*YMY(GT^/RY8[G'VB/&/^6NQ/,_YZ8YS67I?[,/PWT7
MQ+)K%GX%\*PZE,D<4EU%ID7FND9B:,%\=OL\!Y_YY)Z"O%?V8==^,=W\;+#2
M_%%OXBM=)AL[Z'6+2YT^VCTBQMXC;_V9)9W$?[R2XD0R>;F209\S_5^7'7UA
M6H'A?C+]AWPGXP^.>E^/EN-6TJ^TEX[@VEA]GBAFECN9;CS/,\LRQ^9))(9/
M+DC\W/SYK1_;^_Y,Z^('_8.'_HR.O8Z\<_;^_P"3.OB!_P!@X?\ HR.D!['1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >0_MD_\B!X4_P"Q\\+_
M /IZLJ]>KR']LG_D0/"G_8^>%_\ T]65=%\;OC)9_ _PC!JEYIFL:U)>:G::
M59V6FI')<7-Q<2I#%&/,DCC&7<??D ZT >!?M$^#OBAX\^)?C*Z\#Z/JVFW4
M:Z9::7=WCV\4<MQ!!JN^Y@\QY,(DES9_.8@<YQG!K"MO$/QN\:>*/#5QJFB_
M%3PYI%UXLL)7>UETX2V-A;Z=:_:([B".3]Y'<WJ7$?3]W&9)/^>=>K?#3_@H
M;\._B9XYTO0_M5QHMYX@L[>XTY-3C\OSY));R*2W<X\N.6.2SN$P9,2$?NS)
M70#]M3X8 V[#Q9:":YU"33(K=XIQ<231QB4_NO+\SR_*<2>81Y?EG?G'-*'N
M!/WSYR\'?!KXV?!3X6:5HD-QXZN/#4UGIDFL6NG7EE_:6EXN+[[3;Z9_SS_Y
M</\ MEYGE_O*Z/\ 9=O_ -HZR\?>%=)^(.GZ_<6<>N7%_J>JN^G"R_LO^QO+
ML[>381)]H^V\R>5'_K!_SSKV#P?^W?\ "7XA>(8])T?QUI-Y>7F[RD'F1JV+
M?[2!N=/^6EOF1/\ GI&CO'D FK&H?MQ?"NPT&WU2?QA96UG=/<QGS(;B.2V^
MS>7Y_P!HC\OS+?R_-CSYH3_6Q_WQ3 ]BKQWX&_\ )T/QO_Z_]'_]-L==]X*^
M)&@^/IM0AT35K/5)-+>#[6()-_D^;!'<1?\ ?<4D;CV>N!^!W_)T'QP_Z_M'
M_P#3;'0!'8?\I ]4_P"R>6G_ *<KFN\^*.MGPG\.=;U"./4I)+6SDD1-.LY+
MVZWA#_JXX_WDC^F*X.P_Y2!:I_V3VT_].5S7L8.36=2/,K"B?"5[\6_CQ\)/
M#D\D/A_QMJ4EQX-^SVYCT2XU:ZDUS^QM.>W\S_GG_I/VT22?ZOS/]96YK<GQ
M8^-OQ4O;6WUWQ]H-CI'CBTAL'N/"L=N-+@BTZ^^TWD<DEO'%<6\ES(D<?F?:
M/]5')_RTKZ.\9_M#>'O!7Q!M_#%Q'KFH:Q<1Q74\>G:7<7T>E6\DACBDN7CC
M(@CD,<AR_P#SSD]*S/!O[87P[\6>']+U23Q)I>AIK+P0V4.LWD=C/=/+'%+'
M&B2/\\G[^+IW<5?Q#/F#XA_'G]IZ/PC;W6CZ%KG_  F$>EV$HT:/PGYFFW4!
MTWS+V]DN)/\ 5WL=YYD<=GYO_+./]W)YGF5]._LL_$?Q1\3])\6ZGXBTW5M,
MM5\2SV^@)J6E2:;<2:8(K?RY/*D'F<R&7EQDX]JZ72OC?X1OO$=KI*Z]I-OK
M6H2745IIL]S''>W/V>62*4QQ$[W DC?I[UVU,#RG]K__ ));H_\ V.?AC_T_
M6-4_V[/^3:M4_P"PQHG_ *=K*KG[7_\ R2W1_P#L<_#'_I^L:I_MV?\ )M6J
M?]AC1/\ T[65 'L6*^)KGP_\8K#7X?&/A[P_XHM;-?%%_JE[IKRV9U.33)-4
MTT_9TCDDP/-MH+L^7YG<?ZN3%?;->6Z'^U/X-US4?%D?]J/8Z?X)NGLM4U>_
MMY+/2X[B.0QR1)=R8C=XI/W<F#U-9^S ^6?&?@CXX_&'PG<:1K6D_$2SNM3\
M&:Y')"+W3I-,O;NXN[G[%;SQ^9^[EMK;R_WG_+226/\ YY25N7_@?]H;PC\4
MY]&M=4\>:OH.GZO;_P#"*:E)=:<\<L'VF*2\_MA_];)%]G>2.+RX_,XD_P"6
MGEU]0V/[0/@;7/$.GZ38^,O"MUJFL0)<:?9Q:O;R7-]&\9D22./?F2,QY?(S
MD<U!9_M%^![N=(_^$LT"$7EY'I^GRRWT4<>IW$D4<J);/O\ WY*21_ZO-5#W
M9A/WSRC]D34?C'<>/KJW^(6FZ_;Z3HOA_P#L][J\DL_*U74QJ%SYD]N(I#*8
M_LWV?YY GTKM_P!LS_D5_ __ &/_ (<_].,5=]X#^)WASXF6=S=>&_$&BZ];
MV,YM[B33;R.YCBDXRCF,G#^U<#^V9_R*_@?_ +'_ ,.?^G&*J ]BHHHH ***
M* "BBB@ HHHH \?_ &S;>ZO/@/-)8Z?J>I26>N:'>O;Z=927ET8+?6;*666.
M*/\ >2&.-'DPG/%7/^&OO"O_ $!_B;_X;S7O_D.O5** /G'XO?$#X8_&KP"?
M#>L>&OB8FGIY?D"U^'FNVTEL8Y(Y(_+_ -#[21Q]O+.*D^$_Q)^&OP6\"6/A
M[1?#?Q,6TM7WEYOAYKLDDLAEDE\R3_0_^>CR/7T510!X+_PN7X7%(U/@/Q>$
MCN7O4Q\+=9Q'._\ K)/^/+_6'O)^M3ZE\>?ASK<<GVKP;XVN/,AEMG,OPQUJ
M3S(I/WDD?-F?DD].F:]SHH \23]HKX?6VE-8Q^$_'D=H]O\ 9G@3X8:Z(Y(.
M1L\O[%_J_;I5GPW^TMX$\(Z-'I^E>&?B!I=C;#$=K9_#/78XXO\ MG'9U[)1
M0!\\'XAQ_&']K3X>WVBZ'XVCT_0M'UH7UYJOA74=*MH3*;(1Q[[RWB^>3RW_
M ._1KZ'HHH **** "BBB@ HHHH ^?_A]H/Q8^$,'B#3=-\'^!M?T^\\1ZOK%
MG=S^+;BRFECO;VXND$D?]GR;)(Q((^),5U'_  GGQI_Z)KX _P#"\N?_ )5U
MZQ10!Y/_ ,)Y\:?^B:^ /_"\N?\ Y5T?\)Y\:?\ HFO@#_PO+G_Y5UZQ10!X
MEX1^,GQ6\9:3]OTOP#\-[ZU,DL'G1^.[D9>*22*3_F%]I(W%:O\ PGGQI_Z)
MKX _\+RY_P#E73?V+/\ DA,?_8?UW_T[7E::_%.ZO_CK>^$]-MXY+7P[I,6J
MZU,QS)F<RQV]O!'ZG[/)(?;R_P"_F@#._P"$\^-/_1-? '_A>7/_ ,JZXOXZ
M^'/C+\=/A/K?@^7P3\/]'&O1K:RWR^,[FY^S)Y@._P LZ9'OZ=,UTFE?M+R_
M$+X#:_XV\(Z-?F?PS>7MO=:7K<9L;J;^SYI([B+'F'RY)!&_EF3U0R #IZAX
M4\5V7C;PKIFM:;,+BQUBUBO+-]NWS8I$$D?Z'- &Q1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >0_MD_P#(@>%/^Q\\+_\ IZLJW_C[^SYX>_:1
M\$VWASQ3#)=:/'JEEJDELK?N[I[:YCN8TD]4,D8XJ[\6OA7I'QJ\&-H6M?;E
MM?M%O>QR65Y)9W%O/;S1W$4D<D9$D922-#Q7)?\ #&NC_P#0Y?%S_P +W5?_
M (_0 FL_L=>$[^_DDM?MNB6I_L@V]IIOEP6]@=+EDDMO+&S]WCS#^5<+\$?^
M":OA'X*75_>6VN>*-6OM0^T>?->/ LDOF6<=EF3RXX]\GE1@[_XY/WAKNO\
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M_,'M/[IV?X4?A7&?V9\0/^@QX1_\%-Q_\DT?V9\0/^@QX1_\%-Q_\DT>S?\
M,'M/[IV?_ :/^ UXO\ /B!\0/C1\++'Q%)>>#=.DNKB[B,":9<28\BYEM_\
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MZT_Y^+B.RMY(X_QDXK>N_P!KOP_J5M)#/X,^+4D$B%'23X?ZK^\_\@5\7_\
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MYD4B"1'_ !!'YULT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&9[/=I::I<V5[K-YH=Q'%KT<>K26W[S[/;R?9_\ 0O+DCD_T>*223S/,\O\
M=U[K^WW_ ,F8?$O_ + -Q_*I?^&Q- _Z%3XM?^&_UG_Y'KS?]JOX^6GQ<_9Q
M\9>%]#\'_%2YUC7M*DL[2.3P-JMO'))(,?ZR2W\M/QH ]4_;5_Y,Z^+7_8F:
MQ_Z0RUZ%H7_((M?^N$?\JX']K/0+[Q1^RS\2]*TNSNM0U+5/"NJ6MG:VZ;IK
MJ62SECCCC]7)P,>]8VF_M?:#%IMO&WA7XL;HXTS_ ,6_UG_Y'H YK]K2Z^*T
M7Q7\)CX;QQ2VH\.:]_:GV^2\CL?,_P!!^S?ZA#_I'^M\O_MI7B_PL_:$^/\
MX=U#5;?6M"UJ6Q\.^$/,@L9=)N;G4]4DCTJVDCN8Y/L_ER7/VW[1')')<^@\
MOS/]9]*?\-B:#_T*OQ8_\-_K/_R/1_PV)H/_ $*OQ8_\-_K/_P CT%(^2-"\
M;?'3XD7OAOQ1JT_Q \+_ -F:I;:=J%W9:!++_:FEQ:])&)9+>2WC_P!9;/')
M))%;1_N_^6?EU[;^Q$GQ1\+ZU)HOC)M4OO#EYIEWJ5E]MTOR)M'G&JW""W,_
M_+3S+<QR8DY]/DKTS_AL30/^A4^+7_AO]9_^1Z/^&Q- _P"A4^+7_AO]9_\
MD>@D]:KQK]@'_DSSP1_U[2_^E$E6_P#AL30/^A4^+7_AO]9_^1ZA_8<\/ZAX
M;_91\%V6K:??:3J$=H\DMI?0>3=6WF2R28DC_@?GI0!-^P?_ ,F8?"S_ +%;
M3O\ TFCKUJOF']EC]H6T^%_[-G@3PWKG@_XJ6^L:#H=GI]Y;IX%U6;RYXXA'
M)^\CM_+?D=J]$_X;$T#_ *%3XM?^&_UG_P"1Z .1_;"^)-QX*^(G@W2]8\8:
MI\.? VJ6=_)>>(=/BC\TW\)M_LUEYDD<D<?F))<R<QGS/L^RO*_!_P"T%\5K
M7XM:CX=T>X^V'5O$-Y9VVI:_87-Q:V$'VC4I(Y/L\?E9_=6]O_RTC_UE?07_
M  V)H'_0J?%K_P -_K/_ ,CT?\-B:!_T*GQ:_P##?ZS_ /(]9@>"^"/VY?&^
MN^._#L.JPZ3X/L_%$&G7DEUJNGWES;?:)=/TV232K?R_*\NXDDN+GRY)/,_X
M]S^Z-?:E>2_\-B:!_P!"I\6O_#?ZS_\ (]'_  V)H'_0J?%K_P -_K/_ ,CU
MH!ZU7D_AS_D]OQI_V)&@?^G#6J;_ ,-B:!_T*GQ:_P##?ZS_ /(]8OP5\5R_
M$G]I[QIXEM=$\6:7H[>&-#TZ&XUK0[G2?M<\=WJTDD:)<1QR/Y<<\?.,?O?6
M@#4^''_)Z?Q5_P"P!X<_]#U.O8*^=]2\?_\ "G/VN?'FIZIX;\<7^FZ]H.B1
MV=YH_AB]U:WED@DU'S(R]O')L>/S(^#C_6?EUW_#8F@?]"I\6O\ PW^L_P#R
M/0!\R^)/VT_'WP=UCXA00WDOCB\MM>MX_P"U=D<FB>&[.XO;B.*.XMY/L<EO
M<Q1QQQR1R7/ER?ZSS(_]771G]N;XK>&_AM>>/]8\+^';K0='O-/TJ\TG1X;F
M^NI9+S3HI([BWN$D\N2+[;<6\?[N.3]W)(?,S'7N_P#PV)H'_0J?%K_PW^L_
M_(]'_#8F@?\ 0J?%K_PW^L__ "/0!X/-^V7\2?A]\0=9T'4K#2_MUBEW=P6[
M:==R#Q9>16UM_P 2K3'\S]W)YCR/\_F?ZV/TDQZM^P3^T)XJ_:0^%E]KGB>U
M\/PRQ7<<-O+I4D9\R,V\4DD<D<=Q<>7)%+))&?WF3C_5QUT7_#8F@?\ 0J?%
MK_PW^L__ "/1_P -B:!_T*GQ:_\ #?ZS_P#(] 'K5?.G[-W_ "CUN/\ KQU_
M_P!*KVNQ_P"&Q- _Z%3XM?\ AO\ 6?\ Y'KGOV9O!>KG]B"/1I]+OM.UC4+'
M5#%8W\'V6YB-Q<7,D8DC?[G^L3K0!W?[*@_XQ?\ AM_V*^F?^DD5?'?Q+_:4
M^,WA_6?C!X7L-4\0?;/%6L:I'X'U=-#CEC\)P:7%YE['_J_+D_=^7);^9YGF
M2221_P#+.O>O@A\;?$W@#X+>#_#^H_!CXJ-J&AZ)9:?<&--*DC\R*WC1_P#E
M_P#:NL_X:AUS_HB_Q<_[\:5_\GUG[,#YPU;_ (*$_$[P_P#$/Q)H_P#8&@V>
MFZ#;P1R7>I1XNK6.7[#_ ,3F2".X\VXMOW\\DD<=O'Y?E?ZS_65E?#K]LOXA
M>#="M)M4URSFM=8U/4([CQ5JFEWDFB:9;_VSJ4=O<?9_,BD\N6.WMXX_WO\
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M_P#E=0!ZQ17D_P#PH;QC_P!%N^)'_@N\/_\ RNH_X4-XQ_Z+=\2/_!=X?_\
ME=0!ZQ17D_\ PH;QC_T6[XD?^"[P_P#_ "NH_P"%#>,?^BW?$C_P7>'_ /Y7
M4 >L45Y/_P *&\8_]%N^)'_@N\/_ /RNH_X4-XQ_Z+=\2/\ P7>'_P#Y74 >
ML45Y/_PH;QC_ -%N^)'_ (+O#_\ \KJ/^%#>,?\ HMWQ(_\ !=X?_P#E=0!Z
MQ17D_P#PH;QC_P!%N^)'_@N\/_\ RNH_X4-XQ_Z+=\2/_!=X?_\ E=0!ZQ17
MD_\ PH;QC_T6[XD?^"[P_P#_ "NH_P"%#>,?^BW?$C_P7>'_ /Y74 >L45Y/
M_P *&\8_]%N^)'_@N\/_ /RNH_X4-XQ_Z+=\2/\ P7>'_P#Y74 >L45XE\ ]
M7\3:1\;_ (D>$M:\6ZQXNL] M-(N["XU*TL[>YA^T)<^:A^R011R?ZI/^6?&
M:]MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R7]O#_DS
M#XI_]BMJ/_I-)5']N[1O$WB#]F+7-+\'ZIXAT3Q!JE[IEE;ZEH0'VZP274;=
M)98_=(C(:O?MX?\ )F'Q3_[%;4?_ $FDKUJ@#X#@_:'^/FD:)XJ.JZ?XJ\-Z
MA#XHO-/>^C\+W&M0RR6>E67V<V=O_P ^5[<?:9/,_P"6?^K_ '<E2>./C5^T
M%\.[?Q/):-K4VJ:GXCMY9UN]$DEL?"=I)HL=Q&EO)';R?:+?[;YEO(?WGE^7
M_P LY)/,K[XHH \S_9Z\1:YXHT/5[CQ%=37&H1ZD8O+_ +%N--M;4?9XB8[<
MR<W<0D>3%QTDS_TSKTRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /'?A5_R>5\8/^P7X?\ _1=[7L5>._"K_D\KXP?]
M@OP__P"B[VO8J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \E_;P_Y,P^*?_8K:C_Z325ZU7DO[>'_ "9A\4_^Q6U'_P!)I*]:H **\MUW
M]E[1];UZ]OI/$7Q$@:^D9WBMO%^H0Q0Y_P">:)* GX56_P"&/]$_Z&CXG_\
MA9ZC_P#': /6Z*\D_P"&/]$_Z&CXG_\ A9ZC_P#':7_AC[1/^AG^)G_A9ZC_
M /'* ._\.^*=,\60W,FF:A9Z@EK</9W$EM.DGEW"'$D3[.DB8Z=16W7Q)^P/
M_P $8/"O["7[3OQ$^*EC\0/B1XAU[X@:Q>ZDVG7>K2QZ9!'<2B3RY80_^ERQ
M\8GEY]J^VZ /,?'G[1^C_#;XPZ+X1U:QUN*77M,O-4AU,6X_LV*.TC\R5))-
M^1)LYQLKS6W_ ."G7@:70K/4GT?QA:K-<;KVU>SMO.TJQ\JUG&HW \__ (]C
M%?VC_NC)+^]_U?[N3'H'Q9_9=L_C)\5O"_BJ^\1>(+2/PQ:7EG'I5JEE]BOX
M[R/R[CS?,MY)?GCX_=R1G@5YO'_P2^\$1Z'9V,VO>+[AXY/*O+J2YMO-U2Q\
MJQM_[-E_T?BV\K3[1/W7ER_NO]9^\DR0 UO!W[>VB^*/C-JG@?\ L:ZM=:L/
M$']C0I-=Q_O(HY)8Y+B3_GES'F-#GS?M%OLSYG&Y\8_VV_!_P7^)>C>$+NYF
MU#7M6O/L]Q:6\7_(.C^PW-YODD/[O/EV_P#JRXDQ(),>7S4?QC_8D\+_ !L\
M60Z]KM[K$FH6NJ0:C%)YD#[(XO\ 5V:>9$?*B\S]YF/9)YDC_O.:C\=_L1^'
M_B-\2[[Q#=:[XLL[?4KV/4[K2;2YA2QENQITFG?:23%YI/V63R_+\SRLQQOY
M>1DK[ %M_P!NKX5VVF76H2>*HD73Y$@O(XK:XN/(E\GSWC/EHX)CB^>39GR\
M?O"*3XD?MS?#?X1:PVFZCJ]Y>7L>HV>E2)IVESWP2>\EBCC_ 'D<?EC_ %J.
M_)P''TKE_&?_  31\ ^-/".AZ5=7&J;= U.[U2TN)X[*\R;F,13QR17%O);O
M&8T08,?:MZ__ &)M+6;6([#Q7XLT73M5U>W\11V5F;/[/IFH026T@N(M]N?^
M?9/W<ADB_>2?N_1@=3X[_:?\"_#GQ];^&=;\36>G:U<)O$$B.?+^21T\R39Y
M<4D@CE,:2$&3R_D!-17G[6WPUTW3KBYN/&>BQV]IS/)YHV1C[#_:.\G^Y]C_
M 'N?^>=97CG]CS0_&7Q:E\63:CK\8NKO3]1U+1HIHQI^JW-@<V<LN8_,'E\?
MNXY$CD\N/S >_)>%O^":?@'PI8WMG!J'BRX%]H%YX<D^T7D<GEV]S*9!(/W?
M^MCCQ;QR=HD\N@#L]$_;5^&'B2^TJSL?%EO-<:S>OIT"^1<))%<"41".?,?^
MCF222-(_-V>89/W>:P?&W_!0KX9>'?!NL:EI>N-KDVCV>H7OV6RM;@F2.RXN
M#YGE^7'&DF(_,D(C\SY,YJKK?_!.SP'K7[1W_"SG:^'B2:[MKV\2>"RO+:[^
MS^7Y4>+BWD,?E^7Q)%Y<O[P_O.(_+9\1?^"=O@_XG>%_#>AWNJ>)K?2O#"7<
M=L;22VANI_M+R&023^1YNS]Y_JTD$4G_ "TCDK,(>9T47[=7PS&DV>H-XDA7
M2[C[3')/*CQO:W%O+;Q/;R6[XN!)ONX!_JO^6L?_ #TCSWWPO^).B_%KP?9Z
M[X?O%U'2KPR*DZQR0[FCD,<B.D@#I(DB%"CX(P1[#QWXV_L,VOQ!U"?5O#^N
MZQH?B2ZUV#5?MAN8]UL!<Z;)*8P8GS)Y>EQ"/?D99]^<\>J_!7X4V?P:\#+H
M=C?:IJ7^FW.HW=_?&-;F]NKFXDN;B>7RTCCS)+*Y_=QA/05H!W-%%% !1110
M 4444 %%%% 'COPJ_P"3ROC!_P!@OP__ .B[VO8J\=^%7_)Y7Q@_[!?A_P#]
M%WM>Q4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+^WA_
MR9A\4_\ L5M1_P#2:2O6J\E_;P_Y,P^*?_8K:C_Z325ZU0 45YW>_$KQ=8Z7
MK4T?P]UNZFT_45MK.&/4M/7^T[;C_28_WG[N/K\DF)/:KFK_ !!\2VFH:\EO
MX'U:\M]+M4N+"9+^SC_MF3O%&'D_=_6790!W%%<0GC_Q(VL6=N_@C5H;>XTG
M[;/=?;K1DMKG_GSQYF3)_P!-!^[]ZATCXC^*+S_A&S<> M4L1K#R?VDKZG92
M?V#C_5^;LD_>;S_SRWXH [VBOAW_ ()^_P#!0#XY_M-?M0_%+P1XU^ .L>&_
M O@SQ'JFDZ3X[6Y2WLKF*WN9(HXG@D.;B0A1^]MC)'GJ$[_<5 ")]VA_NU\<
M?&GQ#XZ\+_$3XC:A;Z7\2K[QG;7\'_"&/I5O>W.AQZ/);VPN9/*C_P!"DN(_
M],D\NY_>22QQ>7_RSJB/B+^T-J>FM<Z?/XAFT_17O+VP?4?"T=M?^)X(]4MX
M[>*[C\N/[/YML]QQ%'%)B-)/W?0D EH?:K<K2KP*^-?!FK?&?PC'JD)UCXD:
MW!H%QXPU*\2[\-V\EUJDD=[%_95E;R21QQR12V[R21^7_P!<_,C\ORZYOX8_
M&7]H#XE:3%I?B9O''A.&X_M2VTS5+'PKYMUJ<BRQ1V_VPR6<?V.,1N\D<AM[
M?S,?],_WF?-[H'W=17PY\+_C?\;?"=AX&\/W6E_$+7I+RT\-;[[4/"W^E%/+
MNO[8^UR>7'''+YD4$?[SR_\ 61R?\M/,J[^R+XV^,?Q8^,VDZQX]\/>+;+3]
M!N-3BLYK^PDL9)8+C3].D\N5/L]NG[NY^T11YC_Y9?ZR3F0Z ?:U%?#?P+^,
M'[0OQ2\6M:ZM8>+/"^B1:Q]H%W?>'8XKHVW]G2R&R/F6\<:#[2D:&2..7_6^
M7'<2?ZVC6_CA^T1X0UOX9V,&G^*]>O=6TF"[\1S2>'(H[&.YN+>ZDDB_=V_[
MO[-)%!'^\N8_]9'_ ,?'F'R\_:%^S9]R45^>/QQ_:6^.GP1\*:=H]_KNI6VI
M:PT=_%KI\/V<<E@G]E1RW)DMS')_H=O=29D/E^9''\GF9YKN/#OQ:_:$\5:W
M\1!'YEM:PW/V70_+T66YVP'5;:*WO;:3['';3QR:;))<2?Z3<8D_Y9Q^7)%6
MWL^I!]K45\#_ !,^)G[4GPYN[.UTR37O$FFZI>ZA;:AJ8\,1Q76@V]MJ1BL[
MB..WL[CS)+FWV>9_HTG[O]Y'''6I\9=6_:1\0^ [_P#LO6-<L;J33+#3I(]#
MT%(?-DN=%N'O+R![B/[0DD=ZL7E ^7Y>=DD>>8Y ^XB?EHQ\M<;\%+VZN_A)
MX;FOKK6+V[DTV#SKC5;+[#?RR&,9\^#RX_+DR3E/+&#VKLG& *)>ZR(2YD.H
MH!R**"PHHHH **** /'?A5_R>5\8/^P7X?\ _1=[7L5>._"K_D\KXP?]@OP_
M_P"B[VO8J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \E_
M;P_Y,P^*?_8K:C_Z325ZU7DO[>'_ "9A\4_^Q6U'_P!)I*]:H ***X?XT?%R
MU^$>BZ---;->W&NZ[8:%90(^PS37-P(SC_KG'YDG_;.@#N**\/T;]L:QU:"\
MED\+Z]I*Z7XWB\$ZA'?B))+66>.*2*X_=N_[M_M%MCI_K*V_VIOVD]%_95^%
MW_"3ZK9:KJRM=16\-CID:2W,X=_WD@#D?NXX]\DC]HXR: /55&!01D5\D_$7
M_@J-X;\):YXLT72?#>I:IJWAG4);(Q/>01Q2_9[U+.YED$9EN+=(Y98_+,L4
M?F^9'Y?[L^8/9/@[^TGX?^,/@G6O$]E/:V/A_1Y9!]KN+R,2+%'&)))+B/\
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M4_\ L5M1_P#2:2O6J\E_;P_Y,P^*?_8K:C_Z325ZU0 5Y[\?_A!)\7=&\/\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >2_MX?\F8?%/\
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MV:/'/<02?VI/_:L>DRQ2>69/(\NYE0\Y_=G/7]W56W_X*,ZKX^\>> =/\/\
M@O5-+T[5O$UCHGB&ZU=5CFT^>XLKBY-JEN^R0_NXXI!<8\O$G0\UZ!XW\7?
M]_AY8ZIJUOX9U+PSXHTF[U*WNHM.^V0W5G)/%<2R?NT/^LN)+<_\]))9(^LE
M5_ FF_ G4?B MY9Z/X/T_P 2>"=.M[B&74K-+6^TZT^SB6*4&<"6,11W!'F8
M_=B21..:NGM[X3_N')7'_!0C4O /CKQ=8^)O"=]>:1I>N:G8Z;J6FW%N?-BL
MH[>6X#P>9YH\NWD>3S.F(I!C_5^9L_$S_@HWX=^%?P@TGQU<:3>:AHNM:C>1
MVABNHUENM.MI3&^H01Y/F1R#$D?0>7+&9)(LX'6:W\(_@_XHUCQ!=64?@K3_
M !1XZT.[275=/:T74KJTN$_>7"$#,@Z'S#G_ %:9R*Y_0?#?[/WCGP_X6^&X
MC\$>*-/\"Z+;#1+:[:WNDALT22+$<G/F 1V?[U!D8C3?V-3 HW/A5^U['\3O
MB!JVA_\ "*ZUI-O:VNIWNF7\\]O+'JR:?>_8K@^7')YD?[WRS'Y@'F1R9XQ4
M&M_MM6/AK0_"%U>>'-6OKCQAH5GJMGINE'[3?37%Q)%'';IYGEQ?\M/]9))&
M.*Z&Y\7_  P\!V>GZU:_V!]EN(YX[>^TZWCEB,=Q>Q1W!\Q!LV/</'YGO639
M^%O@[\$O'FB^#K'P_H^FZLWEWEC9VFC27 LQY@,<CR1QO';IYL?[KS#&/,C.
MSGH$G*:G_P %*O"6F6^H7RZ?K%UIMGIT>HQ1PP_Z==^9'ILD<21R>7'YG_$S
MC^3S,_NS7NWPW^(.G?%OX?:'XHTAWETGQ)80:C:,Z>7(8I4$B9_ UYMX,_9C
M^$/B[PUKEQI^G:!XKTOQ%=DSN)([VWB\N.WB^S6_E\1QQBS@_=ICF.O5O#?A
MC3_!F@V>EZ79V^GZ780);VMK @CBMHXQA$1.V!_*@#S/X5?\GE?&#_L%^'__
M $7>U[%7COPJ_P"3ROC!_P!@OP__ .B[VO8J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \E_;P_Y,P^*?_8K:C_Z325ZU7DO[>'_)F'Q3
M_P"Q6U'_ -)I*]:H **** #&*\M_:3_9PTS]I#PY;V-[JFI:3+I?VB:SN['8
M);:XDMY(HKE/^FD4D@D0]I(Q7J5>7?'?XAZE\-_%7@.Y@BUN;0[G6)+?5QI>
MEW&HLT;V=SY1=((Y'CC^T>3\_0&@#R:/_@E[X3M?'7A3Q!#J=Q>2>&+_ .V+
M!J</VB.9MED'D'EO&([CS+/S?-Y_>2R<<U#8?\$NM%@\,WFFS>*-0D\PB.WD
MATRSM3#%';W-O!YHCC_TB3%Q^\DDYD\L9Q7(^$?BW\<KSQ9X2\.Z]/JETMCX
MH\W5+NT\%ZA;2W]I'J-T)(_M$<GV:...WCM)/^6GVF.Y/E_ZLUZ%^WA\=?B+
M\-- \'W7PRT7Q)K5YJER+B2.WT26YBD026Q^SW \B22+S(Y9/^>9_=2'S8S'
MY<DQO[H%?Q3_ ,$X+/Q]\6-+\9:OXMU*34+'1X-)V6UC':PXCDCD'EQC/EQG
MR_\ 5_W^?:NM^*G[#7AOXN?$+5_$6J7UQ)>:I!)'$DEI;RBQ>2.QC\V/S(S\
M_P#H$?\ W\DKRC6_BE\>O"\=Y<73:Q)I>L2?O);;PL9KKPG;QZ[]FDEMXTCE
M-Q)]A=)/+DCDR8C+'^[S'6%X2O\ QMX%^!/[/\NL7'Q477O^$\NY=<@M]'U
M&ZT^2]O2\E_!;QR>7&(Y(#Y<A$8\P?\ //,=0 [WQ9_P2S\(^*Y[6XDU:XNO
MLOB2?6K>&^LXKBUM[>3 _L\1QF/]U'^\\OG]WYLG6I/$O_!-;2?%%[K,EWKP
MB@UC4M4NG@CT:W-O;6>H(@N;>,.#Y;RR1B1Y!DDF08'F5X[/\(_'WC?3?$6A
MVNN?$#Q);Z;K=GK&E:SJFF:S;W,VH27-[&=.>WO+CRXXK:.6WD^VVWEQQ^7_
M *N3RZ]8^#GQ&^*>D?LF?$:_3P?J$WC[0[N\>U>YMY_,UV\V9DE2WDCC.(^D
M<<7[J3RXXXY.X*8OMFEXV_X)B>"O$WA+6M(M+HZ;'KMY)J$B0V$<<<K_ -JG
M4HTE2/R_,BCD<Q[#UCXJSK'_  39\%ZGX>OK3=#'->Z?_9WF0:;;XAC_ +&&
ME>4F\$^7A!+Y>_\ UG4]ZX1?CG\>M/T>,:+:ZUXHTN_U&_L],UF_\(265]+'
M;QV]Z+FXM_W?EQR1QZA9Q?NH_,D%M)_RT_>/\5_%G]HH>%X_$^DZ3<-<0Z5I
M^L6OA>YT'']H2:AJ-ZG]G7$_^LCEM;(6?F>DG+]:!GKGQO\ V-[+X\^%_#]K
MJ'B;5M'U30=,_LZ#4=(C2REBE,EM)+/&@R(_,2WDC\L9 CN9!7G_ (X_X)0^
M%?&GBVSNO^$DU:QTS3[/4+*WTV."/R88[R2]DDC3TC_TP_N_^F4=>8>(OC7^
MT#XP_98:'5/^$AL[S7);^WDOM*\)75QJ]J_]E>9;V4EO)9V_E^9>^9']HCB_
M=_NX_,\S][747.H_%;X??%#P-_8H\76LU_X1\*:?+I\GA^2^T^^N/M-S'J/V
MBXQ_H<EM;2>:?]7YACC_ -9_JZ -CX^_\$M;/XB2_;O#_B.;0[K3X=8ETNR-
MFBV-K<:A]MS_ *L92/\ TR3?C.?+CIOP=_X)EKX=A^&>L>++S0;CQ1X!GN)'
M6PM))+&Y\R^^V&X_>.DGVKS#E[@]3_RSJ]\)?VE?B=XR_9K^)?BV^T^]N-7\
M)7,OANUL]*T?S+J[U&P_T;4+RWC_ 'F^*6Y\SR^)/+CBSY<AS&9O GQ!^-OQ
M,_9M\ 23?VEX6\5:UX@U33=8OI= \RXMM/@_M+['<?9Y(X_+\WR+/]Y+%'_K
M?]7'Y@P?#[P>SYPUC_@D[\/]1^']UHL-Y=69N+*TLQ=6=G;12M]FLOLP\S9&
M/,CE_P!9+&>)#6]H7_!.3P=IUMI*S?9=VEV=K8H+33(XX_+B.H^8D?F&22,2
M_P!H2>9^\.=@Z5YLO[0_[05S/;W']AZM!K9TCSI/#Y\)R?8?+_L'[3]M^V?\
M_']J_P"C?8_,\S'_ "S_ .6E=UH_Q/\ C5X&^'_C9M2T.Y\:7&@DW%GJ,%A]
MBOYDDTZWN-EM9[/*O/+N))8_]9&<1X_>2 BE*_O,.?W[&W/^QS>#PQX/T2+6
M-*G7P_X4O/"EQ<7>BP30W,$LEK)')]DQ]G<$V:!X\8._M63'_P $UM M_"\E
MO_PD6M2:U):?83K4D$<E[Y7]FR:=L\W'F>5B3S/+\SKQ7SSK/A/XW?M+^!]<
M\1:Y-XZTG6-,\&>*-*TB.WT3R_,DDU&.*WN8_,MXY/M%S9#_ )YQ_N_]7''7
M369^+/P7\8ZA=:7H'CK4]/T&*?3[..SL+B7[3;V_]M_9O+M_,\O_ )\_W?\
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M,'_8+\/_ /HN]KV*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /)?V\/\ DS#XI_\ 8K:C_P"DTE>M5Y+^WA_R9A\4_P#L5M1_])I*]:H
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M^P7X?_\ 1=[7L5>._"K_ )/*^,'_ &"_#_\ Z+O:]BH **** "BBB@ HHHH
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M"/I__@1<?_'*/^'??P=_Z$?3_P#P(N/_ (Y0![)17C?_  [[^#O_ $(^G_\
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ &8# 2(  A$! Q$!_\0
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M:C\,?$&GZ:;Z>>!Y0N]HD=BP[XW=":U6$22YY6;(==N_*KGT)2$@#).*\/\
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>]2OIM6NKO[8RE89#\D(&>%'X^U%=#16;FV5RH__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F +$# 2(  A$! Q$!_\0
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M*.=%LF^L0-;Z(J($4 *HP .PK/%8E5DDEL71HNFVV24445Q'2%%%% !1110
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>cjjd-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 30 06:45:36 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://chinajojodrugstores.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cjjd="http://chinajojodrugstores.com/20240331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cjjd-20240331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cjjd-20240331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cjjd-20240331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cjjd-20240331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet" id="cjjd_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals" id="cjjd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement" id="cjjd_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ShareholdersEquityType2or3" id="cjjd_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ConsolidatedCashFlow" id="cjjd_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization" id="cjjd_r_DescriptionofBusinessandOrganization">
        <link:definition>995306 - Disclosure - Description of Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies" id="cjjd_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/CommitmentsandContingencies" id="cjjd_r_CommitmentsandContingencies">
        <link:definition>995308 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/TradeReceivables" id="cjjd_r_TradeReceivables">
        <link:definition>995309 - Disclosure - Trade Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/OtherCurrentAssets" id="cjjd_r_OtherCurrentAssets">
        <link:definition>995310 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/PropertyandEquipment" id="cjjd_r_PropertyandEquipment">
        <link:definition>995311 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LongTermInvestment" id="cjjd_r_LongTermInvestment">
        <link:definition>995312 - Disclosure - Long-Term Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/AdvancestoSuppliers" id="cjjd_r_AdvancestoSuppliers">
        <link:definition>995313 - Disclosure - Advances to Suppliers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/Inventory" id="cjjd_r_Inventory">
        <link:definition>995314 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/FarmlandAssets" id="cjjd_r_FarmlandAssets">
        <link:definition>995315 - Disclosure - Farmland Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LongTermDeposits" id="cjjd_r_LongTermDeposits">
        <link:definition>995316 - Disclosure - Long Term Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssets" id="cjjd_r_OtherNoncurrentAssets">
        <link:definition>995317 - Disclosure - Other Noncurrent Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/Leases" id="cjjd_r_Leases">
        <link:definition>995318 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/IntangibleAssets" id="cjjd_r_IntangibleAssets">
        <link:definition>995319 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/NotesPayable" id="cjjd_r_NotesPayable">
        <link:definition>995320 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LoanPayable" id="cjjd_r_LoanPayable">
        <link:definition>995321 - Disclosure - Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/Taxes" id="cjjd_r_Taxes">
        <link:definition>995322 - Disclosure - Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/PostretirementBenefits" id="cjjd_r_PostretirementBenefits">
        <link:definition>995323 - Disclosure - Postretirement Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements" id="cjjd_r_RelatedPartyTransactionsandArrangements">
        <link:definition>995324 - Disclosure - Related Party Transactions and Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ShareholdersEquity" id="cjjd_r_ShareholdersEquity">
        <link:definition>995325 - Disclosure - Shareholder&#8217;s Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/NetLossPerShare" id="cjjd_r_NetLossPerShare">
        <link:definition>995326 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/Segments" id="cjjd_r_Segments">
        <link:definition>995327 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SubsequentEvents" id="cjjd_r_SubsequentEvents">
        <link:definition>995328 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy" id="cjjd_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables" id="cjjd_r_DescriptionofBusinessandOrganizationTables">
        <link:definition>996001 - Disclosure - Description of Business and Organization (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables" id="cjjd_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/TradeReceivablesTables" id="cjjd_r_TradeReceivablesTables">
        <link:definition>996003 - Disclosure - Trade Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/OtherCurrentAssetsTables" id="cjjd_r_OtherCurrentAssetsTables">
        <link:definition>996004 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/PropertyandEquipmentTables" id="cjjd_r_PropertyandEquipmentTables">
        <link:definition>996005 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LongTermInvestmentTables" id="cjjd_r_LongTermInvestmentTables">
        <link:definition>996006 - Disclosure - Long-Term Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/AdvancestoSuppliersTables" id="cjjd_r_AdvancestoSuppliersTables">
        <link:definition>996007 - Disclosure - Advances to Suppliers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/FarmlandAssetsTables" id="cjjd_r_FarmlandAssetsTables">
        <link:definition>996008 - Disclosure - Farmland Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables" id="cjjd_r_OtherNoncurrentAssetsTables">
        <link:definition>996009 - Disclosure - Other Noncurrent Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LeasesTables" id="cjjd_r_LeasesTables">
        <link:definition>996010 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/IntangibleAssetsTables" id="cjjd_r_IntangibleAssetsTables">
        <link:definition>996011 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/NotesPayableTables" id="cjjd_r_NotesPayableTables">
        <link:definition>996012 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/TaxesTables" id="cjjd_r_TaxesTables">
        <link:definition>996013 - Disclosure - Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables" id="cjjd_r_RelatedPartyTransactionsandArrangementsTables">
        <link:definition>996014 - Disclosure - Related Party Transactions and Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/NetLossPerShareTables" id="cjjd_r_NetLossPerShareTables">
        <link:definition>996015 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SegmentsTables" id="cjjd_r_SegmentsTables">
        <link:definition>996016 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails" id="cjjd_r_DescriptionofBusinessandOrganizationDetails">
        <link:definition>996017 - Disclosure - Description of Business and Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable" id="cjjd_r_ScheduleofConsolidatedFinancialStatementsActivitiesTable">
        <link:definition>996018 - Disclosure - Description of Business and Organization (Details) - Schedule of Consolidated Financial Statements Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails" id="cjjd_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable" id="cjjd_r_ScheduleofRevenuebyMajorSourceineachSegmentTable">
        <link:definition>996020 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Major Source in each Segment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" id="cjjd_r_ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable">
        <link:definition>996021 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Reconciliation of Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" id="cjjd_r_ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable">
        <link:definition>996022 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" id="cjjd_r_ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable">
        <link:definition>996023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" id="cjjd_r_ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable">
        <link:definition>996024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails" id="cjjd_r_CommitmentsandContingenciesDetails">
        <link:definition>996025 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/TradeReceivablesDetails" id="cjjd_r_TradeReceivablesDetails">
        <link:definition>996026 - Disclosure - Trade Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable" id="cjjd_r_ScheduleofTradeReceivablesTable">
        <link:definition>996027 - Disclosure - Trade Receivables (Details) - Schedule of Trade Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable" id="cjjd_r_ScheduleofOtherCurrentAssetsTable">
        <link:definition>996028 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/PropertyandEquipmentDetails" id="cjjd_r_PropertyandEquipmentDetails">
        <link:definition>996029 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable" id="cjjd_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996030 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LongTermInvestmentDetails" id="cjjd_r_LongTermInvestmentDetails">
        <link:definition>996031 - Disclosure - Long-Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable" id="cjjd_r_ScheduleofLongTermInvestmentTable">
        <link:definition>996032 - Disclosure - Long-Term Investment (Details) - Schedule of Long-Term Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable" id="cjjd_r_ScheduleofAdvancetoSuppliersTable">
        <link:definition>996033 - Disclosure - Advances to Suppliers (Details) - Schedule of Advance to Suppliers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/InventoryDetails" id="cjjd_r_InventoryDetails">
        <link:definition>996034 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZfg1f/OyMqeFkW4NxCRgc5zrMfOkODGpvnGwO67GcnxcMLoHh2bQdp9cqh7BBV1bpF2FDoEydlb4/CB4Q1RcA6BkFWukNPnSbNdgcFXy0j51Nyr3MVn75aB0UDm6KdgKWkIDFyVjwW12yAP66X3j7uVH+FbGya9WCnnXOUl4XE3uB1TJeQOH3eK29ryfO2nyLkWQ3FLaRkPF0rpKE9KNRxbNRckj0bSeaat2dXHy+qrxZ6iiL61S57] CSR-->
      <link:roleType roleURI="http://chinajojodrugstores.com/role/FarmlandAssetsDetails" id="cjjd_r_FarmlandAssetsDetails">
        <link:definition>996035 - Disclosure - Farmland Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable" id="cjjd_r_ScheduleofFarmlandAssetsTable">
        <link:definition>996036 - Disclosure - Farmland Assets (Details) - Schedule of Farmland Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LongTermDepositsDetails" id="cjjd_r_LongTermDepositsDetails">
        <link:definition>996037 - Disclosure - Long Term Deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails" id="cjjd_r_OtherNoncurrentAssetsDetails">
        <link:definition>996038 - Disclosure - Other Noncurrent Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable" id="cjjd_r_ScheduleofOtherNoncurrentAssetsTable">
        <link:definition>996039 - Disclosure - Other Noncurrent Assets (Details) - Schedule of Other Noncurrent Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable" id="cjjd_r_ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable">
        <link:definition>996040 - Disclosure - Other Noncurrent Assets (Details) - Schedule of Amortizations of the Prepayment for Lease of Land Use Right</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LeasesDetails" id="cjjd_r_LeasesDetails">
        <link:definition>996041 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofleaseTable" id="cjjd_r_ScheduleofleaseTable">
        <link:definition>996042 - Disclosure - Leases (Details) - Schedule of lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" id="cjjd_r_ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable">
        <link:definition>996043 - Disclosure - Leases (Details) - Schedule of Lease Liabilities Under Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/IntangibleAssetsDetails" id="cjjd_r_IntangibleAssetsDetails">
        <link:definition>996044 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable" id="cjjd_r_ScheduleofNetIntangibleAssetsTable">
        <link:definition>996045 - Disclosure - Intangible Assets (Details) - Schedule of Net Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/NotesPayableDetails" id="cjjd_r_NotesPayableDetails">
        <link:definition>996046 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable" id="cjjd_r_ScheduleofCreditFacilitieswithBanksTable">
        <link:definition>996047 - Disclosure - Notes Payable (Details) - Schedule of Credit Facilities with Banks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/LoanPayableDetails" id="cjjd_r_LoanPayableDetails">
        <link:definition>996048 - Disclosure - Loan Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/TaxesDetails" id="cjjd_r_TaxesDetails">
        <link:definition>996049 - Disclosure - Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" id="cjjd_r_ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable">
        <link:definition>996050 - Disclosure - Taxes (Details) - Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/PostretirementBenefitsDetails" id="cjjd_r_PostretirementBenefitsDetails">
        <link:definition>996051 - Disclosure - Postretirement Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="cjjd_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>996052 - Disclosure - Related Party Transactions and Arrangements (Details) - Schedule of Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ShareholdersEquityDetails" id="cjjd_r_ShareholdersEquityDetails">
        <link:definition>996053 - Disclosure - Shareholder&#8217;s Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/NetLossPerShareDetails" id="cjjd_r_NetLossPerShareDetails">
        <link:definition>996054 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable" id="cjjd_r_ScheduleofBasicandDilutedEarningsPerShareTable">
        <link:definition>996055 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SegmentsDetails" id="cjjd_r_SegmentsDetails">
        <link:definition>996056 - Disclosure - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable" id="cjjd_r_ScheduleofSegmentoftheContinuingOperationsTable">
        <link:definition>996057 - Disclosure - Segments (Details) - Schedule of Segment of the Continuing Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable" id="cjjd_r_ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable">
        <link:definition>996058 - Disclosure - Segments (Details) - Schedule of Net Revenue from External Customers through its Retail Drugstores by Main Products</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/SubsequentEventsDetails" id="cjjd_r_SubsequentEventsDetails">
        <link:definition>996059 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://chinajojodrugstores.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract"/>
  <xs:element name="ScheduleOfRevenueByMajorSourceInEachSegmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfLongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfLongTermInvestmentAbstract"/>
  <xs:element name="ScheduleOfAdvanceToSuppliersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfAdvanceToSuppliersAbstract"/>
  <xs:element name="FarmlandAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FarmlandAssetsAbstract"/>
  <xs:element name="ScheduleOfFarmlandAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfFarmlandAssetsAbstract"/>
  <xs:element name="ScheduleOfOtherNoncurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfNetIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfNetIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfCreditFacilitiesWithBanksAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract"/>
  <xs:element name="ScheduleOfSegmentOfTheContinuingOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract"/>
  <xs:element name="ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract17"/>
  <xs:element name="ChangeInOperatingAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract41"/>
  <xs:element name="RetailDrugstoresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_RetailDrugstoresAbstract"/>
  <xs:element name="OnlinePharmacyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OnlinePharmacyAbstract"/>
  <xs:element name="DrugWholesaleAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DrugWholesaleAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
  <xs:element name="OperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OperatingLeasesAbstract"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_UnlabeledAbstract43"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="DueFromRelatedsParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DueFromRelatedsParties"/>
  <xs:element name="FarmlandAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FarmlandAssets"/>
  <xs:element name="CustomerDepositCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_CustomerDepositCurrent"/>
  <xs:element name="StatutoryReserves" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_StatutoryReserves"/>
  <xs:element name="StockIssuedDuringPeriodValueForReverseStockSplit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit"/>
  <xs:element name="StockIssuedDuringPeriodValueSaleOfStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodShareSaleOfStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants"/>
  <xs:element name="IncreaseDecreaseInLongTermDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_IncreaseDecreaseInLongTermDeposit"/>
  <xs:element name="IncreaseDecreaseInCustomerDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_IncreaseDecreaseInCustomerDeposit"/>
  <xs:element name="AdditionsToLeaseholdImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AdditionsToLeaseholdImprovements"/>
  <xs:element name="RepaymentOfOtherPayablesrelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_RepaymentOfOtherPayablesrelatedParties"/>
  <xs:element name="CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_CashlessExerciseOfWarrants"/>
  <xs:element name="AdvancesToSuppliersTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AdvancesToSuppliersTextBlock"/>
  <xs:element name="FarmlandAssetsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FarmlandAssetsTextBlock"/>
  <xs:element name="LongTermDepositsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LongTermDepositsTextBlock"/>
  <xs:element name="LoanPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LoanPayableTextBlock"/>
  <xs:element name="CreditLossRollForwardPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_CreditLossRollForwardPolicyTextBlock"/>
  <xs:element name="FarmlandAssetsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FarmlandAssetsPolicyTextBlock"/>
  <xs:element name="NotesPayablePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_NotesPayablePolicyTextBlock"/>
  <xs:element name="ValueAddedTaxPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ValueAddedTaxPolicyTextBlock"/>
  <xs:element name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock"/>
  <xs:element name="AdvanceToSuppliersTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AdvanceToSuppliersTableTextBlock"/>
  <xs:element name="ScheduleOfFarmlandAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ScheduleOfFarmlandAssetsTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems"/>
  <xs:element name="FiniteLivedIntangibleAssetUsefulLifeDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription"/>
  <xs:element name="AccumulatedImpairmentPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment"/>
  <xs:element name="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable"/>
  <xs:element name="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems"/>
  <xs:element name="AdvancesOnInventoryPurchasesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AdvancesOnInventoryPurchasesGross"/>
  <xs:element name="AllowanceForAdvancesToSuppliers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AllowanceForAdvancesToSuppliers"/>
  <xs:element name="FarmlandAssetsGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FarmlandAssetsGross"/>
  <xs:element name="ImpairmentsOfFarmlandAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ImpairmentsOfFarmlandAssets"/>
  <xs:element name="ForestLandUseRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ForestLandUseRights"/>
  <xs:element name="Others" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_Others"/>
  <xs:element name="ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
  <xs:element name="DebtInstrumentIOriginationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DebtInstrumentIOriginationDate"/>
  <xs:element name="IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants"/>
  <xs:element name="EarningsPerShareBasicBeforeNoncontrollingInterest" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest"/>
  <xs:element name="EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest"/>
  <xs:element name="EarningsPerShareDilutedBeforeNoncontrollingInterest" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest"/>
  <xs:element name="EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest"/>
  <xs:element name="CapitalExpenditureContinuedOperations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_CapitalExpenditureContinuedOperations"/>
  <xs:element name="DescriptionofBusinessandOrganizationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_DescriptionofBusinessandOrganizationDetailsTable"/>
  <xs:element name="DescriptionofBusinessandOrganizationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems"/>
  <xs:element name="SharesRepurchasePercentage" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SharesRepurchasePercentage"/>
  <xs:element name="WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_WorkingCapitalDeficit"/>
  <xs:element name="BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl"/>
  <xs:element name="VATPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_VATPercentage"/>
  <xs:element name="PropertyandEquipmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_PropertyandEquipmentDetailsTable"/>
  <xs:element name="LongTermInvestmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_LongTermInvestmentDetailsTable"/>
  <xs:element name="LongTermInvestmentDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LongTermInvestmentDetailsLineItems"/>
  <xs:element name="InvestmentPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cjjd_InvestmentPercentage"/>
  <xs:element name="InjectedFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_InjectedFunds"/>
  <xs:element name="LongTermInvestmentImpairmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LongTermInvestmentImpairmentLoss"/>
  <xs:element name="OtherNoncurrentAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_OtherNoncurrentAssetsDetailsTable"/>
  <xs:element name="OtherNoncurrentAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OtherNoncurrentAssetsDetailsLineItems"/>
  <xs:element name="DescriptionOfLeasePrepaymentLife" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DescriptionOfLeasePrepaymentLife"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_LeasesDetailsTable"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_NotesPayableDetailsTable"/>
  <xs:element name="LoanPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_LoanPayableDetailsTable"/>
  <xs:element name="LoanPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LoanPayableDetailsLineItems"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_ShareholdersEquityDetailsTable"/>
  <xs:element name="AggregateSharePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AggregateSharePercentage"/>
  <xs:element name="StatutoryAccountsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_StatutoryAccountsPercentage"/>
  <xs:element name="ReserveFundPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ReserveFundPercentage"/>
  <xs:element name="NetLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_NetLossPerShareDetailsTable"/>
  <xs:element name="SegmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_SegmentsDetailsTable"/>
  <xs:element name="SegmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SegmentsDetailsLineItems"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="cjjd_SubsequentEventsDetailsTable"/>
  <xs:element name="BankLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_BankLoanMember"/>
  <xs:element name="DirectorAndCEOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DirectorAndCEOMember"/>
  <xs:element name="DrugWholesaleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DrugWholesaleMember"/>
  <xs:element name="EntityEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntityEightMember"/>
  <xs:element name="EntityFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntityFiveMember"/>
  <xs:element name="EntityFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntityFourMember"/>
  <xs:element name="EntityNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntityNineMember"/>
  <xs:element name="EntitySevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntitySevenMember"/>
  <xs:element name="EntitySixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntitySixMember"/>
  <xs:element name="EntityThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntityThreeMember"/>
  <xs:element name="EntityTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_EntityTwoMember"/>
  <xs:element name="FarmlandDevelopmentCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_FarmlandDevelopmentCostMember"/>
  <xs:element name="GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember"/>
  <xs:element name="HangzhouKahamadiBiotechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember"/>
  <xs:element name="HangzhouUnitedBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_HangzhouUnitedBankMember"/>
  <xs:element name="HongtongServiceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_HongtongServiceMember"/>
  <xs:element name="JiuyiTechnologyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_JiuyiTechnologyMember"/>
  <xs:element name="JiuzhenHealthMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_JiuzhenHealthMember"/>
  <xs:element name="JiuzhouClinicOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_JiuzhouClinicOneMember"/>
  <xs:element name="JiuzhouDigitalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_JiuzhouDigitalMember"/>
  <xs:element name="KahamadiBioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_KahamadiBioMember"/>
  <xs:element name="LandUseRightsAndPropertyOwnershipMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LandUseRightsAndPropertyOwnershipMember"/>
  <xs:element name="LandUseRightsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LandUseRightsMember"/>
  <xs:element name="LinjiaMedicalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LinjiaMedicalMember"/>
  <xs:element name="LiquidityAndCapitalResourcesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_LiquidityAndCapitalResourcesMember"/>
  <xs:element name="MedicalDevicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_MedicalDevicesMember"/>
  <xs:element name="MotorVehiclesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_MotorVehiclesMember"/>
  <xs:element name="NutritionalSupplementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_NutritionalSupplementsMember"/>
  <xs:element name="OTCDrugsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OTCDrugsMember"/>
  <xs:element name="OnlinePharmacyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OnlinePharmacyMember"/>
  <xs:element name="OriginationDateEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateEightMember"/>
  <xs:element name="OriginationDateEighteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateEighteenMember"/>
  <xs:element name="OriginationDateElevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateElevenMember"/>
  <xs:element name="OriginationDateFifteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateFifteenMember"/>
  <xs:element name="OriginationDateFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateFiveMember"/>
  <xs:element name="OriginationDateFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateFourMember"/>
  <xs:element name="OriginationDateFourteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateFourteenMember"/>
  <xs:element name="OriginationDateNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateNineMember"/>
  <xs:element name="OriginationDateNineteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateNineteenMember"/>
  <xs:element name="OriginationDateOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateOneMember"/>
  <xs:element name="OriginationDateSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateSevenMember"/>
  <xs:element name="OriginationDateSeventeenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateSeventeenMember"/>
  <xs:element name="OriginationDateSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateSixMember"/>
  <xs:element name="OriginationDateSixteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateSixteenMember"/>
  <xs:element name="OriginationDateTenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTenMember"/>
  <xs:element name="OriginationDateThirteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateThirteenMember"/>
  <xs:element name="OriginationDateThirtyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateThirtyMember"/>
  <xs:element name="OriginationDateThirtyOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateThirtyOneMember"/>
  <xs:element name="OriginationDateThirtyTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateThirtyTwoMember"/>
  <xs:element name="OriginationDateThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateThreeMember"/>
  <xs:element name="OriginationDateTwelveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwelveMember"/>
  <xs:element name="OriginationDateTwentyEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyEightMember"/>
  <xs:element name="OriginationDateTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyFiveMember"/>
  <xs:element name="OriginationDateTwentyFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyFourMember"/>
  <xs:element name="OriginationDateTwentyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyMember"/>
  <xs:element name="OriginationDateTwentyNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyNineMember"/>
  <xs:element name="OriginationDateTwentyOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyOneMember"/>
  <xs:element name="OriginationDateTwentySevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentySevenMember"/>
  <xs:element name="OriginationDateTwentySixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentySixMember"/>
  <xs:element name="OriginationDateTwentyThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyThreeMember"/>
  <xs:element name="OriginationDateTwentyTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwentyTwoMember"/>
  <xs:element name="OriginationDateTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OriginationDateTwoMember"/>
  <xs:element name="OtherReceivablesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OtherReceivablesMember"/>
  <xs:element name="PrescriptionDrugsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_PrescriptionDrugsMember"/>
  <xs:element name="RenovationInvestmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_RenovationInvestmentMember"/>
  <xs:element name="RenovationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_RenovationMember"/>
  <xs:element name="RetailDrugstoresMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_RetailDrugstoresMember"/>
  <xs:element name="SapSoftwareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SapSoftwareMember"/>
  <xs:element name="ShouantangBioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ShouantangBioMember"/>
  <xs:element name="ShouantangClinicMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ShouantangClinicMember"/>
  <xs:element name="SongluPharmaceuticalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SongluPharmaceuticalMember"/>
  <xs:element name="StatutoryReservesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_StatutoryReservesMember"/>
  <xs:element name="SundryProductsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_SundryProductsMember"/>
  <xs:element name="TCMMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_TCMMember"/>
  <xs:element name="WholesaleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_WholesaleMember"/>
  <xs:element name="ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember"/>
  <xs:element name="ZhetongMedicalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ZhetongMedicalMember"/>
  <xs:element name="ZhuoliServiceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_ZhuoliServiceMember"/>
  <xs:element name="AdvancesToSuppliersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_AdvancesToSuppliersAbstract"/>
  <xs:element name="OtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_OtherCurrentAssetsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="cjjd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>cjjd-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 30 06:45:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedBalanceSheet" roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedIncomeStatement" roleURI="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedCashFlow" roleURI="http://chinajojodrugstores.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofTradeReceivablesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofPropertyandEquipmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofAdvancetoSuppliersTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofFarmlandAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofOtherNoncurrentAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofleaseTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofNetIntangibleAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"/>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Supplies" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_DueFromRelatedsParties" xlink:href="cjjd-20240331.xsd#cjjd_DueFromRelatedsParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="cjjd_DueFromRelatedsParties" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="cjjd_FarmlandAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLoansPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_CustomerDepositCurrent" xlink:href="cjjd-20240331.xsd#cjjd_CustomerDepositCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="cjjd_CustomerDepositCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryReserves" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="cjjd_StatutoryReserves" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainLossOnInvestments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndDebtExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncreaseDecreaseInLongTermDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInLongTermDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cjjd_IncreaseDecreaseInLongTermDeposit" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="9" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZfg1f/OyMqeFkW4NxCRgc5zrMfOkODGpvnGwO67GcnxcMLoHh2bQdp9cqh7BBV1bpF2FDoEydlb4/CB4Q1RcA6BkFWukNPnSbNdgcFXy0j51Nyr3MVn75aB0UDm6KdgKWkIDFyVjwW12yAP66X3j7uVH+FbGya9WCnnXOUl4XE3uB1TJeQOH3eK29ryfO2nyLkWQ3FLaRkPF0rpKE9KNRxbNRckj0bSeYjcW2DQfjZn16WvZCsGxA3] CSR-->
    <loc xlink:type="locator" xlink:label="cjjd_IncreaseDecreaseInCustomerDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInCustomerDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cjjd_IncreaseDecreaseInCustomerDeposit" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnInvestments" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="21" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="22" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdditionsToLeaseholdImprovements" xlink:href="cjjd-20240331.xsd#cjjd_AdditionsToLeaseholdImprovements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="cjjd_AdditionsToLeaseholdImprovements" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cjjd_RepaymentOfOtherPayablesrelatedParties" xlink:href="cjjd-20240331.xsd#cjjd_RepaymentOfOtherPayablesrelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cjjd_RepaymentOfOtherPayablesrelatedParties" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReceivableNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_NotesReceivableNet" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" xlink:href="cjjd-20240331.xsd#cjjd_AccumulatedImpairmentPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesOnInventoryPurchasesGross" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesOnInventoryPurchasesGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Supplies" xlink:to="cjjd_AdvancesOnInventoryPurchasesGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_AllowanceForAdvancesToSuppliers" xlink:href="cjjd-20240331.xsd#cjjd_AllowanceForAdvancesToSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Supplies" xlink:to="cjjd_AllowanceForAdvancesToSuppliers" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsGross" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Land" xlink:to="cjjd_FarmlandAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_ImpairmentsOfFarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentsOfFarmlandAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Land" xlink:to="cjjd_ImpairmentsOfFarmlandAssets" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="cjjd_ForestLandUseRights" xlink:href="cjjd-20240331.xsd#cjjd_ForestLandUseRights"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="cjjd_ForestLandUseRights" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="cjjd_Others" xlink:href="cjjd-20240331.xsd#cjjd_Others"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="cjjd_Others" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofleaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="5" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>cjjd-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 30 06:45:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedBalanceSheet" roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedIncomeStatement" roleURI="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ShareholdersEquityType2or3" roleURI="http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedCashFlow" roleURI="http://chinajojodrugstores.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_DescriptionofBusinessandOrganization" roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SummaryofSignificantAccountingPolicies" roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_CommitmentsandContingencies" roleURI="http://chinajojodrugstores.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TradeReceivables" roleURI="http://chinajojodrugstores.com/role/TradeReceivables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherCurrentAssets" roleURI="http://chinajojodrugstores.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PropertyandEquipment" roleURI="http://chinajojodrugstores.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermInvestment" roleURI="http://chinajojodrugstores.com/role/LongTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_AdvancestoSuppliers" roleURI="http://chinajojodrugstores.com/role/AdvancestoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Inventory" roleURI="http://chinajojodrugstores.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_FarmlandAssets" roleURI="http://chinajojodrugstores.com/role/FarmlandAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermDeposits" roleURI="http://chinajojodrugstores.com/role/LongTermDeposits"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherNoncurrentAssets" roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Leases" roleURI="http://chinajojodrugstores.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_IntangibleAssets" roleURI="http://chinajojodrugstores.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NotesPayable" roleURI="http://chinajojodrugstores.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LoanPayable" roleURI="http://chinajojodrugstores.com/role/LoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Taxes" roleURI="http://chinajojodrugstores.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PostretirementBenefits" roleURI="http://chinajojodrugstores.com/role/PostretirementBenefits"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_RelatedPartyTransactionsandArrangements" roleURI="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ShareholdersEquity" roleURI="http://chinajojodrugstores.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NetLossPerShare" roleURI="http://chinajojodrugstores.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Segments" roleURI="http://chinajojodrugstores.com/role/Segments"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SubsequentEvents" roleURI="http://chinajojodrugstores.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_AccountingPoliciesByPolicy" roleURI="http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_DescriptionofBusinessandOrganizationTables" roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TradeReceivablesTables" roleURI="http://chinajojodrugstores.com/role/TradeReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherCurrentAssetsTables" roleURI="http://chinajojodrugstores.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PropertyandEquipmentTables" roleURI="http://chinajojodrugstores.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermInvestmentTables" roleURI="http://chinajojodrugstores.com/role/LongTermInvestmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_AdvancestoSuppliersTables" roleURI="http://chinajojodrugstores.com/role/AdvancestoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_FarmlandAssetsTables" roleURI="http://chinajojodrugstores.com/role/FarmlandAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherNoncurrentAssetsTables" roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LeasesTables" roleURI="http://chinajojodrugstores.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_IntangibleAssetsTables" roleURI="http://chinajojodrugstores.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NotesPayableTables" roleURI="http://chinajojodrugstores.com/role/NotesPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TaxesTables" roleURI="http://chinajojodrugstores.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_RelatedPartyTransactionsandArrangementsTables" roleURI="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NetLossPerShareTables" roleURI="http://chinajojodrugstores.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SegmentsTables" roleURI="http://chinajojodrugstores.com/role/SegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofConsolidatedFinancialStatementsActivitiesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofRevenuebyMajorSourceineachSegmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofTradeReceivablesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofPropertyandEquipmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofLongTermInvestmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofAdvancetoSuppliersTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofFarmlandAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofOtherNoncurrentAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofleaseTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofNetIntangibleAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofCreditFacilitieswithBanksTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofBasicandDilutedEarningsPerShareTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofSegmentoftheContinuingOperationsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_DescriptionofBusinessandOrganizationDetails" roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_CommitmentsandContingenciesDetails" roleURI="http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TradeReceivablesDetails" roleURI="http://chinajojodrugstores.com/role/TradeReceivablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PropertyandEquipmentDetails" roleURI="http://chinajojodrugstores.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermInvestmentDetails" roleURI="http://chinajojodrugstores.com/role/LongTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_InventoryDetails" roleURI="http://chinajojodrugstores.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_FarmlandAssetsDetails" roleURI="http://chinajojodrugstores.com/role/FarmlandAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermDepositsDetails" roleURI="http://chinajojodrugstores.com/role/LongTermDepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherNoncurrentAssetsDetails" roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LeasesDetails" roleURI="http://chinajojodrugstores.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_IntangibleAssetsDetails" roleURI="http://chinajojodrugstores.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NotesPayableDetails" roleURI="http://chinajojodrugstores.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LoanPayableDetails" roleURI="http://chinajojodrugstores.com/role/LoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TaxesDetails" roleURI="http://chinajojodrugstores.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PostretirementBenefitsDetails" roleURI="http://chinajojodrugstores.com/role/PostretirementBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ShareholdersEquityDetails" roleURI="http://chinajojodrugstores.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NetLossPerShareDetails" roleURI="http://chinajojodrugstores.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SegmentsDetails" roleURI="http://chinajojodrugstores.com/role/SegmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SubsequentEventsDetails" roleURI="http://chinajojodrugstores.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#DocumentAndEntityInformation" roleURI="http://chinajojodrugstores.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_DueFromRelatedsParties" xlink:href="cjjd-20240331.xsd#cjjd_DueFromRelatedsParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="cjjd_DueFromRelatedsParties" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="cjjd_FarmlandAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLoansPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_CustomerDepositCurrent" xlink:href="cjjd-20240331.xsd#cjjd_CustomerDepositCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="cjjd_CustomerDepositCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryReserves" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="cjjd_StatutoryReserves" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndDebtExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryReservesMember" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="cjjd_StatutoryReservesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodValueForReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncreaseDecreaseInLongTermDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInLongTermDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="cjjd_IncreaseDecreaseInLongTermDeposit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncreaseDecreaseInCustomerDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInCustomerDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="cjjd_IncreaseDecreaseInCustomerDeposit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdditionsToLeaseholdImprovements" xlink:href="cjjd-20240331.xsd#cjjd_AdditionsToLeaseholdImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="cjjd_AdditionsToLeaseholdImprovements" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RepaymentOfOtherPayablesrelatedParties" xlink:href="cjjd-20240331.xsd#cjjd_RepaymentOfOtherPayablesrelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cjjd_RepaymentOfOtherPayablesrelatedParties" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_CashlessExerciseOfWarrants" xlink:href="cjjd-20240331.xsd#cjjd_CashlessExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="cjjd_CashlessExerciseOfWarrants" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/TradeReceivables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_OtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LongTermInvestment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/AdvancestoSuppliers" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesToSuppliersTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_AdvancesToSuppliersAbstract" xlink:to="cjjd_AdvancesToSuppliersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/FarmlandAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_FarmlandAssetsAbstract" xlink:to="cjjd_FarmlandAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LongTermDeposits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermDepositsTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_LongTermDepositsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="cjjd_LongTermDepositsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/OtherNoncurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/NotesPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LoanPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_LoanPayableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="cjjd_LoanPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/Taxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/PostretirementBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/Segments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_CreditLossRollForwardPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_CreditLossRollForwardPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_CreditLossRollForwardPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_FarmlandAssetsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_NotesPayablePolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_NotesPayablePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_NotesPayablePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ValueAddedTaxPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ValueAddedTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_ValueAddedTaxPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/TradeReceivablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_OtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OtherCurrentAssetsAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LongTermInvestmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/AdvancestoSuppliersTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvanceToSuppliersTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_AdvanceToSuppliersTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_AdvancesToSuppliersAbstract" xlink:to="cjjd_AdvanceToSuppliersTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/FarmlandAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfFarmlandAssetsTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfFarmlandAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_FarmlandAssetsAbstract" xlink:to="cjjd_ScheduleOfFarmlandAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/NotesPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/TaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RenovationMember" xlink:href="cjjd-20240331.xsd#cjjd_RenovationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_RenovationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntityTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntityThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFourMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntityFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntityFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntitySixMember" xlink:href="cjjd-20240331.xsd#cjjd_EntitySixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntitySixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhouClinicOneMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouClinicOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_JiuzhouClinicOneMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntitySevenMember" xlink:href="cjjd-20240331.xsd#cjjd_EntitySevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntitySevenMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntityEightMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityNineMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_EntityNineMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShouantangBioMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_ShouantangBioMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuyiTechnologyMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuyiTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_JiuyiTechnologyMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_KahamadiBioMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_LinjiaMedicalMember" xlink:href="cjjd-20240331.xsd#cjjd_LinjiaMedicalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_LinjiaMedicalMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShouantangClinicMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangClinicMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_ShouantangClinicMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhenHealthMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhenHealthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_JiuzhenHealthMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_HongtongServiceMember" xlink:href="cjjd-20240331.xsd#cjjd_HongtongServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="cjjd_HongtongServiceMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_ProductOrServiceAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_RetailDrugstoresMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_OnlinePharmacyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_DrugWholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_DrugWholesaleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_DrugWholesaleMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_PrescriptionDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_PrescriptionDrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_PrescriptionDrugsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OTCDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_OTCDrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_OTCDrugsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_NutritionalSupplementsMember" xlink:href="cjjd-20240331.xsd#cjjd_NutritionalSupplementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_NutritionalSupplementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_TCMMember" xlink:href="cjjd-20240331.xsd#cjjd_TCMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_TCMMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_SundryProductsMember" xlink:href="cjjd-20240331.xsd#cjjd_SundryProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_SundryProductsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_MedicalDevicesMember" xlink:href="cjjd-20240331.xsd#cjjd_MedicalDevicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_MedicalDevicesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RetailDrugstoresAbstract" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="cjjd_RetailDrugstoresAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_RetailDrugstoresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OtherReceivablesMember" xlink:href="cjjd-20240331.xsd#cjjd_OtherReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="cjjd_OtherReceivablesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_MotorVehiclesMember" xlink:href="cjjd-20240331.xsd#cjjd_MotorVehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cjjd_MotorVehiclesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_LandUseRightsMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cjjd_LandUseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription" xlink:href="cjjd-20240331.xsd#cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:to="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_NotesReceivableNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfOtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidRent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandDevelopmentCostMember" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandDevelopmentCostMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cjjd_FarmlandDevelopmentCostMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" xlink:href="cjjd-20240331.xsd#cjjd_AccumulatedImpairmentPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZfg1f/OyMqeFkW4NxCRgc5zrMfOkODGpvnGwO67GcnxcMLoHh2bQdp9cqh7BBV1bpF2FDoEydlb4/CB4Q1RcA6BkFWukNPnSbNdgcFXy0j51Nyr3MVn75aB0UDm6KdgKWkIDFyVjwW12yAP66X3j7uVH+FbGya9WCnnXOUl4XE3uB1TJeQOH3eK29ryfO2nyLkWQ3FLaRkPF0rpKE9KNRxbNRckj0bSeYoBn8E7RavEQx7lsS0CDH+] CSR-->
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_KahamadiBioMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ZhetongMedicalMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhetongMedicalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_ZhetongMedicalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_SongluPharmaceuticalMember" xlink:href="cjjd-20240331.xsd#cjjd_SongluPharmaceuticalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_SongluPharmaceuticalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhouDigitalMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouDigitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_JiuzhouDigitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" xlink:href="cjjd-20240331.xsd#cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:href="cjjd-20240331.xsd#cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:href="cjjd-20240331.xsd#cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesOnInventoryPurchasesGross" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesOnInventoryPurchasesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="cjjd_AdvancesOnInventoryPurchasesGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_AllowanceForAdvancesToSuppliers" xlink:href="cjjd-20240331.xsd#cjjd_AllowanceForAdvancesToSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="cjjd_AllowanceForAdvancesToSuppliers" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="us-gaap_Supplies" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfFarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfFarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsGross" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfFarmlandAssetsAbstract" xlink:to="cjjd_FarmlandAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ImpairmentsOfFarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentsOfFarmlandAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfFarmlandAssetsAbstract" xlink:to="cjjd_ImpairmentsOfFarmlandAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfFarmlandAssetsAbstract" xlink:to="us-gaap_Land" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfOtherNoncurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_ForestLandUseRights" xlink:href="cjjd-20240331.xsd#cjjd_ForestLandUseRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="cjjd_ForestLandUseRights" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_Others" xlink:href="cjjd-20240331.xsd#cjjd_Others"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="cjjd_Others" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofleaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OperatingLeasesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OperatingLeasesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="cjjd_OperatingLeasesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_WeightedAverageRemainingLeaseTermAbstract" xlink:href="cjjd-20240331.xsd#cjjd_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="cjjd_WeightedAverageRemainingLeaseTermAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_OperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_SapSoftwareMember" xlink:href="cjjd-20240331.xsd#cjjd_SapSoftwareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cjjd_SapSoftwareMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_UseRightsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_AwardDateAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_HangzhouUnitedBankMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cjjd_HangzhouUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cjjd_EntityFiveMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cjjd_EntityEightMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFourMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSixMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateEightMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateEightMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateNineMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateNineMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTenMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateElevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateElevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateElevenMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwelveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwelveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwelveMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateThirteenMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFourteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFourteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateFourteenMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFifteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFifteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateFifteenMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSixteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSixteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateSixteenMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSeventeenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateSeventeenMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateEighteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateEighteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateEighteenMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateNineteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateNineteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateNineteenMember" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyMember" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyOneMember" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyTwoMember" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyThreeMember" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyFourMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyFourMember" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyFiveMember" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentySixMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentySixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentySixMember" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentySevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentySevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentySevenMember" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyEightMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyEightMember" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyNineMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateTwentyNineMember" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirtyMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateThirtyMember" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirtyOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateThirtyOneMember" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirtyTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="cjjd_OriginationDateThirtyTwoMember" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuer" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_DebtInstrumentIOriginationDate" xlink:href="cjjd-20240331.xsd#cjjd_DebtInstrumentIOriginationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cjjd_DebtInstrumentIOriginationDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouKahamadiBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_DirectorAndCEOMember" xlink:href="cjjd-20240331.xsd#cjjd_DirectorAndCEOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cjjd_DirectorAndCEOMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_RetailDrugstoresMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_OnlinePharmacyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_DrugWholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_DrugWholesaleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_DrugWholesaleMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_CapitalExpenditureContinuedOperations" xlink:href="cjjd-20240331.xsd#cjjd_CapitalExpenditureContinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="cjjd_CapitalExpenditureContinuedOperations" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ConsolidationItemsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_PrescriptionDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_PrescriptionDrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_PrescriptionDrugsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OTCDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_OTCDrugsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_OTCDrugsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_NutritionalSupplementsMember" xlink:href="cjjd-20240331.xsd#cjjd_NutritionalSupplementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_NutritionalSupplementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_TCMMember" xlink:href="cjjd-20240331.xsd#cjjd_TCMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_TCMMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_SundryProductsMember" xlink:href="cjjd-20240331.xsd#cjjd_SundryProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_SundryProductsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_MedicalDevicesMember" xlink:href="cjjd-20240331.xsd#cjjd_MedicalDevicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cjjd_MedicalDevicesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_RetailDrugstoresMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_OnlinePharmacyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_WholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_WholesaleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="cjjd_WholesaleMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionofBusinessandOrganizationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionofBusinessandOrganizationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="cjjd_DescriptionofBusinessandOrganizationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_BankLoanMember" xlink:href="cjjd-20240331.xsd#cjjd_BankLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="cjjd_BankLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_RenovationInvestmentMember" xlink:href="cjjd-20240331.xsd#cjjd_RenovationInvestmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="cjjd_RenovationInvestmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShouantangBioMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="cjjd_ShouantangBioMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="cjjd_EntityFiveMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="cjjd_EntityEightMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_LiquidityAndCapitalResourcesMember" xlink:href="cjjd-20240331.xsd#cjjd_LiquidityAndCapitalResourcesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cjjd_LiquidityAndCapitalResourcesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="cjjd_EntityFiveMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_SharesRepurchasePercentage" xlink:href="cjjd-20240331.xsd#cjjd_SharesRepurchasePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="cjjd_SharesRepurchasePercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_WorkingCapitalDeficit" xlink:href="cjjd-20240331.xsd#cjjd_WorkingCapitalDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="cjjd_WorkingCapitalDeficit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_ProfitLoss" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" xlink:href="cjjd-20240331.xsd#cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLeasehold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfLeasehold" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_VATPercentage" xlink:href="cjjd-20240331.xsd#cjjd_VATPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cjjd_VATPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFDICInsuredAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_Deposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashUninsuredAmount" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/TradeReceivablesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_PropertyandEquipmentDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_PropertyandEquipmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="cjjd_PropertyandEquipmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_PropertyandEquipmentDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LongTermInvestmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_LongTermInvestmentDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermInvestmentDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_LongTermInvestmentDetailsLineItems" xlink:to="cjjd_LongTermInvestmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_LongTermInvestmentDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_KahamadiBioMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ZhuoliServiceMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhuoliServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_ZhuoliServiceMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_EntityFiveMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_SongluPharmaceuticalMember" xlink:href="cjjd-20240331.xsd#cjjd_SongluPharmaceuticalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_SongluPharmaceuticalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhouDigitalMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouDigitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="cjjd_JiuzhouDigitalMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_InvestmentPercentage" xlink:href="cjjd-20240331.xsd#cjjd_InvestmentPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_LongTermInvestmentDetailsLineItems" xlink:to="cjjd_InvestmentPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_LongTermInvestmentDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_InjectedFunds" xlink:href="cjjd-20240331.xsd#cjjd_InjectedFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_LongTermInvestmentDetailsLineItems" xlink:to="cjjd_InjectedFunds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermInvestmentImpairmentLoss" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_LongTermInvestmentDetailsLineItems" xlink:to="cjjd_LongTermInvestmentImpairmentLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/FarmlandAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_FarmlandAssetsAbstract" xlink:to="us-gaap_ImpairmentOfRealEstate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LongTermDepositsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_OtherNoncurrentAssetsDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_OtherNoncurrentAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_OtherNoncurrentAssetsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_OtherNoncurrentAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_OtherNoncurrentAssetsDetailsLineItems" xlink:to="cjjd_OtherNoncurrentAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_OtherNoncurrentAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_LandUseRightsMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="cjjd_LandUseRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_DescriptionOfLeasePrepaymentLife" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionOfLeasePrepaymentLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OtherNoncurrentAssetsDetailsLineItems" xlink:to="cjjd_DescriptionOfLeasePrepaymentLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_OtherNoncurrentAssetsDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_LeasesDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="cjjd_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_LeasesDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/NotesPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_NotesPayableDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cjjd_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_NotesPayableDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_NotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBanksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableToBanksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_HangzhouUnitedBankMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="cjjd_HangzhouUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCollateralAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Deposits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/LoanPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_LoanPayableDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_LoanPayableDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_LoanPayableDetailsLineItems" xlink:to="cjjd_LoanPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_LoanPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_LoanPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_LandUseRightsAndPropertyOwnershipMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsAndPropertyOwnershipMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cjjd_LandUseRightsAndPropertyOwnershipMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cjjd_LandUseRightsAndPropertyOwnershipMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_LoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_LoanPayableDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/TaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/PostretirementBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShareholdersEquityDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cjjd_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_AggregateSharePercentage" xlink:href="cjjd-20240331.xsd#cjjd_AggregateSharePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cjjd_AggregateSharePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryAccountsPercentage" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryAccountsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cjjd_StatutoryAccountsPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="cjjd_ReserveFundPercentage" xlink:href="cjjd-20240331.xsd#cjjd_ReserveFundPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="cjjd_ReserveFundPercentage" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_NetLossPerShareDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_NetLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="cjjd_NetLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_NetLossPerShareDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SegmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cjjd_SegmentsDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SegmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_SegmentsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_SegmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cjjd_SegmentsDetailsLineItems" xlink:to="cjjd_SegmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SegmentsDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SegmentsDetailsTable" xlink:to="srt_ConsolidationItemsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cjjd_SegmentsDetailsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="cjjd_SubsequentEventsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cjjd_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cjjd_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://chinajojodrugstores.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="40" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>cjjd-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 30 06:45:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity attributed to China Jo-Jo</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss attributable to controlling interest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss approximately</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Description of Business and Organization [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for credit losses as of March 31, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0" xml:lang="en-US">Ending allowance for credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1" xml:lang="en-US">Less: allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Trade Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Trade accounts receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OtherCurrentAssetsAbstract" xlink:to="cjjd_OtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfOtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="cjjd_ScheduleOfOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl" xml:lang="en-US">Long-Term Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdvancesToSuppliersAbstract_lbl" xml:lang="en-US">Advances to Suppliers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesToSuppliersAbstract" xlink:to="cjjd_AdvancesToSuppliersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US">Advance to suppliers, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Supplies_lbl0" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FarmlandAssetsAbstract_lbl" xml:lang="en-US">Farmland Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsAbstract" xlink:to="cjjd_FarmlandAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfFarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfFarmlandAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfFarmlandAssetsAbstract_lbl" xml:lang="en-US">Schedule of Farmland Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfFarmlandAssetsAbstract" xlink:to="cjjd_ScheduleOfFarmlandAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Land_lbl" xml:lang="en-US">Farmland assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Land" xlink:to="us-gaap_Land_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAbstract_lbl" xml:lang="en-US">Long Term Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xml:lang="en-US">Other Noncurrent Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfOtherNoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Other Noncurrent Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="cjjd_ScheduleOfOtherNoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other noncurrent assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Amortizations of the Prepayment for Lease of Land Use Right [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Total lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Lease Liabilities Under Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Amortization of prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableAbstract_lbl" xml:lang="en-US">Loan Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="us-gaap_LoansPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Postretirement Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions and Arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Shareholder&#8217;s Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">LOSS PER SHARE:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share [Absttract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DueFromRelatedsParties" xlink:href="cjjd-20240331.xsd#cjjd_DueFromRelatedsParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_DueFromRelatedsParties_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DueFromRelatedsParties" xlink:to="cjjd_DueFromRelatedsParties_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract" xlink:to="cjjd_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">OTHER ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_FarmlandAssets_lbl" xml:lang="en-US">Farmland assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssets" xlink:to="cjjd_FarmlandAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Long-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Long term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract0" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract0" xlink:to="cjjd_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl1" xml:lang="en-US">Bank notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLoansPayableCurrent_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayableCurrent" xlink:to="us-gaap_OtherLoansPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_CustomerDepositCurrent" xlink:href="cjjd-20240331.xsd#cjjd_CustomerDepositCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_CustomerDepositCurrent_lbl" xml:lang="en-US">Customer deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CustomerDepositCurrent" xlink:to="cjjd_CustomerDepositCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract1" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract1" xlink:to="cjjd_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract2" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract2" xlink:to="cjjd_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract3" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract3" xlink:to="cjjd_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares; $0.24 par value; 150,000,000 shares authorized; 1,743,362 and 1,184,861 shares issued and outstanding as of March 31, 2024 and 2023, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Ordinary shares par vale (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common stock, shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Ordinary shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2024 and 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryReserves" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_StatutoryReserves_lbl" xml:lang="en-US">Statutory reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryReserves" xlink:to="cjjd_StatutoryReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Net revenue from external customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract4" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract4" xlink:to="cjjd_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract5" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract5" xlink:to="cjjd_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract6" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract6" xlink:to="cjjd_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">SELLING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingExpense_lbl0" xml:lang="en-US">Selling expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">STOCK BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">IMPAIRMENT OF LONG-LIVED ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0" xml:lang="en-US">Impairment of long lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract7" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract7" xlink:to="cjjd_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract8" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract8" xlink:to="cjjd_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSES):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">INTEREST INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">INVESTMENT LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Investment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">OTHER INCOME (EXPENSES)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract9" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract9" xlink:to="cjjd_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract10" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract10" xlink:to="cjjd_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">PROVISION FOR INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract11" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract11" xlink:to="cjjd_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract12" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract12" xlink:to="cjjd_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract13" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract13" xlink:to="cjjd_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract14" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract14" xlink:to="cjjd_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">FOREIGN CURRENCY TRANSLATION ADJUSTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract15" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract15" xlink:to="cjjd_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract16" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract16" xlink:to="cjjd_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average shares used in basic computation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average shares used in diluted computation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract17" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract17" xlink:to="cjjd_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Net loss attributable to controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Net loss attributable to controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Foreign currency translation loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodValueForReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit_lbl" xml:lang="en-US">Fractional shares issued for reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit" xlink:to="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Fractional shares issued for reverse stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants_lbl" xml:lang="en-US">Issuance of shares and warrants in private placements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants" xlink:to="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants_lbl" xml:lang="en-US">Issuance of shares and warrants in private placements (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants" xlink:to="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Cashless exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Cashless exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt direct write-off and provision and reversal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncreaseDecreaseInLongTermDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInLongTermDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_IncreaseDecreaseInLongTermDeposit_lbl" xml:lang="en-US">Long term deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncreaseDecreaseInLongTermDeposit" xlink:to="cjjd_IncreaseDecreaseInLongTermDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncreaseDecreaseInCustomerDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInCustomerDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_IncreaseDecreaseInCustomerDeposit_lbl" xml:lang="en-US">Customer deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncreaseDecreaseInCustomerDeposit" xlink:to="cjjd_IncreaseDecreaseInCustomerDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract18" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract18" xlink:to="cjjd_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract19" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract19" xlink:to="cjjd_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xml:lang="en-US">Proceeds from short-term bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of shares and warrants in private placements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from other payable-related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract20" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract20" xlink:to="cjjd_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract21" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract21" xlink:to="cjjd_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract22" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract22" xlink:to="cjjd_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract23" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract23" xlink:to="cjjd_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">NON-CASH ACTIVITIES&#65306;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_CashlessExerciseOfWarrants" xlink:href="cjjd-20240331.xsd#cjjd_CashlessExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CashlessExerciseOfWarrants" xlink:to="cjjd_CashlessExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">INTEREST EXPENSE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl" xml:lang="en-US">Notes receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories and biological assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl" xml:lang="en-US">Advances to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other noncurrent assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US">Amount due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Acquisition of equipment and building</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl" xml:lang="en-US">Investment in a joint venture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchases of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdditionsToLeaseholdImprovements" xlink:href="cjjd-20240331.xsd#cjjd_AdditionsToLeaseholdImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cjjd_AdditionsToLeaseholdImprovements_lbl" xml:lang="en-US">Additions to leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdditionsToLeaseholdImprovements" xlink:to="cjjd_AdditionsToLeaseholdImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl" xml:lang="en-US">Repayment of short-term bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of third parties loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_RepaymentOfOtherPayablesrelatedParties" xlink:href="cjjd-20240331.xsd#cjjd_RepaymentOfOtherPayablesrelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cjjd_RepaymentOfOtherPayablesrelatedParties_lbl" xml:lang="en-US">Repayment of other payable-related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RepaymentOfOtherPayablesrelatedParties" xlink:to="cjjd_RepaymentOfOtherPayablesrelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Others (the directors of subsidiaries) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl2" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryReservesMember" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_StatutoryReservesMember_lbl" xml:lang="en-US">Statutory reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryReservesMember" xlink:to="cjjd_StatutoryReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income/(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non- controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS AND ORGANIZATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl" xml:lang="en-US">Background</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract24" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract24" xlink:to="cjjd_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract25" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract25" xlink:to="cjjd_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract26" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract26" xlink:to="cjjd_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract27" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract27" xlink:to="cjjd_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract28" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract28" xlink:to="cjjd_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract29" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract29" xlink:to="cjjd_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract30" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract30" xlink:to="cjjd_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract31" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract31" xlink:to="cjjd_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract32" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract32" xlink:to="cjjd_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract33" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract33" xlink:to="cjjd_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract34" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract34" xlink:to="cjjd_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract35" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract35" xlink:to="cjjd_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract36" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract36" xlink:to="cjjd_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract37" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract37" xlink:to="cjjd_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract38" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract38" xlink:to="cjjd_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract39" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract39" xlink:to="cjjd_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract40" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract40" xlink:to="cjjd_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract41" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract41" xlink:to="cjjd_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Revenue by Major Source in each Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_RetailDrugstoresAbstract" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_RetailDrugstoresAbstract_lbl" xml:lang="en-US">Retail drugstores</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RetailDrugstoresAbstract" xlink:to="cjjd_RetailDrugstoresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OnlinePharmacyAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OnlinePharmacyAbstract_lbl" xml:lang="en-US">Online pharmacy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OnlinePharmacyAbstract" xlink:to="cjjd_OnlinePharmacyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DrugWholesaleAbstract" xlink:href="cjjd-20240331.xsd#cjjd_DrugWholesaleAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_DrugWholesaleAbstract_lbl" xml:lang="en-US">Drug wholesale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DrugWholesaleAbstract" xlink:to="cjjd_DrugWholesaleAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Credit loss expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Property And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:to="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful life of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription" xlink:href="cjjd-20240331.xsd#cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription_lbl" xml:lang="en-US">Estimated useful life of intangible assets, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription" xlink:to="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">TRADE RECEIVABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of Trade Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesReceivableNet_lbl" xml:lang="en-US">Note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US">Prepaid rental expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LONG-TERM INVESTMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-Term Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesToSuppliersTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_AdvancesToSuppliersTextBlock_lbl" xml:lang="en-US">ADVANCES TO SUPPLIERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesToSuppliersTextBlock" xlink:to="cjjd_AdvancesToSuppliersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvanceToSuppliersTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_AdvanceToSuppliersTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_AdvanceToSuppliersTableTextBlock_lbl" xml:lang="en-US">Schedule of Advance to Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvanceToSuppliersTableTextBlock" xlink:to="cjjd_AdvanceToSuppliersTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancesOnInventoryPurchasesGross" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesOnInventoryPurchasesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_AdvancesOnInventoryPurchasesGross_lbl" xml:lang="en-US">Advance to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesOnInventoryPurchasesGross" xlink:to="cjjd_AdvancesOnInventoryPurchasesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_FarmlandAssetsTextBlock_lbl" xml:lang="en-US">FARMLAND ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsTextBlock" xlink:to="cjjd_FarmlandAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfFarmlandAssetsTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfFarmlandAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ScheduleOfFarmlandAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Farmland Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfFarmlandAssetsTableTextBlock" xlink:to="cjjd_ScheduleOfFarmlandAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsGross" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_FarmlandAssetsGross_lbl" xml:lang="en-US">Farmland assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsGross" xlink:to="cjjd_FarmlandAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermDepositsTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_LongTermDepositsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LongTermDepositsTextBlock_lbl" xml:lang="en-US">LONG TERM DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermDepositsTextBlock" xlink:to="cjjd_LongTermDepositsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER NONCURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ForestLandUseRights" xlink:href="cjjd-20240331.xsd#cjjd_ForestLandUseRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ForestLandUseRights_lbl" xml:lang="en-US">Forest land use rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ForestLandUseRights" xlink:to="cjjd_ForestLandUseRights_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_Others" xlink:href="cjjd-20240331.xsd#cjjd_Others"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_Others_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_Others" xlink:to="cjjd_Others_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Amortizations of the Prepayment for Lease of Land Use Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows paid for operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OperatingLeasesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OperatingLeasesAbstract_lbl" xml:lang="en-US">Operating leases:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OperatingLeasesAbstract" xlink:to="cjjd_OperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract42" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract42" xlink:to="cjjd_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_UnlabeledAbstract43" xlink:href="cjjd-20240331.xsd#cjjd_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract43" xlink:to="cjjd_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_WeightedAverageRemainingLeaseTermAbstract" xlink:href="cjjd-20240331.xsd#cjjd_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WeightedAverageRemainingLeaseTermAbstract" xlink:to="cjjd_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Liabilities Under Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of net Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">Schedule of Credit Facilities with Banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuer_lbl" xml:lang="en-US">Endorser</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuer" xlink:to="us-gaap_DebtInstrumentIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DebtInstrumentIOriginationDate" xlink:href="cjjd-20240331.xsd#cjjd_DebtInstrumentIOriginationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_DebtInstrumentIOriginationDate_lbl" xml:lang="en-US">Origination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DebtInstrumentIOriginationDate" xlink:to="cjjd_DebtInstrumentIOriginationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LoanPayableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LoanPayableTextBlock_lbl" xml:lang="en-US">LOAN PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LoanPayableTextBlock" xlink:to="cjjd_LoanPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. Statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign income not recognized in the U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl" xml:lang="en-US">China income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible expenses-permanent difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Not deductible for PRC income tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">POSTRETIREMENT BENEFITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS AND ARRANGEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDER&#8217;S EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants_lbl" xml:lang="en-US">Diluted effect of stock options and warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" xlink:to="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Loss per share &#8211; Basic:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Add: Net loss attributable to noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US">Loss per share &#8211; Diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest_lbl" xml:lang="en-US">Net income before noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Add: Net loss attributable to noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment of the Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_CapitalExpenditureContinuedOperations" xlink:href="cjjd-20240331.xsd#cjjd_CapitalExpenditureContinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_CapitalExpenditureContinuedOperations_lbl" xml:lang="en-US">Total capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CapitalExpenditureContinuedOperations" xlink:to="cjjd_CapitalExpenditureContinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of net revenue from external customers through its retail drugstores by main products</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" xlink:href="cjjd-20240331.xsd#cjjd_AccumulatedImpairmentPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" xlink:to="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AllowanceForAdvancesToSuppliers" xlink:href="cjjd-20240331.xsd#cjjd_AllowanceForAdvancesToSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cjjd_AllowanceForAdvancesToSuppliers_lbl" xml:lang="en-US">Less: reserve for vendor non-performance on advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AllowanceForAdvancesToSuppliers" xlink:to="cjjd_AllowanceForAdvancesToSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ImpairmentsOfFarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentsOfFarmlandAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cjjd_ImpairmentsOfFarmlandAssets_lbl" xml:lang="en-US">Less: Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ImpairmentsOfFarmlandAssets" xlink:to="cjjd_ImpairmentsOfFarmlandAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Less: impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:to="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_RenovationMember" xlink:href="cjjd-20240331.xsd#cjjd_RenovationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_RenovationMember_lbl" xml:lang="en-US">Renovation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RenovationMember" xlink:to="cjjd_RenovationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntityTwoMember_lbl" xml:lang="en-US">Jiuxin Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityTwoMember" xlink:to="cjjd_EntityTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntityThreeMember_lbl" xml:lang="en-US">Shouantang Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityThreeMember" xlink:to="cjjd_EntityThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFourMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntityFourMember_lbl" xml:lang="en-US">Qianhong Agriculture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityFourMember" xlink:to="cjjd_EntityFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntityFiveMember_lbl" xml:lang="en-US">Jiuzhou Pharmacy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityFiveMember" xlink:to="cjjd_EntityFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntitySixMember" xlink:href="cjjd-20240331.xsd#cjjd_EntitySixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntitySixMember_lbl" xml:lang="en-US">Jiuzhou Clinic [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntitySixMember" xlink:to="cjjd_EntitySixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhouClinicOneMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouClinicOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_JiuzhouClinicOneMember_lbl" xml:lang="en-US">Jiuzhou Clinic One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuzhouClinicOneMember" xlink:to="cjjd_JiuzhouClinicOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntitySevenMember" xlink:href="cjjd-20240331.xsd#cjjd_EntitySevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntitySevenMember_lbl" xml:lang="en-US">Jiuzhou Service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntitySevenMember" xlink:to="cjjd_EntitySevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntityEightMember_lbl" xml:lang="en-US">Jiuxin Medicine [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityEightMember" xlink:to="cjjd_EntityEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_EntityNineMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_EntityNineMember_lbl" xml:lang="en-US">Jiutong Medical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityNineMember" xlink:to="cjjd_EntityNineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShouantangBioMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangBioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ShouantangBioMember_lbl" xml:lang="en-US">Shouantang Bio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ShouantangBioMember" xlink:to="cjjd_ShouantangBioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuyiTechnologyMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuyiTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_JiuyiTechnologyMember_lbl" xml:lang="en-US">Jiuyi Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuyiTechnologyMember" xlink:to="cjjd_JiuyiTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_KahamadiBioMember_lbl" xml:lang="en-US">Kahamadi Bio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_KahamadiBioMember" xlink:to="cjjd_KahamadiBioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LinjiaMedicalMember" xlink:href="cjjd-20240331.xsd#cjjd_LinjiaMedicalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LinjiaMedicalMember_lbl" xml:lang="en-US">Linjia Medical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LinjiaMedicalMember" xlink:to="cjjd_LinjiaMedicalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShouantangClinicMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangClinicMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ShouantangClinicMember_lbl" xml:lang="en-US">Shouantang Clinic [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ShouantangClinicMember" xlink:to="cjjd_ShouantangClinicMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhenHealthMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhenHealthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_JiuzhenHealthMember_lbl" xml:lang="en-US">Jiuzhen Health [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuzhenHealthMember" xlink:to="cjjd_JiuzhenHealthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_HongtongServiceMember" xlink:href="cjjd-20240331.xsd#cjjd_HongtongServiceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_HongtongServiceMember_lbl" xml:lang="en-US">Hongtong Service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HongtongServiceMember" xlink:to="cjjd_HongtongServiceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_PrescriptionDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_PrescriptionDrugsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_PrescriptionDrugsMember_lbl" xml:lang="en-US">Prescription drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PrescriptionDrugsMember" xlink:to="cjjd_PrescriptionDrugsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_PrescriptionDrugsMember_lbl0" xml:lang="en-US">Prescription Drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PrescriptionDrugsMember" xlink:to="cjjd_PrescriptionDrugsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_RetailDrugstoresMember_lbl" xml:lang="en-US">Retail drugstores [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RetailDrugstoresMember" xlink:to="cjjd_RetailDrugstoresMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OTCDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_OTCDrugsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OTCDrugsMember_lbl" xml:lang="en-US">OTC drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OTCDrugsMember" xlink:to="cjjd_OTCDrugsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_OTCDrugsMember_lbl0" xml:lang="en-US">OTC Drugs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OTCDrugsMember" xlink:to="cjjd_OTCDrugsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_NutritionalSupplementsMember" xlink:href="cjjd-20240331.xsd#cjjd_NutritionalSupplementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_NutritionalSupplementsMember_lbl" xml:lang="en-US">Nutritional supplements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NutritionalSupplementsMember" xlink:to="cjjd_NutritionalSupplementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_NutritionalSupplementsMember_lbl0" xml:lang="en-US">Nutritional Supplements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NutritionalSupplementsMember" xlink:to="cjjd_NutritionalSupplementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_TCMMember" xlink:href="cjjd-20240331.xsd#cjjd_TCMMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_TCMMember_lbl" xml:lang="en-US">TCM [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_TCMMember" xlink:to="cjjd_TCMMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SundryProductsMember" xlink:href="cjjd-20240331.xsd#cjjd_SundryProductsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_SundryProductsMember_lbl" xml:lang="en-US">Sundry products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SundryProductsMember" xlink:to="cjjd_SundryProductsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_SundryProductsMember_lbl0" xml:lang="en-US">Sundry Products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SundryProductsMember" xlink:to="cjjd_SundryProductsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_MedicalDevicesMember" xlink:href="cjjd-20240331.xsd#cjjd_MedicalDevicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_MedicalDevicesMember_lbl" xml:lang="en-US">Medical devices [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_MedicalDevicesMember" xlink:to="cjjd_MedicalDevicesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_MedicalDevicesMember_lbl0" xml:lang="en-US">Medical Devices [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_MedicalDevicesMember" xlink:to="cjjd_MedicalDevicesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OnlinePharmacyMember_lbl" xml:lang="en-US">Retail drugstores [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OnlinePharmacyMember" xlink:to="cjjd_OnlinePharmacyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_OnlinePharmacyMember_lbl0" xml:lang="en-US">Online Pharmacy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OnlinePharmacyMember" xlink:to="cjjd_OnlinePharmacyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_DrugWholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_DrugWholesaleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_DrugWholesaleMember_lbl" xml:lang="en-US">Drug Wholesale [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DrugWholesaleMember" xlink:to="cjjd_DrugWholesaleMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_DrugWholesaleMember_lbl0" xml:lang="en-US">Drug wholesale [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DrugWholesaleMember" xlink:to="cjjd_DrugWholesaleMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OtherReceivablesMember" xlink:href="cjjd-20240331.xsd#cjjd_OtherReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OtherReceivablesMember_lbl" xml:lang="en-US">Other Receivables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OtherReceivablesMember" xlink:to="cjjd_OtherReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_MotorVehiclesMember" xlink:href="cjjd-20240331.xsd#cjjd_MotorVehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_MotorVehiclesMember_lbl" xml:lang="en-US">Motor vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_MotorVehiclesMember" xlink:to="cjjd_MotorVehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment &amp; furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment and Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Buildings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LandUseRightsMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LandUseRightsMember_lbl" xml:lang="en-US">Land use rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LandUseRightsMember" xlink:to="cjjd_LandUseRightsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_LandUseRightsMember_lbl0" xml:lang="en-US">Land Use Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LandUseRightsMember" xlink:to="cjjd_LandUseRightsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xml:lang="en-US">Trade Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandDevelopmentCostMember" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandDevelopmentCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_FarmlandDevelopmentCostMember_lbl" xml:lang="en-US">Farmland Development Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandDevelopmentCostMember" xlink:to="cjjd_FarmlandDevelopmentCostMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Motor Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ZhetongMedicalMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhetongMedicalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ZhetongMedicalMember_lbl" xml:lang="en-US">Zhuoli Life [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhetongMedicalMember" xlink:to="cjjd_ZhetongMedicalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SongluPharmaceuticalMember" xlink:href="cjjd-20240331.xsd#cjjd_SongluPharmaceuticalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_SongluPharmaceuticalMember_lbl" xml:lang="en-US">Songlu Pharmaceutical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SongluPharmaceuticalMember" xlink:to="cjjd_SongluPharmaceuticalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_JiuzhouDigitalMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouDigitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_JiuzhouDigitalMember_lbl" xml:lang="en-US">Jiuzhou Digital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuzhouDigitalMember" xlink:to="cjjd_JiuzhouDigitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" xlink:href="cjjd-20240331.xsd#cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember_lbl" xml:lang="en-US">Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" xlink:to="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SapSoftwareMember" xlink:href="cjjd-20240331.xsd#cjjd_SapSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_SapSoftwareMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SapSoftwareMember" xlink:to="cjjd_SapSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseRightsMember_lbl" xml:lang="en-US">Land use rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateOneMember_lbl" xml:lang="en-US">10/19/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateOneMember" xlink:to="cjjd_OriginationDateOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_HangzhouUnitedBankMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouUnitedBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_HangzhouUnitedBankMember_lbl" xml:lang="en-US">Hangzhou United Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HangzhouUnitedBankMember" xlink:to="cjjd_HangzhouUnitedBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwoMember_lbl" xml:lang="en-US">10/20/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwoMember" xlink:to="cjjd_OriginationDateTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateThreeMember_lbl" xml:lang="en-US">11/17/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThreeMember" xlink:to="cjjd_OriginationDateThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFourMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateFourMember_lbl" xml:lang="en-US">12/16/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFourMember" xlink:to="cjjd_OriginationDateFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateFiveMember_lbl" xml:lang="en-US">12/26/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFiveMember" xlink:to="cjjd_OriginationDateFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSixMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateSixMember_lbl" xml:lang="en-US">12/28/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSixMember" xlink:to="cjjd_OriginationDateSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateSevenMember_lbl" xml:lang="en-US">01/16/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSevenMember" xlink:to="cjjd_OriginationDateSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateEightMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateEightMember_lbl" xml:lang="en-US">02/27/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateEightMember" xlink:to="cjjd_OriginationDateEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateNineMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateNineMember_lbl" xml:lang="en-US">03/20/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateNineMember" xlink:to="cjjd_OriginationDateNineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTenMember_lbl" xml:lang="en-US">03/23/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTenMember" xlink:to="cjjd_OriginationDateTenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateElevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateElevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateElevenMember_lbl" xml:lang="en-US">11/17/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateElevenMember" xlink:to="cjjd_OriginationDateElevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwelveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwelveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwelveMember_lbl" xml:lang="en-US">12/16/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwelveMember" xlink:to="cjjd_OriginationDateTwelveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateThirteenMember_lbl" xml:lang="en-US">12/21/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirteenMember" xlink:to="cjjd_OriginationDateThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFourteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFourteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateFourteenMember_lbl" xml:lang="en-US">12/29/22 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFourteenMember" xlink:to="cjjd_OriginationDateFourteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateFifteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFifteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateFifteenMember_lbl" xml:lang="en-US">03/20/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFifteenMember" xlink:to="cjjd_OriginationDateFifteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSixteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSixteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateSixteenMember_lbl" xml:lang="en-US">10/12/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSixteenMember" xlink:to="cjjd_OriginationDateSixteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateSeventeenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSeventeenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateSeventeenMember_lbl" xml:lang="en-US">11/21/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSeventeenMember" xlink:to="cjjd_OriginationDateSeventeenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateEighteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateEighteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateEighteenMember_lbl" xml:lang="en-US">12/22/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateEighteenMember" xlink:to="cjjd_OriginationDateEighteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateNineteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateNineteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateNineteenMember_lbl" xml:lang="en-US">12/27/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateNineteenMember" xlink:to="cjjd_OriginationDateNineteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyMember_lbl" xml:lang="en-US">12/28/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyMember" xlink:to="cjjd_OriginationDateTwentyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyOneMember_lbl" xml:lang="en-US">01/03/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyOneMember" xlink:to="cjjd_OriginationDateTwentyOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyTwoMember_lbl" xml:lang="en-US">01/11/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyTwoMember" xlink:to="cjjd_OriginationDateTwentyTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyThreeMember_lbl" xml:lang="en-US">02/06/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyThreeMember" xlink:to="cjjd_OriginationDateTwentyThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyFourMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyFourMember_lbl" xml:lang="en-US">03/13/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyFourMember" xlink:to="cjjd_OriginationDateTwentyFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyFiveMember_lbl" xml:lang="en-US">03/14/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyFiveMember" xlink:to="cjjd_OriginationDateTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentySixMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentySixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentySixMember_lbl" xml:lang="en-US">12/27/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentySixMember" xlink:to="cjjd_OriginationDateTwentySixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentySevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentySevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentySevenMember_lbl" xml:lang="en-US">12/28/23 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentySevenMember" xlink:to="cjjd_OriginationDateTwentySevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyEightMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyEightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyEightMember_lbl" xml:lang="en-US">01/11/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyEightMember" xlink:to="cjjd_OriginationDateTwentyEightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateTwentyNineMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyNineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateTwentyNineMember_lbl" xml:lang="en-US">02/06/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyNineMember" xlink:to="cjjd_OriginationDateTwentyNineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirtyMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateThirtyMember_lbl" xml:lang="en-US">03/15/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirtyMember" xlink:to="cjjd_OriginationDateThirtyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirtyOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateThirtyOneMember_lbl" xml:lang="en-US">03/28/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirtyOneMember" xlink:to="cjjd_OriginationDateThirtyOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OriginationDateThirtyTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_OriginationDateThirtyTwoMember_lbl" xml:lang="en-US">03/29/24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirtyTwoMember" xlink:to="cjjd_OriginationDateThirtyTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouKahamadiBiotechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember_lbl" xml:lang="en-US">Hangzhou Kahamadi Biotechnology Co., Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember" xlink:to="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DirectorAndCEOMember" xlink:href="cjjd-20240331.xsd#cjjd_DirectorAndCEOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_DirectorAndCEOMember_lbl" xml:lang="en-US">Due to a director and CEO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DirectorAndCEOMember" xlink:to="cjjd_DirectorAndCEOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_WholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_WholesaleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_WholesaleMember_lbl" xml:lang="en-US">Wholesale [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WholesaleMember" xlink:to="cjjd_WholesaleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Aggregate of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Percentage of capital stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Total amount of investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xml:lang="en-US">Total proceeds of investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SharesRepurchasePercentage" xlink:href="cjjd-20240331.xsd#cjjd_SharesRepurchasePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_SharesRepurchasePercentage_lbl" xml:lang="en-US">Shares repurchase percentage (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SharesRepurchasePercentage" xlink:to="cjjd_SharesRepurchasePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl" xml:lang="en-US">Total price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_WorkingCapitalDeficit" xlink:href="cjjd-20240331.xsd#cjjd_WorkingCapitalDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WorkingCapitalDeficit" xlink:to="cjjd_WorkingCapitalDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xml:lang="en-US">Investment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares issued per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Gross proceeds of private placement (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Credit borrowing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Line of credit total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" xlink:href="cjjd-20240331.xsd#cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl_lbl" xml:lang="en-US">Voting ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" xlink:to="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLeasehold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl" xml:lang="en-US">Forest land use rights impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_VATPercentage" xlink:href="cjjd-20240331.xsd#cjjd_VATPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_VATPercentage_lbl" xml:lang="en-US">VAT percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_VATPercentage" xlink:to="cjjd_VATPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Advertising and promotion costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Insurance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposits totaling</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Insurance not covered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZfg1f/OyMqeFkW4NxCRgc5zrMfOkODGpvnGwO67GcnxcMLoHh2bQdp9cqh7BBV1bpF2FDoEydlb4/CB4Q1RcA6BkFWukNPnSbNdgcFXy0j51Nyr3MVn75aB0UDm6KdgKWkIDFyVjwW12yAP66X3j7uVH+FbGya9WCnnXOUl4XE3uB1TJeQOH3eK29ryfO2nyLkWQ3FLaRkPF0rpKE9KNRxbNRckj0bSeZ/u8yHSrgqd2TDT7H//qi2] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense for property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_InvestmentPercentage" xlink:href="cjjd-20240331.xsd#cjjd_InvestmentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_InvestmentPercentage_lbl" xml:lang="en-US">Investment percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_InvestmentPercentage" xlink:to="cjjd_InvestmentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xml:lang="en-US">Suffered loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_InjectedFunds" xlink:href="cjjd-20240331.xsd#cjjd_InjectedFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_InjectedFunds_lbl" xml:lang="en-US">Injected funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_InjectedFunds" xlink:to="cjjd_InjectedFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermInvestmentImpairmentLoss" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LongTermInvestmentImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermInvestmentImpairmentLoss" xlink:to="cjjd_LongTermInvestmentImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Reserves inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfRealEstate_lbl" xml:lang="en-US">Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfRealEstate" xlink:to="us-gaap_ImpairmentOfRealEstate_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DescriptionOfLeasePrepaymentLife" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionOfLeasePrepaymentLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_DescriptionOfLeasePrepaymentLife_lbl" xml:lang="en-US">Description of lease prepayment life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DescriptionOfLeasePrepaymentLife" xlink:to="cjjd_DescriptionOfLeasePrepaymentLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCollateralAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCollateralAmount_lbl" xml:lang="en-US">Collateral amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateralAmount" xlink:to="us-gaap_DebtInstrumentCollateralAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Bank credit line facilities available for borrowing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xml:lang="en-US">Short-term bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Employment benefits and pension contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AggregateSharePercentage" xlink:href="cjjd-20240331.xsd#cjjd_AggregateSharePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_AggregateSharePercentage_lbl" xml:lang="en-US">Aggregate share percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AggregateSharePercentage" xlink:to="cjjd_AggregateSharePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_StatutoryAccountsPercentage" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryAccountsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_StatutoryAccountsPercentage_lbl" xml:lang="en-US">Statutory accounts percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryAccountsPercentage" xlink:to="cjjd_StatutoryAccountsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ReserveFundPercentage" xlink:href="cjjd-20240331.xsd#cjjd_ReserveFundPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ReserveFundPercentage_lbl" xml:lang="en-US">Reserve fund percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ReserveFundPercentage" xlink:to="cjjd_ReserveFundPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from calculation of diluted earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Main reportable segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares of restricted stock awards (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Ordinary shares, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Aggregate gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of presentation and consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xml:lang="en-US">Consolidation of variable interest entities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_CreditLossRollForwardPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_CreditLossRollForwardPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_CreditLossRollForwardPolicyTextBlock_lbl" xml:lang="en-US">Credit loss roll forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CreditLossRollForwardPolicyTextBlock" xlink:to="cjjd_CreditLossRollForwardPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_FarmlandAssetsPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_FarmlandAssetsPolicyTextBlock_lbl" xml:lang="en-US">Farmland assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsPolicyTextBlock" xlink:to="cjjd_FarmlandAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_NotesPayablePolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_NotesPayablePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_NotesPayablePolicyTextBlock_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NotesPayablePolicyTextBlock" xlink:to="cjjd_NotesPayablePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ValueAddedTaxPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ValueAddedTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ValueAddedTaxPolicyTextBlock_lbl" xml:lang="en-US">Value added tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ValueAddedTaxPolicyTextBlock" xlink:to="cjjd_ValueAddedTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising and promotion costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_RenovationInvestmentMember" xlink:href="cjjd-20240331.xsd#cjjd_RenovationInvestmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_RenovationInvestmentMember_lbl" xml:lang="en-US">Renovation Investment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RenovationInvestmentMember" xlink:to="cjjd_RenovationInvestmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LiquidityAndCapitalResourcesMember" xlink:href="cjjd-20240331.xsd#cjjd_LiquidityAndCapitalResourcesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LiquidityAndCapitalResourcesMember_lbl" xml:lang="en-US">Liquidity and Capital Resources [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LiquidityAndCapitalResourcesMember" xlink:to="cjjd_LiquidityAndCapitalResourcesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_BankLoanMember" xlink:href="cjjd-20240331.xsd#cjjd_BankLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_BankLoanMember_lbl" xml:lang="en-US">Bank Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_BankLoanMember" xlink:to="cjjd_BankLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ZhuoliServiceMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhuoliServiceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ZhuoliServiceMember_lbl" xml:lang="en-US">Zhetong Service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhuoliServiceMember" xlink:to="cjjd_ZhuoliServiceMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cjjd_ZhuoliServiceMember_lbl0" xml:lang="en-US">Zhuoli Service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhuoliServiceMember" xlink:to="cjjd_ZhuoliServiceMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember_lbl" xml:lang="en-US">Zhejiang Jiuzhou Digital Medicine Technology Co., LTD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" xlink:to="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBanksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableToBanksMember_lbl" xml:lang="en-US">Notes Payable to Banks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBanksMember" xlink:to="us-gaap_NotesPayableToBanksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LandUseRightsAndPropertyOwnershipMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsAndPropertyOwnershipMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cjjd_LandUseRightsAndPropertyOwnershipMember_lbl" xml:lang="en-US">Land Use Rights and Property Ownership [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LandUseRightsAndPropertyOwnershipMember" xlink:to="cjjd_LandUseRightsAndPropertyOwnershipMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xml:lang="en-US">Other Operating Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Subsidiary of LLC or LP [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US">Revenue, Major Customer [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US">Schedule of reconciliation of cash equivalents and restricted cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:to="cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Accounts and Financing Receivables [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:href="cjjd-20240331.xsd#cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable_lbl" xml:lang="en-US">Advances to Suppliers (Details) - Schedule of Advance to Suppliers [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:to="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:href="cjjd-20240331.xsd#cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems_lbl" xml:lang="en-US">Schedule of advance to suppliers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US">Consolidation Items [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl" xml:lang="en-US">Revenue from External Customer [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionofBusinessandOrganizationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DescriptionofBusinessandOrganizationDetailsTable_lbl" xml:lang="en-US">Description of Business and Organization (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsTable" xlink:to="cjjd_DescriptionofBusinessandOrganizationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionofBusinessandOrganizationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems_lbl" xml:lang="en-US">Description of Business and Organization (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="cjjd_DescriptionofBusinessandOrganizationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_PropertyandEquipmentDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_PropertyandEquipmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_PropertyandEquipmentDetailsTable_lbl" xml:lang="en-US">Property and Equipment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PropertyandEquipmentDetailsTable" xlink:to="cjjd_PropertyandEquipmentDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermInvestmentDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LongTermInvestmentDetailsTable_lbl" xml:lang="en-US">Long-Term Investment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermInvestmentDetailsTable" xlink:to="cjjd_LongTermInvestmentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LongTermInvestmentDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LongTermInvestmentDetailsLineItems_lbl" xml:lang="en-US">Long-Term Investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermInvestmentDetailsLineItems" xlink:to="cjjd_LongTermInvestmentDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OtherNoncurrentAssetsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_OtherNoncurrentAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OtherNoncurrentAssetsDetailsTable_lbl" xml:lang="en-US">Other Noncurrent Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OtherNoncurrentAssetsDetailsTable" xlink:to="cjjd_OtherNoncurrentAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_OtherNoncurrentAssetsDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_OtherNoncurrentAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OtherNoncurrentAssetsDetailsLineItems_lbl" xml:lang="en-US">Other Noncurrent Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OtherNoncurrentAssetsDetailsLineItems" xlink:to="cjjd_OtherNoncurrentAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LeasesDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LeasesDetailsTable" xlink:to="cjjd_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_NotesPayableDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NotesPayableDetailsTable" xlink:to="cjjd_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LoanPayableDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LoanPayableDetailsTable_lbl" xml:lang="en-US">Loan Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LoanPayableDetailsTable" xlink:to="cjjd_LoanPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_LoanPayableDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LoanPayableDetailsLineItems_lbl" xml:lang="en-US">Loan Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LoanPayableDetailsLineItems" xlink:to="cjjd_LoanPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_ShareholdersEquityDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholder&#8217;s Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ShareholdersEquityDetailsTable" xlink:to="cjjd_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Shareholder&#8217;s Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_NetLossPerShareDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_NetLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_NetLossPerShareDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NetLossPerShareDetailsTable" xlink:to="cjjd_NetLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SegmentsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_SegmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SegmentsDetailsTable_lbl" xml:lang="en-US">Segments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SegmentsDetailsTable" xlink:to="cjjd_SegmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SegmentsDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SegmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SegmentsDetailsLineItems_lbl" xml:lang="en-US">Segments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SegmentsDetailsLineItems" xlink:to="cjjd_SegmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cjjd_SubsequentEventsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SubsequentEventsDetailsTable" xlink:to="cjjd_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Amount of accumulated impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" xlink:to="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_AdvanceToSuppliersTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of advance to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvanceToSuppliersTableTextBlock" xlink:to="cjjd_AdvanceToSuppliersTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_AdvancesOnInventoryPurchasesGross_lbl0" xml:lang="en-US">Represents carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer before allowance for doubtful accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesOnInventoryPurchasesGross" xlink:to="cjjd_AdvancesOnInventoryPurchasesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_AdvancesToSuppliersTextBlock_lbl0" xml:lang="en-US">The entire disclosure for advances to suppliers consist of deposits with or advances to outside vendors for future inventory purchases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesToSuppliersTextBlock" xlink:to="cjjd_AdvancesToSuppliersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_AggregateSharePercentage_lbl0" xml:lang="en-US">The percentage of aggregate shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AggregateSharePercentage" xlink:to="cjjd_AggregateSharePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_AllowanceForAdvancesToSuppliers_lbl0" xml:lang="en-US">Represents the allowance for advances to suppliers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AllowanceForAdvancesToSuppliers" xlink:to="cjjd_AllowanceForAdvancesToSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl_lbl0" xml:lang="en-US">Represents benchmark percentage of voting ownership interest for control and common control.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" xlink:to="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_CapitalExpenditureContinuedOperations_lbl0" xml:lang="en-US">This element refer to capital expenditure continous operation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CapitalExpenditureContinuedOperations" xlink:to="cjjd_CapitalExpenditureContinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_CashlessExerciseOfWarrants_lbl0" xml:lang="en-US">Amount of cashless excercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CashlessExerciseOfWarrants" xlink:to="cjjd_CashlessExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_CustomerDepositCurrent_lbl0" xml:lang="en-US">The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CustomerDepositCurrent" xlink:to="cjjd_CustomerDepositCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_DebtInstrumentIOriginationDate_lbl0" xml:lang="en-US">Origination date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DebtInstrumentIOriginationDate" xlink:to="cjjd_DebtInstrumentIOriginationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_DescriptionOfLeasePrepaymentLife_lbl0" xml:lang="en-US">A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DescriptionOfLeasePrepaymentLife" xlink:to="cjjd_DescriptionOfLeasePrepaymentLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_DueFromRelatedsParties_lbl0" xml:lang="en-US">Due from related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DueFromRelatedsParties" xlink:to="cjjd_DueFromRelatedsParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest_lbl0" xml:lang="en-US">The amount of net income (loss) for the period per each share of common stock or unit outstanding before noncontrolling interest during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">The amount of net income (loss) for the period per each share of common stock or unit outstanding attributable to noncontrolling interest during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest_lbl0" xml:lang="en-US">The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding before noncontrolling interest during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding attributable to noncontrolling interest during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_FarmlandAssets_lbl0" xml:lang="en-US">Represents the amount of farmland assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssets" xlink:to="cjjd_FarmlandAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_FarmlandAssetsGross_lbl0" xml:lang="en-US">Represents farmland assets gross.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsGross" xlink:to="cjjd_FarmlandAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_FarmlandAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for farmland assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsPolicyTextBlock" xlink:to="cjjd_FarmlandAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_FarmlandAssetsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for farmland assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsTextBlock" xlink:to="cjjd_FarmlandAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ForestLandUseRights_lbl0" xml:lang="en-US">Forest Land Use Rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ForestLandUseRights" xlink:to="cjjd_ForestLandUseRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ImpairmentsOfFarmlandAssets_lbl0" xml:lang="en-US">Represents impairments of farmland assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ImpairmentsOfFarmlandAssets" xlink:to="cjjd_ImpairmentsOfFarmlandAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_IncreaseDecreaseInCustomerDeposit_lbl0" xml:lang="en-US">The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncreaseDecreaseInCustomerDeposit" xlink:to="cjjd_IncreaseDecreaseInCustomerDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants_lbl0" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of options and warrants using the treasury stock method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" xlink:to="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_InvestmentPercentage_lbl0" xml:lang="en-US">Investment percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_InvestmentPercentage" xlink:to="cjjd_InvestmentPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_LongTermDepositsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for long-term deposits. Long term deposits are money deposited with or advanced to landlords for securing retail store leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermDepositsTextBlock" xlink:to="cjjd_LongTermDepositsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_LongTermInvestmentImpairmentLoss_lbl0" xml:lang="en-US">Long-term investment impairment loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermInvestmentImpairmentLoss" xlink:to="cjjd_LongTermInvestmentImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_NotesPayablePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NotesPayablePolicyTextBlock" xlink:to="cjjd_NotesPayablePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_Others_lbl0" xml:lang="en-US">Amount of others assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_Others" xlink:to="cjjd_Others_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of estimated lives of the property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_RepaymentOfOtherPayablesrelatedParties_lbl0" xml:lang="en-US">The amount of repayment of other payables-related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RepaymentOfOtherPayablesrelatedParties" xlink:to="cjjd_RepaymentOfOtherPayablesrelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ReserveFundPercentage_lbl0" xml:lang="en-US">Reserve fund percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ReserveFundPercentage" xlink:to="cjjd_ReserveFundPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of estimated useful lives of intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:to="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ScheduleOfFarmlandAssetsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure for farmland assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfFarmlandAssetsTableTextBlock" xlink:to="cjjd_ScheduleOfFarmlandAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_SharesRepurchasePercentage_lbl0" xml:lang="en-US">Percentage of shares repurchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SharesRepurchasePercentage" xlink:to="cjjd_SharesRepurchasePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_StatutoryAccountsPercentage_lbl0" xml:lang="en-US">The percentage of statutory accounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryAccountsPercentage" xlink:to="cjjd_StatutoryAccountsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_StatutoryReserves_lbl0" xml:lang="en-US">The amount of statutory reserves.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryReserves" xlink:to="cjjd_StatutoryReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants_lbl0" xml:lang="en-US">The amount of sale of stock and warrants, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants" xlink:to="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit_lbl0" xml:lang="en-US">Amount of fractional shares issued for reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit" xlink:to="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants_lbl0" xml:lang="en-US">The amount of sale of stock and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants" xlink:to="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_VATPercentage_lbl0" xml:lang="en-US">VAT percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_VATPercentage" xlink:to="cjjd_VATPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ValueAddedTaxPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for value added tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ValueAddedTaxPolicyTextBlock" xlink:to="cjjd_ValueAddedTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_WorkingCapitalDeficit_lbl0" xml:lang="en-US">Working capital deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WorkingCapitalDeficit" xlink:to="cjjd_WorkingCapitalDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_DrugWholesaleMember_lbl1" xml:lang="en-US">Represents information regarding drug wholesale.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DrugWholesaleMember" xlink:to="cjjd_DrugWholesaleMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_FarmlandDevelopmentCostMember_lbl0" xml:lang="en-US">Represents farmland development cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandDevelopmentCostMember" xlink:to="cjjd_FarmlandDevelopmentCostMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_HangzhouUnitedBankMember_lbl0" xml:lang="en-US">Represents lender bank.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HangzhouUnitedBankMember" xlink:to="cjjd_HangzhouUnitedBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_KahamadiBioMember_lbl0" xml:lang="en-US">Kahamadi Bio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_KahamadiBioMember" xlink:to="cjjd_KahamadiBioMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_LandUseRightsMember_lbl1" xml:lang="en-US">Represents information of Land use rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LandUseRightsMember" xlink:to="cjjd_LandUseRightsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_MedicalDevicesMember_lbl1" xml:lang="en-US">Represents information regarding Medical Devices.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_MedicalDevicesMember" xlink:to="cjjd_MedicalDevicesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_NutritionalSupplementsMember_lbl1" xml:lang="en-US">Represents information regarding Nutritional Supplements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NutritionalSupplementsMember" xlink:to="cjjd_NutritionalSupplementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_OnlinePharmacyMember_lbl1" xml:lang="en-US">Represents information regarding online pharmacy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OnlinePharmacyMember" xlink:to="cjjd_OnlinePharmacyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_OriginationDateElevenMember_lbl0" xml:lang="en-US">Origination Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateElevenMember" xlink:to="cjjd_OriginationDateElevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_PrescriptionDrugsMember_lbl1" xml:lang="en-US">Represents the information regarding prescription drugs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PrescriptionDrugsMember" xlink:to="cjjd_PrescriptionDrugsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_RenovationInvestmentMember_lbl0" xml:lang="en-US">Represents the information regarding Renovation Investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RenovationInvestmentMember" xlink:to="cjjd_RenovationInvestmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_ShouantangBioMember_lbl0" xml:lang="en-US">Represents information regarding Shouantang Bio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ShouantangBioMember" xlink:to="cjjd_ShouantangBioMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cjjd_SundryProductsMember_lbl1" xml:lang="en-US">Sundry Products [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SundryProductsMember" xlink:to="cjjd_SundryProductsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DrugWholesaleMember_lbl2" xml:lang="en-US">Drug Wholesale Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DrugWholesaleMember" xlink:to="cjjd_DrugWholesaleMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SapSoftwareMember_lbl0" xml:lang="en-US">Sap Software Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SapSoftwareMember" xlink:to="cjjd_SapSoftwareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest_lbl1" xml:lang="en-US">Earnings Per Share Basic Before Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl0" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntityNineMember_lbl0" xml:lang="en-US">Entity Nine Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityNineMember" xlink:to="cjjd_EntityNineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LongTermDepositsTextBlock_lbl1" xml:lang="en-US">Long Term Deposits Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermDepositsTextBlock" xlink:to="cjjd_LongTermDepositsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DirectorAndCEOMember_lbl0" xml:lang="en-US">Director And CEOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DirectorAndCEOMember" xlink:to="cjjd_DirectorAndCEOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LandUseRightsAndPropertyOwnershipMember_lbl0" xml:lang="en-US">Land Use Rights And Property Ownership Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LandUseRightsAndPropertyOwnershipMember" xlink:to="cjjd_LandUseRightsAndPropertyOwnershipMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl0" xml:lang="en-US">Proceeds from Other Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntityEightMember_lbl0" xml:lang="en-US">Entity Eight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityEightMember" xlink:to="cjjd_EntityEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntitySixMember_lbl0" xml:lang="en-US">Entity Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntitySixMember" xlink:to="cjjd_EntitySixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember_lbl0" xml:lang="en-US">Zhejiang Jiuzhou Digital Medicine Technology Co LTDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" xlink:to="cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateEightMember_lbl0" xml:lang="en-US">Origination Date Eight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateEightMember" xlink:to="cjjd_OriginationDateEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTenMember_lbl0" xml:lang="en-US">Origination Date Ten Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTenMember" xlink:to="cjjd_OriginationDateTenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract28" xlink:to="cjjd_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract29" xlink:to="cjjd_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl1" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_RetailDrugstoresMember_lbl0" xml:lang="en-US">Retail Drugstores Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RetailDrugstoresMember" xlink:to="cjjd_RetailDrugstoresMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SongluPharmaceuticalMember_lbl0" xml:lang="en-US">Songlu Pharmaceutical Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SongluPharmaceuticalMember" xlink:to="cjjd_SongluPharmaceuticalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateThirtyTwoMember_lbl0" xml:lang="en-US">Origination Date Thirty Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirtyTwoMember" xlink:to="cjjd_OriginationDateThirtyTwoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="cjjd_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract30" xlink:to="cjjd_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LiquidityAndCapitalResourcesMember_lbl0" xml:lang="en-US">Liquidity And Capital Resources Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LiquidityAndCapitalResourcesMember" xlink:to="cjjd_LiquidityAndCapitalResourcesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract33" xlink:to="cjjd_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract34" xlink:to="cjjd_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract31" xlink:to="cjjd_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract32" xlink:to="cjjd_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract37" xlink:to="cjjd_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract38" xlink:to="cjjd_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract35" xlink:to="cjjd_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract36" xlink:to="cjjd_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract39" xlink:to="cjjd_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule Of Reconciliation Of Cash Equivalents And Restricted Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract" xlink:to="cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl0" xml:lang="en-US">Impairment Of Intangible Asset Indefinitelived Excluding Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:to="cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl0" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract40" xlink:to="cjjd_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract41" xlink:to="cjjd_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseRightsMember_lbl0" xml:lang="en-US">Use Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseRightsMember" xlink:to="us-gaap_UseRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract42" xlink:to="cjjd_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract43" xlink:to="cjjd_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_MotorVehiclesMember_lbl0" xml:lang="en-US">Motor Vehicles Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_MotorVehiclesMember" xlink:to="cjjd_MotorVehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateFifteenMember_lbl0" xml:lang="en-US">Origination Date Fifteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFifteenMember" xlink:to="cjjd_OriginationDateFifteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LongTermInvestmentImpairmentLoss_lbl1" xml:lang="en-US">Long Term Investment Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LongTermInvestmentImpairmentLoss" xlink:to="cjjd_LongTermInvestmentImpairmentLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Segment Of The Continuing Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract" xlink:to="cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract11" xlink:to="cjjd_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract12" xlink:to="cjjd_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract10" xlink:to="cjjd_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract15" xlink:to="cjjd_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract16" xlink:to="cjjd_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FarmlandAssetsTextBlock_lbl1" xml:lang="en-US">Farmland Assets Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsTextBlock" xlink:to="cjjd_FarmlandAssetsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract13" xlink:to="cjjd_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract14" xlink:to="cjjd_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_RenovationInvestmentMember_lbl1" xml:lang="en-US">Renovation Investment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RenovationInvestmentMember" xlink:to="cjjd_RenovationInvestmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract19" xlink:to="cjjd_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract17" xlink:to="cjjd_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract18" xlink:to="cjjd_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl0" xml:lang="en-US">Payments to Acquire Interest in Joint Venture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract22" xlink:to="cjjd_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract23" xlink:to="cjjd_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract20" xlink:to="cjjd_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract21" xlink:to="cjjd_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract26" xlink:to="cjjd_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyNineMember_lbl0" xml:lang="en-US">Origination Date Twenty Nine Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyNineMember" xlink:to="cjjd_OriginationDateTwentyNineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract27" xlink:to="cjjd_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl0" xml:lang="en-US">Investment Owned, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract24" xlink:to="cjjd_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract25" xlink:to="cjjd_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyFourMember_lbl0" xml:lang="en-US">Origination Date Twenty Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyFourMember" xlink:to="cjjd_OriginationDateTwentyFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntityFourMember_lbl0" xml:lang="en-US">Entity Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityFourMember" xlink:to="cjjd_EntityFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_JiuzhouDigitalMember_lbl0" xml:lang="en-US">Jiuzhou Digital Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuzhouDigitalMember" xlink:to="cjjd_JiuzhouDigitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateThirteenMember_lbl0" xml:lang="en-US">Origination Date Thirteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirteenMember" xlink:to="cjjd_OriginationDateThirteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateFiveMember_lbl0" xml:lang="en-US">Origination Date Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFiveMember" xlink:to="cjjd_OriginationDateFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_IncreaseDecreaseInLongTermDeposit_lbl0" xml:lang="en-US">Increase Decrease In Long Term Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncreaseDecreaseInLongTermDeposit" xlink:to="cjjd_IncreaseDecreaseInLongTermDeposit_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Consolidated Financial Statements Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract" xlink:to="cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBanksMember_lbl0" xml:lang="en-US">Notes Payable to Banks [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBanksMember" xlink:to="us-gaap_NotesPayableToBanksMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract_lbl" xml:lang="en-US">Schedule Of Credit Facilities With Banks Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract" xlink:to="cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyEightMember_lbl0" xml:lang="en-US">Origination Date Twenty Eight Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyEightMember" xlink:to="cjjd_OriginationDateTwentyEightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_TCMMember_lbl0" xml:lang="en-US">TCMMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_TCMMember" xlink:to="cjjd_TCMMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract3" xlink:to="cjjd_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract2" xlink:to="cjjd_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract5" xlink:to="cjjd_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdditionsToLeaseholdImprovements_lbl0" xml:lang="en-US">Additions To Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdditionsToLeaseholdImprovements" xlink:to="cjjd_AdditionsToLeaseholdImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract4" xlink:to="cjjd_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfRealEstate_lbl0" xml:lang="en-US">Impairment of Real Estate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfRealEstate" xlink:to="us-gaap_ImpairmentOfRealEstate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyMember_lbl0" xml:lang="en-US">Origination Date Twenty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyMember" xlink:to="cjjd_OriginationDateTwentyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract1" xlink:to="cjjd_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract0" xlink:to="cjjd_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl1" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract7" xlink:to="cjjd_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract6" xlink:to="cjjd_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract9" xlink:to="cjjd_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract8" xlink:to="cjjd_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_PrescriptionDrugsMember_lbl2" xml:lang="en-US">Prescription Drugs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_PrescriptionDrugsMember" xlink:to="cjjd_PrescriptionDrugsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Value Sale Of Stock And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants" xlink:to="cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ValueAddedTaxPolicyTextBlock_lbl1" xml:lang="en-US">Value Added Tax Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ValueAddedTaxPolicyTextBlock" xlink:to="cjjd_ValueAddedTaxPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl1" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_WorkingCapitalDeficit_lbl1" xml:lang="en-US">Working Capital Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WorkingCapitalDeficit" xlink:to="cjjd_WorkingCapitalDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OnlinePharmacyMember_lbl2" xml:lang="en-US">Online Pharmacy Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OnlinePharmacyMember" xlink:to="cjjd_OnlinePharmacyMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyOneMember_lbl0" xml:lang="en-US">Origination Date Twenty One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyOneMember" xlink:to="cjjd_OriginationDateTwentyOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_InjectedFunds_lbl0" xml:lang="en-US">Injected Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_InjectedFunds" xlink:to="cjjd_InjectedFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLoansPayableCurrent_lbl0" xml:lang="en-US">Other Loans Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayableCurrent" xlink:to="us-gaap_OtherLoansPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_StatutoryAccountsPercentage_lbl1" xml:lang="en-US">Statutory Accounts Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryAccountsPercentage" xlink:to="cjjd_StatutoryAccountsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WeightedAverageRemainingLeaseTermAbstract" xlink:to="cjjd_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl1" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AllowanceForAdvancesToSuppliers_lbl1" xml:lang="en-US">Allowance For Advances To Suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AllowanceForAdvancesToSuppliers" xlink:to="cjjd_AllowanceForAdvancesToSuppliers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntityThreeMember_lbl0" xml:lang="en-US">Entity Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityThreeMember" xlink:to="cjjd_EntityThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl_lbl1" xml:lang="en-US">Benchmark Percentage Of Voting Ownership Interest For Control And Common Control</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" xlink:to="cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Land_lbl0" xml:lang="en-US">Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Land" xlink:to="us-gaap_Land_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyTwoMember_lbl0" xml:lang="en-US">Origination Date Twenty Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyTwoMember" xlink:to="cjjd_OriginationDateTwentyTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_CapitalExpenditureContinuedOperations_lbl1" xml:lang="en-US">Capital Expenditure Continued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CapitalExpenditureContinuedOperations" xlink:to="cjjd_CapitalExpenditureContinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DebtInstrumentIOriginationDate_lbl1" xml:lang="en-US">Debt Instrument IOrigination Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DebtInstrumentIOriginationDate" xlink:to="cjjd_DebtInstrumentIOriginationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableNet_lbl0" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableNet" xlink:to="us-gaap_NotesReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl2" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_CreditLossRollForwardPolicyTextBlock_lbl0" xml:lang="en-US">Credit Loss Roll Forward Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CreditLossRollForwardPolicyTextBlock" xlink:to="cjjd_CreditLossRollForwardPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OTCDrugsMember_lbl1" xml:lang="en-US">OTCDrugs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OTCDrugsMember" xlink:to="cjjd_OTCDrugsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdvancesToSuppliersTextBlock_lbl1" xml:lang="en-US">Advances To Suppliers Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesToSuppliersTextBlock" xlink:to="cjjd_AdvancesToSuppliersTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateThreeMember_lbl0" xml:lang="en-US">Origination Date Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThreeMember" xlink:to="cjjd_OriginationDateThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_UnlabeledAbstract" xlink:to="cjjd_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateSixMember_lbl0" xml:lang="en-US">Origination Date Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSixMember" xlink:to="cjjd_OriginationDateSixMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LinjiaMedicalMember_lbl0" xml:lang="en-US">Linjia Medical Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LinjiaMedicalMember" xlink:to="cjjd_LinjiaMedicalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SundryProductsMember_lbl2" xml:lang="en-US">Sundry Products Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SundryProductsMember" xlink:to="cjjd_SundryProductsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl0" xml:lang="en-US">Trade Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateThirtyOneMember_lbl0" xml:lang="en-US">Origination Date Thirty One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirtyOneMember" xlink:to="cjjd_OriginationDateThirtyOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCollateralAmount_lbl0" xml:lang="en-US">Debt Instrument, Collateral Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateralAmount" xlink:to="us-gaap_DebtInstrumentCollateralAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FarmlandAssetsPolicyTextBlock_lbl1" xml:lang="en-US">Farmland Assets Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsPolicyTextBlock" xlink:to="cjjd_FarmlandAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Estimated Useful Lives Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:to="cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DueFromRelatedsParties_lbl1" xml:lang="en-US">Due From Relateds Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DueFromRelatedsParties" xlink:to="cjjd_DueFromRelatedsParties_lbl1"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract" xlink:to="cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentySevenMember_lbl0" xml:lang="en-US">Origination Date Twenty Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentySevenMember" xlink:to="cjjd_OriginationDateTwentySevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_JiuzhouClinicOneMember_lbl0" xml:lang="en-US">Jiuzhou Clinic One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuzhouClinicOneMember" xlink:to="cjjd_JiuzhouClinicOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl0" xml:lang="en-US">Impairment of Leasehold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ImpairmentsOfFarmlandAssets_lbl1" xml:lang="en-US">Impairments Of Farmland Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ImpairmentsOfFarmlandAssets" xlink:to="cjjd_ImpairmentsOfFarmlandAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfNetIntangibleAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfNetIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfNetIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Net Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfNetIntangibleAssetsAbstract" xlink:to="cjjd_ScheduleOfNetIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FarmlandAssets_lbl1" xml:lang="en-US">Farmland Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssets" xlink:to="cjjd_FarmlandAssets_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember_lbl0" xml:lang="en-US">Hangzhou Kahamadi Biotechnology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember" xlink:to="cjjd_HangzhouKahamadiBiotechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl0" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl2" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_StatutoryReserves_lbl1" xml:lang="en-US">Statutory Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryReserves" xlink:to="cjjd_StatutoryReserves_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_VATPercentage_lbl1" xml:lang="en-US">VATPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_VATPercentage" xlink:to="cjjd_VATPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ZhetongMedicalMember_lbl0" xml:lang="en-US">Zhetong Medical Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhetongMedicalMember" xlink:to="cjjd_ZhetongMedicalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_CashlessExerciseOfWarrants_lbl1" xml:lang="en-US">Cashless Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CashlessExerciseOfWarrants" xlink:to="cjjd_CashlessExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription_lbl0" xml:lang="en-US">Finite Lived Intangible Asset Useful Life Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription" xlink:to="cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateThirtyMember_lbl0" xml:lang="en-US">Origination Date Thirty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateThirtyMember" xlink:to="cjjd_OriginationDateThirtyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwoMember_lbl0" xml:lang="en-US">Origination Date Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwoMember" xlink:to="cjjd_OriginationDateTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl1" xml:lang="en-US">Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_KahamadiBioMember_lbl1" xml:lang="en-US">Kahamadi Bio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_KahamadiBioMember" xlink:to="cjjd_KahamadiBioMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl2" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateSixteenMember_lbl0" xml:lang="en-US">Origination Date Sixteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSixteenMember" xlink:to="cjjd_OriginationDateSixteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwelveMember_lbl0" xml:lang="en-US">Origination Date Twelve Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwelveMember" xlink:to="cjjd_OriginationDateTwelveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentySixMember_lbl0" xml:lang="en-US">Origination Date Twenty Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentySixMember" xlink:to="cjjd_OriginationDateTwentySixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateFourteenMember_lbl0" xml:lang="en-US">Origination Date Fourteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFourteenMember" xlink:to="cjjd_OriginationDateFourteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateOneMember_lbl0" xml:lang="en-US">Origination Date One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateOneMember" xlink:to="cjjd_OriginationDateOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl0" xml:lang="en-US">Repayments of Other Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Share Sale Of Stock And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants" xlink:to="cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DrugWholesaleAbstract_lbl0" xml:lang="en-US">Drug Wholesale Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DrugWholesaleAbstract" xlink:to="cjjd_DrugWholesaleAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl1" xml:lang="en-US">Selling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl1" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_DescriptionOfLeasePrepaymentLife_lbl1" xml:lang="en-US">Description Of Lease Prepayment Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_DescriptionOfLeasePrepaymentLife" xlink:to="cjjd_DescriptionOfLeasePrepaymentLife_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl0" xml:lang="en-US">Cash, Uninsured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_CustomerDepositCurrent_lbl1" xml:lang="en-US">Customer Deposit Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_CustomerDepositCurrent" xlink:to="cjjd_CustomerDepositCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ForestLandUseRights_lbl1" xml:lang="en-US">Forest Land Use Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ForestLandUseRights" xlink:to="cjjd_ForestLandUseRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_RenovationMember_lbl0" xml:lang="en-US">Renovation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RenovationMember" xlink:to="cjjd_RenovationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl0" xml:lang="en-US">Investment Income, Investment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ReserveFundPercentage_lbl1" xml:lang="en-US">Reserve Fund Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ReserveFundPercentage" xlink:to="cjjd_ReserveFundPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuer_lbl0" xml:lang="en-US">Debt Instrument, Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuer" xlink:to="us-gaap_DebtInstrumentIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Schedule Of Estimates Future Expected Losses On Accounts Receivable And Other Receivables Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract" xlink:to="cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfFarmlandAssetsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Farmland Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfFarmlandAssetsTableTextBlock" xlink:to="cjjd_ScheduleOfFarmlandAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl0" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl0" xml:lang="en-US">Other Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateElevenMember_lbl1" xml:lang="en-US">Origination Date Eleven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateElevenMember" xlink:to="cjjd_OriginationDateElevenMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_HongtongServiceMember_lbl0" xml:lang="en-US">Hongtong Service Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HongtongServiceMember" xlink:to="cjjd_HongtongServiceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FarmlandAssetsGross_lbl1" xml:lang="en-US">Farmland Assets Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandAssetsGross" xlink:to="cjjd_FarmlandAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_JiuzhenHealthMember_lbl0" xml:lang="en-US">Jiuzhen Health Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuzhenHealthMember" xlink:to="cjjd_JiuzhenHealthMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_Others_lbl1" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_Others" xlink:to="cjjd_Others_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OperatingLeasesAbstract_lbl0" xml:lang="en-US">Operating Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OperatingLeasesAbstract" xlink:to="cjjd_OperatingLeasesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl0" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl0" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl0" xml:lang="en-US">Prepaid Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Change In Operating Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_SharesRepurchasePercentage_lbl1" xml:lang="en-US">Shares Repurchase Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_SharesRepurchasePercentage" xlink:to="cjjd_SharesRepurchasePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl0" xml:lang="en-US">License [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_MedicalDevicesMember_lbl2" xml:lang="en-US">Medical Devices Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_MedicalDevicesMember" xlink:to="cjjd_MedicalDevicesMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateNineteenMember_lbl0" xml:lang="en-US">Origination Date Nineteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateNineteenMember" xlink:to="cjjd_OriginationDateNineteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AggregateSharePercentage_lbl1" xml:lang="en-US">Aggregate Share Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AggregateSharePercentage" xlink:to="cjjd_AggregateSharePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl2" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ZhuoliServiceMember_lbl1" xml:lang="en-US">Zhuoli Service Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ZhuoliServiceMember" xlink:to="cjjd_ZhuoliServiceMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OtherReceivablesMember_lbl0" xml:lang="en-US">Other Receivables Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OtherReceivablesMember" xlink:to="cjjd_OtherReceivablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateEighteenMember_lbl0" xml:lang="en-US">Origination Date Eighteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateEighteenMember" xlink:to="cjjd_OriginationDateEighteenMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_HangzhouUnitedBankMember_lbl1" xml:lang="en-US">Hangzhou United Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_HangzhouUnitedBankMember" xlink:to="cjjd_HangzhouUnitedBankMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember_lbl0" xml:lang="en-US">Guoshu Lianren Zhejiang Medical And Health Management Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" xlink:to="cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Earnings Per Share Basic Net Income Loss Attributable To Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract_lbl" xml:lang="en-US">Schedule Of Revenue By Major Source In Each Segment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract" xlink:to="cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateSeventeenMember_lbl0" xml:lang="en-US">Origination Date Seventeen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSeventeenMember" xlink:to="cjjd_OriginationDateSeventeenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_IncreaseDecreaseInCustomerDeposit_lbl1" xml:lang="en-US">Increase Decrease In Customer Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncreaseDecreaseInCustomerDeposit" xlink:to="cjjd_IncreaseDecreaseInCustomerDeposit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LoanPayableTextBlock_lbl0" xml:lang="en-US">Loan Payable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LoanPayableTextBlock" xlink:to="cjjd_LoanPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Earnings Per Share Diluted Net Income Loss Attributable To Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest_lbl1" xml:lang="en-US">Earnings Per Share Diluted Before Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest" xlink:to="cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_WholesaleMember_lbl0" xml:lang="en-US">Wholesale Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_WholesaleMember" xlink:to="cjjd_WholesaleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl1" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl2" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Notes Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl0" xml:lang="en-US">Marketing and Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_StatutoryReservesMember_lbl0" xml:lang="en-US">Statutory Reserves Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StatutoryReservesMember" xlink:to="cjjd_StatutoryReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl0" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit_lbl1" xml:lang="en-US">Stock Issued During Period Value For Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit" xlink:to="cjjd_StockIssuedDuringPeriodValueForReverseStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ShouantangClinicMember_lbl0" xml:lang="en-US">Shouantang Clinic Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ShouantangClinicMember" xlink:to="cjjd_ShouantangClinicMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract" xlink:to="cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdvancesOnInventoryPurchasesGross_lbl1" xml:lang="en-US">Advances On Inventory Purchases Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvancesOnInventoryPurchasesGross" xlink:to="cjjd_AdvancesOnInventoryPurchasesGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl2" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_LandUseRightsMember_lbl2" xml:lang="en-US">Land Use Rights Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_LandUseRightsMember" xlink:to="cjjd_LandUseRightsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntitySevenMember_lbl0" xml:lang="en-US">Entity Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntitySevenMember" xlink:to="cjjd_EntitySevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateSevenMember_lbl0" xml:lang="en-US">Origination Date Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateSevenMember" xlink:to="cjjd_OriginationDateSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl0" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ShouantangBioMember_lbl1" xml:lang="en-US">Shouantang Bio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ShouantangBioMember" xlink:to="cjjd_ShouantangBioMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllOtherSegmentsMember_lbl0" xml:lang="en-US">Other Operating Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_JiuyiTechnologyMember_lbl0" xml:lang="en-US">Jiuyi Technology Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_JiuyiTechnologyMember" xlink:to="cjjd_JiuyiTechnologyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_FarmlandDevelopmentCostMember_lbl1" xml:lang="en-US">Farmland Development Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_FarmlandDevelopmentCostMember" xlink:to="cjjd_FarmlandDevelopmentCostMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl0" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateNineMember_lbl0" xml:lang="en-US">Origination Date Nine Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateNineMember" xlink:to="cjjd_OriginationDateNineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntityTwoMember_lbl0" xml:lang="en-US">Entity Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityTwoMember" xlink:to="cjjd_EntityTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_InvestmentPercentage_lbl1" xml:lang="en-US">Investment Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_InvestmentPercentage" xlink:to="cjjd_InvestmentPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyThreeMember_lbl0" xml:lang="en-US">Origination Date Twenty Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyThreeMember" xlink:to="cjjd_OriginationDateTwentyThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_RetailDrugstoresAbstract_lbl0" xml:lang="en-US">Retail Drugstores Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RetailDrugstoresAbstract" xlink:to="cjjd_RetailDrugstoresAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfLongTermInvestmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfLongTermInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfLongTermInvestmentAbstract_lbl" xml:lang="en-US">Schedule Of Long Term Investment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfLongTermInvestmentAbstract" xlink:to="cjjd_ScheduleOfLongTermInvestmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateFourMember_lbl0" xml:lang="en-US">Origination Date Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateFourMember" xlink:to="cjjd_OriginationDateFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AdvanceToSuppliersTableTextBlock_lbl1" xml:lang="en-US">Advance To Suppliers Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AdvanceToSuppliersTableTextBlock" xlink:to="cjjd_AdvanceToSuppliersTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfAdvanceToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfAdvanceToSuppliersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfAdvanceToSuppliersAbstract_lbl" xml:lang="en-US">Schedule Of Advance To Suppliers Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfAdvanceToSuppliersAbstract" xlink:to="cjjd_ScheduleOfAdvanceToSuppliersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_NotesPayablePolicyTextBlock_lbl1" xml:lang="en-US">Notes Payable Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NotesPayablePolicyTextBlock" xlink:to="cjjd_NotesPayablePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants_lbl1" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" xlink:to="cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_RepaymentOfOtherPayablesrelatedParties_lbl1" xml:lang="en-US">Repayment Of Other Payablesrelated Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_RepaymentOfOtherPayablesrelatedParties" xlink:to="cjjd_RepaymentOfOtherPayablesrelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_NutritionalSupplementsMember_lbl2" xml:lang="en-US">Nutritional Supplements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_NutritionalSupplementsMember" xlink:to="cjjd_NutritionalSupplementsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl0" xml:lang="en-US">Operating Segments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl1" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_EntityFiveMember_lbl0" xml:lang="en-US">Entity Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_EntityFiveMember" xlink:to="cjjd_EntityFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl0" xml:lang="en-US">Provision for Other Credit Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl0" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OnlinePharmacyAbstract_lbl0" xml:lang="en-US">Online Pharmacy Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OnlinePharmacyAbstract" xlink:to="cjjd_OnlinePharmacyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract_lbl" xml:lang="en-US">Schedule Of Net Revenue From External Customers Through Its Retail Drugstores By Main Products Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract" xlink:to="cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Impairment Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment" xlink:to="cjjd_AccumulatedImpairmentPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_lbl0" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl0" xml:lang="en-US">Equity Method Investment, Quoted Market Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_OriginationDateTwentyFiveMember_lbl0" xml:lang="en-US">Origination Date Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_OriginationDateTwentyFiveMember" xlink:to="cjjd_OriginationDateTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl0" xml:lang="en-US">Inventory Valuation Reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl0" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cjjd_BankLoanMember_lbl0" xml:lang="en-US">Bank Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cjjd_BankLoanMember" xlink:to="cjjd_BankLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0" xml:lang="en-US">Short-Term Debt, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>cjjd-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 30 06:45:36 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedBalanceSheet" roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedIncomeStatement" roleURI="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ShareholdersEquityType2or3" roleURI="http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ConsolidatedCashFlow" roleURI="http://chinajojodrugstores.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_DescriptionofBusinessandOrganization" roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SummaryofSignificantAccountingPolicies" roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_CommitmentsandContingencies" roleURI="http://chinajojodrugstores.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TradeReceivables" roleURI="http://chinajojodrugstores.com/role/TradeReceivables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherCurrentAssets" roleURI="http://chinajojodrugstores.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PropertyandEquipment" roleURI="http://chinajojodrugstores.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermInvestment" roleURI="http://chinajojodrugstores.com/role/LongTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_AdvancestoSuppliers" roleURI="http://chinajojodrugstores.com/role/AdvancestoSuppliers"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Inventory" roleURI="http://chinajojodrugstores.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_FarmlandAssets" roleURI="http://chinajojodrugstores.com/role/FarmlandAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermDeposits" roleURI="http://chinajojodrugstores.com/role/LongTermDeposits"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherNoncurrentAssets" roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Leases" roleURI="http://chinajojodrugstores.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_IntangibleAssets" roleURI="http://chinajojodrugstores.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NotesPayable" roleURI="http://chinajojodrugstores.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LoanPayable" roleURI="http://chinajojodrugstores.com/role/LoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Taxes" roleURI="http://chinajojodrugstores.com/role/Taxes"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PostretirementBenefits" roleURI="http://chinajojodrugstores.com/role/PostretirementBenefits"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_RelatedPartyTransactionsandArrangements" roleURI="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ShareholdersEquity" roleURI="http://chinajojodrugstores.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NetLossPerShare" roleURI="http://chinajojodrugstores.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_Segments" roleURI="http://chinajojodrugstores.com/role/Segments"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SubsequentEvents" roleURI="http://chinajojodrugstores.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_AccountingPoliciesByPolicy" roleURI="http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_DescriptionofBusinessandOrganizationTables" roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TradeReceivablesTables" roleURI="http://chinajojodrugstores.com/role/TradeReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherCurrentAssetsTables" roleURI="http://chinajojodrugstores.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PropertyandEquipmentTables" roleURI="http://chinajojodrugstores.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermInvestmentTables" roleURI="http://chinajojodrugstores.com/role/LongTermInvestmentTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_AdvancestoSuppliersTables" roleURI="http://chinajojodrugstores.com/role/AdvancestoSuppliersTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_FarmlandAssetsTables" roleURI="http://chinajojodrugstores.com/role/FarmlandAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherNoncurrentAssetsTables" roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LeasesTables" roleURI="http://chinajojodrugstores.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_IntangibleAssetsTables" roleURI="http://chinajojodrugstores.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NotesPayableTables" roleURI="http://chinajojodrugstores.com/role/NotesPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TaxesTables" roleURI="http://chinajojodrugstores.com/role/TaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_RelatedPartyTransactionsandArrangementsTables" roleURI="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NetLossPerShareTables" roleURI="http://chinajojodrugstores.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SegmentsTables" roleURI="http://chinajojodrugstores.com/role/SegmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofConsolidatedFinancialStatementsActivitiesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofRevenuebyMajorSourceineachSegmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofTradeReceivablesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofPropertyandEquipmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofLongTermInvestmentTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofAdvancetoSuppliersTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofFarmlandAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofOtherNoncurrentAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofleaseTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofNetIntangibleAssetsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofCreditFacilitieswithBanksTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofBasicandDilutedEarningsPerShareTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofSegmentoftheContinuingOperationsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable" roleURI="http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_DescriptionofBusinessandOrganizationDetails" roleURI="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_CommitmentsandContingenciesDetails" roleURI="http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TradeReceivablesDetails" roleURI="http://chinajojodrugstores.com/role/TradeReceivablesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PropertyandEquipmentDetails" roleURI="http://chinajojodrugstores.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermInvestmentDetails" roleURI="http://chinajojodrugstores.com/role/LongTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_InventoryDetails" roleURI="http://chinajojodrugstores.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_FarmlandAssetsDetails" roleURI="http://chinajojodrugstores.com/role/FarmlandAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LongTermDepositsDetails" roleURI="http://chinajojodrugstores.com/role/LongTermDepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_OtherNoncurrentAssetsDetails" roleURI="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LeasesDetails" roleURI="http://chinajojodrugstores.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_IntangibleAssetsDetails" roleURI="http://chinajojodrugstores.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NotesPayableDetails" roleURI="http://chinajojodrugstores.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_LoanPayableDetails" roleURI="http://chinajojodrugstores.com/role/LoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_TaxesDetails" roleURI="http://chinajojodrugstores.com/role/TaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_PostretirementBenefitsDetails" roleURI="http://chinajojodrugstores.com/role/PostretirementBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_ShareholdersEquityDetails" roleURI="http://chinajojodrugstores.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_NetLossPerShareDetails" roleURI="http://chinajojodrugstores.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SegmentsDetails" roleURI="http://chinajojodrugstores.com/role/SegmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cjjd-20240331.xsd#cjjd_r_SubsequentEventsDetails" roleURI="http://chinajojodrugstores.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueFromRelatedsParties" xlink:href="cjjd-20240331.xsd#cjjd_DueFromRelatedsParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="DueFromRelatedsParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="FarmlandAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLoansPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLoansPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerDepositCurrent" xlink:href="cjjd-20240331.xsd#cjjd_CustomerDepositCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="CustomerDepositCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserves" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="StatutoryReserves" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndDebtExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReservesMember" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StatutoryReservesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="6.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueForReverseStockSplit" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodValueForReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueForReverseStockSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSaleOfStockAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSaleOfStockAndWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareSaleOfStockAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodShareSaleOfStockAndWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ChangeInOperatingAssetsAndLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidSupplies" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLongTermDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInLongTermDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="IncreaseDecreaseInLongTermDeposit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInCustomerDeposit" xlink:href="cjjd-20240331.xsd#cjjd_IncreaseDecreaseInCustomerDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="IncreaseDecreaseInCustomerDeposit" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedTaxesPayable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInJointVenture"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInterestInJointVenture" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionsToLeaseholdImprovements" xlink:href="cjjd-20240331.xsd#cjjd_AdditionsToLeaseholdImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="AdditionsToLeaseholdImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfOtherPayablesrelatedParties" xlink:href="cjjd-20240331.xsd#cjjd_RepaymentOfOtherPayablesrelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfOtherPayablesrelatedParties" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfWarrants" xlink:href="cjjd-20240331.xsd#cjjd_CashlessExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CashlessExerciseOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/TradeReceivables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LongTermInvestment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/AdvancestoSuppliers" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="AdvancesToSuppliersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/FarmlandAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="FarmlandAssetsTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FarmlandAssetsAbstract" xlink:to="FarmlandAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LongTermDeposits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermDepositsTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_LongTermDepositsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="LongTermDepositsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/OtherNoncurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/NotesPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LoanPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="LoanPayableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="LoanPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/Taxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/PostretirementBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/Segments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditLossRollForwardPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_CreditLossRollForwardPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CreditLossRollForwardPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FarmlandAssetsPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FarmlandAssetsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesPayablePolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_NotesPayablePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NotesPayablePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValueAddedTaxPolicyTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ValueAddedTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValueAddedTaxPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEstimatedUsefulLivesTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/TradeReceivablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCurrentAssetsAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LongTermInvestmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/AdvancestoSuppliersTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="AdvancesToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvanceToSuppliersTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_AdvanceToSuppliersTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancesToSuppliersAbstract" xlink:to="AdvanceToSuppliersTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/FarmlandAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFarmlandAssetsTableTextBlock" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfFarmlandAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FarmlandAssetsAbstract" xlink:to="ScheduleOfFarmlandAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/NotesPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/TaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SegmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RenovationMember" xlink:href="cjjd-20240331.xsd#cjjd_RenovationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="RenovationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntityTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntityThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityFourMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntityFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntityFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntitySixMember" xlink:href="cjjd-20240331.xsd#cjjd_EntitySixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntitySixMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiuzhouClinicOneMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouClinicOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JiuzhouClinicOneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntitySevenMember" xlink:href="cjjd-20240331.xsd#cjjd_EntitySevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntitySevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntityEightMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityNineMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="EntityNineMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShouantangBioMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShouantangBioMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiuyiTechnologyMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuyiTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JiuyiTechnologyMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="KahamadiBioMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LinjiaMedicalMember" xlink:href="cjjd-20240331.xsd#cjjd_LinjiaMedicalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="LinjiaMedicalMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShouantangClinicMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangClinicMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShouantangClinicMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiuzhenHealthMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhenHealthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JiuzhenHealthMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HongtongServiceMember" xlink:href="cjjd-20240331.xsd#cjjd_HongtongServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="HongtongServiceMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenueByMajorSourceInEachSegmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenueByMajorSourceInEachSegmentAbstract" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RetailDrugstoresMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OnlinePharmacyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DrugWholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_DrugWholesaleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="DrugWholesaleMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="srt_ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrescriptionDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_PrescriptionDrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="PrescriptionDrugsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OTCDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_OTCDrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OTCDrugsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NutritionalSupplementsMember" xlink:href="cjjd-20240331.xsd#cjjd_NutritionalSupplementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="NutritionalSupplementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TCMMember" xlink:href="cjjd-20240331.xsd#cjjd_TCMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="TCMMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SundryProductsMember" xlink:href="cjjd-20240331.xsd#cjjd_SundryProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SundryProductsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalDevicesMember" xlink:href="cjjd-20240331.xsd#cjjd_MedicalDevicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MedicalDevicesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RetailDrugstoresAbstract" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="RetailDrugstoresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetailDrugstoresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivablesMember" xlink:href="cjjd-20240331.xsd#cjjd_OtherReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="OtherReceivablesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherCreditLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="us-gaap_ProvisionForOtherCreditLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MotorVehiclesMember" xlink:href="cjjd-20240331.xsd#cjjd_MotorVehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="MotorVehiclesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LandUseRightsMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="LandUseRightsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedIntangibleAssetUsefulLifeDescription" xlink:href="cjjd-20240331.xsd#cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLifeDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZfg1f/OyMqeFkW4NxCRgc5zrMfOkODGpvnGwO67GcnxcMLoHh2bQdp9cqh7BBV1bpF2FDoEydlb4/CB4Q1RcA6BkFWukNPnSbNdgcFXy0j51Nyr3MVn75aB0UDm6KdgKWkIDFyVjwW12yAP66X3j7uVH+FbGya9WCnnXOUl4XE3uB1TJeQOH3eK29ryfO2nyLkWQ3FLaRkPF0rpKE9KNRxbNRckj0bSeapbe8XcIHse6sj0agXKfo2] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_NotesReceivableNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherCurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FarmlandDevelopmentCostMember" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandDevelopmentCostMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="FarmlandDevelopmentCostMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedImpairmentPropertyPlantAndEquipment" xlink:href="cjjd-20240331.xsd#cjjd_AccumulatedImpairmentPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedImpairmentPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfLongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermInvestmentAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="KahamadiBioMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhetongMedicalMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhetongMedicalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="ZhetongMedicalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SongluPharmaceuticalMember" xlink:href="cjjd-20240331.xsd#cjjd_SongluPharmaceuticalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="SongluPharmaceuticalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiuzhouDigitalMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouDigitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="JiuzhouDigitalMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" xlink:href="cjjd-20240331.xsd#cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdvanceToSuppliersAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfAdvanceToSuppliersAbstract"/>
    <loc xlink:type="locator" xlink:label="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:href="cjjd-20240331.xsd#cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable"/>
    <loc xlink:type="locator" xlink:label="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:href="cjjd-20240331.xsd#cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdvanceToSuppliersAbstract" xlink:to="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable" xlink:to="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AdvancesOnInventoryPurchasesGross" xlink:href="cjjd-20240331.xsd#cjjd_AdvancesOnInventoryPurchasesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="AdvancesOnInventoryPurchasesGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForAdvancesToSuppliers" xlink:href="cjjd-20240331.xsd#cjjd_AllowanceForAdvancesToSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="AllowanceForAdvancesToSuppliers" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems" xlink:to="us-gaap_Supplies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfFarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="FarmlandAssetsGross" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFarmlandAssetsAbstract" xlink:to="FarmlandAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentsOfFarmlandAssets" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentsOfFarmlandAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFarmlandAssetsAbstract" xlink:to="ImpairmentsOfFarmlandAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Land"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFarmlandAssetsAbstract" xlink:to="us-gaap_Land" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherNoncurrentAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfOtherNoncurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ForestLandUseRights" xlink:href="cjjd-20240331.xsd#cjjd_ForestLandUseRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="ForestLandUseRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Others" xlink:href="cjjd-20240331.xsd#cjjd_Others"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="Others" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherNoncurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofleaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_OperatingLeasesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="OperatingLeasesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="cjjd-20240331.xsd#cjjd_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetIntangibleAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfNetIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SapSoftwareMember" xlink:href="cjjd-20240331.xsd#cjjd_SapSoftwareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="SapSoftwareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_UseRightsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" xlink:href="cjjd-20240331.xsd#cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCreditFacilitiesWithBanksAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCreditFacilitiesWithBanksAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EntityFiveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EntityEightMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_AwardDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OriginationDateOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateFourMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateSixMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateSevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateEightMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateEightMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateNineMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateNineMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTenMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateElevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateElevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateElevenMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwelveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwelveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwelveMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateThirteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateThirteenMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateFourteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFourteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateFourteenMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateFifteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateFifteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateFifteenMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateSixteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSixteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateSixteenMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateSeventeenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateSeventeenMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateEighteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateEighteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateEighteenMember" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateNineteenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateNineteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateNineteenMember" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyMember" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyOneMember" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyTwoMember" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyThreeMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyThreeMember" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyFourMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyFourMember" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyFiveMember" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentySixMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentySixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentySixMember" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentySevenMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentySevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentySevenMember" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyEightMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyEightMember" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateTwentyNineMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateTwentyNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateTwentyNineMember" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateThirtyMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateThirtyMember" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateThirtyOneMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateThirtyOneMember" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginationDateThirtyTwoMember" xlink:href="cjjd-20240331.xsd#cjjd_OriginationDateThirtyTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OriginationDateThirtyTwoMember" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HangzhouUnitedBankMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HangzhouUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuer" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentIOriginationDate" xlink:href="cjjd-20240331.xsd#cjjd_DebtInstrumentIOriginationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentIOriginationDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HangzhouKahamadiBiotechnologyCoLtdMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouKahamadiBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="HangzhouKahamadiBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="DirectorAndCEOMember" xlink:href="cjjd-20240331.xsd#cjjd_DirectorAndCEOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DirectorAndCEOMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" xlink:href="cjjd-20240331.xsd#cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarningsPerShareBasicBeforeNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="EarningsPerShareBasicBeforeNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarningsPerShareDilutedBeforeNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="EarningsPerShareDilutedBeforeNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="cjjd-20240331.xsd#cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentOfTheContinuingOperationsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentOfTheContinuingOperationsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RetailDrugstoresMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OnlinePharmacyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DrugWholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_DrugWholesaleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="DrugWholesaleMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalExpenditureContinuedOperations" xlink:href="cjjd-20240331.xsd#cjjd_CapitalExpenditureContinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="CapitalExpenditureContinuedOperations" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RetailDrugstoresMember" xlink:href="cjjd-20240331.xsd#cjjd_RetailDrugstoresMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RetailDrugstoresMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnlinePharmacyMember" xlink:href="cjjd-20240331.xsd#cjjd_OnlinePharmacyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="OnlinePharmacyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WholesaleMember" xlink:href="cjjd-20240331.xsd#cjjd_WholesaleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="WholesaleMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ConsolidationItemsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="srt_ProductOrServiceAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrescriptionDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_PrescriptionDrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="PrescriptionDrugsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OTCDrugsMember" xlink:href="cjjd-20240331.xsd#cjjd_OTCDrugsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OTCDrugsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NutritionalSupplementsMember" xlink:href="cjjd-20240331.xsd#cjjd_NutritionalSupplementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="NutritionalSupplementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TCMMember" xlink:href="cjjd-20240331.xsd#cjjd_TCMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="TCMMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SundryProductsMember" xlink:href="cjjd-20240331.xsd#cjjd_SundryProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="SundryProductsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalDevicesMember" xlink:href="cjjd-20240331.xsd#cjjd_MedicalDevicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MedicalDevicesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandOrganizationDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionofBusinessandOrganizationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionofBusinessandOrganizationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="DescriptionofBusinessandOrganizationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RenovationInvestmentMember" xlink:href="cjjd-20240331.xsd#cjjd_RenovationInvestmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="RenovationInvestmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShouantangBioMember" xlink:href="cjjd-20240331.xsd#cjjd_ShouantangBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ShouantangBioMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EntityFiveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityEightMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityEightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EntityEightMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankLoanMember" xlink:href="cjjd-20240331.xsd#cjjd_BankLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BankLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EntityFiveMember_0" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="EntityFiveMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndCapitalResourcesMember" xlink:href="cjjd-20240331.xsd#cjjd_LiquidityAndCapitalResourcesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LiquidityAndCapitalResourcesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsTable" xlink:to="DescriptionofBusinessandOrganizationDetailsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesRepurchasePercentage" xlink:href="cjjd-20240331.xsd#cjjd_SharesRepurchasePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="SharesRepurchasePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentQuotedMarketValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalDeficit" xlink:href="cjjd-20240331.xsd#cjjd_WorkingCapitalDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="WorkingCapitalDeficit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_ProfitLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionofBusinessandOrganizationDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" xlink:href="cjjd-20240331.xsd#cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLeasehold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfLeasehold" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VATPercentage" xlink:href="cjjd-20240331.xsd#cjjd_VATPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="VATPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFDICInsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_Deposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashUninsuredAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/TradeReceivablesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_PropertyandEquipmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LongTermInvestmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="LongTermInvestmentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="KahamadiBioMember" xlink:href="cjjd-20240331.xsd#cjjd_KahamadiBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="KahamadiBioMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhuoliServiceMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhuoliServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="ZhuoliServiceMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EntityFiveMember" xlink:href="cjjd-20240331.xsd#cjjd_EntityFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="EntityFiveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SongluPharmaceuticalMember" xlink:href="cjjd-20240331.xsd#cjjd_SongluPharmaceuticalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="SongluPharmaceuticalMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" xlink:href="cjjd-20240331.xsd#cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiuzhouDigitalMember" xlink:href="cjjd-20240331.xsd#cjjd_JiuzhouDigitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="JiuzhouDigitalMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentDetailsTable" xlink:to="LongTermInvestmentDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestmentPercentage" xlink:href="cjjd-20240331.xsd#cjjd_InvestmentPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentDetailsLineItems" xlink:to="InvestmentPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InjectedFunds" xlink:href="cjjd-20240331.xsd#cjjd_InjectedFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentDetailsLineItems" xlink:to="InjectedFunds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentImpairmentLoss" xlink:href="cjjd-20240331.xsd#cjjd_LongTermInvestmentImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentDetailsLineItems" xlink:to="LongTermInvestmentImpairmentLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryValuationReserves" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/FarmlandAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="FarmlandAssetsAbstract" xlink:href="cjjd-20240331.xsd#cjjd_FarmlandAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfRealEstate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FarmlandAssetsAbstract" xlink:to="us-gaap_ImpairmentOfRealEstate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LongTermDepositsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherNoncurrentAssetsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_OtherNoncurrentAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OtherNoncurrentAssetsDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_OtherNoncurrentAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="OtherNoncurrentAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncurrentAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LandUseRightsMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="LandUseRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncurrentAssetsDetailsTable" xlink:to="OtherNoncurrentAssetsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfLeasePrepaymentLife" xlink:href="cjjd-20240331.xsd#cjjd_DescriptionOfLeasePrepaymentLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncurrentAssetsDetailsLineItems" xlink:to="DescriptionOfLeasePrepaymentLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncurrentAssetsDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/NotesPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="NotesPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HangzhouUnitedBankMember" xlink:href="cjjd-20240331.xsd#cjjd_HangzhouUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="HangzhouUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBanksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_NotesPayableToBanksMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCollateralAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCollateralAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Deposits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/LoanPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="LoanPayableDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LoanPayableDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_LoanPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansPayableAbstract" xlink:to="LoanPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LandUseRightsAndPropertyOwnershipMember" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsAndPropertyOwnershipMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LandUseRightsAndPropertyOwnershipMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LandUseRightsAndPropertyOwnershipMember_0" xlink:href="cjjd-20240331.xsd#cjjd_LandUseRightsAndPropertyOwnershipMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LandUseRightsAndPropertyOwnershipMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanPayableDetailsTable" xlink:to="LoanPayableDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanPayableDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/TaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/PostretirementBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateSharePercentage" xlink:href="cjjd-20240331.xsd#cjjd_AggregateSharePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="AggregateSharePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryAccountsPercentage" xlink:href="cjjd-20240331.xsd#cjjd_StatutoryAccountsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="StatutoryAccountsPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReserveFundPercentage" xlink:href="cjjd-20240331.xsd#cjjd_ReserveFundPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ReserveFundPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_NetLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="NetLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SegmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_SegmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SegmentsDetailsLineItems" xlink:href="cjjd-20240331.xsd#cjjd_SegmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="SegmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_AllOtherSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsDetailsTable" xlink:to="srt_ConsolidationItemsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsDetailsTable" xlink:to="SegmentsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsDetailsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://chinajojodrugstores.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="cjjd-20240331.xsd#cjjd_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193052640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">China
Jo-Jo Drugstores, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001856084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Renxin Yaju<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 5 Floor 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Gong Shu District<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hangzhou City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">310008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value $0.24 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CJJD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">1,743,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Lei
Liu<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Renxin
Yaju<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 5 Floor 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Gong Shu District<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hangzhou
City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">310008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">571-88219579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190230000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">YCM CPA, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">6781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine,
California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869191473280">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,149,806<span></span>
</td>
<td class="nump">$ 18,807,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,724,365<span></span>
</td>
<td class="nump">12,762,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,824,103<span></span>
</td>
<td class="nump">14,119,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,248,373<span></span>
</td>
<td class="nump">15,309,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,938,049<span></span>
</td>
<td class="nump">2,725,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advances to suppliers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">914,776<span></span>
</td>
<td class="nump">142,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">569,544<span></span>
</td>
<td class="nump">616,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,682,362<span></span>
</td>
<td class="nump">64,482,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,906,589<span></span>
</td>
<td class="nump">5,100,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,195,261<span></span>
</td>
<td class="nump">1,772,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssets', window );">Farmland assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">634,153<span></span>
</td>
<td class="nump">666,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Long-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,119,006<span></span>
</td>
<td class="nump">1,038,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">682,437<span></span>
</td>
<td class="nump">790,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,827,360<span></span>
</td>
<td class="nump">13,924,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,009,922<span></span>
</td>
<td class="nump">3,195,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,374,728<span></span>
</td>
<td class="nump">26,487,812<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,057,090<span></span>
</td>
<td class="nump">90,970,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">276,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,630,131<span></span>
</td>
<td class="nump">26,990,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">31,676,335<span></span>
</td>
<td class="nump">29,255,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayableCurrent', window );">Other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,493,482<span></span>
</td>
<td class="nump">1,314,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CustomerDepositCurrent', window );">Customer deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">518,241<span></span>
</td>
<td class="nump">695,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">682,239<span></span>
</td>
<td class="nump">1,706,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">386,395<span></span>
</td>
<td class="nump">756,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,862,766<span></span>
</td>
<td class="nump">5,131,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,360,095<span></span>
</td>
<td class="nump">66,535,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,403,858<span></span>
</td>
<td class="nump">7,768,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,763,953<span></span>
</td>
<td class="nump">74,303,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares; $0.24 par value; 150,000,000 shares authorized; 1,743,362 and 1,184,861 shares issued and outstanding as of March 31, 2024 and 2023, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">418,407<span></span>
</td>
<td class="nump">284,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2024 and 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,413,978<span></span>
</td>
<td class="nump">83,958,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StatutoryReserves', window );">Statutory reserves</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,309,109<span></span>
</td>
<td class="nump">1,309,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(73,507,246)<span></span>
</td>
<td class="num">(69,273,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,005,762<span></span>
</td>
<td class="nump">1,735,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity attributed to China Jo-Jo</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,640,010<span></span>
</td>
<td class="nump">18,014,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,346,873)<span></span>
</td>
<td class="num">(1,346,859)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,293,137<span></span>
</td>
<td class="nump">16,667,152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,057,090<span></span>
</td>
<td class="nump">90,970,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DueFromRelatedsParties', window );">Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">313,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,833,509<span></span>
</td>
<td class="nump">$ 683,560<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_CustomerDepositCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_CustomerDepositCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_DueFromRelatedsParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due from related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_DueFromRelatedsParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of farmland assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_StatutoryReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_StatutoryReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188220624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">1,743,362<span></span>
</td>
<td class="nump">1,184,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">1,743,362<span></span>
</td>
<td class="nump">1,184,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189713376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES, NET</a></td>
<td class="nump">$ 154,541,077<span></span>
</td>
<td class="nump">$ 148,811,976<span></span>
</td>
<td class="nump">$ 164,392,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF GOODS SOLD</a></td>
<td class="nump">123,432,529<span></span>
</td>
<td class="nump">114,531,512<span></span>
</td>
<td class="nump">127,873,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">31,108,548<span></span>
</td>
<td class="nump">34,280,464<span></span>
</td>
<td class="nump">36,519,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">SELLING EXPENSES</a></td>
<td class="nump">27,385,587<span></span>
</td>
<td class="nump">29,177,163<span></span>
</td>
<td class="nump">30,876,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">7,257,524<span></span>
</td>
<td class="nump">15,668,684<span></span>
</td>
<td class="nump">8,187,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,360,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">IMPAIRMENT OF LONG-LIVED ASSETS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">148,795<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">34,643,111<span></span>
</td>
<td class="nump">55,205,847<span></span>
</td>
<td class="nump">39,212,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(3,534,563)<span></span>
</td>
<td class="num">(20,925,383)<span></span>
</td>
<td class="num">(2,693,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">INTEREST INCOME</a></td>
<td class="nump">516,637<span></span>
</td>
<td class="nump">883,908<span></span>
</td>
<td class="nump">401,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">INTEREST EXPENSE</a></td>
<td class="num">(13,604)<span></span>
</td>
<td class="num">(65,854)<span></span>
</td>
<td class="num">(262,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">INVESTMENT LOSS</a></td>
<td class="num">(1,607,537)<span></span>
</td>
<td class="num">(2,316,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">OTHER INCOME (EXPENSES)</a></td>
<td class="nump">467,687<span></span>
</td>
<td class="nump">1,680,087<span></span>
</td>
<td class="nump">455,547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(4,171,380)<span></span>
</td>
<td class="num">(20,744,236)<span></span>
</td>
<td class="num">(2,098,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="nump">62,862<span></span>
</td>
<td class="nump">394,541<span></span>
</td>
<td class="nump">1,099,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(4,234,242)<span></span>
</td>
<td class="num">(21,138,777)<span></span>
</td>
<td class="num">(3,198,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(6,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.</a></td>
<td class="num">(4,234,228)<span></span>
</td>
<td class="num">(21,138,525)<span></span>
</td>
<td class="num">(3,192,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">FOREIGN CURRENCY TRANSLATION ADJUSTMENTS</a></td>
<td class="num">(729,373)<span></span>
</td>
<td class="num">(2,617,857)<span></span>
</td>
<td class="nump">1,534,807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (4,963,615)<span></span>
</td>
<td class="num">$ (23,756,634)<span></span>
</td>
<td class="num">$ (1,663,559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">1,444,263<span></span>
</td>
<td class="nump">509,828<span></span>
</td>
<td class="nump">173,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="nump">1,444,263<span></span>
</td>
<td class="nump">509,828<span></span>
</td>
<td class="nump">173,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (2.93)<span></span>
</td>
<td class="num">$ (41.46)<span></span>
</td>
<td class="num">$ (18.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="num">$ (2.93)<span></span>
</td>
<td class="num">$ (41.46)<span></span>
</td>
<td class="num">$ (18.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869192698128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Statutory reserves</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income/(loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 41,752<span></span>
</td>
<td class="nump">$ 66,516,033<span></span>
</td>
<td class="nump">$ 1,309,109<span></span>
</td>
<td class="num">$ (44,942,374)<span></span>
</td>
<td class="nump">$ 2,818,185<span></span>
</td>
<td class="num">$ (1,340,360)<span></span>
</td>
<td class="nump">$ 24,402,345<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">173,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,192,119)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,247)<span></span>
</td>
<td class="num">(3,198,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,534,807<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,534,807<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 41,752<span></span>
</td>
<td class="nump">66,516,033<span></span>
</td>
<td class="nump">1,309,109<span></span>
</td>
<td class="num">(48,134,493)<span></span>
</td>
<td class="nump">4,352,992<span></span>
</td>
<td class="num">(1,346,607)<span></span>
</td>
<td class="nump">22,738,786<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">173,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StockIssuedDuringPeriodValueForReverseStockSplit', window );">Fractional shares issued for reverse stock split</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Fractional shares issued for reverse stock split (in Shares)</a></td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants', window );">Issuance of shares and warrants in private placements</a></td>
<td class="nump">$ 71,400<span></span>
</td>
<td class="nump">7,253,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants', window );">Issuance of shares and warrants in private placements (in Shares)</a></td>
<td class="nump">297,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">10,324,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 135,118<span></span>
</td>
<td class="num">(135,118)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Cashless exercise of warrants (in Shares)</a></td>
<td class="nump">562,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,138,525)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(21,138,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,617,857)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,617,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 284,367<span></span>
</td>
<td class="nump">83,958,418<span></span>
</td>
<td class="nump">1,309,109<span></span>
</td>
<td class="num">(69,273,018)<span></span>
</td>
<td class="nump">1,735,135<span></span>
</td>
<td class="num">(1,346,859)<span></span>
</td>
<td class="nump">16,667,152<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">1,184,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StockIssuedDuringPeriodValueForReverseStockSplit', window );">Fractional shares issued for reverse stock split</a></td>
<td class="nump">$ 14,520<span></span>
</td>
<td class="num">(14,520)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Fractional shares issued for reverse stock split (in Shares)</a></td>
<td class="nump">60,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants', window );">Issuance of shares and warrants in private placements</a></td>
<td class="nump">$ 119,520<span></span>
</td>
<td class="nump">2,470,080<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,589,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants', window );">Issuance of shares and warrants in private placements (in Shares)</a></td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,234,228)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(4,234,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(729,373)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(729,373)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 418,407<span></span>
</td>
<td class="nump">$ 86,413,978<span></span>
</td>
<td class="nump">$ 1,309,109<span></span>
</td>
<td class="num">$ (73,507,246)<span></span>
</td>
<td class="nump">$ 1,005,762<span></span>
</td>
<td class="num">$ (1,346,873)<span></span>
</td>
<td class="nump">$ 14,293,137<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">1,743,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of stock and warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_StockIssuedDuringPeriodValueForReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fractional shares issued for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_StockIssuedDuringPeriodValueForReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869197679216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,234,242)<span></span>
</td>
<td class="num">$ (21,138,777)<span></span>
</td>
<td class="num">$ (3,198,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">790,449<span></span>
</td>
<td class="nump">718,002<span></span>
</td>
<td class="nump">1,256,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt direct write-off and provision and reversal</a></td>
<td class="num">(249,257)<span></span>
</td>
<td class="nump">7,579,886<span></span>
</td>
<td class="nump">939,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of Right-of-use assets</a></td>
<td class="nump">4,594,172<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment</a></td>
<td class="nump">107,251<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">148,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,360,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investment loss</a></td>
<td class="nump">1,607,537<span></span>
</td>
<td class="nump">2,316,994<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,804,440)<span></span>
</td>
<td class="num">(2,531,755)<span></span>
</td>
<td class="num">(2,657,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivables', window );">Notes receivable</a></td>
<td class="nump">19,943<span></span>
</td>
<td class="num">(20,861)<span></span>
</td>
<td class="nump">40,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories and biological assets</a></td>
<td class="num">(1,699,621)<span></span>
</td>
<td class="num">(522,550)<span></span>
</td>
<td class="nump">1,523,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(672,830)<span></span>
</td>
<td class="num">(958,671)<span></span>
</td>
<td class="num">(1,927,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidSupplies', window );">Advances to suppliers</a></td>
<td class="num">(839,221)<span></span>
</td>
<td class="nump">201,984<span></span>
</td>
<td class="num">(171,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_IncreaseDecreaseInLongTermDeposit', window );">Long term deposit</a></td>
<td class="num">(132,568)<span></span>
</td>
<td class="nump">589,653<span></span>
</td>
<td class="num">(159,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">19,076<span></span>
</td>
<td class="nump">331,426<span></span>
</td>
<td class="nump">376,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="nump">69,539<span></span>
</td>
<td class="num">(30,483)<span></span>
</td>
<td class="nump">62,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="num">(317,828)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">6,002,186<span></span>
</td>
<td class="nump">1,765,488<span></span>
</td>
<td class="num">(3,558,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other payables and accrued liabilities</a></td>
<td class="nump">868,975<span></span>
</td>
<td class="num">(1,341,447)<span></span>
</td>
<td class="nump">99,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_IncreaseDecreaseInCustomerDeposit', window );">Customer deposits</a></td>
<td class="num">(144,761)<span></span>
</td>
<td class="num">(1,035,456)<span></span>
</td>
<td class="nump">678,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Taxes payable</a></td>
<td class="num">(948,277)<span></span>
</td>
<td class="nump">433,054<span></span>
</td>
<td class="nump">1,162,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(6,191,522)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,155,439)<span></span>
</td>
<td class="num">(3,283,513)<span></span>
</td>
<td class="num">(5,385,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of equipment and building</a></td>
<td class="num">(330,677)<span></span>
</td>
<td class="num">(118,272)<span></span>
</td>
<td class="num">(89,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInJointVenture', window );">Investment in a joint venture</a></td>
<td class="num">(1,116,212)<span></span>
</td>
<td class="num">(4,379)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(66,973)<span></span>
</td>
<td class="num">(12,774)<span></span>
</td>
<td class="num">(7,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdditionsToLeaseholdImprovements', window );">Additions to leasehold improvements</a></td>
<td class="num">(525,988)<span></span>
</td>
<td class="num">(180,672)<span></span>
</td>
<td class="num">(209,166)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,039,850)<span></span>
</td>
<td class="num">(316,097)<span></span>
</td>
<td class="num">(306,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Proceeds from short-term bank loan</a></td>
<td class="nump">1,116,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherShortTermDebt', window );">Repayment of short-term bank loan</a></td>
<td class="num">(837,159)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(779,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of third parties loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,811,558)<span></span>
</td>
<td class="num">(2,613,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">56,875,403<span></span>
</td>
<td class="nump">57,965,013<span></span>
</td>
<td class="nump">65,370,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(52,997,171)<span></span>
</td>
<td class="num">(60,273,598)<span></span>
</td>
<td class="num">(57,829,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares and warrants in private placements</a></td>
<td class="nump">2,589,600<span></span>
</td>
<td class="nump">7,325,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from other payable-related parties</a></td>
<td class="nump">1,257,406<span></span>
</td>
<td class="nump">43,785<span></span>
</td>
<td class="nump">689,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RepaymentOfOtherPayablesrelatedParties', window );">Repayment of other payable-related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(882,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,004,291<span></span>
</td>
<td class="nump">2,366,156<span></span>
</td>
<td class="nump">4,836,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">EFFECT OF EXCHANGE RATE ON CASH</a></td>
<td class="num">(1,505,475)<span></span>
</td>
<td class="num">(2,535,479)<span></span>
</td>
<td class="nump">1,522,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">1,303,527<span></span>
</td>
<td class="num">(3,768,933)<span></span>
</td>
<td class="nump">666,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year</a></td>
<td class="nump">31,570,644<span></span>
</td>
<td class="nump">35,339,577<span></span>
</td>
<td class="nump">34,672,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year</a></td>
<td class="nump">32,874,171<span></span>
</td>
<td class="nump">31,570,644<span></span>
</td>
<td class="nump">35,339,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">149,023<span></span>
</td>
<td class="nump">63,668<span></span>
</td>
<td class="nump">3,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">13,604<span></span>
</td>
<td class="nump">64,943<span></span>
</td>
<td class="nump">262,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH ACTIVITIES&#65306;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 135,118<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdditionsToLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdditionsToLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cashless excercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_IncreaseDecreaseInCustomerDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_IncreaseDecreaseInCustomerDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_IncreaseDecreaseInLongTermDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_IncreaseDecreaseInLongTermDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_RepaymentOfOtherPayablesrelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of repayment of other payables-related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_RepaymentOfOtherPayablesrelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869390579136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS AND ORGANIZATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 &#8211; DESCRIPTION OF BUSINESS AND
ORGANIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">China Jo-Jo Drugstores, Inc. (&#8220;Jo-Jo Drugstores&#8221;
or the &#8220;Company&#8221;), was incorporated in Nevada on December 19, 2006, originally under the name &#8220;Kerrisdale Mining Corporation&#8221;.
On September 24, 2009, the Company changed its name to &#8220;China Jo-Jo Drugstores, Inc.&#8221; in connection with a share exchange
transaction as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2009, the Company completed a
share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (&#8220;Renovation&#8221;), whereby 7,900,000 shares of ordinary
shares were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share
exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization
and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the
accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date
of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment
Management Co., Ltd. (&#8220;Jiuxin Management&#8221;), Zhejiang Shouantang Medical Technology Co., Ltd. (&#8220;Shouantang Technology&#8221;)
and Hangzhou Jiutong Medical Technology Co., Ltd (&#8220;Jiutong Medical&#8221;), Hangzhou Jiuyi Medical Technology Co. Ltd. (&#8220;Jiuyi
Technology&#8221;), its wholly-owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an online and offline retailer
and wholesale distributor of pharmaceutical and other healthcare products in the People&#8217;s Republic of China (&#8220;China&#8221;
or the &#8220;PRC&#8221;). The Company&#8217;s offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou
Jiuzhou Grand Pharmacy Chain Co., Ltd. (&#8220;Jiuzhou Pharmacy&#8221;), a company that the Company controls through contractual arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s offline retail business also
includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (&#8220;Jiuzhou Clinic&#8221;)
and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (&#8220;Jiuzhou Service&#8221;), both of which are also controlled by
the Company through contractual arrangements. In May 2014, Shouantang Technology established Hangzhou Shouantang Bio-technology Co., Ltd.
(&#8220;Shouantang Bio&#8221;). In May 2016, Shouantang Bio set up and held 49% of Hangzhou Kahamadi Bio-technology Co., Ltd. (&#8220;Kahamadi
Bio&#8221;), a joint venture specializing in brand name development for nutritional supplements. In 2018, Jiuzhou Pharmacy invested a
total of $741,540 (RMB5,100,000) in and held 51% of Zhejiang Jiuzhou Linjia Medical Investment and Management Co. Ltd (&#8220;Linjia Medical&#8221;),
which has ceased its operation as of March 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently conducts its online retail
pharmacy business through Jiuzhou Pharmacy, which holds the Company&#8217;s online pharmacy license. On September 10, 2015, Renovation
set up Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November
2015, the technical support function was transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s wholesale business is primarily
conducted through Zhejiang Jiuxin Medicine Co., Ltd. (&#8220;Jiuxin Medicine&#8221;), which is licensed to distribute prescription and
non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. On April 20,
2018, 10% of Jiuxin Medicine shares were sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of $79,625 (RMB 507,760). On
January 29, 2021, The Company bought back the 10% of Jiuxin Medicine for a total price of $77,410(RMB<span style="-sec-ix-hidden: hidden-fact-100">507, 760</span>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s herb farming business is conducted
by Hangzhou Qianhong Agriculture Development Co., Ltd. (&#8220;Qianhong Agriculture&#8221;), a wholly-owned subsidiary of Jiuxin Management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2021, China Jo-Jo Drugstores, Inc.,
a Nevada corporation (&#8220;CJJD&#8221;), completed a corporate reorganization (the &#8220;Reorganization&#8221; or &#8220;Redomicile
Merger&#8221;), resulting in China Jo-Jo Drugstores Holdings, Inc., a company incorporated under the laws of the Cayman Islands (&#8220;CJJD
Cayman&#8221;), becoming the publicly held parent company of CJJD, with CJJD merged with and into CJJD Cayman, pursuant to the Agreement
and Plan of Merger, dated as of May 14, 2021, by and between CJJD and CJJD Cayman (the &#8220;Merger Agreement&#8221;). Prior to the Reorganization,
shares of CJJD&#8217;s ordinary shares were registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;), and listed on the NASDAQ Capital Market under the symbol &#8220;CJJD.&#8221; As a result of the Reorganization,
each issued and outstanding share of CJJD&#8217;s ordinary shares was converted into the right to receive one CJJD Cayman ordinary share,
which shares were issued by CJJD Cayman as part of the Reorganization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 7, 2022, the Company effected a 1-for-12&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 12 shares of the Company&#8217;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#8217;s percentage
interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2024, the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 20 shares of the Company&#8217;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#8217;s percentage
interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
reflect the activities of the Company and each of the following entities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Name</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></td> <td style="width: 1%">&#160;</td> <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovation</span></td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuxin&#160;Management</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#8220;WFOE&#8221;) under PRC law &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Technology</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qianhong Agriculture</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Pharmacy (1)</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates the &#8220;Jiuzhou Grand Pharmacy&#8221; stores in Hangzhou</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Clinic (1)</span></td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003</span></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores</span></td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Service (1)</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Name</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></td> <td style="width: 1%">&#160;</td> <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuxin Medicine</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiutong Medical</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Currently has no operation</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Bio</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuyi Technology</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kahamadi Bio</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Clinic</span></td> <td style="width: 1%">&#160;</td> <td rowspan="8" style="width: 48%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics</p></td> <td style="width: 1%">&#160;</td> <td rowspan="8" style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhen Health</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million&#160;</p></td> <td style="width: 1%">&#160;</td> <td style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hongtong Service</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Daily service</p></td> <td style="width: 1%">&#160;</td> <td style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#8220;Owners&#8221;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#8217;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#8220;VIE&#8221;) under the accounting standards of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Liquidity and capital resources</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, we had cash of approximately
$32.9 million and a working capital deficit of $4.7 million. During the year ended March 31, 2024, we had a net loss of approximately
$4.2 million and net cash used in operating activities were $2.9 million. However, non-cash expenses such as investment loss accounts
for approximately $1.6 million, respectively. Excluding these non-cash expenses, the net loss is approximately $2.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts have been prepared
in accordance with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) on a going concern
basis. The going concern basis assumes that assets are realized and liabilities are extinguished in the ordinary course of business at
amounts disclosed in the financial statements. The Company&#8217;s ability to continue as a going concern depends upon aligning its sources
of funding (debt and equity) with its expenditure requirements and repayment of the short-term debts as and when they become due.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to meet its capital demand, the Company
strived to raise funds in the capital market, increase its credit line from the local banks, and improve its store performance in the
near future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2023, the Company closed a private
placement of 498,000 shares of ordinary shares at $5.20 per share with gross proceeds of $2,589,600. On April 29, 2024, the Company entered
into certain Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant
to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering,
an aggregate of 900,000 ordinary shares (the &#8220;Shares&#8221;), par value $0.24 per share, of the Company (&#8220;Ordinary Shares&#8221;),
at a purchase price of $1.70 per Share (the &#8220;Purchase Price&#8221;), for aggregate gross proceeds to the Company of $1,530,000.
On May 10, 2024, the Company entered into certain Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors
(the &#8220;Investors&#8221;) pursuant to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from
the Company, in a registered direct offering, an aggregate of 1,610,000 ordinary shares (the &#8220;Shares&#8221;), par value $0.24 per
share, of the Company (&#8220;Ordinary Shares&#8221;), at a purchase price of $1.70 per Share (the &#8220;Purchase Price&#8221;), for
aggregate gross proceeds to the Company of $2,737,000. On June 11, 2024, the Company entered into certain Share Purchase Agreements (the
&#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to sell to
the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an aggregate of 1,980,000 ordinary
shares (the &#8220;Shares&#8221;), par value $0.24 per share, of the Company (&#8220;Ordinary Shares&#8221;), at a purchase price of $1.70
per Share (the &#8220;Purchase Price&#8221;), for an aggregate gross proceeds to the Company of $3,366,000. The private placements raised
a total gross proceeds of $10,222,600.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a credit line agreement from a
local bank as described in detail in Note 15 and Note 16. As of March 31, 2024, approximately $1.55 million of the aforementioned bank
credit line was available for further borrowing. On June 6, 2024, bank credit line increased by $5.54 million (RMB 40,000,000). As the
economy growth slows down, the national interest continues to decrease. local banks are encouraged to provide low interest rate loans
to local enterprises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also obtained additional government
insurance reimbursement certificates for its stores opened in the last two years. In a mature store, nearly half of the revenue are generated
by customers utilizing the government insurance program. With these certificates, mature stores are able to attract more customers who
are eligible for the insurance program, and its sales may significantly increase in the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the above factors, the Company believes
it can support its operations for at least the next 12 months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869317888736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of presentation and consolidation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). The
consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant
inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Consolidation of variable interest entities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with accounting standards regarding
consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without
additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the
Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary
is required to consolidate the VIE for financial reporting purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has concluded, based on the contractual
arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each
a VIE and that the Company&#8217;s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities
of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual
returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Control and common control are defined under the
accounting standards as &#8220;an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership
interest of each entity.&#8221; Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and
have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting
rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly,
the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin
Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin
Management, in turn, is owned by Renovation, which is owned by the Company. <b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with&#160;U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial
statements relate to the assessment of the carrying values of accounts receivable, related allowance for doubtful accounts, losses. Because
of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair value measurements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company establishes a three-level valuation
hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; Quoted prices in active markets
for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of
the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; Unobservable inputs that are supported
by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Classification within the hierarchy is determined
based on the lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value of
the Company&#8217;s financial instruments including cash, restricted cash, accounts receivable, advances to suppliers, other current assets,
accounts payable, due to related parties, other current liabilities, short-term bank loans and bank acceptance notes payable approximate
their recorded values due to their short-term maturities. The fair value of longer term long-term bank loan and operating lease liabilities
approximate their recorded values as their stated interest rates approximate the rates currently available.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Long-term investments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Long-term
investments include equity investments. Equity investments include investments in common stock or in-substance common stock of entities.
For those equity investments over which the Group can exercise significant influence but does not own a majority equity interest or control,
the equity method is applied, and the Group adjusts the carrying amount of an investment and recognizes investment income or loss for
the Group&#8217;s share of the earnings or loss of the investee after the date of investment. For those equity investments accounted for
other than under the equity method, the fair value method is applied. However, for equity investments that do not have readily determinable
fair values, the Group chooses to account for them at cost minus impairment, if any, plus or minus changes resulting from observable price
changes in orderly transactions for the identical or a similar investment of the same issuer. If this measurement alternative is elected,
changes in the carrying value of the equity investments will be required to be made whenever there are observable price changes in transactions
for identical or similar investments of the same issuer. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 31, 2018, the Company began recognizing
revenue under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;),
using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company&#8217;s
consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict
the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be
entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 1: Identify the contract with the customer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 2: Identify the performance obligations in the contract</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 3: Determine the transaction price</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to identify the performance obligations
in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or
service that is distinct. A performance obligation meets ASC 606&#8217;s definition of a &#8220;distinct&#8221; good or service (or bundle
of goods or services) if both of the following criteria are met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a good or service is not distinct, the good
or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenue is net of value added
tax (&#8220;VAT&#8221;) collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers,
net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant
PRC tax authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain contract liabilities primarily represent
the Company&#8217;s obligation to transfer additional goods or services to a customer for which the Company has received consideration,
for example, membership points. The consideration received remains a contract liability until goods or services have been provided to
the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a discussion of the Company&#8217;s
revenue recognition policies by segment under the new revenue recognition accounting standard:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacy retail sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The physical pharmacies sell prescription drugs,
over-the-counter (&#8220;OTC&#8221;) drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products.
Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and
pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer
pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after
the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local
government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The
Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made
to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services.
Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal
compared to pharmacy retail sales, it is included as part of the pharmacy retail sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company deduct the membership rewards directly
from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification.
Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has
determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers
can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership
rewards are reflected as a&#160;contract&#160;liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Online pharmacy sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from online pharmacy sales is recognized
when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer&#8217;s
location. Any loss caused in a shipment will be reimbursed by the Company&#8217;s courier company. The Company&#8217;s sales policy allows
for the return of certain merchandises without reason within seven days after a customer&#8217;s receipt of the applicable merchandise.
Historically, sales returns seven days after merchandise receipts have been minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Wholesale</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiuxin Medicine purchases medicine in quantity
and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers
is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenue is net of VAT collected
on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases,
is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disaggregation of Revenue</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table disaggregates the Company&#8217;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>For the year ended March 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Retail drugstores</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,269,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,212,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,503,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,542,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,358,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,658,864</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,890,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,737,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,664,071</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,405,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,719,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,353,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,544,639</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,440,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,241,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,503,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total retail revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75,678,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,351,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,228,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Online pharmacy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,151,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,606,244</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,331,652</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,969,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,870,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,473,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,740,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">571,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,231</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,448,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,271,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,432,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,603,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,814,284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total online revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,857,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,385,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,219,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Drug wholesale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,784,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,617,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,116,991</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,289,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,903,824</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">741,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,502</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">692,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,073,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">333,663</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total wholesale revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">47,004,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">33,075,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,944,699</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,541,077</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,811,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">164,392,555</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted cash</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s restricted cash consists of
cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is
required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in
nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,149,806</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,807,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,724,365</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,762,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,874,171</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,570,644</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable represents the following:
(1) amounts due from banks relating to retail sales that are paid or settled by the customers&#8217; debit or credit cards, (2) amounts
due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine,
and medical services that are paid or settled by the customers&#8217; medical insurance cards, (3) amounts due from non-bank third party
payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts, as&#160;necessary. In the Company&#8217;s retail
business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance
programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines
to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated
reserves on related outstanding accounts receivable based on expected credit loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the Company&#8217;s online pharmacy business,
accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce
platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to
certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month.
Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In its wholesale business, the Company uses the
expected credit loss method to estimate the allowance for anticipated uncollectible receivable balances. At each reporting period, the
allowance balance is adjusted to reflect the amount computed as a result of the expected credit loss method. When facts subsequently become
available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account
as a change in estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Credit loss roll forward</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the adoption of the current expected credit
loss standard in 2020, the company estimates future expected losses on accounts receivable and other receivables over the remaining collection
period of the instrument. The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year end March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Account <br/> receivable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Other <br/> receivables</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Allowance for credit losses as of March 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,313,306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,329,440</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,642,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Credit loss reversal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,389,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,446,772</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,836,412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Ending allowance for credit losses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">923,666</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,882,668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,806,334</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventories</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts
on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct
costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such
as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs
costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses
and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities
on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Farmland assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Herbs that the Company farms are recorded at their
cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland,
and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has
been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All related costs described in the above are accumulated
until the time of harvest and then allocated to harvested herbs when they are sold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost, net
of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of
the assets, taking into consideration the assets&#8217; estimated residual value. Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#8217;s property
and equipment:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful&#160;Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3-10 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Motor vehicles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office equipment &amp; furniture</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Buildings</td><td>&#160;</td>
    <td style="text-align: center">35 years</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maintenance, repairs and minor renewals are charged
to expenses as incurred. Major additions and betterment to property and equipment are capitalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Intangible assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets are acquired individually or
as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction
is allocated to the individual assets based on their relative fair values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated useful lives of the Company&#8217;s
intangible assets are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">50 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Software</td><td>&#160;</td> <td style="text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">license</td><td>&#160;</td> <td style="text-align: center">Infinite</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates intangible assets for impairment
whenever events or changes in circumstances indicate that the assets might be impaired.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates long lived tangible and
intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable
from its estimated future cash flows. Recoverability is measured by comparing the assets&#8217; net book value to the related projected
undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections,
market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset
is considered impaired, and a second test is performed to measure the amount of impairment loss. The forest rights certificate from the
local village extends the life of the lease to January 31, 2060. In the year ended March 31, 2022, we evaluated the use rights of the
forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company recorded
an impairment of $148,795. In the year ended March 31, 2023, we evaluated the use rights of the forest land, which is currently used to
cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended
March 31, 2024, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation
of the forest land use rights, the Company did not record an impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the normal course of business, the Company
regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The
Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short
maturity period of six to nine months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income taxes</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows FASB ASC Topic 740, &#8220;Income
Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax
consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each
period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting standards clarify the accounting
and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition
and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition,
classification, interest and penalties, accounting in interim periods, disclosures, and transition.&#160;No significant penalties, uncertain
tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Value added tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue represents the invoiced value of
goods, net of VAT. All of the Company&#8217;s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT
rates&#160;range up to 13%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials
and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments
in the accompanying financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share-based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The Company accounts for share-based payment
awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the
fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest
is recognized as an expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. Share-based
awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option
award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using
the Black-Scholes valuation model as permitted under FASB ASC 718 &#8220;Compensation - Stock Compensation.&#8221; The assumptions used
in calculating the fair value of share-based payment awards represent the Company&#8217;s best estimates. The Company&#8217;s estimates
of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain
variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates
of forfeitures, and the related income tax impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Advertising and promotion costs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising and promotion costs are expensed as
incurred and amounted to $304,075, $491,684&#160;and $355,078 for the year ended March 31, 2024, 2023 and 2022, respectively. Such costs
consist primarily of print and promotional materials such as flyers to local communities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign currency translation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the United States dollar (&#8220;U.S.
dollars&#8221; or &#8220;USD&#8221;) for financial reporting purposes. The Company&#8217;s subsidiaries and VIEs maintain their books
and records in their functional currency the Renminbi (&#8220;RMB&#8221;), the currency of the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, for consolidation purposes, the Company
translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at
the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period.
As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes
in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the
translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The balance sheet amounts, with the exception
of equity, at March 31, 2024 and 2023 were translated at 1 USD to 7.2203 RMB and at 1 USD to 6.8676 RMB, respectively. The average translation
rates applied to income and cash flow statement amounts for years ended March 31, 2024 and 2023 were at 1 USD to 7.1671 RMB and at 1 USD
to 6.8516 RMB, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s management does not believe
that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the
accompanying consolidated financial statements.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194034592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Risks and Uncertainties</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operations of the Company are located in the
PRC. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#8217;s operations in the PRC are subject
to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include
risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company&#8217;s
results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not
experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization
and structure disclosed in Note 1, this may not be indicative of future results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has significant cash deposits with
suppliers in order to obtain and maintain inventory. The Company&#8217;s ability to obtain products and maintain inventory at existing
and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors
are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest
on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party
who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party.
If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings
in China, to recover all or a portion of the amount on deposit with its suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Members of the current management team own controlling
interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements
which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the
Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the
Company would not retain control of the VIEs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentrations and Credit Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain financial instruments, which subject the
Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions
located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection
Board&#8217;s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered
by insurance up to RMB 500,000 (USD 79,600) per bank. As of March 31, 2024 and 2023, the Company had deposits totaling $32,247,552 and
$31,558,338 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD79,<span style="-sec-ix-hidden: hidden-fact-101">600</span>) per bank in PRC will not
be covered. To date, the Company has not experienced any losses in such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended March 31, 2024, one
vendor collectively accounted for more than 10% of the Company&#8217;s total purchases and two suppliers accounted for more than 10% of
total advances to suppliers.&#160;For the fiscal year ended March 31, 2023, four vendors collectively accounted for more than 10% of the
Company&#8217;s total purchases and four suppliers accounted for more than 10% of total advances to suppliers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended March 31, 2024, one
customer accounted for more than 10% of the Company&#8217;s total sales but no customer accounted for more than 10% of total accounts
receivable. For the fiscal year ended March 31, 2023, one customer accounted for more than 10% of the Company&#8217;s total sales but
no customer accounted for more than 10% of total accounts receivable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194016944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Trade Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">TRADE RECEIVABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; TRADE RECEIVABLES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trade receivables consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,747,769</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,412,099</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(923,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,313,306</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,824,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,098,793</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Note receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Trade receivables</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,824,103</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,119,606</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended March 31, 2024 and 2023, $56,170
and $50,275 in accounts receivable were directly written off, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869186742192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 &#8211; OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other current assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid rental expenses <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">513,170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">530,611</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,374</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">569,544</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,008</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190219376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;6 &#8211; PROPERTY AND EQUIPMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Building</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,617,617</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,072,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,503,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,134,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Farmland development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,656,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,741,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office equipment and furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,729,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,811,887</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">421,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,542</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,928,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,118,955</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,355,233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,266,513</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Impairment*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,666,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,752,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,906,589</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,100,264</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total depreciation expense for property and equipment
was $693,537 and $625,739 for the year ended March 31, 2024 and 2023, respectively. There were no fixed assets impaired in the years ended
March 31, 2024 and March 31, 2023.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193931360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LONG-TERM INVESTMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;7 &#8211; LONG-TERM INVESTMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-term investment consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kahamadi Bio <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhuoli Life <sup>(2)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,680,337</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Songlu Pharmaceutical <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Digital <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,368</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,108,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Long-term investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,195,261</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,772,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $0 and $0 in the year ended March 31, 2024 and 2023.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 39% investment in Zhejiang Zhuoli Life Service Co., LTD (&#8220;Zhuoli Service&#8221;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $1,443,752 into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $2,402,376 in the year ended March 31, 2023. An impairment loss of $1,607,537 was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was <span style="-sec-ix-hidden: hidden-fact-107">nil</span>.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 0.37% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#8220;Songlu Pharmaceutical&#8221;). The investment is recorded based on cost method.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 25.92% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $4,379 into Jiuzhou Digital. The investment is recorded based on equity method.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 8% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $1,113,650(RMB 8,000,000) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189363664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advances to Suppliers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdvancesToSuppliersAbstract', window );"><strong>Advances to Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdvancesToSuppliersTextBlock', window );">ADVANCES TO SUPPLIERS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;8 &#8211; ADVANCES TO SUPPLIERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advances to suppliers consist of deposits, with
or advances to, outside vendors for future inventory purchases. Most of the Company&#8217;s suppliers require a certain amount of money
to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears
no interest. As of March 31, 2024 and March 31, 2023, advance to suppliers consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,177,399</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">362,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: reserve for vendor non-performance on advances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(262,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(219,630</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Advance to suppliers, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">914,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">142,417</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdvancesToSuppliersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for advances to suppliers consist of deposits with or advances to outside vendors for future inventory purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdvancesToSuppliersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193987824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9 &#8211; INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consisted of finished goods, valued
at $16,248,373 and $15,309,100 as of March 31, 2024 and March 31, 2023, respectively. The Company constantly monitors its potential obsolete
products and is allowed to return products close to their expiration date to its suppliers. Any loss on damaged items is immaterial and
will be recognized immediately. As a result, <span style="-sec-ix-hidden: hidden-fact-108"><span style="-sec-ix-hidden: hidden-fact-109">no</span></span> reserves were made for inventory as of March 31, 2024 and March 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193906720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Farmland Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssetsAbstract', window );"><strong>Farmland Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssetsTextBlock', window );">FARMLAND ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 &#8211; FARMLAND ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Farmland assets consist of ginkgo trees planted
in 2012 and expected to be harvested and sold in several years. As of March 31, 2024 and March 31, 2023, farmland assets are valued as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Farmland assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,176,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,287,836</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Impairment*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,541,926</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,621,115</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Farmland assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">634,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">666,721</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $148,795.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for farmland assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869297613440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAbstract', window );"><strong>Long Term Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermDepositsTextBlock', window );">LONG TERM DEPOSITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;11 &#8211; LONG TERM DEPOSITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024 and March 31, 2023, long
term deposits amounted to $1,119,006 and $1,038,125, respectively.&#160;Long term deposits are sums deposited with, or advanced to, landlords
for the purpose of securing retail store leases that the Company does not anticipate applying or being returned within the next twelve
months. Most of the Company&#8217;s landlords require a minimum payment of nine months&#8217; rent, paid up front, plus additional deposits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_LongTermDepositsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term deposits. Long term deposits are money deposited with or advanced to landlords for securing retail store leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_LongTermDepositsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869300604816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Noncurrent Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Noncurrent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">OTHER NONCURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;12 &#8211; OTHER NONCURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other noncurrent assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Forest land use rights*</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">639,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">691,537</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">682,437</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">790,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amortization of the prepayment for the lease
of land use right was approximately $18,477 and $19,328 for the years ended March 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s amortizations of the prepayment
for lease of land use right for the next five years and thereafter are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Years ending March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">547,029</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193851552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 13 &#8211; Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases most of its retail stores and
corporate offices under operating leases, typically with initial terms of 3 to 10 years. Usually within one to three months prior to the
expiration date of a lease, the Company is required to notify the lessor and has a priority to continue renting the lease property if
a lessor intends to lease property. The lease itself does not have restriction or covenants. If both parties agree to continue, a new
lease contract with new lease terms has to been signed by both parties. Usually the rent may increase year by year based on the lease
contract. Sublease is typically not allowed. Any damage, if made by the lessee, to the property and equipment within the property has
to been fixed or reimbursed by the lessee. The Company does not have any leases entered into but which have not yet commenced. The net
lease cost for the year ended March 31, 2024 is $7,487,456. The Company does not have finance lease according to the definition of ASU
2016-02, <i>Leases </i>(Topic 842). Supplemental cash flow information related to leases for the year ended March 31, 2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt">Operating cash flows paid for operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,487,456</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental balance sheet information related
to leases as of March 31, 2024 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Operating leases:</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">13,827,360</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of operating lease liabilities</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,862,766</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,403,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,266,624</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average remaining lease term</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.93 years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.8</td><td style="text-align: left">%</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the maturity of
lease liabilities under operating leases as of March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Operating</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">For the year ending March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Leases</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,294,771</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,872,270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,913,295</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,107,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">448,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">621,050</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,257,539</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(990,915</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,266,624</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188024992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;14 &#8211; INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net intangible assets consisted of the following
at:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,305,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,354,534</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,115,192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,172,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,350,574</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,419,936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,771,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,946,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,155,807</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,114,028</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: impairment <sup>(4)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(606,035</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(637,159</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,009,922</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,195,748</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense of intangibles amounted to
$96,912 and $92,263 for the years ended March 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#8217; business and liquidate all of the stores&#8217; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#8217; health. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2013, the Company purchased the land use rights of a plot of land in Lin&#8217;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#8217;s farming business in Lin&#8217;an has not grown, the Company does not expect completion of the plant in the near future.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020. </span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190219376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;15 &#8211; NOTES PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has credit facilities with Hangzhou
United Bank (&#8220;HUB&#8221;), Bank of Hangzhou (&#8220;BOH&#8221;), and China Merchant Bank (&#8220;CMB&#8221;) that provided working
capital in the form of the following bank acceptance notes. Usually, the Company applies to issue a note, which is guaranteed by the bank,
to its supplier to pay off its debt in a future date. Before the payment date, the bank will ask the Company to inject cash into the bank.
On the payment date, the bank will pay the amount to whoever legally holds the note. As of at March 31, 2024 and March 31, 2023, the balances
of notes payable are as follow:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">Origination</td><td>&#160;</td> <td style="text-align: center">Maturity</td><td>&#160;</td> <td colspan="2" style="text-align: center">March&#160;31,</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Endorser</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">date</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">date</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Jiuzhou Pharmacy</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">HUB</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">10/19/22</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">04/19/23</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,289,434</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">10/20/22</td><td>&#160;</td> <td style="text-align: center">04/19/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">36,403</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">11/17/22</td><td>&#160;</td> <td style="text-align: center">05/17/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,576,213</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/16/22</td><td>&#160;</td> <td style="text-align: center">06/16/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,207,565</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/26/22</td><td>&#160;</td> <td style="text-align: center">06/27/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">659,883</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/28/22</td><td>&#160;</td> <td style="text-align: center">06/29/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,654,696</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/16/23</td><td>&#160;</td> <td style="text-align: center">07/16/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">346,545</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">02/27/23</td><td>&#160;</td> <td style="text-align: center">08/27/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,242,559</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/20/23</td><td>&#160;</td> <td style="text-align: center">09/20/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,573,664</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/23/23</td><td>&#160;</td> <td style="text-align: center">09/23/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">440,391</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">11/17/22</td><td>&#160;</td> <td style="text-align: center">05/17/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,303,221</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/16/22</td><td>&#160;</td> <td style="text-align: center">06/16/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,704,790</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/21/22</td><td>&#160;</td> <td style="text-align: center">06/21/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,741</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/29/22</td><td>&#160;</td> <td style="text-align: center">06/29/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,215,854</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/20/23</td><td>&#160;</td> <td style="text-align: center">09/20/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">803,817</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">10/12/23</td><td>&#160;</td> <td style="text-align: center">04/12/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,126,621</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">11/21/23</td><td>&#160;</td> <td style="text-align: center">05/21/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,703,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#160;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/22/23</td><td>&#160;</td> <td style="text-align: center">06/22/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,040,374</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/27/23</td><td>&#160;</td> <td style="text-align: center">06/27/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">274,683</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/28/23</td><td>&#160;</td> <td style="text-align: center">06/28/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">151,882</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/03/24</td><td>&#160;</td> <td style="text-align: center">07/03/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">102,713</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/11/24</td><td>&#160;</td> <td style="text-align: center">07/11/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">248,086</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">02/06/24</td><td>&#160;</td> <td style="text-align: center">08/06/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,189,602</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/13/24</td><td>&#160;</td> <td style="text-align: center">09/13/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,274,739</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/14/24</td><td>&#160;</td> <td style="text-align: center">09/14/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">969,489</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/27/23</td><td>&#160;</td> <td style="text-align: center">06/27/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">415,495</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/28/23</td><td>&#160;</td> <td style="text-align: center">06/28/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,689,726</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/11/24</td><td>&#160;</td> <td style="text-align: center">07/11/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,234,494</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">02/06/24</td><td>&#160;</td> <td style="text-align: center">08/06/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">186,973</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/15/24</td><td>&#160;</td> <td style="text-align: center">09/15/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">415,495</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/28/24</td><td>&#160;</td> <td style="text-align: center">09/28/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">293,080</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Jiuxin Medicine</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">HUB</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">03/29/24</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">09/29/24</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">359,179</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,676,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29,255,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, the Company had a credit
line of approximately $19.25 million in the aggregate&#160;from HUB. By putting up a three-year deposit of $4.50 million and the restricted
cash of $8.16 million deposited in the banks, the total credit line was $31.91 million. As of March 31, 2024, the Company had approximately
$31.68 million of bank notes payable and approximately $0.23 million bank credit line was still available for further borrowing. The bank
notes are secured by three shops of Jiuzhou Pharmacy and guaranteed by the Company&#8217;s major shareholders.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190307488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableAbstract', window );"><strong>Loan Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LoanPayableTextBlock', window );">LOAN PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 16 &#8211; LOAN PAYABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 4, 2023, Jiuzhou&#160;Service signed
a Maximum Amount Pledge Contract with Industrial and Commercial Bank of China, pledging Mr. Lei Liu&#8217;s land use rights and property
ownership as security, for a loan facility with a maximum principal amount of US$1.60(RMB11.49) million during the period from August
4, 2023 to August 4, 2028. As of March 31, 2024, the outstanding amount of the short-term bank loan under this pledge contract was US$276,997(RMB2,000,000)
..</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_LoanPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_LoanPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188008032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note&#160;17 &#8211; TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income tax</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax expense includes a provision for federal,
state and foreign taxes based on the annual estimated effective tax rate applicable to the Company and its subsidiaries, adjusted for
items which are considered discrete to the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rates on income before income
taxes for the year ended March 31, 2024 was (1.5)%. The (1.5)% rate adjustments for the year ended March 31, 2024 represent expenses that
primarily include legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rates on income before income
taxes for the year ended March 31, 2023 was (1.9)%. The (1.9)% rate adjustments for the year ended March 31, 2023 represent expenses that
primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC
income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through the rest
of the year as a result of the unpredictable impact of COVID-19 on the Company&#8217;s operating activities.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effective tax rates on income before income
taxes for the year ended March 31, 2022 was (52.4)%. The (52.4)% rate adjustments for the year ended March 31, 2022 represent expenses
that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible
for PRC income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through
the rest of the year as a result of the unpredictable impact of COVID-19 on the Company&#8217;s operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the income tax provision at
the federal statutory rate and the effective rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year ended <br/> March 31</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">U.S. Statutory rates</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign income not recognized in the U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">China income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-deductible expenses-permanent difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52.4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.9</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(52.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has recorded $0 unrecognized benefit
as of March 31, 2024. On the information currently available, the Company does not anticipate a significant increase or decrease to its
unrecognized benefit within the next 12 months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869317433920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Postretirement Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Postretirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">POSTRETIREMENT BENEFITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 18 &#8211; POSTRETIREMENT BENEFITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulations in the PRC require the Company to
contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage
of the employee&#8217;s current compensation as required by the local government. The Company contributed $1,325,312, $1,284,218 and $1,301,315
in employment benefits and pension for the years ended March 31, 2024, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193230176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions and Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions and Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS AND ARRANGEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 19 &#8211; RELATED PARTY TRANSACTIONS
AND ARRANGEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summary of Balances with Related Parties as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due from related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hangzhou Kahamadi Biotechnology Co., Ltd<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32,825</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others (the directors of subsidiaries)<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lend to related parties</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due to related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to a director and CEO<sup>(2)</sup>:</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,580,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">683,560</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup>:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,452</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,833,509</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">683,560</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances to directors of our subsidiaries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to foreign exchange restrictions, the Company&#8217;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical borrowed from its non-controlling shareholder.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190216128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder&#8217;s Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholder&#8217;s Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDER&#8217;S EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 20 &#8211; SHAREHOLDER&#8217;S EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Ordinary shares</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 26, 2023, the Company closed a private
placement of 498,000 shares of ordinary shares at $5.20 per share with gross proceeds of $2,589,600.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2024, the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 20 shares of the Company&#8217;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#8217;s percentage
interest in the Company&#8217;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the registered direct offering
of common stock that closed on April 15, 2019, the Company issued to several investors in a private placement warrants to purchase up
to 12,501 shares of common stock. In connection with the offering, the Company also issued a warrant to its placement agent of this offering,
pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 1,000 shares
at an exercise price of $750 per share. The warrant became exercisable on October 11, 2019 and has expired on April 11, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the registered direct offering
of common stock that closed on June 3, 2020, the Company issued to several investors in a private placement warrants to purchase up to
15,625 shares of common stock. In connection with the offering, the Company also issued warrants to its placement agent of this offering,
pursuant to which the agent may purchase up to 6.5% of the aggregate number of shares of common stock sold in the offering, i.e. 1,250
shares at an exercise price of $616.8 per share. The warrant becomes exercisable on December 2, 2020 and will expire on June 2, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the registered direct offering
of ordinary shares that closed on September 26, 2023, the Company issued to several investors warrants to purchase up to 996,000 shares
of ordinary shares at an exercise price of $5.20. The warrant became exercisable on September 26, 2023 and valid for three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Statutory reserves</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Statutory reserves represent restricted retained
earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts
on an annual basis to the Statutory Surplus Reserve Fund (the &#8220;Reserve Fund&#8221;). Once the total amount set aside in the Reserve
Fund reaches 50% of the entity&#8217;s registered capital, further appropriations become discretionary. The Reserve Fund can be used to
increase the entity&#8217;s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC
GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise,
except in the event of liquidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Appropriations to the Reserve Fund are accounted
for as a transfer from unrestricted earnings to statutory reserves. During the years ended March 31, 2024 and 2023, the Company did not
make appropriations to statutory reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no legal requirements in the PRC to
fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194119728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 21 &#8211; NET LOSS PER SHARE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reports earnings per share in accordance
with the provisions of the FASB&#8217;s related accounting standard. This standard requires presentation of basic and diluted earnings
per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes
dilution, but includes vested restricted stocks and is computed by dividing income available to ordinary shareholders by the weighted
average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur
if securities or other contracts to issue ordinary shares were exercised and converted into ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a reconciliation of the basic
and diluted earnings per share computation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss attributable to controlling interest</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,234,228</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(21,138,525</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,192,119</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average shares used in basic computation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,444,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted effect of stock options and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average shares used in diluted computation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,444,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share &#8211; Basic:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss before noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: Net loss attributable to noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share &#8211; Diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net income before noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: Net loss attributable to noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended March 31, 2024, 1,024,126 shares
underlying outstanding purchase warrants to several investors, and 2,250 shares underlying outstanding purchase warrants to an investment
placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190297408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 22 &#8211; SEGMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates within three main reportable
segments: retail drugstores, online pharmacy, and drug wholesale. The retail drugstores segment sells prescription and over-the-counter
(&#8220;OTC&#8221;) medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers.&#160;The online pharmacy
sells prescription drugs, OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms
such as Alibaba&#8217;s Tmall, JD.com and Amazon.com, and the Company&#8217;s own platform all over China. The drug wholesale segment
includes supplying the Company&#8217;s own retail&#160;drugstores with prescription and OTC medicines, TCM, dietary supplement, medical
devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors
and hospitals. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable
segments and are included in the retail drugstores segment. The segments&#8217; accounting policies are the same as those described in
the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest
and income taxes not including nonrecurring gains and losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s reportable business segments
are strategic business units that offer different products and services. Each segment is managed separately because they require different
operations and markets to distinct classes of customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,678,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31,857,883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,004,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,541,077</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,056,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,249,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,126,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,432,529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,622,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,608,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,878,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31,108,548</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,680,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,770,855</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934,223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,385,587</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,195,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">466,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,596,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,257,524</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,253,531</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,629,006</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,347,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,534,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">754,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">790,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">855,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">856,665</td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83,351,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,385,089</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,075,119</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">148,811,976</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,551,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,506,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,473,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,531,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,800,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,878,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,601,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,280,464</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,644,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,266,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,266,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,177,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,803,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,425,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,668,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,360,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,360,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21,007,343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(827,605</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">909,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(20,925,383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">686,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">718,002</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">303,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">304,016</td><td style="text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">84,228,492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,219,364</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,944,699</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,392,555</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,290,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,621,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,961,351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,873,515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,937,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,598,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,983,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36,519,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,186,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,972,465</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,718,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,876,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,766,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,136,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,187,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,795</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,163,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(659,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,129,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,693,890</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,234,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,256,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">296,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">299,473</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have long-lived assets located
outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB&#8217;s accounting standard, the Company&#8217;s
net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2024, 2023 and
2022 were as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,269,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,212,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,503,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,542,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,358,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,658,864</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,890,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,737,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,664,071</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,405,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,719,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,353,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,544,639</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,440,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,241,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,503,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75,678,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,351,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,228,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s net revenue from external
customers through online pharmacy by main product category is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years&#160;ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,151,412</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,606,244</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,331,652</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,969,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,870,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,473,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,740,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">571,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,231</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,448,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,271,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,432,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,603,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,814,284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,857,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,385,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,219,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s net revenue from external
customers through wholesale by main product category is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years&#160;ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,784,949</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,617,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,116,991</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,289,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,903,824</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">741,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,502</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">692,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,073,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">333,663</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,004,724</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,075,119</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,944,699</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189945008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 23 &#8211; SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2024, the compensation committee of
our board of directors granted 420,715 ordinary shares (the &#8220;Shares&#8221;) of restricted stock awards (with the vesting conditions
waived) to Lei Liu, Chief Executive Officer and Director. The Shares were granted under the Company&#8217;s Third Amended and Restated
2010 Equity Incentive Plan. The issuance of the Shares is registered under a Registration Statement on Form S-8 filed with the Securities
and Exchange Commission and became effective on March 12, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2024, the Company entered into certain
Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of 900,000 ordinary shares (the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Shares&#8221;), par value $0.24 per share,
of the Company (&#8220;Ordinary Shares&#8221;), at a purchase price of $1.70 per Share (the &#8220;Purchase Price&#8221;), for aggregate
gross proceeds to the Company of $1,530,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2024, the Company entered into certain
Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of 1,610,000 ordinary shares (the &#8220;Shares&#8221;), par value $0.24 per share, of the Company (&#8220;Ordinary Shares&#8221;),
at a purchase price of $1.70 per Share (the &#8220;Purchase Price&#8221;), for aggregate gross proceeds to the Company of $2,737,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 11, 2024, the Company entered into certain
Share Purchase Agreements (the &#8220;Purchase Agreement&#8221;) with several investors (the &#8220;Investors&#8221;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of 1,980,000 ordinary shares (the &#8220;Shares&#8221;), par value $0.24 per share, of the Company (&#8220;Ordinary Shares&#8221;),
at a purchase price of $1.70 per Share (the &#8220;Purchase Price&#8221;), for an aggregate gross proceeds to the Company of $3,366,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188021744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (4,234,228)<span></span>
</td>
<td class="num">$ (21,138,525)<span></span>
</td>
<td class="num">$ (3,192,119)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189935936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193108704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation and consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of presentation and consolidation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;). The
consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant
inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Consolidation of variable interest entities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Consolidation of variable interest entities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with accounting standards regarding
consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without
additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the
Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary
is required to consolidate the VIE for financial reporting purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has concluded, based on the contractual
arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each
a VIE and that the Company&#8217;s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities
of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual
returns.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Control and common control are defined under the
accounting standards as &#8220;an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership
interest of each entity.&#8221; Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and
have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting
rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly,
the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin
Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin
Management, in turn, is owned by Renovation, which is owned by the Company. <b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements
in conformity with&#160;U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial
statements relate to the assessment of the carrying values of accounts receivable, related allowance for doubtful accounts, losses. Because
of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair value measurements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company establishes a three-level valuation
hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the
following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; Quoted prices in active markets
for identical assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of
the assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; Unobservable inputs that are supported
by little or no market activity and that are significant to the fair value of the assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Classification within the hierarchy is determined
based on the lowest level of input that is significant to the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value of
the Company&#8217;s financial instruments including cash, restricted cash, accounts receivable, advances to suppliers, other current assets,
accounts payable, due to related parties, other current liabilities, short-term bank loans and bank acceptance notes payable approximate
their recorded values due to their short-term maturities. The fair value of longer term long-term bank loan and operating lease liabilities
approximate their recorded values as their stated interest rates approximate the rates currently available.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Long-term investments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Long-term investments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Long-term
investments include equity investments. Equity investments include investments in common stock or in-substance common stock of entities.
For those equity investments over which the Group can exercise significant influence but does not own a majority equity interest or control,
the equity method is applied, and the Group adjusts the carrying amount of an investment and recognizes investment income or loss for
the Group&#8217;s share of the earnings or loss of the investee after the date of investment. For those equity investments accounted for
other than under the equity method, the fair value method is applied. However, for equity investments that do not have readily determinable
fair values, the Group chooses to account for them at cost minus impairment, if any, plus or minus changes resulting from observable price
changes in orderly transactions for the identical or a similar investment of the same issuer. If this measurement alternative is elected,
changes in the carrying value of the equity investments will be required to be made whenever there are observable price changes in transactions
for identical or similar investments of the same issuer. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective March 31, 2018, the Company began recognizing
revenue under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;),
using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company&#8217;s
consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict
the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be
entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 1: Identify the contract with the customer</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 2: Identify the performance obligations in the contract</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 3: Determine the transaction price</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to identify the performance obligations
in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or
service that is distinct. A performance obligation meets ASC 606&#8217;s definition of a &#8220;distinct&#8221; good or service (or bundle
of goods or services) if both of the following criteria are met:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).</span></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: .25in; text-align: justify">&#160;</td>
    <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a good or service is not distinct, the good
or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenue is net of value added
tax (&#8220;VAT&#8221;) collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers,
net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant
PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain contract liabilities primarily represent
the Company&#8217;s obligation to transfer additional goods or services to a customer for which the Company has received consideration,
for example, membership points. The consideration received remains a contract liability until goods or services have been provided to
the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a discussion of the Company&#8217;s
revenue recognition policies by segment under the new revenue recognition accounting standard:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacy retail sales</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The physical pharmacies sell prescription drugs,
over-the-counter (&#8220;OTC&#8221;) drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products.
Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and
pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer
pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after
the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local
government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The
Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made
to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services.
Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal
compared to pharmacy retail sales, it is included as part of the pharmacy retail sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company deduct the membership rewards directly
from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification.
Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has
determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers
can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership
rewards are reflected as a&#160;contract&#160;liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Online pharmacy sales</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from online pharmacy sales is recognized
when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer&#8217;s
location. Any loss caused in a shipment will be reimbursed by the Company&#8217;s courier company. The Company&#8217;s sales policy allows
for the return of certain merchandises without reason within seven days after a customer&#8217;s receipt of the applicable merchandise.
Historically, sales returns seven days after merchandise receipts have been minimal.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Wholesale</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jiuxin Medicine purchases medicine in quantity
and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers
is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenue is net of VAT collected
on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases,
is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disaggregation of Revenue</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table disaggregates the Company&#8217;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>For the year ended March 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Retail drugstores</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,269,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,212,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,503,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,542,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,358,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,658,864</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,890,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,737,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,664,071</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,405,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,719,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,353,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,544,639</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,440,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,241,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,503,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total retail revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75,678,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,351,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,228,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Online pharmacy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,151,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,606,244</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,331,652</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,969,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,870,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,473,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,740,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">571,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,231</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,448,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,271,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,432,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,603,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,814,284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total online revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,857,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,385,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,219,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Drug wholesale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,784,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,617,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,116,991</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,289,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,903,824</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">741,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,502</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">692,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,073,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">333,663</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total wholesale revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">47,004,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">33,075,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,944,699</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,541,077</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,811,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">164,392,555</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Restricted cash</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s restricted cash consists of
cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is
required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in
nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,149,806</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,807,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,724,365</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,762,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,874,171</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,570,644</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable represents the following:
(1) amounts due from banks relating to retail sales that are paid or settled by the customers&#8217; debit or credit cards, (2) amounts
due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine,
and medical services that are paid or settled by the customers&#8217; medical insurance cards, (3) amounts due from non-bank third party
payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts, as&#160;necessary. In the Company&#8217;s retail
business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance
programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines
to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated
reserves on related outstanding accounts receivable based on expected credit loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the Company&#8217;s online pharmacy business,
accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce
platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to
certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month.
Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In its wholesale business, the Company uses the
expected credit loss method to estimate the allowance for anticipated uncollectible receivable balances. At each reporting period, the
allowance balance is adjusted to reflect the amount computed as a result of the expected credit loss method. When facts subsequently become
available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account
as a change in estimate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CreditLossRollForwardPolicyTextBlock', window );">Credit loss roll forward</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Credit loss roll forward</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the adoption of the current expected credit
loss standard in 2020, the company estimates future expected losses on accounts receivable and other receivables over the remaining collection
period of the instrument. The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year end March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Account <br/> receivable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Other <br/> receivables</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Allowance for credit losses as of March 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,313,306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,329,440</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,642,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Credit loss reversal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,389,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,446,772</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,836,412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Ending allowance for credit losses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">923,666</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,882,668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,806,334</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventories</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts
on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct
costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such
as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs
costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses
and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities
on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssetsPolicyTextBlock', window );">Farmland assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Farmland assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Herbs that the Company farms are recorded at their
cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland,
and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has
been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All related costs described in the above are accumulated
until the time of harvest and then allocated to harvested herbs when they are sold.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and equipment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost, net
of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of
the assets, taking into consideration the assets&#8217; estimated residual value. Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#8217;s property
and equipment:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful&#160;Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3-10 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Motor vehicles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office equipment &amp; furniture</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Buildings</td><td>&#160;</td>
    <td style="text-align: center">35 years</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maintenance, repairs and minor renewals are charged
to expenses as incurred. Major additions and betterment to property and equipment are capitalized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Intangible assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets are acquired individually or
as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction
is allocated to the individual assets based on their relative fair values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated useful lives of the Company&#8217;s
intangible assets are as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">50 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Software</td><td>&#160;</td> <td style="text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">license</td><td>&#160;</td> <td style="text-align: center">Infinite</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates intangible assets for impairment
whenever events or changes in circumstances indicate that the assets might be impaired.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of long-lived assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates long lived tangible and
intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable
from its estimated future cash flows. Recoverability is measured by comparing the assets&#8217; net book value to the related projected
undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections,
market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset
is considered impaired, and a second test is performed to measure the amount of impairment loss. The forest rights certificate from the
local village extends the life of the lease to January 31, 2060. In the year ended March 31, 2022, we evaluated the use rights of the
forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company recorded
an impairment of $148,795. In the year ended March 31, 2023, we evaluated the use rights of the forest land, which is currently used to
cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended
March 31, 2024, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation
of the forest land use rights, the Company did not record an impairment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_NotesPayablePolicyTextBlock', window );">Notes payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Notes payable</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the normal course of business, the Company
regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The
Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short
maturity period of six to nine months.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows FASB ASC Topic 740, &#8220;Income
Taxes,&#8221; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax
consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each
period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting standards clarify the accounting
and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition
and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition,
classification, interest and penalties, accounting in interim periods, disclosures, and transition.&#160;No significant penalties, uncertain
tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ValueAddedTaxPolicyTextBlock', window );">Value added tax</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Value added tax</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales revenue represents the invoiced value of
goods, net of VAT. All of the Company&#8217;s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT
rates&#160;range up to 13%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials
and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments
in the accompanying financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Share-based compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">The Company accounts for share-based payment
awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the
fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest
is recognized as an expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. Share-based
awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option
award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using
the Black-Scholes valuation model as permitted under FASB ASC 718 &#8220;Compensation - Stock Compensation.&#8221; The assumptions used
in calculating the fair value of share-based payment awards represent the Company&#8217;s best estimates. The Company&#8217;s estimates
of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain
variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates
of forfeitures, and the related income tax impact.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and promotion costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Advertising and promotion costs</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising and promotion costs are expensed as
incurred and amounted to $304,075, $491,684&#160;and $355,078 for the year ended March 31, 2024, 2023 and 2022, respectively. Such costs
consist primarily of print and promotional materials such as flyers to local communities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign currency translation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the United States dollar (&#8220;U.S.
dollars&#8221; or &#8220;USD&#8221;) for financial reporting purposes. The Company&#8217;s subsidiaries and VIEs maintain their books
and records in their functional currency the Renminbi (&#8220;RMB&#8221;), the currency of the PRC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, for consolidation purposes, the Company
translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at
the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period.
As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes
in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the
translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The balance sheet amounts, with the exception
of equity, at March 31, 2024 and 2023 were translated at 1 USD to 7.2203 RMB and at 1 USD to 6.8676 RMB, respectively. The average translation
rates applied to income and cash flow statement amounts for years ended March 31, 2024 and 2023 were at 1 USD to 7.1671 RMB and at 1 USD
to 6.8516 RMB, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s management does not believe
that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the
accompanying consolidated financial statements.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_CreditLossRollForwardPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_CreditLossRollForwardPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for farmland assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_NotesPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_NotesPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ValueAddedTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ValueAddedTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194058624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Consolidated Financial Statements Activities</a></td>
<td class="text">The accompanying consolidated financial statements
reflect the activities of the Company and each of the following entities:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Name</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></td> <td style="width: 1%">&#160;</td> <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovation</span></td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuxin&#160;Management</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#8220;WFOE&#8221;) under PRC law &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Technology</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qianhong Agriculture</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Pharmacy (1)</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates the &#8220;Jiuzhou Grand Pharmacy&#8221; stores in Hangzhou</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Clinic (1)</span></td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003</span></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores</span></td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou&#160;Service (1)</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE&#160;by&#160;contractual arrangements (2)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 25%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity Name</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background</span></td> <td style="width: 1%">&#160;</td> <td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuxin Medicine</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiutong Medical</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Currently has no operation</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Bio</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuyi Technology</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kahamadi Bio</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements</p></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49%</span></td></tr> <tr style="vertical-align: top; "> <td>&#160;</td> <td>&#160;</td> <td style="padding-left: 0.25in; text-indent: -0.25in">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical</span></td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics</p></td> <td>&#160;</td> <td><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shouantang Clinic</span></td> <td style="width: 1%">&#160;</td> <td rowspan="8" style="width: 48%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics</p></td> <td style="width: 1%">&#160;</td> <td rowspan="8" style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhen Health</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million&#160;</p></td> <td style="width: 1%">&#160;</td> <td style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hongtong Service</span></td> <td style="width: 1%">&#160;</td> <td style="width: 48%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;&#160;&#160;&#160;&#160;&#160;Daily service</p></td> <td style="width: 1%">&#160;</td> <td style="width: 25%"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 10pt">VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#8220;Owners&#8221;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#8217;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#8220;VIE&#8221;) under the accounting standards of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869191497056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Revenue by Major Source in each Segment</a></td>
<td class="text">The following table disaggregates the Company&#8217;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>For the year ended March 31,</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Retail drugstores</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,269,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,212,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,503,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,542,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,358,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,658,864</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,890,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,737,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,664,071</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,405,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,719,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,353,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,544,639</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,440,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,241,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,503,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total retail revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75,678,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,351,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,228,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Online pharmacy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,151,412</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,606,244</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,331,652</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,969,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,870,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,473,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,740,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">571,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,231</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,448,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,271,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,432,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,603,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,814,284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total online revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,857,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,385,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,219,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Drug wholesale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prescription drugs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">30,784,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,617,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41,116,991</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,289,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,903,824</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">741,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,502</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">692,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,073,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">333,663</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total wholesale revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">47,004,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">33,075,119</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">49,944,699</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total revenue</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,541,077</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">148,811,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">164,392,555</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/>2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20,149,806</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,807,936</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,724,365</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,762,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,874,171</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,570,644</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables</a></td>
<td class="text">The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year end March 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Account <br/> receivable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Other <br/> receivables</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -9pt; padding-left: 9pt">Allowance for credit losses as of March 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,313,306</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,329,440</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,642,746</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Credit loss reversal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,389,640</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,446,772</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,836,412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Ending allowance for credit losses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">923,666</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,882,668</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,806,334</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Lives of Property And Equipment</a></td>
<td class="text">Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#8217;s property
and equipment:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful&#160;Life</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3-10 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Motor vehicles</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Office equipment &amp; furniture</td><td>&#160;</td>
    <td style="text-align: center">3-5 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Buildings</td><td>&#160;</td>
    <td style="text-align: center">35 years</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives of Intangible Assets</a></td>
<td class="text">The estimated useful lives of the Company&#8217;s
intangible assets are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated <br/>Useful Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt">Land use rights</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">50 years</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Software</td><td>&#160;</td> <td style="text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">license</td><td>&#160;</td> <td style="text-align: center">Infinite</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated lives of the property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189941408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Trade Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Trade Receivables</a></td>
<td class="text">Trade receivables consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts receivable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,747,769</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,412,099</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(923,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,313,306</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,824,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,098,793</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Note receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Trade receivables</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">15,824,103</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,119,606</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193220688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text">Other current assets consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid rental expenses <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">513,170</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">530,611</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,374</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">569,544</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,008</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194101648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Building</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,617,617</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,072,388</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,503,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,134,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Farmland development cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,656,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,741,422</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office equipment and furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,729,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,811,887</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Motor vehicles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">421,234</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">358,542</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,928,409</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,118,955</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,355,233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,266,513</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Impairment*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,666,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,752,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,906,589</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,100,264</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869290799552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Investment</a></td>
<td class="text">Long-term investment consists of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kahamadi Bio <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zhuoli Life <sup>(2)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,680,337</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Songlu Pharmaceutical <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Digital <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,155</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,368</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,108,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Long-term investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,195,261</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,772,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $0 and $0 in the year ended March 31, 2024 and 2023.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 39% investment in Zhejiang Zhuoli Life Service Co., LTD (&#8220;Zhuoli Service&#8221;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $1,443,752 into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $2,402,376 in the year ended March 31, 2023. An impairment loss of $1,607,537 was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was <span style="-sec-ix-hidden: hidden-fact-107">nil</span>.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 0.37% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#8220;Songlu Pharmaceutical&#8221;). The investment is recorded based on cost method.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 25.92% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $4,379 into Jiuzhou Digital. The investment is recorded based on equity method.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 8% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $1,113,650(RMB 8,000,000) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.&#160;</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869290953888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Advances to Suppliers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdvancesToSuppliersAbstract', window );"><strong>Advances to Suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdvanceToSuppliersTableTextBlock', window );">Schedule of Advance to Suppliers</a></td>
<td class="text">As of March 31, 2024 and March 31, 2023, advance to suppliers consist of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,177,399</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">362,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: reserve for vendor non-performance on advances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(262,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(219,630</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Advance to suppliers, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">914,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">142,417</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdvanceToSuppliersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of advance to suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdvanceToSuppliersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdvancesToSuppliersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdvancesToSuppliersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189930000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Farmland Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssetsAbstract', window );"><strong>Farmland Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ScheduleOfFarmlandAssetsTableTextBlock', window );">Schedule of Farmland Assets</a></td>
<td class="text">Farmland assets consist of ginkgo trees planted
in 2012 and expected to be harvested and sold in several years. As of March 31, 2024 and March 31, 2023, farmland assets are valued as
follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Farmland assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,176,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,287,836</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Impairment*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,541,926</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,621,115</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Farmland assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">634,153</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">666,721</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $148,795.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ScheduleOfFarmlandAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for farmland assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ScheduleOfFarmlandAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190314672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Noncurrent Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Noncurrent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Noncurrent Assets</a></td>
<td class="text">Other noncurrent assets consisted of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Forest land use rights*</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">639,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">691,537</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,023</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">682,437</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">790,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Amortizations of the Prepayment for Lease of Land Use Right</a></td>
<td class="text">The Company&#8217;s amortizations of the prepayment
for lease of land use right for the next five years and thereafter are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Years ending March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">547,029</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193209984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease</a></td>
<td class="text">Supplemental cash flow information related to leases for the year ended March 31, 2024 is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 9pt">Operating cash flows paid for operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,487,456</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table>Supplemental balance sheet information related
to leases as of March 31, 2024 is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Operating leases:</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; padding-bottom: 4pt">Operating lease right-of-use assets</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">13,827,360</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current portion of operating lease liabilities</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,862,766</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,403,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,266,624</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted average remaining lease term</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.93 years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.8</td><td style="text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Liabilities Under Operating Leases</a></td>
<td class="text">The following table summarizes the maturity of
lease liabilities under operating leases as of March 31, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Operating</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">For the year ending March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Leases</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,294,771</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,872,270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,913,295</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,107,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">448,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">621,050</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,257,539</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(990,915</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,266,624</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194086144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of net Intangible Assets</a></td>
<td class="text">Net intangible assets consisted of the following
at:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,305,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,354,534</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,115,192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,172,465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land use rights <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,350,574</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,419,936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,771,764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,946,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,155,807</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,114,028</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: impairment <sup>(4)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(606,035</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(637,159</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Intangible assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,009,922</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,195,748</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#8217; business and liquidate all of the stores&#8217; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#8217; health. </span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2013, the Company purchased the land use rights of a plot of land in Lin&#8217;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#8217;s farming business in Lin&#8217;an has not grown, the Company does not expect completion of the plant in the near future.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020. </span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869317784512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facilities with Banks</a></td>
<td class="text">As of at March 31, 2024 and March 31, 2023, the balances
of notes payable are as follow:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">Origination</td><td>&#160;</td> <td style="text-align: center">Maturity</td><td>&#160;</td> <td colspan="2" style="text-align: center">March&#160;31,</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">March 31,</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">Endorser</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">date</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid">date</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Jiuzhou Pharmacy</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">HUB</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">10/19/22</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">04/19/23</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,289,434</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">10/20/22</td><td>&#160;</td> <td style="text-align: center">04/19/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">36,403</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">11/17/22</td><td>&#160;</td> <td style="text-align: center">05/17/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,576,213</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/16/22</td><td>&#160;</td> <td style="text-align: center">06/16/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,207,565</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/26/22</td><td>&#160;</td> <td style="text-align: center">06/27/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">659,883</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/28/22</td><td>&#160;</td> <td style="text-align: center">06/29/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,654,696</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/16/23</td><td>&#160;</td> <td style="text-align: center">07/16/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">346,545</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">02/27/23</td><td>&#160;</td> <td style="text-align: center">08/27/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,242,559</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/20/23</td><td>&#160;</td> <td style="text-align: center">09/20/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,573,664</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/23/23</td><td>&#160;</td> <td style="text-align: center">09/23/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">440,391</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">11/17/22</td><td>&#160;</td> <td style="text-align: center">05/17/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,303,221</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/16/22</td><td>&#160;</td> <td style="text-align: center">06/16/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,704,790</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/21/22</td><td>&#160;</td> <td style="text-align: center">06/21/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">200,741</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/29/22</td><td>&#160;</td> <td style="text-align: center">06/29/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,215,854</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/20/23</td><td>&#160;</td> <td style="text-align: center">09/20/23</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">803,817</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">10/12/23</td><td>&#160;</td> <td style="text-align: center">04/12/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,126,621</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">11/21/23</td><td>&#160;</td> <td style="text-align: center">05/21/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,703,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#160;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/22/23</td><td>&#160;</td> <td style="text-align: center">06/22/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,040,374</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/27/23</td><td>&#160;</td> <td style="text-align: center">06/27/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">274,683</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/28/23</td><td>&#160;</td> <td style="text-align: center">06/28/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">151,882</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/03/24</td><td>&#160;</td> <td style="text-align: center">07/03/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">102,713</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/11/24</td><td>&#160;</td> <td style="text-align: center">07/11/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">248,086</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">02/06/24</td><td>&#160;</td> <td style="text-align: center">08/06/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,189,602</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/13/24</td><td>&#160;</td> <td style="text-align: center">09/13/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,274,739</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuzhou Pharmacy</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/14/24</td><td>&#160;</td> <td style="text-align: center">09/14/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">969,489</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/27/23</td><td>&#160;</td> <td style="text-align: center">06/27/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">415,495</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">12/28/23</td><td>&#160;</td> <td style="text-align: center">06/28/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,689,726</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">01/11/24</td><td>&#160;</td> <td style="text-align: center">07/11/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,234,494</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">02/06/24</td><td>&#160;</td> <td style="text-align: center">08/06/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">186,973</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/15/24</td><td>&#160;</td> <td style="text-align: center">09/15/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">415,495</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Jiuxin Medicine</td><td>&#160;</td> <td style="text-align: center">HUB</td><td>&#160;</td> <td style="text-align: center">03/28/24</td><td>&#160;</td> <td style="text-align: center">09/28/24</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">293,080</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Jiuxin Medicine</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">HUB</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">03/29/24</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">09/29/24</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">359,179</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,676,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29,255,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: .25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194081200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate</a></td>
<td class="text">A reconciliation of the income tax provision at
the federal statutory rate and the effective rate is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the year ended <br/> March 31</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">U.S. Statutory rates</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign income not recognized in the U.S.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">China income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.0</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-deductible expenses-permanent difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52.4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.5</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.9</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(52.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193199600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions and Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions and Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Balances with Related Parties</a></td>
<td class="text">Summary of Balances with Related Parties as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due from related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hangzhou Kahamadi Biotechnology Co., Ltd<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32,825</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others (the directors of subsidiaries)<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">313,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lend to related parties</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Due to related parties:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to a director and CEO<sup>(2)</sup>:</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,580,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">683,560</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup>:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,452</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,833,509</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">683,560</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to foreign exchange restrictions, the Company&#8217;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.35in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical borrowed from its non-controlling shareholder.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194079328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text">The following is a reconciliation of the basic
and diluted earnings per share computation:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss attributable to controlling interest</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,234,228</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(21,138,525</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,192,119</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average shares used in basic computation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,444,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Diluted effect of stock options and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted average shares used in diluted computation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,444,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,828</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,966</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share &#8211; Basic:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss before noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: Net loss attributable to noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share &#8211; Diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net income before noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Add: Net loss attributable to noncontrolling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributable to controlling interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2.93</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(41.46</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(18.35</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869295451376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment of the Continuing Operations</a></td>
<td class="text">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,678,470</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31,857,883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">47,004,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">154,541,077</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,056,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,249,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,126,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123,432,529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,622,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,608,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,878,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31,108,548</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,680,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,770,855</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934,223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,385,587</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,195,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">466,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,596,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,257,524</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,253,531</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,629,006</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,347,974</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,534,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">754,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">790,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">855,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">856,665</td><td style="text-align: left">&#160;</td></tr>
  </table>The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83,351,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,385,089</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,075,119</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">148,811,976</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,551,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,506,228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,473,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,531,512</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,800,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,878,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,601,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,280,464</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,644,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,266,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,266,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,177,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,803,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,425,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,668,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,360,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,360,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21,007,343</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(827,605</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">909,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(20,925,383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">686,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">718,002</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">303,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">304,016</td><td style="text-align: left">&#160;</td></tr>
  </table>The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Retail <br/> drugstores</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Online <br/> Pharmacy</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Drug <br/> wholesale</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">84,228,492</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,219,364</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,944,699</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">164,392,555</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Cost of goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,290,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,621,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,961,351</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,873,515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,937,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,598,050</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,983,348</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36,519,040</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,186,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,972,465</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,718,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,876,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,766,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,136,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,187,176</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Impairment of long-lived assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,795</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss&#160;from operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,163,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(659,477</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,129,020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,693,890</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,234,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,256,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">296,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">299,473</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of net revenue from external customers through its retail drugstores by main products</a></td>
<td class="text">In accordance with the enterprise-wide disclosure requirements of FASB&#8217;s accounting standard, the Company&#8217;s
net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2024, 2023 and
2022 were as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,269,177</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,212,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28,503,283</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,542,597</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,358,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,658,864</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,890,985</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,737,519</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,664,071</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,405,979</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,719,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,353,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,544,639</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,440,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,241,095</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,503,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75,678,470</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">83,351,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">84,228,492</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>The Company&#8217;s net revenue from external
customers through online pharmacy by main product category is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years&#160;ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,151,412</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,606,244</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,331,652</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,969,313</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,870,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,473,177</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,284,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,740,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,014,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">571,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">315,231</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,448,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,129,701</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,271,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,432,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,603,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,814,284</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">31,857,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32,385,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">30,219,364</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>The Company&#8217;s net revenue from external
customers through wholesale by main product category is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">For the years&#160;ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prescription drugs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,784,949</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,617,636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,116,991</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">OTC drugs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,323,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,289,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,903,824</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nutritional supplements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">741,883</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">424,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>TCM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,502</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sundry products</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">692,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,338</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Medical devices</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,073,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">333,663</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">164,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47,004,724</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33,075,119</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">49,944,699</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869181477184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 10, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 29, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>CNY (&#165;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 17, 2009 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 06, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 06, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 07, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,362<span></span>
</td>
<td class="nump">1,184,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,362<span></span>
</td>
<td class="nump">1,184,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,234,242)<span></span>
</td>
<td class="num">$ (21,138,777)<span></span>
</td>
<td class="num">$ (3,198,366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,155,439)<span></span>
</td>
<td class="num">(3,283,513)<span></span>
</td>
<td class="num">(5,385,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Investment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,234,228)<span></span>
</td>
<td class="num">$ (21,138,525)<span></span>
</td>
<td class="num">$ (3,192,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,222,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par vale (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Credit borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,540,000<span></span>
</td>
<td class="nump">&#165; 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cjjd_LiquidityAndCapitalResourcesMember', window );">Liquidity and Capital Resources [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Total amount of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 741,540<span></span>
</td>
<td class="nump">&#165; 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=cjjd_BankLoanMember', window );">Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Credit borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_RenovationInvestmentMember', window );">Renovation Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_ShouantangBioMember', window );">Shouantang Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Total proceeds of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,625<span></span>
</td>
<td class="nump">&#165; 507,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SharesRepurchasePercentage', window );">Shares repurchase percentage (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Total price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,410<span></span>
</td>
<td class="nump">&#165; 507,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in Shares) | shares</a></td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds</a></td>
<td class="nump">$ 3,366,000<span></span>
</td>
<td class="nump">$ 2,737,000<span></span>
</td>
<td class="nump">$ 1,530,000<span></span>
</td>
<td class="nump">$ 2,589,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par vale (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems', window );"><strong>Description of Business and Organization (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par vale (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_DescriptionofBusinessandOrganizationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_DescriptionofBusinessandOrganizationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_SharesRepurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_SharesRepurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cjjd_LiquidityAndCapitalResourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cjjd_LiquidityAndCapitalResourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cjjd_EntityFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cjjd_EntityFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=cjjd_BankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=cjjd_BankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_RenovationInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_RenovationInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_ShouantangBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_ShouantangBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_EntityFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_EntityFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_EntityEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cjjd_EntityEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869187054496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization (Details) - Schedule of Consolidated Financial Statements Activities<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_RenovationMember', window );">Renovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntityTwoMember', window );">Jiuxin Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#8220;WFOE&#8221;) under PRC law &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntityThreeMember', window );">Shouantang Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntityFourMember', window );">Qianhong Agriculture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Operates the &#8220;Jiuzhou Grand Pharmacy&#8221; stores in Hangzhou<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntitySixMember', window );">Jiuzhou Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_JiuzhouClinicOneMember', window );">Jiuzhou Clinic One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntitySevenMember', window );">Jiuzhou Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005 &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#8217;s stores<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_EntityNineMember', window );">Jiutong Medical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Currently has no operation<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_ShouantangBioMember', window );">Shouantang Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology &#160; &#9679;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_JiuyiTechnologyMember', window );">Jiuyi Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_KahamadiBioMember', window );">Kahamadi Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_LinjiaMedicalMember', window );">Linjia Medical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017 &#160; &#9679;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_ShouantangClinicMember', window );">Shouantang Clinic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022 &#160; &#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Operates local clinics<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_JiuzhenHealthMember', window );">Jiuzhen Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022 &#160; &#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cjjd_HongtongServiceMember', window );">Hongtong Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Subsidiary of Limited Liability Company or Limited Partnership [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Background</a></td>
<td class="text">&#9679;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160; &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160; &#9679;&#160;&#160;&#160;&#160;&#160;Daily service<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#8220;Owners&#8221;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#8217;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#8220;VIE&#8221;) under the accounting standards of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State in which the subsidiary of the limited liability company or limited partnership was organized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_RenovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_RenovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntityTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntityTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntityThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntityThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntityFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntityFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntityFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntityFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntitySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntitySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_JiuzhouClinicOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_JiuzhouClinicOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntitySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntitySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntityEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntityEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_EntityNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_EntityNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_ShouantangBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_ShouantangBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_JiuyiTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_JiuyiTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_KahamadiBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_KahamadiBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_LinjiaMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_LinjiaMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_ShouantangClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_ShouantangClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_JiuzhenHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_JiuzhenHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cjjd_HongtongServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cjjd_HongtongServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869191425872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl', window );">Voting ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Forest land use rights impairment</a></td>
<td class="nump">$ 148,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_VATPercentage', window );">VAT percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and promotion costs</a></td>
<td class="nump">$ 304,075<span></span>
</td>
<td class="nump">$ 491,684<span></span>
</td>
<td class="nump">$ 355,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents benchmark percentage of voting ownership interest for control and common control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_VATPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>VAT percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_VATPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188098000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Major Source in each Segment - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 154,541,077<span></span>
</td>
<td class="nump">$ 148,811,976<span></span>
</td>
<td class="nump">$ 164,392,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">75,678,470<span></span>
</td>
<td class="nump">83,351,768<span></span>
</td>
<td class="nump">84,228,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Prescription Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">25,269,177<span></span>
</td>
<td class="nump">27,212,994<span></span>
</td>
<td class="nump">28,503,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | OTC Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">31,542,597<span></span>
</td>
<td class="nump">32,358,339<span></span>
</td>
<td class="nump">35,658,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Nutritional Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,890,985<span></span>
</td>
<td class="nump">8,737,519<span></span>
</td>
<td class="nump">9,664,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | TCM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,405,979<span></span>
</td>
<td class="nump">9,719,653<span></span>
</td>
<td class="nump">5,353,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Sundry Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,129,647<span></span>
</td>
<td class="nump">1,082,168<span></span>
</td>
<td class="nump">1,544,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Medical Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,440,085<span></span>
</td>
<td class="nump">4,241,095<span></span>
</td>
<td class="nump">3,503,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">31,857,883<span></span>
</td>
<td class="nump">32,385,089<span></span>
</td>
<td class="nump">30,219,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Prescription Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,151,412<span></span>
</td>
<td class="nump">10,606,244<span></span>
</td>
<td class="nump">10,331,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | OTC Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">12,969,313<span></span>
</td>
<td class="nump">13,870,953<span></span>
</td>
<td class="nump">11,473,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Nutritional Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,284,556<span></span>
</td>
<td class="nump">2,740,253<span></span>
</td>
<td class="nump">2,014,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | TCM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">571,769<span></span>
</td>
<td class="nump">434,920<span></span>
</td>
<td class="nump">315,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Sundry Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,448,537<span></span>
</td>
<td class="nump">1,129,701<span></span>
</td>
<td class="nump">2,271,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Medical Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,432,296<span></span>
</td>
<td class="nump">3,603,018<span></span>
</td>
<td class="nump">3,814,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">47,004,724<span></span>
</td>
<td class="nump">33,075,119<span></span>
</td>
<td class="nump">49,944,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member] | Prescription Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">30,784,949<span></span>
</td>
<td class="nump">21,617,636<span></span>
</td>
<td class="nump">41,116,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member] | OTC Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11,323,730<span></span>
</td>
<td class="nump">10,289,987<span></span>
</td>
<td class="nump">7,903,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member] | Nutritional Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">741,883<span></span>
</td>
<td class="nump">310,909<span></span>
</td>
<td class="nump">424,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member] | TCM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">388,396<span></span>
</td>
<td class="nump">458,502<span></span>
</td>
<td class="nump">241,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member] | Sundry Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">692,101<span></span>
</td>
<td class="nump">64,422<span></span>
</td>
<td class="nump">93,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug Wholesale [Member] | Medical Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RetailDrugstoresAbstract', window );"><strong>Retail drugstores</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,073,665<span></span>
</td>
<td class="nump">$ 333,663<span></span>
</td>
<td class="nump">$ 164,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_RetailDrugstoresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_RetailDrugstoresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_PrescriptionDrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_PrescriptionDrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_OTCDrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_OTCDrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_NutritionalSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_NutritionalSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_TCMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_TCMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_SundryProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_SundryProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190165648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Reconciliation of Cash Equivalents and Restricted Cash - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Schedule of reconciliation of cash equivalents and restricted cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,149,806<span></span>
</td>
<td class="nump">$ 18,807,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">12,724,365<span></span>
</td>
<td class="nump">12,762,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 32,874,171<span></span>
</td>
<td class="nump">$ 31,570,644<span></span>
</td>
<td class="nump">$ 35,339,577<span></span>
</td>
<td class="nump">$ 34,672,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869186974192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses as of March 31, 2022</a></td>
<td class="nump">$ 7,642,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit loss expense</a></td>
<td class="num">(3,836,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending allowance for credit losses</a></td>
<td class="nump">3,806,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses as of March 31, 2022</a></td>
<td class="nump">2,313,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit loss expense</a></td>
<td class="num">(1,389,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending allowance for credit losses</a></td>
<td class="nump">923,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cjjd_OtherReceivablesMember', window );">Other Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses as of March 31, 2022</a></td>
<td class="nump">5,329,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit loss expense</a></td>
<td class="num">(2,446,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending allowance for credit losses</a></td>
<td class="nump">$ 2,882,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cjjd_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cjjd_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188067744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">35 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Motor vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office equipment &amp; furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Motor vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office equipment &amp; furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cjjd_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cjjd_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188422528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_LandUseRightsMember', window );">Land use rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription', window );">Estimated useful life of intangible assets, description</a></td>
<td class="text">Infinite<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_LandUseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_LandUseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869192903664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Insurance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,600<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits totaling</a></td>
<td class="nump">$ 32,247,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,558,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Insurance not covered</a></td>
<td class="nump">$ 79,600<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869317433024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Trade Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Accounts receivable</a></td>
<td class="nump">$ 56,170<span></span>
</td>
<td class="nump">$ 50,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869197686608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Receivables (Details) - Schedule of Trade Receivables - Trade Accounts Receivable [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
<td class="nump">$ 16,747,769<span></span>
</td>
<td class="nump">$ 16,412,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(923,666)<span></span>
</td>
<td class="num">(2,313,306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">15,824,103<span></span>
</td>
<td class="nump">14,098,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Note receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">$ 15,824,103<span></span>
</td>
<td class="nump">$ 14,119,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869193201984">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets (Details) - Schedule of Other Current Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ScheduleOfOtherCurrentAssetsAbstract', window );"><strong>Schedule of Other Current Assets [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rental expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 513,170<span></span>
</td>
<td class="nump">$ 530,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,374<span></span>
</td>
<td class="nump">85,397<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 569,544<span></span>
</td>
<td class="nump">$ 616,008<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ScheduleOfOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ScheduleOfOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189317328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense for property and equipment</a></td>
<td class="nump">$ 693,537<span></span>
</td>
<td class="nump">$ 625,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869187036848">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,928,409<span></span>
</td>
<td class="nump">$ 17,118,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,355,233)<span></span>
</td>
<td class="num">(10,266,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AccumulatedImpairmentPropertyPlantAndEquipment', window );">Impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,666,587)<span></span>
</td>
<td class="num">(1,752,178)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,906,589<span></span>
</td>
<td class="nump">5,100,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,617,617<span></span>
</td>
<td class="nump">6,072,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,503,702<span></span>
</td>
<td class="nump">3,134,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cjjd_FarmlandDevelopmentCostMember', window );">Farmland Development Cost [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,656,357<span></span>
</td>
<td class="nump">1,741,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,729,499<span></span>
</td>
<td class="nump">5,811,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor Vehicles [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 421,234<span></span>
</td>
<td class="nump">$ 358,542<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AccumulatedImpairmentPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AccumulatedImpairmentPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cjjd_FarmlandDevelopmentCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cjjd_FarmlandDevelopmentCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190270080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investment (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InvestmentPercentage', window );">Investment percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InjectedFunds', window );">Injected funds</a></td>
<td class="nump">$ 1,113,650<span></span>
</td>
<td class="nump">&#165; 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentImpairmentLoss', window );">Impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,607,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_KahamadiBioMember', window );">Kahamadi Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InvestmentPercentage', window );">Investment percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Suffered loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_ZhuoliServiceMember', window );">Zhuoli Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InvestmentPercentage', window );">Investment percentage</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Suffered loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InjectedFunds', window );">Injected funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,443,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_SongluPharmaceuticalMember', window );">Songlu Pharmaceutical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InvestmentPercentage', window );">Investment percentage</a></td>
<td class="nump">0.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember', window );">Zhejiang Jiuzhou Digital Medicine Technology Co., LTD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InvestmentPercentage', window );">Investment percentage</a></td>
<td class="nump">25.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_JiuzhouDigitalMember', window );">Jiuzhou Digital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LongTermInvestmentDetailsLineItems', window );"><strong>Long-Term Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_InjectedFunds', window );">Injected funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_InjectedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_InjectedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_InvestmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_InvestmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_LongTermInvestmentDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_LongTermInvestmentDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_LongTermInvestmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term investment impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_LongTermInvestmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_KahamadiBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_KahamadiBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_ZhuoliServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_ZhuoliServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_EntityFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_EntityFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_SongluPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_SongluPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_JiuzhouDigitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_JiuzhouDigitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869187650688">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investment (Details) - Schedule of Long-Term Investment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,195,261<span></span>
</td>
<td class="nump">$ 1,772,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_KahamadiBioMember', window );">Kahamadi Bio [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_ZhetongMedicalMember', window );">Zhuoli Life [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,680,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_SongluPharmaceuticalMember', window );">Songlu Pharmaceutical [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">83,099<span></span>
</td>
<td class="nump">87,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_JiuzhouDigitalMember', window );">Jiuzhou Digital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">4,155<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember', window );">Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 1,108,007<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $0 and $0 in the year ended March 31, 2024 and 2023.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 39% investment in Zhejiang Zhuoli Life Service Co., LTD (&#8220;Zhuoli Service&#8221;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $1,443,752 into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $2,402,376 in the year ended March 31, 2023. An impairment loss of $1,607,537 was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was <span style="-sec-ix-hidden: hidden-fact-107">nil</span>.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 0.37% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#8220;Songlu Pharmaceutical&#8221;). The investment is recorded based on cost method.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 25.92% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $4,379 into Jiuzhou Digital. The investment is recorded based on equity method.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">It represents 8% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $1,113,650(RMB 8,000,000) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_KahamadiBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_KahamadiBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_ZhetongMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_ZhetongMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_SongluPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_SongluPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_JiuzhouDigitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_JiuzhouDigitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869297617392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Advances to Suppliers (Details) - Schedule of Advance to Suppliers - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems', window );"><strong>Schedule of advance to suppliers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AdvancesOnInventoryPurchasesGross', window );">Advance to suppliers</a></td>
<td class="nump">$ 1,177,399<span></span>
</td>
<td class="nump">$ 362,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AllowanceForAdvancesToSuppliers', window );">Less: reserve for vendor non-performance on advances</a></td>
<td class="num">(262,623)<span></span>
</td>
<td class="num">(219,630)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advance to suppliers, net</a></td>
<td class="nump">$ 914,776<span></span>
</td>
<td class="nump">$ 142,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdvancesOnInventoryPurchasesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer before allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdvancesOnInventoryPurchasesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AllowanceForAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the allowance for advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AllowanceForAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189925088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, finished goods</a></td>
<td class="nump">$ 16,248,373<span></span>
</td>
<td class="nump">$ 15,309,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserves inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189411760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Farmland Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssetsAbstract', window );"><strong>Farmland Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfRealEstate', window );">Impairment</a></td>
<td class="nump">$ 148,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings in the period to reduce the carrying amount of real property to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188805472">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Farmland Assets (Details) - Schedule of Farmland Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ScheduleOfFarmlandAssetsAbstract', window );"><strong>Schedule of Farmland Assets [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_FarmlandAssetsGross', window );">Farmland assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,176,079<span></span>
</td>
<td class="nump">$ 2,287,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ImpairmentsOfFarmlandAssets', window );">Less: Impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,541,926)<span></span>
</td>
<td class="num">(1,621,115)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Farmland assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 634,153<span></span>
</td>
<td class="nump">$ 666,721<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $148,795.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_FarmlandAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents farmland assets gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_FarmlandAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ImpairmentsOfFarmlandAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents impairments of farmland assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ImpairmentsOfFarmlandAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ScheduleOfFarmlandAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ScheduleOfFarmlandAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869194119232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Deposits (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAbstract', window );"><strong>Long Term Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Long term deposits</a></td>
<td class="nump">$ 1,119,006<span></span>
</td>
<td class="nump">$ 1,038,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869181381968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Noncurrent Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_OtherNoncurrentAssetsDetailsLineItems', window );"><strong>Other Noncurrent Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DescriptionOfLeasePrepaymentLife', window );">Description of lease prepayment life</a></td>
<td class="text">The forest rights certificate from the local village extends the life of the lease to January 31, 2060.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortization of prepayment</a></td>
<td class="nump">$ 3,009,922<span></span>
</td>
<td class="nump">$ 3,195,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_LandUseRightsMember', window );">Land Use Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_OtherNoncurrentAssetsDetailsLineItems', window );"><strong>Other Noncurrent Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortization of prepayment</a></td>
<td class="nump">$ 18,477<span></span>
</td>
<td class="nump">$ 19,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_DescriptionOfLeasePrepaymentLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_DescriptionOfLeasePrepaymentLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_OtherNoncurrentAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_OtherNoncurrentAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_LandUseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_LandUseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190338128">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Noncurrent Assets (Details) - Schedule of Other Noncurrent Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ScheduleOfOtherNoncurrentAssetsAbstract', window );"><strong>Schedule of Other Noncurrent Assets [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ForestLandUseRights', window );">Forest land use rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 639,414<span></span>
</td>
<td class="nump">$ 691,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_Others', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,023<span></span>
</td>
<td class="nump">98,519<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 682,437<span></span>
</td>
<td class="nump">$ 790,056<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ForestLandUseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forest Land Use Rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ForestLandUseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_Others">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of others assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_Others</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ScheduleOfOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ScheduleOfOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869187404192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Noncurrent Assets (Details) - Schedule of Amortizations of the Prepayment for Lease of Land Use Right<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Amortizations of the Prepayment for Lease of Land Use Right [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 18,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">18,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 547,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190053760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost (in Dollars)</a></td>
<td class="nump">$ 7,487,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">lease term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189629776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for operating leases</a></td>
<td class="nump">$ 7,487,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_OperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">13,827,360<span></span>
</td>
<td class="nump">$ 13,924,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">4,862,766<span></span>
</td>
<td class="nump">5,131,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">6,403,858<span></span>
</td>
<td class="nump">$ 7,768,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 11,266,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term Operating leases</a></td>
<td class="text">3 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_OperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_OperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190096576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of Lease Liabilities Under Operating Leases<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Lease Liabilities Under Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 5,294,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,872,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,913,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,107,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">448,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">621,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">12,257,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(990,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 11,266,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869188397808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 96,912<span></span>
</td>
<td class="nump">$ 92,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869192357296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of Net Intangible Assets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,771,764<span></span>
</td>
<td class="nump">$ 4,946,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,155,807)<span></span>
</td>
<td class="num">(1,114,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill', window );">Less: impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(606,035)<span></span>
</td>
<td class="num">(637,159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,009,922<span></span>
</td>
<td class="nump">3,195,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,305,998<span></span>
</td>
<td class="nump">2,354,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_SapSoftwareMember', window );">Software [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,115,192<span></span>
</td>
<td class="nump">1,172,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember', window );">Land use rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 1,350,574<span></span>
</td>
<td class="nump">$ 1,419,936<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#8217; business and liquidate all of the stores&#8217; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#8217; health.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2013, the Company purchased the land use rights of a plot of land in Lin&#8217;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#8217;s farming business in Lin&#8217;an has not grown, the Company does not expect completion of the plant in the near future.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_SapSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cjjd_SapSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_UseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869178124480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 06, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 06, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Bank notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,676,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#165; 228,712,642<span></span>
</td>
<td class="nump">$ 29,255,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,247,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,558,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit total</a></td>
<td class="nump">$ 5,540,000<span></span>
</td>
<td class="nump">&#165; 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes Payable to Banks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Bank notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,680,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cjjd_HangzhouUnitedBankMember', window );">Hangzhou United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Bank notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,255,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#165; 200,916,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,657,839<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">91,393,395<span></span>
</td>
<td class="nump">12,217,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">83,905,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Bank credit line facilities available for borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,250,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cjjd_HangzhouUnitedBankMember', window );">Hangzhou United Bank [Member] | Notes Payable to Banks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,160,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,501,198<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#165; 32,500,000<span></span>
</td>
<td class="nump">$ 4,732,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#165; 32,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Bank credit line facilities available for borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,910,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cjjd_HangzhouUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cjjd_HangzhouUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869183843488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - Schedule of Credit Facilities with Banks<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th" colspan="2">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31,676,335<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#165; 228,712,642<span></span>
</td>
<td class="nump">$ 29,255,776<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 10/19/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Oct. 19,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Apr. 19,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,289,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 10/20/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Oct. 20,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Apr. 19,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,403<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 11/17/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Nov. 17,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">May 17,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,576,213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 12/16/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 16,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 16,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,565<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 12/26/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 26,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 27,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 12/28/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 28,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 29,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,654,696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 01/16/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jan. 16,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jul. 16,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,545<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 02/27/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Feb. 27,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Aug. 27,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,242,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 03/20/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 20,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 20,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,573,664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 03/23/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 23,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 23,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 10/12/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Oct. 12,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Apr. 12,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,126,621<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 11/21/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Nov. 21,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">May 21,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,703,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 12/22/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 22,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 22,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6,040,374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 12/27/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 27,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 27,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 274,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 12/28/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 28,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 28,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 151,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 01/03/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jan.  03,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jul.  03,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 102,713<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 01/11/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jan. 11,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jul. 11,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 248,086<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 02/06/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Feb.  06,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Aug.  06,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,189,602<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 03/13/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 13,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 13,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,274,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember', window );">Jiuzhou Pharmacy [Member] | 03/14/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 14,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 14,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 969,489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 11/17/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Nov. 17,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">May 17,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 12/16/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 16,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 16,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,704,790<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 12/21/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 21,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 21,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 12/29/22 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 29,  2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 29,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215,854<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 03/20/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 20,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 20,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803,817<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 12/27/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 27,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 27,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 415,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 12/28/23 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Dec. 28,  2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jun. 28,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,689,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 01/11/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jan. 11,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Jul. 11,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,234,494<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 02/06/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Feb.  06,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Aug.  06,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 186,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 03/15/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 15,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 15,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 415,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 03/28/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 28,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 28,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 293,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember', window );">Jiuxin Medicine [Member] | 03/29/24 [Member] | Hangzhou United Bank [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuer', window );">Endorser</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">HUB<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_DebtInstrumentIOriginationDate', window );">Origination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 29,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Sep. 29,  2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 359,179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_DebtInstrumentIOriginationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Origination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_DebtInstrumentIOriginationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the contractual issuer of the debt instrument (for example, a subsidiary of the reporting entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cjjd_EntityFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cjjd_EntityFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cjjd_HangzhouUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cjjd_HangzhouUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cjjd_EntityEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cjjd_EntityEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cjjd_OriginationDateThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cjjd_OriginationDateThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869182911456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LoanPayableDetailsLineItems', window );"><strong>Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Short-term bank loan</a></td>
<td class="nump">$ 276,997<span></span>
</td>
<td class="nump">&#165; 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cjjd_LandUseRightsAndPropertyOwnershipMember', window );">Land Use Rights and Property Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LoanPayableDetailsLineItems', window );"><strong>Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 11.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cjjd_LandUseRightsAndPropertyOwnershipMember', window );">Land Use Rights and Property Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_LoanPayableDetailsLineItems', window );"><strong>Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_LoanPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_LoanPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cjjd_LandUseRightsAndPropertyOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cjjd_LandUseRightsAndPropertyOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cjjd_LandUseRightsAndPropertyOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cjjd_LandUseRightsAndPropertyOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190083056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(52.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Not deductible for PRC income tax.</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(52.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189209488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Statutory rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income not recognized in the U.S.</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign', window );">China income taxes</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses-permanent difference</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(52.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(52.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190324880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Postretirement Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Postretirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Employment benefits and pension contribution</a></td>
<td class="nump">$ 1,325,312<span></span>
</td>
<td class="nump">$ 1,284,218<span></span>
</td>
<td class="nump">$ 1,301,315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869187783520">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions and Arrangements (Details) - Schedule of Balances with Related Parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 313,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,833,509<span></span>
</td>
<td class="nump">683,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cjjd_HangzhouKahamadiBiotechnologyCoLtdMember', window );">Hangzhou Kahamadi Biotechnology Co., Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,825<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Due from related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">280,521<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">253,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=cjjd_DirectorAndCEOMember', window );">Due to a director and CEO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 1,580,057<span></span>
</td>
<td class="nump">$ 683,560<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lend to related parties</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical borrowed from its non-controlling shareholder.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to foreign exchange restrictions, the Company&#8217;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cjjd_HangzhouKahamadiBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cjjd_HangzhouKahamadiBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cjjd_DirectorAndCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cjjd_DirectorAndCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189643328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholder&#8217;s Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th"><div>Jun. 03, 2020</div></th>
<th class="th"><div>Apr. 15, 2019</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder&#8217;s Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds of private placement (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,222,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184,861<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,743,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184,861<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,000<span></span>
</td>
<td class="nump">15,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_AggregateSharePercentage', window );">Aggregate share percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 616.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_StatutoryAccountsPercentage', window );">Statutory accounts percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ReserveFundPercentage', window );">Reserve fund percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder&#8217;s Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder&#8217;s Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued per share (in Dollars per share)</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds of private placement (in Dollars)</a></td>
<td class="nump">$ 3,366,000<span></span>
</td>
<td class="nump">$ 2,737,000<span></span>
</td>
<td class="nump">$ 1,530,000<span></span>
</td>
<td class="nump">$ 2,589,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholder&#8217;s Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_AggregateSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of aggregate shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_AggregateSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ReserveFundPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserve fund percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ReserveFundPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_StatutoryAccountsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of statutory accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_StatutoryAccountsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190338128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted earnings per share</a></td>
<td class="nump">1,024,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of diluted earnings per share</a></td>
<td class="nump">2,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869197074640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Basic and Diluted Earnings Per Share - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract', window );"><strong>Schedule of Basic and Diluted Earnings Per Share [Absttract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to controlling interest (in Dollars)</a></td>
<td class="num">$ (4,234,228)<span></span>
</td>
<td class="num">$ (21,138,525)<span></span>
</td>
<td class="num">$ (3,192,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in basic computation (in Shares)</a></td>
<td class="nump">1,444,263<span></span>
</td>
<td class="nump">509,828<span></span>
</td>
<td class="nump">173,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants', window );">Diluted effect of stock options and warrants (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in diluted computation (in Shares)</a></td>
<td class="nump">1,444,263<span></span>
</td>
<td class="nump">509,828<span></span>
</td>
<td class="nump">173,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share &#8211; Basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest', window );">Net loss before noncontrolling interest</a></td>
<td class="num">$ (2.93)<span></span>
</td>
<td class="num">$ (41.46)<span></span>
</td>
<td class="num">$ (18.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest', window );">Add: Net loss attributable to noncontrolling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss attributable to controlling interest</a></td>
<td class="num">(2.93)<span></span>
</td>
<td class="num">(41.46)<span></span>
</td>
<td class="num">(18.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Loss per share &#8211; Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest', window );">Net income before noncontrolling interest</a></td>
<td class="num">(2.93)<span></span>
</td>
<td class="num">(41.46)<span></span>
</td>
<td class="num">(18.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest', window );">Add: Net loss attributable to noncontrolling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss attributable to controlling interest</a></td>
<td class="num">$ (2.93)<span></span>
</td>
<td class="num">$ (41.46)<span></span>
</td>
<td class="num">$ (18.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding before noncontrolling interest during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding attributable to noncontrolling interest during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding before noncontrolling interest during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding attributable to noncontrolling interest during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869189933632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other Operating Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_SegmentsDetailsLineItems', window );"><strong>Segments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Main reportable segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_SegmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_SegmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190673952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details) - Schedule of Segment of the Continuing Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 154,541,077<span></span>
</td>
<td class="nump">$ 148,811,976<span></span>
</td>
<td class="nump">$ 164,392,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods</a></td>
<td class="nump">123,432,529<span></span>
</td>
<td class="nump">114,531,512<span></span>
</td>
<td class="nump">127,873,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,108,548<span></span>
</td>
<td class="nump">34,280,464<span></span>
</td>
<td class="nump">36,519,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">27,385,587<span></span>
</td>
<td class="nump">29,177,163<span></span>
</td>
<td class="nump">30,876,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">7,257,524<span></span>
</td>
<td class="nump">15,668,684<span></span>
</td>
<td class="nump">8,187,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">148,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,360,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,534,563)<span></span>
</td>
<td class="num">(20,925,383)<span></span>
</td>
<td class="num">(2,693,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">790,449<span></span>
</td>
<td class="nump">718,002<span></span>
</td>
<td class="nump">1,256,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CapitalExpenditureContinuedOperations', window );">Total capital expenditures</a></td>
<td class="nump">856,665<span></span>
</td>
<td class="nump">304,016<span></span>
</td>
<td class="nump">299,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">75,678,470<span></span>
</td>
<td class="nump">83,351,768<span></span>
</td>
<td class="nump">84,228,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods</a></td>
<td class="nump">53,056,339<span></span>
</td>
<td class="nump">56,551,607<span></span>
</td>
<td class="nump">57,290,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">22,622,131<span></span>
</td>
<td class="nump">26,800,161<span></span>
</td>
<td class="nump">26,937,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">21,680,509<span></span>
</td>
<td class="nump">23,644,339<span></span>
</td>
<td class="nump">25,186,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,195,153<span></span>
</td>
<td class="nump">13,803,165<span></span>
</td>
<td class="nump">6,766,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,253,531)<span></span>
</td>
<td class="num">(21,007,343)<span></span>
</td>
<td class="num">(5,163,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">754,448<span></span>
</td>
<td class="nump">686,777<span></span>
</td>
<td class="nump">1,234,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CapitalExpenditureContinuedOperations', window );">Total capital expenditures</a></td>
<td class="nump">855,497<span></span>
</td>
<td class="nump">303,312<span></span>
</td>
<td class="nump">296,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">31,857,883<span></span>
</td>
<td class="nump">32,385,089<span></span>
</td>
<td class="nump">30,219,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods</a></td>
<td class="nump">28,249,883<span></span>
</td>
<td class="nump">28,506,228<span></span>
</td>
<td class="nump">26,621,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,608,000<span></span>
</td>
<td class="nump">3,878,861<span></span>
</td>
<td class="nump">3,598,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">4,770,855<span></span>
</td>
<td class="nump">4,266,799<span></span>
</td>
<td class="nump">3,972,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">466,151<span></span>
</td>
<td class="nump">439,667<span></span>
</td>
<td class="nump">285,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,629,006)<span></span>
</td>
<td class="num">(827,605)<span></span>
</td>
<td class="num">(659,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CapitalExpenditureContinuedOperations', window );">Total capital expenditures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember', window );">Drug wholesale [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">47,004,724<span></span>
</td>
<td class="nump">33,075,119<span></span>
</td>
<td class="nump">49,944,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods</a></td>
<td class="nump">42,126,307<span></span>
</td>
<td class="nump">29,473,677<span></span>
</td>
<td class="nump">43,961,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,878,417<span></span>
</td>
<td class="nump">3,601,442<span></span>
</td>
<td class="nump">5,983,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">934,223<span></span>
</td>
<td class="nump">1,266,025<span></span>
</td>
<td class="nump">1,718,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,596,220<span></span>
</td>
<td class="nump">1,425,852<span></span>
</td>
<td class="nump">1,136,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">2,347,974<span></span>
</td>
<td class="nump">909,565<span></span>
</td>
<td class="nump">3,129,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">36,001<span></span>
</td>
<td class="nump">31,225<span></span>
</td>
<td class="nump">22,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cjjd_CapitalExpenditureContinuedOperations', window );">Total capital expenditures</a></td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 2,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cjjd_CapitalExpenditureContinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element refer to capital expenditure continous operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cjjd_CapitalExpenditureContinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cjjd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_DrugWholesaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869192683600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details) - Schedule of Net Revenue from External Customers through its Retail Drugstores by Main Products - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Prescription Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">$ 25,269,177<span></span>
</td>
<td class="nump">$ 27,212,994<span></span>
</td>
<td class="nump">$ 28,503,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | OTC Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">31,542,597<span></span>
</td>
<td class="nump">32,358,339<span></span>
</td>
<td class="nump">35,658,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Nutritional Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">9,890,985<span></span>
</td>
<td class="nump">8,737,519<span></span>
</td>
<td class="nump">9,664,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | TCM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">3,405,979<span></span>
</td>
<td class="nump">9,719,653<span></span>
</td>
<td class="nump">5,353,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Sundry Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">1,129,647<span></span>
</td>
<td class="nump">1,082,168<span></span>
</td>
<td class="nump">1,544,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Medical Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">4,440,085<span></span>
</td>
<td class="nump">4,241,095<span></span>
</td>
<td class="nump">3,503,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember', window );">Retail drugstores [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">75,678,470<span></span>
</td>
<td class="nump">83,351,768<span></span>
</td>
<td class="nump">84,228,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Prescription Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">9,151,412<span></span>
</td>
<td class="nump">10,606,244<span></span>
</td>
<td class="nump">10,331,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | OTC Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">12,969,313<span></span>
</td>
<td class="nump">13,870,953<span></span>
</td>
<td class="nump">11,473,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Nutritional Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">4,284,556<span></span>
</td>
<td class="nump">2,740,253<span></span>
</td>
<td class="nump">2,014,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | TCM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">571,769<span></span>
</td>
<td class="nump">434,920<span></span>
</td>
<td class="nump">315,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Sundry Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">1,448,537<span></span>
</td>
<td class="nump">1,129,701<span></span>
</td>
<td class="nump">2,271,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Medical Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">3,432,296<span></span>
</td>
<td class="nump">3,603,018<span></span>
</td>
<td class="nump">3,814,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember', window );">Online Pharmacy [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">31,857,883<span></span>
</td>
<td class="nump">32,385,089<span></span>
</td>
<td class="nump">30,219,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | Prescription Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">30,784,949<span></span>
</td>
<td class="nump">21,617,636<span></span>
</td>
<td class="nump">41,116,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | OTC Drugs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">11,323,730<span></span>
</td>
<td class="nump">10,289,987<span></span>
</td>
<td class="nump">7,903,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | Nutritional Supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">741,883<span></span>
</td>
<td class="nump">310,909<span></span>
</td>
<td class="nump">424,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | TCM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">388,396<span></span>
</td>
<td class="nump">458,502<span></span>
</td>
<td class="nump">241,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | Sundry Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">692,101<span></span>
</td>
<td class="nump">64,422<span></span>
</td>
<td class="nump">93,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | Medical Devices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">3,073,665<span></span>
</td>
<td class="nump">333,663<span></span>
</td>
<td class="nump">164,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember', window );">Wholesale [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue from external customers</a></td>
<td class="nump">$ 47,004,724<span></span>
</td>
<td class="nump">$ 33,075,119<span></span>
</td>
<td class="nump">$ 49,944,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_RetailDrugstoresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_PrescriptionDrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_PrescriptionDrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_OTCDrugsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_OTCDrugsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_NutritionalSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_NutritionalSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_TCMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_TCMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_SundryProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_SundryProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cjjd_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cjjd_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_OnlinePharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cjjd_WholesaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139869190022896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 11, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Apr. 29, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares of restricted stock awards (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of ordinary shares (in Shares)</a></td>
<td class="nump">1,980,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Aggregate gross proceeds (in Dollars)</a></td>
<td class="nump">$ 3,366,000<span></span>
</td>
<td class="nump">$ 2,737,000<span></span>
</td>
<td class="nump">$ 1,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M6Y*!4A55VDX)Q[*5:%1S&K7C-(M2E@815*GN.'(BI9!D*J2L9/'++&;SQEF
M_XJ-[7[-=K\=VYL%2#,P2Y8L?4&*B,/9:+F.$48'13I)5:1>0#<4EZ5W$*VP
M9)I#[9JG@ 7Q#E4T=T.RW99S( A$#C33N>[A-&0R;*2%PWW:N]DC[R>3*XP<
M->0HBG8ZG5V321Y&"L;91"F>J5(\]#AK9(?C63O4.(&+ZO9X C4+RXFQC0H.
M8*5B--YM*?)77$8BU":J!U>CWEN@:M\LC!-C9[3?;2G^LR@+0#WN.)-D!B>S
M1GXXF(V5$7ZWI?)7K*K2;>>%P\WN,%9&_]TAFB]JE6B?+ES4!MX8+USC#BXN
MW!7CM;%#02]9TCSR<*#I OQEYTQTSP0YEOD<LBKPW85:!'L84^,,+J[E%=,I
M=+J$#C^%I/E,?N4OC5QQ*,=QW%%_X(RPL4B--]!6WC"+8DXN\^2^.4);0(!2
MUW>&Z/2@QA0HKN+U0 R$!.LLAN)N:?RD<'PP"@G%%&%C7]O0]S&2QAPH+N:5
M=WXE+)CV6>"Z7<?K>BY&S;@#Q<6]JM_O$$*ZCZE80=KE+!,I#\EIEN5;>AC'
MO!08->,6%)?XBMIG$4,?PM*Y&'>R4?0L2#@A8Q 4U_3UQ*QZL\QJ50I1S6IL
M0<2C$34F07%5KYA]E24;Z> P-J>GQA\H'NHWE (F(0SSN9#-C'"<2Y%V61!P
M@ &0L 3$&!H_H*W\X"3A<J[[\#T@J 5:O/^V,J#& .A^&W.="ACV01&68$*F
M/+9:+$7=X(T6ZQE[\%K9PR0, 1T<L?I "M8?TT:ILT!>\_0Y2LD=^RO'*!J[
M\%K913/%VY5HI(A#'N51'.H1U(> +<!S,&/SC&=XN,CC3!>2-Y<3!WTOM%HM
M<G*L0U 4*(SJQEY3*P^IJ4[U$13B%NRDD20.]X&E\W\6(B]P,(+&2;Q63F((
MEJF@D1N.-+W$"!DG\5HY24WH2L!R,29_1,NM2<6"Z+F0]488.6,FWJ"-_)S#
M$(%AG=FW#5%3>:OJ&*OQ<(NXC13$4?% 7/KC_4\07X)<?C-P*J8XTD<)\U@'
MC7(;=I<L(:<]L3CGY'MGC_ID"696?(<1-P[DX89Q*UFA&S<OR;V(&_E:5B)G
M9\<8$V,X'KY,6->,G#P'"YA]?.O:R )T.;DYGOR&;0<;,_%;F0GX<5)LP8K@
M$7)]T3'D8ZXRO?$#U6O<*BZ1^P6R?C[S-':'ON<-Z$'OJ8F4L0_?IO49G $5
M7GOSEPNNET&-\P+'>NM^NC$0G_X_*<)'/>2MO(V;^+C\?TMXVV"T )WS:.<\
MPG*#O_%TXG4.TB;:6"#+:+-CB3:^\13_=9[2)MI8(%\5;7QC,'ZKU<HKHXT%
M]#71QC?FXK=:Q[2.-A:X=;39L40;WYB(WVH9TR;:6)#0:.,;+_%;[5Z])MI8
M$*W1IF],I>^TT<2KA8"1-F//U2Z6/>/T4;-ZHR;VC>_T<=\IAMU$<K:UAA:
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M0UPN=4=:Y\^!56$0<OU"XT[&:5%J5X5"MS+]5@/<1^?I/-E$T%O3D=$_$ 6
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M  "N"@  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U66V_3,!3^*U9
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M@DNT9X1ZDXD_[$\GO?Y(1,I#KB>"YDY\;]O?[ LHR+PN4=I8KIH02#2G,E\
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M2@L!^/MC N7J[I?B OO7W\[_#U!+ P04    " "X@/Y836338 P5  #41@
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M@<!-2.0:PY^-1AZ*D5OC4O#(TJ'J16[!]DS!$YR/I:#9-((T%1@S>A'.S<P
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M<VSD"\>B#Z?;-%8FN#D=']<I>U$/]\50>=//: 1]:%+Z":;J4T")G&OH!2:
M#/!+1QE6Z84_"FV\ 6;$!*XJ%R21S?VZ?I[B,/BE$1KXOZ"C82IJS8^.^*O^
M)UO&YI=*ZN7F]U[ T&? )-A_"H\.^J?'>Z;=Z+Z4<DF_6S*1)3";/LX%AXH)
M%\#]J03/8;_@!OZ';%[^!U!+ P04    " "X@/Y8OX#.Z(<F  "8<P  &
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M0ID'=IV!AT\F$^KYI&C6]:;)[)B0-!9RLDA,452JZ1);FJ.V D!DJ[TF0UF
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MH02+#HR5FNF."+<!FQV-;B"+P##96;Q.+%X_G1*% U,\#)T$  [,4#.\>6$
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MS A-^@@D8>@FZF ^LG@//>*F3 /'#B0L<99R.UME[]4 0U')UF 8&\A8ZRN
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MDA%I6,9L'&"O/"VB&FM1U.#B5O;Z -X3X:.'-P+N]T;MO_%>(8P<3?XC;-^
M(,%T/&CIJ\-PN. T+B2=-HO-!HUO<%!LA7?[P@-5 T3W5FURS%DN)IIG)V+;
M..N\.$%5BI]N^I&C^XHBP]W2;"DR%Q 0R%BK"O)-(CGH*S+O;VIT@^W3+EBB
MXLO@1;L?7K"%$<9VX&B[&R$+!A%?I]F6',O$4,S^D!5'+6*>@[CH8:W-'C@S
MZ"UH[E$YZ>[<RF[(X>HD=TEF?JLE80^<2N 46C MX ALGKCE@9$J\IKJ4E[2
MM-5 PW+/S4E\(87!U,X]B8B2QF9[7H(4SITN IH;>9Y*ZF.=,T6$K=MH[1,U
MYT(1%B..^7A,I,PEZAX.J.*^NJV)W<4\4[3#KQH<<G_Q \M\ASR\8257TL5=
M1F^4!3^#$]&OQ< "8  7ZB;ESA7PM7-']D6B,S+],\H1"^])5MS;-T$C"4D*
M_K[&7UFXN(FI?*([(UU+Q,W4XFC#G-9H7(R6QEJ\\BGW0MU0\T;_H6T*?\L^
MN>U;C9X)]<.6B+;-DSZ6>*U [B62-?WJA>MK?-OSCOW:NCN.OVAQ;D4I !NF
M=KVM30M K[EU=4Z,>'P@LI6[MTGX1]2>:2/B1V 8"N[7<5<@IC" %%K)T@+3
M=;W$VS]W:8&7=+SKC:UW]UZ+NRILHP,DW$93A+K5SCN3-(]1N[(+K":[P[@'
MDRV'>_8%K<)IFZ]];ZQ,RBU%*+E%CY,NW$N0!SCVF\EP2A7PZIOI:A3.EZS"
MOYG,9O!X>5(+\;6+-Z&Y!D4][L57(Y@"4U#F2LQ(9Z72K--N ?#J=)U)S6VR
M(Q9QV6MI6/G5Y'(MZ2WXU6 "B:,>2W/([%3CF.*ESH_O).#'1:Y= O:0#_A9
M9?@-T&!_EN<'VTSA+_W>B+NHV/N[-YBF82N9G!>,W+'Z-SZR_6H#AIT@RNT8
MUOFH<Q"7Z]1NY..[U[8MHE?/$]N?^@#KB"(GXCISP]#V[]^8K;3C" ;!@LXS
MKAA&^.IS^Z7T&+7K%U1[2L/SJVSO)S;%0$AAD171/3=2:973D_)U'-969\)G
MMJY=RN-+;>F%4R(1!I:W)TL_U%,_N'259*&58(;!T>#LQY#MZ&_3CP*PN58@
M0-I&2L;9HY9K^),/'&^1*'Q@+4*_>,S^$I,LTL*8;3ALK;%3A'@7PTN6_Y>V
M'NVD>2N:3#[_/?#+!K8QZ=D?@FI==_32O-+#&JBQU#O\!;\[YSK?GA"%;:-E
MZWHU%5E*:([;M5)CI3/>##M#;:2,%$@"/-K% 'AMHH#96+IZ7\T'R_EBCE]U
MY2+I;Z$S#UN!;3MM^EKV$:U')H;4D''/WX[L;*0-_6B^&)U 'S#TLU$O]!\U
M=9;P?\:N+/("'<Z3WS>P8L_['0[;*5I^6D5ZCK$GPJ%6BD_BKS(U-;UYQ*R%
MZ4\;]OOES2'AN$RZ\7MT8U$C14NH32K_T(V+3/*DPAO!7_M1N('J^WF]Y]ZO
M)>YUN:7?A*RXRHQ_.-$^5>9G)R_YUQ;=Z_R;E7",6[1I,[V!H</!8O:$H\;F
M0UT<Z+<7UT5=%WOZ<Z<CL"_Q!?A^4Q2U^8 +V!_C?/6_4$L#!!0    ( +B
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MPZXB7\L2 4MY30KZH X >;5JC8S.;U( W6X%#?. :C2Q<NVJVBG=2G*4,_6
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M965T<R]S:&5E=#$R+GAM;)64WV_:,!#'W_M7G-*IVB36_.1'*42"CJE[:(N
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ME=?]>9_EHN!MY3[I]1^BXS,AO$Q7UO_/UD$W@7+66J?KSA@1U%*%7_[4Y>'
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MX$KJ'TO\#2 ,*>!]H7$!Z0[D8/=7Q<W_4$L#!!0    ( +B _ECLH[+L00<
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MT+OHKI 6KWVH*##GG0Q#V3TO&]&YO0Q.M0&<;0Q7&4RL:WS@9&UNF@W*E2'
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M-GF;C8>1^F<@Z/PA>^J&->I=?Y%E&W_)IYL+* HWX?W;_>\(%^'Z?! //T+
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MU6]M 6,8'LUX%,,"3*9%AG-7?^8?'N @^ R5A#%-H)Y0,4FAQ4$X? C>>3_
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M2H)IR #OUS6$HW] !>/'LIO_ E!+ P04    " "X@/Y8F,2[4"$#  !Q!@
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M6-$W 8T_0/M;33793?P+^J_,_!=02P,$%     @ N(#^6)8JHM;F!   S0T
M !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULQ5=M;]LV$/ZN7T&H2]$
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M63S^NV:*]RW09(#CB<)#8/U!$[0WN.G?4$L#!!0    ( +B _EA4<C/O^ (
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M6%5Z95DI2SKEESE]&% [ [I?*^J[_<8%:#XUHW]02P,$%     @ N(#^6)Q
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M8SPSMI>9PH7_:=O,/9H.*:N=-V5<# 2ETLU?\3GRT%MPDKRP8!H73 /NQE%
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M/ 'OEP;WV/B#'73?L"Y_!5!+ P04    " "X@/Y8J[=T).4$  !"#   &0
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MRJ220RHQ<Y].P:%TVK.Z#8J7.PFH[7O)O^ABU]N .A,E"K6F@%L3]Z>4?Y*
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M:,A'PQ?H_5I3Y^\VK&#XMV'Q'U!+ P04    " "X@/Y8.>0]I54*  ""&0
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M3-V:D3;@^86U?K.@ [9_=CG^#U!+ P04    " "X@/Y8O*[I;V4$  "_#0
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M/_?\?'<Q#U$KY)W* 32ZKTJN%CC7NCXG1*4Y5$Q-1 W<[&R%K)@V4[DCJI;
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M,TW2<@A)]X<T/B!L@="92I$?[HKL#BCI")H)B%'INRAKB+9@08D&] "M,;\
MXY)PW0)B</$B:/%6F58?F4I+?4_8EQLP/;%FW\M!BIL$*RMY-H][S;L*K!0/
M52!@ %,D1)KR!(BI>'"SH$-4X2C$XDE(RCU1!3,77"=QWT092"O@QSUS?,B[
M^N^T^1WV2+T_1& :H*)D48&3];(CC0=R 68P]/$LM,/< -FG,3UH+MT"J:=
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M$N\AG@7E5\10@MD+%EW-?$&,U8!C@YX)D$5@A,!%O,XL7G\Z)PH'IKAA.@D
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M7RA4:#07;X^)1[L*@>&T!:ZK^_4$=[[<%%7RHP:'_!V6$ZM'ASP\*"R=523
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MU>())X_,C[HXT9?-MT5=%T?Z\Z C<!KP ;B_*XK:_, )[+?N7_TO4$L#!!0
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MK%K\7DKMD<7[,L(:>!#_\>CZDEG%O@O#AI*LY($L0^<KTK!I25@67,8O@28
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MFW#['$/Q*$U;;E.#YJ<6*+#Z['ZA3L(!B"\I',&._95JG\H\6G2_5,SR7.&
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M 9>R& G*:0+/D7\!-OT"0-C#JD.!EK7:#RZVIP@[CTB6 \PP!0<23)#H,$Q
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M.3$NX$*H6FS\U"[ (JOV83C?N9HW2B_=#Q"&N:HRW-*GU>DWCK/A:K_=/OQ
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MR-^[7&X A[L!;=<<ZXHE>-JAMM"HOF)G^OI5,/;?[J$[;.D.]Z%/;ZD+T[I
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MN2\W#T96[HYZ+PW=>-TRI[\8J*P O<\DC?35@S70_FF9_@M02P,$%     @
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MM=J#=MJ$Y@0?JK<F<ERZHCQ83;><[.SR5UNAAE^4S+=:H[1P8PQ: ]\^LI5
M\]T\M.3%Z89YBWC;(":O(,8)?%;25@9^D 46+P%"HM=Q3(X<;Y.KB)^9'L P
M[D,2)>D5O&$7\]#C#?]GS'_>K(S5U"=_78JZP4PO8[K9F9D-RW$1T' 8U#L,
MEF_?Q./H_17&:<<XO8:^?*!9++8"097P"OM+E*^#-D#R!,2:-.2*1LY8+)PW
MTH%2"9I=+M>S'I4BKWPM.JE'TX'&@F"R@*U!T&X0S#OX!L;#:3^-4R=-X_YH
MF/6\3P/IL!\E0YA.^J-XVGM4E@FG-$GZZ3 C*9M&_6@TAG?P2/XIH1MVJ!U%
MVD(@D*;0<2LO.@9N:$ *!*N @5 Y8:_5#K7T"%RZ &6[%/;<5L DT)+3S%*(
M#5KC@JTUHC,:>!K^AL#;=(F#<UHX-SFM +YC%N$G+I_6"BP9FL:J)=ERRU%;
M7O+<Z99:U3Z_#<<=%X+6(."S15F8YH:7>*Q"PXF\?61R2_NSG8AQ-+C28*.N
MP4;_N<%N:D4D_V$N0>;H_?YE#3X=:_#))>4KR7Z=7VK"JXXOSXW+VYVJ-TP>
MWKZ9)''VW@"[Q.K4&;T7G?&R)3QCIRXIMU#2*P '9-2&3LLU)++2TB@P334W
M;;N;6>\/KT3%<'UQZGS*SY8<NF5$K1I/^FF6N=/H3!Z?R=F9/#G*CR>WHS2C
M:9C"I3*&9YN]1KWV[Y<;46+0+/GN:_=$WC0OPTF]>5\I@#6GU DLR30:9%08
MW;Q9S<&JC7\G5LK2J^/%BIYYU$Z![DNE[/'@''3_."S_!5!+ P04    " "X
M@/Y80'+U3=0#   ?"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-
M5DUOXS80O?M7#-1ML0LHT;=DI[:!).VB!;)HL,EV#T4/M#2VB*5$+4G%27]]
MAY2C.(GC]I!80W+>O!G.TVB^E>J;KA$-W#>BU0NO-J8["P)=UM@P?2H[;&EG
M+57##)EJ$^A.(:N<4R.". SSH&&\]99SMW:MEG/9&\%;O%:@^Z9AZN$"A=PN
MO,A[7/C,-[6Q"\%RWK$-WJ#YTETKLH(1I>(-MIK+%A2N%]YY=':1V?/NP)\<
MMWKO&6PF*RF_6>/W:N&%EA *+(U%8/1SAY<HA 4B&M]WF-X8TCKN/S^B?W2Y
M4RXKIO%2BJ^\,O7"FWI0X9KUPGR6V]]PEX\C6$JAW7_8#F>SQ(.RUT8V.V=B
MT/!V^&7WNSKL.4S#-QSBG4/L> ^!',M?F&'+N9);4/8TH=D'EZKS)G*\M9=R
M8Q3M<O(SRRNDE#2\OV4K@?K#/# $:K>"<@=P,0#$;P!$,7R2K:DU_-I66#T'
M"(C-2"E^I'01'T7\Q-0I))$/<1BG1_"2,<7$X27'4_SK?*6-HB[X^U"2 T1Z
M&,(JXTQWK,2%1ZVO4=VAM_SIAR@/?SY",!T)IL?0ES>DM*H7"'(-PI(]1/ _
M(/JN$TAB,4Q R70-:Y(;\':0[: @P0Q68.001 /M@:D1'I I0'M[0+4OZ['X
MP#4P>TX0F#Z;7%K@CO'*N;)&]JW1%*04O77FK8-K"+U7CLR8$0C.5EQPPY%P
M_NA0$:EV\T15/^'*<7?'\QT4?CJEORR?N+?&B5R?] 3*M$8B(%>&WCX# ;PO
M:]9NT"$-H>5*\(VKP;/0._ 3>+ET]G(%U(&@[R!*_&E<^$D>PF6OE$VWD\K5
MFM)^D<5^ <@W]:=Y[!=Y#E>RW9P85,U1C]Q/0PJ73>%6VBL^CAY%?ISG?DXW
M^-6]EJ@V[(X\J"YT,52L)T\7^E55DM-9XOI"OT:HN"[MS0.Y(*2G4_CQB BR
M4039_Q:!4RQ<[>7TA;I3[=$<-'U()T>C'!;R;8V['K?0QKX)=T.*_T.Q74\S
MTRMN'HC=Y'7%>\?N5=^2="B9YY+:Z\#)QQ?ZLZY/IX<4)^24T95F?CQ+_:*(
M[$(.L3\M8C\N0FL6$/DSZL9XEEES2F84%GZ1)=:<09I.J7W"">5)<WM--PYY
M'/EA1DNNFX:,.O9@-:LA(N2L\+-D-KE"37K@3=<;IR_R16W@_6P64L@,/CQ#
M>+,+#_5'L#>T&E0;-YHUN-8:YM>X.D[_\V'H/1T?/AVH:!O>:F*Q)M?PM* F
M4,,X'@PC.S<"5]+00'6/-7W!H+(':'\MI7DT;(#QFVCY+U!+ P04    " "X
M@/Y8+D<=?OT&  #A$   &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6S=
M6%USV[82??>OP*B=3CS#2M2WY=J><9RV229I72N]]Z'3!XA<B9B0  . 5M1?
MW[,@*5&.[73ZV!<+)!>+LV<_X8NML1]=1N3%YR+7[K*7>5^>#P8NR:B0KF]*
MTOBR-K:0'H]V,W"E)9F&344^&,7Q;%!(I7M7%^'=K;VZ,)7/E:9;*UQ5%-+N
M7E)NMI>]8:]]<:<VF><7@ZN+4FYH2?[W\M;B:;#7DJJ"M%-&"TOKR][U\/SE
MA.6#P/\4;5UG+=B2E3$?^>%->MF+&1#EE'C6(/%S3S>4YZP(,#XU.GO[(WEC
M=]UJ_RG8#EM6TM&-R?^O4I]=]LYZ(J6UK')_9[:OJ;%GROH2D[OP5VQKV?&D
M)Y+*>5,TFX&@4+K^E9\;'CH;SN(G-HR:#:. NSXHH'PEO;RZL&8K+$M#&R^"
MJ6$WP"G-3EEZBZ\*^_S5&^VEWJA53N+:.?).O/@@\>1.+P8>^EEJD#2Z7M:Z
M1D_H&H[$>Z-]YL2/.J7T6,$ P/;H1BVZEZ-G-;Z7MB_&PTB,XM'D&7WCO;7C
MH&_\CZW]XWKEO$5L_/F8O;6VR>/:.%_.72D3NNPA(1S9>^I=???-<!;_\ S6
MR1[KY#GM5TOD7UH!J5D+C>S\ OMC@)]5^3C@7Z!;'73+FI?$(.^<IY2/]QF)
MM<F1P$IO3J0_/X%CDBQX9K\Z>:<2)"N)%\-3\:T81>-X&BT69_5Z.HFFX\G)
MTJS]5EH(C4[%,!H.I]%P,>+5?!1-9M.3=U*GHH(6R^F$:!RSW'@:1]/Y!*O)
M<!$MQK.3#\;+_!'<DV@^'T;SV02KQ60&6>@DY\Z1_TE55+EDFV1AK%=_R5 8
M7N#TZ30ZB^?B-#P,)U$\.A.GS495E%)9%"(O7DP@,8MG43R>LO!L/,?>!43?
M/$02!:=]*\91' /R:!36P\4TFD_. D<?,N50UX(G-* 'EG&2N)=Y12WO><VJ
MXV>E766E3G!&6>(#)ZI(;;5!F8 6F/BI4A;VK:TIA(0BJ\CO>&M'RE5PF'1B
M*74FC;C-)*I;LA/,O*-[LB V-PG^UAOZ0-K!(3D.1 GN:M0&ZYU8[> U1$<'
M8R)M"G%_I*9%BA"PI(I595V+EZU]7152BSMRIK)L)B M3:* 94E)916,>46E
MM#ZX W:]!NM_9:82-_C61Y*@5,!_0=F-@>?T[D#+ XLC4+3G12096EC0L*32
M4[$BR[KF3^AJF=)H/(U1:)%!MJQL:=S>@^\KK1)5L@VU*>\I54SO74M ,.:W
M2N9JC0\A*&\( 1J>F+E?M7@K=86N*1:A&,9/H)*-Y[XPB[G?2W6"(2')#H R
M!%[][KMOSD;#^0]BQ0Y%!@0OY I[4Z!A_[>6'<LCP4S%(2'7'MR]555PS"&^
MVN.QM0A$U[7C8,X#U")#E*;*.9/?LVV H;@T=:@16X(T"KAV:[)!N>FZA(<7
MWNIKO+* ,&:*<#J_V9&T@KA;'0H9 QH^P>\:<2DXSH\3;YLI[,WD/8D5D3ZP
ME39D^)9^I]B]_2_9@81NX893.E9LE<^:(HP/W8I0>WMC$(LZ1%'1Q-8A#>U1
ME)76;*PLODK 4RGD,TOTWV" 6Q#28A>*46D5AE*5!QAB>7TK?KR[%6Z'%EC4
M5*#"XPC4]!NT596(5TINM$&3%!_(8C+C>AG$0Z &\C)K:DG'60:"->;< **6
M;.L5:LR6:O* &HTMKU,90S:7U"X21A:JY<\X%)[IAS< (:$BS[__J,U68T!\
M<!*WU)2+-._A0N4K36(:QVCT[&'%5>:-9T4KXC.;#LG]_SYXC]W.P>+8^2"5
M,[$!*VN'!ELXE1^Q17.K?H*^90<ALA?C&.E-'0SPM5RIG,L^]QFR? L1)@PV
MJ RMACKX"K0A0+.!ZR)4D3 _ [Y#5 4JV37R.<<\ +,BS\%;\QEV%]B)F S8
MBM E]@4P(YG[K!]F%I#QMD(TP;OCXU1"=T!U:XJNR!_,.XAH*<K<A.86/J(.
MOE.Z.4/J:-_RHL!I2-VV\Q (7^7*96U[!/$9V14'?8)2SA24T,H37YU.E:\L
MRN%KL^5^%O%<T ';G(K6)CG$-X>>\ !5*-4:J#>8<O6QP:FA^AM]+G$7"Q&7
M4^AR31\Y@J2Y(K6X>.#Z2J5ZT J)IZ=0=_[U]-0 *:7SX<:''*C?H!>%%H<W
M:/"*[Y.8<EQ63VQ]\0IC&X*F;HU6)1PZG<IT % :G+_;.P&QA/+V"?V==P#J
M&@>AG@23#R9VYT+7L2VT24HX*=(^+@>((-B#:^DQ,Y828],F&P\S[== \/E]
M\=B%9M"Y=B++-N%RS5<'4%3?0/=O]_?WZ_K:>A"O+__PZ ;TH.2ML37NSZ>]
M.B/:!V_*<(E=&8^4#DND6TJ6!?!];8QO'_B _7\UKOX&4$L#!!0    ( +B
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M(4 R$B.?;JK>AXR"0!*34(I,3/K8]4C?N+!B,^C!G!\#Y",@#P":4NAS-@6
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MELZ0[9]3_<";=7S"W!D/#Z(H5O "U38HP/\K [R'07"P>]/._P902P,$%
M  @ N(#^6.VER]?P @  @P8  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULC55=3]LP%'WOK[C*U FDD31IR[:NK00,-!Z8$(7M8=J#F]PT%HZ=V4Y;
M]NMW[:2A3*S:2VS?C^-S;-^;Z4;I1U,@6MB60II94%A;3:+(I 66S(2J0DF>
M7.F265KJ560JC2SS2:6(DL'@-"H9E\%\ZFVW>CY5M15<XJT&4Y<ETT_G*-1F
M%L3!SG#'5X5UAF@^K=@*%V@?JEM-JZA#R7B)TG E06,^"\[BR?G(Q?N ;QPW
M9F\.3LE2J4>WN,YFP< 10H&I=0B,AC5>H! .B&C\:C&#;DN7N#_?H5]Y[:1E
MR0Q>*/&=9[:8!1\"R#!GM;!W:O,%6SUCAY<J8?P7-FWL(("T-E:5;3(Q*+EL
M1K9MS^%_$I(V(?&\FXT\R\_,LOE4JPUH%TUH;N*E^FPBQZ6[E(75Y.649^?W
M;(L&CN[94J YGD:6,)TG2MO\\R8_^4=^G,"-DK8P<"DSS%X"1$2F8Y3L&)TG
M!Q%OF YA&+^#9)",#N -.X5#CS<\J/#'V=)836_@YVL:&X31ZPBN+B:F8BG.
M GKX!O4:@_G;-_'IX-,!?J..W^@0^GQ!=9;5 D'E<"U352(09;C5:LW]TV<6
M;(%PA1EJ)F!AF:VMTD]PQRP"DQE<YCGZU^U-KPD\3.&,RBM5,N6",U\K1,5M
MR1LZENA4>W1ZSI>W=$Q'1^_H.#=VE+R9&V &<B6H"9A)CPK*1STATX#NX?3<
M;;LK'[I/TGL(%^&>5 =B((G# ?1?#@Z+2D_NR$IEO9J5Y+\Q(ZO?R,,=^8SC
MO\?>1<$EVQ/K=AJ3I_M0!),K=QZP9J)NSH@Y+4RF2#CC%N_%V/NJY E)J^D<
MJ+H M]1)#9J3"JF=2)06,D['I-&#Q.'8Y<;A1S>,DW!$$,\WZR[!'V43V&\C
M^[O0_FM/,=IK#"7JE6]_!E)52]OTB,[:==BSIK$\AS?MF<IRQ:4!@3FE#L+W
MXP!TT_*:A565;S-+9:EI^6E!?PG4+H#\N5)VMW ;=/^=^1]02P,$%     @
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M?(+C] 1&@YQ9)/DYG$VR07Z6= [ <<;\\FPPSM.>W6@PR5@F^9'7>^F L;?
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M>,X3R70SJ]LXW80YL=*.ITY85CSFR7@!OE]K+L;]QAOH_SC,_P%02P,$%
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MG)"N*/=6TU=!=G;S"]7]9V4,W*&&^YIKA%>?^*Y!<[-*+#EP:DDQ@&T#&+L
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M-<U\U$Z!OE=*V:/@')S^16S^!E!+ P04    " "X@/Y87:J:D, '   J$@
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MGUP #G['"2"O% GQD@)//<XG#?NU5-NS7I@\9[B0[DELHJ!$3,?L.,&5C("
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M& =#N\YO R[; 4DT/RY34::.-F#]JFV'W8 NV+\>.OL?4$L#!!0    ( +B
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MY:Z;2-:RN*__MV/Y/ST...H><'/(]+Y^R*^+CV?K8Z*ZJ+X79U>;3V/PCZX
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MJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF64UHZ>9AH
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M9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF64U@Z2I@!]+"PB%-R\VW=.%/%
MO2]<HW7GJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ)91
M6CN2FKKS\6,-XUO>V(L^Z1W55%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5
M0E2+4"U&M0354E3+**V=34W]^UA<__Y7;[U"'R2/:NI.>W6&%714'=4,5#-1
MS4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+:.T=L(TU?3C$YXW_Q=OXD)+
M[%%-W6FOS-B"CJFCFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:IE
ME-;*F$E3.C\1/YF>OGM /%S?P$$U=:>)[UG0T#%U5#-0S40U"]5L5'-0S44U
M#]5\5 M0+42U"-5B5$M0+46UC-(> ^>\OBN*I9HO\ZL/]T5U6WPNYO-:NBY7
MB^7F=MX7[TI5\74=2/+[WY2S\X/W=?F](7>\;\GOG:[W7?F]U_5^)+^/N]Y/
MY/?I]OWS9C&O/CSDMX675[>S12W-BZ_K11Z\FX[/I&IV>_?\P[)\6!^FG$E?
MRN6RO-^^O"ORFZ+:-%C__FM9+I]^V SPHZR^;3^6J_\'4$L#!!0    ( +B
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M96P#O=K+^^!]!NBX9= "_&\P\H"SSRLHW< -QI=E=M.AK(=S^<*!W]_=?]]
MU9'&)!,M!?0(E;%:6F7?9G-N[YHT=UT(^->H?W,^N5CJ/S ",H;[T[NJ"V:-
M+F7?C--_Z&SW:.4K7=3./TWB6=O,2A;3[=S;"JG0UGJ]CTD*F#>MP3Y8-Y./
M6B\JRIB<F_<W*6(ZMWKI2W.U>4?4N7DSTKWK%^[)I;ONNG=RN>[^\T/GY!((
MQ+I?FM=0C:Q)U4NLKJB<<TBH*9N!><[!(:R-9/5>J.I+(1;FU4I3410B,Q\3
M1J'_]0WP^TS K%M_T0TT;^<Z^R]02P,$%     @ N(#^6* [HI,9 P  &PL
M !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULK99=;]HP%(;_BI5-4R=M
MY).0=A )RJ;MHAHJ:W<Q[<(D!V(UL3/;0/?O9SLA YIF1>,&;.><]_@\_CK#
M+>,/(@.0Z+'(J1A9F93EE6V+)(,"BQXK@:HO2\8++%67KVQ1<L"I<2IRVW.<
MT"XPH58\-&,S'@_96N:$PHPCL2X*S']/(&?;D>5:NX%;LLJD'K#C88E7, =Y
M5\ZXZMF-2DH*H((PBC@L1];8O9I&VMX8W!/8BKTVTIDL&'O0G2_IR'+TA""'
M1&H%K/XV< UYKH74-'[5FE834CONMW?JGTSN*I<%%G#-\N\DE=G(BBR4PA*O
M<WG+MI^ASJ>O]1*6"_.+MI5MZ%LH60O)BMI9S: @M/K'CS6'/0<W?,;!JQV\
M8X?@&0>_=O!?ZA#4#H$A4Z5B.$RQQ/&0LRWBVEJIZ8:!:;Q5^H3J99]+KKX2
MY2?C>;7<B"W1G*PH69($4XG&2<+65!*Z0C.6DX2 0!=3D)CDXBUZC^[F4W3Q
M^NW0EFH.6LE.ZGB3*I[W3#S70S>,RDR@CS2%]%# 5I-O,O!V&4R\3L4;S'O(
M=]\AS_&"E@E=O]S=;W&?OMS=Z\C&;];#-WK^_Z_'C_%"2*X.SL^V9:C"!.UA
M]&5R)4J<P,A2MX4 O@$K?O/*#9T/;0C/*38]D]@!WJ#!&W2IQ_?,,&1;"EQD
MI$2$2E!A9!O"2LIUC):^/S>QT^L/[<T^FLYXIZ(YD]@!FGZ#IM^)YFO#I 2>
M )7JUF^CTG]*Q3UBTAGH5"9G$CM@$C9,PDXFZFE1>P/EF*9H+0!Q_8H(1(H2
M$ZX>O]9M4TF&^WR":'!YO'$Z(Y\*Z4QB!Y &#:1!]YD:?_O'EAFT'237/P+2
M&>54(&<2.P 2-4"B3B#C= -<$J%O&KUS2LX*9JJ<A DIV@A%3_:,[P3.X'C/
M/#4++MTP"@[-IBUJ_;XSB!JS*BU[KVPH@*],^260>6FJ][<9;2J\L2ELCL8G
MJO*K"K6_,E79J)['%:$"Y;!4DDYOH$XSKTJQJB-9:8J3!9.JU#'-3%6OP+6!
M^KYD3.XZ.D!3#\=_ %!+ P04    " "X@/Y868)X2B8)  !L3@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,RYX;6RU7%V3XK@5_2LNDDKM5B6#OFU/NJF:
M:265/'2V:YC-/J3RX 8U.&ML8IONG:K]\2L;!B%;%GA\]Z4;P[U'UD$''U\N
MNGLKRI^KK5)U\,LNRZO[V;:N]^_G\VJU5;ND>E?L5:Y?>2G*75+KPW(SK_:E
M2M9MTBZ;$X3$?)>D^6QQUS[W5"[NBD.=I;EZ*H/JL-LEY9>/*BO>[F=X]O6)
M3^EF6S=/S!=W^V2CEJK^<?]4ZJ/Y&66=[E1>I44>E.KE?O8!OY<B;!+:B'^G
MZJVZ>!PT4WDNBI^;@W^N[V>H.2.5J57=0"3ZWZMZ4%G6(.GS^/\)='8>LTF\
M?/P5_>_MY/5DGI-*/1393^FZWM[/HEFP5B_)(:L_%6__4*<)\09O5615^S=X
M.\6B6; Z5'6Q.R7K,]BE^?%_\LN)B(L$+ 82R"F!=!/80 (])=!;$]@I@;7,
M'*?2\B"3.EG<E<5;4#;1&JUYT)+99NOIIWGSOB_K4K^:ZKQZL3R^WT'Q$BS3
M39Z^I*LDKX,/JU5QR.LTWP1/19:N4E4%WTE5)VE6?1_\)5CJ];<^9*K)^Z1>
M57Y0P?.7X#'Y7U$&R^)0KE20YH%*5MM@J39ZH=0ZZ\>E#+[[X_=W\UJ?>3/^
M?'4ZRX_'LR0#9XE)\%CD];8*_I:OU=H&F.LIG^=-OL[[(_$B/B;ENX#B/P<$
M$>8XH8?;TZDC7=Z>3CRSH>=WD;9X= #O4_O.!.ORL-$KIE25B^(C!'-#-)\O
M[ZM]LE+W,_T!4JGR5<T6?_H#%NBO+GH@P200F$4=.U/'?.B+ST6=9/H3K%W#
M+MJ.Z:)-;SY%7Q>8,\XP"L.[^>LE)XY(%D48QZ&P(Z4C4C :$\[Y.=*:#3_/
MAGMGTUL(P7\>U>Y9E?]U3<V+-79%0())(#"+0W'F4$P7DX"D#A), H%9U(5G
MZL)I8CJF\XN%'W(11BQ$'2WU R-*.0Y%U)&2(Y 1$K&8N)44G:<2?:.2@E^#
M)WV\*M-]:UUD$^+5F7>DL8L%$DP"@5D,QV>&X^DZBR&I@P230& 6=1@9VX:F
M*>V4?RD,PHF(<>^RY8H,"29QS#I:<T5&'%$24;?8\(4-Q=\NMQ\^/]R@,O\(
M8]<**)J$0K/9)89=,EUJ)PPH_B#1)!2:S9^QU]AK06]0&^TI@VJ;2'C<4YLC
MDE"NKVYQ5VV.2"YX% DVH#;C>;'?]'K5]J]#7:;-E4U/>7G8[S/5W+Y=T9YW
MO-%K!Q)-0J'97!M'CCF ]D"M."B:A$*S^3-N''L=ZPW:$SV=Q%&,XHAWI=</
MC$(:<MQ3G@-1"(9"/" \XX^QWR![A??YX=$O,B_VZ$4"B2:AT&Q>C5G'$8#(
M0'TX*)J$0K/Y,U8<>^WJ#2*+^Q<CAO3E+>Z*K!\8AS@6G'9%U@_DE-,8(;?(
MB/'&Q.^-O2);'O)U^47?P17KP^K*5<T_SM@% XHFH=!LCHU?)WBZX BH(P=%
MDU!H-G_&D1.O8[TNN%/^I3RPOB<3K&LH78$H(KA7*7$%<L;$A?&T)V/L,?';
M8Z_@'M4Z7>FY2O6:KJX4)/WCC%XPH$5J*#2;8V/9"0,0'*@-!T634&@V?\:&
M$W]E_+K@>$\>C#&$>C;2%4@81C'O"JX?2#FB(1TH\A/CB8G?$__0/A,\;9-R
MEZR^^#4%6JH&19-0:#:-QHV3$$!3H*X;%$U"H=G\&==-_#7RZYJ*'&61B(=1
M1+NB<D02&G$4=6_.7)&(X)@.E46(<<'$[X*'9#6^XN\?:/2B 2U<0Z'9WU0;
M=TX1P'?5H,X;%$U"H=G\&>=-_97RJZ([Y5MW8)ACADE'<XY C 02A'4+_\Y(
M2K'@ ]^R46.$J=\(>S1W6]G?CS]ZJ8"6K:'0;&XOND(@VD)@^T)@&T-^#\]-
MC>>F$WM#3OF6+O0]6DQQ]_KFBJ11J$UCMR[BBL0LI)=?W-GS,1Z8^CVP1VO?
M4O3WCS9ZY8 6K:'0;*:-0:< /204U)F#HDDH-)L_X\SIQ$82VN_[8"1BG(NN
M\/J!)&2(]'7G"$28(3Q0]*?&)E._3?;([EK)WX\\>HF EJRAT&Q6C5FG .TC
M%-2'@Z))*#2[[='X<#:Q@X3UNSUXB$/1K?@[XAAE,>FT=$E'',6<T %],>.(
MF=\1>_0UIMKO'V7L6@%%DU!H-L/&I#. _A$&:L1!T204FLV?,>)L8O\(Z_=Z
M8,8B3GL]QHY ;3E#A+MJZP<2$F*$!JK][*)AVN^*/7(;4^OWCS)ZN8#6JJ'0
M;(:-3V< +2,,U'V#HDDH-)L_X[[9Q)81UF_PH(P2?>O6E9LC4""*</?+-5=@
MA!M+.B W8X69WPHW%9#@IVV1J2K)E%]2H*5J4#0)A6:S:#PX V@08:!N&Q1-
M0J'9_!FWS28VB+!^.P<+$6(A85U-.5I)* HY[O5AN3#CF#$1#US$N'&_W.]^
M!U0UOM+O'V?TCVA *]50:#;'QI=S@!X1#NJZ0=$D%)K-GW'=?&*/".]W=&@A
M12QFW7LT1R3!0M_,T>Y/TQR1#&.L)3=PG\:-"^9^%SRLN=LJ_7[XT4L%M%(-
MA693:SPY!^@.X:".&Q1-0J'9_%W\;')B=PCO]W)@3 D-:?>7:ZY(1*(XCL*N
MU/J188QH1 8\(S<&F/L-\+#2OJ7.[Q]L]+H!K5-#H=E$&W/. 3I(.*@M!T63
M4&@V?\:6\XD=)+S?[1$RW.\?<<11C&+4M92..$88P0--Q]P89.XWR,.2NU;C
M]P./7AZ@-6HH-/N'V,:E"X!>$0'JP$'1)!2:S9]QX&)BKXCH-W90+:Y>'<01
MQWC$4:>E1#KBB)8KB=SR$L8+"[\7'I;7F!*_?Y#12P6T1 V%9A-LS+D Z!41
MH X<%$U"H=G\&0<N)O:*B'Y?AXCUA0=WI>:(8XSTE-8/BRFE0T(S3ECXG?"P
MT,84]_V#C%XHH,5I*#2;X(O=12"V%X'=7P1V@Y'?PW(+8[G%Q-:04_[E[CH4
MA52(;B._*Y#JN&YGB",."\915VOSBVVX=JK<M-N954&[D]9Q9ZKSL^<MTSZT
M&X5UGO^(W\OCQF<&YK@/VV-2;M*\"C+UHB'1NU"OY?*XM=GQH"[V[69?ST5=
M%[OVX58E:U4V ?KUEZ*HOQXT YPWF%O\!E!+ P04    " "X@/Y8J8KU9>@"
M  #K"0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RM5EUOVC 4_2M6
M-DVMU#;?">T@4EN8MH=)"-3M8=J#22Y@U;&I;:#[][.=- LT953B)?''/2?W
MGN/8[F^Y>)1+ (6>2\KDP%DJM;IQ79DOH<3RBJ^ Z9DY%R56NBL6KEP)P(4%
ME=0-/"]Q2TR8D_7MV%AD?;Y6E# 8"R3798G%GSN@?#MP?.=E8$(62V4&W*R_
MP@N8@GI8C87NN0U+04I@DG"&!,P'SJU_,XI-O WX06 K6VUD*IEQ_F@ZWXJ!
MXYF$@$*N# /6KPW< Z6&2*?Q5',ZS2<-L-U^8?]B:]>US+"$>TY_DD(M!T[/
M007,\9JJ"=]^A;H>FV#.J;1/M*UC/0?E:ZEX68-U!B5AU1L_USJT '[T!B"H
M <&Q@+ &A,<"HAH0'0N(:X MW:UJM\(-L<)97_ M$B9:LYF&5=^BM5Z$F74R
M54+/$HU3V;1:'XC/T90L&)F3'#.%;O.<KYDB;('&G)*<@$1G0U"84'F.+M%4
MK]=B3<'@)I!SEA-*L+5>C]QCN42CIS798 I,2819H<.D$B174%3SE^AA.D1G
M'\_[KM*%F'3<O$[ZKDHZ>"/I[UA<H="_0($71!WP^^/A80=\>#P\Z("/CH?[
MNW!7F]<X&#0.!I8O?,O!EA7BE16YD1KVK!#_K+#SOVYG>D#_L[^[O*@^'W5_
MWNQC-W*%<Q@X>J.2(#;@9)\^^(GWN<N94Y(-3TDV.A'9CH=AXV%XB#VS/X1Q
M9M^N+C\JJL12F6-@DP6>'UWWO*3O;MI:OP[T>STOO0[W H<'DWNOCB<BV]$Q
M:G2,#NHXV5W87>I5!'%;E" -HC")]]3K#$R"U.OMJ7<PI?>J=R*R'?7B1KWX
MOZOPXJ@=HTO8^-5J"X->&OFIOR=L1Z ?IUX217O"=@3&87@=I^ENX*@C,$K2
MH,U8">*V#DIS#=)[\8(PB2C,-=2[2C63J*X654?QE3T[9USID]@VE_HV!L($
MZ/DYY^JE8X[CYGZ7_0502P,$%     @ N(#^6&">32UA P  R0T  !D   !X
M;"]W;W)K<VAE971S+W-H965T-34N>&ULW5=-C],P$/TK5D ()-C$3NJF2QMI
M/P42*U9; 0?$P4VFC45B%]MMEW^/G:1I@#0'1 ]P:6W'\^;-\]AC3W=2?=4Y
M@$&/92'TS,N-69_[ODYS*)D^DVL0]LM2JI(9VU4K7Z\5L*PR*@N?! 'U2\:%
METRKL7N53.7&%%S O4)Z4Y9,?;^$0NYF'O;V P]\E1LWX"?3-5O!',R'];VR
M/;]%R7@)0G,ID(+ES+O YY>8.H-JQD<..]UI(Q?*0LJOKO,VFWF!8P0%I,9!
M,/NWA2LH"H=D>7QK0+W6IS/LMO?HMU7P-I@%TW EBT\\,_G,BSV4P9)M"O,@
M=V^@"6CD\%)9Z.H7[9JY@8?2C3:R;(PM@Y*+^I\]-D)T# @Y8D : U+QKAU5
M+*^98<E4R1U2;K9%<XTJU,K:DN/"K<K<*/N56SN3S.O50'*)YGPE^)*G3!AT
MD:9R(PP7*W0O"YYRT.CY-1C&"_T"O4)SFQW9I@!G=Z,-M_+8&;<;LU& ;A[7
M5G/(T#NIM1VVXC=X&CU "GS+%M:4B0R]-SFHSJ">^L9&Y;CY:1/!91T!.1(!
M)NA."I-K=",RR'X&\*T<K29DK\DE&42\8^H,A?@E(@&)T(?Y-7K^],4 ;MAJ
M'5:XX3^B-?K\SC)$;PV4^DN?\'4X47\X[KPXUVN6PLRS!X(&M04O>?8$T^#U
M@%A1*U8TA)Y<%/; 8"(%9(\>E"K(N$%%'2333@N[3&F^7R?2Q[_V0"L/[GC:
M)F,:D7%$I_ZVA]JHI38:I'9U((/ ZB\T]'FO048=[Z_".*01)OWN:>N>#KJW
M:>YRA1T7J(\-_8U-& <T#*-^,N.6S'AXF7J2[?,=E M0O2DUB/:'*16W7./_
M:__%)Q!KTHHU.?G^F_R6<R3$81@<V7\X.!2MX&_LP ;EIRV(PWA"H^ (@T[9
MQ"?8A UHE]"$A)0>$X0<Z)!!.CVY-; )A\'^,+'PH0SB_ZP.XE,40GRHA/CT
MI;!QT<V\44@FT=&=<"B&^*]40]Q3#DD4T?'X2#G$AWJ(3U$0&]#N[8#$,:$T
M_H6/W[E=EZ!6U1M"HRJYZHMV.]J^4R[JV_EA>OW(L>NTXD*C I;6-#@;6SE4
M_6ZH.T:NJ[OZ0AI[\Z^:N7UK@7(3[/>EE&;?<0[:UUOR U!+ P04    " "X
M@/Y8L;^Y?VH#  "P%   &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6S5
M6&UOVC 0_BM6)E6;M#5Q>"EM :DOFU:I:*BHVX=J'TQR :MVG-H.M-)^_.P
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MGLI(2[-*C9WNCQ:G@42"1G22TH1&)-7H(HI$GFJ:3M!0,!I14.C]-6A"F?J
M/J&144><,[!VGY6FAAZ(T;V")&?HUO"L[,I0&O5(_8(NTAA]?LII9LY3=WUM
M@-OP?K0$>;D &;X"<D#D,6K@CR@,PN:?YK[)MTPZ+),."W_-5_Q=YI3%)C>%
M'@; QR!_;L+D]&'?EC.5D0AZGGD=%,@9>/VC=[@=G#L0-DJ$C<)[X_\Y%O1P
M:T"@&PU<;>2C40,?S9*/IO/$JF3R13)LE4RV2H:89,"E,7>$1@N] )'* ;95
M@FTY70UH2GG.2W&A7^@6S"_'5+ 846X0S\""=,O/&6-'NMME!NV#DU^[!CY.
M2CY.:I>?.T)CJ_HZ)=;.6]4W$%I(-(,IC1BX5>?TO2/+IR7RTX-3W6D-?."@
M*LY![;K;$F*[\/!:+X'?*KUOB3E%J!"B(\*S<Y3D,J4ZE^ 4HSO<KNQ770(.
M#TZ/N(ZN!%=M"796^?T(TAWB+P19=0W87=0'Y'D/E=@=9%?.JVX"MPY/AG5T
M)[AJ3["SVN]'ANX0.-BNPZI]P.[JOD&';ZC);N>[DEWU$[AS>/JKHT_!5:."
MG75_/_ISA]C^=R2LVHC07>,WR.^?ZK([W([LAU6;$>*#$V181ZL2KEUHN&\T
M]B'(+2$<@O37[I_L7=Z R E-%6*0&%?!\8FI%G)Q/;:8:)$55U)CH;7@Q7 *
M) 9I-YCU1 B]FMA;KO*2LO\;4$L#!!0    ( +B _EA%VH<NS0(  ,H*   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;-56:VO;,!3]*\*#L4%7/_)J
MN\20M!T+I! :NGTH^Z#8U[:H+'F2W+3_?I+L.!DD&I06UB^V7O?HG*MKZXPW
M7#S( D"AIY(R.?$*I:H+WY=) 266I[P"IF<R+DJL=%?DOJP$X-0&E=2/@F#H
MEY@P+Q[;L:6(Q[Q6E#!8"B3KLL3B>0:4;R9>Z&T';DE>*#/@Q^,*Y[ "=5<M
MA>[Y'4I*2F"2<(8$9!-O&E[,0AM@5_P@L)%[;62DK#E_,)UY.O$"PP@H),I
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M09@ /;[D7+UV3%'3E-7Q'U!+ P04    " "X@/Y8>#/20D("  "2!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RM5$V/VC 0_2M66E6[4HOS!50T
M1.*CU?:P$H)N>ZAZ,,E K'7LU#9D^^]K.R%E5P'MH1?B&<][?L]X)JF%?%0%
M@$9/)>-JZA5:5Q.,559 2=1 5,#-SD[(DF@3RCU6E022.U#)<.C[(UP2RKTT
M<;F53!-QT(QR6$FD#F5)Y)\Y,%%/O< [)=9T7VB;P&E2D3UL0#]4*VDBW+'D
MM 2NJ.!(PF[JS8+)(K;UKN [A5J=K9%ULA7BT09?\ZGG6T' (-.6@9C/$1;
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M%F9H@K0%9G\GA#X%]H!N#*=_ 5!+ P04    " "X@/Y87X'?/-@"   D"
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M#6ZWYP6NX[\1:P@,G'XOZOMFL6$K-CPJ5E^.OYR$HP3FPTI,AS[<L^ Y/?>
M_JC5'QW57]>T5P/&$Q'M'U%SE@V!@>OVP[TC86_5</U^8O6:9UA>&,P0ZIQ'
M:%/4;U(]4'Q9E?4I5_A(5-T%/N,@= "NSSA^B&:@7XKVCT'\!U!+ P04
M" "X@/Y8=6Z6WN<"   ""   &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6RM54UOVS ,_2N"-PPML-;?=ILE!MH$PW88%C3M=AAV4&PF%FI;GB0G[;\?
M);M>DCIM#[LD$LWW1#Y*Y'C+Q;W, 11Y*(M*3JQ<J7IDVS+-H:3RG-=0X9<5
M%R55N!5K6]8":&9 96%[CA/9)665E8R-;2Z2,6]4P2J8"R*;LJ3B\1H*OIU8
MKO5DN&'K7&F#G8QKNH8%J+MZ+G!G]RP9*Z&2C%=$P&IB7;FC6:S]C<,/!ENY
MLR8ZDR7G]WKS-9M8C@X("DB59J#XMX$I%(4FPC#^=)Q6?Z0&[JZ?V#^;W#&7
M)94PY<5/EJE\8EU8)(,5;0IUP[=?H,LGU'PI+Z3Y)=O.U[%(VDC%RPZ,$92L
M:O_I0Z?##L#UCP"\#N = H(C +\#^&\%!!T@,,JTJ1@=9E319"SXE@CMC6QZ
M8<0T:$R?5;KL"R7P*T.<2KZK' 29-D) I<B5E* D.9F!HJR0I^2,+/"B94T!
MA*_(H/,9N5O,R,G[T[&M,"!-:Z?=X=/V<._(X=^H.">^^Y%XCA<,P&=OA_O[
M<!MEZ+7P>BT\P^<?X7LUU5]72ZD$7M7?0[FVY,$PN7Z^(UG3%"86OD\)8@-6
M\N&=&SF?AC+_3V1[.OB]#OY+[,E<0$U91G3JM"#P@#U&@AP(\_IEHE_NH% M
M*#(@W98V2>CZ;NR,[<VN! -NOA.Y;N^VEUS0)Q>\*3E:982;(J==D:DI\E#
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MK8HJP;LK(C'-Q'MP!NY5K\W+C "V #WF9^#;_15X]_O[L2L5*0WMIC6!V8X
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M-E#O%XS)EP<]07/Q._T/4$L#!!0    ( +B _E@YH.P@+P4  .4H   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;+6::W.C-A2&_XJ&=CKIS#: L+&=
M=3RS,=IIVJ2366?;:7?Z00'9L O(!3G>]-=77 (62V33.<F'F(O.(_$>?.07
M--_S[$L>,B;0UR1.\TLC%&)[89JY'[*$YN=\RU)Y9LVSA JYFVW,?)LQ&I1!
M26QBRW+-A$:IL9B7Q^ZRQ9SO1!RE["Y#^2Y):/9TQ6*^OS1LX_G AV@3BN*
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M!9B0X,^W6KMC$"[HOS[Y'U!+ P04    " "X@/Y8FZI54#P#  #^"   &0
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M_5ML]62.;ZF$\;^P;WU' 2RWQJJZ!5,&-9?-/[MKZW  B)(G '$+B(\!Z1.
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MF=%QT5U?["96[7VGN%66^HX?UO0K@=H9T'ZEE'V<. ?#S\GZ'U!+ P04
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MEX9K+LPU#=(N,/,S(?1+Q]X<W<5?_ 902P,$%     @ N(#^6!4?"WA( @
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M8G\AZ&^VR']?P$1>8O1)# O<SCD9XWPE\T_V^8T6J?V(/1=:B\1>1D!#D$8
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MRVZ89ZY<3WFUO;TZ$/FJW/L\R87(T_+CDM$9XZJ!O#[/Y1C4!\K!YH\,AO\
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M],:>E_^WA!)@BZO&7T\T!MG'"*9\<$OM84;FA4K4\PS1)VC%!A$R$,@X="#
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M*[VE#,5+P@-$/&63[AB[P.$.[K1GN5>76B$O#2U>$@8@ZBE;=>.H>?,<E]T
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MKS<MS\-?N@,\;+:_[[&=_1]02P,$%     @ N(#^6!UL.^E: P  .!$  !D
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MDS>OW/'H0QLK[&:=[[8#Y/B:->P(*>J#>3JD1MJ&M:!##1_V$A3]O))VZ%)
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M(&BA^] 5%;*KU8<)X!B8,I#G-Y2*QX%:H'Y9$OP%4$L#!!0    ( +B _EA
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M9CBA@S0!^'XAA-XNS >:F3_Z#U!+ P04    " "X@/Y8:^OPFG "  "@!@
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ME$6_\<,*?R&@70*N+Y6RN\!MT/^4LK]02P,$%     @ N(#^6(01"YK!!
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MJ^I2J7HQLG37+#?2&)F[QPP9B64-Z/M"4@]3O]@)FJN]Z7]02P,$%     @
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MZ[9MMX95M6^5*V6Q\?IAA2\=:.> ZZ52=F>X#?JW,_L)4$L#!!0    ( +B
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M:'RA*6DP8^YF#B TA0JEK&<;GEGR96'RO:928?[VGZ*,$+>,!'2F$P4B+FA
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M3"I04*L BB:AT&QFC5O P;SY8H'&/3EA;1\%<S-;7R!*"!:)*U!/(&=,G*7
M]A)-[H[#R7M0H'=JF2_T:J5ZSA?J"P(-SC-Z&T&B22@TFV-C'W ZJ4!![0(H
MFH1"LP]CC6$@P;3Y4H$>4<_EQ!A#J)?6^@()PRAU J4GD')$8\K] B4F<R?A
MS#U\%K135=;DVU5T.ID/:30\U=B=!(HFH=!LFHU[(&1*C1)0_P"*)J'0;&:-
M?R#A(L.E&J4]1<5<Q F+D2O2?F1"*<=Q[VO4%\D(25A*!F1J<GD2SN5_[IZ)
M[M=9M<D6G_]"(24\T>BM!'KJ#X5FDVS<!.&3BA340X"B22@TFUGC(4BXXG"I
M2$7?86*.&2:N1ON!& DD"'-K*MY(2K'@0QHUZ3P)I_,!C;ZMJ!+&'[V!0"L
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M]OCK\OOBY+U<<:[O*X:GOU!+ P04    " "X@/Y8S1YDO$ "  !Z-   $P
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MV:9_S<_FOQS=_ 102P$"% ,4    " "X@/Y8!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +B _EBK
M/,4<[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( +B _EB97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ N(#^6&?[^B[S!@
M0R(  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( +B _EC>U<??-0(  *<%   8              " @3</
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "X@/Y8TU15
MB0<*  #]*P  &               @(&B$0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ N(#^6* @D)/X @  K@H  !@
M ("!WQL  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( +B
M_ECRB*WW00<  +X?   8              " @0T?  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " "X@/Y8J8Q8&N0'  #6/   &
M        @(&$)@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ N(#^6*#6E]%!"P  "C<  !@              ("!GBX  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +B _EA-9--@#!4  -1&   8
M              " @14Z  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " "X@/Y8OX#.Z(<F  "8<P  &               @(%73P  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ N(#^6!"=;%,="
M?10  !D              ("!%'8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " "X@/Y8B,A[&O0"  !0!@  &0              @(%H
M?@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +B _EB>
M@59]O (  .@%   9              " @9.!  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ N(#^6,:7W+[% P  [@<  !D
M     ("!AH0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M" "X@/Y8R)3O>_\$  #/#   &0              @(&"B   >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +B _EA![@;"1@,  #,'   9
M              " @;B-  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!
M A0#%     @ N(#^6.!CDX?> @    8  !D              ("!-9$  'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "X@/Y8[E8U0TX#
M  !\!P  &0              @(%*E   >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;%!+ 0(4 Q0    ( +B _ECL4_*0!0,  'T&   9              "
M@<^7  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ N(#^
M6!Z;0M2\ P  0 @  !D              ("!"YL  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " "X@/Y8H8&$/6L%  !A#   &0
M        @('^G@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( +B _ECLH[+L00<  &D1   9              " @:"D  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ N(#^6(2Q+ X0!P  .!,
M !D              ("!&*P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " "X@/Y8F,2[4"$#  !Q!@  &0              @(%?LP
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +B _EB6*J+6
MY@0  ,T-   9              " @;>V  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ N(#^6%1R,^_X @  =@8  !D
M ("!U+L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "X
M@/Y8G$!%-PX$  "H"   &0              @($#OP  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +B _ECB/*6($0<  ,\2   9
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M970S,2YX;6Q02P$"% ,4    " "X@/Y80KQ&4 \"  #<!   &0
M    @(%HX0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M +B _EBTB;W.S"<  /=^   9              " @:[C  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ N(#^6'8D5M]U"   ?!L  !D
M             ("!L0L! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " "X@/Y82B1;B5,'   %$@  &0              @(%=% $ >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( +B _EB9;31HG (
M -D%   9              " @><; 0!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ N(#^6*[T3AZH @  V04  !D              ("!
MNAX! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "X@/Y8
M@;TK2E$#  #C!@  &0              @(&9(0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( +B _EBTSV$_ZP0  , ,   9
M      " @2$E 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ N(#^6,I^_+N/ @  T@4  !D              ("!0RH! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "X@/Y87S._W#T#  !Q!P
M&0              @($)+0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( +B _EC8:@ ,DP,  $0(   9              " @7TP 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ N(#^6$!R]4W4
M P  'PD  !D              ("!1S0! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " "X@/Y8+D<=?OT&  #A$   &0
M@(%2. $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( +B
M_EA@:R;\004  -\.   9              " @88_ 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ N(#^6.VER]?P @  @P8  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( +B _EC'F_1K-PP  *E+   9
M  " @89L 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
MN(#^6* [HI,9 P  &PL  !D              ("!]'@! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " "X@/Y868)X2B8)  !L3@  &0
M            @(%$? $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( +B _EBIBO5EZ (  .L)   9              " @:&% 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ N(#^6&">32UA P
MR0T  !D              ("!P(@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6Q02P$"% ,4    " "X@/Y8L;^Y?VH#  "P%   &0              @(%8
MC $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( +B _EA%
MVH<NS0(  ,H*   9              " @?F/ 0!X;"]W;W)K<VAE971S+W-H
M965T-3<N>&UL4$L! A0#%     @ N(#^6*G$_A.] @  8@L  !D
M     ("!_9(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +B _EB:=*+QH 0   06   9              "
M@46A 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ N(#^
M6#F@[" O!0  Y2@  !D              ("!'*8! 'AL+W=O<FMS:&5E=',O
M<VAE970V-"YX;6Q02P$"% ,4    " "X@/Y8Q.?A9O@%   W&@  &0
M        @(&"JP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0
M   ( +B _EA'K[?;?0(  )@&   9              " @;&Q 0!X;"]W;W)K
M<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ N(#^6$@*\WXP @  TP4
M !D              ("!9;0! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q0
M2P$"% ,4    " "X@/Y8&;F,Z!8"  ")!   &0              @(',M@$
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( +B _EB;JE50
M/ ,  /X(   9              " @1FY 0!X;"]W;W)K<VAE971S+W-H965T
M-CDN>&UL4$L! A0#%     @ N(#^6!%&$, / @  \@0  !D
M ("!C+P! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " "X
M@/Y8^'C\9OT"  !_"0  &0              @('2O@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( +B _EBF75)=/P,  *@(   9
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M970W-BYX;6Q02P$"% ,4    " "X@/Y8%1\+>$@"  "3!0  &0
M    @('IT0$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    (
M +B _EA6E3@5ZP8  $09   9              " @6C4 0!X;"]W;W)K<VAE
M971S+W-H965T-S@N>&UL4$L! A0#%     @ N(#^6!*,W2_$!@  <#   !D
M             ("!BML! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"
M% ,4    " "X@/Y8@TQZ-H<6   A$P$ &0              @(&%X@$ >&PO
M=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( +B _E@=;#OI6@,
M #@1   9              " @4/Y 0!X;"]W;W)K<VAE971S+W-H965T.#$N
M>&UL4$L! A0#%     @ N(#^6$!@AIRV @  S @  !D              ("!
MU/P! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " "X@/Y8
MJA,G'%(#  #_"P  &0              @('!_P$ >&PO=V]R:W-H965T<R]S
M:&5E=#@S+GAM;%!+ 0(4 Q0    ( +B _EAKZ_":< (  * &   9
M      " @4H# @!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%
M  @ N(#^6(01"YK!!   YA,  !D              ("!\04" 'AL+W=O<FMS
M:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " "X@/Y824%_>Z (  #,8P
M&0              @('I"@( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+
M 0(4 Q0    ( +B _E@E"Q2MB@(  $<'   9              " @< 3 @!X
M;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ N(#^6+,6 E<H
M!   &Q,  !D              ("!@18" 'AL+W=O<FMS:&5E=',O<VAE970X
M."YX;6Q02P$"% ,4    " "X@/Y8M.9!5S8"  !6!0  &0
M@('@&@( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( +B
M_E@N^<"%KP@  .DR   9              " @4T= @!X;"]W;W)K<VAE971S
M+W-H965T.3 N>&UL4$L! A0#%     @ N(#^6+G5R^P."0  B5   !D
M         ("!,R8" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4
M    " "X@/Y84]^8 5\#   0#P  &0              @(%X+P( >&PO=V]R
M:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( +B _EA,E&@*7P,  .H5
M   -              "  0XS @!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !D &0 <QL  #Y# @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>364</ContextCount>
  <ElementCount>343</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>116</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Description of Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization</Role>
      <ShortName>Description of Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Trade Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/TradeReceivables</Role>
      <ShortName>Trade Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Long-Term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LongTermInvestment</Role>
      <ShortName>Long-Term Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Advances to Suppliers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/AdvancestoSuppliers</Role>
      <ShortName>Advances to Suppliers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Farmland Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/FarmlandAssets</Role>
      <ShortName>Farmland Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Long Term Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LongTermDeposits</Role>
      <ShortName>Long Term Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Other Noncurrent Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/OtherNoncurrentAssets</Role>
      <ShortName>Other Noncurrent Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://chinajojodrugstores.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LoanPayable</Role>
      <ShortName>Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/Taxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Postretirement Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/PostretirementBenefits</Role>
      <ShortName>Postretirement Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Related Party Transactions and Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements</Role>
      <ShortName>Related Party Transactions and Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Shareholder???s Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholder???s Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995326 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995327 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995328 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Description of Business and Organization (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables</Role>
      <ShortName>Description of Business and Organization (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Trade Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/TradeReceivablesTables</Role>
      <ShortName>Trade Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/TradeReceivables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/OtherCurrentAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/PropertyandEquipment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Long-Term Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LongTermInvestmentTables</Role>
      <ShortName>Long-Term Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LongTermInvestment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Advances to Suppliers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/AdvancestoSuppliersTables</Role>
      <ShortName>Advances to Suppliers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/AdvancestoSuppliers</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Farmland Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/FarmlandAssetsTables</Role>
      <ShortName>Farmland Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/FarmlandAssets</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Other Noncurrent Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables</Role>
      <ShortName>Other Noncurrent Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/OtherNoncurrentAssets</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/IntangibleAssets</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://chinajojodrugstores.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/NotesPayable</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/TaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/Taxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Related Party Transactions and Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables</Role>
      <ShortName>Related Party Transactions and Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/NetLossPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/Segments</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Description of Business and Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails</Role>
      <ShortName>Description of Business and Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Description of Business and Organization (Details) - Schedule of Consolidated Financial Statements Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable</Role>
      <ShortName>Description of Business and Organization (Details) - Schedule of Consolidated Financial Statements Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Major Source in each Segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Major Source in each Segment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Reconciliation of Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Reconciliation of Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/CommitmentsandContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Trade Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/TradeReceivablesDetails</Role>
      <ShortName>Trade Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/TradeReceivablesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Trade Receivables (Details) - Schedule of Trade Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable</Role>
      <ShortName>Trade Receivables (Details) - Schedule of Trade Receivables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/TradeReceivablesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable</Role>
      <ShortName>Other Current Assets (Details) - Schedule of Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Long-Term Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LongTermInvestmentDetails</Role>
      <ShortName>Long-Term Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LongTermInvestmentTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Long-Term Investment (Details) - Schedule of Long-Term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable</Role>
      <ShortName>Long-Term Investment (Details) - Schedule of Long-Term Investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LongTermInvestmentTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Advances to Suppliers (Details) - Schedule of Advance to Suppliers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable</Role>
      <ShortName>Advances to Suppliers (Details) - Schedule of Advance to Suppliers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/AdvancestoSuppliersTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/Inventory</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Farmland Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/FarmlandAssetsDetails</Role>
      <ShortName>Farmland Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/FarmlandAssetsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Farmland Assets (Details) - Schedule of Farmland Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable</Role>
      <ShortName>Farmland Assets (Details) - Schedule of Farmland Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/FarmlandAssetsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Long Term Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LongTermDepositsDetails</Role>
      <ShortName>Long Term Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LongTermDeposits</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Other Noncurrent Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails</Role>
      <ShortName>Other Noncurrent Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Other Noncurrent Assets (Details) - Schedule of Other Noncurrent Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable</Role>
      <ShortName>Other Noncurrent Assets (Details) - Schedule of Other Noncurrent Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Other Noncurrent Assets (Details) - Schedule of Amortizations of the Prepayment for Lease of Land Use Right</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable</Role>
      <ShortName>Other Noncurrent Assets (Details) - Schedule of Amortizations of the Prepayment for Lease of Land Use Right</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LeasesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Leases (Details) - Schedule of lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofleaseTable</Role>
      <ShortName>Leases (Details) - Schedule of lease</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LeasesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Leases (Details) - Schedule of Lease Liabilities Under Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable</Role>
      <ShortName>Leases (Details) - Schedule of Lease Liabilities Under Operating Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LeasesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/IntangibleAssetsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Intangible Assets (Details) - Schedule of Net Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of Net Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/IntangibleAssetsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://chinajojodrugstores.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/NotesPayableTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Notes Payable (Details) - Schedule of Credit Facilities with Banks</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable</Role>
      <ShortName>Notes Payable (Details) - Schedule of Credit Facilities with Banks</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/NotesPayableTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Loan Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/LoanPayableDetails</Role>
      <ShortName>Loan Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/LoanPayable</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/TaxesDetails</Role>
      <ShortName>Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/TaxesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Taxes (Details) - Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable</Role>
      <ShortName>Taxes (Details) - Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/TaxesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Postretirement Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/PostretirementBenefitsDetails</Role>
      <ShortName>Postretirement Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/PostretirementBenefits</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Related Party Transactions and Arrangements (Details) - Schedule of Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Related Party Transactions and Arrangements (Details) - Schedule of Balances with Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Shareholder???s Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholder???s Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/ShareholdersEquity</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/NetLossPerShareTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Basic and Diluted Earnings Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/NetLossPerShareTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SegmentsDetails</Role>
      <ShortName>Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SegmentsTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Segments (Details) - Schedule of Segment of the Continuing Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable</Role>
      <ShortName>Segments (Details) - Schedule of Segment of the Continuing Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SegmentsTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Segments (Details) - Schedule of Net Revenue from External Customers through its Retail Drugstores by Main Products</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable</Role>
      <ShortName>Segments (Details) - Schedule of Net Revenue from External Customers through its Retail Drugstores by Main Products</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SegmentsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ea0209917-20f_chinajojo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinajojodrugstores.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://chinajojodrugstores.com/role/SubsequentEvents</ParentRole>
      <Position>92</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cjjd-20240331.xsd</File>
    <File>cjjd-20240331_cal.xml</File>
    <File>cjjd-20240331_def.xml</File>
    <File>cjjd-20240331_lab.xml</File>
    <File>cjjd-20240331_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0209917-20f_chinajojo.htm">ea0209917-20f_chinajojo.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1093">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0209917-20f_chinajojo.htm": {
   "nsprefix": "cjjd",
   "nsuri": "http://chinajojodrugstores.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "cjjd-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cjjd-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cjjd-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cjjd-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cjjd-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0209917-20f_chinajojo.htm"
     ]
    }
   },
   "keyStandard": 292,
   "keyCustom": 51,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 78,
   "hidden": {
    "total": 164,
    "http://fasb.org/us-gaap/2024": 126,
    "http://chinajojodrugstores.com/20240331": 34,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 364,
   "entityCount": 1,
   "segmentCount": 116,
   "elementCount": 841,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1093,
    "http://xbrl.sec.gov/dei/2024": 46,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization",
     "longName": "995306 - Disclosure - Description of Business and Organization",
     "shortName": "Description of Business and Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://chinajojodrugstores.com/role/CommitmentsandContingencies",
     "longName": "995308 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://chinajojodrugstores.com/role/TradeReceivables",
     "longName": "995309 - Disclosure - Trade Receivables",
     "shortName": "Trade Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://chinajojodrugstores.com/role/OtherCurrentAssets",
     "longName": "995310 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://chinajojodrugstores.com/role/PropertyandEquipment",
     "longName": "995311 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://chinajojodrugstores.com/role/LongTermInvestment",
     "longName": "995312 - Disclosure - Long-Term Investment",
     "shortName": "Long-Term Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://chinajojodrugstores.com/role/AdvancestoSuppliers",
     "longName": "995313 - Disclosure - Advances to Suppliers",
     "shortName": "Advances to Suppliers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:AdvancesToSuppliersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:AdvancesToSuppliersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://chinajojodrugstores.com/role/Inventory",
     "longName": "995314 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://chinajojodrugstores.com/role/FarmlandAssets",
     "longName": "995315 - Disclosure - Farmland Assets",
     "shortName": "Farmland Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:FarmlandAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:FarmlandAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://chinajojodrugstores.com/role/LongTermDeposits",
     "longName": "995316 - Disclosure - Long Term Deposits",
     "shortName": "Long Term Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:LongTermDepositsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:LongTermDepositsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://chinajojodrugstores.com/role/OtherNoncurrentAssets",
     "longName": "995317 - Disclosure - Other Noncurrent Assets",
     "shortName": "Other Noncurrent Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://chinajojodrugstores.com/role/Leases",
     "longName": "995318 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://chinajojodrugstores.com/role/IntangibleAssets",
     "longName": "995319 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://chinajojodrugstores.com/role/NotesPayable",
     "longName": "995320 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://chinajojodrugstores.com/role/LoanPayable",
     "longName": "995321 - Disclosure - Loan Payable",
     "shortName": "Loan Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:LoanPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:LoanPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://chinajojodrugstores.com/role/Taxes",
     "longName": "995322 - Disclosure - Taxes",
     "shortName": "Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://chinajojodrugstores.com/role/PostretirementBenefits",
     "longName": "995323 - Disclosure - Postretirement Benefits",
     "shortName": "Postretirement Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements",
     "longName": "995324 - Disclosure - Related Party Transactions and Arrangements",
     "shortName": "Related Party Transactions and Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://chinajojodrugstores.com/role/ShareholdersEquity",
     "longName": "995325 - Disclosure - Shareholder\u2019s Equity",
     "shortName": "Shareholder\u2019s Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://chinajojodrugstores.com/role/NetLossPerShare",
     "longName": "995326 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://chinajojodrugstores.com/role/Segments",
     "longName": "995327 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://chinajojodrugstores.com/role/SubsequentEvents",
     "longName": "995328 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c52",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c52",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables",
     "longName": "996001 - Disclosure - Description of Business and Organization (Tables)",
     "shortName": "Description of Business and Organization (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://chinajojodrugstores.com/role/TradeReceivablesTables",
     "longName": "996003 - Disclosure - Trade Receivables (Tables)",
     "shortName": "Trade Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://chinajojodrugstores.com/role/OtherCurrentAssetsTables",
     "longName": "996004 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://chinajojodrugstores.com/role/PropertyandEquipmentTables",
     "longName": "996005 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://chinajojodrugstores.com/role/LongTermInvestmentTables",
     "longName": "996006 - Disclosure - Long-Term Investment (Tables)",
     "shortName": "Long-Term Investment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://chinajojodrugstores.com/role/AdvancestoSuppliersTables",
     "longName": "996007 - Disclosure - Advances to Suppliers (Tables)",
     "shortName": "Advances to Suppliers (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:AdvanceToSuppliersTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cjjd:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:AdvanceToSuppliersTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cjjd:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://chinajojodrugstores.com/role/FarmlandAssetsTables",
     "longName": "996008 - Disclosure - Farmland Assets (Tables)",
     "shortName": "Farmland Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:ScheduleOfFarmlandAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cjjd:FarmlandAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:ScheduleOfFarmlandAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cjjd:FarmlandAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables",
     "longName": "996009 - Disclosure - Other Noncurrent Assets (Tables)",
     "shortName": "Other Noncurrent Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://chinajojodrugstores.com/role/LeasesTables",
     "longName": "996010 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://chinajojodrugstores.com/role/IntangibleAssetsTables",
     "longName": "996011 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://chinajojodrugstores.com/role/NotesPayableTables",
     "longName": "996012 - Disclosure - Notes Payable (Tables)",
     "shortName": "Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://chinajojodrugstores.com/role/TaxesTables",
     "longName": "996013 - Disclosure - Taxes (Tables)",
     "shortName": "Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables",
     "longName": "996014 - Disclosure - Related Party Transactions and Arrangements (Tables)",
     "shortName": "Related Party Transactions and Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://chinajojodrugstores.com/role/NetLossPerShareTables",
     "longName": "996015 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://chinajojodrugstores.com/role/SegmentsTables",
     "longName": "996016 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
     "longName": "996017 - Disclosure - Description of Business and Organization (Details)",
     "shortName": "Description of Business and Organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable",
     "longName": "996018 - Disclosure - Description of Business and Organization (Details) - Schedule of Consolidated Financial Statements Activities",
     "shortName": "Description of Business and Organization (Details) - Schedule of Consolidated Financial Statements Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c75",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c75",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable",
     "longName": "996020 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Major Source in each Segment",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Major Source in each Segment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable",
     "longName": "996021 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Reconciliation of Cash Equivalents and Restricted Cash",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Reconciliation of Cash Equivalents and Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable",
     "longName": "996022 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable",
     "longName": "996023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c167",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c167",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable",
     "longName": "996024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c168",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c168",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails",
     "longName": "996025 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c171",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c171",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://chinajojodrugstores.com/role/TradeReceivablesDetails",
     "longName": "996026 - Disclosure - Trade Receivables (Details)",
     "shortName": "Trade Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable",
     "longName": "996027 - Disclosure - Trade Receivables (Details) - Schedule of Trade Receivables",
     "shortName": "Trade Receivables (Details) - Schedule of Trade Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c172",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c172",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable",
     "longName": "996028 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets",
     "shortName": "Other Current Assets (Details) - Schedule of Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PrepaidRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://chinajojodrugstores.com/role/PropertyandEquipmentDetails",
     "longName": "996029 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c174",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c174",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996030 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
     "longName": "996031 - Disclosure - Long-Term Investment (Details)",
     "shortName": "Long-Term Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "cjjd:InvestmentPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "cjjd:InvestmentPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable",
     "longName": "996032 - Disclosure - Long-Term Investment (Details) - Schedule of Long-Term Investment",
     "shortName": "Long-Term Investment (Details) - Schedule of Long-Term Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c196",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable",
     "longName": "996033 - Disclosure - Advances to Suppliers (Details) - Schedule of Advance to Suppliers",
     "shortName": "Advances to Suppliers (Details) - Schedule of Advance to Suppliers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "cjjd:AdvancesOnInventoryPurchasesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "cjjd:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "cjjd:AdvancesOnInventoryPurchasesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "cjjd:AdvancesToSuppliersTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://chinajojodrugstores.com/role/InventoryDetails",
     "longName": "996034 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://chinajojodrugstores.com/role/FarmlandAssetsDetails",
     "longName": "996035 - Disclosure - Farmland Assets (Details)",
     "shortName": "Farmland Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ImpairmentOfRealEstate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "cjjd:FarmlandAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ImpairmentOfRealEstate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "cjjd:FarmlandAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable",
     "longName": "996036 - Disclosure - Farmland Assets (Details) - Schedule of Farmland Assets",
     "shortName": "Farmland Assets (Details) - Schedule of Farmland Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "cjjd:FarmlandAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "cjjd:FarmlandAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "cjjd:FarmlandAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "cjjd:FarmlandAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://chinajojodrugstores.com/role/LongTermDepositsDetails",
     "longName": "996037 - Disclosure - Long Term Deposits (Details)",
     "shortName": "Long Term Deposits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DepositsAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails",
     "longName": "996038 - Disclosure - Other Noncurrent Assets (Details)",
     "shortName": "Other Noncurrent Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cjjd:DescriptionOfLeasePrepaymentLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:DescriptionOfLeasePrepaymentLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable",
     "longName": "996039 - Disclosure - Other Noncurrent Assets (Details) - Schedule of Other Noncurrent Assets",
     "shortName": "Other Noncurrent Assets (Details) - Schedule of Other Noncurrent Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "cjjd:ForestLandUseRights",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "cjjd:ForestLandUseRights",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable",
     "longName": "996040 - Disclosure - Other Noncurrent Assets (Details) - Schedule of Amortizations of the Prepayment for Lease of Land Use Right",
     "shortName": "Other Noncurrent Assets (Details) - Schedule of Amortizations of the Prepayment for Lease of Land Use Right",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://chinajojodrugstores.com/role/LeasesDetails",
     "longName": "996041 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofleaseTable",
     "longName": "996042 - Disclosure - Leases (Details) - Schedule of lease",
     "shortName": "Leases (Details) - Schedule of lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable",
     "longName": "996043 - Disclosure - Leases (Details) - Schedule of Lease Liabilities Under Operating Leases",
     "shortName": "Leases (Details) - Schedule of Lease Liabilities Under Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://chinajojodrugstores.com/role/IntangibleAssetsDetails",
     "longName": "996044 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable",
     "longName": "996045 - Disclosure - Intangible Assets (Details) - Schedule of Net Intangible Assets",
     "shortName": "Intangible Assets (Details) - Schedule of Net Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://chinajojodrugstores.com/role/NotesPayableDetails",
     "longName": "996046 - Disclosure - Notes Payable (Details)",
     "shortName": "Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c215",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable",
     "longName": "996047 - Disclosure - Notes Payable (Details) - Schedule of Credit Facilities with Banks",
     "shortName": "Notes Payable (Details) - Schedule of Credit Facilities with Banks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c216",
      "name": "us-gaap:DebtInstrumentIssuer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://chinajojodrugstores.com/role/LoanPayableDetails",
     "longName": "996048 - Disclosure - Loan Payable (Details)",
     "shortName": "Loan Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShorttermDebtAverageOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "cjjd:LoanPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShorttermDebtAverageOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "cjjd:LoanPayableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://chinajojodrugstores.com/role/TaxesDetails",
     "longName": "996049 - Disclosure - Taxes (Details)",
     "shortName": "Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable",
     "longName": "996050 - Disclosure - Taxes (Details) - Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate",
     "shortName": "Taxes (Details) - Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://chinajojodrugstores.com/role/PostretirementBenefitsDetails",
     "longName": "996051 - Disclosure - Postretirement Benefits (Details)",
     "shortName": "Postretirement Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "996052 - Disclosure - Related Party Transactions and Arrangements (Details) - Schedule of Balances with Related Parties",
     "shortName": "Related Party Transactions and Arrangements (Details) - Schedule of Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://chinajojodrugstores.com/role/ShareholdersEquityDetails",
     "longName": "996053 - Disclosure - Shareholder\u2019s Equity (Details)",
     "shortName": "Shareholder\u2019s Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://chinajojodrugstores.com/role/NetLossPerShareDetails",
     "longName": "996054 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable",
     "longName": "996055 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Earnings Per Share",
     "shortName": "Net Loss Per Share (Details) - Schedule of Basic and Diluted Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://chinajojodrugstores.com/role/SegmentsDetails",
     "longName": "996056 - Disclosure - Segments (Details)",
     "shortName": "Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c326",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c326",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable",
     "longName": "996057 - Disclosure - Segments (Details) - Schedule of Segment of the Continuing Operations",
     "shortName": "Segments (Details) - Schedule of Segment of the Continuing Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
     "longName": "996058 - Disclosure - Segments (Details) - Schedule of Net Revenue from External Customers through its Retail Drugstores by Main Products",
     "shortName": "Segments (Details) - Schedule of Net Revenue from External Customers through its Retail Drugstores by Main Products",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c92",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c92",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://chinajojodrugstores.com/role/SubsequentEventsDetails",
     "longName": "996059 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c357",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c357",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0209917-20f_chinajojo.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r955"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r74"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r772"
     ]
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r257",
      "r258",
      "r1045"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r718",
      "r782",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade receivables",
        "terseLabel": "Trade accounts receivables",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r149",
      "r564"
     ]
    },
    "cjjd_AccumulatedImpairmentPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AccumulatedImpairmentPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment",
        "documentation": "Amount of accumulated impairment.",
        "label": "Accumulated Impairment Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r77",
      "r159",
      "r558",
      "r600",
      "r601"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income/(loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r14",
      "r484",
      "r487",
      "r529",
      "r596",
      "r597",
      "r924",
      "r925",
      "r926",
      "r938",
      "r939",
      "r940",
      "r942"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r772",
      "r1078"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r938",
      "r939",
      "r940",
      "r942",
      "r1019",
      "r1079"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "cjjd_AdditionsToLeaseholdImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdditionsToLeaseholdImprovements",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to leasehold improvements",
        "label": "Additions To Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_AdvanceToSuppliersTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdvanceToSuppliersTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AdvancestoSuppliersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Advance to Suppliers",
        "documentation": "Tabular disclosure of advance to suppliers.",
        "label": "Advance To Suppliers Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_AdvancesOnInventoryPurchasesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdvancesOnInventoryPurchasesGross",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable": {
       "parentTag": "us-gaap_Supplies",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance to suppliers",
        "documentation": "Represents carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer before allowance for doubtful accounts.",
        "label": "Advances On Inventory Purchases Gross"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_AdvancesToSuppliersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdvancesToSuppliersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances to Suppliers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_AdvancesToSuppliersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdvancesToSuppliersTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AdvancestoSuppliers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADVANCES TO SUPPLIERS",
        "documentation": "The entire disclosure for advances to suppliers consist of deposits with or advances to outside vendors for future inventory purchases.",
        "label": "Advances To Suppliers Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of advance to suppliers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AdvancestoSuppliersDetailsScheduleofAdvancetoSuppliersTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances to Suppliers (Details) - Schedule of Advance to Suppliers [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and promotion costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "cjjd_AggregateSharePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AggregateSharePercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate share percentage",
        "documentation": "The percentage of aggregate shares of common stock.",
        "label": "Aggregate Share Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r821",
      "r837",
      "r872"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r840",
      "r875"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r867",
      "r876",
      "r880",
      "r888"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Segment [Member]",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r739",
      "r740"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "cjjd_AllowanceForAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "AllowanceForAdvancesToSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable": {
       "parentTag": "us-gaap_Supplies",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: reserve for vendor non-performance on advances",
        "documentation": "Represents the allowance for advances to suppliers.",
        "label": "Allowance For Advances To Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable": {
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable",
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Allowance for credit losses as of March 31, 2022",
        "periodEndLabel": "Ending allowance for credit losses",
        "negatedLabel": "Less: allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r262",
      "r270",
      "r271",
      "r274",
      "r1045"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/TradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r290",
      "r297",
      "r748"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from calculation of diluted earnings per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r124",
      "r152",
      "r187",
      "r220",
      "r228",
      "r246",
      "r250",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r477",
      "r481",
      "r501",
      "r553",
      "r660",
      "r739",
      "r740",
      "r772",
      "r789",
      "r982",
      "r983",
      "r1032"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r164",
      "r187",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r477",
      "r481",
      "r501",
      "r772",
      "r982",
      "r983",
      "r1032"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r477",
      "r481",
      "r501",
      "r982",
      "r983",
      "r1032"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "cjjd_BankLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "BankLoanMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Loan [Member]",
        "label": "Bank Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and consolidation",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "cjjd_BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl": {
     "xbrltype": "percentItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting ownership interest",
        "documentation": "Represents benchmark percentage of voting ownership interest for control and common control.",
        "label": "Benchmark Percentage Of Voting Ownership Interest For Control And Common Control"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings [Member]",
        "verboseLabel": "Building [Member]",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r473",
      "r757",
      "r758"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r473",
      "r757",
      "r758"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r817"
     ]
    },
    "cjjd_CapitalExpenditureContinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "CapitalExpenditureContinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total capital expenditures",
        "documentation": "This element refer to capital expenditure continous operation.",
        "label": "Capital Expenditure Continued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r727"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r90",
      "r183"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r90"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r1043"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance amount",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH ACTIVITIES\uff1a",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance not covered",
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_CashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "CashlessExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise of warrants",
        "documentation": "Amount of cashless excercise of warrants.",
        "label": "Cashless Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ChangeInOperatingAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ChangeInOperatingAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Change In Operating Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r154",
      "r155",
      "r156",
      "r187",
      "r210",
      "r211",
      "r213",
      "r215",
      "r222",
      "r223",
      "r267",
      "r319",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r358",
      "r359",
      "r362",
      "r365",
      "r372",
      "r501",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r646",
      "r669",
      "r692",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r912",
      "r933",
      "r943"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder\u2019s Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r222",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r611",
      "r612",
      "r613",
      "r614",
      "r754",
      "r912",
      "r933"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of warrants",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r115",
      "r555",
      "r645"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r311",
      "r312",
      "r720",
      "r972",
      "r977"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "verboseLabel": "Common Stock [Member]",
        "netLabel": "Ordinary Shares [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r781",
      "r783",
      "r784",
      "r785",
      "r786",
      "r938",
      "r939",
      "r942",
      "r1019",
      "r1076",
      "r1079"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary shares par vale (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r646"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "verboseLabel": "Ordinary shares issued (in Shares)",
        "netLabel": "Common stock, shares, issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding",
        "verboseLabel": "Ordinary shares outstanding (in Shares)",
        "netLabel": "Common stock, shares, outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r646",
      "r666",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares; $0.24 par value; 150,000,000 shares authorized; 1,743,362 and 1,184,861 shares issued and outstanding as of March 31, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r557",
      "r772"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Postretirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "COMPREHENSIVE LOSS",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r166",
      "r168",
      "r174",
      "r549",
      "r571",
      "r572"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r726",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r969",
      "r970"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r49",
      "r50",
      "r256",
      "r719"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r49",
      "r50",
      "r256",
      "r603",
      "r719"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable",
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r191",
      "r220",
      "r230",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r739",
      "r740",
      "r982",
      "r983"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r191",
      "r220",
      "r230",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r739",
      "r740",
      "r982",
      "r983"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation of variable interest entities",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r45"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COST OF GOODS SOLD",
        "verboseLabel": "Cost of goods",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r545"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r980"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r980",
      "r981"
     ]
    },
    "cjjd_CreditLossRollForwardPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "CreditLossRollForwardPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit loss roll forward",
        "label": "Credit Loss Roll Forward Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_CustomerDepositCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "CustomerDepositCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer deposits",
        "documentation": "The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.",
        "label": "Customer Deposit Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOTES PAYABLE",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r185",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r317",
      "r318",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r346",
      "r353",
      "r354",
      "r356",
      "r514"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r58",
      "r59",
      "r113",
      "r114",
      "r191",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r770",
      "r934",
      "r973",
      "r974",
      "r975",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCollateralAmount",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral amount",
        "label": "Debt Instrument, Collateral Amount",
        "documentation": "Amount of assets pledged to secure a debt instrument."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "cjjd_DebtInstrumentIOriginationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DebtInstrumentIOriginationDate",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Origination date",
        "documentation": "Origination date.",
        "label": "Debt Instrument IOrigination Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIssuer": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuer",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Endorser",
        "label": "Debt Instrument, Issuer",
        "documentation": "Identification of the contractual issuer of the debt instrument (for example, a subsidiary of the reporting entity)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r36"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r770",
      "r934",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r749",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r191",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r770",
      "r934",
      "r973",
      "r974",
      "r975",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r36",
      "r37",
      "r53",
      "r104",
      "r105",
      "r191",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r770",
      "r934",
      "r1023",
      "r1024"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r830",
      "r844"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/CommitmentsandContingenciesDetails",
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits totaling",
        "verboseLabel": "Deposit",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_DepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/LongTermDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term deposits",
        "verboseLabel": "Long term deposits",
        "label": "Deposits Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense for property and equipment",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r33"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r220",
      "r233",
      "r250",
      "r739",
      "r740"
     ]
    },
    "cjjd_DescriptionOfLeasePrepaymentLife": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DescriptionOfLeasePrepaymentLife",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of lease prepayment life",
        "documentation": "A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.",
        "label": "Description Of Lease Prepayment Life"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_DescriptionofBusinessandOrganizationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DescriptionofBusinessandOrganizationDetailsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Organization (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_DescriptionofBusinessandOrganizationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DescriptionofBusinessandOrganizationDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Organization (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_DirectorAndCEOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DirectorAndCEOMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to a director and CEO [Member]",
        "label": "Director And CEOMember"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r830",
      "r844"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817",
      "r868"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817",
      "r868"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "cjjd_DrugWholesaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DrugWholesaleMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Wholesale [Member]",
        "verboseLabel": "Drug wholesale [Member]",
        "documentation": "Represents information regarding drug wholesale.",
        "label": "Drug Wholesale Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_DueFromRelatedsParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "DueFromRelatedsParties",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from related parties",
        "documentation": "Due from related parties.",
        "label": "Due From Relateds Parties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]",
        "terseLabel": "LOSS PER SHARE:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "verboseLabel": "Net loss attributable to controlling interest",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r208",
      "r210",
      "r213",
      "r214",
      "r215",
      "r219",
      "r471",
      "r475",
      "r491",
      "r492",
      "r550",
      "r573",
      "r732"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share \u2013 Basic:",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EarningsPerShareBasicBeforeNoncontrollingInterest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EarningsPerShareBasicBeforeNoncontrollingInterest",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss before noncontrolling interest",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding before noncontrolling interest during the reporting period.",
        "label": "Earnings Per Share Basic Before Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: Net loss attributable to noncontrolling interest",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding attributable to noncontrolling interest during the reporting period.",
        "label": "Earnings Per Share Basic Net Income Loss Attributable To Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Dollars per share)",
        "verboseLabel": "Net loss attributable to controlling interest",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r210",
      "r213",
      "r214",
      "r215",
      "r219",
      "r471",
      "r475",
      "r491",
      "r492",
      "r550",
      "r573",
      "r732"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share \u2013 Diluted:",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EarningsPerShareDilutedBeforeNoncontrollingInterest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EarningsPerShareDilutedBeforeNoncontrollingInterest",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income before noncontrolling interest",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding before noncontrolling interest during the reporting period.",
        "label": "Earnings Per Share Diluted Before Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add: Net loss attributable to noncontrolling interest",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding attributable to noncontrolling interest during the reporting period.",
        "label": "Earnings Per Share Diluted Net Income Loss Attributable To Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r216",
      "r217",
      "r218"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EFFECT OF EXCHANGE RATE ON CASH",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable",
      "http://chinajojodrugstores.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r761"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Statutory rates",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r441",
      "r461",
      "r761"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r761",
      "r936",
      "r1013"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign income not recognized in the U.S.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r444",
      "r761",
      "r936",
      "r1013"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable",
      "http://chinajojodrugstores.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses-permanent difference",
        "verboseLabel": "Not deductible for PRC income tax.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r936",
      "r1013"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofIncomeTaxProvisionattheFederalStatutoryRateandEffectiveRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1013",
      "r1014"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EntityEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntityEightMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuxin Medicine [Member]",
        "label": "Entity Eight Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "cjjd_EntityFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntityFiveMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuzhou Pharmacy [Member]",
        "label": "Entity Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EntityFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntityFourMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qianhong Agriculture [Member]",
        "label": "Entity Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EntityNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntityNineMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiutong Medical [Member]",
        "label": "Entity Nine Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EntitySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntitySevenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuzhou Service [Member]",
        "label": "Entity Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "cjjd_EntitySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntitySixMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuzhou Clinic [Member]",
        "label": "Entity Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EntityThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntityThreeMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shouantang Technology [Member]",
        "label": "Entity Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_EntityTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "EntityTwoMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuxin Management [Member]",
        "label": "Entity Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r139",
      "r170",
      "r171",
      "r172",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r221",
      "r268",
      "r269",
      "r302",
      "r374",
      "r459",
      "r460",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r515",
      "r518",
      "r529",
      "r570",
      "r596",
      "r597",
      "r598",
      "r622",
      "r692"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r467",
      "r914",
      "r915",
      "r916",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of capital stock",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total price",
        "label": "Equity Method Investment, Quoted Market Value",
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suffered loss",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r931"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r821",
      "r837",
      "r872"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r818",
      "r834",
      "r869"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r765"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FarmlandAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FarmlandAssets",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Farmland assets",
        "documentation": "Represents the amount of farmland assets.",
        "label": "Farmland Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FarmlandAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FarmlandAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Farmland Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FarmlandAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FarmlandAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable": {
       "parentTag": "us-gaap_Land",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Farmland assets",
        "documentation": "Represents farmland assets gross.",
        "label": "Farmland Assets Gross"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FarmlandAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FarmlandAssetsPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Farmland assets",
        "documentation": "Disclosure of accounting policy for farmland assets.",
        "label": "Farmland Assets Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FarmlandAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FarmlandAssetsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/FarmlandAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FARMLAND ASSETS",
        "documentation": "The entire disclosure for farmland assets.",
        "label": "Farmland Assets Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FarmlandDevelopmentCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FarmlandDevelopmentCostMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Farmland Development Cost [Member]",
        "documentation": "Represents farmland development cost.",
        "label": "Farmland Development Cost Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_FiniteLivedIntangibleAssetUsefulLifeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "FiniteLivedIntangibleAssetUsefulLifeDescription",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of intangible assets, description",
        "label": "Finite Lived Intangible Asset Useful Life Description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r279",
      "r296",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1081"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r723",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r723",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r723",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r723",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAmortizationsofthePrepaymentforLeaseofLandUseRightTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r723",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails",
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable",
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r299",
      "r300",
      "r546",
      "r547",
      "r723"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amortizations of the Prepayment for Lease of Land Use Right [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r296",
      "r547",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296",
      "r299",
      "r300",
      "r301",
      "r546",
      "r723",
      "r748"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails",
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r299",
      "r300",
      "r723"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 7.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails",
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, net",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Amortization of prepayment",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r967"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "cjjd_ForestLandUseRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ForestLandUseRights",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forest land use rights",
        "documentation": "Forest Land Use Rights.",
        "label": "Forest Land Use Rights"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r828"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT LOSS",
        "negatedLabel": "Investment loss",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r911"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "verboseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r671"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r959",
      "r960"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "GROSS PROFIT",
        "terseLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r82",
      "r123",
      "r187",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r501",
      "r734",
      "r739",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r982"
     ]
    },
    "cjjd_GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd [Member]",
        "label": "Guoshu Lianren Zhejiang Medical And Health Management Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_HangzhouKahamadiBiotechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "HangzhouKahamadiBiotechnologyCoLtdMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hangzhou Kahamadi Biotechnology Co., Ltd [Member]",
        "label": "Hangzhou Kahamadi Biotechnology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_HangzhouUnitedBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "HangzhouUnitedBankMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hangzhou United Bank [Member]",
        "documentation": "Represents lender bank.",
        "label": "Hangzhou United Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_HongtongServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "HongtongServiceMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hongtong Service [Member]",
        "label": "Hongtong Service Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r805",
      "r817"
     ]
    },
    "cjjd_ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: impairment",
        "label": "Impairment Of Intangible Asset Indefinitelived Excluding Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forest land use rights impairment",
        "label": "Impairment of Leasehold",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMPAIRMENT OF LONG-LIVED ASSETS",
        "verboseLabel": "Impairment of long lived assets",
        "netLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32",
      "r99",
      "r764"
     ]
    },
    "us-gaap_ImpairmentOfRealEstate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfRealEstate",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/FarmlandAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Impairment of Real Estate",
        "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r971"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r100"
     ]
    },
    "cjjd_ImpairmentsOfFarmlandAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ImpairmentsOfFarmlandAssets",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable": {
       "parentTag": "us-gaap_Land",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Impairment",
        "documentation": "Represents impairments of farmland assets.",
        "label": "Impairments Of Farmland Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r119",
      "r123",
      "r551",
      "r566",
      "r734",
      "r739",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/Taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r436",
      "r441",
      "r448",
      "r449",
      "r450",
      "r452",
      "r455",
      "r462",
      "r464",
      "r465",
      "r466",
      "r616",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROVISION FOR INCOME TAXES",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r135",
      "r204",
      "r205",
      "r220",
      "r236",
      "r250",
      "r440",
      "r441",
      "r463",
      "r575",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r438",
      "r439",
      "r452",
      "r453",
      "r454",
      "r458",
      "r610"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r182",
      "r456",
      "r457"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "cjjd_IncreaseDecreaseInCustomerDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "IncreaseDecreaseInCustomerDeposit",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer deposits",
        "documentation": "The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.",
        "label": "Increase Decrease In Customer Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amount due from related parties",
        "label": "Increase (Decrease) in Due from Related Parties",
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories and biological assets",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cjjd_IncreaseDecreaseInLongTermDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "IncreaseDecreaseInLongTermDeposit",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term deposit",
        "label": "Increase Decrease In Long Term Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInNotesReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInNotesReceivables",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes receivable",
        "label": "Increase (Decrease) in Notes Receivables",
        "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r918",
      "r930"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables and accrued liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other noncurrent assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidSupplies",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Advances to suppliers",
        "label": "Increase (Decrease) in Prepaid Supplies",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cjjd_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted effect of stock options and warrants (in Shares)",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Stock Options And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r867",
      "r876",
      "r880",
      "r888"
     ]
    },
    "cjjd_InjectedFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "InjectedFunds",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Injected funds",
        "label": "Injected Funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r892"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r892"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r892"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "INTEREST EXPENSE",
        "label": "Interest and Debt Expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTEREST INCOME",
        "label": "Interest Income (Expense), Operating",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r947"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r180",
      "r181"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "verboseLabel": "Inventory, finished goods",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r728",
      "r772"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r145",
      "r161",
      "r276",
      "r277",
      "r278",
      "r544",
      "r731"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves inventory",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r922"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInvestmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment loss",
        "label": "Investment Income, Investment Expense",
        "documentation": "Amount of expenses related to the generation of investment income."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r787",
      "r1046"
     ]
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total amount of investment",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r634",
      "r635",
      "r701",
      "r704",
      "r708",
      "r710",
      "r781",
      "r789",
      "r1077"
     ]
    },
    "cjjd_InvestmentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "InvestmentPercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment percentage",
        "documentation": "Investment percentage.",
        "label": "Investment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r606",
      "r607",
      "r608",
      "r609",
      "r702",
      "r703"
     ]
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER NONCURRENT ASSETS",
        "label": "Investments and Other Noncurrent Assets [Text Block]",
        "documentation": "The entire disclosure for investments and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor [Member]",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1029"
     ]
    },
    "cjjd_JiuyiTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "JiuyiTechnologyMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuyi Technology [Member]",
        "label": "Jiuyi Technology Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_JiuzhenHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "JiuzhenHealthMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuzhen Health [Member]",
        "label": "Jiuzhen Health Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_JiuzhouClinicOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "JiuzhouClinicOneMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuzhou Clinic One [Member]",
        "label": "Jiuzhou Clinic One Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_JiuzhouDigitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "JiuzhouDigitalMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiuzhou Digital [Member]",
        "label": "Jiuzhou Digital Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_KahamadiBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "KahamadiBioMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kahamadi Bio [Member]",
        "documentation": "Kahamadi Bio.",
        "label": "Kahamadi Bio Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Land": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Land",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofFarmlandAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Farmland assets, net",
        "label": "Land",
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "cjjd_LandUseRightsAndPropertyOwnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LandUseRightsAndPropertyOwnershipMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land Use Rights and Property Ownership [Member]",
        "label": "Land Use Rights And Property Ownership Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LandUseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LandUseRightsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails",
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights [Member]",
        "verboseLabel": "Land Use Rights [Member]",
        "documentation": "Represents information of Land use rights.",
        "label": "Land Use Rights Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease cost (in Dollars)",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r771"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of lease",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "verboseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r528"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Liabilities Under Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "lease term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r58",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r65",
      "r187",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r478",
      "r481",
      "r482",
      "r501",
      "r644",
      "r733",
      "r789",
      "r982",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r117",
      "r561",
      "r772",
      "r935",
      "r956",
      "r1022"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r144",
      "r187",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r478",
      "r481",
      "r482",
      "r501",
      "r772",
      "r982",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable",
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License [Member]",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit borrowing",
        "verboseLabel": "Line of credit total",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r114",
      "r1042"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank credit line facilities available for borrowing",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61",
      "r318",
      "r934",
      "r980"
     ]
    },
    "cjjd_LinjiaMedicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LinjiaMedicalMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Linjia Medical [Member]",
        "label": "Linjia Medical Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LiquidityAndCapitalResourcesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LiquidityAndCapitalResourcesMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Capital Resources [Member]",
        "label": "Liquidity And Capital Resources Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LoanPayableDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LoanPayableDetailsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Payable (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LoanPayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LoanPayableDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LoanPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LoanPayableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOAN PAYABLE",
        "label": "Loan Payable Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/TradeReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE RECEIVABLES",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r951"
     ]
    },
    "us-gaap_LoansPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM INVESTMENT",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "cjjd_LongTermDepositsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LongTermDepositsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG TERM DEPOSITS",
        "documentation": "The entire disclosure for long-term deposits. Long term deposits are money deposited with or advanced to landlords for securing retail store leases.",
        "label": "Long Term Deposits Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LongTermInvestmentDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LongTermInvestmentDetailsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LongTermInvestmentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LongTermInvestmentDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_LongTermInvestmentImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "LongTermInvestmentImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "documentation": "Long-term investment impairment loss.",
        "label": "Long Term Investment Impairment Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investment",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and promotion costs",
        "label": "Marketing and Advertising Expense",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails",
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r399",
      "r435",
      "r493",
      "r543",
      "r594",
      "r595",
      "r602",
      "r636",
      "r637",
      "r700",
      "r705",
      "r706",
      "r707",
      "r709",
      "r721",
      "r722",
      "r744",
      "r754",
      "r759",
      "r766",
      "r767",
      "r768",
      "r769",
      "r774",
      "r984",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "cjjd_MedicalDevicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "MedicalDevicesMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical devices [Member]",
        "verboseLabel": "Medical Devices [Member]",
        "documentation": "Represents information regarding Medical Devices.",
        "label": "Medical Devices Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails",
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r399",
      "r435",
      "r493",
      "r543",
      "r594",
      "r595",
      "r602",
      "r636",
      "r637",
      "r700",
      "r705",
      "r706",
      "r707",
      "r709",
      "r721",
      "r722",
      "r744",
      "r754",
      "r759",
      "r766",
      "r767",
      "r768",
      "r774",
      "r984",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r116",
      "r187",
      "r267",
      "r319",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r501",
      "r560",
      "r648"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "cjjd_MotorVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "MotorVehiclesMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicles [Member]",
        "label": "Motor Vehicles Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.",
        "verboseLabel": "Net loss attributable to controlling interest (in Dollars)",
        "netLabel": "Net loss approximately",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r92",
      "r120",
      "r142",
      "r165",
      "r167",
      "r172",
      "r187",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r212",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r471",
      "r475",
      "r492",
      "r501",
      "r569",
      "r668",
      "r690",
      "r691",
      "r787",
      "r982"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r109",
      "r165",
      "r167",
      "r201",
      "r204",
      "r205",
      "r568",
      "r926"
     ]
    },
    "cjjd_NetLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "NetLossPerShareDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r867",
      "r876"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r374",
      "r938",
      "r939",
      "r940",
      "r942",
      "r1079"
     ]
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/NotesPayableDetails",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "verboseLabel": "Balance",
        "netLabel": "Bank notes payable",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "cjjd_NotesPayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "NotesPayableDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_NotesPayablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "NotesPayablePolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "documentation": "Disclosure of accounting policy for notes payable.",
        "label": "Notes Payable Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableToBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableToBanksMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable to Banks [Member]",
        "label": "Notes Payable to Banks [Member]",
        "documentation": "A written promise to pay a note to a bank."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note receivable",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r655",
      "r953",
      "r1044"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Main reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r743",
      "r946"
     ]
    },
    "cjjd_NutritionalSupplementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "NutritionalSupplementsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nutritional supplements [Member]",
        "verboseLabel": "Nutritional Supplements [Member]",
        "documentation": "Represents information regarding Nutritional Supplements.",
        "label": "Nutritional Supplements Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OTCDrugsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OTCDrugsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTC drugs [Member]",
        "verboseLabel": "OTC Drugs [Member]",
        "label": "OTCDrugs Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment &amp; furniture [Member]",
        "verboseLabel": "Office Equipment and Furniture [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OnlinePharmacyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OnlinePharmacyMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retail drugstores [Member]",
        "verboseLabel": "Online Pharmacy [Member]",
        "documentation": "Represents information regarding online pharmacy.",
        "label": "Online Pharmacy Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OPERATING EXPENSES",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r734",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Liabilities Under Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLeaseLiabilitiesUnderOperatingLeasesTable",
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows paid for operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r523"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r771"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r771"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OperatingLeasesAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases:",
        "label": "Operating Leases Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable",
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments [Member]",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r739",
      "r740"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Organization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DESCRIPTION OF BUSINESS AND ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r108",
      "r604",
      "r605"
     ]
    },
    "cjjd_OriginationDateEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateEightMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "02/27/23 [Member]",
        "label": "Origination Date Eight Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateEighteenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/22/23 [Member]",
        "label": "Origination Date Eighteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateElevenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "11/17/22 [Member]",
        "documentation": "Origination Date",
        "label": "Origination Date Eleven Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateFifteenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/20/23 [Member]",
        "label": "Origination Date Fifteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateFiveMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/26/22 [Member]",
        "label": "Origination Date Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateFourMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/16/22 [Member]",
        "label": "Origination Date Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateFourteenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/29/22 [Member]",
        "label": "Origination Date Fourteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateNineMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/20/23 [Member]",
        "label": "Origination Date Nine Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateNineteenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/27/23 [Member]",
        "label": "Origination Date Nineteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateOneMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "10/19/22 [Member]",
        "label": "Origination Date One Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateSevenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "01/16/23 [Member]",
        "label": "Origination Date Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateSeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateSeventeenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "11/21/23 [Member]",
        "label": "Origination Date Seventeen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateSixMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/28/22 [Member]",
        "label": "Origination Date Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateSixteenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "10/12/23 [Member]",
        "label": "Origination Date Sixteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/23/23 [Member]",
        "label": "Origination Date Ten Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateThirteenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/21/22 [Member]",
        "label": "Origination Date Thirteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateThirtyMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/15/24 [Member]",
        "label": "Origination Date Thirty Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateThirtyOneMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/28/24 [Member]",
        "label": "Origination Date Thirty One Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateThirtyTwoMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/29/24 [Member]",
        "label": "Origination Date Thirty Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateThreeMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "11/17/22 [Member]",
        "label": "Origination Date Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwelveMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/16/22 [Member]",
        "label": "Origination Date Twelve Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyEightMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "01/11/24 [Member]",
        "label": "Origination Date Twenty Eight Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyFiveMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/14/24 [Member]",
        "label": "Origination Date Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyFourMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "03/13/24 [Member]",
        "label": "Origination Date Twenty Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/28/23 [Member]",
        "label": "Origination Date Twenty Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyNineMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "02/06/24 [Member]",
        "label": "Origination Date Twenty Nine Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyOneMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "01/03/24 [Member]",
        "label": "Origination Date Twenty One Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentySevenMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/28/23 [Member]",
        "label": "Origination Date Twenty Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentySixMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12/27/23 [Member]",
        "label": "Origination Date Twenty Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyThreeMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "02/06/24 [Member]",
        "label": "Origination Date Twenty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwentyTwoMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "01/11/24 [Member]",
        "label": "Origination Date Twenty Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OriginationDateTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OriginationDateTwoMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "10/20/22 [Member]",
        "label": "Origination Date Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ASSETS",
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r772"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrentDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation loss",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r75",
      "r76",
      "r77",
      "r503",
      "r504",
      "r506"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FOREIGN CURRENCY TRANSLATION ADJUSTMENTS",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r570"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER COMPREHENSIVE LOSS",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r772"
     ]
    },
    "us-gaap_OtherLoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other Loans Payable, Current",
        "documentation": "Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r642",
      "r643"
     ]
    },
    "cjjd_OtherNoncurrentAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OtherNoncurrentAssetsDetailsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_OtherNoncurrentAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OtherNoncurrentAssetsDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSES)",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSES):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from related parties",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r654",
      "r740",
      "r1044"
     ]
    },
    "cjjd_OtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "OtherReceivablesMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Receivables [Member]",
        "label": "Other Receivables Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables, net",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "cjjd_Others": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "Others",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofOtherNoncurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "documentation": "Amount of others assets.",
        "label": "Others"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r839",
      "r874"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r826",
      "r842",
      "r877"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r826",
      "r842",
      "r877"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInterestInJointVenture",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in a joint venture",
        "label": "Payments to Acquire Interest in Joint Venture",
        "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of equipment and building",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/PostretirementBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employment benefits and pension contribution",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/PostretirementBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "POSTRETIREMENT BENEFITS",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r756"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r646"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r646",
      "r666",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2024 and 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r556",
      "r772"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid rental expenses",
        "label": "Prepaid Rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r745",
      "r958"
     ]
    },
    "cjjd_PrescriptionDrugsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "PrescriptionDrugsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prescription drugs [Member]",
        "verboseLabel": "Prescription Drugs [Member]",
        "documentation": "Represents the information regarding prescription drugs.",
        "label": "Prescription Drugs Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of shares and warrants in private placements",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Gross proceeds of private placement (in Dollars)",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from notes payable",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from short-term bank loan",
        "label": "Proceeds from Other Short-Term Debt",
        "documentation": "Amount of cash inflow from short-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from other payable-related parties",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total proceeds of investment",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r545",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r725",
      "r755",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r978",
      "r979",
      "r985",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r545",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r725",
      "r755",
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r978",
      "r979",
      "r985",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r165",
      "r167",
      "r178",
      "r187",
      "r195",
      "r201",
      "r204",
      "r205",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r471",
      "r475",
      "r476",
      "r479",
      "r480",
      "r492",
      "r501",
      "r551",
      "r567",
      "r621",
      "r668",
      "r690",
      "r691",
      "r762",
      "r763",
      "r788",
      "r926",
      "r982"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r130",
      "r133",
      "r134"
     ]
    },
    "cjjd_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of Property And Equipment",
        "documentation": "Tabular disclosure of estimated lives of the property and equipment.",
        "label": "Property Plant And Equipment Estimated Useful Life Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r148",
      "r565"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Member]",
        "label": "Property, Plant and Equipment [Member]",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r528",
      "r552",
      "r565",
      "r772"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r130",
      "r133",
      "r563"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives of property and equipment",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_PropertyandEquipmentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "PropertyandEquipmentDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt direct write-off and provision and reversal",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r272"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit loss expense",
        "label": "Provision for Other Credit Losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r118"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails",
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r386",
      "r399",
      "r427",
      "r428",
      "r429",
      "r435",
      "r493",
      "r541",
      "r542",
      "r543",
      "r594",
      "r595",
      "r602",
      "r636",
      "r637",
      "r700",
      "r705",
      "r706",
      "r707",
      "r709",
      "r721",
      "r722",
      "r744",
      "r754",
      "r759",
      "r766",
      "r767",
      "r768",
      "r769",
      "r774",
      "r781",
      "r976",
      "r984",
      "r1020",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LeasesDetails",
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r315",
      "r316",
      "r386",
      "r399",
      "r427",
      "r428",
      "r429",
      "r435",
      "r493",
      "r541",
      "r542",
      "r543",
      "r594",
      "r595",
      "r602",
      "r636",
      "r637",
      "r700",
      "r705",
      "r706",
      "r707",
      "r709",
      "r721",
      "r722",
      "r744",
      "r754",
      "r759",
      "r766",
      "r767",
      "r768",
      "r769",
      "r774",
      "r781",
      "r976",
      "r984",
      "r1020",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r263",
      "r954"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r818",
      "r834",
      "r869"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/LoanPayableDetails",
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r390",
      "r533",
      "r534",
      "r554",
      "r562",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r665",
      "r667",
      "r699"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Others (the directors of subsidiaries) [Member]",
        "netLabel": "Related Party [Member]",
        "label": "Other [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r533",
      "r534",
      "r535",
      "r536",
      "r554",
      "r562",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r665",
      "r667",
      "r699"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r1031"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r672",
      "r673",
      "r676"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions and Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/LoanPayableDetails",
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r390",
      "r533",
      "r534",
      "r554",
      "r562",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r665",
      "r667",
      "r699",
      "r1031"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS AND ARRANGEMENTS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r534",
      "r537",
      "r617",
      "r618",
      "r619",
      "r674",
      "r675",
      "r676",
      "r696",
      "r698"
     ]
    },
    "cjjd_RenovationInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "RenovationInvestmentMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renovation Investment [Member]",
        "documentation": "Represents the information regarding Renovation Investment.",
        "label": "Renovation Investment Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_RenovationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "RenovationMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renovation [Member]",
        "label": "Renovation Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_RepaymentOfOtherPayablesrelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "RepaymentOfOtherPayablesrelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of other payable-related parties",
        "documentation": "The amount of repayment of other payables-related parties.",
        "label": "Repayment Of Other Payablesrelated Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_RepaymentsOfOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfOtherShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of short-term bank loan",
        "label": "Repayments of Other Short-Term Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of third parties loan",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "cjjd_ReserveFundPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ReserveFundPercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve fund percentage",
        "documentation": "Reserve fund percentage.",
        "label": "Reserve Fund Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r819",
      "r835",
      "r870"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r820",
      "r836",
      "r871"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r827",
      "r843",
      "r878"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r932",
      "r1040",
      "r1043"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r146",
      "r183"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of cash equivalents and restricted cash [Abstract]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "cjjd_RetailDrugstoresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "RetailDrugstoresAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retail drugstores",
        "label": "Retail Drugstores Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_RetailDrugstoresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "RetailDrugstoresMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retail drugstores [Member]",
        "label": "Retail Drugstores Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r106",
      "r559",
      "r599",
      "r601",
      "r615",
      "r647",
      "r772"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r268",
      "r269",
      "r302",
      "r459",
      "r460",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r483",
      "r485",
      "r486",
      "r488",
      "r490",
      "r515",
      "r518",
      "r596",
      "r598",
      "r622",
      "r1079"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r220",
      "r229",
      "r230",
      "r244",
      "r250",
      "r253",
      "r255",
      "r256",
      "r383",
      "r384",
      "r545"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r724"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES, NET",
        "verboseLabel": "Revenue",
        "netLabel": "Net revenue from external customers",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r173",
      "r187",
      "r220",
      "r229",
      "r230",
      "r244",
      "r250",
      "r253",
      "r255",
      "r256",
      "r267",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r501",
      "r551",
      "r739",
      "r982"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r771"
     ]
    },
    "cjjd_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:",
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock units",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SapSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SapSoftwareMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Sap Software Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable",
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "auth_ref": [
      "r206",
      "r400",
      "r913",
      "r941"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r74",
      "r258",
      "r955"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/TradeReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Receivables",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r74"
     ]
    },
    "cjjd_ScheduleOfAdvanceToSuppliersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfAdvanceToSuppliersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Advance To Suppliers Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfBasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfBasicAndDilutedEarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Earnings Per Share [Absttract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfConsolidatedFinancialStatementsActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Consolidated Financial Statements Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfCreditFacilitiesWithBanksAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfCreditFacilitiesWithBanksAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Credit Facilities With Banks Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Investment",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r36",
      "r37",
      "r53",
      "r104",
      "r105",
      "r750",
      "r752",
      "r937",
      "r1023"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/TaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Provision at the Federal Statutory Rate and Effective Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r761",
      "r1013"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of net revenue from external customers through its retail drugstores by main products",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r467",
      "r914",
      "r915",
      "r916",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "cjjd_ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfEstimatedUsefulLivesOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives of Intangible Assets",
        "documentation": "Tabular disclosure of estimated useful lives of intangible assets.",
        "label": "Schedule Of Estimated Useful Lives Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfEstimatesFutureExpectedLossesOnAccountsReceivableAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimates Future Expected Losses On Accounts Receivable And Other Receivables Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfFarmlandAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfFarmlandAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Farmland Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfFarmlandAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfFarmlandAssetsTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/FarmlandAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Farmland Assets",
        "documentation": "Tabular disclosure for farmland assets.",
        "label": "Schedule Of Farmland Assets Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296",
      "r299",
      "r300",
      "r301",
      "r546",
      "r723",
      "r748"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of net Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r966"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Credit Facilities with Banks",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r61"
     ]
    },
    "cjjd_ScheduleOfLongTermInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfLongTermInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Long Term Investment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfNetIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfNetIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfNetRevenueFromExternalCustomersThroughItsRetailDrugstoresByMainProductsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Revenue From External Customers Through Its Retail Drugstores By Main Products Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Noncurrent Assets",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "cjjd_ScheduleOfOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfOtherNoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfOtherNoncurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Noncurrent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r528"
     ]
    },
    "cjjd_ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfReconciliationOfCashEquivalentsAndRestrictedCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reconciliation Of Cash Equivalents And Restricted Cash Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r672",
      "r673",
      "r676"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/RelatedPartyTransactionsandArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r110",
      "r1043"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Cash Equivalents and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r110",
      "r1043"
     ]
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Source in each Segment",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfRevenueByMajorSourceInEachSegmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfRevenueByMajorSourceInEachSegmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue By Major Source In Each Segment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ScheduleOfSegmentOfTheContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ScheduleOfSegmentOfTheContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Segment Of The Continuing Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment of the Continuing Operations",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Financial Statements Activities",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/OtherNoncurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortizations of the Prepayment for Lease of Land Use Right",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r968"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r220",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r256",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r301",
      "r309",
      "r310",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r736",
      "r739",
      "r740",
      "r747",
      "r776",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENTS",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r240",
      "r242",
      "r243",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r735",
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SegmentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SegmentsDetailsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SegmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SegmentsDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SELLING EXPENSES",
        "verboseLabel": "Selling expenses",
        "label": "Selling Expense",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow",
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK BASED COMPENSATION",
        "verboseLabel": "Share-based compensation",
        "netLabel": "Stock based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r405",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434"
     ]
    },
    "cjjd_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder\u2019s Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in Dollars per share)",
        "verboseLabel": "Shares issued per share (in Dollars per share)",
        "netLabel": "Purchase price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SharesRepurchasePercentage": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SharesRepurchasePercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchase percentage (in Shares)",
        "documentation": "Percentage of shares repurchase.",
        "label": "Shares Repurchase Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term loan payable",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r113",
      "r772",
      "r1041"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_ShorttermDebtAverageOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShorttermDebtAverageOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/LoanPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank loan",
        "label": "Short-Term Debt, Average Outstanding Amount",
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r677"
     ]
    },
    "cjjd_ShouantangBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ShouantangBioMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shouantang Bio [Member]",
        "documentation": "Represents information regarding Shouantang Bio.",
        "label": "Shouantang Bio Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ShouantangClinicMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ShouantangClinicMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shouantang Clinic [Member]",
        "label": "Shouantang Clinic Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r184"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "cjjd_SongluPharmaceuticalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SongluPharmaceuticalMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails",
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Songlu Pharmaceutical [Member]",
        "label": "Songlu Pharmaceutical Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable",
      "http://chinajojodrugstores.com/role/ScheduleofSegmentoftheContinuingOperationsTable",
      "http://chinajojodrugstores.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r141",
      "r220",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r256",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r301",
      "r303",
      "r309",
      "r310",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r736",
      "r739",
      "r740",
      "r747",
      "r776",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r154",
      "r155",
      "r156",
      "r187",
      "r210",
      "r211",
      "r213",
      "r215",
      "r222",
      "r223",
      "r267",
      "r319",
      "r322",
      "r323",
      "r324",
      "r328",
      "r329",
      "r358",
      "r359",
      "r362",
      "r365",
      "r372",
      "r501",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r646",
      "r669",
      "r692",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r912",
      "r933",
      "r943"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r71",
      "r72",
      "r139",
      "r170",
      "r171",
      "r172",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r221",
      "r268",
      "r269",
      "r302",
      "r374",
      "r459",
      "r460",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r515",
      "r518",
      "r529",
      "r570",
      "r596",
      "r597",
      "r598",
      "r622",
      "r692"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r221",
      "r518",
      "r545",
      "r606",
      "r633",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r670",
      "r671",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692",
      "r782"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable",
      "http://chinajojodrugstores.com/role/ScheduleofReconciliationofCashEquivalentsandRestrictedCashTable"
     ],
     "auth_ref": [
      "r206",
      "r400",
      "r913",
      "r917",
      "r941"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r221",
      "r257",
      "r518",
      "r545",
      "r606",
      "r633",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r670",
      "r671",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r692",
      "r782"
     ]
    },
    "cjjd_StatutoryAccountsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "StatutoryAccountsPercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory accounts percentage",
        "documentation": "The percentage of statutory accounts.",
        "label": "Statutory Accounts Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_StatutoryReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "StatutoryReserves",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserves",
        "documentation": "The amount of statutory reserves.",
        "label": "Statutory Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_StatutoryReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "StatutoryReservesMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserves",
        "label": "Statutory Reserves Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r822",
      "r838",
      "r873"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_StockIssuedDuringPeriodShareSaleOfStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "StockIssuedDuringPeriodShareSaleOfStockAndWarrants",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares and warrants in private placements (in Shares)",
        "documentation": "The amount of sale of stock and warrants, shares.",
        "label": "Stock Issued During Period Share Sale Of Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in Shares)",
        "verboseLabel": "Shares issued",
        "netLabel": "Aggregate of ordinary shares (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r106",
      "r611",
      "r692",
      "r712"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of restricted stock awards (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fractional shares issued for reverse stock split (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise of warrants (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r106",
      "r411"
     ]
    },
    "cjjd_StockIssuedDuringPeriodValueForReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "StockIssuedDuringPeriodValueForReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fractional shares issued for reverse stock split",
        "documentation": "Amount of fractional shares issued for reverse stock split.",
        "label": "Stock Issued During Period Value For Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds (in Dollars)",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_StockIssuedDuringPeriodValueSaleOfStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "StockIssuedDuringPeriodValueSaleOfStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares and warrants in private placements",
        "documentation": "The amount of sale of stock and warrants.",
        "label": "Stock Issued During Period Value Sale Of Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r66",
      "r67",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cashless exercise of warrants",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r71",
      "r72",
      "r106"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity attributed to China Jo-Jo",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r71",
      "r72",
      "r95",
      "r648",
      "r666",
      "r693",
      "r694",
      "r772",
      "r789",
      "r935",
      "r956",
      "r1022",
      "r1079"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r47",
      "r139",
      "r140",
      "r171",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r268",
      "r269",
      "r302",
      "r374",
      "r459",
      "r460",
      "r468",
      "r469",
      "r470",
      "r472",
      "r474",
      "r475",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r507",
      "r508",
      "r512",
      "r516",
      "r529",
      "r597",
      "r598",
      "r620",
      "r648",
      "r666",
      "r693",
      "r694",
      "r716",
      "r788",
      "r935",
      "r956",
      "r1022",
      "r1079"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder\u2019s Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDER\u2019S EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r186",
      "r357",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r489",
      "r695",
      "r697",
      "r717"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity, Reverse Stock Split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r539"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r540"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofConsolidatedFinancialStatementsActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Background",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, State",
        "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails",
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofIntangibleAssetsTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Intangible Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatedUsefulLivesofPropertyAndEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimated Useful Lives of Property And Equipment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesLineItems",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofEstimatesFutureExpectedLossesonAccountsReceivableandOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of Estimates Future Expected Losses on Accounts Receivable and Other Receivables [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_SundryProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "SundryProductsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sundry products [Member]",
        "verboseLabel": "Sundry Products [Member]",
        "documentation": "Sundry Products [Member].",
        "label": "Sundry Products Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet",
      "http://chinajojodrugstores.com/role/ScheduleofAdvancetoSuppliersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Advance to suppliers, net",
        "terseLabel": "Advances to suppliers",
        "label": "Prepaid Supplies",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r746",
      "r958"
     ]
    },
    "cjjd_TCMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "TCMMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable",
      "http://chinajojodrugstores.com/role/ScheduleofRevenuebyMajorSourceineachSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TCM [Member]",
        "label": "TCMMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1030"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofCreditFacilitieswithBanksTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAccountsReceivableMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofTradeReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable [Member]",
        "label": "Trade Accounts Receivable [Member]",
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/TaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits (in Dollars)",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r451",
      "r760"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r128",
      "r129",
      "r131",
      "r132"
     ]
    },
    "us-gaap_UseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseRightsMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land use rights [Member]",
        "label": "Use Rights [Member]",
        "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r967",
      "r969",
      "r970"
     ]
    },
    "cjjd_VATPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "VATPercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT percentage",
        "documentation": "VAT percentage.",
        "label": "VATPercentage"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ValueAddedTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ValueAddedTaxPolicyTextBlock",
     "presentation": [
      "http://chinajojodrugstores.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value added tax",
        "documentation": "Disclosure of accounting policy for value added tax.",
        "label": "Value Added Tax Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableInterestEntityOwnershipPercentage",
     "presentation": [
      "http://chinajojodrugstores.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor Vehicles [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r780",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Shares)",
        "verboseLabel": "Weighted average shares used in diluted computation (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r215"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://chinajojodrugstores.com/role/ConsolidatedIncomeStatement",
      "http://chinajojodrugstores.com/role/ScheduleofBasicandDilutedEarningsPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "verboseLabel": "Weighted average shares used in basic computation (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r215"
     ]
    },
    "cjjd_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofleaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Weighted Average Remaining Lease Term Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_WholesaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "WholesaleMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofNetRevenuefromExternalCustomersthroughitsRetailDrugstoresbyMainProductsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wholesale [Member]",
        "label": "Wholesale Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://chinajojodrugstores.com/role/DescriptionofBusinessandOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital deficit",
        "documentation": "Working capital deficit.",
        "label": "Working Capital Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "cjjd_ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zhejiang Jiuzhou Digital Medicine Technology Co., LTD [Member]",
        "label": "Zhejiang Jiuzhou Digital Medicine Technology Co LTDMember"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ZhetongMedicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ZhetongMedicalMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/ScheduleofLongTermInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zhuoli Life [Member]",
        "label": "Zhetong Medical Member"
       }
      }
     },
     "auth_ref": []
    },
    "cjjd_ZhuoliServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://chinajojodrugstores.com/20240331",
     "localname": "ZhuoliServiceMember",
     "presentation": [
      "http://chinajojodrugstores.com/role/LongTermInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zhetong Service [Member]",
        "verboseLabel": "Zhuoli Service [Member]",
        "label": "Zhuoli Service Member"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001013762-24-002657-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001013762-24-002657-xbrl.zip
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M2Z)U-H,Q$W-D4A !2/L/((Z=JG*UAM!O50X66LOLG4)[C:E3S[8A=GVR//4
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M=PN%>Z<@U=<._S$T N(QD/>-AN7,9FYK=1W[Z?[O)PC.4MBS86[D(,*#&\?
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M<\&!(BC-F%?\GO.:'VZ.%SK^4R,@A--\Q0/<[HW_>>MNRM&54I 3O^2DP#E
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MU.6\MV K<1^RK49&]]^H*(VH0M4;%$O5*DFYM2LUA-@.TZM <WP7/R?)FEV
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M%[S=0 W6ZCO,)GM[@4D P-\'@X1GTH+/!$K7]=8$'?F&ECMH-MT7U9AO\J3
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MZ5%53J-D#4?=Z%!TF$4[3E1J'%&NS.@"D\IG5@)2R&/H(<L$YT"=/DVT:[N
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M]E9,]_($@H*3ZX<P6)9.,Z,-.HZ"PS<9@[MR)'; &3(UWQVNA$RUUUB],+?
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M]77%=D^09'24XFB/,"/MT9EZ#3=<MKS,"AH'>&>$^0#>G7H-.+85N!B)=VL
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M;Q+J5<76F.I=<U;_P-@V*DISW#M*Y"IIR;O4&'M93L@FR$A8G(9^D.5)G=1
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M'_R:;4P,/%^GK'&01WZRNP(9@"C\T$D"LAFBX@D/)N$8 _N!^H%'PE-:,&,
MK/##&0 KGK!.IZNO*<FS34G^^CSDZ_.0>3T/L7D:(GH6<J! 6CP*^?H&H8<Q
M:"#8Y&$":JK'Z=Z@C!=UQ(5$_G6R)%&5*W1:Z+?]//J%2"Q>9.G3[0&I?K)E
M,[#EJS)]4H(4B_'\3]_ <;3H]H_5C+&#Z.1H%7K-']+ #TBRO2/%(W5>:1@C
MQ4%*!^]H&72FCUKGK2"M'$6T0B)[0E=DS?Z)W<!1@^ $L755<L/04FY)3 ,^
M\!NN/G'X) @]Z;G-C8 5H&:?LE')82<A25-$K2FE\T5H33F*6(5WFY10M*2
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M H9.&4)[Y/?6Q3G["4SHICOF' Y=*1XU_$!=#_JT2G%#H]\<=0;^,04DM0#
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ME!3U^/MK/OP#22F?^_\/4$L#!!0    ( +B _EBL>#>NY,   /^9"0 5
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M4A;I_<*1Y\[&::VT[)7363Z+%B*]PKLP]GKS]QP-;S"I1YVVX(R.LC-ZVF$
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MN)YM\KG),P=\$0<X)^1#(&VQ;7-07=!Z8&VC[B_#+0WIR>OMSG'BI14K3&3
MEZ9L^/"AP!J4-R<D?RZZH0L<X#7T%,-.UGM5J==RWBNMC_8A9XY]6J#LSHF2
MEV5$3&0R(D5\;_GO&\@9M6>;N '3SK)NB/5#Y8YLUQ]%$:WWDM?@'$+\F:R4
MJPGT)19'4R<"8_?@8A%1&@+6A-F- 9@-H["KA PEX-36/;=(PM6G3>@3&SRF
M&:Z2%^H*[DE[-1 SZ[@1,P,=:C9.A--.?_KC-V>G[_\:H[3S4#9..8%6"P8W
M+H2NCV?L1 $Q!.,['+&5Z^OL#9$Q&60',0%=&.$$W81QC$A[Q#H,YWS;(+7*
M&4 TZSX"F9ONXD4,\6[A;V:+!;H;S]'B^]%\_)WU$UE':W^BE:'D\!#PPHF]
M%;&<KSQ_3[8=N0^Y\36H[*@6WH5*LB;A[&(C,4LV&POE@]6_=7N&;3MI<QZ.
MJBR?OF,J*V4_QSL:IA$\]F6G0&1,[B<0$Q "T^;#N2QHDE7%!!'-52.:FMYD
M7Y*S5NA[+O,!3!*\E:[LV1"&  QL ALP>;C.]*$Q8JWMGGZ:)9-'(@CFJ>VM
M6>P?8OSKGD!M_-1CTEV0C%'] 3 !Z8^B.4K;#^9 TR"S:HH_P9S;5"X4I,!H
M'\72;TZ,YD)G,BDP1HO%>+FP;1W#>2P$DVDM][R,2Y_BK]/H.F6%' AJ7$";
MROU\/IXNT9 P <CH&!J\*>H;I)=.O*%%=<E_J.ODR?&9VDDNG2AZ(8;,1\?O
M_*V6'$WSSU>E^((@13JQ(].*_@,?NMN]A%*1;N7Z27HIM"\ "'R]%3EIV4"@
M*G7S6%3D$+Q!R$=AN+1<MEE+XM4K!/5%T<1GD3ZW^\=8E:'-(ZM,OB'W<>4Q
MOM6<Q\ 3D:.Y=&QU2#S3J;/ ?RB5M7F%UE[@Q1OR/3Z&H6O]&:_J^IYH7Z2P
M#%"EDNR]5<,6$#)MDL*L"!- EHHN#^!!7;/@CA)]P5-6MU.9E_9JCZ\)4]D-
M<DROD(^*/P"N>Z"K.;4KX )  6F,J P($-+[_UW:W X.) 10>-,%T]1-ZGD?
ML)^PJW1A<]S+L,"/& !D;;.J,+BTA3SYLVB3ENJ0![#_K,#V'%(<)B"-O_Q^
M/*_[(>QF<I1,X]M9OICCPF(=0X)'P3@D.$R(*H#1$EK(*]K:3B</RZBA1EPK
MW5\M22"E^&M=C(F90URN6H"UNW/^X@(U1%HZ&8M\\_WF3@;)&/_:(4X:/WDW
MZVC54],D+FXI 3BMLND3N8@E;@ 5+>< K+X=?=N5 )1CJ(I]OI*<BR7GG:WO
MXS3[1M<6FY"6>=M-Q YDQ=7RB$:TU^MP_7H?XX%4G9<1*)PRD+<,G9WH3O2.
M=/74X39.=2<2QSK[Y[J3H]T=F(AVGNE#1LE1X!Z'8_>5/$&6K(7T_K*\01;!
M9'0QN9DL)^,%&DVOTMC>[V<W5^/Y(HO;1^-_W$^6/]NM"JPH^,II066%.D!F
MOT$0 D*FW<XP*PWA$"70V;: FN4&0*G;Z(C%)HP2>J2]"*,H_$P#@CO&#8^"
M<9N'PP3X?(BT3(\J/DT&LTOSJ=B-KX.%5 FM R;9)KIJM0KW09)GE>GG0@L@
M8O[BF,\(%&Z7-3Y&B)40*Z&@*C%6\"0USU+ES'3]((1'P;@.X3 AS#0X!,TA
M$ V46_#X-M.T>P/@AN?9N'!\6N%\0"D<U5?YI#/[Z=MTB0.<:"PO+]?JA1-\
M0@$7S5_<,I]JNXKHE5 YMUJ/81T\,G8N]SB<"&,Z,GQ8#J=JDM7151\TS;97
MP,<&>R]P.:9BXT$OP(L@^B,)!;$?%I$#2NT8./SI*K][8MZJRWV<A%L<9:YN
M+F( KR'0U7 T")\+Z#2>-3Z^C3#M2!2O>^%,%,RNA9Y@B2-[W5)X%(SO)APF
MA)DTAV V"T135@30U-H=N*,]=GO?/F Z%ES)(#/PT9NVYY=4LW7\%HNM=@(7
M3%<[_IA?;J@GZT-,S$:U82%'X$Z4%AMF;]K3<A)?5L5$D972O""J4./?K)WJ
MW6Z>#N!V\_2+N-T\/3)(@(ETK#KZ*P'?2,_**::)J\;8)AG=8>MX(RMB"17"
MBX%JKT;.]-3(V0#4R-D7H4;.FM7(62LU<AENMUX:%4M?+K(DPX\X6!V]9.DB
M[2](R<*K:I@;R.Z8W=Y.EK?CZ3(-?KB<39>3Z8?Q]+)\,VTGIV^3"&LY?(4S
MUTEP=@3*<SW%<#X Q7#^12B&\V;%<-XNQV2?,5*<2"BSV0QEHIUDHIOL& ;-
M84Q L)*F@X.JC#!@P5"]9-ZH#V\Z-JG. '1I$KE>X$0O**:Y]^*_HO_OY*NS
MM]09CIYHM[^BTZ]/7IV<L/]EC9"S3S9AY/V&7?+G5^_?GK\Z?W?&<G*<OCK]
MYNVK;]Z=YDV].*8>$OJW<)_$"?D'M4N=F)YQ;PD^-NC\]!6BZ\<:D7^<OT*D
MYRZM%^"_V+W(@6!2WWV.EKI%HIC#<'=.-(MHM1/LLI'S'(G]@16D:,&5(L&6
M'*I?'?",_NP%Z"KT?2>*$3E6I"W^8MEMIR!R 'C"!>IZ+Y*(G9!DC1=+41->
M+CL9T?W^9'>B?JSE4&##Q:-";?>G/XXHV3D& =S(JHNC?<[V6:A!C@"PN-/7
MKZU3'7;"=O:^D911L>&' WA1Q%!J  W&B.')3HB>TJ1MU.86\".S=V3F)]TY
MTNY#VBY:R.*D2WM,+EQ/P TO9"]MCF+:_E7Q41Q]#5^P#$Z[L?'386>'PU'?
M*K5,:A!ZM<20HG(M'2D'IF$Y\A3"JKX&@]"U-:9D%&[YD#]DK=M2/D/0OS66
MY)4P_ZOY7<BEC4Z^(_H61Q%V>W,*\B@8]Q-SF(#J/N8MR\[!DY/3BG=0Z!P,
M/%_+ VCSN"6 01F)T#*V<$E7AS3D^Y,D:L-0D&.M&;RI]I-W 5H'G8H?26&1
MM#U)51H].Y,:B%GP0XLYDL4?[%.RL_7*"16&&N1<Z@QAO3B8!(1,W]#!K"A"
MJG:H'@B6X#-UP\2[LN#Z/E@W41L"GIJ/UA"H>(>$@2"KX8P@LP[Z&!NYKD=C
MM!W_SO'<27#I[+S$\3O&%D3%AAD&\ *]B2A:$XO+<U\36VN5=K#]-$(LN,K#
M",&,]:),J4FVI^G=YSC&T9-D2NWC7H:?TQTQ (45Y>UHY 9K:,6:%B_UH10E
M=U8M#FYSG#A><"AE.5JM]ML]>U9ZA=?>RNLZUDR"H'&_0C-/\"NJO"%RTY9V
MG;GRXJR63)&:?[LW>?F([.GO9;C=17B#@]A[PI-@%6XQ+1,]Q<ELO72>N]Z2
M%*E;29NCPJ$$'$.64F!5'@=Y;"#;CE--+-2>_RDOEV;PP*T7D$-B\C()B!!Q
MW+4Z/!K>M.E=9P#,QT-6-4C(F#YU@7I9:^N/<B#QE-'"G:*^&3W'3SC8=_X@
MHQC6AJ&<$X=*A(T_CJ?WX\4K-!TO;9ZIZFM?W<5*<[!Q"5EF@'?AF/W=MH4@
MMX(6K@G+Y'E7@D2=$R.=M4EKW^!G FQZ7%MEV27LID2775J=FS[^FY*W4F<Q
M3C?[[WK>?A'O>MZ692F:B/Z#OYC8*!]HG3>:X):<Z;P5CA>AWWUX(DC(_/L.
MB!7PK=]BB6;7Z,-L=K5 B]G-E?6@]R:I56_^A?/M_EI(*F!&Q!-O]Z(]Z+UW
MK2;A%[[Z]03Q+93QUWK*^.L!*..OOPAE_'6S,OZZPZ0<[_3D^6X \GSW1<CS
M7;,\W[7:7!>8G5;'SSL<Q%U'G]0&-Y^/NT(?\FZ/;VXFTP]H_-/=>+JPG[*=
M+Y%*!N[C:=E)H7O,"&]7S%J1HPAK9CEWI\[R:M?_^8 #'#D^V51'[I96+$YH
MII,GW,_GUD3-M!';P _P/7X83\?ST0W+6#&ZNIU,)XOE?+2<?!P??Z(6\",I
MTC*@9-;!BH4KP1CO@\ZZL7A.I]*1]XW_?H2D90@76H5&*EPX,7:I)YX,Z= [
MZ*XW7#X1\Y<U?$:@'7@YN_P[NA@MQC1'S2W]QLGW/IO:_,S%XJK6PP"GVK'"
ME=F106:X.S-M_?J!-F?78'E[RU]O%VM_TIVU*>>9A5GA^6E9\!(2K_R7NO2G
MVH>1R7;G>!%-]#1;TWQW-T3_9I53O\>^>QU&]YT;37(TS6M0*;X A3JYO1M-
MYC3Q%W4)WLRF'U[?$/OIJEX@VPK$E(1<1IS\BIC7N]*\\=3PH3-U'OJTC*I/
M^ULL;6Q.6,85M31G/+U]+*K77%']/F6EKMGY+JOW>F[#]P-P&[[_(MR&[\MB
M%DVD&WE^HR?/;P8@SV^^"'E^TRS/;]KE9J8A8M,P*'(+IQ%BV>&WIYR*DD2M
MU9II9 W*9[#\?CQ'DRDYRX[1GW.GU5^^L[H[J$GXJ!"-W%IHOT',X\XJ0T\[
MKY$.DC%^-0%Q EGTT^5X/EXL,U19/J W2:MB7(@FVL*?]L'Q AK .@LFP1,9
MGZ4'[MJASJ5AW(W.XP+$R4>"$G;RNYDM[#K*10*J>%[!^?417O=((Z*UEIM[
M="N:D,- ;-WMW7K)6[FXQ1N%4>/!2FT8(4=JML( ZALV"E+>1NCPJ/&MWE'C
MVP$<-;[](HX:WY;%*YI(1V5]3O0$>MJAWTBSJL])DSRMR_*PN(*:/B<MWWJD
M7_K2><X^]@L<X'7G;R(A*C8.AP OT!/\^>SC9#&93='UK-#TR]%/U4@C*U:\
M4'!5(QZ><4>%>4YU"WR=6E<$C?6]["L"F>)>IYJ* !A.L]+2Z9EU>3866K(O
M3XDJ2Z=G+14[.:0?WHF.DB3R'O8)+4*Z#*M/'7MZ]ZE.W[@71YE%J+C;>+'X
MCCX<9*=V-%HNYY.+^^7HXH9L%3,TG4UI[:;Y+(U4S9U!=@\)VO H;RQZ"]C9
M>X13S:I/I^?6E51CT2?[2DJBXM/I>;>;CN9KO].WUN79^-C/OCPE7OJ=OFVY
MZ8AR%1#[L\^;* FJQC<82<:$SB4:4CD??S^>+F@,=<4M;,^[)"_B(S>3Y'*T
M=60"9*[#"'N/05K@>/6RC)P@)B2],!@%+OO)9Y%P(_>7?>I8[2EC2T],FK[=
MZ&<:P =!3N#CR8<INKR?S\?3RY_1<CZ:+FY8M#$:7?UPG]Z=6+TWZ1=\LE]3
MRZ7O;$/7?#%Z^K7U#;WQP:C]#5WBM>CIU]W*4_/%Z.D[Z_)L?#!J7YX2KT5/
MW[4TT'XD:F&3D &?<.0\XNE^^X"CV?HH$6=/EIHR>1L.8E4F 63]2/:J[Y<T
M;/OC>#[Z,$;3^]L+8M#-KA&K]+JP&U&DBX3R%J2U4MI11K+4+IS86UD";DK;
MPO6U$H, 8MG?^)5A!@S0BKAUT'E8$@NU.)69Y,6QY(,@)QTESQ.]IP^4B#@?
MF&#I2Z5]PNP^J/S/_P@QMRC;"="Z\OP]^6W?2<U5J9M_]J3((:"'LN9<D X'
MH4U"E\"H<%W,/X/2X%)'&[F9>)OUT?\889]T%8^C^3;G]+WU UKCTQS[!S2)
M=SFG[UL>T/(,U7EQH#Z,63X-TZY#+A>-ENG@RL,+!596"_!\K60/ =GAJ72:
MF)1&2".G=,F+DA#Q4B9_\0)I%49='S53^SU_PCD5&_X2@!<)XT[X,0\ .C79
MB<!3GK2-U,P"?KK[H+]8D9ST<*<M>\>2O]8815Y,V+O:1^3_$QZ]T#5\M]@E
MQX.Y2^]P4M"U8TH!K3(2*#F,6GLW-* +QQ[@*7/[V+4X=(/%6(J>M'!=>6Q6
M>)/P2+.5$\"E5<AV?CW@':SYI#BH\6<KJAQ"D(]2F3E^M8XA6H<1RU!/!DEK
MTJ&8#F-GVVXEZ%+%*8TETT[8RB>6.@6.2'7](E:5NH7,<VH<=@3?P=QY:,*C
MDME+8P45\Z,V?C8+Q\>S-6M!M/Z/3D3T?AW,&BH6&-;@;9LFB]!S;S*&0S!!
MDQ'E%8@#%WW.>E%?Z2[RGIP$HYWOK#![YVOUO:&^T*74K6#U.H0H^Q2ZAZAH
MV(% 5,!BEQ"UKDY;2K\)JTW+J)EN6OAE&,D_J\Z A4@'=2ZAQ+4#S9^J#0,)
M,Z!IE7JQ:VV"5\B!Z2L/#1X5L6M=]78 "&EKM@''G2(Y_7#HWV8[2B4>/^-H
MY<6=>_;5Z9LOS*'*(E3URHDW/HYCA+.&U,K(30O+=29T42"M@\%U:I.E7OBU
MV .OB('A6! "+G4 /)3P)7U0R"MB(9@U7Z_3Q;V+PB?/Q>[%RST9<1+,\@1%
MHU7B/7F)A^.>(M4U&+" 9'4N(22/%M^CZYO9CPMT/9_=HMG=F%9MF7Y H\OE
MY.-D.;$=KZZ/B-J+=9T%TX7QX7U5O SGF$[3\W'EV?PRM OT7E@T;I+T,0NH
M!OV!%+TPCW)B*,COU,EOZ;]7A%P1]%BD5D-.0>@[RR?-/M%9*6;?EW!:F$I7
M>$<DY[$3 _FWC[,KRM$VC!+OMSY.J%(D31])99B"(GE*7=-J4J4^MDNAJ,BW
MC%7I]= _83*4QV2<ZS"Z"O</R7KOCU:K<-]]"EPA*1NQ8B*&P-A/%[GX(4&N
M1R23H,^1E^#7X7K-,+?+!V0_I7=[CF\;?3(B+J.N<5FT7ZP4*O0&.S&>T\CT
MV9IH5U8@H@SJGO*\JI*WDBY>D4G(,"BUI =!-A !ZFMB QQ5&+$2*J2)A4K<
MC\Y:Z249O-R0U<5E*X"M(5'&-Y[SX/D"JQBXN5,;T?2EG1)WT#F.C5$S.-DP
M3#_ZAX&^LWJ1K"7;XEY.?:5TKH^)=1I1D%_A]+^3@);76>)H2PR#,):,&6L>
MQ7B06"-+4)X[6MN*#+TE^S%K9^]R5UHV!6;D)JU=^^YH]'S[OG->6$:\R'$[
M+WXG1]12DET)UJ"--&N*=FE;^YEV%61;2[PKNPHM:J_4:;#0W!HA>H)9K:(]
M+FO(WN$HSXF%"B[:S$+IVFC_'++I=NND?<O;KMT:<^VQ(H:WVAKJQG8?T[W<
MQTFXQ5&[C;D^R@ VYAI+D-67M<KW93LH4Y.-8&/F3;K3C9F"<>D\XQRB)O;E
M(YH6BM+*\ 5 C#7A;<C#T&,"H39NR-P5T(SAXZC$RH$Y5X$O_>^] %W3#F9I
MSJ!MM3C'^K0Y?R\=!@@;1-VP=0I6I;/\?9JE/D^_L9X>HK'2I_WT$!)E/D^_
M:7EW -Q?IW7 +,9%B!@83ER$@$O)N(BT0M\7$!<A@0B)N(BF!>LH:XUF6;#3
M;ZVKI<:J8/;5DD1)L--O^U%+UU[@!"N+:DG$P'#4DH!+2;5T/9F.II=?@%J2
M0(2$6FI:,-W#(J&SPMB-K\E4F"MCL0FC)/41/W0-V09B%N IY@@JD)9U0E3^
M**8]7K,[@@<G^(3\T+']GD9.J+7;^*9UZ )ATS#IRP,!DC'N9X4XD4)30#L<
M.1TL8X@G-@@]1S-N$;%6'C=_ECE;7X;;;1BP .P>,<2G9RF 2,R5%+"\+^GE
MM3( (#3"ZZ5]^U0>?H[)E\I6:K:>8Y]6ZKYSHN2EY[U32-;R+BKB30JH8?E2
MZ764#D%^CNS[OU1%#Z&R<8VZ.62>:98J/K->JOAL^*6*SR1*%9^U+54\7J_Q
M*IFMQ\\K%O\S)U"9!?1\0/\W_G5/%+9/<33'A**W(D"B?Q@%;O47I98=JZ4^
M.+22T;'[>0 0'E]?CR^7M";&^*?+[T?3#V,T'RW':#9%](QK.Y5H?XBK)"[L
M:;D[JNU\IEG;^<QZ;>>SX==V/I.H[7S6;6WG,\W:SF?6:SN?#;^V\V%Q!?)L
M6]MYL=_M?'8H<7SZX5_[X>=Q^HN^'*Q2)(WGTY!@"DJ@<7]W=S.FY0)'-^AJ
MLKB\F2WNYV.Z$Q7.53297L_FMZR^H+5P:1V95QYNRZZ1/AS39WQ9"(5'\W=V
M']U0)V IJ+7&AB O #FD>6G"08]U0PGM9S^4%9!4+3B!-\\6(:II'NF^P%$=
MW<*1O\:")"KJV?*MX($KF2H8CN?6T8E<LWS[F?7R[6?#+]]^)E&^_4RW?'N.
MC7P_F1+NR#\/T0*!R[FBN_+BE1_&^PCW9*.T9L?X[4A;C@$83F?3U\R*.=P&
M_^F/[[X^/WGW5YNW*%W!I:R>.EE!W4#T//]/GO-FME9*)"KH;LJ2;N"C7>(N
MXX\*&\5Q>$$HGG)K4X? C_JO^WE4#1#I+J#\VQ0U 7ZDWG@9RZ?*"I1,=KH<
MS\>+)1K_=#>>+L:VCU1B8?&,(,XT-0/%\_H'LR!-)'L7T0>[R<L=6;&$.O)V
M](36,7 DB79YMI*'DAQSX-/4.+LQ<[UX%\:.3U72+AN"7>[B? C+9S UR9=1
MJ+!"'3XGS)]SS?$*>T^FGLO427:U(:JHMF:VFAZP1D7+@;W[@X4J]WZUM@2M
M?$<U$BQFYC!^_Z]4CPAV=@QH [8Z5Y"IST*D!HLS2)ABE''GWB)TZI@"/2<$
MI(.)5]!E6H. 5HDAR%([M&![YX,7^N&CMR+;ZE$BFV$ C2-0,<;JB] IO%C4
MJ$D==D1P$$"K<R5\.7_08<-[V >(4^(Q?*]:["["U)_,KGA,:+(Z/3L'A4:^
MP,2=3S3ZD>7GC-.F46S3'R8M4#'.>+/O.IU(6L\O2?,LF=%F59)#L/^/V1(J
MM+1>9#*(U&\J8I70:L>+T.4)@)&@#EWSH#NB.IQ]M,Z:$'M!T7BH!IM0R!(0
MY"Y'I[OKU1ZG\<E%3+*)/99/=1 PY+(&)\/<$_"Y>YRZY<#0]4& 42AJ,1CA
M16GSUB>+B%^&H]6O>R_"%5??*'#[\A K$+9QW2#/'NB9(PUB+T_16OB$TU/N
MWO-=+WBT^M),6?*5=Q5JZZ-Y=W%$);\>F00_A%Z0?"1_W$>=OVF4I&I!54JR
M)G"VI.GQZ;LS!_U"NZ"GM(_M.S)%60O!*%B5+G4E(4.6UZ.IY_JP')OIV3D6
M-_(%/3@CO&S(5A93A>@5?3AVXU#PQY5N$_*.ET+O><3(==GV009GF9HVH>].
MMC0-?1I3*Q7YT3B(R<U5BB/0IY)UHTX5/^^(O%)/:S%QLI(J@D*DUJ"%IBJ_
M=.P]O40#L0ZC9.55E)@G &)%I_2QMCB_A T5)2?6LGZ26 ?=!!,&'V%+/+RV
M"3#)]]85>"4;+RK.J%5P60:6S*MJJ9?4K5'58]H2D(P%FQ[B109&_+PEMB'4
ME+A$.&/=$-EBT$S396/&D<"K!AA-DD.9U3P*G,D@1S;?@W%C2DV.A4FEL#*J
M.YZ+O?]<[&,OP'%\&1(#?Y7<XNT#C@1**<:KKQ[#IS>D;ZJ/R#\.:@@>T>";
M(I )J#Q6UA9EC>W<,S4*@R)"/#5-9U1YHVN4O]ZF=$3 QN/#8S9 ?9(J#=;2
MKOD"2::ZZW#GU7EV]"<</80Z2WP"7;+%Z,_D/UE9NC!B_I-X_Q![KN?0L**_
MH'^EH_S;[MUO&SF<]')03-2E<-J$=-YB?VFK?=K#1N,K+_49>*O\Y>/YK,UK
MQT/2M%XVFN/QS9>(..(!BC*(7"]PHI>LP+W5,PXHE\H[0>[$.GYF)[''</G@
M;3%I0\1:'G]X7]0R=YA!36X+X7+!VT%J,.;N(5_66I]J>PYS[[?CTZ?^D^#2
MV7F)X_>BZL2T+%2/%[#3<//A^"RGPVLO0*NTFVWP2 FR6I^]:?JZWI]%XB1[
M\K>7.8YQ](1C'IH =P_4UWA5+H 1*+%0WAI%67,[UI+,^A=N&M$4]6\B$H<<
M]=VQ$P5>\,@5?0>'<RX1\X83GQ'X?>!^NT\/+RY>>ZM2*54K!K5(4E6C&IRE
MIONFM!1I9'&XW45X@X/8>\)I(J)^=B!INJ:3FDES)@&NU)V\*H^0I:-Z\V<_
MC.._V(2=LN@K>Y;2*K6H;$+F$08)F1/YZV,>P=0+)(6D;+@<10R!SU&#UZC4
MB9/FR@;49*18J3O2-'/MF]19].@$WF\.M;<NPR .?<]E/XP"]XY:#$'"?IRM
ML_0UCD\WYS0 Y9"^9HF?DPN_^Z3_G;-G(1M;UW, H'XU7ES.)W<T.23-&GEQ
MOYA,QXL%&DVOT&S^832=_)-ECK1]'.@+<>7OI9<EUS4\%ZL-=O<T0<8B]\:_
MS-8WWM9+#C6(7^B&X00OLRC[ W44!@1:&V]WA>-5Y.THPWU]9_WP:.%CZV4B
MT-$JHT4O6@XH(V9. 2IT0!4Z9/VR:>3T"L9*GM?>!*']'>KQP438]>?6AA4;
M7U4+?J$X 6?UZ3$*]X%K>T/J A?5#,<M%\LPP&>?LW_D=N4PP'[,EGDO2E>L
M0[=6>3NK.T+'J.G@4^"OGZ)'!\@Q^U;*V<OK9SO)[]OA)_E]6P:!<!J=%8_X
M6E.>7UN7Y]?#E^?7$O+\NEMYOM.4YSOK\GPW?'F^DY#GNV[E^5Y3GN^MR_/]
M\.7Y7D*>[[N5YS>:\OS&NCR_&;X\OY&0YS?=RE.SUOV9]5KW9\.O=7\F4>O^
M3+?6/7^X<\VRDN?6RTJ>#[^LY+E$6<ESW;*2P'":Q>[.K1>[.Q]^L;MSB6)W
MY]T6NSO7+'9W;KW8W?GPB]T=%E<@3]UB=\!PFD6#SJT7#3H??M&@<XFB0>>Z
M18. X33]0^?6_4/GP_</G4OXA\Z[]0^=:_J'SJW[A\Z'[Q\ZE_ /G7?K'SK7
M] ^=6_</G0_?/W0NX1\Z[]8_=*[I'SJW[A\Z'[Y_Z%S"/W3>K7_H7-,_=&[=
M/W0^?/_0N81_Z+Q;_]"YIG_HW+I_Z'SX_J%S"?_0>;?^H;>:_J&WUOU#;X?O
M'WHKX1]ZVZU_Z*VF?^BM=?_0V^'[A]Y*^(?>ZOJ'BA@)[S'PUMZ*)L1-JUEY
MP>-=Z'LK#\>]Q7O*$;41Y2_'&A22>7][.YK_3 .@%Y,/T\GUY'(T7:+1Y>7L
M?KJ<3#^@N]G-Y'(R7EB/.E,2>R6H1GZ!M)\%'*(WY_@)!WM\\7+K_!)&E_LX
M";=$A!<O<[P+(TIZ@1_3[*8TDU+_ <K:#)E^.-6>98FXXVQH]/""V.!HP29"
M,S=C9[5!V<!6$R)T!R9^@'&KY=7<B-G+0_\JVC\2:@0^_!+B8.8XH+/9+1EB
M TSD1)LCMVAO\2%QT_*7$KX)YJB_:6>0HY46:.8P.N*/7K+)L3<)5OZ>INZG
MZ9W)_[E+Y[ECA:C#@6D-J,$C@+UEF#@^BM+QK&=4TI9]]>VRWN)H*JQ90'Z%
M[S9.M'56+TKJ"NAJ+AQ;P 446<T:HUW6VF:F2O'"%XI*,#W=;!=4Z_VX(3S&
MCH^5),[O:4I]P"Q 3Q])6_0Y;VS%UFE>\$+2\,PZ,=?)>-XJP>ZE$V]& ?L/
MK;+R1(A1"\B ?2[+@4V#7))'*0N<PL+S/2>OXD,'0Z716#&? TGV]\$8Y(IP
M@2QPE?74-[N.RWV/?#_\3,MH7A/+/\*NE]"*]+T>1369,)]%2HM/"<2/X\3;
M.C2E^/6>5LQ!X^<=9LBFP]'"+0$J2LX?J+//($W<.!]*;=UV@*HE -%=[3;%
MAJ+PR8N)WB$TTKPC!:'.:P.*:1F'MY = ,5I$T13S2!,0!O$V"[^I.17*274
M.&M=:Q$LS99_[NY]C-=[_\9;8Y%^!4S*%L,;S["FSZN"]G11.@BZ\9[28E<Y
M641(HH*F+4=U1Z HS-Z6BZK[*!HD>Z#6O9YLI&CA#;\$6P!Z#XC=IXCU<\3N
M<L32K1US$&M'I<H*O*98I99'%8<,^P=+^0CL9"4UM*G2@&:]RBJLM5*7AR)Z
M:%2M#6@\K:6&> ^Y+E772__X=.T%7H+IN&ZM F%ORE"*I&E'@ Q3\KIPC9LJ
M55K0@BJB+JM!Z:71=$/+C%_*_".E#%7'-.RX5F2O-?!>(?<PFDW/MZ:L"\VH
MLW MSM(T?[G'ZA['U(,5LK@*'-"HBOX3'2H2-ZTQU=B#3M^SV]O)\G8\7:99
M"2]G+"1G/!U"/(Z>].OY[Q772'\KOPF=(&95\9:1XV)"D'D#2HZU_C&KQX.-
MF#(M3J&KZ/GH:HSFX\OQY./HXL8^<EM!H0Q@_57JX.(J]Y\R^HP30C]+I!@\
M'GCH_P)+G1/COL\6S$H<N9CTA^.C[P C_%LKO;5K86$<WQ%\B,*X:S\]1,6&
MX@5X@5/%IY=&4='<ZCUI@[S$US^'B6IK1P;,PXA3W'5J1@X!.XG=ZVR Z=P3
MS 6'G23ND'2JJ=NY<]-/V,XN??911.S,U.W56^YU 27SJ3@%W$ Q8,OOQW-T
M>3^?C^D3@,5BO%Q852<2HJLD,6^8L6:%D\/^QR%@QL)J)&PATZLT<Q(&5!KD
MD(U1=T[;-J)DI<ZWF:161Q.9=Q&FI<OF9.C.K^0.(YMVG91H ]#)6B"ZIHZ?
M!R;81@Q'&M7[LNJT]%T9V4CC=-KYJ3,%5X:T?N @I&CEAK:1K08$T6O8K,92
MIGSJ=Q'V@"0C7P[ &E>C\\" _AUG2J1M!%9)<P?A<3Z[&\^7/S,W[_@?]Y,[
MZO6UF>5<1]I2X0%BUVZWR#2.QR&B4,40NRO'I_ BJH:$1#W\]8^Z/GQ4#<2&
M%!XE<EBQ9VFV_?]R@I,"4]5GI7<O%3PN<;2]P@^]J2L^#=-V/9<+ "<WL^F'
MU\OQ_!9-IA_'BZ7MW5 HI>J5$#3)%@DOBL,D'742Q$FTWYIYFP02M'B# _$D
ML;U1Z;RFXD&3X G'265SL^ID:)(LW[D@7 K=N/:1^T0?8<3+<+'?[7R/2$8M
MUE(X@/'8=!$WT+7*U<?1]'*\0,L96MS?W=U,QO.%M6!)&7D4(4"-L]4*Q\U&
M+0^J'H+;.(CA,+,F?B3T238$2D)4#&(;)XU"JF-%O !MM<@LH*HVH+7I[XC\
M-DZ,8XZ!W*!*X%&LZ1.0)4BI'+ 2'V'%L"6L)J$CY2*>NJXE7(S9OS])2,K&
MA:Z((0!/U#">+F?SGZWZ*F6$5K9=&B>J?,^;1KXZT9:LCBN\X(6BH8&^QC4+
MP @@_^O1_/:&N@OK%[465$G#\A\"E 4S;/E.J#9TFQ="PJ&,HT*.+PEC)>]^
M=+]J[_6/C- X[WX:%T(+2]51Y6T47C^S+\@X'$!*(\= [9K+KL+@6QO0K#0?
MTAP\,[LP]E0W";BW0=>KF!.!*PTQ5]K5^&ZVF%C>*AK%4,A?/%'-D(F#WR?.
M;TBGA&,3X6%*I(W[UU2X$\:/36?3 860Z<B[;J\J+4N+"Z5:T% Z^H&:H3 S
MF*R%2R99WJ1CS Y].6%F X@S:Q2Z(,I,O#IZ-A%- 9K<D%WX/L9S[W&32-I$
MG'Z&;:)C#B";B+5$S"S:QQA%K+'%7*V"13\81\#T=)-=4OS(B39K:C2W84H3
MVG;8'ZUFK*RLWB%#Y8'KUN^]PC7\N#=.LXJ-MC1W\V\LJUX6!&8D/+D3UFRE
M-NR">9F+@M(8+!<'@09B 7LOU+9 ZS!"-]B)TUM*JHG(9XW8=SV(Q(==PH^W
M@W4FACYR?<0<TE-"=?D9^T_X-@R23=?A/BV9,?\<H!W#P!=$E\7F]7PWD)#+
M%B*]3)H'7S7*/V,G6GX.K:(ZY\'&?8P6IS"*O[:JQ%N)7A^]Y571MG\T2!*P
MFDO*).;"PHE9DU48N^\L/ZMIB8"6^"W61O=66YWF-0&%=?PR)HP[(?7XA+'[
M?J@YQ61DWPZYQ<*T<$AJ4"5M[6.7,O$E8)>TA;'[S1>'W9+L6V(W7QACV!VM
MB7P' > J)P-'<859Z,G'!D?8H0V_*$."BPA]6!^O5 MLW]#Z1GBVPY%#4Z8Q
MQU%OUY8-Q"R8N&*.H&MPULKJ&Q(IJ54>DS1/5/O9$1WK,HR37EW$$!4K*>WX
MO$@X;WW:T_8]88/ JK"!9ZH77DFKT]PYGGL=1D2WT;1-:;4UJOJ(?K\E!/<1
MII[LV9I1O_&<!\_W$D^QT&,GA(R'Z'7!-90"E)9&8JD*Z!6!DXZ.O&QX6K64
MWB1L#Q0*P"+_0.0[:X%>72*GN%CK;+UUM6=5)=^EESA=WP$ 1"QDDN(R MW&
MYHW1BD)W[8>?XP. P^*O?G4_MI-?2BC&2FHI> D4_?%ID55ZL3=;W\>9P3A[
M2!POH/ =/Z\V9#EI"21&:O;@>X_IM:%:Q=Q6%(Q>[K=B%2J]2\=\':Y?TX".
M--85A=FXK-1S-C(#9:HNP\/@]M1E)\ XU/)MO;+:?OL::2[EZD>5Z^B7CM5H
M&TZ,'[];,-NHCX\TKA6=VP$P*D6!6RZ8[O/&VJ%,K3PPT->XW0HP(HFD[^R]
M(&E8_4,$EF""6O&0]P'[";OY4&_/I$3.ZV<V'I+# 2!G:YN?8'$+B4+3T(Q[
M/![N7%.>Y];E>3Y\>9Y+R/.\C3Q_Q'0_(*,]D0__$<_QEFP'^?=/'Y,H*6KY
MT8P:S-)L 8#(^R,G'0!%^0B9*4S(;ZT^$E(68X$GM;713RI=V5@:B9[VZAJ0
M(&_#X:K*9!NT(MC,M>Y7D$<'['&07+U^\$R?ZE,OV]Q)\!TF,.D\OZPR^<'A
MF<.D+)[=K"LBHUO.T*\+ VG@0LND#5S>%5EQPKMUDGU$_MOS'9<Z!\93[ZGS
M*)--C:G?DF\=W0<NCDJZN';I:NGB3!LA37>Q,DO8HF*9B&+N@K[:]_T409N-
M08%<P*A4V/8 L2L! 6D -RU/_RCNY\6!*G7SEVN*',K$:0\8J(+'!3H+H?D6
M1HE4#\\)U.D;OXA09G&P0=C:PM8&9^7-@ &UV<.# 67R=B*ZU)B4BK4>.$*A
M!P)::]'/J:M.K?N(:F7R@T>G\"7 MU\..H%8::VUZ!V=?0;]Z_$P9)QJQ_H/
M&+.-0?[ZBZ.-W@]AZ'[V?'\4'+TKZ#\QKB)QTT=\-?; Q+G+T?3#Y.)F?)PZ
MU0)6]>1=!JG&JG11C$+P ,9064QY#FREEU'@4<+A&N $'0896IU,93SP4YFI
M+5@O^5[Z*.#42&Y0.5L::S@A[X##>LE$.T"4E:?D&[Y*OED=?-':+/UOV! 5
M&Y8DP M4FGRV'"_0W>CG$=F);?HN&P15QHMHAJU3O,W6-UY _O]EA%TON796
MV:U:__MH$UU[NV<#9Q)[9MH7'3JCSUZR01=.\,GJ:U!EJ?-W2YD%TM\CJ_6E
M)G&\QUU[&KDD+#PJYO$!P&L<N"$9S?(95R2;NL[B3DPK +HVVBSR'KV /1RY
M<I*:$P6(JFP8PG0^=3$[4"S\H15RK87M*$BD")"4F&X+@^<P<AX2<0R+CE5&
MA9#IG0IF!0!.WJ2.&OL:A"<P6(\<356[*H,3W#DOZN5:N!W-UV(X9@(LPS":
M'EF[%M2%:,%+I1> >6E775B%6[QTGDV4]A*0LE/:"V8(.F&/?AI;]DK*2*Q:
M)Z%AEAT<C\;K-5XEY+!>$*-AI'-,IT,,7[:)&?(\:K!BM7J".K\21ZMT+$0&
MHW7CG[R86D-.PC)27&,71XZ/%@G9*&B]-T0)IF7E<U[8KX9Q!M.'%O]8IKG>
MNODH9,B-DDPFA4@JC3O^5+K@R+Q'M .N@>_F_JO%5Z6/@8;ZVWVCTB%DRI]
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M?=&H'JYN7/:R8BG@(#7E%J=0.FY _OQ"G] P.V:.8QP]=9[V1D#(QK-T/BL
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M14!,CM1 1D-T9#@25VFEB2L1H>33U^NTM[VP:14Y%2$\TBN@'=%39#GL_^S
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MIO5  S\-D3.O$.O'+)*BIVT$*0I6*H2FO=;XYV9/#DM9S@(%U<'K9U9_<#@
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M/?%(F$4.CP4H\*G^&'X8J1-$<JJ$/T$SU;)/6([R.^>%*BWE;07L;.P !'$
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MV5E\7=3Y_>7DUBV3L$$&/U=PWHS6JY$=P2;\6>%,/DE3FMXFWU_1@"Z*<24
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M!K;5;0@'>^T/2[W$7B<%D7"0A,$D'5#2024"+ &XA ,F )EPT!&%Z\5DM?X
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MVD#3"5(A]46+*';R  U(?N?A+?*2.]DVM/I/FE07;(*QJ+E-7%T1 +7A:LD
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MDWX\NX(6<OD8\, N&"O*8:(0ZZKYOY^R(GMH'QQ;6PS2A=& )-86.R2J 9.
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M 7)A1-/-/+KJ1@GPW(<8&%,/H&K80S5,=A?F%I$Z]XDVNS*%$(*ZL3XDXRH
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M6:ULB(9TRB"E<=Q].PPUA0R].R)5T+ AAGI2/$@1[B! JES=7#'=ZVM->8B
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MS\YGVH"S^;HJG[*4IJ<O3"1F4C(3F9-BPQ9X D9$:]@%!'IQ?[Z"0>Y>R!L
MPS2\MZ2#1'I0D?4(?YRQ"V8NQ4)>_LIS+;/G!GG15F^]'+Y",L CNNK'2-@<
M]1BZ(<G.]@([T,W+-2,OI#E Z,8CO$&=)<R0M\EG,64.YO' F&[F:FKWBQ/Y
M:$$+8X@/(8)+U0-_H]TJ./6Q(J$K\?VKYK 5"ZZAHX-I43-U2N4@7)?L>:--
M5O'$-UGKQI'U)$$,RE*/H1 )IB:\/.Z;&_K$))8D!P$6?O,V\ALS@P3H09I+
MP; I@[+'E_TXR4%8 %@4EHP6C1$=P2IX2Z'VH>4ZRSE]K.A&^&G9OW/:B.TP
M3 <PWK:6!U_!)\,/@"5)?H(?N''=RLD[M1H_5%'OQM<BF$&X>$5F')CH>)KD
MT"*J_I8UNX%6F^V=ON@!,%A[CCFK\L@U5$ (0!E9,[(EZ(C[,!5):_ D5?#2
M)4]9+7K5GY?M7;-M<R6DSVJ--FB#UE?Y4V_\V]@OB0U-@UCL($MH-M'')$MO
M+$^%'$)NX@>)#E:+$W>"3,B8@S/>8FI0ZUH&VA7I(,O#9<<20*!_5V_1DL$?
MD/\\@(1V\ I>HVT.SMH-M@?%PCU$D+!;W]!'!G$'K1"<!6;$#-)/6425&3,>
M^H/B0#GLQ815D>O\+JIYV'DK:HFS+\\LL;?J_5TK2#>]8^QB5X<JS<X QO1T
MS$4>NPSW(V!H)K-%08>'RX=']C"*:CCVP,]N"AG.037+*(PS(H3SR(%_2-,E
M%!+,[@MA.MV\W#(%N&87+^^26*3\QUPT3?2,49$ B8)(AB"YZC@$NM#23WM3
M!0T_.HS$(7?#5;8!4=MNUY&#%F/7&2T:/7 Z5I%Z?HI@?%O9A/[%&A5/6$B[
MSW[]&)V-:(:*9__$E,9-DI]3WE:LYS?6P$..)7+P$G((L.5K IL9QV!B\B1_
MX7-6T(921Q%8+7=#34,H'SEY8XR0[KQWHQ^Z.(*GU'<"#>==S8WFRLZBBSW2
MW&C!(O2($(?(T0A%8[:3'C79LC\O4Z;&?L5GM!JSXAPP7.GD_KZB]^P*X$JT
MVUC0C1=ES5!30?"[SX2$=NW9L0U\XYWD>?D,]F_$HMK;D4UO/VIR[D"2;5D-
M#="Q3X8?KJ@+:P:5 IZ;O^]:INAH"7G8D1%#C2F'P4\+LG3MH!C1"UUC@/<^
MYOTTKRNV%%61T!C^(IM"\QG@]@6*=T488Y\"$S9H)(P5\X"9)>"Q*EH*5>W/
MH*X=4_O!7Z?:EWB:5"044=]?P2'/X-WL>K@L+1%H'N88$_>A7> 3=IM\IYZQ
MEGRH)= R HN0U6-\,"(9LH5G^?!0%OQ V[5Z,5!<84LQ#VN+QZALP#"<3C\I
M%NQ0YK62S M0XE$,=.W=@F@H.]6T  3T[YEO0%'3ED![&T(N PJ&_O@BW[?I
M/,3I7S 1V! D!6B_5J]Y_5.AI3W+6DQ!4\/>\CR%@\]""QS%D/@\&&EH(H]3
M(&CD^3?*MW5Z\D0KIB5_;F%S,Z&4^]O7;5,W20&UD%W!(0H.D8"(@,0%=1%\
M, "V(N=9WL)HO(MBC*C;F73 .+L?+0-JM']E'/M]5[9?H=! >IH4O]G56C6>
MB D$9BS@&C>AH=W@=GP#WWP&<Z!#(+>9MZ?2^7+,H18YW8<,<?HZGV?U)B^A
M];A'A8NN?%L_:T&-,6TX84QQTR#@+?5S6]:[ENV,@NV(O^_HK^Q?]]*?>%*D
MLK)04K K%I[1L_*J2>TRJ8!()$BB8!+E7(7P155CJ8-+SDK"(,<WYNU/#^U"
M/)2T89/B0,ODW:_2\[:"QF2TRLI4/*?\CVM>#J/^^)U6FZRFJ=%D"%/>G2:0
M[ ME$6A1"P7E!#)I)+OO7LAPG/2>D9/GI$K!S<@_M2+J8S44AA(KBEK6=#:1
M<)ET/U*'+4[\WRU[*#[19E>F?8/'KI;%V-6#;0,!@ @(@[:7PZHAL9U=LY'%
MV#F34M$KL\G8^"_MXV,^OSJ;R@%0TZ,_O7;L#.^O#TD"/L)H?ZC/M.ECIH9-
M<6[+<4N<85T9O^99HG<6&;3CX4DUH\X[MQZ==X*_SJ]#*.VE?DWZ'YC4)ST<
MIR^?DE_+Z@O?8Y?%QV2S^T+OX6+9,[?/'V[XOH/>:_-(]%-^L5/V]  T(L!!
M(@T )!(BEC03+^EO-M.1W+]Y1 PJ2PR2>*3FZ3)P#69TFO=B:JR;T<%>&Q?R
M(3/3)D;V+[!E]G R=/.FZEID%\,$'Y>/ 44_F'--ET*4%_N</I9U9GS..\%,
MS82[K?/YR\D1KS4G8AI?/$D1JQ'$P%IFK-C6-='1JR7%B9S4EH^:!PU(!JYP
MD3[1JLEJ)DI!E1;?I*+!-%'OQ1KN$B5(SXX8QA$O6H1\,J[*I)"!'DZ.P%@5
MSH*UB@Q]$V%KURX?,X+!GH*I^B']=3]2 50NP8-5P-@:X+ZT<NJ AS$A8!S4
MV,<S<8O>T(<D*]0?;VGU<.3M_-*\S!TP,8( N(4DH7GB[O:1^=)OP3GPKYC'
MHV?P+#B!YS5R=V*F[7#S(W>/)+D*5ODH?N$L%S*<VX?M$#5].:$?/DBB3A-O
MXH24C@R/QBG=EA5]M4=:@'.^Q0MYBFW(^[ZZ;@(&SJ@#18DMIQQG,\LJ5'Z=
M H?3NT1N">&MX8!&4QV=N!K524\JA>7?=)LY51GD-.(!)S&\E29D4.^D'?-P
MK?V^[=B?Z\35+;H;MH#0M\F2M<L+12ED:0Z?AHZJMM8YW=*JHBD;)"P^OR1Y
MRT=T&8'&P^#=6%A6+<L*HC['Q\K"9=T7^[Q*M.EPE$/UNJ1$C^*/X%9 1?,J
M*^AZ*Y)@C469RN+^':A)!$;S&'(^/FX%@,'"<1?-%+&PS5FXXZXVI2^IOR\A
M=0^-IQ@C$/9AUUT'G\N&#A*9Y\:W\.G#+*;8%Y,;0[\8%YPN(3NJX6%O<+'1
M>0&&/)%/0"("E(P-7/$GACTJ8H@$V$41IG&-5;,)@.K!^U$Q()\_)=5OE!?Q
M+-*!.\-1V[^;)8J-#WP[<F)DNX4=*XQ3/G0()WY#(E0+C15O:$VK)U<R9S><
MJ/&Q??T&!/2(&!NB05W(7XN*R7;W1?8[E^-4<PH3R8?#N=2L)D3>^08TL"UO
MQ3BV8'"RV50M7U>7NCY3-I 0R"AO/W)K50\L_>0#(WE"RL+31&SHJ^5(V9IF
MG:_ I[F0KE5F=(SF,POR(0W;-C'CHJQ$U7TA<'QYS,WZH%E6$Z(:8<"(A":E
M-@XO8IWLF9@C#] ^I%M"L@]?HO@U6Z@L5F1\KSS$</E'J)VEH,56IV:A/E<
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M&P#)('""NR<^][;9@8L="7@(P7&YR\J]J5G$_K[*".NRK3HJF)UMGV\&'Y!
MM_%;DMR$<7Q'HHR0[J)M? VHI0NR,A'PX3-(D!;I8TQ^3]FXESL3GIJ?0YF3
M]FGH;)_]25?).@:"XE7E//I@<HC1&!@P_J%T-C6:C];08':J>10T8ETR"!SL
M[6.A$9_28<#@%)T.C5CM& C,H6T=%(TXE0X#!JK@P&C$J7P<P/VK?G SXE,X
M!""+PG.2^8*2C 3HRV>'*#/EK'X*QU'S(&7$FV00."ZK1RLC#@4#0+I7V0G'
M;,.I? EE#A6/"$;\ZHT-N-0;CKJ9%@C' +M"*!QW,Y^I_C'<Z<U=$R_U2;BL
MW@!=,4X"ESK^X68MGC$Y[FA2.F:Z[)N2 0/_P, ]84>4E#SN/S!NHT5V+<\\
M:L==%Q@/FY_B\*"'MPIQEVU1U*=.?EC@-WG<J=HY?G%/<\^<@HBZQ2W?T*F:
M4+,S\\LXH1NF1/%5FJ01N7S>$DZ6+V<2AT%QO(B/KCL_/_$]O>G,&Z,!QX%=
MA+R/,5FF_@UE3FRX++WO6=/['HR#*AW (VL/#T(W!'B>8AIV)"H\C!K/1SP:
MO/V5'$V-^9:-9P=SZ6G5F'_YB)"QQ@,YR2'6F'W9>';@+PZVS7.M,?>R\>QP
M+SCN&G,N&LN"5R@_]PY;L.(AX:W-;!-&21$C9>:9D;Z+R-;9<T5=AE%V:F9*
MS(!D9OR>KM8#EX,I/2MKW>?4ALVG,H0=<\3'OZ'.(W,CN=?_,?!(--_R)%L:
MK"I!#7,#I4P!7OO8@1+6Z9 .:.- &!&/)E>.6P#W1)/UF1-\'GH [![6BI;E
M::(/SC/;;'>4)WL["5N:5X2I0G[Z3'E&S#USY_@VO%P2?@PE_._#)CN8L 6Y
M%NF^&?"5<,W@DWW?N/#+Z\R)^>61=T']E%&[=** +>EZ_&; =!0&AY]3$27(
MMHX\J3)E9 M[Q?:489-2&]W&D8Q9KB(TLHS"S>5S0J+ \<]3QNN&N5W).@K3
MU9KR W+B4/_B, T>2:$!6S]>Z@*83S@F3GEO?)'Q8^/BN!P9-IM Y8+7;$YZ
M8P/N)AWYSF8S41C0VN6W&<>R46PG+IMQVS429/I=\_QKQJU\'$ =/N3^FO'8
M^AS*!-8/LV;,B<> 3B$HTX&'";DY"N0"$AZOS=CM' J2Y_P49HAI[5M(KIHG
M+=-%(QX%-,>Q<GUMQJ5H!,!4_$.BL>FZ:0T ?CUON"56/X7;5<3)QX;[8.=8
M%O. #1T\Z3CVL@4,UXQX$,#34W'I;PADXVO(R$HCW]?4E1>/8K"T.;F8T<N>
MDL?$_=,JW+WQ"'W#N>=_R*:13R'<D:C-:>O+C$4O=%,.(G/6^5?Z$&HPYE!M
MKF:I1Y/K@-<>.#QWS=C;,J#9+V0_O&'<%#SQKP>^:Z_-F+ 3=."1[%W^OW%H
M_N:';NTW?%X2((S*SWSGD?A__R:-7Z\<9_OK(>]COCSD@MQQSXBQ/7MD9LMQ
MDPX\ET[\F!4.*,;+025^$I<_.:*K13+W&LVG4T0I[#!>"PR:\\C4@ERS/\:V
M^#P2."[HAFK.HCKK3N26W+ _UK2U72BB^(TWVZQBP6NFSKY7?LW#.V9JEH1R
M>881VY2*,B%L&DO"W&+O)L=7RF;&8R:$H_G0EIHLK>YL7_V7V3.%EJ8&X7+?
M0Y9Q;>U5I:F#(8RD!XOZ(MPX-+ HTH( ]@+55V^98$O$"@&^90(T-.;543^0
MS2.)+,JA(/!RY% B9KZ0$N;_DYN6W1RE:1%MJL7,WPTP(29JFP<9RGPH.SZ4
MF,:!84P1M;R:JI@DV%1LQ4 =-1$8SXR=!5XC>7:6G#M1M*?!ZA?'3Z%]236:
MN!MZIR)7I:H(()B4S3:3:B+TJ<6M2WTB@M<&%6PS,C+,K03P6Y(4LX2VSUVD
ML'T,9?%V V:^O4(8[<--V"V!%EYMZ(FLQ#H<A6B^0UEFS2<5UA99!R%,3TA9
M9EU %1+\\U )&@6H\DQL\+!4.>QD[-\1B$(<?SFMK;M(R17CO#C5Q44NG](-
M@>33D5LSV80+^+\'.\,:6+0:\S8L69W 9!:)")Q"7C_@N 8V)351(8GE\^\&
M\@D3QQ\HGXK&6 J/B"@<W9G11D>$P$ =F4PD52;PW?D\Q[.2Q0?O='>2PEYG
M'1I;E5\W7%#A#Q-!MG,;H;T[$074):<H,R$R*&&*9@U7!2]/7+EUE'@W9P<7
M/3!:$&7^9\[.,<,2>%5(R8Q95/T8X<<7+,M-3 ,SJJ H,PDX4.$$4X^O]M@S
M>W0[7WZ,\WQ<:-%UTIK"NNM!"RP682+)*QK0A/!2&UXSK1K>)^PAAGPIK2C-
M/L3@8AOF9V5K=G2*)E1J/4W"&8WC\@ 969',=.0!&;0P.T(="QC8S>WH(#3^
M!(\NE' O#!?K,$KX2>\LC*+PB;\DA[[@$%! ]3?Z5;9VVR$"""XS9]"5??'T
MR.YE?8,([EV)GNQD.*'F6U1?M-F1G(C"A%:<$"#DP$BV*?/7?G8E)R4S(?')
MH0*+CPR186LN5D38IH(=K#<1H@ KN)")C@C+2BA%[$TH.4DP6/+I%+8QV:SA
MTBZ,UE'VM-BJ&111F) %% *$G*S!7*$H901MFS\Y'>2XE+;G*(,++HL#(FI<
M<KBWM)MU$YN43/N &Q!) 1&L];4Y>:^D8SG^B)2T(]8I>S=PO?2P):J8T]./
M&^!I8>ARM+<.<2/-JLHK68.#XF  BZ]2J&[6ZAD.*K$N2B-Y7MZYW#J10KX%
MSVOI6+HU: P^@6S')AQ0ASW3!18&BR1T/UMY[=D<'M,8BM6PN8CJ:"!? ]R5
M)*U)2$0!=0WU2TD("NX#2\_+*KHX_IU#O>O@W-E2MOE!'[PE5+#]P7Z)2?&!
MBOGK".U8^IPA%>T4WQ6UO\+U"N2@"^:'FK:8%;0.CF7,9ZZ;;M+LH=,%65*7
M0GL$"@1';N%4( /SZ0QCC25#>1.D<,-X6),@ICN2=Q[@]0EO23)?/CC/\!%(
M+>IC7:G&: )>#QA6<F,;;ZU0)G1&29O ^'<Y$2H#[@1JQV<3*7V@01@Q+JX#
M)G420YO9UO#C]NW;: "&^6$6$5OJ?NIEO02B#+LDB>ACFF2M@4,>M&''>L8
M&VUE2:A 3"'?&IBL53/P<1^45B)UL\"S;I5[R8U]H^W'"^ZN(:^&^Z99#M=V
ME=Q?[S*<UB2AKN,?XT]?B^9V!K\8:O,HH^5E 86RLK:]>)B4XEA*#FI6K%4"
M$S"<-E3B&4?Q+$W6S"WX@WCV)-VB-)+[!',!M[%##;^U.+N.X]2^1 LJV <3
M,'F6J.$^5VBQ-4^3.'$"[IK9EFB5U(L1:PT_N"OWX=<9)]IS%8E.5=ZJF.*D
M]8JYM+SW]A";J(/5!R%V4%#$GY6-N(/0*-X) LBUL14/3BF&DJ>]O;B/VDN1
MK&@W'AR!/%FD(;^,.. ACRX8VI#&^)9B"C(J@UIG9+U]X7N@%,-B>R<]@JE?
M7I90X)_V8[9DWX>AEX7[2+2C+HD7H0]_-)02PK1;&D+K@@JND8:)$-]'O-%=
M%"[!\P2J(T]$3#4P!IS3 >X>%B2["KE\WI(@!N\X5A\<-5U#0SQ-3*!.VT;K
MA@0D<GRVFF?>A@:4<YW0';$CL#YJ4UE??:#AGJ(S%_+,B8G'4T081WGK1>"U
M)R:"&[366802D)#?U%YOM@Z-\E,$K[V9%<;*2_S\1'SO*HP^@J]*-9J3D:PB
MA-A%T\LW-X71@#X3M,>?C  %T""7&#MP=$RSLR6N"H6I^#-"=*!27HP+?-R&
M05AGK% GFT75^XE.Z(BN"N. ;!B0 WR99U5CST;?(PD9_**IRKI>[XDD@PVS
M%'O)%7.N+\AC8N<<(B&"NT,.EV03,X.0S(^Y' .RXH'<84=+AP9\+Y@']LKJ
MBVF@5^TTDJ($+]P\B^[IG'0+Q;Z1-9=L'XBH#Z^.3AOO+94_"4\9CX57QYLK
MDV48%2],LI)&E\]LJHQI&CC1/GO ?)*L<YN<3B3R9%58Y78!4,5A@"8RIHN%
M<48" A_/EU&9D&,N!:J4(%8W),:$A;-Q96#D+4!#1E4T2K$@W<$PG_YH-Q!>
M"^G3GTKDPP#94A=P-OL:PS;%/"5SV@"EE)#)[0U,Z$KRLI<9?)NQ*P6J4UF7
MRBB6LL;I%M/%YA7SXN@JR,O;N?N'R EBQC*'._"RO_DY^-YO:7Y6M/2,WA*3
MZ&=T]46FJEE#1(9<04@P(TOJU$5I,C=4G7"5-F7P:WY387XBO"<6\68[=BA<
MD=MT\TBB^;*566II,]$F/R%701_:4AL@LG>M:<*9$U,720URVL@'.],E8Z(;
M!=A@%A]0,2ZHG[*?VL[BUZ6.NR]8U TYWG#9M&:U.(N24N7#,%M5.65DIG+0
MD.-4"G!X%7$(^=DP\&(:J.5]>K2V2W+05AE&;H6!L"RYD@JV(S9$?@>DH"RG
MU==2&<NUHC(/#-AW8?3=-S6@ZX^E!A9C:5>RL5^-I8.F>7YS.?P##[7:XCT?
MW-0 RVL\0_-Y)("]?+54K5YFJRY0\R7L#Z]96+"2<\T/^F' $S%FS]2:"(6T
MQE&BO+;$A#(3 P4APH%U03X0[F3#AZ\:XX^D3$^7ODH*?Y0 83_ E-1]MB*_
M;EKC6'.JHNS!#:784JNLM$B*JL6SJRML"H*13AXWAZ]9)]K*PI(0F9AUE$&%
MW8-(H?:S'7.I3'<4E3>4+:<ZG,A-<<1I)%9DW4EJ,C98#3C,9CJ-&5R$&V9R
MH",\0AJ36J,2F"K/-D<QG?X#4B4"8.X'^$,T[FL-<>1>7L!UQ U.:EL2T=!C
MW$8)1'4!BY>#8[O^4Y0PY!6>6%BZ!S&F<GF!N(LTXHJ6#9J5>[P*(UY^B6UD
M><FQK=_,LI>>T#0''8W;(!2>/D9@!SEC,]YF-U>]%K/PT4H]ZI-8M;J( IX#
MH1;SPO%)$7"?!=XG)XJ<UCM+@^4L&7;4VZT)3$CGNR[-@Y=HU[!3E&@G3,@5
M?#J5\"25F?09&+4.# $6K,@/^'Z-J0J='(SB5&V^:_=H D ;+W"CP/]MOLU>
M[UX^D\BE,7C&CS[]<5R%F1L$,:@#JA(-COMUJRV>$G0Q,.6-H1-8L)I%7U]*
M#Y"<Z)$T0!H"Y%L\U4==9?66641CIH)513SQPSQ(CB>P"YQ$<&"%%1#C][^^
M'6T$?^0J!H?_@$H0>5#X,O &'U";H6IXQ1AOFRR]('Y59 8QO[;(3M:"X]R)
MUU=^^-213CXPF[RD$-M/(F^3&I!*PXPZ'X^Y'CO*H#C;?XQYQY)#$=,9VR-V
M>?-7.Q,S8& LSER'U!L%-;0A1GT.^04XY.9JW^.P8SV5.E91B!_">\(V7)?Z
MI%;+Y2'$7>E66!R'2ZYH">P("?")E[;:71!&T:49Z.S//BE.%+,-]P3_L!'%
M52*)Z47;7(I5;5+#'MDN97.,&2?L 'H1IH_),O5GKANF\-5O.TEAN]RG4HIN
MO#%-Q6$B-\2)R3VO #!?LCEFO2BJ.FNIFJXN^2]%8_3E I7V,ZR,=G[AS2;/
M^$_V=[Z3)]-NJST6P>MJ=Q+]4C1&508&Z4&2@NM?NP=-44_T6@\9Y!SM2/08
M#@XG?[']P4ZE!_#-Q4 $_V5V9#C])B'JWZ"3@@30A.-\[00K4IU#9H788>F&
M.H_4[PA[2%(+]4:<2,12$R:X=[RF!?(C[K)>D/S_KX/RH,/4FM"=A7(H2B0Q
M5K>1@C>*Z"N :1!,D'IT0#*_#1-2X1':@"L01 E!6A!X&TFXCDE PN9;2< ^
MH">0<Y762Q%Q#3\#\VU7NEGNRBF7<HO@2Y%S&TG LSB,L.\BPDZ'WB+=;OU3
M+.<F/:Q@C05IMZ T.%$#.-EMQOBA_X%$FPNR#6/%1Y7]HTQ.<@K 8%9@D)B/
M/%4PR2=Y&E-<)_E"_&@1F'"G8# _NNS*YYY>["VJ+VH;;F-J\/C&[EY\D1+>
M0.^>9#6 [IPH.<6.+*;Z4F0OP=3@R8U=V9?'_#MGGZ7K1HYWNJA)C>CD]G5=
M4 $[@P/:_ :O/('$=:.45&=_FGU B9.78A\TL =["S3,FS]/XR3<D&B8-]\<
M97*K7@$8W/<Q0G/$E2IK@%NHVBE,?(LFSG6G'?O>!G1(7U-+]KV6VE/.=F_?
MFDOHOI03G0Q6N&ZFEM]RH+WAF*H)T($6K&,JK!KDU_"(3WJZ&)C(!?D0B,&*
M91FE83O[(N5CYOZ>THC4<O;8.K"5.JE!&#<9RGS5U-*O-7"&O$P'T8GR:>YU
M\(^0!LDO[!_3"-I35*6*^K#'DC+(  :\9P?4!;9E4GXHM1$)[J>'G4QM3P4:
MN )>P^O)OFR8P9C+'%G^I/]ZLV43)H)42,D!OW>0*5OU?H0@4]QM>WMH7MZD
M=< $YP%5-&L' $!]N**!$[B(WG\7 R_#^^^$&*RPJN$C3)<0+^874EG<>;$.
MHR1/0'@$]_B[B8WSX;_"\FB\LNP$%/G1[3W9%G['?&E=WCW$7H2\^P"%<^"'
MBKMRW[RW+.P6J9&Z[ -DW483S5L7F9XL8]O.A8Z4S!C/Y0.L=QU"N(+V0]>Q
M1=%*R;P T<HAA,N)A5BYO#XKFQ=A'N>Q ZG%)2RF]S(,M@*N8$7PA\K]A%NU
M,MD7X:&I@PQ6!%]/&PY,%1YD89CBJ"/I4A)S4QQJVJM;%2^X9%J[T1:T*,LX
MHV^:RUL'YP%5[0='WRZ72^(RE;U\=K.4@WNF8?. L\[_QR__=HY/LE>U;++4
M+6J3S@*O_H/*;P(KC@T.L2V-;@#/BI0 &^T8J=X@]O,*W^U4IZ*N<Q6H'#Q@
MK3PQ\Q,+.)]:M -<I'H"T\GU>$QJ.8Y2[J=0L2']A"3=/4^N.>!EWP&VU"]#
M>RIEY0U\-KA& /SY=#9IQR\G?9G_P%I1=Q624[(B:AC"O8,R3),/-Z1(W:>\
MJPE\/GR3 +J#K*';C=SW%E9P=YMFTLM3Z&R)KCXZMI]H++8&2%!U?X?LS)QY
M_A::_?&8-!-X@B/\!8U=/XS3B%BRNX/9F535^>'@PS4CTRK:QYCU27SH4S=?
M:C7_[?@<<TN%6@I9O;X.A*#,M-4>/1<D=B.:M2,,EV=I3 ,V&R?PYM'*"1KM
M P0]>\SJD%?&/O8(RDOGWU4F-%\6\G#\PXJSY0C"\&1ZXAY$_:BA#TPV9S[\
M/28X>\B[.J@"UBJY@\L1U->S9T86Z6;C1/MPN:"K@"ZIR]_:Y$_KLZ9T/G4K
M-S M0V+4;Z<UO*VN.7)"IIUWNT"RM8@5B6(?E/K%6CON*B(YD67$4R9H7JB9
M[<',@O#ID*!S[1B?"(ZT9@U:]MU_+=H#XI$J=&PM.$WBJ"ZQB2[43CB:0 .F
M9]M=D5GA($%%5"A?N#*TI;4FHF#JI]Z$3A!G67T9+DS4S3JG]I>5&0_8VUJ'
MG*OKR!#@21PUY34M!_F#[6&UV@AT?&[:9JLUHK5S60<EG.NK?F&T6Z5+D()]
MP6-/K<OZ HZ@A -0EV-I"0-+6T8_O6%)V.+![6\=6J11(\S*$F]DX&H@.XD]
MHRS3?.Q@ QI#: ]ORPOKHF1\%7<L8OV8V'.W1#0P#RL*0JN[5$*0(/M[V]/_
MF;?CCRG8CXO:\E''"42O]$0^\,-Q8"VWJ>M[;7T6#"919W5N\%U_!8CS$A==
MDY](X*IL:[*'T<[C-7HQK/6(5!>E :D2K4%MF>E.4MB'7P4QUI,GNF";RKG@
MRHDVS!'S>HZZ6HI5'U/+8$L^U=;M^CAZ9EKV+99^=L/)55(ZVXG8Y4:;$_#P
M93FN):O<&EXS)-.<OIZZRK]&OK^6H<XUMF/*TW!Y.]N@@*6@9+7?LZ&/I*P[
M&:I4S>N.'T]$1>2X":1-_T.9-&IH15/T3<=$'=]I++>LK![X^LI'M15+J0]N
M?)E%F,1(O92XM?710PQY0Q&+JQ9%Z0%K(OZ0K*@JE-Z_#T/OB?H^,P]-4M9W
M%SW:YDD52G1LK2--XIAQ2B-=J#5PUP1Z,DD5HM)*8'E-U<%M%=@4D3!?4#PR
M;7_ER*A@!X>ZY%5=#5*4)N)GA4Z@H/+&63EV-5Y(0E_C*R#H'L4%'V([31VP
MYR=QT60G<>V:O3<$3F(XO&0\02Q?3FGXH]53Q/([2&&;:P4Q"M^O3CJ6?Q>R
M&9*$1ME+C3,2D&5/,-4T77E+@KA\,7)_H'B*A&QERD-R?QB-G$)>44P(ZPGR
M@$S90,[1UE6.6G*0,?03.=I7ZPP^1&QK9D#PSA'\]H8_R5S5>VK 7%#+B%K+
MY>XA-Z#RK7AD^XM1AS+VYJ<J[GI!7 UDI[(A+M8,*]Z,A5'E:8:)//'#Z($<
M+QI;&YZ?$FW5@.DF-J">C7!@^RM*G2YN91L5&=<>^ZGC.9U0&$ENPIB7B,N6
M%/"9Z]*) AJL#L-;6D%2,J97,\T!;:T4.1WDV$*?X&JU-.5@3<1U6Y!5MV]F
M9'WS0>_)-HRR\AZ6=@\9&5/=;PYX@OU"@2)V':8>8=:V"14 I[(RTL>8_)ZR
M,2YWW:<7TY)[]?&ME=F3D#%>)(T!K2T-*1WL!=$CN'I-0"E8$UD&[=H.9_OL
M3QWYYF:*->&J(F=.3./YLEIG9A9X*+5&!K&"O++T"I , QWXF&(0<*[4*/K%
MB2B_K"IK%UXRKI/&,@,+-ZO2Q3RAZFF"!I90Q2!-1/Z1%ZF[C!.Z<1+PGAB-
MP5'S//6DUX3%H,L<9/_(*X=&OSA^2CX0AWNNW*'-M2?_KRW#K4YW.@M3 TNH
M[G/#DK?MBEA.9U(;;P=<8)U^C>]2F)N=$MX(BU="XC/X1)/U><K<V@V_>K,I
M7DWBTUG&NJA"=8,Q\JOR@OM]!?F;?4*LN%I#6)F411@&.F!3NJ&%P&P;""FA
M*1D#.5KFG5#,%_XY(T&SFYS[T/>OPNC)B;Q..<IJ9JL,-'XYJ>$QH$\<2".#
MXIFY?7]+2&9"IR,Y5'"=1 :\0C=9:-TC3$ V/1#@= PX9)O)2E'976O*9"?E
MV*B#60H=);+4\5S)KM0U".,V]=(3NPZ>I> !XE5&6^EFZ] HZX@27=!X&\:.
M/U_R4@0W=$=4K/3P;=:$A2FI@QG&I6(,#FGI*4;U49?)[MSU_12$UCG_4B9H
M :K#HPS;GJ^$S 2\JWZH2BF>O-UP%LN>>1[Q^B0H65R= V"G6*N)IQN#4C2#
M@SE&J2D\!^_,B8E7?;$QWQ97PTRA& +,8G-OSD[(SX2#\8<4!N%;:L3@H)!9
M4HFW8_X[C=D,S\/8MB?41VTZHN[%K13K\ B2T25M&!&Z"O("YF[]04C@97_U
M,W M"]R<CRFX4@!HEVJ"U._VECQ5IAJ% ?NCF[]&.\6=OC;Y:;@ YNB6N1VC
M?V6ETISQH;<MC5F!O*\]&IM^G;LF7NJ3^9+GTU*/.M&>G;_IAB9,>:CS2'V:
M[+E/X@3[>53\ W_V%S"E6=-M19K6TI6M\/A2NS5:DNA$<JK56C;VF9<O+,?Z
MJ#)%.LK9_@-#."JS4.*S_>'=2?FJZ:&CW W@BC=F:#KG 0CT >OO#-*>[JR4
M4ZB+*@?3U ]E?#&3L8OIQ<=TEIGOAT^\'P0[[AR3**R:$$,F)A3$-849*0E<
M>M];YJ=['V.R3/T;NB1=FB$)_PX8?AHGPR'X066 Z\K\:+I:3.Y(Y_J72%EK
MP FL93V H%+ [5;9:_26M724GU:+V:.<2ZN=W:5FQ1;96BZ.>,'J2-.^KZ3/
M">J"4NPU.PCI:11=%308!3S/CJ[S[%&BDHG;7RJ]A*?0EU8'QZE4[!*UJ>W?
M<$!S/U]4M]J3I[".9'.![4P[M<+([=ZC-@*D$V]+>S2?O&;[=<#&2S>GB6I)
M":*N&<V.M2KX3:; G:"#;>^VHZ-T8VQD^]"8J][)O7<0'!=*KYUM!P33.#HT
M.C]"JNP(NG@>38Q@GJ:!ILZAQMOC4Q6+B=SKBMO26<H2>9%M%!O'OR:E$QVB
MY62Q\S',&RBJ(PNZV(PU(.0I)30AV0N;YB.LJS3AT]WP^^8\.^7RF><C=][)
M@&D)"&N85[L :@0C'J@+8-N&O>BY:,>23Z-A)QN&)X);76 R*MAWGRH].B7X
M8.:\B!J''G+K/CALC;+_MRQ0?0XP#:-9,]9>3*=BYIIVW)+!^Q(ZM59.-O)]
M\D070^H<3+IGJQ'DDPGF59\U]ZQ+HX<RDVO=>A0WPY/]-\\ENW)<;HHM%EA6
MIXNYFE1;NVJ@.)FEDK70M'/!.O%.FI5,KN62N/RM[H'.O9/PC"AV'F2B/[YO
MLK^,#%A!#L-H-N(<AOHD+F<5.P""QO*/.5<OI!%@-8=>3.-D[UF4R&,?RTU:
M NIC/)4LHT8[,SO[WU2[FE5,<&-HWD7"96>."^JG":]I<IH]3XN+"75$,P9Z
M(E=\M;=MP+E'DVV;=GS,VQCZ.EB&T29#^VQ?_.,)'F!K<8'=34JGO9HIT..X
MTF,V(>O%\HEZI,)PI;K\)5M!4>#XE5>E=U'HI6["T^(7)-I1]Q0G>V@^45/@
MS#0,7%1@07"[]OUPOWFL=T \474#?H[+0R1\*X!RM(X"4*:OE<4T9'RT\ATU
MA,=2KR-G:D#\THPL#]-=,QE!]X\:S Z*C0-8+J!E20I--;=UONDKUCA*?IT_
M%6S,GJF2?K"/*KK!_G;4B_9XV(X2J!7A4A= !B(X';'=DR#<93!^()M'$BD9
M\=9'&#<-4H7CT+:GA9$(D?LP#T^A!K;-;Y"TOA/=UKP $PQ, &: $GV(*U_A
MI-6K8%R=&EA-"GV(K\(TTD:X\M'H#$1[6A@-  LNZ$Y??2L?C17<RK0 BS)H
M@KN@S]K8'K\9K_6MS NJW9VN]?T'3?]8A^DY^QEUYX&.#DL^':$=EDT2K&F<
M@4KS*(B^4E>^&B'.@JE!=7,S@/B2KM:)-L35KT8+<6UJ8&W8]"&^I5H6H_71
M2'>]ZK2@.J1I!?"8L7*RI,,SJG/N$'V'$E+IQ%@X.[A^9_H;X)X^$'<=A'ZX
MVNOM?X(O1Z?2D@F"]1K30OMG9^UL'(_JZ77[JQ%:9L'4D-IZW=#@-^I\(!YU
M'5\#9M%WXS,?PMD!]LG2O&LY&+/<NS2RUK5/1ZC:LDD"=L+2/K.0X"?B^,E:
M]\#2^&Y\^BV<'5JWJI_"8)6$O!YS=AFK@;;XR]%MCY()@O6@>DF7'7#7CN9A
M4,,[DH&L9Y> X[@MS5G!OD@#NG@&T*I"-,CI26:\'ZS2=<"X(#%XFAX46[B=
MID:D;0*) 5^<G2(OJ<C!>LS[+RS"-'() \MQUV7>7V<^DEDR4KWI0T[T.K@\
M$C5,0E(?=W!=UF-"FV8'BQ-D&>IR9&SK6B1K!%N+#BJ=7Y$J<@J1MI+W94YJ
M*QI,WI#1.BDSI<I>9R5GJJE$.BN@D]9(_.[!YJ*F'-WH(J2+-9*#+\*-0P-H
M.=?&QGXMIJ3A-:'5H:DXJ0997HE#_8O#OJZ5ZR7\%-FI4\52-G'(9'#UHO$!
M^QNY6SO1QG%U;@N$'V*?XE1%()ZU^2%^1Z+'T%0$7!,^K=DPL>/K!*1$W^%N
M%*KP"V<,V.I&-T>X>*0QCXJ@&5"JL'!89",%NY?+P8,(B!F*L?K61GT/5Y.E
M8&R\^XTNM6U(1X3)D,W[+CKV&LUV,@V[)?L6RQE2@5(Z7_-->]">,7\XUX6]
M\0G:15$?U,VI >[*6A#?IDE$.2:.G]4.S]_,: #>.<"8E;U[YN;[]""-?SC_
MH(']\;='J^>5"6%D(B_2P(L.SU-UKOE%'R+F)/?A+)ZH>7YRVZIHX5XD>ER0
M;"_6P%WXX8AQ%T_4/$59BOOTW6CM2+2Y#38.CC6C%EJ7&]*/4<^KFH%_4>SF
MB )L222#@E^'*@3G89#Q](DFZW(RUX'KIQXO=!#'O%JO]^ \ T<V33C R)[I
M4^3J@C1"=1+%Z:IWI]5*>^&RT9K<";QZ]W([5ZE5'N9-'F9-'HQO5@W)#+YH
M[6T ;_5258VZ\05JW_"9%6V94S"SHT4<P^+ Z;FL:I^2<IW^(I6[B8>@\,(E
M@1/1$"BX*AX7_4+-;,67T3H)6!7)&5;!*,?[&,1;XM(E)1Y8:%0^-EYHM%/K
M#FC+06G&1B>I4:;V^=2Q^Y)/,7>SY-R)HCWSLGYQ_!1ZDU2CB7MI8[:_5C5
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M+[ \0["5>)Y&'(13+,B2U)2%VHWA@.99]25ZHKAA7G<AY]Y>REF;BF%Z6<=
MQGF>9.M0[QY^!51'QGU@W ]_/=VR@@AN&D+!"J\9$<2'TI'Y%.R8+16*6$FX
MP^39#2)JL17K4I4*<3I2[! :E#]XBOVFS.5V- J7F.TY@ 5*%$J1#+RADJ:X
MV[V2ZB%K?N23#FSKGD2!($[1)"U]%%^5]"D'7DC[ZS/MSG"MVJHV?7 ])GES
MYJS4&E:AB"QOPP>(2EC6*XA\?0=ZLG>@!HM+T!+X:UF#\94U,/"6VY+5RO-S
MH@V;AG=!=L0/LUF<A[$PAUZ6U=<YPI1670\6<(^POQ8^0"Y\8! !;2TS$Q%V
MU1 9++L)%QJ1X5.(ZR\O(C\"T.&^&<$C BES-A(B>HB-U<GNO*OI Q WNCUS
MW723^OR*_8(P\F[>B)G]V2<9M($WVX110O_(?BZ=#/S-'0Q;(W4A^V[W@&0"
MF':AHUR5"3 GV*$1YT91=23NI^:0HW1EA$+7Q<I@(Y!FTH#N!_"9&)VDL*_O
M@3>#H7D9&-U ;\)@]4"BS76P(W'2?XMB=H?2IF)X@](QD&%<ZX(\)M<!&R.U
M=4TBHF!Z*JF/9>L21$8%_ZZS7Y&J*U4H6Z3>>IQSYNQM.$^6[C2$))#][8[E
M50NX"=%!>ZS39,?*E82$"*ZWVZ6F70*3M3?40?]G9^UL'(^>T5 CJ-G^:MP(
M"F:)4Y[\O]8D"?F%A4==Q]= 7/@ALIWI0UT\6:A*&UI>$6/#3^_63K1Q7)(F
MFN!W?(YY8.K#OVO6**G,_Z#I'^LPO: KFF@)0/CAR+5?/-D!.<;&VO\^#>-U
M>D.=@,V)+<K?V)_*5<G.4C\1QT_6'YS 69'\4N<F\32$,V!X[,-HGPR'( <7
MG!^])RD](0%$WTU=R?J)Q8;;WZ2 >J/4<TAMNI$M= #[!IPBA#+S=OSU7!(N
MTNW6IXP%&R&4@LK#D8IA"*5C($T5+T:**S-OU=KI :<[7CQ@?.UPMQ$M20 &
M=#YC"K_T*V$6#A^B%RC-Q18,QVS77+@D<"(: C6*$X^+)4> ]5HV>9( 5A&>
M?G)H-FXQW,<@WA*7+BGQU&,O?<*0CHT3,.A5O /8<E":X9;)*M5@^PM39\)H
MSY@'W'T)V"_L[]+(73LQB069%3V[@GR4:=D+H;^G !52]<1J]8.2R\K^IB;"
MGC$P C.0PNN#"+TR1,$+],GJ,.P+6(%MJ,!>_9WHG%7F_*H\+S<\9-5)&!ZP
M)(,8YWOGXZAO**+OD-^L=>-:3>BN319I2SCF\,1-UI4$T/4]=JN1?DETSA[=
MTO,>!]#Q,S[DZ!=('8"IV>[LU?EM&+CJ%4(T%:3Q'KY):TB=$.E8ND&F*PY/
M4FO3H6;1!=\A*ZP2R)EA%\T9HS-LQK$:WL6OCJ#8B@K"Y<1PL@@$=26.3 -;
M:C&-B8BI!R@HBWZJ2X]*\GH<+MF<LO(P>^XW+,,H>T 9+JO+'K(Z1XEE1]^5
MJS1)(U)ELRQ<8Z?B_"!6S/VA#K("@K<,\8<GXN_(AS!(UB?LFZ;"S&A;,BGK
MDF*K-"7)8.R19KS_)W&BAZ<059E*'K"S.'"UZ" )U#)<!CPSG3E=&Z-N+I#3
M7$:@0+DP +N0G4:)KL(4^IVV(1-C;1YY(@7*!0%7@^%$ZL-^%U]].!-?NOID
M@H!*3CV%^LR6C.8H=*C.R1>L2 V1@%:G.,7YVN<':!M'YNQDSFOE6#H'M\?7
M7H3G3KR^<ZC'KYLW68WLZ\#U4X\+_F%-/C *3'UXI&&^S,C=4.>1^C2ALGYR
MDC@?""'L$X=4H'SQP$")>12=;TGD\':.&7MW>80).G A(8(3D(!4_UK@48(D
MAG2SB.!\^3$N+/C\,7%HP&=X^>RNF7'GN289G_-'GZ[R,*/6VAY& ?4I5=>"
M'@@<<D?P!O="YNMJ6NKV'GC%#^$$Q:T"63%5<S!(%B@7>#5F]*R![-M1;][2
M"6,\6Q7O(@TELKHM-VFA+,,>)93OMRVD<&N&25:VI;8)W<20(J[&HFRCA;RM
M2MBS=P_?2P_+K@Z7*="=/$ SDY/X05T^SC0%"%>"2TMLGP@W\,2;[1A7*W)/
M^ .=DCG^Q%7+7U$?;;0G%0U  ,LU#U]IO7Q_:W4)*I#'6IO:*BY?K2H@ V9_
MPZO%!8VS]GWW3D+N2.3:WF05R+\\M1""#.AKG:S(8B-*]S%@4VCL=*#)T-U;
M)..@C/Y=I+;RX;1(F_I(-X2=I8C$$:@0LISW9LP&YN9MHAOU'AFFV",]Z]%E
MW$Y:FRYUW*3(4RD)?.+:*93#0M::/GW42_Z3Z@=P7IIM];"0CZ9-'CN^?4K]
M@$T[LZX=\*E"VN2_*.T S2JSJ1TVL\G,>,#6$]-U9:(KXL0QM""$*MM(>H*=
M+3]H39FHQR"-,(\N*['Y,?"*@ GQ+I]=]JMY_M I=4/*PXNW(7+TD3KX?-D7
M22 K1N>Z"6J+.$5 \I8DS1QJ*_5T!'0,"S%TC62<!%&IOR%/+K?1$D:#L(TG
M##>6^L8HD<1]KJ^@D;5J61H: M-.'5K69_L/S"!$Y[[#C!M\SQD=RMA;@?YR
M5WQ_TL881A> 5>'(Y*VSL=/31I?Z:)_\RY:-HD:(H:Y7:S7R_ZG+7S?9Z>)>
M&QM[L0Z430,HK&N%A;-=A,ODB4U7I\=+ZZM)KA/!Y#$SEP_UIZRLGN;HXRTC
MH+)\6E@!]^AY2;O_#6P1:N!-WT:+[UYRHS57K9./HHRA"Y)"OTD_-B"NOH4^
MG=AE#(S7"IIJ@A1JI"C?L5SK?-G@]3KPR#*;B<]G<OG,7Y'28/4^#+TGZOM*
MOLB0\<=:?T H^T% 8G?T[I@L?$_O'F(O;\V#-O8^89CWG'%(DRO'+:[5GVBR
M/G."S[W)IF;1WB:Y3R4YPYAO_WA#+E:9+C1([&V$>N5TS&,\7WH7<&5%JT<$
MI (_?;2.M_5YH F?#-M<Z(YZJ>,#-9T2CXL=S^E=;V6W(PDL)V[;+N2$Z]D]
M\?.W]6NZ?0@O@X3- ZQ%E2Y%% >K5W>EDNS#SSP^FH_#[^TUPFRMCS"NII30
M;$\/Z<5QSL@E#PUI UW]"J_CFB+6M2D"EL(TVN]G3T[D7;!C@H4+O/K8D]@E
M)+!@!=\.;%BY46N.CGRZ$JJB4"@]+0H5:[Y$=,6..GR"?,QYH&/?I1^CQB6D
M",KGBM/9H<'/PU-HCOWQXTE@7YDKG.T?@CU_^C( _<KGF$\.E>&O3A>P., 0
M$?#7)>82J'P]5@/>,5^X6KR#)*#GW<N_GHH$VNX^0/W:(1)8T&=S 1P_GL06
M4)EK ?[WJ%O @NQ(, #]RN=3V )JTRT$\ /R%J![[.WX? HB$!V!_QU9!+=T
MR F@\O5$]H#J? L1_(B[!SP,L4(/51LT?O0?6B;HVU,7K6BN27_8-E#['C=+
M1]D,^8*MX-O3=C9J'0^S<B8#3L.5[Z<AA?J42RF<M@A#ZY1(HX0,,D?U$:9A
MDQJS+D5QZN)Y@N/B,&$T1IB$,)JS+H6!?E)>#I1%;0#L2P'U _-2) R8IB\#
MSLS#9%$?8"JR:$R[E,4(SM #I=$88B+GB-;,2X&,XDP]2"*-$2:Q;S1G74H#
MXG@]\'0]3!B-$28AC.:L2V%@'[2?V/SV@PX9Q^\G<\BH3+F\>3OM:PLA2X/N
MG9M#3&3+:,V\E,?)'U$*&1MX'5T?8E(B$5Q.GSPS2<S8P%OJUB!3LEJB.^MW
M4,\E!PAEV+UU:XPI7%RT)U[*XZ1U_\1<#;K$;HTQ(7&T;[/?#3Z9#Q;'H!OM
MYA"3VD7:]]OO  [G  9KX$5W>Y I[2*B:^]WP\_H@X4R\.J[/<B4A"+,!1]^
M5!\LE&&7X:TQIK.7"&[%WPT^K0^]B1IR5*]^/Y&549MRF:.)>U3/6!IV5&\,
M,94=O3GS4A[H1_6,L6%']<80DQ))^ZC^'=HCHNSA'?'N',Y7Y 2QXW)FX[-]
M]5\LO##2((QK^VYT'A_IP&F>PF[T=E7$HI6W20("V/>3^EHN$^KP1ZD_.<'J
MCW68?N2%)3S^0%W##$H_1KU3,8-7#@38RZ9I& UIX0;S%Q;#WB[6&;J.XQ2\
M,)Z0!/(NWE- 0RZR$B&40F -5AH>AY)5Z1EB_&+IPP"Y$W>=O0].DD:\OD%+
M/,"KJD8(\QQOO+#J4.$\NBPYNPV3K 41M^+G5AJHBRB@[F(:<A.B8^[A[DCT
M&#9%=HKB6-<!^R%Y<)[OHG!'8S:@DR1K<D783!Q_P6BD[-L][SWK!-[E<DF8
MJ[,C_.^ O1)*5 _C']CBA,[#(*%!2H-5T7V"N5K%/]T3-PRXNY&KB9TFKE!<
M&1Y@Q.0;-)*FQ&J_?!) ]#C"/>0"*UK5,H"("[7$JLH,KIA!H:N@]AL7E'W(
MD:>.CZ!QO2QAG\J1E:Y?9#@5-G3FP'ZX($GBDZQ153$C!%T3\_%%VS2):% ;
MU:KP?;YV@A7[A8N"-_9+>;W37QP_S9'Q_?#)"5R,;52'.U3?&5G[M*0(6$S%
MEE;>AMR/3MFO,2?[\GG+VW@@J)^0#<RC-;*:B<6"V4]7'1"T4]&7MB^*P1]0
MO*;5,?44D8$SQ^?6,BN77;G6H*2W;K9AX>R2X*<60</*V0H#FCH61R)J=T%V
MVR?J\ !_=]Z*D]F],;^IE^!&+,"MKK#B9HI:J@-2G1M0ZJ=+D1A!3L2@Y:Z0
M+X'=+E'"EO5TB3:M,=[KJ^1)"%!KE'PUR9GXV5D[&\>C9S1,B+L.0C]<[<_#
MF\0SR*'H'0SYWE,1?75L<,-9U>E8Z;4G(( =X1RP@ 94FCWT$$H,,PIHQ+SX
M,)H%WOGE7&-E"3^<QBH2SQDN,/(U-W.*?DA7WN:@BO+#%>)KZN;I4S?E=OK7
MMZ?9S%Z &(Z #>F-F+2#SB_0_MRT<D&'9(L;6IUYLB;1/7$)W7'VH3>;UO"8
MX735D$Y5=FU\4+,5,G9NJ/-8M$&SDZLFHS+2[:)?@"+$8--&3Q.DCJGK!-X%
M]5,&PZ43!318Q7<D6JP9=M8BU8SJ3$K5.%RM-JKI0KGE+5SY-<4-?"_L^MA8
MB\)80K7,SCI,YK:MG=-I)K=/)*N3YLW8@,Z*W*;<GY@OLXG$\S2)$[8 V.RR
M.0/+58\VDG<"(G9-E,U-94LM='2":6:4)=@X_GFXV81!SM\L22+ZF";<W#V$
MV>SICN2WDVP.2>A^GF\S_XR!\\F)V$:1Q$KF"90@AJ<S2#E@X<;-YY<H>(%&
M2\]/8TBDU/'O]J MB1QHR&<#9CDDC=GED[>43-])"^7,#R+U'@R1FD<)N3HC
M2^9/WX;,RPD21H-]L+H.&!T2J_FL^J/BIB:JJ'?6]%0?+;"C+X!<:YYK?8^"
M%K8^*>3(U3 =,$ 6\"P-9]-/8<MQTT-5Q=P#D[FKUMR2(617;$<GVI&;U";G
MM2O#"-5/<(CE+I@"WY-5QAW32I7HN,@D*T$&MS$#2/<T.[,Q,>3\[,&:@+L]
M UKXTUAV]$L+#8GW @:W4Y_PVF)!5CRJ%"Z3M>0A0L^]A>'%14%WOGP0TS6\
MN5 >UGS!M(C=DVT8)=F:9MO )B-TMB_^T6ZZO3H'AOY?!X'6Q1[4[%1(XGJ"
MNLHK3KK74!^(?&PC\3-@LZCS61HS[..X8"NVD/K630LU;#-@R==$WXTF7M)]
MP8>5Q+;ZV-C[O9)"UV16AZ:12:^%]CU)'.I?'+9CC?1>R:?(*:"J6,HF#EQL
M4+$B;L#^1NZ8Y[9Q7*T:T:(/L;/@5$4@GC6@QZJ5Y<XTX=.:#1,[ODYQ:-%W
MN/N"*OS"&<-=MNF 'T?)K\QGB4.?>AE6F4.ENI^SKRM&G_WM:/ [!I[RYMV%
M%T@^^G#AJ>_;VN([;MLGEU^_HLK%(]NNS=(Z<[\^6)6KV\H;*AD5+(])#?Y>
MC. OGZ9G0O0.TVC%R7<D2,%SS _#HLM0(Y)1?Q]0XH*??WD>QLE\^3X,/9[.
MM2#1CKHD7H0^=+BV@Q#F38VI#+MP TR?-)+I^RB,X[LH7%+HV]3JR%.46@T9
MJ(Q%L_!(=F5CI_958W!<5]E04DV <$XV![TA 2]HRE;ZS-O0@/)8;)85:T5^
M?=0FN?+Z$#3/(80QFM>;K4.C/ 9_$P:K&\:<EU?9^XGXWE48?007M!I-Y)"<
MH< 5\33(4A$_&S4SPT56%/'.PPU7Q&Q>T.983&2:8I4A5LA1I[\HH!P/9T5K
M;\!$%":YL0JA*J0WO NI:4L-1M0M*A*R'6+#I_2'C;7816F:"[(3NT*NIVUD
M>NYL:>+XV<[NT22-R@MMXLGJ=4JB\VHC34MNBN@4DAO<\O1T:3^W)"D"&QR@
MRV?&1^#XYRG[8L-82M91F*[6-(F;=W>/^P\.#=BIC)>>M55_\\C=E8B[AYR[
MZS9W9S7N#'.(H*D/K^QYR70NV7^B'JDH;!>/9_L#%\=XA]U4)$@>!V0S:G+1
M6O50^8[&?& _-[2T]L0I4*"*#9,_\S5/"N*>Q(+%.G4FU=?4GN&I/2?N/_XU
MM:>9VG/JJA F:3VBE)XI "]+Z#EY1_$O.*7'TCYC.^GG:\[/UYR?KSD_-NQ@
ML;KG4;&V@:R@<-BQ5."U: 3%<,)4Q#25;95I,#,H'QM'RGVZW!"0"),A;Q7N
MV$S=B&:EHS+O7L.?DWV+:=7ZH)3.%\F/GC^<Z\+>^ 3%05.!NCDUR&>S.A#?
MIDE$.2:.OTBWVZ);I ;@G0.,6=F[9PY8 TQ'' _G'S2P/_[V:/6\,B&,KGR+
M-/"BPSZO :WP0Z0SN0K.XHF:%U096,GN _&HZ_@7)-N+-7 7?CABW,43-4@M
MZ</])?K6 /=5YD;EZSN!KHH@0V\0P1X/2)H)V4L/N#CZP.&RC'XZ@3>/5DY0
MI*E<9 '_XV2;=_Y&P9;*^+7P UM!=Y5)S9=7C/O I<QO*8.TDDO^X:$9$)ZT
M7\:J2T!PFR][-JL[J,'Q7(-&:\% ,7^#?(=N19VSU\/:6H'6HG.1/L;4HTZT
M7SC9>SE>@=K&);B4#I+G8+IR:[?:<O 0:X,<6;EU-NR/MKMR*A#$O7SJ4_&:
M2!70:UU8&,GI+J([9D3N?,?-+(F5"PL)$>1 N(Y 9#!!W5D,RAXZ]YTXMF@T
MI72F;#3EX.&U"ZSR8L5("@A@'YQZM;CV(E< $,C%;=$<@X]KQ0*VQQ])II82
MZFUPL)X_\PA3)<KR>TIY?\)D'7K7P8[$"9]2^Z>$\%T4Z$YW$'D<J0\QF,,1
M1[KVE3$%=O?;0P#O AAB@92B[T-Q6&6[(-SE"2,'WK128*6?8R4A02'?A0Q.
M4_C%.DP=!F2P.J.ASK60X#NTNS<H\0C!P"@UD4>=K^A.)W&V]='45TL;!9PV
M\#D?E[QYEK8XJE]-?^<0(('4/ZIZVB>_IWP.._:?!_:)I?BBB K6(0LJO"A$
M#N F$4J4=B**4CK8U\S=NMPC/-!S<V-\*V=G,0W4 CG& L!UXHX%/L(H>2#1
MYH(\6C.%0AH84@,Q@F+$S-.%AK\=;7)DQP9*J*!'#;LTN%-P,-<G9T[P^29T
M @T_K_$)[F54'WS-^6'><Y1+=N8R[S/.,E MV"L9E2F[;E+DS-/MAKEN(H;X
M'R-BQWSUT\,V9#W*W2?-!G@-HS8DE/#K6^-@PKCA%$T4I:7$,=O/=Q+BW3E1
MLJ_<\UNP<5V4IG<SH82?>=6S@>FN0IZL&+EN6JA^AH)J*T@2P+K=4&8//+;N
M9X%75.>Z)W&81GK)]@K#3 %O%32 3>)$;(I90JIY";ZA>9/\3OXZCE/B7:01
M#59W)**AEQ7PC&_)4_9/\/E 2D0GX#C?="7AJV(+5;/&J&Z9,$H_?PK8R&NZ
M91R['/45=/TV=;HC#_AT:H &NLC=>.O<>;.$MRX EKF8QI3E*T$-L!Z/649N
MZ!+BQ?S54)Z9*M9#:+.N3G?*,M= %^X263/3@F\P]V3+W+&U$Q.9$9<F7$@_
MGZ+<NM# >!_=O3?\,PV9^_W!B3Z3Y!?'3T^S[[:ICMWO-MAV!=":W[X 1&TJ
M2;&YCN:NHKV\X1J5J3O74O0@'X*#B'6>)G'"9L@. +9E6R7UX@1<P]$\*@<D
M92=><S.S8QX ?SV9G#M1M&>LV3#:/<3&_XBF6] ]4(*U)] K*!I&GQD/17#K
M@BRIVVR4)BLK*OQRBJZ3! .HK@.&9YLE32RT;JD,//'U5(6HC"H,KX=L9B9O
M2<*7-V-I1SWBG>T_QH2Y9(<*CC,WH3N:4/ 0HP;AT=];=4I;!^%2&TR"3"&S
M (-6[M$1SWL*57*"K?3'ZZ<W=0]) =%2XL-#48:KWUJKK?K84Q=E ZE2;#J1
M(^B&=\6!ZBZB+H^99#\#SPV4T9GX%MP!8"E:K&<,U? E9] )7#)?-JL36(P,
M=Q"=^BI6Q;;4 ?2XTYT3S:/L);>7';8LK7,5BA-?\4J@EG('B$V9")Y/8+X\
M9R3!6W[7AIZV0UU'J139X*:75@OH+=+-QHGVX7)!5P%EQW0G2&:N&Z:\9^#J
M+O39P9W$?27TS,Q)FXZERG@=A#07Q!D)W#4#[//Q+FB^_"7D0Q_NYJ\#)C_F
M3E^%$6^]R&#FJ4[9*B_^KA0, B*%_%ZL7\99RC\0K"@]G,JI_N)$E.=TE8SF
MR;[V$V+4Z6*^6U-3! ,L,9^'U)J0$R<FZ]"'OH83TYB.*"48890L^&7VH)G1
M4/\"^\&&&O"-60*FDABMD?S:G,<3 V_F,6\TH<S#6MD)W?40F\1FJ H<8%4#
MNSXFWZ1IGMGD\"T[0X#M^"J.I>DQM: W:]*CL>N'<1H12ZZF'NT!1>.<>'UU
M<7U^'? !>5OV%#SV(J:!N?,82;9Y8RR #<QO-)3F!=F&,05/JSP,B[UQ#9;;
M$2#4YW)<?3X&U/*::U) ?=8#LN1:F,'E.5O=N1XBQR/WQ"5TQT\CO=N5V7.]
MP_"6]B01!=,5,//]\(E'I]DQ_"),'Y-EZA=N37RD\RFB"3O!+Z$-FBYUW ?!
M'9*M+A!M2(%W*WO+YRX*M\QMW3.OCZ=I;;D5Z0\E&M].9;3N?![!K!"TM*CZ
MZ1GX QV J3?/Z!W$.'51.N=66-PVR$>"J)NCLM+E#1O[A O0,L%$K%<.C;+[
MIK/]+(Y)7I?90@D .1VD<[GJ<JM:ZPZPT%J82-704D>%;FJ8!\1>56Y<NG?#
M!G\L'+ERJQAX,-?=\* <$9=F^,$?EH]#XSJ.ZOMLXXQ<P68R3N)-&*QX.;!C
M#J*=V^8V'5OGK2Y*VC9>"H^Z0]@SA'X04CJ@Q _4Y6LDWIV"QF0537HDA.86
M<,82NY4VA220O#FUE5)+V!$"A.2%-YFQ4J])0@1WN^O2TRYQ0?2!^-E9.QO'
MHWJ=!=I?C1M!P2QQJ@#_USH-?5KT&-8 7/0=^M[0A;APHN:N\Z ^]9>3[=2@
MBG9[AF!9#UKE,QB;?GJW=J*-XY(TX<W&=?J5R#\?,_A=LP;+4= S,N0WZ@2K
M?]#TCW687M 5?X2:-7]GCN4#<==!Z(>K_7EX\W"A983TQQVSX(QP0BE\T>10
M663"#Y&S@/K$(IZL>7$*4;[<*-URE6,E1(-,'<T[\J*9.2C\<&PG(V$\23QE
MU-1J<5F>>^+X] _BO6>G /[Z<1Y<T'@;QDXCP=Y2Z:,.\E@Q7SU!FZ.+<WBX
M#GXC;D*\JS3PU"),]2^F(97&+ $K @Z,\1T3N=N/LI4C?(U!<([->@+I1P*V
M6I^]4#N?0<!^ME=(PC MU)"-?TMLI5T(20PK7EH.9Y%3Y/!0EUR:92&.:)CO
M^#"%L@[<\ O=#*Y[AERT Z_XTD$(\_BF+34!3H"U@>V:IBLGVOA.X&6W]@KO
M3;4TJCZXV#))=C#)I^9*77D-Q3VLRY@_]X96:#$1'"/4#;[LI5@5F\E=99?9
MZC;2A<NQ+>VOK>$-;[,.XV12OPT#-XVXAMABMTD&]7) )B/1BX8V0'#[KE5E
MGR=K$AWY5C/<)JJ4$6K"9/TAERI5W9!&%VSJ*1W]HQ@<^;H&;9V,C-F[J25W
MX"U23;7B:U=!=FC)'E<TH FYH3M>PX^WAZ>,GYS#L_T'MHHC:VF]&I2Q0C#*
MJZZ6ZJL#*83@@>5^9)'W2;>23Z)+'7?)&ZP117T00UU/3-&*OC&'^6-,[GD7
M>ZTF88+O4%TA0\B%\S=?8NV Q-AMD.)>#'$=IJ68E5I913F/NXALG7V>G;Q4
M\UYZ!\$Q$UK^3Z-CFP0,U%NSCK4''^[L(89T\ZDM4E7LP&V1Q:@$5TPK)[-\
M9%M9]/7!M;MN5F>MD2O?_FQ 78=#+>ULV"($)CE*#3^Q=A/#SGH1ZDJVUPLD
M=?)C5!PEO]ZS9:Z<),\^J B%_>THD/I8*#DW4N7G@#?F"H*U&=CJ[Q-5X*ZE
M=YT>=*$*U? 6O"LT4M0/;'/:I!LP].KC(1F*3O@:,\;)/\D8<9YAH:^--TKH
MZS,&K=PR)JNHNF>#'+D,W2W&"ZGS=T\"\N3X_-8)W/_JIH9Y-:[F5]7>#O5A
MAUT"+./(0NO<X[BH<2 3B1T  37W-M.KZ@=%&T>N]V'H/5&?USYND;-]):9'
MV]S.S39AE!1UU^?+)BG@2?400SXU&8F[5ERJ!TM LV=U;=V&"8GOG#W?M:T4
M#:T2L+1^A"3TEXD "O7XAO1C\XH<C\EUP":3VBP$):."7=BR2VOX,I3+"N;4
M;5;%,NM0<>6XU*?)WL*-L(  EJ#Z%DNM4J4 %[3[_#HS5BYOA220-SRY;LHE
M):L#H(7[3VQCY,_N/O*XOW?F!)\UKEVE'^.6;NW$4CYAG.A*R?5BS3R6![ME
M2\0T,$ZT.O9)@@Q 0 )$3E9LE(P*]L;?J:6=0I-:J\%NZT/(5[$P7034=ZW3
M0=XPE 71@13P*XGQ6A"ILV[^@FV@FU/E_MQ*BKB( G)V>.>)2::SYP/RP\4=
M7LVJE3/&*7^?RNNZ XNJ,?A4I-3$!+,C59WM\]#W'3:HXUMI5M!##'EGT)!@
M'VJH-4]O*FTE2V>^N)0["Z,H?*+!ZMS9LG])]M"7!SJDI[)<]?"$>ML]Y!$5
M^+(=25L8K17:: !C4%)J4!$UD?987&W(F?*&RVE(>:B3/EZ["9U \3;!K):G
M$UB^3!"2,"GEVP1"IZZP^%NC:B/-H20W"<JLW(SDF5F7*N35120".'U:GGCQ
M6PB_"0C@U>;IU'^YDXC[ZJO.B[7G75(R(_+U9/$>.41#TB]K#Y-F@5>6ZC^T
M)C9]K-4QUHC!5H8#]T[AGO #G7?G,-8>(F:0F1%F$,9G^^J_6+!T&H2Q2F$I
MVS\=$)'N)*J,6#&( @+8ARA]W98)%?C9JMP<_/H6W#Y.3@ :4 %>3XS1OG3Z
M_F@7$XU]+PA2Q[^+:.#2+?M#_L;3KELL)HE3PK?W=-;A*$N@@\T\-+N^+LLP
MSW8D<E9DGB9QPM8E[[EN(UZN1G,LCD"GC!7AFTS]N0?G6:$;O:&N70>,#F$D
MK*=H=U$R-H67RR5A6]J.'$:_9]M:W@HZ9<(N<OO9E@<\&PW"V 4V>P5<*[BL
M >@ ,QDFCC_PX"3F])ZX8< O3C(F;T.^/%+V:\QV7#YO21!#%S0T9@.W?B>
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M.Y4^RA) P.*_4M/[MS><CT<G)OQO_Q]02P,$%     @ N(#^6!0-@;/,4P,
M_YDA !L   !E83 R,#DY,3<M,C!F7V-H:6YA:F]J;RYH=&WLO6EWVSB6,/R=
MOP+C[IIQSDLKVI<DE><XME/EZB3VV$[7U,R9,X<B(0D5BE1QL:/^]>^]%P 7
M2;8DQ[))FW.F*PE% A? W3>\^W_?IRZ[YD$H?._G_VC4ZO_!N&?[CO#&/__'
MX>71Z>E__+_WQKM_.SA@OW"/!U;$'3:<LR-_.KNT!;L*+"\<^<&4[4?35^R
M3:)H]N;UZYN;FYH-[X2V"'CHQX'-0WS #@[4<$<!Q\'>L*N8L]]BE[7JK-Y]
MT^Z\:?78UZLCUJPWV_+U201  J!>^,;^\T_GYSTUB3T1GO6G_Z?O!/$XC/Q
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M%_[4\DSYP&27/!"C/?H* 7B-?[Z;;3O 6S:U@K'PWK ZC/5ZMC >LKN/@KO
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M2.OYNDP6$!-, JK!E .%JVP%H]'"67,60P9YM9\)L1A_QEKH!\'F?_IN[$7
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MTCP1NAQ'?;@\+E+!+2#JT;2!TV@.#YI:XF95P^=KY3Z+M+@?*!I3@/9_*F+
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MIR< \>^<.3[MR,2ZY@PAY%16CF#P()R(F1YC&(>X8P1G.L"I%T;<<DQVPUG
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MP12DV,R'P^,>_&#3QM;8I<"SD\B>[K>108;<J0 9 9"PRQ%*@8D83V# A(B
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M$Q$QW%$X(;L(,=;EEG,K[1F2]E(<)YT9\4LY-F!8<G^HH?54.:V<D.,K& L
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M8Q]HS\>=B)+1/Y)8"1 OV0=@B>,X<%RHD\,V<V\, Z)!/9W&7G)CIN\E-C$
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MV@U0V(K T?'<FD5Q#Q3E>+I-L]_=,CG[807+%QXQ%U2P^RUTDS89^UVSW=_
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M<!CQ@AUJ%[V>[%$3+U9+TB>+D38'77/0*(K_L8O.<Z"KY2Y#3Y=WT1]@T+8
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MEMG:LNU>(;SNZ/AM_L!56$\;[:B;74#'_G(Q;M$WO@E&6A.3/<NY\7@=50?
MKP(&);4.\-Z=@O2E: +]%L!?49BC:=6[9F.3A@=E\)H4*V* 5WX5)US0A2WO
MFNWETKG'1WZ017T0IKUMVS_NTI/9K^,5J07@#&VSW\+..4_42ZF*&CQ<*FT;
M&Y=MTKKE4>!I-OMF:UD%?"J2:]8[9J=7 ()KF)UFTVRT"]L'L*3A@T+UL\7B
MDA9>*%@ \0?(UNFMNHO[A0<1NMVN.5AN![\9&>XDC* G>MAF27LK(A+_=G#
M/@KN.F_8N37F;^&SOV+NV1Q&;[QE_[3<&/_*#@[4A[3M\EOXCX9'SG(0^3-X
MN8D,0CW1;KHN/EOG#=R[UPJ7/8C)[ 1/?04X<C?06YF=[V!D384[?[-N1GHW
M%/_B$L"]W#;J#7S+KN8S>.,PL(;"?LN^6%,N-_F+C]O9S7[T6G]%&_T: 9.'
ME>ST;3L_!'[[[6#(1WX P\_H#+.K[ZY8/9Y0=J]OP[W5DV?!QN6DN%%X]!^^
M/_%@HVPN&T7/V=F('8%1YK)/V=[1C]2G;$&P-G>X]DWFK]<ZPMM[_SMG5@#_
M\T"SYM,9]G&S_2D@Y-P Z>X',S^@YFX@X:,)9T?6'*9FIZ$+HCYD0VY;8 >C
M8FZ#6F+!6T/N\9&(0NQF[]N"/KX1T01^(+-X<8C%:4T6QC9H$B&;^7A"H.D8
MJ%9PV_?\J;!A8]1QF@0U60;BFL,R'0'SN2R<AQ&?PJ]L9%T#^!B$C:SOR7-<
MAS4,B?X <"0EV*?4LH")HL!WF1\PFWJ-VW,6\# *A$T!%@*'!KFVA*MQ"T::
M!?Z(AR&\@U?GP$MA/(/] W;'@VMA\[#&?O5O."APYJK-G,":+9 ]8<@<>,GU
M9^A3\!T:.^0 "R$L<ZT;W%V#-BR =R*?AOOJ"=S'RPCV/*3YE6<BE(/"OR).
M2\ U*T^A'P!4IQY#!0]_,A>ADL>"\SH^\_P(P(3-AD/P4",T8.XPYDQR) )C
MQ('KPP;8?AP &@#L2\#5'I[8GYR0+N,A;DH$&.C.&?P'5PY;H&YU,)#*7-\F
M>O#C*(1S6;$Q^:.P )8__4"A%P[FB ".$ Z-SM<?C0"M @#= W'C D5\X@*8
M6PRG.!%\Q$Z^ ]H0=9S)5PEWCR:6"/",U=E\\*T !V/'>O2W[#,2ZW]/+%\/
M]5%ZMN!@U5#ZZR-)MV]A7O:? O$'B$=XG/T.U&2RWP3\X>)_V*_<9+]P;SR)
M+>,7@/$<YA@!&+_#W]6&W4S\*3&D=*'Y:4SZ588Z+3=$(@7:%'@4].J?0"6A
MHRB5^?!E )];WFH*,6A:."- XN3X&-(L4HF<6>@C9!L>X2&2,0 5NY')1 1G
M. ?Z@!7AOL'#//4!]1J2B6DVH5B)C32+G%.L CZ>(8" $8IMXBK@+>#%,T (
M6+M)3WPV#(CM>N20A&^L,7#I,%K\5CTV<F.P55.;^BGP*"_"S8W8W(]AB:Z
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M+>AR VF/(:&#*>1GJB/^P>?LG K:/>Y*AU;61,J;/6D>=HAJ#=?.+PH743<
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M\VOD.6=VGZJ%0@%*ZO5*0F;,U1I8HDWZ,28<OXK1!R*P-CR8Q'S%S1[8'Z>
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ME+U!3?2"7N%*"*N5V!2[+?U5V6X(,TM1HY2R(]3Y^M'_O6C\IS:')!T?]#G
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MF9/)U[0Q/>Y\2M,*>])OXR4B*$.\U?E@*B;4I P6B3\=B?_QBJ*^+=&^".M
M, "EPED1OC/(*NF.5)6QJ8;&JK0X>1*RBK@0""E$7@)D2I]PR[=-,YK>VK7$
MI6D*G=^2JS"Y=&ZC(,))E;HNYF$3^S*<:(-LX9=,@MP1X'(T43*]5--3O7*C
M,QW:02;PB(>I30U#(9[ MVX%1?M9[7!E.C0'$;&L9/A>3Q5.87DW)=OXVPJ*
MD-]8'VY[8PKANP/^(Y\KM#]PE@1?"WY'I-=XY_67J;YEL.3]Y-K5)0S%C3V?
M6W-B#%V(9?]D3MY]N6Y[MI ("AT)G02& \DYP M6VFUD!HA@@J5IKZ$D#1B[
M=<^#KE/'"K"+MPB=8IA*.++ .(J5BCHERJO)?X5=Q+072L@B0K;NPMXY3KE4
MCI[[!%>U']IND&91W#[A)GM>7I=5]KS9%/' >UG=#=6EQOF_\Z_UQMMC3I'Z
M)VV823+:SRY)J>:T)E3VW\OE2_C-2"<3\47@(9#LP&;@!F!E1RB?2-Y;-3 U
MX ,0C[!$T%\]>_&<O7W\B[MZ;8!>DVNK_+_/-EYLRXZX)/VKOBOR3G5>]@.]
MQPC *^!+LY<T.7BR_!0OP:^*?5]0F1S9L(^_6&5;KK)@_@TI(^I#D^X,3C+U
ML*JS9WX5JNS)E_CF^6>:"X1-#;)BJ>I0EAMJMP$O1T@AT>QL\ *+)8HDM52X
MBQDWZ(Y9&%Y)]262B3G>KXT :!E-M/8ZA)\;%OE/8JZ]B,#E;X$-HZ7NL9'/
M&W]1EE4B';%;((N*%Y-SM"?W0Z#8R[Y@P%VR$VYG=X(YO91]S']I"J'N5@IT
M_IM6Y'SKG\:[G_R*3@**68"1I&MVCJ5#7^$,2EMR8+$V)74UZ2'4#B7"M_G]
MW["]RI(3P>-\8IFU-">XE$G]S"LX )T(C<;P,'\:+D!#AFLW(!HSJ=P4_%4L
MY2S>%&MB70+'1O%5M&[,F2VH?U+9704^8M;U8<R;IN@<Z\W1.1W\*:Z(#-P*
MV/B,&KD\R[YGS7'^!0G_XU7Z35D,E<ZQ'^YF_'#JO\/M)]]K9>5B6/_,FN29
MN"E4W47;Y%37Y06\%XK\39$3H)<$R+ $@>!W-O$;;="JN#Y0@(2[V+7%=?/:
M(C1,Q5EL=1K)DX@(351!74#I("V[%59P)IDA+4E';.U'T)H>?41N!'N(8L>X
M<J :+@D:L1$7D-L.NOFV@Q<-(3Y#=9\?//0H+$$8:2T;!/X1Z(AIF00/\M44
M  0_G(-(BES9SO@MSE:$@#<'%[\-_HY+3]*FQN.7SEJR%@=C8E81^UU?NFBP
M6G02ET).S,9ZCLWMEE&/"O-B":6-JN>U4":Z*%"Q'>)\I6-;Q'&/ ."0&NK[
M)>6,UZ4V!U=6+BT.Y8Z) 5@ _",'7YP*([\[1;_.%4..WA\"-8,@R@2K3G*>
M()]1LF^ ;3//TPK6<;'BVZ/_[UJ\N"CO4U+>3#Y"4'SU]C;28V[N6%I5(N?R
MK9Y=>[?VJ+'E:J(U5>6F+5*39-:H,,^2UMU$LK>WWD4$,(X7DKEX_O#1RBQU
MU?0:JZKV\#_KR__SN\>_HY\[-**7G]]YCC?EIK_"1Q__/N! P(V<[SL_,OW7
M[X S^(^^???G@WP?QKDN7-_L?R>@A7[SLX?[R1?[-[_VAO2;?WW<3S[Y5<;]
MY6>??_D+#?P]CU4-0QJ@K6I+C1+3?YE-IQ *TK1!,EW_?^VI2.P]$M)EJ,>'
MNHC4:0[U_JBZV+Y=]9T->DGR* UXOX.F^W>R#\1FN'_L58MULU@W']^19\XA
M.>W!XQ;'RR2.R*D)] $21I\<_/F$&1*MRTUU\J)PKX>ZB-1I#O7^:,(0UJ<1
M#MUQ)3>*Y2;AHQBR-L%>&^O]2OH,+,)[Z@)QKX>ZB-1I#O7^Z,/$,J3<UMFO
MYM9]Z$CVO<R^('6>4HCF-E482X ,ST0Q2@ZFE!/$596$.T>=;N8[C;K9)J+S
M+4>YRT]##0&7=-X[C_^=BG*?+D6Y[[,H]XNE*/<W=?S>>S:]=O\J1/CG H)#
M<T7%B+N[8<3/LN_7#+99%Y,+2/J&_4N@$'<'4$A _ LD=-^6ZV-$L%-6/$(]
MW>$6=6F$; [@,X>P)[:43MK'$G_1J%FE<%K2;X&99)?S&-V'XYI*9H4*72W\
MQYI=N1;"$*E'4D)*_U:_7>UMF/8I4X@60"M_J:#%PV#,E=\!Y:ME4($1,K)#
M);R\TE1.O&HC%)L"]=O%6?:=5X,-(5#+0&1\2T6UNY5#BKI\EOW0,X%6!-."
ML#ENTNU\S0&),DNES$72V!<N8A#\7+&)!:5$1\@++=S)HZ6@)G2\  2<X15K
MYTB*%WOI0Y(H?.^-W5M(N[BWP#SYV%TU5%#.VE*:8:&X$+P<4;-+?_SF8?=R
M_@#')H$NWNRI_X3_HG H'4(;1#K9@4K5$":\K=@Q-'YR($%G3J;;*)+DV!R8
M?-3K4IQZ/Z+_]__YXLF3QU_%-],OSK_"A%,L?],N+ &G:;+\R(S+Y@00<+LH
M<,DV>Q'?'6Y40> ^NLB[P U&3+ 14#L FQ> ?A%D/8^BK@6PK&45+@IS(%0V
M$-X9AOVDO$.KF*0 H5U?\8:=?TIU"%\R;/!ON1A5+XMF7Q40V?//O^I !WW9
MPG0A,'L>?E_KYRL4,>#. )BPV1RR!WB<G(&_O7PNPO\PEL7<5EW#Y[QOFM?&
M$_]K7@]^N638*X?:*YK-UWXEJ1+IR6=V+KCBTA*=Y-TO4#!!.$HRC'Y@?.;V
M#N-:YU1KYQ>=!^?BX+@8"N/Z<8(V[Z2^+#"+$*\, -^&:N7'HV^_D]IS8(<@
M,R@4BJ<$,WFKW&P;6Q%^![4XI[9BD[SCNI+WRW+*N=#8O.1*B-PO:;^^\H>[
MXD]'R#C7XVR\V5<' U:D:BKQJF%IIGSNH)]CP92?^J8P,W%Q)H9K8T(1B6D)
MO)\./#LM:?767/^)1/IH;[G# TV<M[XJ<C\"5Q7%3<[E%H(<OLL[PC+%ZK]$
MWDT5'1=R'-O: NKINBQN_-6K%(2[^:*S9!I,J0HJS NBWY^I?=@=(;P/Q*8S
M='VR!>Z6TNE8)C&1O)DF([RFBWEY4I<KX@$?MN(RTXI+]TM47!Y1VU0$96[*
MV%4MWMI394DJ>^6*-VCX+66N\*YO_T)*(E;6QGS@)5"2T:(D[2::5 V%:*,V
MX6]^2:_*BS+^S5$US?&S=O>5$=W4A9K0VV86@<G^/<?&[6X9MUT+TA\2[=!]
M]V]J<:$6.6NP6"X72BNXD"@IK3">NRFM.',O1S7ER:JP,#]G_MA@2VV3ZJ.N
MN&1=]^#!^4,MLHW<4*OLP9.'WBHBGWH?R",>/'U('+!%EU?$GQRYH*1O 8V'
MXS1"LR3CH.9N)=V75+8=Z>>X!NS!)P^S;8[0Q"4WN"^X]XA?H0L$@ JFK_='
M*T3FE)-O)Y1+#S42L471.TZ\R,S1/?-V07'9M(>S+-@,75E+1Z2TQ-E8YE!@
MHA.&/=\KV#GG?;-(+B"<O'U?$54<[;D?F_89E*H^NM$*T%#'!<LAJM@</\MB
M,[-E)%Z"/&V&KB*'-]!,%>X.TQ7*O6.WI]J2QR_/V\DH^-)T=[@T>?,A']'Q
M/\;56W:_K$8)_4."(V%W7)\<J[%E?["]MM!1+(3YPBUSY;BY*^<X?SN9TU75
MW$CT<YYG:6:9TF'E7>#MP%>]Z*#*?>4,9<>H\!)]?W  ;V5P9%3.)(8[5]VH
M$>$8W1RE1=UL6G3F6>\4JEZLL5.RQI(6J>7V9[HA_DT4=0]4(.N@K;P0]_EK
MKY\O#C$\PEK82\->PABAAO(8AV@XV-M\721UO"E?54XOU6@@*_3 DB $#S$T
MDI/2H ;8Z%E%9AX?[[/L3_[F]4M!M%1^ OK)8'%Z(<>4 WL')2#V121&FJEN
MMB69L;X>P79__(F4]/:TDK,-7-YOP'8YI^\5Q/#) F)XGR"&+Q<0PV_M^/W"
M.;&?B++D !U9K\L]Z6+0"97P7<$?N\]+B@J.<\BVD9N!6F\'L:?7>7?%7;\X
MUTQ=:6V)2NQ;2$:XPY>(O"FWE$>::X]<AW$$\%#MN]$I/0Z<:5G6D07@;4 X
M?9<;M7Y<N*Y/VK0[VEZ6(2=WD>V)(P/)FI%O"C-#KJTDFQR88\<2C[8>31>X
M+0$4N.A5]OWWJ,$3.2:8P][[XSA9M0BO.KO*[1S<Y4#;...LNIF!TYLZ?KD$
M0,"%77.J)_&'.2T'&XO/:<I%2D_ V ,!35S-T-=Z UNZO"!BLL[)X1HS_$J[
MSTD[42Q]G[])J#SXA1S/8F^4HR#T8/]A20D1W")ZU4=Y^LDB9E.8_=R;.X.<
M#/0GU38QGI;,/DMF'Q@3%ZOSI%1(XAW>G5I6LMG:VP^',0K$W)697%A-#74T
M**BI%*Y!:FF5TXGKR%7UQWQE&7K**94CGHO?@:_/'U3XC)N\W82^P6^ER+UU
MI*1>4WV&R"&Q@?5(\>$T>\\W] <X?_S[AW%6^=8/_1&.M/<FMWZYP+R;'0HP
MK#&<P)^18S-8<2::GN2 51O(J?2NZ+X:B*_<ZU;5N4Q7R%B\]; ;)&&?[_#8
M (J3[^#+.5&+;LNM/]%A])\FHQ?G7>("PE+JUOG>VRD5&);1,2_NNL15+XJH
M!A!#)<N:N[*TQ76)=L=8@! <KQKOP(80;[/=^B4>,9O-;9$+PL1;I%%)T>EE
MHJ^\+JR[+:(6EA.,/U87O>I/OGDTLJ"7@R1,PT17?L@YQT<DNMR=N6<SW/\K
MI=75H87E[QN_@OX7_W:^>OKXR]7YXR^S!S]\]\?LR]6GYT]73S[_XN%9]OV1
M[VK_\;#(=%Q!%.EO9Q=&R?1K[V94SINUQTW+HS$,[K4QNC0NV^9FY;_SND@2
M]UA&]'7L2FU"G_>1EBYTDJL4Z1LY^E;IT%;A%B8::YP+)Q#@.7MVN80^I._U
MG -ZSJ1!=@3U2<FIR7G9-WW!@4"E)J</!7.*[H$A ?'>BM(F83U8KV=+\70O
M=&WWH5H>WW<1>=]VRG?MF?NV*+-ORX'UZO.KLMAFWS +L)>2[XF%E_M1/K_*
MR]8_5;7<'QM_H>*'KPFSWK2X7+T<^!O,<@E?%P)JAR*9MIKQOGIVZ?51ZXUJ
M0+)A0YN/":U_B,!VPQ[.#RH39Q_[BEVCD1_@YXDY,GH*XZLH7^8=@:8N@M&$
M'KE[:A'@Q\(6 %BQBVJ/Z#F$.O0:T^;+Q(@J7>?E:D/;3&HM?$,-B%C;#_X*
M \$GZ%F19@5JO+R\\G?R=QV&EOU7B87@TYHLL)LL,%XB*R9)-/H&64&S"SQJ
M?((!3#J?T%43'CO=",=?/@.T<:HM8&?T-S U)D;.9M KCV_&Z$H'?42Z!5@W
MLE#P,=U9UBI!D!R30F,="$(L41C_"KIZJ^:05]+68DW=4^E:-=U,Z;6-%YW_
MQ/]5!)'F0;=,7$D6U>V:L7,ZUV,3NI7F=F4YM>$J8@ 4WYI5P[0NWJYM^BNQ
MKG;<UL'[H2$_PQ4%W/HY,.BW>NG/[I=VL_4_-96 @/" ;7[=M"/"?UIK+DI(
MVDB4O2M)['7BP?R,[]$>=+<GA[6W1QJ4\-+>&DF2T(2$V$Q*RH4<+!"0XQB
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M,;F\@H?,W4PIIX&EA5'UJ%#2R14'U23*\H@0S\*7VQ#^Q:_XHFM/?D[?UXY
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M#NH26%P%[7M5Y-[W6G-\E.AEI-G]M0*Q4\I)? D'?=*F6FHY!1,,EJUX:KC
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M-TX)<R3:!E0#>OS:@JP)53=T9[K$U"_'"P%89H&%E_5983$>H2,$>4K;WAQ
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M78.$(25:8-M=2M@T/(>>$&J*<N3;=@7ZW!%/=7RQU(G?H.^W>IT$.8S5'^$
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M-2Z/^50$;H&UW"3I-,/J,EFY!V7"=9/>LTU5N)1CLRLJ)1^GH:XDT<D8Y1A
MV8<:Q-!*MJ-052W=B4<+Q(PT8#JC&N9* LCX)3K9(1,-:#?LA56P8Y+FH ]*
MS&3H.YMT1><72KG"!4PNRJ8=CZ%A1^^Z]"*KVR6SHT#=/M\S#2@ZNG@OU[9Q
M#%EB/')K$Z9,1D:*RGX!5SFW?B2^_[*\91L8@FA,'5+&&">AI"BQW&,2N\;?
MW$QX"J"''VU3UP5*Q;MFS1TCPT&AB753 Z(;!0X#=3^=KJN\Y*PT-5P(7W9Z
MXM@HWQ0VPX^*650B:./%.3%<\0.+W?XJ[XB:7HR5DE+L32U\HE[FO(+PIV>O
M26^)?2%M[AAPEG1\!I>=7!)"Q4J>R]'CH,D&:_MA<OB6!@+%@Z"#^4AZ1<<;
M##YQ6[ W,2XQ& 4A#5TI-Y[B'J.A133'.E<4HA,(K,V8I^*K3>)R^1IC_#O_
MAVY;BE#-SMEN\/RBP,WR:F4CY)A--1@26VL&A)R+K C7?[14>8'9SJU(&<EI
MR39GI/C'=+.=T&W]3NG_)TOZ_WVF_S]?TO_+,?T5O;[S3Z=FM3I^E.7\.DE?
M2=2)+-\_4 ,F3AAIRV1]ZF>2\IG[-J>HT' )(1>VD$87(;"OA'O5FS"VX;WU
MIC,&M>'I9,SK$XX03F;N9F>XS@<IN[R*)(A VDW[2A,5*$'C&,TG:4^N-_2V
M%V4#F!>#JQ&)[\-.%]89%L.;0X.8[V]-V!(D<-:MI0!16B,37V5 RR7HT;/*
MNPXH!"1&'7JG.YXD?DM^ES">O#YV U9C$P>&$JB**39+-@)O<<BDPCY BK6[
MXNAL1RW:21Z3K.1B$YS\G,B,=#&-)@'U2 R3$J*20Q'+4')MWR"_B[T2^?L1
M%$M-J@P3+TD;C-#B1FBIR\XQ2KT;G0[EPD1!HD9*=0SS?)X2E?U10%#2P$%"
MQV7H)4Y.X#9Y'H*]CO!"5&)C\V*]L%6+HR)=[RP+#^<JXJ((E/ZVTC+!)AWC
MRW-*Y+2*E9HQGC8MJVG:269R7"'PM[S;Y/_(BKP%(U)FFJ):N%82A]/ZY_'8
M$PC+!>>'I RAUL;"TQH$?G2MA%PR> )E*/&$X8Z%WU:VU$+"&3;Q#FQJF.W0
M^L?*>H_'1Y@/E#+=$!"E08:B:V*G$#!;T@\)E=+([\Y-6"0,5: N4HA=%Y>4
M#@^D4>KEGDQ)X:(9?UXI12@WY'#ZN]15<#\4<JAC[$93<1IM(K@BQR8Y!/^4
MDS.?Q.!4:(?-C/Q(Z-IJ!BK:T^*-IITO/LA^D>(#BDJZM(R2*@=FGV8K^2+
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M.R"VH.+J0E ?>9U7APY%T5Y>D,,=]6^@ IM%)D]]G^_U4!>1.LVAWC<UIWW
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M7;F/1:(R.\G,;B55MI&"_YF;P<,I*6AM=F9_F9A"3V2Z:<1*!'@0S9%[PI$
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ML1:9\.<Z>A>"WE@[4-LF1H'M0A=,?)ZT7..1U]A@IO3;0.F4[YDIQ$69+LN
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M66)2F1G1X3'JR0&4TCU])*"A;AA/=7"C1(F0;R8)'BSW!+#.-'E\^$9/QZS
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M@U!X$O"VIDLURX&IR*B%R$TD;@'NH$]:8AJS/_VI+?!-RQ'3"]#-DX64NR1
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M\/O%4[?K#=MMKUVF3CW((*^>G'W]E%;>:>X!>,[Y^I\[N3]>//OB=3W,HP]
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MG%EG)WTB?SJ"_C;R:=VSML8#QK1O;\<X#IJT=;-I+RPA#,BV"H,L.'B0_61
MUZ;=]4;[(+(<'*&=.-!XY VZ=7'?CE!1.O)&X]JD(70\5-WT^G7),T, =]CS
MQOND$#UD1.0\3]"^=T/8'BI&M%.2/E0PI(UPHC>H36KBH /0"V\XJLLM1Z";
MM(?N/NVT#AYT'=/&=+W>P\)4F]O2R*%Z4&CMY%#?&Y/JU-^G"O5>YG/:IRO3
M)CVNY@G&[^/D U(HI_XZ($7OT)R6[A3]K].ORS&==/MD)0SW4Q<.'W$CR2C(
M1S68S"G)H)YWVJU!XL])WQN>GGJG=T \^KKBYVPZS5=Y"(^..U/S8'KP;/R3
M[BFO>=2I0XU_M^NUVT28^\B?PT^&-'RZ)8,[=)TYX)7UVB0'AW< 5CK@C>UY
M@_:IU]V'NSY0.Q[Q)JC_Y$%V_;W)FEZ/S(RQ-VK7!4#FI$,\E0BF70MY,Q@+
MPZO#9#I$U>.>U]FG6\PN[:WV"3!-F%C5+$S<M")IPL0/.?DF3-R$B;>"34<1
M)NYTO%'W.!MF],?>Z7A,1O]Q3I_4-2!,]+<UVJ.8_DEO"!1E;S"\6YB[#F'B
MMC<^;7O#]I;_];L)$P\XSK=7XXZ#8^OVO7:7;*F[HDD<;$+COM=I]_;K5WU?
M8>)Q#P#4=8D7P#]/.]2O>^'<O8:)=TO2!XOH=,=#;]RIB[=D"%<?W:MM.*6'
MBQ*/Q@@QU:!<G3:F#P"D?4JSOZTH<2.&CD@,T7R&I_2_NKB$AT-O0&*QVSM8
M9Z"CC!+3G3H=>.W:-.HYZ9"=UFM[HW8MZC([M#5CLKKJ4*YZRNFJW7VR@^X!
M'J0]0)N+_0_IVX@2=[Q>'3+%3CI#Y+MX_7T0V.\C9#T&6,P^3.0>*'/0Z7J]
M?53'P_<.&'O=4])E[]"4YEN.$M=-UG0QH>Y^N9_W)/R&I%)V2&NJ X_O ]=T
MY(T'-4A+HHT90IT<?&9J;!,E;J+$39.'S]ZC)DK<1(F;*'$3)=[X]4VA5M)B
MMH&OCB)."1UU/#S:6NAQVQMT1UZ_?9S3/^F-O?'H=%>_W;I'B0&!W!NA[?7G
MUW$?>9B8[(7!Z:@>_OG.*<T%/I+Z0&2?>B/4^M<FID5,>M2EZU87:WS4\X;]
M@=??3L^LEX/^7L/$NT7I0]%PUQO2I3H=UR7&=-H!N7B=;>R,AW+@C+SAN+\?
M,O^A6> IW:5!QQN-#Q;PJFF<N)%#1R6'3KI>O]/WVG7H(G_:]_I]-$XZ&#;Q
M,0:):4>&W;XWWN="W0_)](FMC;U>'>J7D-G:[W?N!-Y[N,D,O2Y06?9I$7YP
MUN>UD?5W5\YW]'%B8OD=T$0M(I #;S@<UZ,1'-?_CX=WZBER0$6MUZE'@R\.
ML_6P-8>HN#^Z(''M9 VVJ=O&=M5D0F P/6(PG7X=X I@H)[2]G1J4)7?15O0
M$5E?GZF]U3Y(;"9=#RS]0;O!TC\DEOZ@P=+_-B[5X;#TS_UTZ3X/XZL*CGZ#
MH/]P22_'D-ER/S#Y-8KL-^DK3?I*D[Y2Q_25/_,T"^;7^L. >!78\N,Q=!(S
M:2CL?W''F#"ZMDTA\T[RE+A:$#UZLD:[0["XR;7IHQLM7'^:!9>5:,/&3.XS
MJZ'K#<9#KSW:XKMU3VKH>N/A<)=M=QS9) -OV._?N3% +?:]TR$[=GB<.53H
M9C<8[&H?N\^^?RW_[^=R%LU8Z/\N57H#+SF0_Z(N#3I/1G2 =8AF=+TVJ:S#
M?2+8AYY+;<ZFRQ6)HWW %.[=6_QUI?F<5+%H>J\WL.L-:7.'M<FX(1'6Z?30
M]N'A;\ ('62]P5V;/1QL/NAJV_,&=\6-/.#^M'%1]@FU'2+>><>[]VP^5]/,
MC>>N^CA=^M%"N:0Z*S>.Y$KZT4S^0-3GT@]IM.]&_'&5=0UD#JF!=./:M0':
M)\5NV.T2B=<A;(KK3TKFZ?Y1]EK+P2":)LI/%53/A[J ?6*GG=H0&Q$:$DZW
M2QGNG]AZ1&?H$U,745,73MEA8*\[MTHYFGAK$Y]XD/C$_> SU\AUV\0GFOA$
M$Y]HXA,/Y*\]]7J#L3?:K@2KNY_\!'US827=#9JW!C/OH9\;:91W"PG5Q</?
M]=K#@3?N;ME>1S%[,F.[(Y@ZGU5DW,0G'MSLJ,L\3GJ=CG=:BZYA?:]W6H.:
M0]H1%+OM[Q^JM4^F7K$)DM+=@=>N3VR"K/]N>S\XMWOH#=?M@JW7H>:FWQEX
M@VX-N ):"0_W"^4V$8E:"YIQ?^2-AS5PNY.=,-C'(WM?'&C8)WE3B^Z478:7
M[M]!"M=:]M4A'G'2Z^^R2A]$O>H, ,M9 Z;>1WUI$XG85@!.@57:VQ\XM8E"
M-%&(A\?_K)&#MHE"-%&()@K11"$>R"O;[WF].Z*&UL*1#U]R]PN: SYL *7M
M#8D<1]M8 G7?^"[9?5VDI![GQJ-!WX"FW\0@CM3@0">RFL#J=.G^UL %4INC
MZ;6'7F<?O)9C<,34*PB!)HCUB4 ,:<N'7G^[P._^B9]DT8B$Z>E=T6L/Z1P=
MM=$TN@:<H>^->@#^>B HN"80\?42?OO 7=P'>>I>YM/MCKS>M@KX4%>NVQYX
M@],:7+B.-^AVO4Z_MC"F1QJ1J!4<-TI@>FBQ6@/Q1\0V./7Z[;ITD*X+PQP.
MA]YXNYO%?M?PN"(3YJ^:@--U&G"Z0X+3#1MPNAJ T_%_?#>8_>V'#_]N=WJX
M)/[/7VD=\M_6((AV>J._,B-YVG+>O'W]YMG;=__RW#>_G;UZ=^&>O7KJ/OOG
M[R_>O.3 U %1[0Z^P@-SQWWB!7R47W--[Y7C)\I=*G_VG]Q/B'>)6_!7LIG^
MNXQSSSU?!I'?<M^3\705N=DR4<I=)PA P%?1<L](TT,<R0_#:\^-\\2=FGX1
M4/5FUH]=O,I/:18A\ [_\BUNZ"?6=*<0__[KKD3\;\P,V SQ[S_^OBTP[SSC
M[N#'+;$\V2&6O]KY/%7I- G6@K&I#VF'OGCWK?]QER)P0,KZ&I/NC_;8_4.O
MZ[=XZC?'P9/NUN X+NCOOTZ2)[*<DQ1B0;DK1:])'S5G5(LS^@V2E9>B/JZ#
MA*^/6QX:,B/L1>]P"GT^ZR>=?I?OZ/^<GS][]OSYEXB$+:?1#M?2U]S%-TD0
M38.U'^J=5-,\"RY)SYG/@ZGZ.E1SORKI%TSU\TS?@QE-;U7T,8AX,?_R_\S=
M7_(@!'&X V!EQXG;MU0L67.=IO_W.%KPK"Z6N?LT2+,DF&:>4:K=\R C7?E_
ME^K/@#YRWR @2*:W5K8KUO?W07V'9IB=4?\[N\^'WM%_^!$I!M<\/<FV[?4/
M*W..2;0<ZAQK37+UG-41;> QJ</-IMXXTT;=WJUN+_UDY4\#E8IEV?E*UN31
M4.+7G-4??A+$N>QDJ!TH:=5Q^TGU\KO9]:_K2/[Z+.0M$I1DQ?,D7FVYD+^.
M?7/H59R.>9Y9[ )1H]=8,5]?Y\Y#4;A1VD8;77I\7D^S>*(2:.&]1@O_KO6=
M>L[JB#:PT<*_B4UMM/"=&_6<E/#0CV8\XWF<N$N53-QI'F;!)6N1[DFW4<P_
M?U;_))5[:;R_[^*K*%T&:Z]1R^_=XSL>>D/D<3>[^C6YAYHDA=N7O;[]=J-O
M?M>2O9ZS.J(-;/3-;V)3&WUS=ZJ*T34;M?*+MC&(_N__&74[IS^=259$D530
MJ);WGTS@#=%CI]G4A] L*Q55QU?N\8TD@). ^AK9W_WUQX/?@6,)-)Y)-"^>
MN]E2<0ZG_!VD;J+6<4*L_DH1W0911O^S(*"XSH*#?],XBM24O3A70;;D:HQ.
M]]1=%Z'7%KU>N:]B&KQ#MPPRI=O^Z;>8AGFGDI7[E-Z4!EG*7W1^:HD;@^:C
M7S*+W2C.\"*>A!]=TXR(%01^Z*J4",2:$ND:URM4]+IQPD_0-Z@+07$(_5Q_
M2]N:K%(N,%G1IKJ16L19@-7S$K 7\%>1_C-+"Z<5;3D=AHI2+%7O6*7LA-_)
M3(KV):-)TS'H+_)UC#H6%23\:@V#YLGG5\M@*OM6O)06>$US_D^N:'8^SY[G
M88J96^[OI#O1G-;KD*X(KO>;M^?T_!4?V-*_1,%,$"=!=NW&=)'<F-Z>N&LZ
M!-H3VHE0I:FBF?&"$Y6N@5U D\[,OH-8XT2Y8!$,8H!O4G\E.<#E!OIA&ILC
M4A]Y&)Q02B0;S&ENM#NS -FM</<)R=!RU!6.#$.JCT%JDY2U566B,:V*ID\4
MJM(@4;.6^SI/>![3>+7*(ZR29ROE/E%,E!>&V$'0QJ6B/U-\@I>#_+D&'"^?
M!Q^S/.%9I<&,UI?325@CT93H7KFK^!)[W'+/4CZ-E-;"&SV+>1;6VG&,LR1?
MR.;I"X,X.>WM1!6$2X-B#OZ,SB;%_'Q&CQ" %NS?W ]"FAD>X^VZE=1D$@6Y
MM0YI(WP)"SXTUST2=?^]W"%A6(;9N C#\[_>J'@=*JUZI^[?<7\C9EO$=8RO
MU_TC(/FZ4&XNC,#MM1]? Y)41F7:D+(ZH^60>M-IMYBQ,B$13Y.K;"9PY:?$
M--3:#_BY>2X7YJ5O'BW9>+=@XZ^9K[R*(T.?9\17LM33S)RI7)[I%\^\(%X<
M+0)PK>JO33 ?4WHN*$7$JBXRNC3,U'<3]I%H9Z;4?0]0WHWZW/Y7K<^]CZK<
M%^^>O73Z9R2F7KU]=O'ZMS^>/74OWIT]?^Z>OWZ)JMR+IBSWEOG?8PDUW5S5
M^F8/8N,B#8[R(LD:!RT'9>YG[UZ\^CM7N#]_\>KLU?F+L]_<M\_^>/'L/7_X
MYNWKBS?/SK_Q^[5QK,,CQB\X^VOP<XO6%?Q<GBZQS-]_>W?1^J;/\"@K[>FP
M2']R!$P 1LLL2*=YRB8AZ_.1'UZG9#V3I@9+0$P%^6=I"K"V5Z@W9*4*F@%;
MF6*5P*IUH<ZEI,EM0<SWI=VM@W$X+2]=QGDX@WU!UN%,6^5_YM&&65Z^,RU4
MJL(4(AM&I:)\Q:G:_=MLZ6=L%Y$=&N:8EPI3Q::9$T2VWX M-'MW]!, 8DBN
M_&3V.(SC#]A!:_@)FYUL !IM4JPJ8T+A]4%T&8=DWB9!^D%F3^LD,P4^"K(O
M/8=M.%)EL>(U*;9TG/'D3[@H+G&TE1'Q.#T'FYC^2?;=-,MIR>;8S-YD0"Y?
M,+3?)<]TROL-NY:47\NFTSH\;2 =#EE.P1J X2[OC<*NWKQXOS0M\2+?C?(5
MTBOI[[D_)6N2YBZ;*)8S#HET9PQ)QRM6 .:J=>RWM#WN<_V@4:_U=^=^SN@9
M9!.0:AZ0>?]6+6A:&/BYGN%O>H:E\FUK]'H@"]@ \_PE3X-(I<4O4_$+R3[>
M3"GO%9"!W2MV?)C3TV\H=[&P*/0W0!!>[?@<1[[U61*# #8_%O]03LO<W"$R
ML&+KX^*=3#N;GTY4&!!=;'[,=#7;_'3E7V]^=$66W.9G<J,WIS6U/RP7IV;!
M-+./)R5Z#7UVH!!%I<;_$( K$I>\A0SI"H1$6_EB"?>&7IGVTY3WQM$#[TO:
MQ#'D;L=P_O@IT1Z,/S]-\]5:2 1,2L9R)P@_&@[Z(8JO0C5;*//!1!.9Y^!?
M?O7"?OI>&IYD3]U>OKXRPFMD.)!)$DSRC+TQ3*#R!D!7I8[F;![-+-/NI\Q%
MKP/<_"SV;GCOKHNZ<7$V?+%R4W#1,_\#7D-\C:0?'XE#,\O7[,!=Y_3I--1N
MI)M/17R:U_I F+.YP9S=2$$TAPN-YS!1TQA"TK_TB:9P;+'Q)FIF&$^)6^M5
M.?,<#C7] ]K$2*31:AT&/I"^"@?KQ;-S-\E#)=PA48L\%.)J01EJU)Z:J3UP
MN.[6'Q(E7B/M;OJ]==%RGR+XDQCY2K=T2LR]/'_\.V??/+S4 $0 '2Q41"H2
MNT:G4[4N!:?[>\27B651VG+@A]*WYYF!VGV+KPH>F G+$C;"5\A<*5"]3=YT
MN4E[B$IOM(R7,G9OBI'$/?]61:0#3 +WQ-S;E[_HUSURKN";SA+2-4(M[^DZ
M5C;"//7[Q5,S29J(_O!_S$!XW:546;F,7Q5!!YK)3* TTC/EY_17$,^:^_+@
M1OKK2Y5<!NJJL=?JQKC>*T=;$J%I8,- P'-;DR#>L!!>1M]P\LI?4"E*,HF,
MBK",YM![3KJ/2(<)Z3$3W[RF#WN/B$G$Q,+\D-444C=G^93&,WI8%CNB!+!6
M08K5U$](^49$%49*$2GU^):?]!^1RI^PR<':G I#_(VL^52::+"EF/@&!8]G
M#4UF!540LS/\YMWY2\-<OETOWZ'F?R?@V&X#'+LOQ_P<X-C3!CCVN[I^AY8,
MT&=+S@[\+0444?KG2D%Q1;J08F5,(85B;KBTRCD@7O!XVRD#F[CPAX!S(W+[
MF-3*QZSNT@L,6W[][KQ0'GD6GAOE9&1J=I[F:]*(62;10LY?>M#U4OZ*U4!>
M,X2(LN;!O)]^,5.7P=3($E)OR4@+^*[LFC)]3S8XS#K/2<4R#^5)^O4JUO,A
M[7NU!;MJ\DS(V%01A-(L%M.9-HNN#AP(*:TY*H42AJ75P N0TI LQ7@"8::S
M/-1'WR3'L'<SH^N:F= W<CVPL4&H+0]BA-.EFI$1.7.7)$EIBD_SQ*CR' W?
MX3WM>/SU.=FDG*@2DXD?T'!VNJO[CR!'?JNC 22NZ><MS_TMFQ5'N.OGYDP]
M;30D.1PO*C(I)23P?X,-I<&XR$@ CD*H&V)A[UBPQYD0V%2I&;;3^9].=^ -
M.OV6^UH,(C&OD;)2GL-$*6W.1)G.TJ+=@CFOWZY=+ 4BV$IE2;PF49+1C(B6
M?,YOH8W>=#;S&V9.-:O+!GYPI\C *7V0DOPR27PQP/2.Z4UR_\Z?FYTU65^'
M1(!O..$M:[I UK9CLCQ*>N+$+B8JHX!J-[M+W,O57&N+Z=S QH0="M42G9#R
M6RC)HD]+2M>&;LUOAB\N88]DJB[A((!!G\P>K_V$B&Y-%C>L^=)S?!8&$W_B
M%_DS[Y#YY;G_>-HB!L+S.%OY_XTC_-,K7/R:'9BG' !/F[%=I(YQ%IT&IGX1
MV3$:W)*VQ]I\PC<@=C\HM6:OE\H"QG>$$TSOWNVSU[/5A^"D:\E>+'RF=)&)
MTTTALB(0SP<E-QUVA-E1LU_BW=SY/HG/P& I?XXQJLMF^1+06XBP'''/Z!2U
M4E*2Y</N>TG9HY]?PL8"KU8)^XH,B03$Z!/X@%+2NZ8?2!5J+)):,0(REHV)
M[%L&;6$F&SHA/OX1>6%&K,^X+&229R)Y+6K;K3*Y)Z5=K)WCL(<#W6:6V$ I
M91Z5!,B_ALW+:@MN:Z!LOB*BU-+IC#5?IJG"JB[NH65.T[^@E\"!SZP/'OR5
M/Z/KQQ=$>R%O4BCZK6/W87V+U"R:H,.\_?4?+YX^[HR)MC(V )F_(J"5L&8\
M(WJ?J2F+'GW69?#5<#KW,D"2.K1.,$JAL9;[+G;]RSB 4CY59$,^QO^77'44
M2A5\TLF$<A!!6L;K0NJ]V)0:G&[-7O+B62V47.WJ#DQ^])5_S?H:!EPC7(EE
MT5U4T8)^$"'>1C-]W7U-DC.!?*9)^"NCG"*(E,K+C1 F(=:B.5T&OKN*)T$(
M21Q#<5^O15+.5!@@8]F2-4:'+3.Q.=A6V2.HA&M.39"\>8=8!J>I+DGBL8JA
M./U94K4YWA:'H5S,4N0^55.U$L2A;E>4>'GUHLR0Q8"2O1YP.)!'*H3\3*V8
M7T1&*#FEJRY/%HI_E2@LH.6>&\>A5Q(0AH_B2G)[0)P(>=_BRRNR/!K9]I >
M^7/HH#C?LS+2](8LG:D1&<]T]D#:^.SKQKA?1([$$XU>Z^<S#O_!50#')^N@
M.V.17SO4Z!"[.B,.3*3$O!4*,:IR4(,"SK="'/[/?+;0KAJ3DR(T9J<W2.84
M,[F_N"?!(WZ7A/4A?E:88Y$UYG-2/(\1!C[Q86[1^Y-S$N@'D4L0QBD'VN41
MJ]1I]],;,5'EPSW![^>MX5"B)(_06VZ97X*@?Z[8.P,)&G&%EGA==@[*VI?.
MM.$=5Y=^F$/)%/.DW+,B1<08(LL $H1UQU)8>V5*B*-WF933PD>D\\8*I;74
M#XL\NU1:!E42P9(B 8H3\"2)H9A0F?M@AXXE;\%89HYUW(6(C1>*W\WF%,><
M?&0'PLM#M(/7%=3C^A-23Y"T@JX79:H==%&(3FC )(=]J=U@$2OFM)B#+5?L
M>$P?YAC.N-C9 /O B6Z+1$3U.H[TCDG"H;E,UNG!_Y3JO;ISFHU3O+P1A+7B
MKF3DE5E=?F9E #%]PX\CU&VE3%DTBEM?D-45DP$(5!Q&95EF52G:D>OJQ#<D
MQ[)&+9D8&5=J+@WC*E[+)ILF/IYEE3H]=QE?P5-$*NL,NZIS5V/MFM32 G[5
MC9Q<DARHA,0<Z0),_)#%2+I4*C-RQ"QZ0A=3X7[XR34KN+1-]MN*7\&,E&HJ
M9BF[Q%9S0^IU0\AT<ICC:OUCUYEY[G6<F[QK*"8!F5$BV5D<:_VSHGYH_?,G
MMY#CYF)94JJ2S.R(QF#$DJ[V-:F![#(L1ZW*[A2%RF10!1*]*D2YN71T'4RF
MDZ2+:]FXJ;EHWP:RWF];E!:&DOYT$[_@BTLOUNEBM^2D(\5<DE4#4<VXA!#X
ML\[=-$),E1V[F.Q&XG%S[1[,0@M^?JOUR$1-8S*FI1E;D\=6+U9(IIB."_7%
MW_+\[.(7TB;_?_:^M;EM(UGT.WX%3M;>DNM"#,$WXZRK9-E.G&-;/K:RJ3U?
M3H' D$0, @P>DIE??_LQ@P=)291$2B U5;N.! $S/3T]_9I^)!F<MY.OO\.Q
M;-!?CYM#I?-B@0(\[.?1W'?-7K-GF7*O65B?HD_&09<+V6>GRLG%;B*\KIQD
M/AMPH ^C5PK8H G:_"2@:P5@'E/D;:!PS")/!*1,(ZL@*R?ERPAI"$HF-29E
M@V$ LS*A9PB+6X7%K<+B1GS_P4:C(77E'#I?*>DA3[]0XD"2]-\BGQ2@\@2@
M@S49"A0=LW<1;]E]9(N3*/(HJU^ZZIA#Y[<L5/="VF$&31N+<2#XMD?D$HAE
M WPI[0\R^ @VMG94&0)Z*!UL*N15IA^APL? <.P90[-\^8].O!P3TB1.4.V+
MHPO2SG(#%2:<BF".V\*Q 6OY]$B@V<-7R/!8Y20YJ#19<MV6S,.QEK)^%D9A
ME\H<H:38!&\-8249QE,(3$>:14F:6XUJD!)3RC\J1TW @8.=B1?'6#8#'8'Y
M6PWCG)7,T -[$@')/9LRX#[,JF86!_$" N"L4QBR,T9,Y,Y.NXN7#':_.C_J
MV;/\XSQY@NA"#FWP7V4T!U8=2=$W&J,=Z44R:0=H*L]5(-N4L:52">179:/2
MEY']B*4TCJAP"'6PP_"96<8%-^2JF=19X9^!)8S>@+/0/(%#%7#!)7O CA4$
MB-VOI0,&;WX]11;"2DD0R&E9RW" <KQ"S2#E2 Z!FZWV,M\+($08PBC.?)8H
MQ0H8"6L:U24ID%\K/X :.Q^3<_Q6B297BQ2PZ"RB_<32O/ 4DS(2]#Z#03Y+
MR*_,IQ"F^[CRH@6PLO.D-,@\\DD1I0;'KL3]\NWLJ 2Z'Y<]*GBSC,1D! !_
M(/==!<4@/)[@4C6$4S;"8B%="4[.#)!&R"5"##O/1RE=[14Q5:E*IA/*\> C
MOO!&'^G$H0A]/D'%5ZY#P&/BD"?$3'J->/&F,P$&D/"X0%1T+3XV\>89D(F7
M#$2["W.>X9,DO]YA:PR8VJI33)X:(PMY0EC^ZLY)3R!Q8"1%#!A3A)5[W=@P
M+!VV\=7$>4D7"VEA05/F1&(4E668B$HE9/!7I+]08%(D)NG0<<9#3<EK\CQK
MC6J74;]M'?6[RZC?@8[Z?6K';YM&YGN09GZ,.@*JB)X8H[P1QWB'34E:J@H1
M7YEH^[-N]B=ZG91*HJZ-$JD$NGCI+P6MN<'N8@6Y$-W">=IJ7/& ^3&H4"B/
M77J X0&IR#4?@S)V4*HB&*2_H!J$(U.M/I33HQ)86"R.O<)!A)6/"29U,P>Z
M ]98GN,C=)#)E7%:CY_3K%*8@@@CJ4W2TXP\(1%!O/ ]M"9<)YF:8WB-M:51
MV7G6,-&?J>:0"N]:L"BY,*\/6(!1#9<>^V"?&>14B^5>Y*AA,TWI.8P<6JAR
MOI<>Y>&9RCWH*1=Y:35'&2IQ'#S/N$)+!Z_)R (2",D4J%0D+QKF^W'EGF#=
M>(CY@$/9'&DNW0R\17=GQ:Z 78MX#ER9L(QJFDJ 98WONI=WB#FCC+DU>,N1
M9E:0IBZTUZY36M*QIY+.4-%&^[+09]> MGQ:"-/B.\>SWXD0-EN.YMYUX][+
M;.:&LT$57I.R;P<]?RX:/2%H4?0956S-2M>2>$84\; -MXXD)5%11*>%?K>Q
MGRKQ09=_.;5)EED$H2P%*E09HG*])67CNEQ 1CF7\N*Y!D;H>>K*L72#<3-L
ME8%1FX6_I(D2-<5-BQ0#E:*BJP5EC-RCQ,4KE@M7R"@9$QA &,U\MURI(8H7
ME8@*,<9"-(G,MP>+ED. HWCBA/[?3EX#%1A-YA;1XD7"%.5!P9 )K^Y'RM/G
M:K?* H>_'JOZOI;R>V)<"18B*N97<?=4QB,RT44@(^7-9$K>$HGX#,,ZE1\$
M $879*@MYGIQD?>AH8*OUQ?#,F49K#9']>;*E'):QOYDJ@B3G+"D3,%'ZL8"
M9%R1)*[N*%5W,F'^XH??)A$>6A7+*L>0 R.KHF#05!0U7#DP]4+6:*58!BGZ
M G^<N[]D!=C(E)WMY9IZS26?H]+>,&YB91FE158YD^=[,GH(!?B2=%?"? .\
MZ@/QF*&L7YCCX\:?Y>$J.FJU;FP*=NIG_Q4=O=A/^*#>5,!/G; 6>QY&>T^N
MA[BQYY5ZC]Q* S0'S$GZ6R375'F\F<,N4<%/![OQMVI <F4GD:6.(YOB8KD!
MR7)->W;X%F7M\\5@C?&B>KQJ8I7[A]$G_T/YY;S>/ ",B/C7#ZU6OJIU'OB;
M??W_*=&.NA'F&8&&;@_AFEX #XB-WCV1@4?F#FM^=*#;^PATZT&H2[T'BG@J
MCJG5R$^@LU[&SOPJ?*QYM>@P=ZO#^<.U0]X-<R?DR-L2S'NSZL\BQI<=JM+Y
M\RC^\94L8B'ON9\:/C05C$U-!IH,=DL&FXJ;=5U-X\GHJ-7L6*WVP&IUNR_6
MB"39+F[P?$VWTC4]37]0(<TKRY-*Z_/UF['\5A7M./P/KYY=,>9PZ6WR OWP
MRNYVK&['MIK8B_P*8-9-<P6UW1_^:P>^:A'-9J-Y*_"?UP#SG8$UL&UKV.]I
MS#\LYGL=JSUL6=UN]PEB?G-6N,KHE@?=E-V=8N0T<'@.%L<R:@KRZW"VP4:O
M0TRK;77:L+NMX75OK\/\[8!9OVMK(.H/&QN \GS'4-@V</JV;77M%7OML?#2
M7Z7@1\!+JV\-^FW RPHW>#R\##;&RVXUF[L>^%]BO+#GV^G='76@9KLY /UE
M W0]R,ZUF@U[9Q2]$49@,P=-J]-;\7X]%D;:.SSC&V&D!R=[:%&[[GI@I-78
M@ $_HK#^*DLXJI(=N]L;X+SM0=?J#E9LCT?:&[O?V "4'5)K:VC9_;YE]U8<
MP8^%D6%CQ3QYV//;!.G<LX;=NFAS]F#_I;,,UN*VTC,_Q*J,,AEOYX>^#XOI
M@W9>%PG5>>0C;W>M7F]@]09U08C=;&R@">\0(P/+'@ /7/6+/!)"NK=081Y%
M8*>1^TVF;U) 8Y@X7"1A5SMT7).=>5S5TFY:[5[3:C;KHEKNTIX^3+*HIWPN
M<M'0:;:2?J,W4)/Q W"WSL#J#^OB$[N-8^4Q9/ ']'=QJ<52Y.VN]N:H;77;
M':N[B9GX8L<[<]1J; +%#BD5N+ U;'6M]J .Z+ [FY#J;O%A]89M:S#<@('L
M'AV;^ ]>U%H<GU$9F[=L&5M81&.'>]=K]ZR!O8%)NO.=:S8VL$AW2<?VP+;L
M3EU\@X_MVN\.NT#7=3$U-B*.Q[QQSOL?C$&5+C+Q/4%=9WQJ1B;S)I^ )JD-
M0XV'.^*AGC+Y/5>Q2IWORF6]NUWKM:Q!KRY!$X]-PNTA!0S6!AL;J/R[5%&L
MYG!H]5MU<54W;W&9\1AB^9/@6@X[5*"1V\#_.QL<V <PC3=1Y'=J"H(*#<RW
MOQK>^SBF\2:[LDM\M"U[.+#:O4V,TMV;QAO<:2^;QC]2@J1*FCR4K,]:%&CL
MZ *-NRS0.-0%&I_:\=MRR035"&"T@!>IGI.JAK"_*SN G=FTDD5>)>;A=VS7
ME1\>8Q<?HYH%,=_$]+#E&M?6E.T:HIA;M%#C,M50+1&RM\LM*@CIRA8LY1ZY
MLL4ZA925C6T6'[ []ZP^\.XZPKH]A/=<SG4E/.X^3SV!NGL!A]V2E*X<LN>$
M54N@MEJN9)T)MY_Y^T^S:L%S7;/BB>^^WOQ7_P:+CQKY@#'.Z'">+#E(!'"+
M@&TAX(%+EMSA,J?2JR\6J>,')E9FQM+610;1THP/6.>AW[5Z_8'5Z=^N3L(5
M5/@X91XZP_VKKS%H6^VN;?5[*WER^X/W;F__\'[4!WIO6ZWA[?#^HB8H/QJN
MW@Y>#_@C7F17>%\48N]1KLF_XTO#MFT-NGUKL$FH\X-$'+2:.TP0WAPM+<HD
M;P[JDB7<LF^1);R[*^9NJV^UFO6X[-[[./#*F;^<1G#:'?2)2W?WCC'8Z5M-
M6%:_-HG3[=O$ .\.BK;5!$7/MFMS\F]3WV-G4-AM:]@:6KUF71*X.JU'R^!:
M:VS=Z="/'>QR.UDY\G?P6%;O>:XT,#=7KFXWTE4!R=?A:@,@GA "5A3^)[1V
MO?E/>.UZ\Q]'25V&K[.Y$#N_SE.]9MS;[QM\9'I1-@K$1HZ,6XUQ<ZGBJU%S
M!\K=P?IO0;8W(6%=V=<-EW\CTZKMSE]=*EGO_$'O?!?LW:%E-U=,AZ>S[^U5
M1]+M=GU]YL"!!-7M963E%[HK,XJ[,M7.E9M,.J[J7XQQD\Y\'D??J5EKL##Q
M/HBN'"N7SY4 RROZAWE"=4@=+<QG^56!9<"GPT;KN6HW[:D^TE>-U;;PC6?%
M[5K#_.K,Q#$MA5=2G:RZ@F=#D."VU>K;V%;=;C:&SVGA@3!"P*!$"'9KC?U1
M1EV<J]_;5GO8!UG0PNQNA0 _O'[]#?/7Z!);NENF,TX%-F*;11>R8R\UNW2I
MV)+XSK>X1DP].H/,3;F;)O?+=/#78/6R<V797=BF!VZ&^71BG+&QJD(U[CPW
MUJN>*;DC/E:A]K$#'Y".EU$'56ZXREU]Y]Q-.DM11[>P^RH0!I*9Z@R,E0)D
M1V ,448B2,5L'L78@S7)8FY=0HY@28,)]D#VC*D3C*F!LI_@=++KK.HB&T9A
M++"5++5TAX'AF03O=(J^)6%.(B#7$ .H\[[GB1.Z!'#@CU/L^'IZ]N_W;X[M
M8:.T'YK(:K:FU\)ULD2H?KS<(AN()X@N,9#>D@0Y%]$\0.H*B06/@.Z0CL=
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M*9Y4-H]U-2<U4\ Y'E4_\DHF MD$H50P+^&8%RH?XZ5 C8&GTYWZXD)(?,.
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MW.E1=^E.M;GXYPU37VJWG#W>A</9A$U+7=5^(3?6JM)EJ71YI(W6L(_ED09
M>*V!U1G>KLI0O?!NW[)&4@WP?C3H]]:5+=F/HE3V+0G]21:ETM67UA?(L5KV
MT&KWZE*QQQ[4H6)/R[)[F-=9E\HT_5O4Z]&%J=:0N:[ M+;@T= :=CI6;U@7
MM-2C7M>1W;,&O:'5'=2A.WE[37;U0\ET799*%Z?1E8GTYNO-UYN_Q<W79:ET
M<2)=G.A!=K[7L=K#EM7MKIBR>N</>N>/["X:,%:WOV+<+2^A=16[7O%P[M6V
M'PT;=R7ZZSM:'TA(UU[&]=VC+A5>"-VA+E5[N2Z5O"LPH]BP<<1-BU*UN"A5
M<;=VRZ)4MM5%IT1G:'&*YFV+4O5 #@P [LU+4K4;#U&1JLB(Z39ZNB)5_=>$
ML;5R3_,*!)425^8F):YD*'V4)>7<'<ZB01(+H_#XTZ]?3TRJT".\4IZK&V!>
MD!M%<TQ1 #HS**%EYOP9Q5PCR*=\(PS+S0\$YK^0*XJ37>6)D:DZA[5!ATAT
M;S*J8Y' 9KK(BD:9-Q$I;V\4F*JL%/$9?S;*XH3J1"'53&)GQEO/I3@^.;(F
MPJ_""=*IBTE47['2&9;E.?%F?NC#-%Q8YP@+F[6:+Y$2Z4?[Y0N#Z6JE^!H6
M/?&9[5W>D**6B$"XJ2JL%HMY0$'4=(8JQ:PP:XR89<,\CTP$3>64&()J]%06
M)H&D0FQ5!!%(XOM<%8B3I7DPTPY+;RU-2ZGIE0RX2IT53^15O@R5RW8M\JEZ
MG&(5.)GK)%-]]/9D3>]#0Q42(15FC/JUZ4P</Y0%GTKE#XJ<LI$0(;-J8/J7
M44RYB<2H*452L6DI"ZA@E ,'0]&D/%12($1A@H4*5%W$V4SFB4I*9=8/IVB!
M:5WJ/2F-9 T,*M4#3WG@4J$IK@D!R$LXB])5I<!XU-)L\-"H5 63TZ-P4U6Y
M6.*%(L4EKYX=E3X:8"KF*FAA-D;1&DO$(): 9Y@9"T<18Z(FX-$H8XIN4ET'
MU#&@"JI()K5AGJ,Z*-:"\#V QX,W9;JKK"VI"OBY/M 7[*R<?(D9%&4D<%U&
M7F5"'>\D0/+ &F+ 6RD/CZ1XBD\%EFWR4\6<&H=X6@YQ3=LL-F2OE!1J<;&A
M=66(M'2H_9JN+C94*76P9(SF$39DS/:QN/,&AOBU]8:,*E%QD8)*B;2U]8;"
MBA&S8<&A\YD3!)09/ ,IB!4%J+C<3,Q&P&2G_MP@K5+I/YQWCZ^ 0C:-H]!W
M352T<%(7MBF">4K5#930]#%JVL$ZC(7<E%,0B'^(4RPK *M@KHX"=EKHM-_"
MZ#(0P&@-5C)!<'A*R<QG13S&8NP'05Z3KF&^7J!USY5624E%T8,U$@+8>"__
MV"PO<E74K59$,$YR'H&IV)?Y_F"AS$5NT8EJK885J:@&YLSJO#J%VIPW0 YQ
M-/*SF7F*"JV7S8@8DB59:,3BTHD]%*XT7R K+H%BLL@K00#F*#/<\>B."B%5
M@G&-FEPN%#$2:<H%;9>P<%CGOT8\[5;5E7JZNM(NJRO9NKJ2/J8[7M/G4E5Q
MOA+@XM]<T0\8[]0?^709@#X2%NU259%.R,09BY3J>X.P"4OE54>E^H$ANX*P
M8'2I:NW(D<4^+#7F?!D<.66US-*2T"A70*]42>?UH-KRS&Y:O6;/:G4Z-WKL
MEU0D []MPQ][W=9-W[:T8*K]FE;KB57OIHK(552K,73T.1)U,O=3L-=(/0$X
M0==#0N!BDV"7$:UZZ/1$4PYK6!;EQC^04V.:#Y%Q'1U25 WX(L+;('1$<$TI
MTLC$=QA+*4KLY)$UB?-B0^0<4IH2%48O>TI)I<0B'  'G1Y60JL._KQ/AI%#
M)QT*\H!A;70JC)6@MEZ*.B\ME=PJ52=,<<]0N#H(<=GH3W2X(MLHP7HA4R\;
MQA\K8>TYMD!1)F\-%@Z=Q%%"?IBQGTJ2*C$>UHFS&,]OX(!.@;T7)HA/E\M.
M.]_A@"=I7K5D38TNH\IA9-'22IDSG!PD=T"5[5%Q!7;F16C%**T['Y><T%<
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MJ3\/NNJJ/0,KUU0RW)FFBI=S!U768 %0I3/>31?FG89YDA8=55- @565<L7
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M%\N22RN>1@=6#@CTZ7BY?V5^0B560&'!(B6J<EFY1%>Y  R(J21/%UN32_I
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MQ&IVE1F+9>![5KO=K4DB:.T JDN&[)["L5<YNM0A[$9IOW<)>4\^(U$C0"-
M(V +"+B/.G3?!-Q]3;X#C6;8;8-&LW<9E[<@/XV#PTL]U4NOR=(?(^-VOR_E
MMGQ9BG?9([[+-M;=9>L[TWI=%?XA#"^B<!T*>\)HJG+0R=@/'4X]GF0.[&,J
M!(608V:FG^:17OD?.>A'AB&5;I^H_W>XX,Q($S,C*1?T#QGK#/,;Y%07GNF'
MU+)L86)&Y(5#3<K4M6W"$5H8E808^<Y-T/!BM]2,W V<).&$90SXQH[DTRB
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M7,M^*Y%)!^+VWA7\MRJU9NM2:[LLM=;3I=:>VO';9FC(^W#,U]@Z*N2V\#]
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M_PWP'X+Y5[$I+ZXGC=:%''M/ILVAUDMK2'Y5;V2'&.) .R-+&/I%A)-IYA#
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M?WQJ>E!5-A+LC)BB@&3U0D:GYI&I*-H+!4-&!9 (,6!V68D"A3L L&0S( 1
MG]-5"VB-H;8DK6%JJ<D4TIJ74!@N_SL5?U(0TG_\;Q@0NI$%H]8'DM"F"4H3
MKIF#<NS ,'>GYJ]1PK5VR\;+IZ@!O/2SB.:!R*5W_B;!$69Q(O(=J&H*YZ<?
MS3EC!32GLH%!=>/P70)4:0S5N7%@\ZL[C:* ; ^G;'D8:W8#-SR]C"I&L!E1
M)6)!)=/@[YZS #9S#/\!38UU'5$J2VB5%O)7!K1/>@X@DLA*E;%3IHFA39/]
M61/VHE!1UAAAG9LG9(2"GL@\H.(48Z;!Y;!5$"73.L5HE[X&9?)/+-FHR)%4
MW]].F4%95,EL-H_%% X&>E!\+M2.A=4*C1PC)^>R1B'1&]O;TD/CHAXZR^NI
M24>-90+MHF>7]6#T=>')I$LRV>H'X4I*7Y*1[E"Y1<&J;5'E#5[W,GQ]B5TV
M[6[#_!RC74+EXIS4*M!0L%R'["8GP9IM#G<?^F^ PC?/A3L-J0\N+$KB!,TQ
M\^B3DWC.7S^9__WIS?L7"E%.N#!$. & <S:E'!56N=&$A<O*QECY$.O1L>Z?
M.%@@#J:^$(#* *MW\J(::$B1D34#XP"X^K+GHBA])[WD!6+XNCB1!2\EFN']
M%"B*T:T,/L 5N8X09R4D*9<1[8R'Y42YOV6!K KI_/?GC[^8OV;.WT Q:.[E
M?-%@?FU1?3I8%=NNBH083 G0=<#2>M&>I<X[RF9E-Q,ZGPI+F"$NV\) Q\?O
M/Y\9)5/W4R&H@6F7QHLK)421\,#<#_S"/.2]G9 7#0W(XG!%@9=<8[])Z]-8
M<L+EUML'P _\S@($85.6(Z_R<Q3(VHI?72I#RL2S:JV69AQ+.Y3F4,;G!P V
M@XVC.E*G64 EY O3D0O(,CM!?N$)[/%&MBD50JPP$X1;BAU9%S$7/72Z"AY5
M9,=/8*;01 <>L$]F+P5/L<J&+:T/=Y-*-^;U5RM.9!SG+88_)U-Y60"@PI9B
M45-<9X U^4LE3B,33A_^AG(T!RK7%7)_;U[BL<2(&OM^QW:@8K(4 /^K0#%I
M$7'FY%6IW9NP\"MY4L!DBT.Q(%]0U?T';_*E"WM0PA2+^Y(S#1E_ &L7\.\E
M^^*D\VB.C!]FPE;DU49FG:[I,A7B31*/LN1$; Z4XBW=0_V2_[ )BK[RMY<!
M0R)5RC?J\0LGRJ%J&.7A!IU<B>?[@6(XQ@B[[W*5MN!%'YQ+]J_]2O64A8\8
MPBN!:[@/P5#B/$:)R1P6#1[HN5(!UK]DRKS%*Y[4Q[KE\^DBP<NCT"K33BA]
MK,D47DE03J'GU5US:S-&_P92%IB(<#Y0U5KD"DFS+142L#/? -']0C=8QK(\
M^9HZ7%LZC^? O^1'X3.J!'B\"M%YROYSAVX%X9>QB/&L%A,W>>+FL#PQ3?9O
MO.;[# NAZH^&!.&/" 1#3OMEFS0'HZ#Z_+WB7!77O"7->?7/Q2TG7;M9Y(KV
M^.+8H.KB)"]-E^XJKMR;8ANLRLT=C.9.B9M1,VA4;I3:4;E[8'TL(>:C-F$J
MUYR+T)*\9+0"JQE(M#9O0&N^LP*U1?-$Z5X5S-(+UV,P_S W_J_#('4% NJ>
M\=6G!2<+N)K20/*F<5[&_8FNQ-PZ=!3HE*P8L-'%"1$K.38*D8-CO!'S# R=
MCPYKF:DH-,^OT\RG/JI O: E+<Q?T%\0JL[S*[1OK4!HD'I5T*++&J!E"M#.
MG;Q(_G0!ID](ML@D=F9)OI>#@82^N[*7OPK'4WA0U\AO2I8#5]%>W1N:$ ?Q
MPXLHN& ;:AXX8:CVH&0,*JU,CE]8)HU59&+,"/I<D@S6KW1M>]CO\Q)@*4YJ
M5&#*"2T?K;@=XHMK1/[4\4'0.A'H QN>;ZN,"'C^M>!ZN%B$B9OD7JUXJ]5-
MJ9%42<G.XQ*D9NV751^%)S(T5QGR.K7:0+4:!ID4I$44H7:KM!G402#G%\58
M>UR"?-]U?)#;[^A3XPO:L>@DG/IS'1-7.P7K'.60P8WQ3!Z$70]JR["#BO0"
M7U50FJ*4L.V)] )6/,ED/A?>B\+[<5AXK$M7N%JTG^OH*^5=7BD/]97R8PJV
MZ_J![-,Z2,DSWBB]4<OFNLD4[/JP+E_$]"*14%-6V466<A0"U3^<S#39E %-
M#*]PJO\:78H+M+O7EXG- X[7S6KD?<30#O!3],2 48^Z/,R=MR=BYTA2];97
M)HD%>R=3"9DP+WQQ2>6XP<!['W+[(N#W=,F"SA5N*R'[HANK0]YI/?DT'*8=
MHD>)+_;0[BXF+FS46'B\6K01R6)#;P20@%HL7JGAM&B5@/Z$YM\(S!>^S%!=
MX"L1$F@7PW-T&[LE SO?,M4$3[8?'IM\\6=^R0)A=GO-[M'X!5VAP,\]2PU
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M$V'VFJ8SBB[$D]WO]G[L]QGO\D=G8;9MR\1K"<O\F#1,>=%C_I&94\<#&D@
M!""!<1S-S*F(33C./FV\DYB..1.S$3R,QD0@H\B)/?S%\V.@G"A.S"-\_L]_
M#%JMYLO7^&?ZV7[Y MB+@,TD,.8B3J(06$@L'/@!P#B'KWANIC(8$Z$#J#S?
M,\,(>4R2!2G#1=S*3YQ)+)@!7?KIM,++$%[XS\Q)4P W%H%#["F-RF\A:';_
M)?/(49;XH4@2,P+H" A 9\'L"A8'/- %],91 "_,(^"3/FP%/)W'C@ND*Y(G
MHW[L!'[YT \]@8,V&UT_W.::_A"&%Q%)N5D<PQS! DC_ H1>:(H$=\E/IG "
M:&L72#+S.+KP/="SRGP0GO-A2)!8HRPV7ZO3\"8_#2@P@>!\X(,BOD#:8-[J
MP.0.:FCIPC*<()U&V61J7@H&A&XAB0W#)"[P0P<^RHD]86I/HIE0,Q?'#PZI
M)Q(W]D<HWT407<(A$CB2"#V$V1,7\!0V+G.G<)[E(OW0P',1DI#/TBPN,?0'
MV?1])]IMPE\9B>;RA!LQ3_HI@V,18\WJ'UZ=*(HPB"!DB1RS5!UG7S%PB&P'
M)/ ;X;+X'*($MML6GOC*87=*YYR/^9NX 3NJ-#+@)S,\]$Y^Y.&W,8P8"!1T
M%NK?2>; QS#8Y=1W"Z9"XR(+,'(V!G_Q9^:S'N;-P=1AY@3 "Y%G34$=5!P+
M!G46I/0!$#-8UC1 A@&<,@B8'T4,7. DJ>F!A@$ "@>FII<;Y@E8IDB[.+H%
M.@7JFO"=GP;",P#.$8[L!ID'X*&2$>+H&>*$B'V9PX7(8\< 69SPBR"AA61D
MFFOM&]=2)?BKY??W%0D'RK@^.C$<YQ:SK?XF;(N4=]C1#1G7>KZ5LZQ"\Q(&
MVB3/N"*?>?3EX^L!=<9]L<2_1*%Q+3.@I,J!S+MP($-SH/K!?T<.5*0DE].1
M]Q4)!\J!OHIYRKI3AYC08",F!+K3KV)'+(ABE(D#M7M/F0/M>O,?AZ!KP)<*
MS]RC,*7MXJ N;&F[JP+&= 8G$ME2JW<+OL2>S=WPI:'5[@R)+_5JIAF99^$#
M.:"-:QS0J\YG?:[NL(*5J?[K^-A\YXO ^\G\[$S$2QCOKTS ]O]D]@8OS7\[
M0890F\?'\D.Z*N%OX1\%*$]_G$9S>+DU3Q5 QYP? X/A,WDGK9Z]#ASWFVDW
MN@!S L3F_7"GI:^F@N2S$SS-->"L<OC[R8H2&A4"7YKGBSF\<1([(]]]:7YR
M9H*1_"E"=/;:Y:]^5)\1IDN$D:/Z*M2/X$!\.QX)8!,P_IPVL;S\WIKEXQ:5
MD5VBGH(XKYR\##:NIR".PSF"](]C^MZ_?OCV?\#U\.PXK_99(_MY].JT8;P^
M._GRQOS\Y>3T_/WIVZ_ 14?:;'H\VW?TZASDWIHK*/27GD:SF0_*!%Y-ZEVJ
MUVGZ0QB)$-]*&@SIB.6;R"2-(XRMB:.Q2!)?*B_S+.5K:MIB#.J)?>+[>%F(
MN@U>>XL+J3FBM@3C@)HX6; /75USRTM$0UV HU[X!VB801*9RY!-(U3'$KPF
MQP'_ KT2=#-!5Z!XQSB)_92'=^&?*+;H$[I_D(MP /@%!7B8R3<_P#MT?!U?
M Z#!\@D">5$OP@F*A/QJ'Y )OY,630O&&X8H10T1%XQW\C!%YJ8^7>5Z'*8V
M(CL+GHR=9 J+O79I!">JCR!G@WPA='9H6KX^C5)8#%"(#WHN(1?VER$*13RA
M"V.I8*N+$=92\14_3>2 >!@)F)$(?$'S.K"P(%BYTS5F0J3*4A"3"-%#B,?Y
MB0"TS[%6)_JUDPBP@WCO_1#M.SYH23:BG:?(.[1]*I<?%OFK*M[(%0L):8AN
M!/.[7NNJT(,IA0* #CN#"3R#R(O/#)E.,[3T$ 5@/"(>I#WW)0N$V>TUNT?.
MBZ/6"WP90W,^.8GG_&5^\!,*@<&W--75B^K.@(5?00;I-!;"/&J_J/">-T6X
M9SG&$\G!,_G&I[#4KR"R59X&)GO@&<RM@B"ZQ"G"3-GLR,K@"7^81M$W\ZHW
M,90*91N<E"QT0G\69<"D8YPD)%Z/6#Q8"KQ57/>5 =I+@=R;Q^-78S?75ZI8
M#<I<5TE!K1,CX8HWY:(**Q(M]\K+-X^]B1/@HR2WQYK_]Q7*_7D4__A*T6]R
M5;3L-JO\2A+H]YZ#9%HYP<N8403S_%ILJ+?LY^OK9[1V,VS[MOBZGD8#,89-
M/\D\/RTL) 7Y[8CAAU?V/3_<+1&L+KL2T_UXJV_N8DL_1:#S.*2IU&9EE?#?
M@Y%3M8?_Y]&KGWT^XT:)%OQ7VA%21P5VB1E+)P4,P]:)4VB 4R>F@$<T_.<4
M<LAW8V#5.!>.'Z@L%51<+\4H\<%J!PMHFJ;SGW[\\?+RLO&GG_T]C;)VK]D
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MW"B=5-D%B<EP'^0OA[NDFT7]\!ST#HPORR=9$K%-\@X[)!?#\%\Q>OMAITA
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MH%*RO-9:YXE>&PIY8NZH/JVL1>*YQCP3#E^MQ?*$*-4&9S;>&U(YN/O #(.
M!F8<<*,9*T]K[^0S%&.4D?@9ZP*>0WD[+HK&:%V:3<$JH1&9SQCQPE!D],F0
M,W01]]<YC&G9V5T6<A3-L*-$%!33BX*L&ZY?EU@?AMJB4,*/PC(O<_Z.VS\\
M2WD>FD BW)Q<U:+\4?271NL%'1OV,Q'N 2J]09Z-/!B"_W428OV6YN+!1.92
M5P](\&QEH6R:[&P^"]/D73.XP=3D%7GW\:QSW#X[8Z,4__"^<_K,[="E'S_L
M';;2._%I :R!(O&PL.N!EQBT\!$>B>WBSD#'Q_W8M>'\5Z>]VM!E.Z"M(NB;
MHI?'%]S910S1O\>_OIL6<8KA[@WIY:J]ZM['V"J 6V^?3?)I;S+-J16FF)YA
M= &F /61T2SM^]_#WRBKJ1DS1<<A",:W-H(+,[DV)@U_CZ<(X73F;X/[4L']
MD,PVV"0J5,)FG&'1A-[OW*8J%*)[^*O^!E;A*I;&K/J[?>* ;KHQQD5@<X24
M&Y0<-^4'*5=(^6V\GF2U_FEFX2DE+U.7F\<D(MQUE/7&6RU42!R56BWN/ON3
MQ=)AACQX9WK1M&#45.D]_&3$IG/2D2U%Q"_"LDRB=$+=SRW."E](:=B^M+B]
M@=+G&F%M26RN#*=OX;M!C&$T@ZT>.9</0NIZC4DBW"XAOF%NP+#$V34\,V^$
MA9&U VD!4>O&Q:?P,.+RM(T0?RQ8LW"6NR1_04GFX./P@!.U%&M$BL=X\]#(
M,D4KY8)@<P9,%4[D@@@R3L[K'4^8@X!A9O "SG1'"FOP,N_V/, K15(\=VYD
M$!]4E-:-TOGC;&)X]^"%@R3NL7VD&\#SF1:2I [(J.Y32V5,0-#0:;<O] #C
M^V?4+_,B3C!#CX@ S%Y,X3O.88Q7JOE)[UJT?P.5^M,(Z:K.08P+SC@][Q:4
MWQ>55'D<-R0O#J:&/9Y<MA4;GH&Z^'D92(4J;:N8.>@KFU<MYTQNI5%^*OJC
MUU5"'"[CLV4G_XR&T2CJQ^&[."/N=7C^Y0SNP&8C_##I/S9]S]MZ^IZ=[<:;
M>0J3):0?6C!^OR!HT7_GR 7N/(I'(/6_UZ[I>/T4;-8ZK@ "^SD_;OV^N>#N
MJ$D?F!!_^\UF8W=[COGHI?4%F)/UKUJ 1V\-\'2D_W^[T[+?0GB_L[73V'DU
MUYULV1G_[V7NMTK<'6:]JG?_/NUB0M"MK.*557R;57R/F%X6N\@:.,P"VCX1
M!I=ML6M^7F#8/)&=NM78!0-E<_?+R#*7RM3>>[/3V-V;:^OR*,;TXYC.+$$[
MMTC0=V<3;N_N-%[MSC';K4SCE6G\\.;A5N/-#NB-S;<OTCA>H#._"Q/YH=.6
M*YJH+Z&)VGX,FJCOA7"HU;^*TIX0;5AJ% EV89;,#WB]V"J][X39!RQZW4=!
M.&(?%D808K(4RR\Q><:0Q/UL!"^>V5JNJAO0*.7[N1R9:H833-A^;)XU05_#
M(0=9$4H.>2+\2,,8@'))X@FB)+#0?1S-. 6-E=^?L2 ,B1U2^N;'E*K[S_##
M4F>O#R.0,)= 3Z(X"5%G21[)&Q]_ASX+)YT:ZHQA/C0.>,>9&4\HPXPNWRY_
MF-$ ,)QKY)5 %B+N,T3/T,+VR;5)KDPX@J4>%J%)L9RMXDI2DZ)K!(R.HY@R
M]+:&FN9*'Z>!Z*=?ZCGB-7M8$I+[Y,5/_XHC&MZ1Z>,JXRV7D[B0^*%08S]@
M12);"A.&;3Y>R>M3Q^4J2,VM9X'4W&\&G>/S=K=]=GX6GAR&[7^?MKOG7"VT
M?_+Q^*S]807)7+J-.\XF@6L1]WS!T4O1]W9[50#[D 6PKU<%L,MZ_"HWWO9W
M60[+<WS3# X[QZWC_4[K0]@Y/CSI'E'1P?.^W"H;N/,L3)96,]@_.3X[^= Y
MH J3LW/XWU'[6*R6D_/W[6[X C?[N]S/,V,"P4E38>S6FZ;7C(T\97*G5S6N
M3SU^.'D?S&64!*=YUC,&(ZS/&Y_\79ZG0W#9@PE\AJ)5\'^J[,!Z@0OC]TQ.
M<"NQSD&WLB%,B_%E) 4K:1^K,.-1$?:GN=($V[H1KB30^*G6'33#/PR5/".%
M8)K!B\$.A9.,K9+C0ND1QX:+4.8&$4:749P6$RIU2#%(EQL</PPM2ZZPC 5#
M9&,850J+.:#BX71FW^(]RGM-D,0Z*PJ)N9IG_\UQ*@7+^$"95=^5YMMJ'1P4
M_#N),89'5-OX!2:-,CF72'N<C%Y?[D"((CU:ZU(7;FV\7:W,B7$OM-R#<#-4
M+3ZDM;!3MZ4B^D'89"ZFI@#C(_N(3YP+6GK5 \KT($8J[K0?G(+/UYNM5.FR
MR=@?PS@Q08DDP4\O<)E<@HR]H5]H!>=N#.JV+]O+I754Y(7%9A@\Y\I%J9'O
M3?,<QI_,Z 2G??U^+RJ&[B%!EM8I!TTLH--;&$,9T,$4Z^2:5$ W)M%"#4+(
M.V+BCS!M$.6I*'UB.V_06YD<'AX +[2I 4?I (,.S&=8W4(('LJ*'Y,-?0,W
MAF. \-9 WT-9B_)5)-T#>C ^[\'S?9FIN)(Z"/1@^6/,9!"%[$"*"*7"DGDE
M.+.G8X?O#JQ1"=]6@O]>-(XG\*L4;@&^\7P.>60!G)A+K#0=8<\08BN@BQ)&
M\0EO%F(V-J!X1_!TNF!61WB9CC#6LGOG$@3)X(UKY9(S'-4$,)E+MQ_LL/Y,
M-F$T)O3+6[6VY,WVUI:4F%"Y:^"5NQYD:!G8^FL0,2(4K?DJGFNU).1R1TGE
M\EAOZ$18S<G(TEFLJ5!%SRO8VFR&+6E] 4>BXW6.D/>'!TU'%;W/Z:#"_5%>
M(!2X%U/\JKSL^1Z+2H3EU;.(L+QK!F>=WXX[AYW]UO%YN/^^=?Q;>T7-L7Q[
M1:T1G^F&5$[6[G<<?'[;#,[?M\.3P\-VEV*4'SIGYYWCWY[U@:KLW]ZST(RM
M9C"WB^%!^[S5^;#2C\NW8Y@G;[V /'GEK#T/;G:P0DX_M(X1E7( )ZW;>??Q
MB9(XSS&:]:R/WA-O6.4X/@*-].,@Q8Y:W7^VSU<7W?+M#P8ZJK'!21[U#08I
M,!)P'!7]Z#_AO@2\CJ+\DYEX>.!B-KK($@T([/_^^\&S=]T?<:/?1=C53[8"
M6;CROI8>!-AJI$":U.B2*.\H6MP/;>._&YH^+N!VJ^L(Z*&9>!&^:W'_,OW[
M/.C>#YK!6?O#!W0X?,+WE3GT7<SI21&[2W4<7ST/BN-V,SCH?%AY)-_/G%9'
MT![!YU&[<M@,L%SE^*Q-I2L88NV<G7ULK\[C=S&GEWP>'W-.7U3LLK,J=GG(
M8I<W+Z#8Q3ZX]-B;KJ/'*2SQ,W($=C@XZ*#Y5ELC\(0']HZ+]G3%')@&8Q\T
MW&^==LY;'Y9VS1YQ"&?&A*5*AA*>)O#P-#6@GB,SRO(H[4]'%,UI8;U[PD&?
M5E%DO3@JHVE>]E*?I&%KG,=)^)JB6]L-V\\J4#X%IO/'X%BXM0$KO[&US1_*
M#<.C"9@=%F!^3# PATB^.2#7Q[&$[&QS  )G29^BFB<U0OS=+-C:]J)V=2P4
M=^O*P'P+T13T=T0$" G!^'M9BHP(U+P#4=ZI6?"\2DBX&<(M-,B96QZQZ=Y+
M] %,04&=N19/LQEVTF)B(D*RSFH>2=#8ZVR:] GY&O 3E5& XLVT\/1JHKQ"
M<HJQHD%3V'-J^P'_G"*?!:-+Z[:.>Q\4A&HMM:":IC$>N(1[EB#L-$"X;03#
M8,B^]VF[+0+%CZ@7F>#I!6);W<$;FVF8SST#,HT8VJB/HLR4(+@LU+M!5MBN
MQ@3N\XDB]>:6\['.^[*<;:(2"85%I,3B$LP=Z^W-QSO6,!YY1O"DQ]H^+WC:
M8QWJL0Z>\EB']E@'3WBL0W>L@R4[UM]D93X=H!4!(.%1^^BDVSH^^'A$B*M6
M][RS_Z%]%IP<AJVSLY/]#MGL*_/SAU__X"*5",FPS&B,:D30X4&<:IM0[=Y$
M"''X(8D5W.XQ0T77SFR)9C#$L%,D42H%$H2('PRB..>N4-Q<E#MGX=\66[*!
M9\GZ6AT1]Q^BZW -M=2(R*?6RP,H= 32_P@+6JB?;L[@^:BH>=R%2;)K+K6!
MA1B!RH>9X3#F)\;%,J"0AUD.'GZ?#ZBM#H&W?3S[V\Y>8W-KL[&YN2E8>M'3
M:_%ZN+5+?Z _GJC6.+,68(15>^$5QE7P1WC89G/[58"]RWB V+<UW'+/&-O9
M%3<^9'-SBSJ@O2@+X0\II^(>M=03;C2BP@V\EOU:T*NXH$HM*2D2X:(5QSN
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MJ-%(R+GX&@L*I12T([1F!"7H$^KMWN!8!^<Z<%%05=BG9^,X]9P!N:(OT%8
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M2(8XD$H-.(N3ZVQC,HR%;?AN^86J+FEX07PZZ(0'2Z74N.;0E(Q.W)0R!K3
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M%DG+V:[K7BS8%OAP&^?1)T,<L:>6//MEF;-(,37?-(BQ \$MM3-E[,!)&3M
M"H.8RY%"$+D>DHCI^W*.WT2A1M\'+-69[<?2<PP/,->(0YB!HT?Q$?'*1,6T
M64P)YUB O*DQ<X;E*:\GZ;%]+>:)HYE9,%"-*=3)0F^MK.-&$=#HB2K5=HD/
MV_,0YDC"E7!A[MU^:PRA\Q" #[*RT'H+[] 38Q_O,\7\>I5B?L@4\_8JQ?Q$
M*>9.RHX&6P7OLNQ3(? L#".]K OHO8<)+-?5!UQ@*05*"I@21FW*H<TC[[G3
M@-@U8/1<$'ZREXW5%I]B*X/"\3Q:2&(N%X^TC!1B@:(9'"NI2;B6B0^$2,OP
M0*Z,4JFZ+<T+B:63MUF9ZID]BPK1F+4 '2;8?.;EZ4U]C]5V]%:BM\!Q\#*_
M: 5N5$I29V5^_7E.*>R>.\%+Q;8](Z/Y(L..&#7%L]\"'ISCV;-FM"W-<DSG
M5.P3P=U-?;-!'%+R"BW#"]5<84Q8ZQ^_X*NU!,0#,',U-U1J\D<.@%0FEZI!
MX/)V4SAK[R_Q+?NPD0M0(BZ/(%@9V>,'5V&+A[0D>NWC @W5"+#(" OZ/ADS
MMDQ&'N;0-0F@HG-J]UG\S.C2:"1F8Z6@IPRL)885QXE4*H*3B!>U895 )_NK
M949+Y92C7)E2 JFIS>$)_$BC2@#)-5KRX%\XVHWJM,0,B=.0K(R2DEQ'A:74
MM=6_CE(WLD]43[G\5(]_J\>MII3$B+_WDL]H6SLCRW6P.ILW=(V^M5%TF;N2
M(E7E4@6,D<.-,HV+H7'A+[_F CG;)O)&=2$K \%6.4&+6A7R%<[*H%JE-QG.
M=:O&<!%>W5-L)&]+JD9@!F'!^'12T)5<V^A:0%[)3 Z/3]]6U*T6E195?_GS
MTA\U1N[W3)*,08W"7OWCA\T?Z&=P>WKZLPSY.NY/ACCFS1^M ]G+DB0:%^#N
MZ+]J?#+P6/X^R?4QU$NF%R4Z<G"-?A"G9M*OO*L2_)KT%W]PF[O&WYLC^3__
MQ]N]UV]_L0Z@]^Y[?(L%RI'-K#:5*_;.S62:DV]D:S7F;$=-_=.]:4]@:>3P
MG_Q+MJ%NQ6_[W;V\XWO;/\%,^E9Q-C:,A/'-&;\A4VQ]WM4>/<D9NYFI:+4I
MC[$ICO'7B^MB=,-25JSVX;'V06)#\$0R[B;<7C"ZC+#P@&O51H3'5Y .A=X)
M/S^)/D<K3?:8F^7@C-PQ2%)&,:@RQB'@1G)X[J]I'A=]P;8S?C]$G_5FNWFU
ME8^^E1$GFMG5ZD\%Q2E>!#GZJSUYDCTIS"42(>&V8"!TD"5Q9EV^VCWYB5PJ
M<;.6T^E[5-3"F^WMS5\^5*,(]/NM7P)FZK$U]2[*H-$SGQD7;&T](V4 XC2E
M&-U\7?U\2,[/!:S9'N(!_XN;!_3BO#<=83:@ITSIU,D@O<H2@L(/\F@JG25J
MNA7#O6G2WDS::F=I,8S'#*\*XR0!8;(\Z8@_L5 EQ:4$I=>CAM9")4*2.8Y"
M+)_GE1C')F>X=A(/%/FGR9LK$R?K+SGF]_?XUU.+(= BUOC71XR\Z3!T[H_Z
M\L6D&#6(C[@(2JWL'92#JMW(7)\OC/JF/O5$.."UR3"V'WU0BQDI][2O]IWW
MV[?;7L8U'=^K_>G+G1((KEX:A--'M3W#,R_]*%DY@:+TJ)="U+\BKN^9=":@
M>?J=X[U!N!?BAY0?9 '?.E7]XAO8M1UJ@PO>5D$<V:SK9(+Q22:M<:0-EWDV
M'5/@0E/$%H T??@Z+H:)?"4LYLT*%O.0L)B=%2SF-EC,HON,_A.%<?\?/WSZ
M?YNO=F$N/T6_/KZBAYMGOQD>M<[;W4[K0[A_<GS>;>V?GS6?_ I: NNTE21(
M* 8/B1);.%[@ORC33+7$)2CRU':SGUQGQ").1#@]8W$CG(M%W8W@81]$$>*M
MZO5*)7@.?<<J=5377*2GV:J&H%X"!FBCH5A]@NMW[:%)#*H9/T/&=[QB08C2
MMVP,EVAQ2[/@X3>$3")08*8K'26[O)C8>GY\0OOS,+Z()V$'?O-YP8(P_Z@U
M5?O<+%.N>K$SL'R>8"D%V^!]Z@S6#PB@3:][O/(4F[6]*7=;.?A[3WCP#YIA
M^]_[[UO'O[7YX)]\6)U[YA! AA4Y-%0< 9*-;/)!,1V-J'Y'*"6Q$A[M3;(Q
M^41-Q:WS.GAK$QT$58OYA?:U9IS1%+SBMGUP7O>'< 859%?+*UO%<_5MKTJO
MYM@K?I,NFH]@K#U-I9;"JV3E<7,.P92 CSC:&EQ8H8@\29%LVE!5T,E@0#^$
MYT*A^G!5#<NP4@MJVF!-P+]#W.;VYN8N1R[.6H?M0&A8\.=C89;&,##\L@B[
MY &Y=K>M/I(0VQ+S!9MP"#IY(X_B0OG3NYS [J18FT371<L=!WC(039"3HI>
MT!4T2 %7$F$VD!LOCMP6GHEW=BH1$YOIIJ)(G(].XC7,D:,F%Z:' "NOZQ^]
M]#B[8ASK5D.6A,K:HB+0!J'%=#SF[G0"*+VFOM[\*UX!9F"V_6_%5J!QP%_M
M*[9?\3OH%4?1+-Q^2[]XW2A7688"D\/P3Q+E 4Z"+^52@S]7>)7U8#'H=4(.
M$'MM3]!>..WN6XP-57/8:%68"74W>WI(5ZBKK"@;J0@+)#Y%RV:M!]9U<]_A
MEAQ2-IB'.!:JKT(3I)A(O\,PX_/)ALP8NXS27"8N'P$#)SP-49QRO8O2]7LK
M 6\0Q.H-:Z+D3OY:4%U7HDTH=+4HS97^Y<#H<\-'8DJONVO=1-2BJZX,JGL*
M 6#+8VIHC6>$I88Y%BK?L(U%E95*K50Z:4%=!XFYE]88A_SK'A)Y&.F3*_\>
M:*EQHT1"I+W61B:_1'BD%CDV9'F"V!YLZF&+T53W"PQ/P//]O*'TL'7K2@O#
M\0E>W!IA>$G:FM5 59W!*@3N+"-DS[4R=M 3# I/N'T"N0>R?LPO1R9-[!IH
M4[@L&\1\6+70G)*^$@HR?6N%QYZM@M9X4)5THH%A%0!_VGJS2;TWW%O)F!E/
M;%W7'4;!D,+2F2=F)C[T\"WPN[!ALK#/E9=,R7-MWUG&W@A?&+&2(4;>LK#D
M%JDO3_7X:P?>R.)T@'S3UCNI+$ C</F""Z(Q<.>AD+)G!^%*LBCEZTL?GTTG
M]/SJF9:GVVP$E=9Q$U2I3]8E= L;V)I;6*Z2P:BG-RRBQ/"<39\'PFI606>L
MJ[A,VB<%GO:XY]&YHP(:1'$R9;(R;@G!&H=*HTM+3 V%A3ID6G@-$RH%@*E?
MO(A83B+8M0F@AFALI\!\I#2",'5).72*)XC8V_HQ["EH-$8YT!90]),_$_J?
MX6KO3W/K)_TP20@H+)MN^*HW?DS^JR?,+>C+#[1W^H&W2(\^EJ71W7#!43E_
MF8*.24,]![+!&05;YYM2A)FN/I1#.O%DW;I3\,?A29N]P+Z8S4[B&MP4BTJ-
MU5_,!.GLU'#4ZTU'. +3#T1I$%TGF1Q>([X:)B>Z2%SA%I5+47>BRKR(FP[1
MQ$QT=:=)!K[M2HDGPALAD4EBD#,=6?7'F.:$=5W;VOQQ72&QT0#&O#&)/HL.
M#"^HY@'TS,+QNA: '$-#8*UV6@F4=DCIS@=$10./8/)^NW[D3'#Z6:\T_4J.
M+\#[)AY,9F[4N]ZHY]44Z=+"LJB#M$AWPS+)>E1P VR[QV H,V%$E,,0=LBA
MV7Y5'BO:F5$22<=PBCMXK6G</.VL"YD:LZ3];:NYLQ6.XB2QS&75QPO!S6W;
M;!^+>_RW5YO--SOZW.?)KG"CVNR@!1R/PJX?5$KG'>W@+$ZS#?6V?R?JSW_!
MZ*<YYV7W,T02L$@>&8R0)G $X563J<0[7IXF;A$E* ?;;.M&Y$.*V113C_*/
M+$_Z&!WJF_ DOP1-^M\1ZRV!KNBRX[E RY(" S&1HG!_(.G547*OF9[U2O9H
MF!5TQ(54!C:WQW#7@/U5'"0>?21M22VR_S](<QL+9;Z?KXZ1"2T5I5R>8(IF
M7-,&9EPOFFM\+@)18H\JM:DHG$X];=\7B&AX#R*JT2A:/+BWE!Z+WT0QV?<F
M2F!P:[(W1R?O90KK5BOY']]'_BN$QK@O'.Z?'-GOP$IN;VYNLB4INQ#@+LSL
ME 8RI=*.\I77\^8TDCG%WIRT&!K!YN7&(,,X]R^&';D8'#@B8)R0ZY"NSK+&
MM2A\@>"I4 ?(;D8F<AEAFS:62@:[@RQ\I@YB(*.?Z!HHB'K$&\9K&(:6%+OM
M#NA5A(P8S!Q2:P[XM'BU[KI8A&.X,(YLW ^/82H.MIN#:+2+9&:P.W>-Y>D-
M70HSOP;Y-*T_A>+%,F6Z#?D0JF+##;B\^8%$4JH!(@),$)"B=FG!!F3N7?[,
MY)H^LK:]N<Z)Q"6[ .\"OWB[@E\\)/SBU0I^\>6L))7\Z^LGS+^VP:9O_;MU
MWCDY?FGF%P;NU U&!Z!M0^1@;/20:.L</#:L$5Y#_2O7<[MSCK_3^]FY&I7,
MBY^%U="]?-?+QI1-HS,D 0"+8)KVXJ01+$@,_1ZE4XSX<5[HC29EO!<TO' _
MWS.$!HR)1 ,K]V.)RDJN@3@2TPW[L_=M+&OVDP?V3F7*0"U/YH0Q73KH.LI:
MP=\&40\[ UA6,%"??7"R9/EL'%U"LOR8N"A1%^C3='B!&TY#GX-FALWY@(/=
MBU*FTC8:IK=M? LP4Y.(6?"M6>O-D-HY^-D2$@5RWB7-1&YP8/>;&&*FB<-N
MZS;WS0"?[F:P8#T4:2[,"?@W"B?"7Y15(APC[ =M>_,9+FS:5WDHQ@(G:(9'
M"45O,%41$6C(OD-Z1#-B\DID!0P8"9%RRIXM"4:H$NXR-4G#"TZPI#L"3!VT
M3-HMV2_!4/NAQXA&&%&T'F2:NEW[U*1XZG!AE9H1O>]K,K&0_Y+<]/)J$$$E
M1T3GY:89'DQM/PO%QB9(V8M GF%<4"RALD<X)[K!,?7CQ<+(MF78E*&&N(O&
M6\8%ZR?L42()I/0@FFX:8LC8BRNAD3#\1N%LM4^]PB@A6$=Z](V+V0;1I%]$
M1;QL!MF3<>'6[$S@[PPWBR:+.ZQ1<S85??/!)_+D*67,8:/TG=0YG>V>0I#.
MW((:G-PX!W\H<'VJO<X)]:^BMH.Y0MO8_AZ@[K=V^O8N>F+<\MEY'^A?)/UK
MZOX8?289YJ<VF!<I29 48O$4&>Y&O0-!O5]JE)1YI> 9"1(:7@Y+9T<8HP15
MI#K.Y<PNLG1:&!\1-)>/M7D=R[PA:'EVK>:N(U4Z<$58(@L[S^I%O% Q$X /
MHRMW'W/X[6.6C%C-@P*;RB38>ZV YM2TJ%"0I/<4KYBRYINDA!%*1JV!ZK2P
MG3W*J>*YZ'V_Q]//\/0C=Y-<JP-<-BBJZ_BE*Y-*"R/4?0%_1] =()J\T2\K
M_+I0V8D64\.&+ ;?=O.,(Q_IJG8ADQ7K+JE>O&73UY![?V1IUSRH7\Y,U9:_
MJ0"EU).,?"!WLZCG=6IH,*\&HXIZ0^V&:DI[L)!5%WUNJ+;IVU%GUZG7J6"A
MK@QNS+K.SQ;[>Q5%1.$]G0+H3WCLVM8VS !V>5B DL$($>Q!XL&2^1C7+!2M
MQ]RKI#_70 .9+=?_J\S#C6Q POG%%K*JNO=(G_Y/_(\"S_RHYQ73KGB=*%I7
M6<P=UPC5-L5KXERJX^U#3YGP5P%T<8%QL/955%B$3M>!>N#;AJP3=IDP1EIR
ME[PYN9!FX9E:U'3-[[3@KX+?H@T6>BUNFN9"2XPIS\U($O9$)T;42C&GY8W7
MOIC.STRIQ(OU1E GF?,)O1K)A$N2/8ID1EG*VTYH23<S^C#-KB+AYP]*WZO]
M#LP_O<M!]IZ[\ 03WM]SMN0 SYW=;UB=EFWZI:+B7L_6D@+'DIGV?'9ULP$5
MB=GK6;/ .F%^ '7(R!Z#3_G[NB\.L:%S,F/G)86G+_:D]2K6>YVK%65]X?/3
MA T-<)\GCL1!RW[K10$/:%S8)H6EG;\VWJX%+C'  '5**]<')+"0,4&-IYU3
M%GS02S;T,\>L@R'Q<EI NT9E@\"BX3T(/%5SPG4AE8N?\0Z1)#6]?B[)H$\+
MYY[64,^4NV&)]2WL3#;* QZK("+%OZU]3W[S>S(9[81\4")B+Q]\K<5$S!R=
M^2(LG_EFX*DUU#:7C'X"N?MO1_KHPS#M\2LL8M3M@<)9[Z!!/*\D'C!4C=[-
M='I1+NTVY&-PT.,K!0%6IB)A@8[TD:!KK1$Z;\Q'<ZC>6C2L ,>3514OU?2+
MZOD"(6Z&)U_V!4FF1;. AEV,465KDR$X2*AM[9U8<B'G,2EIS79:J""![;Q&
MN![%_XC;AC"W?J!XN!(50#/\PXB/ #+="&T@2,^><RY+:ZY#KT*&[>:_>%5^
M!(9N=J4=,SE07,YPXTUI;3FO: (,2U<W<0;F17J)%H06 \ZGR5T<//3BX/AE
MZ@RJ#;?UCU2JD&YH:430]J3V.&N&>V_?L%4HEX\6#^ ?K$D(3S\ VX7K'38I
ML/U6\\BYB5,0<SS7RN14:H(+ \!C(^5]0D8.&FCA69H,<XIE6+2[VBM79DC4
MV,W0'R0;JP:USR3/(K]#&-+@EAR@2JP^T%@]!^I/O<; _AL:TN<8/:1H+EN.
MW8^HJA =_V1&HRWF$KMT.9<J"-R4 YVQ7T2ADW9(?/L&UT"RMCQBT6M([9LD
M4=$J,YKHBX/*BQNNUUH)33PWOA+J/BH31_'Z.6X!W $*:Q','+]YK53P[,Q1
MJ#P"O90,//VXW:3@6NX]SXXGMN+.X#C%N<O]+5&WAN;JRUM8@0Z*+TO=TWPW
MANLA8-DN!2P<318N-NE*ATJV1@7B!%P93FRA'&L[F^L^WMWN<C,XKPQ#J@!E
M(,3K;Y#N3ONEV#69N(HU&ZYQ69)2^U^+RE@80 ^<G>(:7&.OUBD5:N&\BI*]
MDWE8*!=#X@V1/K!,'<L0&W2/+9/-Q+4&4)]88KJ!J0N0-FK'[EH>4$:%A2Q3
M0E^TECDYTS,;J&PV",.1FPWB'RE\NF]M]2[)%(Z3VAT*6[?,1PP:/SMW/93P
M@2:$[*Z!LH?137FIL/T8HSU\1#P;JJYPE"NJQX@OXZHY;Q&H=0(L&1.>8/V/
MA%?@KOMDL 6 !.GK;JW0N[4<!@Y!249Z#;F&XPC !?' \,Q@FM".S'@+X&S,
MYNWS&]6),C1/"ZVM0ME-HI1N1B?$9Q@/*FGK8$B^^44>FX&FE1I.]J:I',K)
M3'J($@28 QZ/$L;\%KJ2-YLKO,Q#XF5V5WB9>Z(K>?.$J)G#9GC0^5?GH'U\
M<!:VC@_"T]:?G>/?@M9O[>/'Y2U9"N?D./,+29Z^$K(B*6^?4%)^@QODO'7>
M/@+!"-_]&;;_?=KNOD@129=.,'8WGU PWH,*.=G_B')Q%IX<@SXY._W0^O-)
MN4^VER7:(1T_O&"AV%2:S//=' ==*%&=R"?/N)9;&G?PW"P91(M9Z+;>[KPB
MG$3$_;.H7LDYXDC8QWYD,44DMZ&Z)TY+N\@9(PTJ=68N!\MO]D;C#X+_. 8W
MKY?'%^H_#Z8Y&,I#9:E !)?&F//L\RQPK;*D)1!6>6+O<.HIY!@3&;<%=FP\
MQ@9;?G%O[43L>N(7%66&(*J-XAI^K:D"KF4+L#D:>!@SOW<G#C72&KTS*>[?
MVJO9$W\5&G/Q/PY0@S$.'RH8I,\!2C_:C(YFX&KY)/]6[7A /2MLJ[!T0<LQ
MOU$8"L0@)PL-@R(9T>W")&&QN'OZQ^99T^L+<XW45T'AR5M>RCK?312:8#,6
M_>@_(D_"^T^I,9H,.R[NK85)_3X!/$/$MI3VN<2<5=]2P$9K.9$(;Y3.TZ$E
MGO40!?X@FYQ]QJ0199NNC78(P?<$NNCP_4/T?[<W-PXUMB>"4K\9VAP.03$8
M2^F;L2$]X9=,#N)\U A- A*39RD/H;*-*/X9-IW&SH(SQ4Y=FPLLN7_QD>5S
M62:$:4X(JAGIV@0B:_)[V<@&JQ^A1G-ZV-\YBYXJ*VK,WK"BYEI[2TE%\K)@
M$P,8G5-P.%25*$'Y7L4&:VBH+>-UFF01HT3@T#$[@S1?LPQO,#M,8Y*W/IQ,
MQC__]-/U]7433F[S,KNJE 9[$P@TZRR*6=A=RNT%_5+H2H/"\@%0Z'GUKWL;
M_[Q]A3E\B7PD2C]3$-T 8I>9U:[07G3X" Q/9(6G_Q (>17%"<63.'0]OXH-
M5'],NT*1P$;EZ(31),"%^RN>_O<PF^[L;39!+U%B-D/-4;B@U4P!S%P@C/70
M'.G3W+_PA<0)#T%66#.@LK:X-6XU["5#$!(651:(B&)$) 04]VZ41FU!)8A[
MH.(N1(JX;O3U'(#\E<54@"ANL-"T,2 B%!2T.U!:-)%&CLQ6WU5D":I>;L%C
MY^HB?4O GU8QHK>>T(CNP-7S\=U9YZ#3ZOX9=HX/3[I'+[*6Y1"M$V*X) BO
MF$?*$H+,"V"86%!6![1(^*I\FB2AKU2;%(L%(P_.G%]RC,Q5&CW6TMREO$ K
M0KK]A$+Z.[@3Q\<?6Q_";OOTI'L>GI^@,OO8[9S_&;P_^7#0[IZ]-'E=[HC1
M[L[#BPOKK_/V$0]I:ZL9_M?'UO%YYQP4V+_:%%6$7WR0GX.#SMG^AY.SC]WV
M6=AZ=_+Q/#QJ=?_9/@^[G;-_/N-PDO1$%0>IBWYX-RX^/=\)+XB(#-'0Y)H/
M=<_9@NS-,"^&NIO\T3ZVN!28B.-6&,A7KTPZM=0 Q40AW&DVBE--K7>/WG'/
MXA*K++V4\W7X*.'!H_(I:8@2"R',_.,DGL(P0NNAF\^,"T3G7"(M1O<YARTF
M8LQI8>:'S@]B*A=;MJ8Y4&:W96+L08)7560Y*3A%J.] 6?)QUM[Z63 TC?Y\
M'D[GWY7$:"%Y7VQ 5'U80!0^N*P^21M,'TSWV'$U7&<YL7CI!YP393/>7B'2
M&(O38IM#I4WSFJ'Y<R% 5J 0+.GS8)LPI#I/I0KRIW8M^$\/5HQ_=MTJFLB$
M*HTC&@KAMESD,$*J#[)+$^![+.V?/TB%J-L,_4!9S81"CLMH^QYO5+731".D
MK#+XECUP 9A23UF0RPQWP9W7=4XN9(UQ'M>NJT4$0G#)D/ORNI:^R^MK'2_E
M=]G7]KPEQ[-\_/IF?EPW[3D1V+GOEZ'5_@<QJG05)5*AZ W'9N--E*?,QIX+
MAY)FQ9F6EI&R5+R#0"AT/<MG#+W]D?&/E& T$,>+[87,Y:7MEQ1X@Z,5V=[<
M$O:34Y.-$V/']2Y*/[F2")8U>LHHDS:UEGV2<!?Z[MK!44'>D& @.(A!8C['
MKLU3[5>)PZ:T"54%#$J.$6+EO2/RD,_QB*I'^&[9:[[YD?]E@]3^MX+JM\+=
MYI9\P2/\9[)_"F&7N;9V:/&1=*M*Z-LA$$0_QK Q8KP)G(3<)Q,,!PJ$(V3X
M72!%DO _FNDEQGU3KF3+P)2;D=3%(#W2/6:QJM4[IBJ-RG5"C1L;Q*BH'Y=V
MU[PF)B!B6/V)ZX#*\@Z/HA:="X^(9=K4VT?NTYA;^)!V1F<JE;N45H*HE6;2
M$6B$-#@2L]8X  &;+Z("/XR1$_O,Y89];*U@'P\)^]A;P3Z^%O;QZ$;VQ!%M
MZ5V%<5"NRZ &DQC#=*D02Z7)28D2ZP%SQ=+M>RDTA*+BK)7'WVK:5_K0.K(M
MP%#,-9QIXCQ Q!LH)C)<4-LDQ,4K6I)CN8,I!M#]X<I;4RS^9>W:?&0W;@GV
M%^QXY'MLV "ME 5B>HZ-=+1:AZ9/C!,>N%5IX<&VPR ML5B3-86N"?DQPBI<
MN4IF98^F&;*$204*FRR6"X#LXF#1V_UKL81S3FUJ Z4'OVZL+Z1,Q!*4QM_B
ME-%+DL"_PU,F/'.:4Z!S L^-2/=@1)+9HRL^[>&\0;[ T>LIL69ID&%_:NH]
M.[RN?;_,I0)KK.E K E)/+@T(4)L8PO\K74(GSZJ]("!(X7]O]R "![A/A'-
M-IANUGDR12-0FF[#'^&(!RI#*FTD]U+Y>R<9Z&$\<G_;V6KNO5&R5_H*G!8J
M_$#_EXX,?.]OF\W-3?>I&F9;4.;RSJ Z,HI\#$W"F..JR^]@QW\8+5MTNJ'D
MQ ZX2(M-5&X+J92_[BD>[6Z@@Q/MUX=YV$D0L2,"/!"*#]8K.%;,.8YK4/X<
M^FS\,?X$DD A:S&,@ZO:?'5HJU/8U0(Q#<8YN#!YG$CS68X.,*3'5K(0Z)[A
M"1,M3J.%I(4#/4,CE/TK:C=*:NOUF11L*2R> L-#7#!8-VM:_0N3Q.;*<<>4
MBTAGKMN%/U_6<:0*!U&<JP/B@E^23-4/Z?B"G%:B[_B+F+2(!N9* Z@0KR)0
M-%A[F5V@@Z6!M91RN11N2R<QHG_("T.)\6)O=B*X/44@8Z@9)&WB,]>J VG?
M]&+5JKWN0QN<2HOIR.3!:8XUA-PK;VW_M+-.14>1-(@YUO3@.Y#5:$ILJ\B$
MA_SOA8W2-)C.=GN;;9@(*U,N+2 IMLO/95M:A$U\$'VJ:\VQ746P;4NV" >5
MNV;;8"E?Q=FTH%!(,SS-,VF64RA5;^?H$!2D%LG .UJ@D1(<U!9I"0E=W#PT
M,@ C4*K1!3+7;S>W[(C$"B+J=I@V!E\HC,4W!/XHL7GD$:$PQ6V3WFR^7CC?
M @D"Z5':[*2T @TL[2%%!YYW=8CVD_3]YWRNVVJIXIUPFF&N CE-\'R_N$9K
M>$5[21,K;R!5@8>WU3;3R@T2N3[4I5Z#N(1<_S@;"VXK*HJ,HG("WG%8Q1A;
MCF$3PQ8H%/@T/>X/@_C(-&Q/D5I06@P$ IV1%U0>V<!0.MH]&+X3;KZQ;FO#
M.2:4G2(F/Y->Q7F6*E^68]%9Z+"1,1/ 0A%$ H,UFE^J],EF_>?=EZ71\(IE
M99_%IVK OY>_[\*J:!%B8#560F</&DMT@7/=.O"BW[ J!5,C(U#14TJ.V"FZ
M[ U&@Y%GG8KWP2?,"?5%3R6#A'K+F,DPZ[.+*85ZC<!;?T0QI9?/VB[8QXCX
MY$7: S)URL?&F'33RLI@ON\H'57-XU6S2)IK6^XP^/8J#/Z08?#7JS#X=Q &
M/[11-LR;Y5/7.C@89PB!8*XN:RUX&7^T'#R5@%W*33I1ZP&=7T^?D&U1( VF
MA@2HPZ-$:R0P[COU$E?!*$  AC'!6[R88*E7PWR'1EL6 I^;YJX;JKMOO?AL
MR?WGT&K]BPCRDF$A^.509T<,EM@)#[M#(7$/0I5C="1@CG!SQD+Z@\4M\I5K
MM(L>1T$NT_72FM]D9L]3:S*8IE11(T'L$MN38(((H&##1/"V;*1686XN9GZL
MPY,^D*7RU28$V8D3#*]F/W"BJWT9X0T47A<KB7>UW/21RP_T;# A=U$Z DK,
M HIJF$VEM19YB@SPCY)9$=M:-FW_P@;NS&;0*1>5S"Q[KQ9]^?0<EO2A(#P3
M<C",0)W[HVF444UH]_J%1V/LW,G='(G/DG-?LMRNPNC"7!)?N647ITQ]$FN-
M&/ZZLC+$;8(TL45%/R2)(A5<RS20H"DVSVF$ER:[S*/Q<$:@>QT*R@ZY$4@]
MYP&<XT(WR:C1G',''\>4_O1GKP)$??7X0-3M9GC0/MOO=DX12!^>'"I8N=,^
M"T_.W[>[P?G[UG'8_J^/G?,_O3\^:>GJEX#!=Y\0#-["U7UW_ETLV[/'@W^3
M%.T]H12] TNEU>VVL'8<@>+=SF_O'Y=48"5)]R=)3]G_!^M[4*>O%-)W+T9/
M28AST Q;1^UN9Q\,@X/VZ<E9Y[S5_3,X>]_JK@1J^07J+J&QG55H["%#8V]6
MH;%O;:2W^Y!$3QI6!F5WVNJ>AYW.4J0"RBNP]PB,1E5_<0<]FL/6QP_G9PW+
MBA:"==IN=5N_M<\"-% /VA\ZQ__UL7V\_\@&QI+H_N4CO]I[A+K]JJB\:H9'
MK7,P$UH?PJ.3@\XAV L89#C#DFBP0@/V8[R8PY^A%$B3F_/QK(U_.^V>[+?;
M!R]1CI:Y:GKO$8KLJQ*UVPSW3X[/NR<?A(<11>/@XR,;G4^1D_Y[_.M!7/02
MQA[N<_":P[ZG-@"-Q.O/=QT6 H.5RBCLNQ62\#XSY[@0/;;&D4:=7*U,K%M;
M.]'&UNZ:X9;M6[M]^<D5?2Q@[ZICDRNWCY4/!\3ZQNSWZ]+/AHNG,7_&V0J3
M,JZ46X#Z/$J.UNS"Z"1Y_ @1+0U(*7^(@1RQ?:;?X/EC24DC**8C3+[]MR18
M^..NLR:Q7L.^('@L1A@(=UF/768--+5-\CL./&+KUIY\2NM="<='O=YTQ%4Q
M','/1J-I&G/>3IIJC+QN68Y8"?^R/T3^Y?9GV A"/9\P\QV]DO_F\ICR-]X5
MS-^,\Y@*05S]#,PQF058DL$4=CY9E2RWDR9"]/%6*4^>$*1K*6:-Y(5ER6MX
M<Z.MN<2.H))GQ:S(PN^E!-I%5#B6:&)O1R<VKI4K[C/R(0G7?)BEE,NQ+.+8
M$BI7WO.H!RMV90</3\.2&-LSEA*]L,BRH][ 4T/=TBA[6R&YYYY=F"#[:]J_
M5.A599V0A6!#VG!)TU98_6$\)IK#K* N)\&"I5@R+_H)TJ<UQ0>4Q0L,MXNC
M@ASNX$:(5*)JU QGK)1NC;FCYA2=97V7B@C+QX6$60PJ]V@A*H<RN-.A%) =
M2:^5#U?F/E?IA"^Z_7R]>.%XIQE36D2[K+39P5=H3T)S,)\9ZJA&;>E+XXZ[
M0YWG KAU=7,I(SQC6#6]@5/R\$(2/:\T JLAE>+?%B]<F^@3RH=7LI RY)+?
M3FVO'8+#XSC%1L%$NXK'PE#;WB._=;963@A3X5VGAVT)N HT]&89(FME4J:^
M\\8>,&6HM);L/^L23;5BW6);,Z++7'C455(V4@S<@/;1B697]_&%6KK<2$0Z
M/944Y2(VC^K1N.EDU%6V@>$CO"S,7F@[F5!=V53' @>*I#LHF#X"+@U!U<"
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M=]_,=<MW'D'-.PLRVA$=2KIS72&GI9D*M(VT9_:I8^ :9 88 #8(>8Q?#7
M%88H+,:NX] (!Q6_7SQEZHR98T3_5^H12[!E[Q(N9-5R<K?^_F>3XI'SNV_H
MU.D1&(:(^RT3=!/!+N<-QT?E'1Y<8"$'/C> VL,+!PH:@ ZE^M!SQ_3B3,#&
M)GWB^ZX79AIXU/CV3*8J4\7\/OB(<I,N3GQC2GHPX+O[^5SBV$3PA:2#.LV5
MULN )^DD\'05.%7N%P>PU\__.4?/+S/[A1-5BIIZ&5 COQG4S+,S)(65&90!
M/\J;P4^8^" +Y<&.^F:PPVHP1):4(I0!-]J;P4UCXEEVD-11#MSH)X&;AN/,
M3/LU:D1A42$ RRDH72H%:NK'1,W_=P^&M?=$!O]_&4!EG 05_VMF>E/BT<#@
M:T+^UYR0(_=KP&?$,F!(%$X"1<D$-*"&><:E4J#F-(SW)*B);':FVI8$/V_(
M:#<=RMD88Y-+@9VW8[='!;RB5"+\'-5N+Y<:);X=*_IU<4<IT/-V#.FY<YV)
M J44^#FJ,5TR5G-4Z_8X8I-)3;44Z#FJ15TN4I9.P[1M_AA9#Y@HAH6U[&O8
M3\J/AT$Q VDPLPDG*HUEK5VBDUVD4CC7I"(;O2$J:.EOB+)\/*'EB%J_'0MX
M'ALMD6(JO1T;.%ZT6PK4%#1L#3(FY'*8Y1T!6XN 32OS$5-!*K,%;Z8E4S_Z
M(]-YQ$*[\=CR:1K@/"Q*,5,*MYZTA[&]'IXA_"3A_.85 &O) $BE DN8P5[F
M:W,*<VFLQ7I* 7QCW;,.T.DH_<K+:V[J]B55W;[R[/:E5]V^=K\#] ^3LP;_
M./OS=T$WSH(:CCQO^</EUE8:W=F#;PTLTP.V]?.'AQ47+9^]'::18/BVJTZ[
MV[EM73=ZS6ONIM5NM*]:C5NNVX,/OC7;O>YI'KO7^'S;Y#HW')R_5X1C[I3T
MGGQ'R=+CMV7#AQ5I^Y2,+C2J/,?![S1Y/CCEN4V&M(%E\''826[M2+>H_NUO
M0\OY71#$+'D^T[MIH^%XN72L2II53K\NEO9?UYZMJ1PP?EK#CK)+W#_?5?4,
M<9L6<XFP)65; >U0%8/JHI]-FY;1=4>$  ;CW:)EII,KE*LSW7(SMO)&T:ZQ
MA,-=OT1(E'-#8E3Q0+$7#+J !UB;$G<,5O0(ZZZ>"'?K^G[4BO'?Q/1\KND,
M:%.K.,Z9,1%B7CHVYG=UO1_T<BH'PNL5-?Y\SG+@MIJ 4M<&L>0'7A"N^9\9
ME@V7#K=:N6^U>BCLF_Z(N['=YQ)>WUU]U0>]OEJ69VV[4W@^&&H587+>(VJ.
MTV/C9+5_.G^'T5)GAYVZKLN?@B[T_D=\>]#3Z\2=,S?GQW7/B)5W)I5W9FYQ
M'< _<]^\Z]SWT$1OM:^;=TWXH]VKW3>_M+J]YGWSFKO[_OFV=<4UKJXZW]N]
M5OL+=].Z_Y:/IX;N*(103B^PQH^<:4__<09FOM>/H'WQQ^3Q[$,NKSSHR(JS
MRQZ+ZG]VL9\Z: )A/V2JWA]L%W&5DVFCZ_V )P!TH-O.Q'*"$ MK#[E5HN=#
MX0<^^6^$&YE@*9JS@85'Q;.;_3YKCX>>FWX,$+6'P'_@,__!%L*@&JD?<Q!S
M[]"71F@/#?N%YV(-LF(-^5@[K$VN";Z&_V+A89MB*+[+>2X,7<-=-)#["P:R
MY<#/A'MG@Z'\GN?Z<Z/+7V%T$6IT\6P=T-!KPTA#)R9L-(A9OU!-/>@%,@7U
MDYSC1QQLQ'(''%FIPK\^D4-URP6 L3@B.MA Y00 Q<"W@*5A1*YS2(2 O0#,
M<.[, [!0>F=(6 #?JJ\OOOK!?:+!>MI-<6A:'B(3SFO:-A =R";X<@U^/8&=
M^^P-\T5IGRMZTX;!3:.8WX+Q&'QP?"Q]UL*_%K&+'R%FN @SM=28@<<!/K#4
M&"UN&JXUYY[-B0<T9$UL0-8C<6 S-B *?H\)(H/P5=\=O%PURCWHUAMC>&/?
MC/'. ZO?N?/3SZ9OL:L1<-9#1(>.==[>".Y"@EL$+(6&^O%NP,/6@V4C32W>
MA"C191R-@KS@.G!E7WW+HJ8G^8$7$:D_O-)S$?:JQ^G*[=5BV\.N3#1]!AD$
ME0C^!0<2 K=M<A/FU8_1_M#RQD&&#O7[1[D@00 @O-JQ0$ 'K'\?!V$&&LZ[
MA:OQGGL7,+2[JT;G\T)S1-R$AQPXX$(/R+WGX0?Z[H#GA*F1X?N1-<$6O $5
M7M$NOU]T+[@A&>"EY?PH^Z)FF\]^Q&_,R02.0N-.W@QN.:,L_"T</.B,YH<8
M3)#"$:Y+#YB#[E2,"_$;O0W8/QD)*J*F-9A &G0&0 X1(!ETN-[(A7LU_VV
M?WC$!(R##,(Y$ A18.#(H!G&\%5( N[#U(07@B'JNP[%H.G[,X^^&F38#)88
M$?B&MR0#5XI02H%#D!FXR5#,<8C7\!$^6G PH[E3(#(QE<V#K\&N+FB7T8@H
M?93Q"R2-FA@/GWIP-GC7,ZD1YQ%8 /UE<$24A,$1 Q%HH37HP%;@!%//M3G:
MLVQ^ H_&Z^#R77 -'RQQCWYSCA0>(?GZ=@6P@W?-'%2!$ 6P1 W?F?1]//<
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M]4YZ#W?^R;6? IV'*J,6&H0UT /!CG<>*4OR9P]_,/'&XQ;0(V&3'X#'P6/
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M]LK!NXL[;:6'CWJR7.1@\*:/Y473%C++J> IB1''JHS^<89547#B;679JR:
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MK',TYC-,V'3,\KK]PA/=V:8S;3B#9GBHA*[>NB"?72J\(6B\6G]SCK_TT%/
M;D ?.2]IVRV'DG&U\-;<NO 1=GK %A+$GR* 2GI=\"@].$DK.D@BITA=4,\N
M15XT5,"S^-9NR=Y TQ!HNB[Q@KY==2ZDP+@QO;$=MG:8ELTC3EV!X1&82IT,
M<3KHTK+"B^J;"97N#:HZ@$K3>%U*RQ9*P/X'9.+Z5NFN0<C'KH/M,_2V7:>_
MBWUI4 D@&KR0.LNC-+<B$\B)F%_$"T":HE32\"ASP3O1N<LI#E8X7G=%)7K#
MZA*OR&FC@*6[ BF )IU=ZH; "^KALL,.G4D#5A1K+VL3['5,<7'N#L]G;)9
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M4RL U8ZZ+>V.(RL:7\^R.O']B>,K!2-(B2\CPI>ZW:K?%5^GI5.4G@8/ISF
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M-9Z8EH>9XYTAC@6[!:U@T/!],O6_$GMPXWK?$^H'AL R4/2\9A.6*C3>Z_3
MF F29E?X/$Z3$%-82=%DKD G39:<8S#'LZ;(O)A7/?VI(BN%@K8GLD";455>
M$E2^KE3%HX=B\7LB"]05V> E4>(-^>@SKZK8Q9O93#%] UCAPMW<=[[%"F%R
M!M[FEA59B-IY-ZS=NE88H)?+O J"5]W+.7_<5H19R+V](:=BQ0-O2"HOU\L'
MNBRDT-Z@TP!TO&;(?#U!C?A:R%4RI]I,261.I_>U>8\%H9UO3>Y=:$&^_UA
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M#L\^X+DN\:SA)VYL>H\6O H?C>4M3,*E,UIY\5Q]@E ]N^R-"&?V<7*(Z;P
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M6A%$8:>6T>6&;XIHS][P%<\N95XTZKRL;7?[)@'O,9+C&P-4;ZFISDU=SB,
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MZ>&LAZUMTDM/"[GQ00#?%4"/-A$=D,'GE^\ QA@S;$0PW)$12K11OPJ64H*
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M[AW"1!(^O?XU_5C\5',]#D0'%SQUQ<1-\,OW/*B-/HTB>1/7HT+%<F"S3^;
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M>,%%=F8<GYTM[!Q)<$V5I+50(E,0EI86JU+0X6L?>L@-<ZV-+&Q>@HK^=5I
M6NLGQR$_O\MS#AC^DF4P4]/!GPVQFH76>[.:9["_&=<*VS[$RS!@D^YL6HLY
M+&(<+K <J?.4-4L 7LT*DSUD<&!M!^\(VUG0+9@#^!0]0.CR\O%D8Y-6^ 1)
MS(SQT>-0($41P%IHPUJT1L+]?^R]:7/;2+8@^IV_ J.Y?:-J E)A(TBZ:A0A
MRW:U[W@;2^Y^=[Y4@&121!4)L+%(9O_Z=\[)3"PD2&+A LKJB.ZV2"*1>;8\
M^YEATNP<B\B'\"8,4_$^#W[:1H)D(-P.<PSI# $P>'C11B&ML>99RT_9 F!X
M?>+\7WVXXX8RZWDL,J[E%2&?Y9[0!%1PBP&DZ*:*@X4O?5RGE*E[Y3>S-K\=
M4/%;]<%A$CQ>U&/T/V><)9F6 YULRP&5L\UZ:R-^X2>9\ZN7:J9)DF3 GTLU
M1:"+V!E-.PZ1$ ]C.U'V'D\2_HOUAV5!7P=5M!8(R1?XIQ\@0V;(?UN'@0[_
M79@IT"=O4L"&2]Y 0/H$$SUC8PL!-=="8'4K*TUL5IL*=$13@7:Q34V:WT=/
MW0W;O15U_YP.<VUE>+/ "3F@DT8!G<(;")A%J,2@:KC>&*@!D:!FG/0JRGAW
MCOU%4.QQ'Q!V!AH*SRW)?.[1!2+VMD=(M.IA<BK4?,V\T10+([ZP !T>0&J?
M)_^@AAUKDR+?^8& #AA&/.= _%URAJ3=O[CN%B<>C3+5+J)?2-*@I9/<U? #
MZGS!NU-<"3LCZ1>2:?J#';UD41RNM'?H2?VVF%X3V*5@+0NCP8:9UHUZE72H
MD"Q-XMG5HRIIC;72ETDB()%JJ\U'"II;I2CMK+: *7:LIS*[")ETDM%F+BWN
MBI+O*M+9_-I:S7BHV!:5&+" DGUB8THN)E9VR+M5@FSO9!K8.(GB%(',$G!)
M._ED\L;H9=E<,S5%$O+->G,<WND$<%V@BEVM[X42N?"R4%%/Y!<D[/DK\_Q'
MDM&JT"BSWV:[ERB_#1.QS]U[)^M3DFTDF?/>5FA3TGT)21PV)&&^A"2:MREI
M%'"0YGX-=V<5[]*W$+2+M\"[F- 3EG4AY9_*^8G,WNG]1-]X/3*3&VR?,XA0
MNQ'V!S4?N?LY<;_L]EES)005,#1MT'W!CY:4HTO' >8H9-N_S9V_6(H$WOH$
MR\\7W+_+2] G$TQ(YCD;Z%# 5!)1.X[M042%.NA+F:)T59:58^Z%:.8'7,$O
M5OE OHJ=OV(LLIPWN;73/.NBS8BDDK!#]>.RP\4X;7Z2<8D 3OPQ][9DW-T9
M:,R=<9*XL8(2V3Q@1URADW''!VQ&GAJ>L(I ",-LN?I(M++AB<\<M+*C ;=?
M46-6Q3IC;(?G/Y'_#)T^8S\>1I-XECRCDG6-.IQ0](51C0U0<IP')T3+FK)J
M5J"> 1:F?X8(?*Y9 27%,RP$]V,TMV =5%Y!@1N[F+<NC7KRQ<D7G=R(+BUQ
MWSEN0,K+1^8@ 2.:N#'-_[=RQ++T@CDY;;6@S17N7*3BS].]MU!<-\6@O,SK
MX/XHOL3$7$%9R2VURQF(NYG"7=  A,[490$F R^YUUY\#&N/II[[+Y0JB0O2
M'V*O4O+JHZR,O<P'KK>(48)P@P6SVH:,-TZBWA($%V624@9EP:7AR,[$1]D$
M<N/5J5E^KR1BUB:1 [J;/Q )Z$D6R?^-?;P=J%(DY/%K\FWR/AZ\F9.+<^RI
M0:^XB^&SS%5\<D&]5ZQ9M;%V0(<IQUJ:^_.>.$Z$L\AQ*?&**ACE)*3\J2K,
MI1_R4C'TU07D+^5_J4E'KW_E: $Q'[I@H3I!,=Y_77G ]235I+OP_$A0U*_X
M--\PEQ="6\QM%7^#Z9Y#]/0$@3_T>5/TX3+[(_X65/T<OLMXB%[AB*L4I)/$
M6'*'K7S\24?J3\^<<+NU"?> >@,G2S,AW&_K]T9*!R)4R].Z 441)PC/EQ@7
M(9]E&G2BQS+:N&S_FUXV4OM^_@1@UR: [@%#/3. /,^NEX,+A-V0*A]N=J)"
M)Q?U!+T 8Q)<<0%4$LEPU,-3VS&?44#;A>B:6+(/AZ5OW@R[O)%X?L+>7DF3
M-W6=G[*._232FUJ!+GGHLTEGO"]J.%63*0!L+#XH-%F=\2-/$</B:9 ),Z 4
M. ^_/$9Q$*1N ;63K+!PEOSQ<<QX$)<;OB+;8_7YG/,AT_N-BKZHZD>DJV&9
M'>7HD?&,3<*3=V5+YSHR/(P1$'BM,,O%9OB7F==0F0D70N12R$NLF>\]X,V.
MO\1_KVR-=I9V))U1R4CF0)W,OI3B?27A"G(YC/-53[EVE=P/0I\*V&'6HBRF
MN]H6'6BAK9XV"*UIFV]<(&>+VP=DUM(MIQ/"25NUMM 2)VE8!BV'!6@*KDX&
M7(F=*E+$,E]=*6_7/DM^GO],!B=#[![ M>]+H;2.V,J7DR0=YZKSCBK),AEJ
MV66QO"W3=^+WP(\7I#RS[RP8H1#/7H^N-YGQB,\0+M"Q#S!#W1RC]IDLE^0U
M,A<@D %5'LX5W\\9[&HLVMJ"=!ZG7E:^#6>,P WSCDKN=R5'I9?M'LSSVD8^
M;/;?+-=7V*5&MJ2T4>J/'W22=R0W#^^X)]0\Y@38+#1,GA&?\T495@I'8OB$
M]!RG[[M2M@)<W#3HL(6-9&RO=*!%#CYK5^<:V#)]EFG@R/H[2=,9^X0K"LH'
MS!EC#HM4F% &=])WB#(Z00Q3'Y/XJ':1[UW6)LX5FEH%&(8EXA!;;\(2(BZ-
M^ &K<#&+"8S\%Z,I9IR%PI.+Z.0)E:DV3U9@1_[.%>U%9RLIX$EQ9.)3P!*^
MQ-#,(%^V907I"R +8Q9<*>_Q,S?,JG:*,P-(8!WP(PVO8C/*R5*S.UGWER?T
ML@[R)Q=LQR'+Y4X.&??N8R]8Q!?/+ELU7GF[C>Q[,R=?\:1DC.L<4Q<<.BNR
MSWH4B?T2XS]LC-]ZB?&?.,9OUHOQ&Q5C_%]YW!*[J\@$)BQHOQ5%Z355VVJK
MYO3=_B%+'TOJNV+[4I=H9QG<7O H@T^UR>!@N'I+P7^\BK-=9O3^:A+B V!4
MZGR4M"APQU6IPFEFM_XX]2/)8KB;N]ND']N]OP#&L35;520ID(XB02,*-21T
MPNPB^%C:IA6[WO/X_YQ>2BG>H 4GF=]TL1.%":6.&_&H1HVXACO&B7MB$0\@
M*@\HTY>I)0UJ=3(8OM*:2JJWNRO[^*M'U"]=%AAR/0*TH<)7N]+G*F>%HF,"
M _.)%IX\0U4J -:(%&\Z-L;KJ?[4G].0PP??'Y.BF PSQ&*3!,@84O*D[D^O
M#=@$=;10EC6$H!6)5(G"3GH\S3[D>EB'K*,9SWIEW[FR);1*U-O7=B/<*S+$
MR <R@BFP$,T]N";.=>0IYJ@J8J1K%IYM#DS6% )F,QEBG'Z,-"@0NX:V<AVC
MTC#IS&#8&D_O3P$4@]VS@V!7]W/@'=P!DRCZ*^4]&2V39:X,*1V*(EE];9 Z
MXN=TH]3WPB16,R8Q7YCDAV 28X5)LG-+Q#Q=<GZX^5*^Y\@QW68<8[UPS _!
M,>8KY4VN^CGC*N-^M.?(''8SYNB^,,</P1S6*^PMX(]D\'6--Z2M^ /?,[UF
MK&2_L-(/P4K=5\K7-:>&G.B7NC^ ,,,)595LX*ECL]#)W +]9GQUP%*Q[,!"
MMX2V34,\5^Q5)[%6U8SWBYJS\ H;4;RST;6U(EEY*KO<#%5MYQZ&9SOBV21I
M;>S"@;Q1=*7<;-@ZS6,,E8Q;D@+=U!;!E25%CFQ^(->3A?KBO7+/RD_P[V'L
MC6=4TK-VI)\QX#OTHVE2196XRD:!2[Y)<I3-6?0,O6"#9N3>?[E&GOLU<I]Q
M<8G<=*SKC])&-*L,)[+M,;4IHN)]_#+R'QA]3'*()X\$3,RS37.997I'VJQ>
MJ'K)%GYRK]B56OABEP:X\CQZX&F&/"REP\]7SU$+U+5F_#MXX=\?@7]Y*YOD
M(A57-+&6C&@5\=,JZV'&.2_KQ=XCXMKGG>ZRW>7XZNNZ0H9SR^X@HRYD4^=%
M<D!2"BS><'P>/]F]K>L-0^#: 175"4TT7\,D1GLE-E,!WED1X/Y\2,VO,O?$
M%GT4H^0S>!U7\)0B!8_Z$ I:9>-U-?3Y*75ZT_R( Y?HKOMS7&YXI!FRN;!X
M.K\8LWM)EN6#XLKFH+B0+H&HRM\2LL_:1K"&J-N0S1)$>R@&](HJ4#J9PPV2
M$@OE)\IB_>[,%UB'$6+N+I]T$3G?P=*0F0K9B'^RIZW6&A45R]SJB?L=AUK-
M1=^"I-MH\@D:/, Y5XKL&[;R3C?)TTYZ9ZVCQ/=F2WD# "*9S%YPB7M@VT-*
MO16)%-E4:W0S!"%5PJQB-9[',YZI&N23E?Y-'#^;\:3LT2@.4B]%[(DYAUCX
M%H;^R*5<D"0 *P'063LEYIA3$B"6;*"VB;U(GR/#-TQFT _<W[.0X1WAXJ7<
M$^XZ2+T!G8PWP.<3'P7A\"R>F>\Q&BPI^HIC7C_V5N<LMOZ^K2_+NAZH::PD
MR8Z@02#QS3^7SK.QG#[HNZ(YB,MS]ZE0@?YP1&$1[ GV\AP)L6'"@'[ &O),
M<XA$$Y92B#+%(MD%@N'H)\ ^2.TD1^X?-_=)HEUR%R@K=P%3OGR]16&O.'$T
M]8.T/;-LFRHE*K\6X"$ !EY7H(TPD-<W]YG%2:=.$LG4CM@A_FCAN%2%D8RZ
M#%5)N53D1D/T9$'<,A'$&SOPB*;T2C@ESQO7JH2DQU>)70,3LD?L<5]PS.=(
MS0V#^?H!"\MOQ>C?1&/(]H;B+1A=NO3$G(S"HM6,(,M:8KG!9ULU):+!]8Q%
M[.,L>@B/\[J'VLFI2*(3[=1=<+$9%JE(R4H!F\.1PZR>E-(XI]GU_5+5T! '
M+8@A=V,YBSC@PR+E6?BK9?LEV28K[0 #W!/$V,I\=<^4R@KKQBG7<O86TN6J
M;94K-4I7>B^E*X<M7>F^E*Z<N'3%JE>Z8E[LVD?=VZ-AMHQ^P*X6^91R5.:I
M8T(<AIF&?ZN9_"LF']?.!5RQPTW('JB@,2TGS6;O9Y\J:(=^K-C<^L"V@VD?
M#5,\]$.6X+O7R: %<8W2E0<(N'Z&>F##I #]@%D!U/]TN@RIJ';!<8+\A+8Q
MS4@;!2YU)U7&0?P 5@1:HY? 7)>\F#M(+)S/]VDI$?\M:H2))G@[=3ULQHZS
M!$;P3U7QXBB0WU*;$MEQE'X"'XX95\$P22 $K@Z6J(.AGA1>=7(E2HDYE-NQ
M?!7:U;0C/I,V9Z*G;J+<HRYV9*'A'K(P/U%9%^[H+S!Q%M2"=>$LTYKL[ I7
M2O$&N4<Z8[5MW9QHTLI= O T+I-I;$Y[3[7I=#>B)0"JO=PSFC,3OX5QTNDK
M:5V0^47:T2P'$UP4D"R1*]N3!6P"N.$>1&P.T,E"*\3F*H],A%F(8! R-.4C
M!8?$:OKB%73SM\U=#Z<;7"EW$IJTE720<M+DG89-=S(3C"5)I3.%0=7P1LL,
MI/ $V?$HXON K5%+QG[)X9_OAOLS$9M\M%Q2M"<-@:F+W])VT L=N*BIJ>2C
M0JN#.YX7/KI,L5*-]Y7E&QLS#S^BSKO9X=$HJ81!%WO_ NSR6 7?D,M;ZW82
M([S@M!E0\8-?*3>)%4<][M IBZ_&NCW )<T9"+%1A3,2S8TSTB.9!^[.:1J?
M!']25)9GW]6O5[D@Z3DA SUH())-%C"\[$7]6<84NTE],QO?(,BI0TX-L<:B
MZ%92A2LC<7HC9SA!$C\L?.@Y^C,:9OOH!RQRSK9NY;:TD'N)L2U'?\F^C9V$
M^ 7:!,'P7BS"[2$$D@CB 'NA$XT+<QR&L< I7^,TT,U;8P7T?J'))M.V97]L
MX)UL2[>KSL>U/:I*+$3TFK. 2T)08'DHA(N\5-IFF[^Y05;4A/#R,>]V]<AF
MPE&2<;ATTA9RBIQM$G!'NY?UZ&QP9!,(L( TW8NXO+@;6[:1<4FF91SLPF,C
MG^I@BE T)=8>,T8("IGTE#@/Z, 1ER+OFIGW@=)MMTS<FDF/[1B'TH-8X(\R
M;/\U2?SX+O::B3W^PIR'IB.)AE\#$^%91?<H9S?I2.)_)=ZD9\C\1L-4(?V0
MTS+=Z\\>-C%(1?$S-B>,AKD;Q@%S-W+7NE^$DZ((658=QH@8<-Y"#%V4<N%*
M^>?4Q=ZUV'1IS&:@V=(HO@@G*F P;^R EB*5H,P/,/)-/Q(] <=,"D(_J\DE
M7@:*\Y%<N@'!2#VPJ)^_B+#CWDA-2ML<K2J?JUYRT'MA)X%,E\Y)WK0+%\&&
MW!E+/FN =SP2]Q/HRQ0 %^?+23PQOA-S'\.T12@J;!Y")13ZT_I9N2JX2/08
MJN4?\1;!&7NA\_?D%B%-4/BFN0Z_]IHL+L7Z62>ZU.&?(5LVS)HQ#MFAS[W^
MY]0'O 'NGJE0;-J/X8 I#'+8F71')$'7U$,!7X/91JE)-$L%L\L"=QA'W)@B
M(S@3E@/)2"9NUN;"QZ29DSPR9H!QE)[%WH@LLT;8)<^[7(EJA9T-[I(5F9TD
M2JW)[6W2XX>0"PUS&HR3YS3DT@KR^6M%^0JNMX=L!65[MD+GB-D*18=\#C'9
M_DM,]K Q6?LE)GOBF&RW7DS6.E1,UFB8$60<<D25>_W&#9V'AX#)Q,F)5!N>
MJ<[8,$)N'#!"7JF=Y=UHRL;QC'V>B).\7G[$N$[2JN_U\JN<+7?'H^3A/=IY
ME5M<-G]3;I!T3UO-!>#59..4$$4 :U,R -C<%,)2>"D@)?"C6T\F T@;>LF<
M($3'']S_V=:*AD7_:Y+Z#/\P7JV-Y&T3W7-IMD]TKTNZ1BQ1N3'$QM*^E1+
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M)64#Z9ADW6V]*C:\9Q,95<9SMX5XMBZN09'J6H;:'>R6>+M <Q*PVBT$:Q?
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M>;(<7BHF7[[>)AF783S\DZ:"X2 Z6%$Z/1X"&N-#^UL JD32)?RB0[<UAV]
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MC[=W]S]H@G9:O(+8>9].4*N<H+U[I?Q]8E]<(V'P @@<OQI&V?3L\(RRLRL
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MZ0L/I9:+7?0&VT1R2\(7E.)^Z4\N,18LZJS\(4Z(XZS!OH^FCO? LOE*0UB
M1YFW,T5SW\_N'Y[::[F#>?+L<2@/6<9JW]KE5P<#^%(8O/OU0.TC>?+$R20-
M[DZSY-UIK"@A0V=&JE<X92PJ4D0ZJ2)2V&NY0/=8<0R>-B%C-^!.KDR4426R
M?$H^NB>&G(<_F(W7V;U0*NY13=B7;*NN(.3RVE>.S:51_BK9<LGM2I7?H"CL
M(V,^HTFTJKXA[XS!EWV>? MY3**4QM'',*VI]HV>:MJ[9S]MQT89/:2<%J*L
M$G$!9YQ.5S@$-ZV_]5:4LB\PLL1MZ14E.FML5 ?3&I&?C' _B&,L;RN4?_3A
M:K34OFVH/7NWKKQ/PMRMV*TV1O7A,^J 4@*!Y?/4SJ6@;_]T4K%2"&?=V*JE
M@9SKKN=$[ZWB[QAB8<,M2-5_3:AKVUW:RI*S_1-5.5*RX+[45<.V5=O8727_
M<DGNE1L*-.E_TE_880^'73Q@,&/NN%[*!"AWSQ0\NS2$,DZ#?3D,]I>@L"T<
M63H8F>=A200WG :^2A*@+S$XJ>>9&$.E5X/U:"G%)[/E@2>C^'6Z'KOA"/W0
M"D:H#XGITE+7;"!U5S#V1ASN*YSM"PM&V9O]TLC(XT4<Y.L!,4'"NMI]JZ]#
MY&_E2O>>@9^J0EAM/<2?W(\?G2C&D'G=D%OEI?-X[LFZ3]' 2^%>H#"> QA
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M!)6G]Z@$PJ*@W:Y?^$??>3:_"EGE<HY-Q2_'SO*2SVF11S/7\X=7SI6YD][
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MFO>:+FV8?E$>?3$MO%)X2%ZXYU"Z50^%:S^M(4L@)AM+QHYXLWP^QN)$E'&
ML0QI.P<3'EIRH:*L6,D(4? 0.1$2 ACCD_X<!]!WM4<#CC1,IYD_'R-5D!6!
M7!7 TBR,VDV7-]@> \_='U]#E>I-$,4ABMV0!"4SNJ]HR%2AH[GU\0/6O!?S
MYOKN_O;\_M/M^>?SJWOAY/SJ_.+3?4^Z,V_1T]1+1&R6=X;BWW0JX6+!<+!'
M>K+=AVG2_.=@QGYT?1ARE_T=#D].4&'B.4EWH^-Y0AZ40"\3+Y@AF)P'PF;A
M:?@V<O !S;ZT4&7LP%N@9,IY0EG;0O;%>6EO-J8-JQ2P_]/(<&'48EH)C1G+
M\82G !OA/H"[.)LQW^LJR5>C=;O*>5CV8MZ5AC"L0%05753E\JA@<<5&#(8V
M E,+1,721$6F#'2"ZMWW][+6/2$M[\4D1)'P/W+9+]C#QRYA87)D4G60#MY(
M(%EH)XBH[8=IRQ,\!'6"(E3)3Q+;RILQI$$J35.2AVE*[4Y3LH=I2EU,4\HG
M$\(4T?&-$\:S^]#!*HD<_96&#F3C6C=T[+FA<WM^>7Q_?B;<'-_>_T>XOSV^
MNCL^O?]T?76W=WQU)AS?XK_\3(R@GA@_&S;+O$7.N@TRU=Z[J%JL_:.[Z0O>
M[ Q<FQ/'@WQ8E$Q?2M\GP M=Q&IC2T-83N\.KD,FSMIBJ@;I]X_.INEHXC#E
MB$G"$1]9:&L@=DRR A@S23<-EUTE;^UDDU:33KHV3(-:\MR<<?*+XS^1@:"_
M.<_.BS-VA1,7*YW1LX\A?9IA7^M0%"[C\4_1=)+>?S.='!5OP6&\$%Y=[SJ1
M^2T]]"N'B;MQBT;(?05!]'8 #*:96Y29TVM5MK^+C,ZQ7/4F06UNH;WU[S?N
M&:P,<KM9NNS>T,;.&&&:2/@G^(=C[*2.XB D<<[B=*<?*ITP[E+-*\[F9O>_
MJ37/IF))HJZ4)VYOG#VNK>$8(5;E(RXW?UEH>[JTN2M#&\CYM7^G8HV;/"H?
MH8*'8T@R3'57155KY2Y%#JE3^1@IE8]1Q4LGMY3V3/_H^GAO^*72H>[ZW3B5
M:EVGDM,++Z5#E9L;+XUN;KR\1#ZYHVO)A6;]HI^6#H96]V"H_8ZVE!EEB+4,
ML9968RTIVSES)S"Y!>#\.G']E-3U^\A5=$7?R(/3WO;@+EWG(;V>>N4MWK*H
M8U=.TLO3W#F.L[R/[[4J .;XUIO!MV&IHDZY:&$KD9QNXC;)V517G$W^7/TV
MXC)&,URFZ*JHZ>7BF%T/SZRQC2'@PE' 98VSL1!W(95DEHI%LK1^)7P_(R_O
MD6DM2Z5!,AG5]2:S49\EGW7+ 9/W)1<)F;QAIFTG;/)>#JJ%U8_'KTF-"78V
M%O)-P31<R#D=+E@S2YS4.-.T%.C0ZP8ZM"$"^!XK*PU$ ,UN(H"I@YW=RH.^
MCY(!)-DUQ\ $(G76]+)'+A9OWH.*]BCP'<^;80'LQV3N&U9#F'IAM'QS#ZR?
MW+!'AA7'Y!+;9.0X/H&%F=_)!#F?W%P,4_2R6OOL11[THR33M&/']01@Q+1(
MJ !;\@SY+N8VSX,57#+3'F-I$J.7!Q1"U$5/OIC-]PZ^X56S&]VRY[,:YO@;
M\EY1VMM2K&7.HSG)K3D(+S1Q7!)U)3!A7%$[>+89@UUO:O/:PF>0'>_(#K4!
MV6%UE#UP_3]=1_@,D^H=+[U?&:77+,(QQG;; >DXP9B'H?2%RY!K\#>]YI_%
MIK$E=0U7'J1709__-77C&=0J4\JE*Q?95GUAL?Y:5[3VZZ\5:5Y_???+\>WY
M+]>79^>WJ>JX$\[_]>73_7]Z4FY=\2; ZQ#+.:AH)H<@ZLUU@-<+6M/(;OXM
MZG=@1[A! ZX!><6J8F^"'=.DEP[KO?>;MVIT;Y'C\2F*\/D[(U?!WI [_>X(
M_O&>R4?T>HV$1HL^J;E_I-D6]0[1E*;$7U@DL^#$J]K3%GSL]:[33;:2;/$&
M"R"$=TC^]I:7?0,7'9>W9NT?Z8<*95_8BDLVDM3>/X5!%,%E%".$QF2[*_96
MI_<N7>4"*Q/8(;AGUX\W"0?=9 Q4+9P ,W1%W;)%@T*\'MR/@L]@8CW.^^96
M**95>N068;,H0N2#NPDVS!?P*6,#L7B^D]M&R F7#S")#Q0IV768O&8ON>PG
M@A>1JZ3 FEX6AXLZ_5#X,DGON)G?9>*C*,KN1DG?+!3>+ KPM]G[\D25:[10
MPN7C@9\@I7#RJDH065Z90V@2N,)ER94AA FNM)#;V_*.YAFZ!"W@%^X5+\Q>
M%HW$%W*F<0#S"4;$57P@?=-@DI.)X=A'"GQ4>)_P]OL.A2OL1J80PLTX^2)[
MV0O*%RU1^.A0@!O*D3,6!6#N\BO)'5/?@JDW%IZ=5Y2^,;-[R67@A-/)_D@:
M !S'R5[J]9(Y"-_P<<,_3D%K)FXF!1+!(:P?D4;S@NT< 1&!-;SDUEOBQ)*Y
M#1B,D$!=^/:<+(4F<Q<J$N >*O>->Z3>)IL(,0*L\),.^,+M8 0M< E6BN$Y
M-N(0.7&F[4OH[('XK6H"_N&$V#V.^V/[G09^-I: V ?)B7IRHSB]4QDB1)CJ
MCPC,+QAM,")2*F5RPC&I<8C_>(S-0T^0==!ALKUH0J8G&!^A",X)YAX7BXF(
M1&E=/S<MA=RT_)9B&QZ:3+%VA'A-<@Q72&&KAA3VG"BZ?DPI?1W>0I+EBASS
MZ\<[A+&5)$/PB4;CDUG&$>D7*QNCLKI_)&.31BH7Y!=D<Q'9(-5@GSY*MCRG
M5T:=17SCK0=SN9NA,IWT4L QEB5^*DO=*'_5'L8W6&SDB>2Z;7*_-_DVB(@"
M/835]+#7MY!'?_XY_GC\](2Y$7,%48@W<_%7;3ZT(6-'N5R>_8],=3C9VU,Q
M3KI3J+B'_/3\ HP<W^XA5EKO;UVI,87CSH'@'#$(Y@Q8L%H^^858766^(_G3
M=UR@/;A^$<+(&-DNIN\$O)+5CH*JK-5Q5N',G:<0$+=H_N'\H,GK>4BRL7]D
MZN\Y2(D2SP[* QIA$#,TD& GWO+U* Z 460Y$7%$><,PJB0 712">11XT!%%
M'?'K%-N#*D&.U):&@)E *[BUQEBPKC0$C&?118/23]F\AB@B<@L*8I$<U8;U
M-:(@+*P@*$,QNU41:]6==: B;#+CB"(L]_*0V$8J8H'*,FLJ JOJ(ZPG#BES
MG=Y6$@&(UR4M<89&:3 U$7.YBY?F*3,QF'RN[Z2.6(XE+*F)51'I]Y3%VUIA
MU4FL4=36D5; 9M:1;1OO6G#T(/9&)U;;/+3=Q8E5W@A[5['ERAQ&SNDK9NUQ
M6A40HG2V63*IK/W,Y+NST-:85*8,D\I:G52F2L.DLHTFE5&J4#;(J;>7_:X8
M!RS<'8PB%+[V*!M<WAK^80(_^_&\I@QK7E*@Y:/Q'I://M;IT:%PDHU#Q8K:
M#04/&\Z>,)]>O*R_\[FG1(EC!16Y8_2^AI8VC"/--W4\&I%:L+4]!07B=65%
M0QP%4BB#XNR&03+2=1*D&9 4&=$<K4X*PAY,?X7_X^/@P2A9=UY6E]/@;AI.
MO&DDW":T$"XP$R8S52#2KT@_%C\@?Y)__ %F1X^2(;DQ]!^D!7 %)*=N2OKP
M'GEK".-M,;5;(4"Z$BRT/NHUK.7?0#U)+V*1$N>9CX+9.7(F+MZ_*#Q.0RAF
M%YS)) RP\9-.%D[L=VR=1B.8I!J Q928#@OX'F$R/6 +,B*\NC<?H5UI<6QX
M J%AX5>@,YPK#[V"79*/^(4DVG.06(@PF1MY[@NVW]):RL=IC'$B8'D(M9%)
M >/-[>G>S\?'-^GKX60&7C*J&"\!3ST$3C@&',VKH2E;<Y-QX1@#R5!A8AS!
M>2SDJD3@Z)$3/>.OO6+N\<<$Q@ P^@W;<N)>FD]*N0K;XTG$P'/Q 1\37/?
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M-03B^FT<I@)E)KHH6P96&[QVIM<0C)N@S +9:)N*J'';&U%#0&Z",3+R$6H
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M-)"FNSOI;6FM.^FYK+_K>>6=WEEAEE:_\N[;<^"A"+,EES5W'>%9'PK@6BN
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MW0F9 I&Q58@H]J9B;A4BFJ=I;1,BFMBUVP5H,^96I<I0%>+3^&C^X810?-=
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M8SSUT/5C<AX^H_@YP-8AMBOB_)04_XK0E?.""@;)+?*#5S(\/W]L.]%"R3Z
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M&<3HTGU%XT\^1LB3^^"AXRA"<70R^^S\&82GGA,54WR7CC_^$J%;]^EYM<O
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MD$-PQ[8(B_W#65UJ^Y0I>2=4>5>RTJ#R9 RN/8\MS!LZ3IYN[#CI[F##&>3
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M/;(-JM)MKABX044_I*_F%-_5H:_T_ M02P,$%     @ N(#^6)S>QB.%!P
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M)A$\)+X8RSR&AF8H BLAK3N$;"J$GG 8,DM_4C7$#IH_)#0_O#EH"A:!0+*
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M-2TQ7V-H:6YA:F]J;RYH=&W=5DMOVD 0OB/Q'T8^5(V$\0L(!,<2(=" ($5
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MP0'UDL8(Y"&MUQ@_0JI!."%6BBBZ10<%H#06<@MCTX.OCZ()GN>9;KO7Z;E
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M=MB3\_?X'Z+J:SV7+5_MYTD)GQ6E B4.1 *+5/^L;9\5>:.0Z/$DE7#-:EG
MH:LRX(>%)@'L3VK@D"2/\1= /MS'YX%)&NMG)MY),S< MEV0;\-!(:\<,N&L
M:'(<@3-%CKL"1H /U &457@H4198/-[ G"\URP3M7 /C6Y#B8,<\'EA)7%[@
M'+<;/Q+&\AQ7IBER! S./KY?ME.6,$$$5T^BS *&@4+>0\]<">\!/BP\.AR
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MV<EU;&PXV)X8-N#EI=%Y< ;DIAF#4E^9?NAF!OUPFI1[UXS_0*N]]>;.$[>
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M8DI-SY)]^C[51?/(=#K:G51WW81[_FK'[T]W8H?O54RTFO3Y_1^=V[=S)GQ
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M.+.DZ15,7L-A6<(S9%C@ %9S4H']B_:7[+^#W?R_9/^"_=O% .!@T-[QP**
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MF>,S@YJ?"I.;JH@9-[FA4WFM&L]^SXKQ#TQA)[\T>SQ7#%]+FGR>\V0I8__
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M!I"P'EYXH4"PH([*# GB+IB]-Z=F) YD\0U(Y@#% R!P"-1P8RA+ZDZ<D"0
M$9G,L]4S"H1.HDL0[G$K.)!.=QMIYJ_S$+-U=OZA#O[=KME*+?$K<$^8#^#E
M6;G=JWMQN/1,DE7_6+GI(0O#IR]>J3\D'WWI$+7?YT*4Q?[VZ ?5;0&J1@&Q
MC,NEC\#NNB(?CT[_6$>3%SYZ.M>/7<*4_R?\Q 9")4+H(-@KN0:QI7;$JP-<
M)P,N-K58M2:G)>5@MZV@Y!E:B^@YU4.V@"@8]MU^ <.$V+5\Q(F00[))J8[&
MF$"T&@C9TWCDRKV9WXFGQ4?97HM?9<F2[\V 8\_"N('0(DMN"A5PVVM^(^^"
MM2 7P*N3K6';/!\JPO:@#4C'(6.ZL4.*DZ5S& -R[71:3XPXV@1NK$IN(!9Q
M)TV ]S3JHL>71--PF^E8VPM'%G8=]/397Z?3+;Q7N;-^L&8_+[XJLNUX1["3
M;^XO'ZT+Z[L&$VR2#Q0]G77S=CMQ=1%8$EL8MCO4=05L-RX=RKXNB9/<*+QW
MM_95(<,\L+CHC@+1Y:! J!HJ*X GU54@1#_ "0K$Y_9*^28&9-DKTZ>_J5$@
M-E'%RO<C([^&R_F4-4O\M_QNNH'<#*K\R<P9EXK:+-\)>0E:NTTF".JDG]M&
MY2JAT)@GJ(S#DO)LCRN[6PF) H89I-,=K@'FO?K=P67?P+'!E@,)_?Z^CT)C
MI/DJ76S 'Y6^< _>7M C5X?^B$!F+Q+>YGA#+: KQ\R4EXB[SE:16\E'R*9
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MX</M (E\[(C$;LO&8W;I.^J:$#6O65KR43P2LX]T%IH"@CK;#?+.C%(BE.5
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M.QN!E>7>\=[,70FT520,! (?G0_<=:\\4C,;XMY+5XDBJXTP+E2U\RY<..^
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M3>:*6_U.6MV1J*0=3QS546UC4_BY(TKAM0"TS@4I*6_6Y/XAEB6Q0!242;:
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M+01S@J,#*!0(."5E19K- %\%X]SX&1;![. !C%2WQBI)0: !H71%_?KM!S(
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MUE8?.'5!FIU7D$V\MEC7^C,&<1 H<IE"JPS4^(;+?&C/S*/-B4C<"4N%#RQ
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M_@?SY^P!U2=HBO\!EN? 2,:TS_=NXU&#D]W'5C&M-G>92B2ZW!@SN()B_J6
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M7B"0(78O)N0'30P8N3B!<A Y9+W$N<L$/UDO0OZ6(RE_QKFMA=3NT.!=_2"
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M.@M^4=O[_ #K#%L(8IYP,K^^>)TK#EK&+%:#OQ9@YEX+_IGAB+S8E"8S>UM
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MOAOJ((Q(E1S@,VYP6M2>"B."@8(E+.\I17<:0VEF+*T1!C(O8V#K%:28B-@
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M'>\<75%YFAY?)\XZ^/%C#_:I>V7SD]*)BCPYY( <$HF;@(EN26MCZ)M#)8F
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MGHP3J@4> IKY$2QD.KHEK4#L-"U[4[I&^F>7G=@)C^WA:,EV$PS?=/D(+3U
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M2+6'([C?)!HT'K)'F:[SSK07F<G9:HU0([B##<*PYVS&5B>_LBC]>H6;XU2
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M+$VQ!Y'&6' !=<4/:,&?D9"]!(;%KNW]^420%B*1*)R?UT6/(K%^V%-CRVX
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M!/8V&?E/C0+O9!AT%37AR$,D"1T!GBM4(?#%,;FZ"=::0CN@NP.RTK+>+CP
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MI;!OTLX0UA3]0QOM#] \D; 9,@JQ97=9S+0SMO07XRX(NM7KK/>-"'4>]99
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MP56/YM%ZHA94T:ZE-527@B))C8L/G0TS*M/I'7O!,LK$!K)9QN'!3"+3AC"
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MX0(6CDE@=AZ 5-S*M6K\K\*"_S)U,,&>9(@MUE(3*! '1_%2@&M?D@H[WLH
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MN,.4EF!M (T,O\.E\*\!7QL,(WS02D*W :O3'#\[9J'*:+VQXNSMEN9N4H1
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M2X4PAV<M#:VE.* )PU"=^]P<!]Y\B9NW&B:RS'E6C9 5J,?MO8[8'6R$R#&
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M$P?6*WQH.##OFWJ)7]JL>X[6NT6A2RA[I+J_<Q2//^P5:F/;^CSED '*?_5
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MGRVOP1KU59YI(54N%LC?L8F,(\9%[*BKZ[AN:_*T+XL60#WS7\Z&$2<<YME
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MF'2I ?5U7.N?Z]ZFO_5R_:9P3)LQ@2;/B-H(]-[.Y ;CO%SYN:/=;3YKZ0^
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M81?<2J[,VSU"PI7>5NH8>#;E6[V>ZJE3TOSTCO[\NUWE+N=*)YFL&PM5^UD
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M9_+A>V,"=IO7?%!]]:OW_O>_?^]75NW0UAL]K%K>L'//P 55-A(8XLD&QJU
MC5RUI-G/1T4AQU2C,>TU0N<T0MI987?3L3V_7+X VP<3^Y#G1D,#64)8MX40
M]J7VYQ9#*$B@2?P^4"Z0(D$:3+X<:0HABEZ(7I0@UOF730,YT;U5T8 #=4L;
MW8 6**$S,+QO-0LYC&41KP&<0OTXSOR*]1QQWCEH-P6J<8840$M[H"43:&61
M>L^HLBVJV#9#8B'O@@I4MH];TGL%KT'_B0> &8MO?L^QWR7.IA W<B0?AO8*
MHO3 H4,B2X5#N@JT\(2MT%2>G"5[B):CN)C)\C&"PR ;1R?V&L.-)ET]K1Q$
MT.6YO@L72\+;1X23MX5>1Q(5H'HLL.FYEFT@WG_/\BL?AEOHIS+$YY@K5(!*
M1R@*SN V+T#AP"@-3CY; Q6[9UYJ/]\Q@5I=[T3:/AE9C].U\9R(#G5R:$L8
MLA^)"CTIA#EV%-D^\7PI-_"#*IJTT)RIFA<JQD ,C2B+/_N\";3,;D*E^B*?
M>*%VX#8]WC7!X?C+X)'*N;6DK7XZ0N[+['XJT$_31J03=(>;27LAE? T(VI*
M:MI&)\+UR6C2:'!KF3BFA4@3PM*9\N@ ^RR$.&%?D$!ZG!<#JG87,6\U-<Z'
M2V,@M]^'V:!%273Y+"XAWLGFG8D5832(LQD>$^X72M8IK._ZO;UEK[?@.JZ<
M(\DGFURIP8U,G(=L'N"\.$60.E<2KP\M:^,FZ6U=5(#LP;]C>@BW[ ZJ+] "
M<KH9\=2L=6;:["[P9*X_B[2JV*$;.<>4?[]TL_-;"&=R^8"#F*&'>:\1T9TL
MAE2W7J],<OKT^>Y=:_="%WO9<BU<T*5*:^<0Y]ZX"]YC+DCU(]5Q2G<='#BD
MCMN:9L4%>O 9VC/K_3?XCXY$:[TUJ#*3+$<_W0B'-%$KK=M5U%)_YD<3U*#<
M"V,R5@ ER401V.R5WR+WV5[B6;5"9R-# 90/V)R3V+$-#!FU@7*O=\E,;/P\
MQWI 9"E*\@^RCSRMF_)H<CO.5>B&,]I9"JMRL5?"@8)-;U W>Z&'F,+<KQ?]
M:3B@Y5V4CQA[XF[I;X!AZL;K'Y^<R-"",_#Q#BXC?$_3<4SPE@ZG=7-PN]L$
M.IA'!3 \F9SY2DJ2Z0&>*93+(DTULC&)(AU(F=J<+^R&)Y0BP(K2WT!$LNG)
M)9(4#\OB6[[P/0;ULZ8I>_M%P[M];TX($X<L:8U0IMD[BHEE3<BLOM+MAV78
M+9\:CPZ5->XA@>BM'R#Z4QCB;AW-4!V_DVMB-1=UV^=8APU;'#NDQ/M]7-]^
M%ZUNN8C9DU:GP%I(B?;"R'T1("?T2;)0 %OY-7H;5D4&LKERQ7]N"(8CO)WV
MM$;=<<XEC.06/6:MS"N:[?I8[EJRX)BU/+% :KA>M1)R+D6&8<.8>&R.[2\9
MM?KF\N>?CB[J&J_W+U8Y/<X[Y*K_6 O%T'!R>>@FE78I@3;R2# *+7!M>6<@
ML;BY,\KTFS%9)EYL4KKOH4F\-@N^DW?J71D8GAFM&VD&84 9-O-]\?F<2XW/
M6HWZ4[KVXXKZ?R^X^F2)<-@H($>YHK#'O9,PVE>J4FS5.-ZL#)F<"C,Q#F=G
M=IZ@3Y[T//FT+/AX;[@ZO6TC>W!B]>ABPP=+_VJ3MZ$KE$0O*U/ D"##^U,(
M2_#B14(EH'AO45>)'[#3]MS"/&K5!K2QY3_@G:V"2KH,<(D]Q":QE6[0;XZ4
M3) *J<&R8C^-FA@#7+K**6"EH1I7)H2=SZ65[A_U?Z=_YH1K2KBQDZ_HS@X\
MZUQ6?Z_%B 'Q%R^> ]BZ>@LHGF^IBR_[$'RCD"AK*L$["9T &ED?B3OP5]@D
M!.\$5%SA&32,:^PQFLR.HL*7A# XSV\N93RT*?N<$&86[\CYRIE4NEY<KNB<
M76U7<;^ ^IR,+#AWWUON$SI0Q\XT^O.JH\/KSU^<\HV:#FS</S3D<BZX[WYP
MW^XIH]%+;\BN(3$16?X;U[9KFFM;N$/5C4Z5+JB95\TE*K-G3GIE>]DFZ :P
M9R<M"[#+[N7C8?7LV-70ILE8E_!ZO<O9GUM3QEZK#:N^4FK05"T Q'KA*2+
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MP6YP7)J\:_RRNN!A^9]A^]-N6>[X1D:D*E !.TQ.(HTH3?B-IS/<]0MA"*W
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MFJ;ATDLQI'U?IUW SC<R0?)=!\8[C@ADFYZ :C%*29QO'AWR[P39P[\C$IB
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M(OMMQA@8GL2=:K['R?')%5(B0LTL0DQS<ZHL[+XK-IR)B_U9.?3W'%TCK<C
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M2C>:@QMEY>;3*G-$D.:H6Z[M^]ZLDI^'OY:>'K*S*_I>L[%\^;*35Y&4M/[
MMBRRH3@6J;YA)B&+\^&DPZ)+()J#5R,-KL'WUY*T0K-%)T>1BGSL U.B;/-
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M<HYCPS;US6W)_RSRDA^@="%VUY;4:S*'.N')"^I>2;2DI+>J;NA@P!B!?*D
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M".$%<:%G,=U"YG8@/\G8'#M)=1@G_4*PYR=@%8G;:CZ)/R" 7'.RLD@/U'G
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M_4I$.["'(O(&A[LM2R%%NQ&463!+$1VTK"GT 6WNFT^?9)/V#:YB]T)71?N
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M0LCE(PVGUJ^..R\$N#4_-A'PHM&0/C<148]-@\LOH\Q$OPV(=Q.OC!-=!<Z
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M*$ET(UF=B#]% ^'V4!N(G=6I! M_'4!*8'Z7.46>T-(Y(_,VV1$0-\4%UAB
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MZE=#F+H*E%=NP*#ASI+=XZO4#)48GR/Y0;N:*.50*N^>[_G"2P<0R0UGX=Y
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M;>L;S8,?YXB/HI^ A3X ZF/@HN4,#DV8)"LF&3?!/*@K 3J!V5*M\_,.;$9
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MD)/PGSMD /L-&RJI1DOUELE[+'\&S_!/KEF"QC:]^".7!JZ)$WD8J15N%'4
MJ\]'$RK-!*3<SG N4SZN?>%7W@3,FQ)W<92/E,/(7^INZYJPDOV;KT=9SZ4=
MN4OXJZ0\LH#)C$+^NG 4T?+@/#H?+P_7P5XL=+O^<B41L]'3;I/SGMU][8QY
M4?N#6?U*@_/%/<=_:UBAV-]LN5WMJI0UB9R!F3WA-&:51VD\7IGH\PG*]'ZM
M'O9]B4X'T9YNXE[94F<\<BIA(:@NFQ9=6VLOJ-91YQE?:DH)2FFI>EWXN':R
M;SS_R;FNH-%WR+L[<@(OE++86D+$64D'I88@,94?JKN8QB29PUSY9&5,B+O
MFTT@8L]&\NH;0RX(WFG:-_TA_7YB;V6E*9!5GVS &M"#3FQ)$GW: CC4@N>6
MWSKM6,$" ?E>O/J6BIYTK"T.V!B\#6D)(W)'\_7V@?&/,%>'> 45(M/5RE.<
M;EW4LO3 <PXC),VCKZQBJH^<3>TOHTPV*VI:AQEY0MR>L:V&+;02$)=JG^ ^
M)P3$LY24[KN%FWA7.?8[NYPJNKYY/*NH6NL%K^(";.I9O6TA)"G8'O>I*VQ]
M2#6 DM)6V$G1#JPW?6W.T'FM?N4+3QM2A%.036\0!O&R^U@W9Y.6:S_Z]M;&
MC!J7U _)FC$1#-QK12CC5,7* (((/Q$-V44OUM1^/H[NMA '@6V+J4P-=WV.
MF*FV7.84XJ&207\QJF(I/J39J_"M(O.AA<%VF_SC(&F1EJUW#*SC(7/@>YF
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M:G>/LX.>C>5]CZ-Z7Q+9BDQO!7;L]WOB74,O-8M-W3OKTUYG/*J04:?@V:;
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MK5JY>N'WA446+E^X"OE>N4QAV<K_Z4/V$5B[3(ZY:+N\W!9@T5HY^;5RLDH
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M-XSYMXM,^%[Q'Q)B66^D;\S/CU>3EM6Y9VB9M\ AW0B^S;USV(<DV:]D"_[
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M]^WHK$%A(<&HCJ87O]?GAM[D%IIEQ,@^+27$-][T)5 V5^\^V32U*S#S5+'
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M?O77>8:D#"4O,8Q?3:\1SXT8RA)4!5W<"P,WGKZV]N>\)VVV\\A ?7 8ZTS
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M2RLHY\D,D.IR8-3-$YJJ@F=)H?B((X4"?'8WZJ8K^9#6RK(,(4H]G)8?'3\
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M-4!_T)D"=%@8#G1GR2)IK?/OFW20#X:7QZ\8&H^F07\=0,P.QDP5*_,DTX>
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MYKM#FN.AL7F\:Y9G"IQ6WCH=C#3LRB1N^ 6;AXY_HZZY^9P4=G\S![ZLWZ<
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MS3Q4K9U.8P7U9NF%NLGWG$+,#MT#EIUR>5%#(ZR*[I=R^WDC4_!4D:F@^K4
M>2FW@TUQ:34TL0G:[P?D7R>V $87R79+"C='U'2;(+K1G^FRCG(LOXV*Y-U_
MU^1?RF^?G*)-[6-\+7SA;28#,0>2JY(X53):;S@#MDNF3X?*UE*[@ID<G5KL
M)L$[88W+S@)2M3(EP7_LTEMWOJY@1FMVVJ+/J!<5@1.(>^)2UN)I(-=V9@WR
M5=>/IAQ<Q0 G_BNME#S<W=2N1WBO!DYV@<V"HMD"X7%Q)\5PFMX1,7OZL8QC
M95]Q40R;](B5"=&8W.RLH/=R6T'78_'.#.&75/+EP4_Q$GR@IJLUU6Q*67A@
MV+^$1^)W<\%*,"K4[)[!](TVDRF'N<E%Y00>^.4P\+&G%TNV%M*6@J6P\8:H
M_3OC-3$F\#K@1SRD=]0LKFPIS^Z=4/!6+DU3?70>_]CJ"UL*L[^1XH;\&M,H
M'G;MTDG4DLPED1A@+CQ2HD6PK>!M[BAC-YB'G^);GIE %93<UW,O4[V5%,)"
M[<>GB1/0A@US%A\8:DOX';J3JZ!:]LNY'\QR[WBE$_WZ1.N@C:%6-(O-^4*I
MG^L],)1ZQS5F)/X&@1;!C49'P8O-JL%[#M5>I<0</#Y,,]4CW28IF&+)1<UH
M1Q^4PO#J$9>E, >BZ(4L_-20"'+B:YJY<K$66J_&[.U5,W[*7"AKUS?0(7Z=
MVSV\?QNO7JF6EC"S(W;K50:K. ?R^+[Z-SJT/O(P,<;.YK^W3XE.:#Q-S!=:
M);XYJEUPAZW/'Y&$QR\&[-@E'J26S5\-LC(79XHV<4<8'9(='2([CTP?^PVT
MH[L.S4I0&A;UIGA_U$[B!56;H_$-2ZM,E$:F?+F==JW9!GX6'J\96*_&67RJ
MF^LDP#*OEXS\D,+"J$LC5UP.B4G&P Z" Z4VWONPZ/KX#+HM2%]U;ZIJQ/O
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MM/V(Q:YD?9TW>J0(?*P\PZ^N+-:QUWZWF'2ADM@!_X9S;8Z#J:$YX4V>$Q6
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MW/<[*@!]$,ZC618Q4Q N5TUKUHV?S*Y08N6VJ7;0IFRN TH- :FH7X8V#X?
M<9\-1^BME#H[I+2JF*-*"$ GC!^59<CUQ3429%/=@%0_%!JW<'.E%-S5T-A_
M$_ZA6HV%4P#PS4="HGJ@"; Z;@_E^ZX;F&^B3HE'A1:B8,&6%$( #M7N/O3
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MWO5/#<SZKRP81:2L%%+,Q,I#\ZY1UCS/>]U*W?Y"\?H'%1F]:[:)>6\#G%<
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MJNF/NTR)-[HJ@!IDM>2!",G2(RMA)H4@7>F46V2L,03.A+BUD<)X?K5:S]Y
MMPSU8H/*$*@EW,9)PJ0_7.DT^$$>HW=>-D1YM:0 #,@7:]:VVU+9%-$3,,V4
MBC?.,/*OK1$=B'GY6"T6GHZ)Q,R<#U_W/X[CD3AORSW*#<5 R?'"5_S=XH<S
MXY*% \&\,DI^@%8^ ?]S(1N%QW8L$5@.1Q&_K*\<\:IPO?IODBTI!Q?!?+WA
M-[PR9XLR0EO.+IGDJN[#0XXZBC^SZ@D=-?^96?Y9U_W? G_,:/%_ /].KZJK
MS6:"F,RIGIV![EK5?L$O/FT,T-/"TT(+Q(L39#O20=)IU7)+!2 ^6JJK .2
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M4$L! A0#%     @ N(#^6)U1$[/R$@  Q/D  !4              ( !L!P
M &-J:F0M,C R-# S,S%?8V%L+GAM;%!+ 0(4 Q0    ( +B _EC=$%PH(UD
M !2'!0 5              "  =4O  !C:FID+3(P,C0P,S,Q7V1E9BYX;6Q0
M2P$"% ,4    " "X@/Y8K'@WKN3   #_F0D %0              @ $KB0
M8VIJ9"TR,#(T,#,S,5]L86(N>&UL4$L! A0#%     @ N(#^6,M&%A-Z5
M_GH% !4              ( !0DH! &-J:F0M,C R-# S,S%?<')E+GAM;%!+
M 0(4 Q0    ( +B _E@4#8&SS%,# /^9(0 ;              "  >^> 0!E
M83 R,#DY,3<M,C!F7V-H:6YA:F]J;RYH=&U02P$"% ,4    " "X@/Y8)8V:
MT2,'  #9(P  'P              @ 'T\@0 96$P,C Y.3$W,#%E>#$R+3%?
M8VAI;F%J;VIO+FAT;5!+ 0(4 Q0    ( +B _EB<WL8CA0<  ' S   ?
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M:F\N:'1M4$L! A0#%     @ N(#^6/TH&';K"   ;PD   L
M ( !L!\% &9I;E\P,#$N:G!G4$L! A0#%     @ N(#^6.&62'_PH $ [,H!
M  T              ( !Q"@% &EM86=E7S P,2YJ<&=02P$"% ,4    " "X
M@/Y8X]+^+ Z;   "M0  #0              @ '?R08 :6UA9V5?,# R+FIP
79U!+!08     #@ . ,0#   890<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>ea0209917-20f_chinajojo_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cjjd="http://chinajojodrugstores.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cjjd-20240331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">cjjd:StatutoryReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:RenovationInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-09-01</startDate>
            <endDate>2009-09-17</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:RenovationInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-09-17</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:ShouantangBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-20</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-20</startDate>
            <endDate>2018-04-20</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2022-04-07</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-11</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">cjjd:BankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2024-06-06</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:RenovationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntitySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:JiuzhouClinicOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntitySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:EntityNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:ShouantangBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:JiuyiTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:LinjiaMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:ShouantangClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:JiuzhenHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cjjd:HongtongServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cjjd:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cjjd:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cjjd:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:MotorVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:LandUseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:FarmlandDevelopmentCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cjjd:FarmlandDevelopmentCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhuoliServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhuoliServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:SongluPharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhejiangJiuzhouDigitalMedicineTechnologyCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:JiuzhouDigitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:KahamadiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhetongMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:ZhetongMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:SongluPharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:JiuzhouDigitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:JiuzhouDigitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cjjd:GuoshuLianrenZhejiangMedicalAndHealthManagementCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:LandUseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:SapSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cjjd:SapSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:UseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cjjd:EntityEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cjjd:OriginationDateThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:HangzhouUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cjjd:LandUseRightsAndPropertyOwnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cjjd:LandUseRightsAndPropertyOwnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:HangzhouKahamadiBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:HangzhouKahamadiBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:DirectorAndCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cjjd:DirectorAndCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-15</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2019-04-15</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-15</startDate>
            <endDate>2019-04-15</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-15</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2020-06-03</instant>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <startDate>2020-06-03</startDate>
            <endDate>2020-06-03</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:RetailDrugstoresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:OnlinePharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:DrugWholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:PrescriptionDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:OTCDrugsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:NutritionalSupplementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:TCMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:SundryProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cjjd:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cjjd:WholesaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-29</startDate>
            <endDate>2024-04-29</endDate>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-29</instant>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-11</startDate>
            <endDate>2024-06-11</endDate>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001856084</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-11</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-23752">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-23753">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-23754">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-23755">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-23756">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-23757">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-23758">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-23759">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-93">001-40724</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-100">China Jo-Jo Drugstores, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-122">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-23760">Renxin Yaju</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-23761">Building 5 Floor 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c0" id="ixv-23762">Gong Shu District</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-23763">Hangzhou City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-23764">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-23765">310008</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-145">Lei Liu</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-23766">Renxin Yaju</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-23767">Building 5 Floor 4</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c1" id="ixv-23768">Gong Shu District</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-23769">Hangzhou City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-23770">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-23771">310008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1" id="ixv-23772">+86</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-23773">571-88219579</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-186">Ordinary shares, par value $0.24 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-191">CJJD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-23774">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-23775"
      unitRef="shares">1743362</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-23776">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-23777">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-23778">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-23779">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-291">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-301">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-23780">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-23781">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-23782">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c52" id="ixv-23783">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName contextRef="c0" id="ixv-23784">YCM CPA, Inc.</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0" id="ixv-23785">6781</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-16198">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-23786" unitRef="usd">20149806</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-23787" unitRef="usd">18807936</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-23788" unitRef="usd">12724365</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-23789" unitRef="usd">12762708</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" id="ixv-23790" unitRef="usd">15824103</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-23791" unitRef="usd">14119606</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-23792" unitRef="usd">16248373</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-23793" unitRef="usd">15309100</us-gaap:InventoryNet>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="0" id="ixv-23794" unitRef="usd">2938049</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-23795" unitRef="usd">2725015</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:Supplies contextRef="c2" decimals="0" id="ixv-23796" unitRef="usd">914776</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c3" decimals="0" id="ixv-23797" unitRef="usd">142417</us-gaap:Supplies>
    <cjjd:DueFromRelatedsParties contextRef="c4" decimals="0" id="ixv-23798" unitRef="usd">313346</cjjd:DueFromRelatedsParties>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-23799" unitRef="usd">569544</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-23800" unitRef="usd">616008</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-23801" unitRef="usd">69682362</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-23802" unitRef="usd">64482790</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-23803" unitRef="usd">4906589</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-23804" unitRef="usd">5100264</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="0" id="ixv-23805" unitRef="usd">1195261</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c3" decimals="0" id="ixv-23806" unitRef="usd">1772072</us-gaap:LongTermInvestments>
    <cjjd:FarmlandAssets contextRef="c2" decimals="0" id="ixv-23807" unitRef="usd">634153</cjjd:FarmlandAssets>
    <cjjd:FarmlandAssets contextRef="c3" decimals="0" id="ixv-23808" unitRef="usd">666721</cjjd:FarmlandAssets>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-23809" unitRef="usd">1119006</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-23810" unitRef="usd">1038125</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-23811" unitRef="usd">682437</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-23812" unitRef="usd">790056</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-23813" unitRef="usd">13827360</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-23814" unitRef="usd">13924826</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" id="ixv-23815" unitRef="usd">3009922</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-23816" unitRef="usd">3195748</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-23817" unitRef="usd">25374728</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ixv-23818" unitRef="usd">26487812</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-23819" unitRef="usd">95057090</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-23820" unitRef="usd">90970602</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" id="ixv-23821" unitRef="usd">276997</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="0" id="ixv-23822" unitRef="usd">31630131</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ixv-23823" unitRef="usd">26990250</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="0" id="ixv-23824" unitRef="usd">31676335</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="0" id="ixv-23825" unitRef="usd">29255776</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent contextRef="c2" decimals="0" id="ixv-23826" unitRef="usd">2493482</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:OtherLoansPayableCurrent contextRef="c3" decimals="0" id="ixv-23827" unitRef="usd">1314919</us-gaap:OtherLoansPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-23828" unitRef="usd">1833509</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-23829" unitRef="usd">683560</us-gaap:OtherLiabilitiesCurrent>
    <cjjd:CustomerDepositCurrent contextRef="c2" decimals="0" id="ixv-23830" unitRef="usd">518241</cjjd:CustomerDepositCurrent>
    <cjjd:CustomerDepositCurrent contextRef="c3" decimals="0" id="ixv-23831" unitRef="usd">695931</cjjd:CustomerDepositCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-23832" unitRef="usd">682239</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c3" decimals="0" id="ixv-23833" unitRef="usd">1706909</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-23834" unitRef="usd">386395</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-23835" unitRef="usd">756516</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-23836" unitRef="usd">4862766</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-23837" unitRef="usd">5131373</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-23838" unitRef="usd">74360095</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-23839" unitRef="usd">66535234</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-23840" unitRef="usd">6403858</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-23841" unitRef="usd">7768216</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-23842" unitRef="usd">80763953</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-23843" unitRef="usd">74303450</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-23844"
      unitRef="usdPershares">0.24</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="2"
      id="ixv-23845"
      unitRef="usdPershares">0.24</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-23846"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-23847"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-23848"
      unitRef="shares">1743362</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-23849"
      unitRef="shares">1743362</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-23850"
      unitRef="shares">1184861</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-23851"
      unitRef="shares">1184861</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-23852" unitRef="usd">418407</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-23853" unitRef="usd">284367</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-23854"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-23855"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-23856"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-23857"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-23858" unitRef="usd">86413978</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" id="ixv-23859" unitRef="usd">83958418</us-gaap:AdditionalPaidInCapital>
    <cjjd:StatutoryReserves contextRef="c2" decimals="0" id="ixv-23860" unitRef="usd">1309109</cjjd:StatutoryReserves>
    <cjjd:StatutoryReserves contextRef="c3" decimals="0" id="ixv-23861" unitRef="usd">1309109</cjjd:StatutoryReserves>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-23862" unitRef="usd">-73507246</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-23863" unitRef="usd">-69273018</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-23864" unitRef="usd">1005762</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ixv-23865" unitRef="usd">1735135</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-23866" unitRef="usd">15640010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-23867" unitRef="usd">18014011</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" id="ixv-23868" unitRef="usd">-1346873</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c3" decimals="0" id="ixv-23869" unitRef="usd">-1346859</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-23870" unitRef="usd">14293137</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-23871" unitRef="usd">16667152</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-23872" unitRef="usd">95057090</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-23873" unitRef="usd">90970602</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-23874" unitRef="usd">154541077</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-23875" unitRef="usd">148811976</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-23876" unitRef="usd">164392555</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-23877" unitRef="usd">123432529</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c6" decimals="0" id="ixv-23878" unitRef="usd">114531512</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c7" decimals="0" id="ixv-23879" unitRef="usd">127873515</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-23880" unitRef="usd">31108548</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" id="ixv-23881" unitRef="usd">34280464</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-23882" unitRef="usd">36519040</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" id="ixv-23883" unitRef="usd">27385587</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c6" decimals="0" id="ixv-23884" unitRef="usd">29177163</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c7" decimals="0" id="ixv-23885" unitRef="usd">30876959</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-23886" unitRef="usd">7257524</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-23887" unitRef="usd">15668684</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-23888" unitRef="usd">8187176</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" id="ixv-23889" unitRef="usd">10360000</us-gaap:ShareBasedCompensation>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c7" decimals="0" id="ixv-23890" unitRef="usd">148795</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-23891" unitRef="usd">34643111</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" id="ixv-23892" unitRef="usd">55205847</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="0" id="ixv-23893" unitRef="usd">39212930</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-23894" unitRef="usd">-3534563</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" id="ixv-23895" unitRef="usd">-20925383</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-23896" unitRef="usd">-2693890</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="0" id="ixv-23897" unitRef="usd">516637</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c6" decimals="0" id="ixv-23898" unitRef="usd">883908</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c7" decimals="0" id="ixv-23899" unitRef="usd">401921</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestAndDebtExpense contextRef="c0" decimals="0" id="ixv-23900" unitRef="usd">13604</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c6" decimals="0" id="ixv-23901" unitRef="usd">65854</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c7" decimals="0" id="ixv-23902" unitRef="usd">262218</us-gaap:InterestAndDebtExpense>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="0" id="ixv-23903" unitRef="usd">-1607537</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c6" decimals="0" id="ixv-23904" unitRef="usd">-2316994</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-23905" unitRef="usd">467687</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="0" id="ixv-23906" unitRef="usd">1680087</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-23907" unitRef="usd">455547</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-23908" unitRef="usd">-4171380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-23909" unitRef="usd">-20744236</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-23910" unitRef="usd">-2098640</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-23911" unitRef="usd">62862</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="0" id="ixv-23912" unitRef="usd">394541</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="0" id="ixv-23913" unitRef="usd">1099726</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-23914" unitRef="usd">-4234242</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" id="ixv-23915" unitRef="usd">-21138777</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-23916" unitRef="usd">-3198366</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-23917" unitRef="usd">-14</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c6" decimals="0" id="ixv-23918" unitRef="usd">-252</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c7" decimals="0" id="ixv-23919" unitRef="usd">-6247</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-23920" unitRef="usd">-4234228</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-23921" unitRef="usd">-21138525</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-23922" unitRef="usd">-3192119</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-23923" unitRef="usd">-729373</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c6" decimals="0" id="ixv-23924" unitRef="usd">-2617857</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c7" decimals="0" id="ixv-23925" unitRef="usd">1534807</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" id="ixv-23926" unitRef="usd">-4963615</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c6" decimals="0" id="ixv-23927" unitRef="usd">-23756634</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="0" id="ixv-23928" unitRef="usd">-1663559</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-23929"
      unitRef="shares">1444263</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-23930"
      unitRef="shares">509828</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-23931"
      unitRef="shares">173966</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-23932"
      unitRef="shares">1444263</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-23933"
      unitRef="shares">509828</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ixv-23934"
      unitRef="shares">173966</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-23935"
      unitRef="usdPershares">-2.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-23936"
      unitRef="usdPershares">-41.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-23937"
      unitRef="usdPershares">-18.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-23938"
      unitRef="usdPershares">-2.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-23939"
      unitRef="usdPershares">-41.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-23940"
      unitRef="usdPershares">-18.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-23941"
      unitRef="shares">173966</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-23942" unitRef="usd">41752</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c9" decimals="0" id="ixv-23943" unitRef="usd">66516033</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c10" decimals="0" id="ixv-23944" unitRef="usd">1309109</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-23945" unitRef="usd">-44942374</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" id="ixv-23946" unitRef="usd">2818185</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" id="ixv-23947" unitRef="usd">-1340360</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" id="ixv-23948" unitRef="usd">24402345</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c18" decimals="0" id="ixv-23949" unitRef="usd">-3192119</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c20" decimals="0" id="ixv-23950" unitRef="usd">-6247</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-23951" unitRef="usd">-3198366</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c19" decimals="0" id="ixv-23952" unitRef="usd">1534807</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c7" decimals="0" id="ixv-23953" unitRef="usd">1534807</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c21"
      decimals="0"
      id="ixv-23954"
      unitRef="shares">173966</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="0" id="ixv-23955" unitRef="usd">41752</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="0" id="ixv-23956" unitRef="usd">66516033</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c23" decimals="0" id="ixv-23957" unitRef="usd">1309109</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="0" id="ixv-23958" unitRef="usd">-48134493</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="0" id="ixv-23959" unitRef="usd">4352992</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="0" id="ixv-23960" unitRef="usd">-1346607</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="0" id="ixv-23961" unitRef="usd">22738786</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c28"
      decimals="0"
      id="ixv-23962"
      unitRef="shares">402</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit contextRef="c28" decimals="0" id="ixv-23963" unitRef="usd">97</cjjd:StockIssuedDuringPeriodValueForReverseStockSplit>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit contextRef="c29" decimals="0" id="ixv-23964" unitRef="usd">-97</cjjd:StockIssuedDuringPeriodValueForReverseStockSplit>
    <cjjd:StockIssuedDuringPeriodShareSaleOfStockAndWarrants
      contextRef="c28"
      decimals="0"
      id="ixv-23965"
      unitRef="shares">297500</cjjd:StockIssuedDuringPeriodShareSaleOfStockAndWarrants>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants contextRef="c28" decimals="0" id="ixv-23966" unitRef="usd">71400</cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants contextRef="c29" decimals="0" id="ixv-23967" unitRef="usd">7253600</cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants contextRef="c6" decimals="0" id="ixv-23968" unitRef="usd">7325000</cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c28"
      decimals="0"
      id="ixv-23969"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c28" decimals="0" id="ixv-23970" unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c29" decimals="0" id="ixv-23971" unitRef="usd">10324000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c6" decimals="0" id="ixv-23972" unitRef="usd">10360000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c28"
      decimals="0"
      id="ixv-23973"
      unitRef="shares">562993</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c28" decimals="0" id="ixv-23974" unitRef="usd">135118</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c29" decimals="0" id="ixv-23975" unitRef="usd">-135118</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ProfitLoss contextRef="c31" decimals="0" id="ixv-23976" unitRef="usd">-21138525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c33" decimals="0" id="ixv-23977" unitRef="usd">-252</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" id="ixv-23978" unitRef="usd">-21138777</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c32" decimals="0" id="ixv-23979" unitRef="usd">-2617857</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c6" decimals="0" id="ixv-23980" unitRef="usd">-2617857</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c34"
      decimals="0"
      id="ixv-23981"
      unitRef="shares">1184861</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="0" id="ixv-23982" unitRef="usd">284367</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="0" id="ixv-23983" unitRef="usd">83958418</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c36" decimals="0" id="ixv-23984" unitRef="usd">1309109</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c37" decimals="0" id="ixv-23985" unitRef="usd">-69273018</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c38" decimals="0" id="ixv-23986" unitRef="usd">1735135</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c39" decimals="0" id="ixv-23987" unitRef="usd">-1346859</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" id="ixv-23988" unitRef="usd">16667152</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c40"
      decimals="0"
      id="ixv-23989"
      unitRef="shares">60501</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit contextRef="c40" decimals="0" id="ixv-23990" unitRef="usd">14520</cjjd:StockIssuedDuringPeriodValueForReverseStockSplit>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit contextRef="c41" decimals="0" id="ixv-23991" unitRef="usd">-14520</cjjd:StockIssuedDuringPeriodValueForReverseStockSplit>
    <cjjd:StockIssuedDuringPeriodShareSaleOfStockAndWarrants
      contextRef="c40"
      decimals="0"
      id="ixv-23992"
      unitRef="shares">498000</cjjd:StockIssuedDuringPeriodShareSaleOfStockAndWarrants>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants contextRef="c40" decimals="0" id="ixv-23993" unitRef="usd">119520</cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants contextRef="c41" decimals="0" id="ixv-23994" unitRef="usd">2470080</cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants contextRef="c0" decimals="0" id="ixv-23995" unitRef="usd">2589600</cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants>
    <us-gaap:ProfitLoss contextRef="c43" decimals="0" id="ixv-23996" unitRef="usd">-4234228</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c45" decimals="0" id="ixv-23997" unitRef="usd">-14</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-23998" unitRef="usd">-4234242</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c44" decimals="0" id="ixv-23999" unitRef="usd">-729373</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c0" decimals="0" id="ixv-24000" unitRef="usd">-729373</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c46"
      decimals="0"
      id="ixv-24001"
      unitRef="shares">1743362</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-24002" unitRef="usd">418407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" id="ixv-24003" unitRef="usd">86413978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-24004" unitRef="usd">1309109</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-24005" unitRef="usd">-73507246</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-24006" unitRef="usd">1005762</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" id="ixv-24007" unitRef="usd">-1346873</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-24008" unitRef="usd">14293137</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-24009" unitRef="usd">-4234242</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" id="ixv-24010" unitRef="usd">-21138777</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="0" id="ixv-24011" unitRef="usd">-3198366</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="0" id="ixv-24012" unitRef="usd">790449</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c6" decimals="0" id="ixv-24013" unitRef="usd">718002</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c7" decimals="0" id="ixv-24014" unitRef="usd">1256491</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c0" decimals="0" id="ixv-24015" unitRef="usd">-249257</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c6" decimals="0" id="ixv-24016" unitRef="usd">7579886</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c7" decimals="0" id="ixv-24017" unitRef="usd">939720</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" id="ixv-24018" unitRef="usd">4594172</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-24019" unitRef="usd">-107251</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c7" decimals="0" id="ixv-24020" unitRef="usd">148795</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" id="ixv-24021" unitRef="usd">10360000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="0" id="ixv-24022" unitRef="usd">-1607537</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c6" decimals="0" id="ixv-24023" unitRef="usd">-2316994</us-gaap:GainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-24024" unitRef="usd">1804440</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c6" decimals="0" id="ixv-24025" unitRef="usd">2531755</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c7" decimals="0" id="ixv-24026" unitRef="usd">2657283</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInNotesReceivables contextRef="c0" decimals="0" id="ixv-24027" unitRef="usd">-19943</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInNotesReceivables contextRef="c6" decimals="0" id="ixv-24028" unitRef="usd">20861</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInNotesReceivables contextRef="c7" decimals="0" id="ixv-24029" unitRef="usd">-40260</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-24030" unitRef="usd">1699621</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c6" decimals="0" id="ixv-24031" unitRef="usd">522550</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c7" decimals="0" id="ixv-24032" unitRef="usd">-1523098</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c0" decimals="0" id="ixv-24033" unitRef="usd">672830</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c6" decimals="0" id="ixv-24034" unitRef="usd">958671</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c7" decimals="0" id="ixv-24035" unitRef="usd">1927692</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c0" decimals="0" id="ixv-24036" unitRef="usd">839221</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c6" decimals="0" id="ixv-24037" unitRef="usd">-201984</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <us-gaap:IncreaseDecreaseInPrepaidSupplies contextRef="c7" decimals="0" id="ixv-24038" unitRef="usd">171783</us-gaap:IncreaseDecreaseInPrepaidSupplies>
    <cjjd:IncreaseDecreaseInLongTermDeposit contextRef="c0" decimals="0" id="ixv-24039" unitRef="usd">-132568</cjjd:IncreaseDecreaseInLongTermDeposit>
    <cjjd:IncreaseDecreaseInLongTermDeposit contextRef="c6" decimals="0" id="ixv-24040" unitRef="usd">589653</cjjd:IncreaseDecreaseInLongTermDeposit>
    <cjjd:IncreaseDecreaseInLongTermDeposit contextRef="c7" decimals="0" id="ixv-24041" unitRef="usd">-159508</cjjd:IncreaseDecreaseInLongTermDeposit>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="0" id="ixv-24042" unitRef="usd">-19076</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="0" id="ixv-24043" unitRef="usd">-331426</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="0" id="ixv-24044" unitRef="usd">-376134</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="0" id="ixv-24045" unitRef="usd">-69539</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c6" decimals="0" id="ixv-24046" unitRef="usd">30483</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c7" decimals="0" id="ixv-24047" unitRef="usd">-62394</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties contextRef="c0" decimals="0" id="ixv-24048" unitRef="usd">317828</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="0" id="ixv-24049" unitRef="usd">6002186</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c6" decimals="0" id="ixv-24050" unitRef="usd">1765488</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="0" id="ixv-24051" unitRef="usd">-3558050</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-24052" unitRef="usd">868975</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c6" decimals="0" id="ixv-24053" unitRef="usd">-1341447</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c7" decimals="0" id="ixv-24054" unitRef="usd">99132</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <cjjd:IncreaseDecreaseInCustomerDeposit contextRef="c0" decimals="0" id="ixv-24055" unitRef="usd">-144761</cjjd:IncreaseDecreaseInCustomerDeposit>
    <cjjd:IncreaseDecreaseInCustomerDeposit contextRef="c6" decimals="0" id="ixv-24056" unitRef="usd">-1035456</cjjd:IncreaseDecreaseInCustomerDeposit>
    <cjjd:IncreaseDecreaseInCustomerDeposit contextRef="c7" decimals="0" id="ixv-24057" unitRef="usd">678601</cjjd:IncreaseDecreaseInCustomerDeposit>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c0" decimals="0" id="ixv-24058" unitRef="usd">-948277</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c6" decimals="0" id="ixv-24059" unitRef="usd">433054</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c7" decimals="0" id="ixv-24060" unitRef="usd">1162084</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-24061" unitRef="usd">-6191522</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-24062" unitRef="usd">-3155439</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="0" id="ixv-24063" unitRef="usd">-3283513</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ixv-24064" unitRef="usd">-5385973</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-24065" unitRef="usd">330677</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="0" id="ixv-24066" unitRef="usd">118272</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="0" id="ixv-24067" unitRef="usd">89960</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c0" decimals="0" id="ixv-24068" unitRef="usd">1116212</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireInterestInJointVenture contextRef="c6" decimals="0" id="ixv-24069" unitRef="usd">4379</us-gaap:PaymentsToAcquireInterestInJointVenture>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c0" decimals="0" id="ixv-24070" unitRef="usd">66973</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c6" decimals="0" id="ixv-24071" unitRef="usd">12774</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c7" decimals="0" id="ixv-24072" unitRef="usd">7012</us-gaap:PaymentsToAcquireIntangibleAssets>
    <cjjd:AdditionsToLeaseholdImprovements contextRef="c0" decimals="0" id="ixv-24073" unitRef="usd">525988</cjjd:AdditionsToLeaseholdImprovements>
    <cjjd:AdditionsToLeaseholdImprovements contextRef="c6" decimals="0" id="ixv-24074" unitRef="usd">180672</cjjd:AdditionsToLeaseholdImprovements>
    <cjjd:AdditionsToLeaseholdImprovements contextRef="c7" decimals="0" id="ixv-24075" unitRef="usd">209166</cjjd:AdditionsToLeaseholdImprovements>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-24076" unitRef="usd">-2039850</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="0" id="ixv-24077" unitRef="usd">-316097</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="0" id="ixv-24078" unitRef="usd">-306138</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromOtherShortTermDebt contextRef="c0" decimals="0" id="ixv-24079" unitRef="usd">1116212</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="c0" decimals="0" id="ixv-24080" unitRef="usd">837159</us-gaap:RepaymentsOfOtherShortTermDebt>
    <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="c7" decimals="0" id="ixv-24081" unitRef="usd">779059</us-gaap:RepaymentsOfOtherShortTermDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c6" decimals="0" id="ixv-24082" unitRef="usd">1811558</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-24083" unitRef="usd">2613965</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="c0" decimals="0" id="ixv-24084" unitRef="usd">56875403</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c6" decimals="0" id="ixv-24085" unitRef="usd">57965013</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c7" decimals="0" id="ixv-24086" unitRef="usd">65370181</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c0" decimals="0" id="ixv-24087" unitRef="usd">52997171</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c6" decimals="0" id="ixv-24088" unitRef="usd">60273598</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c7" decimals="0" id="ixv-24089" unitRef="usd">57829269</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" id="ixv-24090" unitRef="usd">2589600</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c6" decimals="0" id="ixv-24091" unitRef="usd">7325000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-24092" unitRef="usd">1257406</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c6" decimals="0" id="ixv-24093" unitRef="usd">43785</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-24094" unitRef="usd">689010</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <cjjd:RepaymentOfOtherPayablesrelatedParties contextRef="c6" decimals="0" id="ixv-24095" unitRef="usd">882486</cjjd:RepaymentOfOtherPayablesrelatedParties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-24096" unitRef="usd">8004291</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="0" id="ixv-24097" unitRef="usd">2366156</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="0" id="ixv-24098" unitRef="usd">4836898</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-24099" unitRef="usd">-1505475</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="0" id="ixv-24100" unitRef="usd">-2535479</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="0" id="ixv-24101" unitRef="usd">1522146</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-24102" unitRef="usd">1303527</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="0" id="ixv-24103" unitRef="usd">-3768933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="0" id="ixv-24104" unitRef="usd">666933</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-24105" unitRef="usd">31570644</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="0" id="ixv-24106" unitRef="usd">35339577</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c14" decimals="0" id="ixv-24107" unitRef="usd">34672644</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-24108" unitRef="usd">32874171</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-24109" unitRef="usd">31570644</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="0" id="ixv-24110" unitRef="usd">35339577</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c0" decimals="0" id="ixv-24111" unitRef="usd">149023</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c6" decimals="0" id="ixv-24112" unitRef="usd">63668</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c7" decimals="0" id="ixv-24113" unitRef="usd">3955</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-24114" unitRef="usd">13604</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="0" id="ixv-24115" unitRef="usd">64943</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="0" id="ixv-24116" unitRef="usd">262218</us-gaap:InterestPaidNet>
    <cjjd:CashlessExerciseOfWarrants contextRef="c6" decimals="0" id="ixv-24117" unitRef="usd">135118</cjjd:CashlessExerciseOfWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-19094">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 &#x2013; DESCRIPTION OF BUSINESS AND
ORGANIZATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;China Jo-Jo Drugstores, Inc. (&#x201c;Jo-Jo Drugstores&#x201d;
or the &#x201c;Company&#x201d;), was incorporated in Nevada on December 19, 2006, originally under the name &#x201c;Kerrisdale Mining Corporation&#x201d;.
On September 24, 2009, the Company changed its name to &#x201c;China Jo-Jo Drugstores, Inc.&#x201d; in connection with a share exchange
transaction as described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 17, 2009, the Company completed a
share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (&#x201c;Renovation&#x201d;), whereby 7,900,000 shares of ordinary
shares were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share
exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization
and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the
accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date
of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment
Management Co., Ltd. (&#x201c;Jiuxin Management&#x201d;), Zhejiang Shouantang Medical Technology Co., Ltd. (&#x201c;Shouantang Technology&#x201d;)
and Hangzhou Jiutong Medical Technology Co., Ltd (&#x201c;Jiutong Medical&#x201d;), Hangzhou Jiuyi Medical Technology Co. Ltd. (&#x201c;Jiuyi
Technology&#x201d;), its wholly-owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an online and offline retailer
and wholesale distributor of pharmaceutical and other healthcare products in the People&#x2019;s Republic of China (&#x201c;China&#x201d;
or the &#x201c;PRC&#x201d;). The Company&#x2019;s offline retail business is comprised primarily of pharmacies, which are operated by Hangzhou
Jiuzhou Grand Pharmacy Chain Co., Ltd. (&#x201c;Jiuzhou Pharmacy&#x201d;), a company that the Company controls through contractual arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s offline retail business also
includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (&#x201c;Jiuzhou Clinic&#x201d;)
and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (&#x201c;Jiuzhou Service&#x201d;), both of which are also controlled by
the Company through contractual arrangements. In May 2014, Shouantang Technology established Hangzhou Shouantang Bio-technology Co., Ltd.
(&#x201c;Shouantang Bio&#x201d;). In May 2016, Shouantang Bio set up and held 49% of Hangzhou Kahamadi Bio-technology Co., Ltd. (&#x201c;Kahamadi
Bio&#x201d;), a joint venture specializing in brand name development for nutritional supplements. In 2018, Jiuzhou Pharmacy invested a
total of $741,540 (RMB5,100,000) in and held 51% of Zhejiang Jiuzhou Linjia Medical Investment and Management Co. Ltd (&#x201c;Linjia Medical&#x201d;),
which has ceased its operation as of March 31, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company currently conducts its online retail
pharmacy business through Jiuzhou Pharmacy, which holds the Company&#x2019;s online pharmacy license. On September 10, 2015, Renovation
set up Jiuyi Technology to provide additional technical support such as webpage development to our online pharmacy business. In November
2015, the technical support function was transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s wholesale business is primarily
conducted through Zhejiang Jiuxin Medicine Co., Ltd. (&#x201c;Jiuxin Medicine&#x201d;), which is licensed to distribute prescription and
non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. On April 20,
2018, 10% of Jiuxin Medicine shares were sold to Hangzhou Kangzhou Biotech Co. Ltd. for a total proceeds of $79,625 (RMB 507,760). On
January 29, 2021, The Company bought back the 10% of Jiuxin Medicine for a total price of $77,410(RMB&lt;span style="-sec-ix-hidden: hidden-fact-100"&gt;507, 760&lt;/span&gt;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s herb farming business is conducted
by Hangzhou Qianhong Agriculture Development Co., Ltd. (&#x201c;Qianhong Agriculture&#x201d;), a wholly-owned subsidiary of Jiuxin Management.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 30, 2021, China Jo-Jo Drugstores, Inc.,
a Nevada corporation (&#x201c;CJJD&#x201d;), completed a corporate reorganization (the &#x201c;Reorganization&#x201d; or &#x201c;Redomicile
Merger&#x201d;), resulting in China Jo-Jo Drugstores Holdings, Inc., a company incorporated under the laws of the Cayman Islands (&#x201c;CJJD
Cayman&#x201d;), becoming the publicly held parent company of CJJD, with CJJD merged with and into CJJD Cayman, pursuant to the Agreement
and Plan of Merger, dated as of May 14, 2021, by and between CJJD and CJJD Cayman (the &#x201c;Merger Agreement&#x201d;). Prior to the Reorganization,
shares of CJJD&#x2019;s ordinary shares were registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the
&#x201c;Exchange Act&#x201d;), and listed on the NASDAQ Capital Market under the symbol &#x201c;CJJD.&#x201d; As a result of the Reorganization,
each issued and outstanding share of CJJD&#x2019;s ordinary shares was converted into the right to receive one CJJD Cayman ordinary share,
which shares were issued by CJJD Cayman as part of the Reorganization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 7, 2022, the Company effected a 1-for-12&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 12 shares of the Company&#x2019;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#x2019;s percentage
interest in the Company&#x2019;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 1, 2024, the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 20 shares of the Company&#x2019;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#x2019;s percentage
interest in the Company&#x2019;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
reflect the activities of the Company and each of the following entities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity Name&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Background&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Renovation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuxin&#160;Management&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#x201c;WFOE&#x201d;) under PRC law &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shouantang Technology&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Qianhong Agriculture&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou&#160;Pharmacy (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates the &#x201c;Jiuzhou Grand Pharmacy&#x201d; stores in Hangzhou&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&#160;by&#160;contractual arrangements (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou&#160;Clinic (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&#160;by&#160;contractual arrangements (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#x2019;s stores&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou&#160;Service (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#x2019;s stores&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&#160;by&#160;contractual arrangements (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity Name&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Background&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuxin Medicine&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiutong Medical&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Currently has no operation&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shouantang Bio&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuyi Technology&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kahamadi Bio&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Linjia Medical&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates local clinics&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shouantang Clinic&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td rowspan="8" style="width: 48%"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates local clinics&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td rowspan="8" style="width: 25%"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhen Health&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hongtong Service&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Daily service&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#x201c;Owners&#x201d;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#x2019;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#x201c;VIE&#x201d;) under the accounting standards of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Liquidity and capital resources&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2024, we had cash of approximately
$32.9 million and a working capital deficit of $4.7 million. During the year ended March 31, 2024, we had a net loss of approximately
$4.2 million and net cash used in operating activities were $2.9 million. However, non-cash expenses such as investment loss accounts
for approximately $1.6 million, respectively. Excluding these non-cash expenses, the net loss is approximately $2.6 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounts have been prepared
in accordance with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) on a going concern
basis. The going concern basis assumes that assets are realized and liabilities are extinguished in the ordinary course of business at
amounts disclosed in the financial statements. The Company&#x2019;s ability to continue as a going concern depends upon aligning its sources
of funding (debt and equity) with its expenditure requirements and repayment of the short-term debts as and when they become due.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In order to meet its capital demand, the Company
strived to raise funds in the capital market, increase its credit line from the local banks, and improve its store performance in the
near future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 26, 2023, the Company closed a private
placement of 498,000 shares of ordinary shares at $5.20 per share with gross proceeds of $2,589,600. On April 29, 2024, the Company entered
into certain Share Purchase Agreements (the &#x201c;Purchase Agreement&#x201d;) with several investors (the &#x201c;Investors&#x201d;) pursuant
to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering,
an aggregate of 900,000 ordinary shares (the &#x201c;Shares&#x201d;), par value $0.24 per share, of the Company (&#x201c;Ordinary Shares&#x201d;),
at a purchase price of $1.70 per Share (the &#x201c;Purchase Price&#x201d;), for aggregate gross proceeds to the Company of $1,530,000.
On May 10, 2024, the Company entered into certain Share Purchase Agreements (the &#x201c;Purchase Agreement&#x201d;) with several investors
(the &#x201c;Investors&#x201d;) pursuant to which the Company agreed to sell to the Investors, and the Investors agreed to purchase from
the Company, in a registered direct offering, an aggregate of 1,610,000 ordinary shares (the &#x201c;Shares&#x201d;), par value $0.24 per
share, of the Company (&#x201c;Ordinary Shares&#x201d;), at a purchase price of $1.70 per Share (the &#x201c;Purchase Price&#x201d;), for
aggregate gross proceeds to the Company of $2,737,000. On June 11, 2024, the Company entered into certain Share Purchase Agreements (the
&#x201c;Purchase Agreement&#x201d;) with several investors (the &#x201c;Investors&#x201d;) pursuant to which the Company agreed to sell to
the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an aggregate of 1,980,000 ordinary
shares (the &#x201c;Shares&#x201d;), par value $0.24 per share, of the Company (&#x201c;Ordinary Shares&#x201d;), at a purchase price of $1.70
per Share (the &#x201c;Purchase Price&#x201d;), for an aggregate gross proceeds to the Company of $3,366,000. The private placements raised
a total gross proceeds of $10,222,600.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a credit line agreement from a
local bank as described in detail in Note 15 and Note 16. As of March 31, 2024, approximately $1.55 million of the aforementioned bank
credit line was available for further borrowing. On June 6, 2024, bank credit line increased by $5.54 million (RMB 40,000,000). As the
economy growth slows down, the national interest continues to decrease. local banks are encouraged to provide low interest rate loans
to local enterprises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has also obtained additional government
insurance reimbursement certificates for its stores opened in the last two years. In a mature store, nearly half of the revenue are generated
by customers utilizing the government insurance program. With these certificates, mature stores are able to attract more customers who
are eligible for the insurance program, and its sales may significantly increase in the next 12 months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based on the above factors, the Company believes
it can support its operations for at least the next 12 months.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c53"
      decimals="0"
      id="ixv-24118"
      unitRef="shares">7900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c54" decimals="2" id="ixv-24119" unitRef="pure">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c55" decimals="2" id="ixv-24120" unitRef="pure">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedAtCost contextRef="c56" decimals="0" id="ixv-24121" unitRef="usd">741540</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost contextRef="c56" decimals="0" id="ixv-24122" unitRef="cny">5100000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c57" decimals="2" id="ixv-24123" unitRef="pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c58" decimals="2" id="ixv-24124" unitRef="pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c59" decimals="0" id="ixv-24125" unitRef="usd">79625</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c59" decimals="0" id="ixv-24126" unitRef="cny">507760</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <cjjd:SharesRepurchasePercentage
      contextRef="c59"
      decimals="0"
      id="ixv-24127"
      unitRef="shares">10</cjjd:SharesRepurchasePercentage>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue contextRef="c60" decimals="0" id="ixv-24128" unitRef="usd">77410</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="c61"
      decimals="0"
      id="ixv-24129"
      unitRef="shares">12</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c61"
      decimals="0"
      id="ixv-24130"
      unitRef="shares">12</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c62"
      decimals="0"
      id="ixv-24131"
      unitRef="shares">20</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c62"
      decimals="0"
      id="ixv-24132"
      unitRef="shares">20</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-24133">The accompanying consolidated financial statements
reflect the activities of the Company and each of the following entities:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity Name&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Background&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Renovation&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuxin&#160;Management&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#x201c;WFOE&#x201d;) under PRC law &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shouantang Technology&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Qianhong Agriculture&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou&#160;Pharmacy (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates the &#x201c;Jiuzhou Grand Pharmacy&#x201d; stores in Hangzhou&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&#160;by&#160;contractual arrangements (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou&#160;Clinic (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&#160;by&#160;contractual arrangements (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#x2019;s stores&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou&#160;Service (1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#x2019;s stores&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE&#160;by&#160;contractual arrangements (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity Name&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Background&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%; border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuxin Medicine&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiutong Medical&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Currently has no operation&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shouantang Bio&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuyi Technology&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kahamadi Bio&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="padding-left: 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Linjia Medical&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates local clinics&lt;/p&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shouantang Clinic&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td rowspan="8" style="width: 48%"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates local clinics&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td rowspan="8" style="width: 25%"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhen Health&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million&#160;&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="width: 25%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hongtong Service&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 48%"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#x25cf;&#160;&#160;&#160;&#160;&#160;Daily service&lt;/p&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 25%"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;VIE by contractual arrangements as a controlled subsidiary of Jiuzhou Pharmacy (2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#x201c;Owners&#x201d;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#x2019;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#x201c;VIE&#x201d;) under the accounting standards of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c75" id="ixv-19151">&#x25cf;&#160;&#160;&#160;&#160;&#160;Incorporated in Hong Kong SAR on September 2, 2008</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c75" decimals="2" id="ixv-24134" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c76" id="ixv-19167">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on October 14, 2008 &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Deemed a wholly foreign owned enterprise (&#x201c;WFOE&#x201d;) under PRC law &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of $30.0 million</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c76" decimals="2" id="ixv-24135" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c77" id="ixv-19187">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Deemed a WFOE under PRC law &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Invests and finances the working capital of Quannuo Technology</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c77" decimals="2" id="ixv-24136" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c78" id="ixv-19209">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on August 10, 2010 by Jiuxin&#160;Management &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Carries out herb farming business</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c78" decimals="2" id="ixv-24137" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c79" id="ixv-19229">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 9, 2003 &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 5 million fully paid &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Operates the &#x201c;Jiuzhou Grand Pharmacy&#x201d; stores in Hangzhou</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c80" id="ixv-19249">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC as a general partnership on&#160;October 10, 2003</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c81" id="ixv-19264">&#x25cf;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#x2019;s stores</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c82" id="ixv-19279">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on November 2, 2005 &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 500,000 fully paid &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Operates a medical clinic adjacent to one of Jiuzhou&#160;Pharmacy&#x2019;s stores</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c83" id="ixv-19319">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in PRC on December 31, 2003 &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Acquired by Jiuzhou Pharmacy in August 2011 &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million fully paid &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Carries out pharmaceutical distribution services</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c84" id="ixv-19341">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on December 20, 2011 by Renovation &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered&#160;capital of $2.6 million fully paid &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Currently has no operation</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c84" decimals="2" id="ixv-24138" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c85" id="ixv-19361">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in October, 2014 by Shouantang Technology &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Shouantang Technology &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 1,000,000 fully paid &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Sells nutritional supplements under its own brand name</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c85" decimals="2" id="ixv-24139" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c86" id="ixv-19383">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC on September 10, 2015 &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Renovation &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Technical support to online pharmacy</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c86" decimals="2" id="ixv-24140" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c87" id="ixv-19403">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 2016 &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;49% held by Shouantang Bio &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 10 million &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Develop brand name for nutritional supplements</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c87" decimals="2" id="ixv-24141" unitRef="pure">0.49</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c88" id="ixv-19425">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 27, 2017 &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;51% held by Jiuzhou Pharmacy &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 20 million &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Operates local clinics</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c89" id="ixv-19460">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in September 2, 2022 &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Operates local clinics</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c90" id="ixv-19503">&#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in November 11, 2022 &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c91" id="ixv-19520">&#x25cf;&#160;&#160;&#160;&#160;&#160;Health care delivery &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Established in the PRC in May 12, 2022 &#160; &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;100% held by Jiuzhou Pharmacy&#160; &#160; &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Registered capital of RMB 0.1 million &#160; &#x25cf;&#160;&#160;&#160;&#160;&#160;Daily service</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="-5" id="ixv-24143" unitRef="usd">32900000</us-gaap:CashEquivalentsAtCarryingValue>
    <cjjd:WorkingCapitalDeficit contextRef="c63" decimals="-5" id="ixv-24144" unitRef="usd">4700000</cjjd:WorkingCapitalDeficit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-5" id="ixv-24145" unitRef="usd">-4200000</us-gaap:ProfitLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c64" decimals="-5" id="ixv-24146" unitRef="usd">-2900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c0" decimals="-5" id="ixv-24147" unitRef="usd">1600000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:NetIncomeLoss contextRef="c64" decimals="-5" id="ixv-24148" unitRef="usd">2600000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="c65"
      decimals="0"
      id="ixv-24149"
      unitRef="shares">498000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c65"
      decimals="2"
      id="ixv-24150"
      unitRef="usdPershares">5.2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c66" decimals="0" id="ixv-24151" unitRef="usd">2589600</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockSharesIssued
      contextRef="c67"
      decimals="0"
      id="ixv-24152"
      unitRef="shares">900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c67"
      decimals="2"
      id="ixv-24153"
      unitRef="usdPershares">0.24</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c67"
      decimals="2"
      id="ixv-24154"
      unitRef="usdPershares">1.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c68" decimals="0" id="ixv-24155" unitRef="usd">1530000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockSharesIssued
      contextRef="c69"
      decimals="0"
      id="ixv-24156"
      unitRef="shares">1610000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c69"
      decimals="2"
      id="ixv-24157"
      unitRef="usdPershares">0.24</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c69"
      decimals="2"
      id="ixv-24158"
      unitRef="usdPershares">1.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c70" decimals="0" id="ixv-24159" unitRef="usd">2737000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CommonStockSharesIssued
      contextRef="c71"
      decimals="0"
      id="ixv-24160"
      unitRef="shares">1980000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c71"
      decimals="2"
      id="ixv-24161"
      unitRef="usdPershares">0.24</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c71"
      decimals="2"
      id="ixv-24162"
      unitRef="usdPershares">1.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c72" decimals="0" id="ixv-24163" unitRef="usd">3366000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="0" id="ixv-24164" unitRef="usd">10222600</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:LineOfCredit contextRef="c73" decimals="-4" id="ixv-24165" unitRef="usd">1550000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c74" decimals="-4" id="ixv-24166" unitRef="usd">5540000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="c74" decimals="0" id="ixv-24167" unitRef="cny">40000000</us-gaap:LineOfCredit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-19598">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;). The
consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant
inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Consolidation of variable interest entities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with accounting standards regarding
consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without
additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the
Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary
is required to consolidate the VIE for financial reporting purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has concluded, based on the contractual
arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each
a VIE and that the Company&#x2019;s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities
of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual
returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Control and common control are defined under the
accounting standards as &#x201c;an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership
interest of each entity.&#x201d; Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and
have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting
rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly,
the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin
Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin
Management, in turn, is owned by Renovation, which is owned by the Company. &lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with&#160;U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial
statements relate to the assessment of the carrying values of accounts receivable, related allowance for doubtful accounts, losses. Because
of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company establishes a three-level valuation
hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the
following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; Quoted prices in active markets
for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of
the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; Unobservable inputs that are supported
by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Classification within the hierarchy is determined
based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless otherwise disclosed, the fair value of
the Company&#x2019;s financial instruments including cash, restricted cash, accounts receivable, advances to suppliers, other current assets,
accounts payable, due to related parties, other current liabilities, short-term bank loans and bank acceptance notes payable approximate
their recorded values due to their short-term maturities. The fair value of longer term long-term bank loan and operating lease liabilities
approximate their recorded values as their stated interest rates approximate the rates currently available.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Long-term
investments include equity investments. Equity investments include investments in common stock or in-substance common stock of entities.
For those equity investments over which the Group can exercise significant influence but does not own a majority equity interest or control,
the equity method is applied, and the Group adjusts the carrying amount of an investment and recognizes investment income or loss for
the Group&#x2019;s share of the earnings or loss of the investee after the date of investment. For those equity investments accounted for
other than under the equity method, the fair value method is applied. However, for equity investments that do not have readily determinable
fair values, the Group chooses to account for them at cost minus impairment, if any, plus or minus changes resulting from observable price
changes in orderly transactions for the identical or a similar investment of the same issuer. If this measurement alternative is elected,
changes in the carrying value of the equity investments will be required to be made whenever there are observable price changes in transactions
for identical or similar investments of the same issuer. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective March 31, 2018, the Company began recognizing
revenue under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;),
using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company&#x2019;s
consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict
the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be
entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 1: Identify the contract with the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 3: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 5: Recognize revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In order to identify the performance obligations
in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or
service that is distinct. A performance obligation meets ASC 606&#x2019;s definition of a &#x201c;distinct&#x201d; good or service (or bundle
of goods or services) if both of the following criteria are met:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If a good or service is not distinct, the good
or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s revenue is net of value added
tax (&#x201c;VAT&#x201d;) collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers,
net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant
PRC tax authorities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain contract liabilities primarily represent
the Company&#x2019;s obligation to transfer additional goods or services to a customer for which the Company has received consideration,
for example, membership points. The consideration received remains a contract liability until goods or services have been provided to
the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a discussion of the Company&#x2019;s
revenue recognition policies by segment under the new revenue recognition accounting standard:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Pharmacy retail sales&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The physical pharmacies sell prescription drugs,
over-the-counter (&#x201c;OTC&#x201d;) drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products.
Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and
pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer
pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after
the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local
government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The
Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made
to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services.
Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal
compared to pharmacy retail sales, it is included as part of the pharmacy retail sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company deduct the membership rewards directly
from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification.
Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has
determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers
can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership
rewards are reflected as a&#160;contract&#160;liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Online pharmacy sales&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenue from online pharmacy sales is recognized
when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer&#x2019;s
location. Any loss caused in a shipment will be reimbursed by the Company&#x2019;s courier company. The Company&#x2019;s sales policy allows
for the return of certain merchandises without reason within seven days after a customer&#x2019;s receipt of the applicable merchandise.
Historically, sales returns seven days after merchandise receipts have been minimal.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Wholesale&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Jiuxin Medicine purchases medicine in quantity
and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers
is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s revenue is net of VAT collected
on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases,
is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table disaggregates the Company&#x2019;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;For the year ended March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Retail drugstores&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,269,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,212,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,503,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,542,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,358,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,658,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,890,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,737,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,664,071&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,405,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,719,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,353,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,544,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,440,085&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,241,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,503,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total retail revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Online pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,151,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,606,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,331,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,969,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,870,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,473,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,284,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,740,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,448,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,271,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,432,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,603,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,814,284&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total online revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Drug wholesale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30,784,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21,617,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,116,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,289,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,903,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;741,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,073,665&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;333,663&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;164,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total wholesale revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154,541,077&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;148,811,976&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;164,392,555&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s restricted cash consists of
cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is
required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in
nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,149,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,807,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,724,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,762,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,874,171&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,570,644&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable represents the following:
(1) amounts due from banks relating to retail sales that are paid or settled by the customers&#x2019; debit or credit cards, (2) amounts
due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine,
and medical services that are paid or settled by the customers&#x2019; medical insurance cards, (3) amounts due from non-bank third party
payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts, as&#160;necessary. In the Company&#x2019;s retail
business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance
programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines
to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated
reserves on related outstanding accounts receivable based on expected credit loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the Company&#x2019;s online pharmacy business,
accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce
platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to
certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month.
Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In its wholesale business, the Company uses the
expected credit loss method to estimate the allowance for anticipated uncollectible receivable balances. At each reporting period, the
allowance balance is adjusted to reflect the amount computed as a result of the expected credit loss method. When facts subsequently become
available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account
as a change in estimate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Credit loss roll forward&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;With the adoption of the current expected credit
loss standard in 2020, the company estimates future expected losses on accounts receivable and other receivables over the remaining collection
period of the instrument. The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year end March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Account &lt;br/&gt; receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Other &lt;br/&gt; receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;Allowance for credit losses as of March 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,313,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,329,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,642,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Credit loss reversal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,389,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,446,772&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,836,412&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Ending allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;923,666&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,882,668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,806,334&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost or
net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts
on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct
costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such
as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs
costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses
and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities
on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Farmland assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Herbs that the Company farms are recorded at their
cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland,
and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has
been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All related costs described in the above are accumulated
until the time of harvest and then allocated to harvested herbs when they are sold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost, net
of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of
the assets, taking into consideration the assets&#x2019; estimated residual value. Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#x2019;s property
and equipment:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Estimated &lt;br/&gt;Useful&#160;Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;3-10 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Motor vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Office equipment &amp;amp; furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Buildings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;35 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Maintenance, repairs and minor renewals are charged
to expenses as incurred. Major additions and betterment to property and equipment are capitalized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are acquired individually or
as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction
is allocated to the individual assets based on their relative fair values.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The estimated useful lives of the Company&#x2019;s
intangible assets are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Estimated &lt;br/&gt;Useful Life&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;50 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;license&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Infinite&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates intangible assets for impairment
whenever events or changes in circumstances indicate that the assets might be impaired.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates long lived tangible and
intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable
from its estimated future cash flows. Recoverability is measured by comparing the assets&#x2019; net book value to the related projected
undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections,
market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset
is considered impaired, and a second test is performed to measure the amount of impairment loss. The forest rights certificate from the
local village extends the life of the lease to January 31, 2060. In the year ended March 31, 2022, we evaluated the use rights of the
forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company recorded
an impairment of $148,795. In the year ended March 31, 2023, we evaluated the use rights of the forest land, which is currently used to
cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended
March 31, 2024, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation
of the forest land use rights, the Company did not record an impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Notes payable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the normal course of business, the Company
regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The
Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short
maturity period of six to nine months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows FASB ASC Topic 740, &#x201c;Income
Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax
consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each
period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounting standards clarify the accounting
and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition
and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition,
classification, interest and penalties, accounting in interim periods, disclosures, and transition.&#160;No significant penalties, uncertain
tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Value added tax&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales revenue represents the invoiced value of
goods, net of VAT. All of the Company&#x2019;s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT
rates&#160;range up to 13%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials
and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments
in the accompanying financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;The Company accounts for share-based payment
awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the
fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest
is recognized as an expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. Share-based
awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option
award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using
the Black-Scholes valuation model as permitted under FASB ASC 718 &#x201c;Compensation - Stock Compensation.&#x201d; The assumptions used
in calculating the fair value of share-based payment awards represent the Company&#x2019;s best estimates. The Company&#x2019;s estimates
of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain
variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates
of forfeitures, and the related income tax impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Advertising and promotion costs&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising and promotion costs are expensed as
incurred and amounted to $304,075, $491,684&#160;and $355,078 for the year ended March 31, 2024, 2023 and 2022, respectively. Such costs
consist primarily of print and promotional materials such as flyers to local communities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the United States dollar (&#x201c;U.S.
dollars&#x201d; or &#x201c;USD&#x201d;) for financial reporting purposes. The Company&#x2019;s subsidiaries and VIEs maintain their books
and records in their functional currency the Renminbi (&#x201c;RMB&#x201d;), the currency of the PRC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In general, for consolidation purposes, the Company
translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at
the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period.
As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes
in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the
translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The balance sheet amounts, with the exception
of equity, at March 31, 2024 and 2023 were translated at 1 USD to 7.2203 RMB and at 1 USD to 6.8676 RMB, respectively. The average translation
rates applied to income and cash flow statement amounts for years ended March 31, 2024 and 2023 were at 1 USD to 7.1671 RMB and at 1 USD
to 6.8516 RMB, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s management does not believe
that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the
accompanying consolidated financial statements.&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-19602">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Basis of presentation and consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;). The
consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries and VIEs. All significant
inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c0" id="ixv-19609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Consolidation of variable interest entities&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with accounting standards regarding
consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without
additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the
Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary
is required to consolidate the VIE for financial reporting purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has concluded, based on the contractual
arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each
a VIE and that the Company&#x2019;s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities
of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual
returns.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Control and common control are defined under the
accounting standards as &#x201c;an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership
interest of each entity.&#x201d; Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and
have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized in the voting
rights agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly,
the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin
Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin
Management, in turn, is owned by Renovation, which is owned by the Company. &lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <cjjd:BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl contextRef="c0" decimals="2" id="ixv-24168" unitRef="pure">0.50</cjjd:BenchmarkPercentageOfVotingOwnershipInterestForControlAndCommonControl>
    <us-gaap:VariableInterestEntityOwnershipPercentage contextRef="c0" decimals="2" id="ixv-24169" unitRef="pure">1</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-19637">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with&#160;U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues
and expenses during the reporting period. The significant estimates made in the preparation of the accompanying consolidated financial
statements relate to the assessment of the carrying values of accounts receivable, related allowance for doubtful accounts, losses. Because
of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-19644">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company establishes a three-level valuation
hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the
following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; Quoted prices in active markets
for identical assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; Inputs other than Level 1 that
are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of
the assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; Unobservable inputs that are supported
by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Classification within the hierarchy is determined
based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless otherwise disclosed, the fair value of
the Company&#x2019;s financial instruments including cash, restricted cash, accounts receivable, advances to suppliers, other current assets,
accounts payable, due to related parties, other current liabilities, short-term bank loans and bank acceptance notes payable approximate
their recorded values due to their short-term maturities. The fair value of longer term long-term bank loan and operating lease liabilities
approximate their recorded values as their stated interest rates approximate the rates currently available.&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0" id="ixv-19666">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Long-term investments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Long-term
investments include equity investments. Equity investments include investments in common stock or in-substance common stock of entities.
For those equity investments over which the Group can exercise significant influence but does not own a majority equity interest or control,
the equity method is applied, and the Group adjusts the carrying amount of an investment and recognizes investment income or loss for
the Group&#x2019;s share of the earnings or loss of the investee after the date of investment. For those equity investments accounted for
other than under the equity method, the fair value method is applied. However, for equity investments that do not have readily determinable
fair values, the Group chooses to account for them at cost minus impairment, if any, plus or minus changes resulting from observable price
changes in orderly transactions for the identical or a similar investment of the same issuer. If this measurement alternative is elected,
changes in the carrying value of the equity investments will be required to be made whenever there are observable price changes in transactions
for identical or similar investments of the same issuer. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-19688">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective March 31, 2018, the Company began recognizing
revenue under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;),
using the modified retrospective transition method. The impact of adopting the new revenue standard was not material to the Company&#x2019;s
consolidated financial statements. The core principle of this new revenue standard is that a company should recognize revenue to depict
the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be
entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 1: Identify the contract with the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 3: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Step 5: Recognize revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In order to identify the performance obligations
in a contract with a customer, a company must assess the promised goods or services in the contract and identify each promised good or
service that is distinct. A performance obligation meets ASC 606&#x2019;s definition of a &#x201c;distinct&#x201d; good or service (or bundle
of goods or services) if both of the following criteria are met:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If a good or service is not distinct, the good
or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s revenue is net of value added
tax (&#x201c;VAT&#x201d;) collected on behalf of the PRC tax authorities with respect to the sales of merchandise. VAT collected from customers,
net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant
PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain contract liabilities primarily represent
the Company&#x2019;s obligation to transfer additional goods or services to a customer for which the Company has received consideration,
for example, membership points. The consideration received remains a contract liability until goods or services have been provided to
the retail customer. The estimated amount based on accrued membership points was deducted from sales revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a discussion of the Company&#x2019;s
revenue recognition policies by segment under the new revenue recognition accounting standard:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Pharmacy retail sales&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The physical pharmacies sell prescription drugs,
over-the-counter (&#x201c;OTC&#x201d;) drugs, traditional Chinese medicine, nutritional supplements, medical devices and sundry products.
Revenue from sales of prescription medicine at drugstores is recognized when the prescription is filled and the customer picks up and
pays for the prescription. Revenue from sales of other merchandise at drugstores is recognized at the point of sale, which is when a customer
pays for and receives the merchandise. Usually the majority merchandise, such as prescription and OTC drugs, are not refundable after
the customers leave the counter. Returns of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local
government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. The
Company based on historical experience, a reserve for potential losses from denial of reimbursement on certain unqualified drugs is made
to the receivables from the government agency. Additionally, several onsite clinics adjacent to pharmacies provide limited medical services.
Revenue from medical services is recognized after the service has been rendered to a customer. As revenue from medical services is minimal
compared to pharmacy retail sales, it is included as part of the pharmacy retail sales.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company deduct the membership rewards directly
from the retail revenue, and present such amounts in net sales as opposed to the current reduction of operation expense classification.
Membership rewards, usually membership points, are accumulated by customers based on their historical spending levels. The Company has
determined that there is an additional performance obligation to those customers at the time of the initial transaction. The customers
can then redeem these points against the prices of merchandises they purchase in the future. At the end of each period, unredeemed membership
rewards are reflected as a&#160;contract&#160;liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Online pharmacy sales&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenue from online pharmacy sales is recognized
when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer&#x2019;s
location. Any loss caused in a shipment will be reimbursed by the Company&#x2019;s courier company. The Company&#x2019;s sales policy allows
for the return of certain merchandises without reason within seven days after a customer&#x2019;s receipt of the applicable merchandise.
Historically, sales returns seven days after merchandise receipts have been minimal.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Wholesale&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Jiuxin Medicine purchases medicine in quantity
and distributes products primarily to local pharmacies and medical products dealers. Revenue from sales of merchandise to non-retail customers
is recognized when the merchandise is transferred to customers. Historically, sales returns have been minimal.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s revenue is net of VAT collected
on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases,
is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table disaggregates the Company&#x2019;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;For the year ended March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Retail drugstores&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,269,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,212,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,503,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,542,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,358,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,658,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,890,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,737,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,664,071&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,405,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,719,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,353,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,544,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,440,085&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,241,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,503,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total retail revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Online pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,151,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,606,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,331,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,969,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,870,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,473,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,284,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,740,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,448,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,271,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,432,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,603,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,814,284&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total online revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Drug wholesale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30,784,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21,617,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,116,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,289,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,903,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;741,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,073,665&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;333,663&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;164,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total wholesale revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154,541,077&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;148,811,976&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;164,392,555&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c0" id="ixv-24170">The following table disaggregates the Company&#x2019;s
revenue by major source in each segment for the years ended March 31, 2024, 2023 and 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;For the year ended March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Retail drugstores&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,269,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,212,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,503,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,542,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,358,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,658,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,890,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,737,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,664,071&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,405,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,719,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,353,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,544,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,440,085&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,241,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,503,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total retail revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Online pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9,151,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,606,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10,331,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,969,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,870,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,473,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,284,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,740,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,448,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,271,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,432,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,603,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,814,284&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total online revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Drug wholesale&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Prescription drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30,784,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21,617,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,116,991&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,289,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,903,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;741,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 0.25in"&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,073,665&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;333,663&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;164,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total wholesale revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;154,541,077&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;148,811,976&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;164,392,555&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c92" decimals="0" id="ixv-24171" unitRef="usd">25269177</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c93" decimals="0" id="ixv-24172" unitRef="usd">27212994</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c94" decimals="0" id="ixv-24173" unitRef="usd">28503283</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c95" decimals="0" id="ixv-24174" unitRef="usd">31542597</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c96" decimals="0" id="ixv-24175" unitRef="usd">32358339</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c97" decimals="0" id="ixv-24176" unitRef="usd">35658864</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c98" decimals="0" id="ixv-24177" unitRef="usd">9890985</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c99" decimals="0" id="ixv-24178" unitRef="usd">8737519</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c100" decimals="0" id="ixv-24179" unitRef="usd">9664071</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c101" decimals="0" id="ixv-24180" unitRef="usd">3405979</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c102" decimals="0" id="ixv-24181" unitRef="usd">9719653</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c103" decimals="0" id="ixv-24182" unitRef="usd">5353900</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c104" decimals="0" id="ixv-24183" unitRef="usd">1129647</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c105" decimals="0" id="ixv-24184" unitRef="usd">1082168</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c106" decimals="0" id="ixv-24185" unitRef="usd">1544639</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c107" decimals="0" id="ixv-24186" unitRef="usd">4440085</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c108" decimals="0" id="ixv-24187" unitRef="usd">4241095</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c109" decimals="0" id="ixv-24188" unitRef="usd">3503735</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c110" decimals="0" id="ixv-24189" unitRef="usd">75678470</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c111" decimals="0" id="ixv-24190" unitRef="usd">83351768</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c112" decimals="0" id="ixv-24191" unitRef="usd">84228492</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c113" decimals="0" id="ixv-24192" unitRef="usd">9151412</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c114" decimals="0" id="ixv-24193" unitRef="usd">10606244</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c115" decimals="0" id="ixv-24194" unitRef="usd">10331652</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c116" decimals="0" id="ixv-24195" unitRef="usd">12969313</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c117" decimals="0" id="ixv-24196" unitRef="usd">13870953</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c118" decimals="0" id="ixv-24197" unitRef="usd">11473177</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c119" decimals="0" id="ixv-24198" unitRef="usd">4284556</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c120" decimals="0" id="ixv-24199" unitRef="usd">2740253</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c121" decimals="0" id="ixv-24200" unitRef="usd">2014011</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c122" decimals="0" id="ixv-24201" unitRef="usd">571769</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c123" decimals="0" id="ixv-24202" unitRef="usd">434920</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c124" decimals="0" id="ixv-24203" unitRef="usd">315231</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c125" decimals="0" id="ixv-24204" unitRef="usd">1448537</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c126" decimals="0" id="ixv-24205" unitRef="usd">1129701</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c127" decimals="0" id="ixv-24206" unitRef="usd">2271009</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c128" decimals="0" id="ixv-24207" unitRef="usd">3432296</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c129" decimals="0" id="ixv-24208" unitRef="usd">3603018</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c130" decimals="0" id="ixv-24209" unitRef="usd">3814284</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c131" decimals="0" id="ixv-24210" unitRef="usd">31857883</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c132" decimals="0" id="ixv-24211" unitRef="usd">32385089</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c133" decimals="0" id="ixv-24212" unitRef="usd">30219364</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c134" decimals="0" id="ixv-24213" unitRef="usd">30784949</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c135" decimals="0" id="ixv-24214" unitRef="usd">21617636</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c136" decimals="0" id="ixv-24215" unitRef="usd">41116991</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c137" decimals="0" id="ixv-24216" unitRef="usd">11323730</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c138" decimals="0" id="ixv-24217" unitRef="usd">10289987</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c139" decimals="0" id="ixv-24218" unitRef="usd">7903824</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c140" decimals="0" id="ixv-24219" unitRef="usd">741883</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c141" decimals="0" id="ixv-24220" unitRef="usd">310909</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c142" decimals="0" id="ixv-24221" unitRef="usd">424210</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c143" decimals="0" id="ixv-24222" unitRef="usd">388396</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c144" decimals="0" id="ixv-24223" unitRef="usd">458502</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c145" decimals="0" id="ixv-24224" unitRef="usd">241828</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c146" decimals="0" id="ixv-24225" unitRef="usd">692101</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c147" decimals="0" id="ixv-24226" unitRef="usd">64422</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c148" decimals="0" id="ixv-24227" unitRef="usd">93338</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c149" decimals="0" id="ixv-24228" unitRef="usd">3073665</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c150" decimals="0" id="ixv-24229" unitRef="usd">333663</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c151" decimals="0" id="ixv-24230" unitRef="usd">164508</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c152" decimals="0" id="ixv-24231" unitRef="usd">47004724</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c153" decimals="0" id="ixv-24232" unitRef="usd">33075119</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c154" decimals="0" id="ixv-24233" unitRef="usd">49944699</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-24234" unitRef="usd">154541077</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c6" decimals="0" id="ixv-24235" unitRef="usd">148811976</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c7" decimals="0" id="ixv-24236" unitRef="usd">164392555</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0" id="ixv-20228">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s restricted cash consists of
cash and long-term deposits in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is
required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in
nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,149,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,807,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,724,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,762,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,874,171&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,570,644&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c0" id="ixv-24237">The following represents a reconciliation of cash
and cash equivalents in the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statements
of cash flows as of March 31, 2024 and 2023:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,149,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,807,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,724,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,762,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,874,171&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,570,644&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-24238" unitRef="usd">20149806</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-24239" unitRef="usd">18807936</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-24240" unitRef="usd">12724365</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" id="ixv-24241" unitRef="usd">12762708</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-24242" unitRef="usd">32874171</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-24243" unitRef="usd">31570644</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0" id="ixv-20282">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable represents the following:
(1) amounts due from banks relating to retail sales that are paid or settled by the customers&#x2019; debit or credit cards, (2) amounts
due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine,
and medical services that are paid or settled by the customers&#x2019; medical insurance cards, (3) amounts due from non-bank third party
payment instruments such as Alipay and certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are recorded at net realizable
value consisting of the carrying amount less an allowance for uncollectible accounts, as&#160;necessary. In the Company&#x2019;s retail
business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance
programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which it determines
to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated
reserves on related outstanding accounts receivable based on expected credit loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the Company&#x2019;s online pharmacy business,
accounts receivable primarily consist of amounts due from non-bank third party payment instruments such as Alipay and certain e-commerce
platforms. To purchase pharmaceutical products from an e-commerce platforms such as Tmall, customers are required to submit payment to
certain non-bank third party payment instruments, such as Alipay, which, in turn, reimburse the Company within seven days to a month.
Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In its wholesale business, the Company uses the
expected credit loss method to estimate the allowance for anticipated uncollectible receivable balances. At each reporting period, the
allowance balance is adjusted to reflect the amount computed as a result of the expected credit loss method. When facts subsequently become
available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account
as a change in estimate.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <cjjd:CreditLossRollForwardPolicyTextBlock contextRef="c0" id="ixv-20298">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Credit loss roll forward&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;With the adoption of the current expected credit
loss standard in 2020, the company estimates future expected losses on accounts receivable and other receivables over the remaining collection
period of the instrument. The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year end March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Account &lt;br/&gt; receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Other &lt;br/&gt; receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;Allowance for credit losses as of March 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,313,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,329,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,642,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Credit loss reversal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,389,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,446,772&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,836,412&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Ending allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;923,666&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,882,668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,806,334&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</cjjd:CreditLossRollForwardPolicyTextBlock>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c0" id="ixv-24244">The roll forward for the allowance for credit losses for the year end March 31, 2024, is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year end March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Account &lt;br/&gt; receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Other &lt;br/&gt; receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -9pt; padding-left: 9pt"&gt;Allowance for credit losses as of March 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,313,306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,329,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,642,746&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Credit loss reversal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,389,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,446,772&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,836,412&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Ending allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;923,666&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,882,668&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,806,334&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c155" decimals="0" id="ixv-24245" unitRef="usd">2313306</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c156" decimals="0" id="ixv-24246" unitRef="usd">5329440</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c3" decimals="0" id="ixv-24247" unitRef="usd">7642746</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c157" decimals="0" id="ixv-24248" unitRef="usd">-1389640</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c158" decimals="0" id="ixv-24249" unitRef="usd">-2446772</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses contextRef="c0" decimals="0" id="ixv-24250" unitRef="usd">-3836412</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c159" decimals="0" id="ixv-24251" unitRef="usd">923666</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c160" decimals="0" id="ixv-24252" unitRef="usd">2882668</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c2" decimals="0" id="ixv-24253" unitRef="usd">3806334</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-20383">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost or
net realizable value. Cost is determined using the first in first out (FIFO) method. The Company carries out physical inventory counts
on a monthly basis at each store and warehouse location. Herbs that the Company farms are recorded at their cost, which includes direct
costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such
as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs
costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses
and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities
on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <cjjd:FarmlandAssetsPolicyTextBlock contextRef="c0" id="ixv-20390">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Farmland assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Herbs that the Company farms are recorded at their
cost, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland,
and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has
been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All related costs described in the above are accumulated
until the time of harvest and then allocated to harvested herbs when they are sold.&lt;/p&gt;</cjjd:FarmlandAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-20400">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost, net
of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of
the assets, taking into consideration the assets&#x2019; estimated residual value. Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#x2019;s property
and equipment:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Estimated &lt;br/&gt;Useful&#160;Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;3-10 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Motor vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Office equipment &amp;amp; furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Buildings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;35 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Maintenance, repairs and minor renewals are charged
to expenses as incurred. Major additions and betterment to property and equipment are capitalized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cjjd:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c0" id="ixv-24254">Leasehold improvements are amortized over the shorter
of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company&#x2019;s property
and equipment:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Estimated &lt;br/&gt;Useful&#160;Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;3-10 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Motor vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Office equipment &amp;amp; furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-5 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Buildings&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;35 years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cjjd:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c161" id="ixv-24255">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c162" id="ixv-24256">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c163" id="ixv-24257">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c164" id="ixv-24258">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c165" id="ixv-24259">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c166" id="ixv-24260">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c167" id="ixv-24261">P35Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0" id="ixv-20435">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are acquired individually or
as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction
is allocated to the individual assets based on their relative fair values.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The estimated useful lives of the Company&#x2019;s
intangible assets are as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Estimated &lt;br/&gt;Useful Life&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;50 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;license&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Infinite&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates intangible assets for impairment
whenever events or changes in circumstances indicate that the assets might be impaired.&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <cjjd:ScheduleOfEstimatedUsefulLivesTableTextBlock contextRef="c0" id="ixv-24262">The estimated useful lives of the Company&#x2019;s
intangible assets are as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Estimated &lt;br/&gt;Useful Life&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Land use rights&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;50 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3 years&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;license&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Infinite&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</cjjd:ScheduleOfEstimatedUsefulLivesTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c168" id="ixv-24263">P50Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c169" id="ixv-24264">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <cjjd:FiniteLivedIntangibleAssetUsefulLifeDescription contextRef="c170" id="ixv-24265">Infinite</cjjd:FiniteLivedIntangibleAssetUsefulLifeDescription>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-20483">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates long lived tangible and
intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable
from its estimated future cash flows. Recoverability is measured by comparing the assets&#x2019; net book value to the related projected
undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections,
market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset
is considered impaired, and a second test is performed to measure the amount of impairment loss. The forest rights certificate from the
local village extends the life of the lease to January 31, 2060. In the year ended March 31, 2022, we evaluated the use rights of the
forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company recorded
an impairment of $148,795. In the year ended March 31, 2023, we evaluated the use rights of the forest land, which is currently used to
cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended
March 31, 2024, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation
of the forest land use rights, the Company did not record an impairment.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLeasehold contextRef="c0" decimals="0" id="ixv-24266" unitRef="usd">148795</us-gaap:ImpairmentOfLeasehold>
    <cjjd:NotesPayablePolicyTextBlock contextRef="c0" id="ixv-20490">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Notes payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the normal course of business, the Company
regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The
Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short
maturity period of six to nine months.&lt;/p&gt;</cjjd:NotesPayablePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-20497">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows FASB ASC Topic 740, &#x201c;Income
Taxes,&#x201d; which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events
that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax
consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each
period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect
taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounting standards clarify the accounting
and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition
and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition,
classification, interest and penalties, accounting in interim periods, disclosures, and transition.&#160;No significant penalties, uncertain
tax provisions or interest relating to income taxes were incurred during the periods ended March 31, 2024 and 2023.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cjjd:ValueAddedTaxPolicyTextBlock contextRef="c0" id="ixv-20507">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Value added tax&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Sales revenue represents the invoiced value of
goods, net of VAT. All of the Company&#x2019;s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT
rates&#160;range up to 13%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials
and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments
in the accompanying financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</cjjd:ValueAddedTaxPolicyTextBlock>
    <cjjd:VATPercentage contextRef="c0" decimals="2" id="ixv-24267" unitRef="pure">0.13</cjjd:VATPercentage>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-20528">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;The Company accounts for share-based payment
awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the
fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest
is recognized as an expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. Share-based
awards are attributed to expenses using the straight-line method over the vesting period. The Company determines the value of each option
award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using
the Black-Scholes valuation model as permitted under FASB ASC 718 &#x201c;Compensation - Stock Compensation.&#x201d; The assumptions used
in calculating the fair value of share-based payment awards represent the Company&#x2019;s best estimates. The Company&#x2019;s estimates
of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain
variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates
of forfeitures, and the related income tax impact.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c0" id="ixv-20536">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Advertising and promotion costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advertising and promotion costs are expensed as
incurred and amounted to $304,075, $491,684&#160;and $355,078 for the year ended March 31, 2024, 2023 and 2022, respectively. Such costs
consist primarily of print and promotional materials such as flyers to local communities.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c0" decimals="0" id="ixv-24268" unitRef="usd">304075</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c6" decimals="0" id="ixv-24269" unitRef="usd">491684</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c7" decimals="0" id="ixv-24270" unitRef="usd">355078</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-20543">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the United States dollar (&#x201c;U.S.
dollars&#x201d; or &#x201c;USD&#x201d;) for financial reporting purposes. The Company&#x2019;s subsidiaries and VIEs maintain their books
and records in their functional currency the Renminbi (&#x201c;RMB&#x201d;), the currency of the PRC.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In general, for consolidation purposes, the Company
translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at
the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period.
As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes
in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the
translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The balance sheet amounts, with the exception
of equity, at March 31, 2024 and 2023 were translated at 1 USD to 7.2203 RMB and at 1 USD to 6.8676 RMB, respectively. The average translation
rates applied to income and cash flow statement amounts for years ended March 31, 2024 and 2023 were at 1 USD to 7.1671 RMB and at 1 USD
to 6.8516 RMB, respectively.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-20556">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s management does not believe
that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the
accompanying consolidated financial statements.&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-20576">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The operations of the Company are located in the
PRC. Accordingly, the Company&#x2019;s business, financial condition, and results of operations may be influenced by political, economic,
and legal environments in the PRC, as well as by the general state of the PRC economy. The Company&#x2019;s operations in the PRC are subject
to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include
risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company&#x2019;s
results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not
experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization
and structure disclosed in Note 1, this may not be indicative of future results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has significant cash deposits with
suppliers in order to obtain and maintain inventory. The Company&#x2019;s ability to obtain products and maintain inventory at existing
and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors
are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest
on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party
who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party.
If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings
in China, to recover all or a portion of the amount on deposit with its suppliers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Members of the current management team own controlling
interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements
which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the
Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the
Company would not retain control of the VIEs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Concentrations and Credit Risk&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain financial instruments, which subject the
Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions
located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection
Board&#x2019;s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered
by insurance up to RMB 500,000 (USD 79,600) per bank. As of March 31, 2024 and 2023, the Company had deposits totaling $32,247,552 and
$31,558,338 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD79,&lt;span style="-sec-ix-hidden: hidden-fact-101"&gt;600&lt;/span&gt;) per bank in PRC will not
be covered. To date, the Company has not experienced any losses in such accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the fiscal year ended March 31, 2024, one
vendor collectively accounted for more than 10% of the Company&#x2019;s total purchases and two suppliers accounted for more than 10% of
total advances to suppliers.&#160;For the fiscal year ended March 31, 2023, four vendors collectively accounted for more than 10% of the
Company&#x2019;s total purchases and four suppliers accounted for more than 10% of total advances to suppliers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the fiscal year ended March 31, 2024, one
customer accounted for more than 10% of the Company&#x2019;s total sales but no customer accounted for more than 10% of total accounts
receivable. For the fiscal year ended March 31, 2023, one customer accounted for more than 10% of the Company&#x2019;s total sales but
no customer accounted for more than 10% of total accounts receivable.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c171" decimals="0" id="ixv-24271" unitRef="cny">500000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount contextRef="c171" decimals="0" id="ixv-24272" unitRef="usd">79600</us-gaap:CashFDICInsuredAmount>
    <us-gaap:Deposits contextRef="c2" decimals="0" id="ixv-24273" unitRef="usd">32247552</us-gaap:Deposits>
    <us-gaap:Deposits contextRef="c3" decimals="0" id="ixv-24274" unitRef="usd">31558338</us-gaap:Deposits>
    <us-gaap:CashUninsuredAmount contextRef="c2" decimals="0" id="ixv-24275" unitRef="cny">500000</us-gaap:CashUninsuredAmount>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-20612">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; TRADE RECEIVABLES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Trade receivables consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,747,769&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,412,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(923,666&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,313,306&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,824,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,098,793&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Note receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,824,103&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,119,606&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended March 31, 2024 and 2023, $56,170
and $50,275 in accounts receivable were directly written off, respectively.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0" id="ixv-24276">Trade receivables consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,747,769&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,412,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(923,666&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,313,306&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,824,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,098,793&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Note receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Trade receivables&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;15,824,103&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,119,606&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c172" decimals="0" id="ixv-24277" unitRef="usd">16747769</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c173" decimals="0" id="ixv-24278" unitRef="usd">16412099</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c172" decimals="0" id="ixv-24279" unitRef="usd">923666</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c173" decimals="0" id="ixv-24280" unitRef="usd">2313306</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNet contextRef="c172" decimals="0" id="ixv-24281" unitRef="usd">15824103</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c173" decimals="0" id="ixv-24282" unitRef="usd">14098793</us-gaap:AccountsReceivableNet>
    <us-gaap:NotesReceivableNet contextRef="c173" decimals="0" id="ixv-24283" unitRef="usd">20813</us-gaap:NotesReceivableNet>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c172" decimals="0" id="ixv-24284" unitRef="usd">15824103</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c173" decimals="0" id="ixv-24285" unitRef="usd">14119606</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs contextRef="c0" decimals="0" id="ixv-24286" unitRef="usd">56170</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs contextRef="c6" decimals="0" id="ixv-24287" unitRef="usd">50275</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-20686">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 &#x2013; OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other current assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid rental expenses &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;513,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;530,611&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;85,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;569,544&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,008&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-24288">Other current assets consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid rental expenses &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;513,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;530,611&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Prepaid and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;85,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;569,544&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,008&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidRent contextRef="c2" decimals="0" id="ix_0_fact" unitRef="usd">513170</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent contextRef="c3" decimals="0" id="ix_1_fact" unitRef="usd">530611</us-gaap:PrepaidRent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-24291" unitRef="usd">56374</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-24292" unitRef="usd">85397</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-24293" unitRef="usd">569544</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-24294" unitRef="usd">616008</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-20748">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;6 &#x2013; PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Building&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,617,617&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,072,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,503,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,134,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Farmland development cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,656,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,741,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office equipment and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,729,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,811,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Motor vehicles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;421,234&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,542&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,928,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,118,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,355,233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,266,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,666,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,752,178&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,906,589&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,100,264&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total depreciation expense for property and equipment
was $693,537 and $625,739 for the year ended March 31, 2024 and 2023, respectively. There were no fixed assets impaired in the years ended
March 31, 2024 and March 31, 2023.&#160;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-24295">Property and equipment consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Building&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,617,617&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,072,388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,503,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,134,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Farmland development cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,656,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,741,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office equipment and furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,729,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,811,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Motor vehicles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;421,234&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;358,542&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,928,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,118,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,355,233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,266,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Impairment*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,666,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,752,178&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,906,589&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,100,264&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c167" decimals="0" id="ixv-24296" unitRef="usd">5617617</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c176" decimals="0" id="ixv-24297" unitRef="usd">6072388</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c177" decimals="0" id="ixv-24298" unitRef="usd">3503702</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c178" decimals="0" id="ixv-24299" unitRef="usd">3134716</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c179" decimals="0" id="ixv-24300" unitRef="usd">1656357</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c180" decimals="0" id="ixv-24301" unitRef="usd">1741422</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c181" decimals="0" id="ixv-24302" unitRef="usd">5729499</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c182" decimals="0" id="ixv-24303" unitRef="usd">5811887</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c183" decimals="0" id="ixv-24304" unitRef="usd">421234</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c184" decimals="0" id="ixv-24305" unitRef="usd">358542</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-24306" unitRef="usd">16928409</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-24307" unitRef="usd">17118955</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-24308" unitRef="usd">10355233</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-24309" unitRef="usd">10266513</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <cjjd:AccumulatedImpairmentPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ix_2_fact" unitRef="usd">1666587</cjjd:AccumulatedImpairmentPropertyPlantAndEquipment>
    <cjjd:AccumulatedImpairmentPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ix_3_fact" unitRef="usd">1752178</cjjd:AccumulatedImpairmentPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-24312" unitRef="usd">4906589</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-24313" unitRef="usd">5100264</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c174" decimals="0" id="ixv-24314" unitRef="usd">693537</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c175" decimals="0" id="ixv-24315" unitRef="usd">625739</us-gaap:Depreciation>
    <us-gaap:LongTermDebtTextBlock contextRef="c0" id="ixv-20881">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;7 &#x2013; LONG-TERM INVESTMENT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-term investment consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kahamadi Bio &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Zhuoli Life &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,680,337&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Songlu Pharmaceutical &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou Digital &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd &lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,108,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Long-term investment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,195,261&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,772,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $0 and $0 in the year ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 39% investment in Zhejiang Zhuoli Life Service Co., LTD (&#x201c;Zhuoli Service&#x201d;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $1,443,752 into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $2,402,376 in the year ended March 31, 2023. An impairment loss of $1,607,537 was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was &lt;span style="-sec-ix-hidden: hidden-fact-107"&gt;nil&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 0.37% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#x201c;Songlu Pharmaceutical&#x201d;). The investment is recorded based on cost method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 25.92% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $4,379 into Jiuzhou Digital. The investment is recorded based on equity method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 8% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $1,113,650(RMB 8,000,000) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0" id="ixv-24316">Long-term investment consists of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kahamadi Bio &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Zhuoli Life &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,680,337&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Songlu Pharmaceutical &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Jiuzhou Digital &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,155&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd &lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,108,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Long-term investment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,195,261&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,772,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $0 and $0 in the year ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 39% investment in Zhejiang Zhuoli Life Service Co., LTD (&#x201c;Zhuoli Service&#x201d;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $1,443,752 into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $2,402,376 in the year ended March 31, 2023. An impairment loss of $1,607,537 was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was &lt;span style="-sec-ix-hidden: hidden-fact-107"&gt;nil&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 0.37% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#x201c;Songlu Pharmaceutical&#x201d;). The investment is recorded based on cost method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 25.92% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $4,379 into Jiuzhou Digital. The investment is recorded based on equity method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It represents 8% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $1,113,650(RMB 8,000,000) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermInvestments contextRef="c196" decimals="0" id="ix_4_fact" unitRef="usd">1680337</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c191" decimals="0" id="ix_5_fact" unitRef="usd">83099</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c197" decimals="0" id="ix_6_fact" unitRef="usd">87367</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c198" decimals="0" id="ix_7_fact" unitRef="usd">4155</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c199" decimals="0" id="ix_8_fact" unitRef="usd">4368</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c200" decimals="0" id="ix_9_fact" unitRef="usd">1108007</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="0" id="ixv-24323" unitRef="usd">1195261</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c3" decimals="0" id="ixv-24324" unitRef="usd">1772072</us-gaap:LongTermInvestments>
    <cjjd:InvestmentPercentage
      contextRef="c185"
      decimals="2"
      id="ixv-24325"
      unitRef="pure">0.49</cjjd:InvestmentPercentage>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c186" decimals="0" id="ixv-24326" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c187" decimals="0" id="ixv-24327" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <cjjd:InvestmentPercentage
      contextRef="c188"
      decimals="2"
      id="ixv-24328"
      unitRef="pure">0.39</cjjd:InvestmentPercentage>
    <cjjd:InjectedFunds contextRef="c189" decimals="0" id="ixv-24329" unitRef="usd">1443752</cjjd:InjectedFunds>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c190" decimals="0" id="ixv-24330" unitRef="usd">2402376</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <cjjd:LongTermInvestmentImpairmentLoss contextRef="c3" decimals="0" id="ixv-24331" unitRef="usd">1607537</cjjd:LongTermInvestmentImpairmentLoss>
    <cjjd:InvestmentPercentage
      contextRef="c191"
      decimals="4"
      id="ixv-24332"
      unitRef="pure">0.0037</cjjd:InvestmentPercentage>
    <cjjd:InvestmentPercentage
      contextRef="c192"
      decimals="4"
      id="ixv-24333"
      unitRef="pure">0.2592</cjjd:InvestmentPercentage>
    <cjjd:InjectedFunds contextRef="c193" decimals="0" id="ixv-24334" unitRef="usd">4379</cjjd:InjectedFunds>
    <cjjd:InvestmentPercentage contextRef="c2" decimals="2" id="ixv-24336" unitRef="pure">0.08</cjjd:InvestmentPercentage>
    <cjjd:InjectedFunds contextRef="c0" decimals="0" id="ixv-24337" unitRef="usd">1113650</cjjd:InjectedFunds>
    <cjjd:InjectedFunds contextRef="c0" decimals="0" id="ixv-24338" unitRef="cny">8000000</cjjd:InjectedFunds>
    <cjjd:AdvancesToSuppliersTextBlock contextRef="c0" id="ixv-21021">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;8 &#x2013; ADVANCES TO SUPPLIERS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advances to suppliers consist of deposits, with
or advances to, outside vendors for future inventory purchases. Most of the Company&#x2019;s suppliers require a certain amount of money
to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears
no interest. As of March 31, 2024 and March 31, 2023, advance to suppliers consist of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Advance to suppliers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,177,399&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;362,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: reserve for vendor non-performance on advances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(262,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(219,630&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Advance to suppliers, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;914,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;142,417&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cjjd:AdvancesToSuppliersTextBlock>
    <cjjd:AdvanceToSuppliersTableTextBlock contextRef="c0" id="ixv-24339">As of March 31, 2024 and March 31, 2023, advance to suppliers consist of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Advance to suppliers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,177,399&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;362,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: reserve for vendor non-performance on advances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(262,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(219,630&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Advance to suppliers, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;914,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;142,417&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cjjd:AdvanceToSuppliersTableTextBlock>
    <cjjd:AdvancesOnInventoryPurchasesGross contextRef="c2" decimals="0" id="ixv-24340" unitRef="usd">1177399</cjjd:AdvancesOnInventoryPurchasesGross>
    <cjjd:AdvancesOnInventoryPurchasesGross contextRef="c3" decimals="0" id="ixv-24341" unitRef="usd">362047</cjjd:AdvancesOnInventoryPurchasesGross>
    <cjjd:AllowanceForAdvancesToSuppliers contextRef="c2" decimals="0" id="ixv-24342" unitRef="usd">262623</cjjd:AllowanceForAdvancesToSuppliers>
    <cjjd:AllowanceForAdvancesToSuppliers contextRef="c3" decimals="0" id="ixv-24343" unitRef="usd">219630</cjjd:AllowanceForAdvancesToSuppliers>
    <us-gaap:Supplies contextRef="c2" decimals="0" id="ixv-24344" unitRef="usd">914776</us-gaap:Supplies>
    <us-gaap:Supplies contextRef="c3" decimals="0" id="ixv-24345" unitRef="usd">142417</us-gaap:Supplies>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-21083">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 9 &#x2013; INVENTORY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory consisted of finished goods, valued
at $16,248,373 and $15,309,100 as of March 31, 2024 and March 31, 2023, respectively. The Company constantly monitors its potential obsolete
products and is allowed to return products close to their expiration date to its suppliers. Any loss on damaged items is immaterial and
will be recognized immediately. As a result, &lt;span style="-sec-ix-hidden: hidden-fact-108"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;no&lt;/span&gt;&lt;/span&gt; reserves were made for inventory as of March 31, 2024 and March 31, 2023.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" id="ixv-24346" unitRef="usd">16248373</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-24347" unitRef="usd">15309100</us-gaap:InventoryNet>
    <cjjd:FarmlandAssetsTextBlock contextRef="c0" id="ixv-21093">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 10 &#x2013; FARMLAND ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Farmland assets consist of ginkgo trees planted
in 2012 and expected to be harvested and sold in several years. As of March 31, 2024 and March 31, 2023, farmland assets are valued as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Farmland assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,176,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,287,836&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Impairment*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,541,926&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,621,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Farmland assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;634,153&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;666,721&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $148,795.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</cjjd:FarmlandAssetsTextBlock>
    <cjjd:ScheduleOfFarmlandAssetsTableTextBlock contextRef="c0" id="ixv-24348">Farmland assets consist of ginkgo trees planted
in 2012 and expected to be harvested and sold in several years. As of March 31, 2024 and March 31, 2023, farmland assets are valued as
follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Farmland assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,176,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,287,836&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Impairment*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,541,926&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,621,115&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Farmland assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;634,153&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;666,721&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $148,795.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</cjjd:ScheduleOfFarmlandAssetsTableTextBlock>
    <cjjd:FarmlandAssetsGross contextRef="c2" decimals="0" id="ixv-24349" unitRef="usd">2176079</cjjd:FarmlandAssetsGross>
    <cjjd:FarmlandAssetsGross contextRef="c3" decimals="0" id="ixv-24350" unitRef="usd">2287836</cjjd:FarmlandAssetsGross>
    <cjjd:ImpairmentsOfFarmlandAssets contextRef="c2" decimals="0" id="ix_10_fact" unitRef="usd">1541926</cjjd:ImpairmentsOfFarmlandAssets>
    <cjjd:ImpairmentsOfFarmlandAssets contextRef="c3" decimals="0" id="ix_11_fact" unitRef="usd">1621115</cjjd:ImpairmentsOfFarmlandAssets>
    <us-gaap:Land contextRef="c2" decimals="0" id="ixv-24353" unitRef="usd">634153</us-gaap:Land>
    <us-gaap:Land contextRef="c3" decimals="0" id="ixv-24354" unitRef="usd">666721</us-gaap:Land>
    <us-gaap:ImpairmentOfRealEstate contextRef="c7" decimals="0" id="ixv-24355" unitRef="usd">148795</us-gaap:ImpairmentOfRealEstate>
    <cjjd:LongTermDepositsTextBlock contextRef="c0" id="ixv-21159">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;11 &#x2013; LONG TERM DEPOSITS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2024 and March 31, 2023, long
term deposits amounted to $1,119,006 and $1,038,125, respectively.&#160;Long term deposits are sums deposited with, or advanced to, landlords
for the purpose of securing retail store leases that the Company does not anticipate applying or being returned within the next twelve
months. Most of the Company&#x2019;s landlords require a minimum payment of nine months&#x2019; rent, paid up front, plus additional deposits.&lt;/p&gt;</cjjd:LongTermDepositsTextBlock>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-24356" unitRef="usd">1119006</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-24357" unitRef="usd">1038125</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="c0" id="ixv-21167">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;12 &#x2013; OTHER NONCURRENT ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other noncurrent assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Forest land use rights*&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;639,414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;691,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,519&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;682,437&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;790,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The amortization of the prepayment for the lease
of land use right was approximately $18,477 and $19,328 for the years ended March 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s amortizations of the prepayment
for lease of land use right for the next five years and thereafter are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Years ending March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;547,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="c0" id="ixv-24358">Other noncurrent assets consisted of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Forest land use rights*&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;639,414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;691,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,519&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;682,437&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;790,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <cjjd:ForestLandUseRights contextRef="c2" decimals="0" id="ix_12_fact" unitRef="usd">639414</cjjd:ForestLandUseRights>
    <cjjd:ForestLandUseRights contextRef="c3" decimals="0" id="ix_13_fact" unitRef="usd">691537</cjjd:ForestLandUseRights>
    <cjjd:Others contextRef="c2" decimals="0" id="ixv-24361" unitRef="usd">43023</cjjd:Others>
    <cjjd:Others contextRef="c3" decimals="0" id="ixv-24362" unitRef="usd">98519</cjjd:Others>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-24363" unitRef="usd">682437</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-24364" unitRef="usd">790056</us-gaap:OtherAssetsNoncurrent>
    <cjjd:DescriptionOfLeasePrepaymentLife contextRef="c0" id="ixv-24365">The forest rights certificate from the local village extends the life of the lease to January 31, 2060.</cjjd:DescriptionOfLeasePrepaymentLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c168" decimals="0" id="ixv-24366" unitRef="usd">18477</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c202" decimals="0" id="ixv-24367" unitRef="usd">19328</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-24368">The Company&#x2019;s amortizations of the prepayment
for lease of land use right for the next five years and thereafter are as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Years ending March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;547,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c2" decimals="0" id="ixv-24369" unitRef="usd">18477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c2" decimals="0" id="ixv-24370" unitRef="usd">18477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c2" decimals="0" id="ixv-24371" unitRef="usd">18477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c2" decimals="0" id="ixv-24372" unitRef="usd">18477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c2" decimals="0" id="ixv-24373" unitRef="usd">18477</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c2" decimals="0" id="ixv-24374" unitRef="usd">547029</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-21286">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 13 &#x2013; Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company leases most of its retail stores and
corporate offices under operating leases, typically with initial terms of 3 to 10 years. Usually within one to three months prior to the
expiration date of a lease, the Company is required to notify the lessor and has a priority to continue renting the lease property if
a lessor intends to lease property. The lease itself does not have restriction or covenants. If both parties agree to continue, a new
lease contract with new lease terms has to been signed by both parties. Usually the rent may increase year by year based on the lease
contract. Sublease is typically not allowed. Any damage, if made by the lessee, to the property and equipment within the property has
to been fixed or reimbursed by the lessee. The Company does not have any leases entered into but which have not yet commenced. The net
lease cost for the year ended March 31, 2024 is $7,487,456. The Company does not have finance lease according to the definition of ASU
2016-02, &lt;i&gt;Leases &lt;/i&gt;(Topic 842). Supplemental cash flow information related to leases for the year ended March 31, 2024 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 9pt"&gt;Operating cash flows paid for operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,487,456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Supplemental balance sheet information related
to leases as of March 31, 2024 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; padding-bottom: 4pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;13,827,360&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Current portion of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,862,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Long-term operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,403,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,266,624&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.93 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the maturity of
lease liabilities under operating leases as of March 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Operating&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;For the year ending March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,294,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,872,270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,913,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,107,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;448,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;621,050&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,257,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(990,915&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,266,624&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c203" id="ixv-24375">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c204" id="ixv-24376">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" id="ixv-24377" unitRef="usd">7487456</us-gaap:LeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-24378">Supplemental cash flow information related to leases for the year ended March 31, 2024 is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 9pt"&gt;Operating cash flows paid for operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,487,456&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;Supplemental balance sheet information related
to leases as of March 31, 2024 is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left; padding-bottom: 4pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;13,827,360&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Current portion of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,862,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Long-term operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,403,858&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,266,624&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.93 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-24379" unitRef="usd">7487456</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-24381" unitRef="usd">13827360</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-24382" unitRef="usd">4862766</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-24383" unitRef="usd">6403858</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-24384" unitRef="usd">11266624</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-24385">P3Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-24386" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-24387">The following table summarizes the maturity of
lease liabilities under operating leases as of March 31, 2024:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Operating&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;For the year ending March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,294,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,872,270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,913,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,107,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;448,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;621,050&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,257,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(990,915&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,266,624&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="0" id="ixv-24388" unitRef="usd">5294771</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="0" id="ixv-24389" unitRef="usd">2872270</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="0" id="ixv-24390" unitRef="usd">1913295</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c2" decimals="0" id="ixv-24391" unitRef="usd">1107753</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c2" decimals="0" id="ixv-24392" unitRef="usd">448400</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c2" decimals="0" id="ixv-24393" unitRef="usd">621050</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="0" id="ixv-24394" unitRef="usd">12257539</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="0" id="ixv-24395" unitRef="usd">990915</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" id="ixv-24396" unitRef="usd">11266624</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-21467">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;14 &#x2013; INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Net intangible assets consisted of the following
at:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,305,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,354,534&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,115,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,172,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,350,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,419,936&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,771,764&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,946,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,155,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,114,028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: impairment &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(606,035&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(637,159&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,009,922&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,195,748&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amortization expense of intangibles amounted to
$96,912 and $92,263 for the years ended March 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#x2019; business and liquidate all of the stores&#x2019; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#x2019; health. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In July 2013, the Company purchased the land use rights of a plot of land in Lin&#x2019;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#x2019;s farming business in Lin&#x2019;an has not grown, the Company does not expect completion of the plant in the near future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-24397">Net intangible assets consisted of the following
at:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;License &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,305,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,354,534&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,115,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,172,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Land use rights &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,350,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,419,936&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,771,764&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,946,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,155,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,114,028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: impairment &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(606,035&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(637,159&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,009,922&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,195,748&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#x2019; business and liquidate all of the stores&#x2019; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#x2019; health. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In July 2013, the Company purchased the land use rights of a plot of land in Lin&#x2019;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#x2019;s farming business in Lin&#x2019;an has not grown, the Company does not expect completion of the plant in the near future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c205"
      decimals="0"
      id="ix_14_fact"
      unitRef="usd">2305998</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c206"
      decimals="0"
      id="ix_15_fact"
      unitRef="usd">2354534</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c207"
      decimals="0"
      id="ix_16_fact"
      unitRef="usd">1115192</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c208"
      decimals="0"
      id="ix_17_fact"
      unitRef="usd">1172465</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c209"
      decimals="0"
      id="ix_18_fact"
      unitRef="usd">1350574</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c210"
      decimals="0"
      id="ix_19_fact"
      unitRef="usd">1419936</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c2" decimals="0" id="ixv-24404" unitRef="usd">4771764</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-24405" unitRef="usd">4946935</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c2" decimals="0" id="ixv-24406" unitRef="usd">1155807</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-24407" unitRef="usd">1114028</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cjjd:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill contextRef="c2" decimals="0" id="ix_20_fact" unitRef="usd">606035</cjjd:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill>
    <cjjd:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill contextRef="c3" decimals="0" id="ix_21_fact" unitRef="usd">637159</cjjd:ImpairmentOfIntangibleAssetIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="0" id="ixv-24410" unitRef="usd">3009922</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-24411" unitRef="usd">3195748</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-24412" unitRef="usd">96912</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c6" decimals="0" id="ixv-24413" unitRef="usd">92263</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-21613">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;15 &#x2013; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has credit facilities with Hangzhou
United Bank (&#x201c;HUB&#x201d;), Bank of Hangzhou (&#x201c;BOH&#x201d;), and China Merchant Bank (&#x201c;CMB&#x201d;) that provided working
capital in the form of the following bank acceptance notes. Usually, the Company applies to issue a note, which is guaranteed by the bank,
to its supplier to pay off its debt in a future date. Before the payment date, the bank will ask the Company to inject cash into the bank.
On the payment date, the bank will pay the amount to whoever legally holds the note. As of at March 31, 2024 and March 31, 2023, the balances
of notes payable are as follow:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Origination&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Maturity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beneficiary&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Endorser&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 40%; text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;HUB&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;10/19/22&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;04/19/23&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,289,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/20/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;04/19/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;11/17/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;05/17/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,576,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/16/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,207,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/26/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/28/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/29/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,654,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;02/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;08/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,242,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,573,664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/23/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/23/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;11/17/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;05/17/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,303,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/16/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,704,790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/21/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/21/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/29/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/29/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,215,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;803,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/12/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;04/12/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,126,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;11/21/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;05/21/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,703,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/22/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/22/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,040,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/27/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;274,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/28/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/03/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/03/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;02/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;08/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,189,602&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/13/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/13/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,274,739&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/14/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/14/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;969,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/27/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/28/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,689,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,234,494&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;02/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;08/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/15/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/15/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;HUB&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;03/29/24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;09/29/24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;359,179&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,676,335&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,255,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2024, the Company had a credit
line of approximately $19.25 million in the aggregate&#160;from HUB. By putting up a three-year deposit of $4.50 million and the restricted
cash of $8.16 million deposited in the banks, the total credit line was $31.91 million. As of March 31, 2024, the Company had approximately
$31.68 million of bank notes payable and approximately $0.23 million bank credit line was still available for further borrowing. The bank
notes are secured by three shops of Jiuzhou Pharmacy and guaranteed by the Company&#x2019;s major shareholders.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c0" id="ixv-24416">As of at March 31, 2024 and March 31, 2023, the balances
of notes payable are as follow:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Origination&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Maturity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beneficiary&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Endorser&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 40%; text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;HUB&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;10/19/22&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;04/19/23&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,289,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/20/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;04/19/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;11/17/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;05/17/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,576,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/16/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,207,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/26/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/28/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/29/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,654,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;02/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;08/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,242,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,573,664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/23/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/23/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;440,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;11/17/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;05/17/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,303,221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/16/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/16/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,704,790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/21/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/21/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/29/22&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/29/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,215,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/20/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;803,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/12/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;04/12/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,126,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;11/21/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;05/21/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,703,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/22/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/22/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,040,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/27/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;274,683&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/28/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/03/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/03/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;02/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;08/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,189,602&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/13/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/13/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,274,739&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuzhou Pharmacy&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/14/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/14/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;969,489&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/27/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/27/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;12/28/23&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;06/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,689,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;01/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;07/11/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,234,494&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;02/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;08/06/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;186,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/15/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/15/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;415,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;HUB&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;03/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;09/28/24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Jiuxin Medicine&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;HUB&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;03/29/24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;09/29/24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;359,179&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,676,335&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,255,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: .25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentIssuer contextRef="c216" id="ix_22_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c216" id="ix_23_fact">2022-10-19</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c216" id="ix_24_fact">2023-04-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c218"
      decimals="0"
      id="ix_25_fact"
      unitRef="usd">3289434</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c219" id="ix_26_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c219" id="ix_27_fact">2022-10-20</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c219" id="ix_28_fact">2023-04-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c221"
      decimals="0"
      id="ix_29_fact"
      unitRef="usd">36403</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c222" id="ix_30_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c222" id="ix_31_fact">2022-11-17</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c222" id="ix_32_fact">2023-05-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c224"
      decimals="0"
      id="ix_33_fact"
      unitRef="usd">5576213</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c225" id="ix_34_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c225" id="ix_35_fact">2022-12-16</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c225" id="ix_36_fact">2023-06-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c227"
      decimals="0"
      id="ix_37_fact"
      unitRef="usd">1207565</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c228" id="ix_38_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c228" id="ix_39_fact">2022-12-26</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c228" id="ix_40_fact">2023-06-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c230"
      decimals="0"
      id="ix_41_fact"
      unitRef="usd">659883</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c231" id="ix_42_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c231" id="ix_43_fact">2022-12-28</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c231" id="ix_44_fact">2023-06-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c233"
      decimals="0"
      id="ix_45_fact"
      unitRef="usd">2654696</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c234" id="ix_46_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c234" id="ix_47_fact">2023-01-16</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c234" id="ix_48_fact">2023-07-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c236"
      decimals="0"
      id="ix_49_fact"
      unitRef="usd">346545</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c237" id="ix_50_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c237" id="ix_51_fact">2023-02-27</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c237" id="ix_52_fact">2023-08-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c239"
      decimals="0"
      id="ix_53_fact"
      unitRef="usd">3242559</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c240" id="ix_54_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c240" id="ix_55_fact">2023-03-20</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c240" id="ix_56_fact">2023-09-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c242"
      decimals="0"
      id="ix_57_fact"
      unitRef="usd">4573664</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c243" id="ix_58_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c243" id="ix_59_fact">2023-03-23</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c243" id="ix_60_fact">2023-09-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c245"
      decimals="0"
      id="ix_61_fact"
      unitRef="usd">440391</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c246" id="ix_62_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c246" id="ix_63_fact">2022-11-17</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c246" id="ix_64_fact">2023-05-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c248"
      decimals="0"
      id="ix_65_fact"
      unitRef="usd">1303221</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c249" id="ix_66_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c249" id="ix_67_fact">2022-12-16</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c249" id="ix_68_fact">2023-06-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c251"
      decimals="0"
      id="ix_69_fact"
      unitRef="usd">3704790</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c252" id="ix_70_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c252" id="ix_71_fact">2022-12-21</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c252" id="ix_72_fact">2023-06-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c254"
      decimals="0"
      id="ix_73_fact"
      unitRef="usd">200741</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c255" id="ix_74_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c255" id="ix_75_fact">2022-12-29</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c255" id="ix_76_fact">2023-06-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c257"
      decimals="0"
      id="ix_77_fact"
      unitRef="usd">1215854</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c258" id="ix_78_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c258" id="ix_79_fact">2023-03-20</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c258" id="ix_80_fact">2023-09-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c260"
      decimals="0"
      id="ix_81_fact"
      unitRef="usd">803817</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c261" id="ix_82_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c261" id="ix_83_fact">2023-10-12</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c261" id="ix_84_fact">2024-04-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c262"
      decimals="0"
      id="ix_85_fact"
      unitRef="usd">5126621</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c264" id="ix_86_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c264" id="ix_87_fact">2023-11-21</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c264" id="ix_88_fact">2024-05-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c265"
      decimals="0"
      id="ix_89_fact"
      unitRef="usd">5703704</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c267" id="ix_90_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c267" id="ix_91_fact">2023-12-22</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c267" id="ix_92_fact">2024-06-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c268"
      decimals="0"
      id="ix_93_fact"
      unitRef="usd">6040374</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c270" id="ix_94_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c270" id="ix_95_fact">2023-12-27</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c270" id="ix_96_fact">2024-06-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c271"
      decimals="0"
      id="ix_97_fact"
      unitRef="usd">274683</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c273" id="ix_98_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c273" id="ix_99_fact">2023-12-28</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c273" id="ix_100_fact">2024-06-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c274"
      decimals="0"
      id="ix_101_fact"
      unitRef="usd">151882</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c276" id="ix_102_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c276" id="ix_103_fact">2024-01-03</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c276" id="ix_104_fact">2024-07-03</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c277"
      decimals="0"
      id="ix_105_fact"
      unitRef="usd">102713</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c279" id="ix_106_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c279" id="ix_107_fact">2024-01-11</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c279" id="ix_108_fact">2024-07-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c280"
      decimals="0"
      id="ix_109_fact"
      unitRef="usd">248086</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c282" id="ix_110_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c282" id="ix_111_fact">2024-02-06</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c282" id="ix_112_fact">2024-08-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c283"
      decimals="0"
      id="ix_113_fact"
      unitRef="usd">3189602</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c285" id="ix_114_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c285" id="ix_115_fact">2024-03-13</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c285" id="ix_116_fact">2024-09-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c286"
      decimals="0"
      id="ix_117_fact"
      unitRef="usd">3274739</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c288" id="ix_118_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c288" id="ix_119_fact">2024-03-14</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c288" id="ix_120_fact">2024-09-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c289"
      decimals="0"
      id="ix_121_fact"
      unitRef="usd">969489</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c291" id="ix_122_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c291" id="ix_123_fact">2023-12-27</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c291" id="ix_124_fact">2024-06-27</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c292"
      decimals="0"
      id="ix_125_fact"
      unitRef="usd">415495</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c294" id="ix_126_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c294" id="ix_127_fact">2023-12-28</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c294" id="ix_128_fact">2024-06-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c295"
      decimals="0"
      id="ix_129_fact"
      unitRef="usd">1689726</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c297" id="ix_130_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c297" id="ix_131_fact">2024-01-11</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c297" id="ix_132_fact">2024-07-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c298"
      decimals="0"
      id="ix_133_fact"
      unitRef="usd">3234494</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c300" id="ix_134_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c300" id="ix_135_fact">2024-02-06</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c300" id="ix_136_fact">2024-08-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c301"
      decimals="0"
      id="ix_137_fact"
      unitRef="usd">186973</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c302" id="ix_138_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c302" id="ix_139_fact">2024-03-15</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c302" id="ix_140_fact">2024-09-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c303"
      decimals="0"
      id="ix_141_fact"
      unitRef="usd">415495</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c304" id="ix_142_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c304" id="ix_143_fact">2024-03-28</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c304" id="ix_144_fact">2024-09-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c305"
      decimals="0"
      id="ix_145_fact"
      unitRef="usd">293080</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentIssuer contextRef="c306" id="ix_146_fact">HUB</us-gaap:DebtInstrumentIssuer>
    <cjjd:DebtInstrumentIOriginationDate contextRef="c306" id="ix_147_fact">2024-03-29</cjjd:DebtInstrumentIOriginationDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c306" id="ix_148_fact">2024-09-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:NotesPayableCurrent
      contextRef="c307"
      decimals="0"
      id="ix_149_fact"
      unitRef="usd">359179</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="0" id="ix_150_fact" unitRef="usd">31676335</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="0" id="ix_151_fact" unitRef="usd">29255776</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="0" id="ixv-24547" unitRef="usd">31676335</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="0" id="ixv-24548" unitRef="cny">228712642</us-gaap:NotesPayableCurrent>
    <us-gaap:RestrictedCash contextRef="c211" decimals="0" id="ixv-24549" unitRef="usd">12657839</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c211" decimals="0" id="ixv-24550" unitRef="cny">91393395</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentCollateralAmount contextRef="c212" decimals="0" id="ixv-24551" unitRef="usd">4501198</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount contextRef="c212" decimals="0" id="ixv-24552" unitRef="cny">32500000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:NotesPayableCurrent contextRef="c213" decimals="0" id="ixv-24553" unitRef="usd">29255776</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c213" decimals="0" id="ixv-24554" unitRef="cny">200916968</us-gaap:NotesPayableCurrent>
    <us-gaap:RestrictedCash contextRef="c213" decimals="0" id="ixv-24555" unitRef="usd">12217616</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c213" decimals="0" id="ixv-24556" unitRef="cny">83905700</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentCollateralAmount contextRef="c214" decimals="0" id="ixv-24557" unitRef="usd">4732366</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount contextRef="c214" decimals="0" id="ixv-24558" unitRef="cny">32500000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c211"
      decimals="-4"
      id="ixv-24559"
      unitRef="usd">19250000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:Deposits
      contextRef="c212"
      decimals="-4"
      id="ixv-24560"
      unitRef="usd">4500000</us-gaap:Deposits>
    <us-gaap:RestrictedCash
      contextRef="c212"
      decimals="-4"
      id="ixv-24561"
      unitRef="usd">8160000</us-gaap:RestrictedCash>
    <us-gaap:LineOfCredit
      contextRef="c212"
      decimals="-4"
      id="ixv-24562"
      unitRef="usd">31910000</us-gaap:LineOfCredit>
    <us-gaap:NotesPayableCurrent
      contextRef="c215"
      decimals="-4"
      id="ixv-24563"
      unitRef="usd">31680000</us-gaap:NotesPayableCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c212"
      decimals="-4"
      id="ixv-24564"
      unitRef="usd">230000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cjjd:LoanPayableTextBlock contextRef="c0" id="ixv-22233">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 16 &#x2013; LOAN PAYABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 4, 2023, Jiuzhou&#160;Service signed
a Maximum Amount Pledge Contract with Industrial and Commercial Bank of China, pledging Mr. Lei Liu&#x2019;s land use rights and property
ownership as security, for a loan facility with a maximum principal amount of US$1.60(RMB11.49) million during the period from August
4, 2023 to August 4, 2028. As of March 31, 2024, the outstanding amount of the short-term bank loan under this pledge contract was US$276,997(RMB2,000,000)
..&lt;/p&gt;</cjjd:LoanPayableTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c309" decimals="2" id="ixv-24565" unitRef="usd">1.6</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c310" decimals="2" id="ixv-24566" unitRef="cny">11.49</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c0" decimals="0" id="ixv-24567" unitRef="usd">276997</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c0" decimals="0" id="ixv-24568" unitRef="cny">2000000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-22241">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note&#160;17 &#x2013; TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Income tax&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income tax expense includes a provision for federal,
state and foreign taxes based on the annual estimated effective tax rate applicable to the Company and its subsidiaries, adjusted for
items which are considered discrete to the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effective tax rates on income before income
taxes for the year ended March 31, 2024 was (1.5)%. The (1.5)% rate adjustments for the year ended March 31, 2024 represent expenses that
primarily include legal, accounting and other expenses incurred by the Company that are not deductible for PRC income tax.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effective tax rates on income before income
taxes for the year ended March 31, 2023 was (1.9)%. The (1.9)% rate adjustments for the year ended March 31, 2023 represent expenses that
primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible for PRC
income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through the rest
of the year as a result of the unpredictable impact of COVID-19 on the Company&#x2019;s operating activities.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The effective tax rates on income before income
taxes for the year ended March 31, 2022 was (52.4)%. The (52.4)% rate adjustments for the year ended March 31, 2022 represent expenses
that primarily include stock option expenses and legal, accounting and other expenses incurred by the Company that are not deductible
for PRC income tax. The effective tax rate is based on forecasted annual results and these amounts may fluctuate significantly through
the rest of the year as a result of the unpredictable impact of COVID-19 on the Company&#x2019;s operating activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the income tax provision at
the federal statutory rate and the effective rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended &lt;br/&gt; March 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;U.S. Statutory rates&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foreign income not recognized in the U.S.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;China income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-deductible expenses-permanent difference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(52.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(52.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has recorded $0 unrecognized benefit
as of March 31, 2024. On the information currently available, the Company does not anticipate a significant increase or decrease to its
unrecognized benefit within the next 12 months.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="3" id="ixv-24569" unitRef="pure">-0.015</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c0" decimals="3" id="ixv-24570" unitRef="pure">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c6" decimals="3" id="ixv-24571" unitRef="pure">-0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c6" decimals="3" id="ixv-24572" unitRef="pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c7" decimals="3" id="ixv-24573" unitRef="pure">-0.524</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c7" decimals="3" id="ixv-24574" unitRef="pure">-0.524</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-24575">A reconciliation of the income tax provision at
the federal statutory rate and the effective rate is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the year ended &lt;br/&gt; March 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;U.S. Statutory rates&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foreign income not recognized in the U.S.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;China income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-deductible expenses-permanent difference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1.5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(52.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(52.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" id="ixv-24576" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="3" id="ixv-24577" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="3" id="ixv-24578" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="3" id="ixv-24579" unitRef="pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c6" decimals="3" id="ixv-24580" unitRef="pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c7" decimals="3" id="ixv-24581" unitRef="pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign contextRef="c0" decimals="3" id="ixv-24582" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign contextRef="c6" decimals="3" id="ixv-24583" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign contextRef="c7" decimals="3" id="ixv-24584" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" id="ixv-24585" unitRef="pure">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="3" id="ixv-24586" unitRef="pure">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="3" id="ixv-24587" unitRef="pure">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c0" decimals="3" id="ixv-24588" unitRef="pure">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c6" decimals="3" id="ixv-24589" unitRef="pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c7" decimals="3" id="ixv-24590" unitRef="pure">-0.524</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="3" id="ixv-24591" unitRef="pure">-0.015</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c6" decimals="3" id="ixv-24592" unitRef="pure">-0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c7" decimals="3" id="ixv-24593" unitRef="pure">-0.524</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c2" decimals="0" id="ixv-24594" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c0" id="ixv-22366">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 18 &#x2013; POSTRETIREMENT BENEFITS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Regulations in the PRC require the Company to
contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage
of the employee&#x2019;s current compensation as required by the local government. The Company contributed $1,325,312, $1,284,218 and $1,301,315
in employment benefits and pension for the years ended March 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c0" decimals="0" id="ixv-24595" unitRef="usd">1325312</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c6" decimals="0" id="ixv-24596" unitRef="usd">1284218</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="c7" decimals="0" id="ixv-24597" unitRef="usd">1301315</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-22385">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 19 &#x2013; RELATED PARTY TRANSACTIONS
AND ARRANGEMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Summary of Balances with Related Parties as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Due from related parties:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hangzhou Kahamadi Biotechnology Co., Ltd&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,825&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Others (the directors of subsidiaries)&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;280,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;313,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lend to related parties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Due to related parties:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due to a director and CEO&lt;sup&gt;(2)&lt;/sup&gt;:&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,580,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;683,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;sup&gt;(3)&lt;/sup&gt;:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;253,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,833,509&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683,560&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advances to directors of our subsidiaries.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due to foreign exchange restrictions, the Company&#x2019;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Linjia Medical borrowed from its non-controlling shareholder.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-24598">Summary of Balances with Related Parties as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Due from related parties:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hangzhou Kahamadi Biotechnology Co., Ltd&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,825&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Others (the directors of subsidiaries)&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;280,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;313,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lend to related parties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Due to related parties:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due to a director and CEO&lt;sup&gt;(2)&lt;/sup&gt;:&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,580,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;683,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;sup&gt;(3)&lt;/sup&gt;:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;253,452&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,833,509&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;683,560&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due to foreign exchange restrictions, the Company&#x2019;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.35in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Linjia Medical borrowed from its non-controlling shareholder.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherReceivables
      contextRef="c311"
      decimals="0"
      id="ix_152_fact"
      unitRef="usd">32825</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="c313"
      decimals="0"
      id="ix_153_fact"
      unitRef="usd">280521</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c4" decimals="0" id="ixv-24601" unitRef="usd">313346</us-gaap:OtherReceivables>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c315"
      decimals="0"
      id="ix_154_fact"
      unitRef="usd">1580057</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c316"
      decimals="0"
      id="ix_155_fact"
      unitRef="usd">683560</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c313"
      decimals="0"
      id="ix_156_fact"
      unitRef="usd">253452</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-24605" unitRef="usd">1833509</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="0" id="ixv-24606" unitRef="usd">683560</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-22524">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 20 &#x2013; SHAREHOLDER&#x2019;S EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Ordinary shares&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 26, 2023, the Company closed a private
placement of 498,000 shares of ordinary shares at $5.20 per share with gross proceeds of $2,589,600.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 1, 2024, the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares. Upon the effectiveness of the reverse stock split, every 20 shares of the Company&#x2019;s issued and
outstanding ordinary shares were automatically be converted into one issued and outstanding ordinary share. No fractional shares were
issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split were rounded up
to the next whole number. The reverse stock split affects all shareholders uniformly and will not alter any shareholder&#x2019;s percentage
interest in the Company&#x2019;s outstanding ordinary shares, except for adjustments that may result from the treatment of fractional shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concurrent with the registered direct offering
of common stock that closed on April 15, 2019, the Company issued to several investors in a private placement warrants to purchase up
to 12,501 shares of common stock. In connection with the offering, the Company also issued a warrant to its placement agent of this offering,
pursuant to which the agent may purchase up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 1,000 shares
at an exercise price of $750 per share. The warrant became exercisable on October 11, 2019 and has expired on April 11, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concurrent with the registered direct offering
of common stock that closed on June 3, 2020, the Company issued to several investors in a private placement warrants to purchase up to
15,625 shares of common stock. In connection with the offering, the Company also issued warrants to its placement agent of this offering,
pursuant to which the agent may purchase up to 6.5% of the aggregate number of shares of common stock sold in the offering, i.e. 1,250
shares at an exercise price of $616.8 per share. The warrant becomes exercisable on December 2, 2020 and will expire on June 2, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concurrent with the registered direct offering
of ordinary shares that closed on September 26, 2023, the Company issued to several investors warrants to purchase up to 996,000 shares
of ordinary shares at an exercise price of $5.20. The warrant became exercisable on September 26, 2023 and valid for three years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Statutory reserves&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Statutory reserves represent restricted retained
earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts
on an annual basis to the Statutory Surplus Reserve Fund (the &#x201c;Reserve Fund&#x201d;). Once the total amount set aside in the Reserve
Fund reaches 50% of the entity&#x2019;s registered capital, further appropriations become discretionary. The Reserve Fund can be used to
increase the entity&#x2019;s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC
GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividends or otherwise,
except in the event of liquidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Appropriations to the Reserve Fund are accounted
for as a transfer from unrestricted earnings to statutory reserves. During the years ended March 31, 2024 and 2023, the Company did not
make appropriations to statutory reserves.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There are no legal requirements in the PRC to
fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c66"
      decimals="0"
      id="ixv-24607"
      unitRef="shares">498000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c65"
      decimals="2"
      id="ixv-24608"
      unitRef="usdPershares">5.2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c66" decimals="0" id="ixv-24609" unitRef="usd">2589600</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c0" id="ixv-24610">the Company effected a 1-for-20&#160;reverse
stock split on its ordinary shares</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="c317"
      decimals="0"
      id="ixv-24611"
      unitRef="shares">20</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c317"
      decimals="0"
      id="ixv-24612"
      unitRef="shares">20</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c318"
      decimals="0"
      id="ixv-24613"
      unitRef="shares">12501</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <cjjd:AggregateSharePercentage
      contextRef="c319"
      decimals="2"
      id="ixv-24614"
      unitRef="pure">0.06</cjjd:AggregateSharePercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c320"
      decimals="0"
      id="ixv-24615"
      unitRef="shares">1000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c321"
      decimals="0"
      id="ixv-24616"
      unitRef="usdPershares">750</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c322"
      decimals="0"
      id="ixv-24617"
      unitRef="shares">15625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <cjjd:AggregateSharePercentage
      contextRef="c322"
      decimals="3"
      id="ixv-24618"
      unitRef="pure">0.065</cjjd:AggregateSharePercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c323"
      decimals="0"
      id="ixv-24619"
      unitRef="shares">1250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c322"
      decimals="1"
      id="ixv-24620"
      unitRef="usdPershares">616.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c324"
      decimals="0"
      id="ixv-24621"
      unitRef="shares">996000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c324"
      decimals="2"
      id="ixv-24622"
      unitRef="usdPershares">5.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cjjd:StatutoryAccountsPercentage contextRef="c0" decimals="2" id="ixv-24623" unitRef="pure">0.10</cjjd:StatutoryAccountsPercentage>
    <cjjd:ReserveFundPercentage contextRef="c0" decimals="2" id="ixv-24624" unitRef="pure">0.50</cjjd:ReserveFundPercentage>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-22569">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 21 &#x2013; NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reports earnings per share in accordance
with the provisions of the FASB&#x2019;s related accounting standard. This standard requires presentation of basic and diluted earnings
per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes
dilution, but includes vested restricted stocks and is computed by dividing income available to ordinary shareholders by the weighted
average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur
if securities or other contracts to issue ordinary shares were exercised and converted into ordinary shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is a reconciliation of the basic
and diluted earnings per share computation:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss attributable to controlling interest&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,234,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21,138,525&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,192,119&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average shares used in basic computation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,444,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Diluted effect of stock options and warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average shares used in diluted computation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,444,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loss per share &#x2013; Basic:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss before noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Add: Net loss attributable to noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loss per share &#x2013; Diluted:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net income before noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Add: Net loss attributable to noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended March 31, 2024, 1,024,126 shares
underlying outstanding purchase warrants to several investors, and 2,250 shares underlying outstanding purchase warrants to an investment
placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-24625">The following is a reconciliation of the basic
and diluted earnings per share computation:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net loss attributable to controlling interest&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,234,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21,138,525&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,192,119&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average shares used in basic computation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,444,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Diluted effect of stock options and warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average shares used in diluted computation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,444,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;509,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,966&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loss per share &#x2013; Basic:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss before noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Add: Net loss attributable to noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loss per share &#x2013; Diluted:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net income before noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Add: Net loss attributable to noncontrolling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss attributable to controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(41.46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-24626" unitRef="usd">-4234228</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" id="ixv-24627" unitRef="usd">-21138525</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-24628" unitRef="usd">-3192119</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-24629"
      unitRef="shares">1444263</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-24630"
      unitRef="shares">509828</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-24631"
      unitRef="shares">173966</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-24632"
      unitRef="shares">1444263</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-24633"
      unitRef="shares">509828</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ixv-24634"
      unitRef="shares">173966</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest
      contextRef="c0"
      decimals="2"
      id="ixv-24635"
      unitRef="usdPershares">-2.93</cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest>
    <cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest
      contextRef="c6"
      decimals="2"
      id="ixv-24636"
      unitRef="usdPershares">-41.46</cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest>
    <cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest
      contextRef="c7"
      decimals="2"
      id="ixv-24637"
      unitRef="usdPershares">-18.35</cjjd:EarningsPerShareBasicBeforeNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-24638"
      unitRef="usdPershares">-2.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-24639"
      unitRef="usdPershares">-41.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-24640"
      unitRef="usdPershares">-18.35</us-gaap:EarningsPerShareBasic>
    <cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest
      contextRef="c0"
      decimals="2"
      id="ixv-24641"
      unitRef="usdPershares">-2.93</cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest>
    <cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest
      contextRef="c6"
      decimals="2"
      id="ixv-24642"
      unitRef="usdPershares">-41.46</cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest>
    <cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest
      contextRef="c7"
      decimals="2"
      id="ixv-24643"
      unitRef="usdPershares">-18.35</cjjd:EarningsPerShareDilutedBeforeNoncontrollingInterest>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-24644"
      unitRef="usdPershares">-2.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-24645"
      unitRef="usdPershares">-41.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-24646"
      unitRef="usdPershares">-18.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-24647"
      unitRef="shares">1024126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c325"
      decimals="0"
      id="ixv-24648"
      unitRef="shares">2250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-22787">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 22 &#x2013; SEGMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates within three main reportable
segments: retail drugstores, online pharmacy, and drug wholesale. The retail drugstores segment sells prescription and over-the-counter
(&#x201c;OTC&#x201d;) medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers.&#160;The online pharmacy
sells prescription drugs, OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms
such as Alibaba&#x2019;s Tmall, JD.com and Amazon.com, and the Company&#x2019;s own platform all over China. The drug wholesale segment
includes supplying the Company&#x2019;s own retail&#160;drugstores with prescription and OTC medicines, TCM, dietary supplement, medical
devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors
and hospitals. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable
segments and are included in the retail drugstores segment. The segments&#x2019; accounting policies are the same as those described in
the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest
and income taxes not including nonrecurring gains and losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s reportable business segments
are strategic business units that offer different products and services. Each segment is managed separately because they require different
operations and markets to distinct classes of customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Retail &lt;br/&gt; drugstores&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Online &lt;br/&gt; Pharmacy&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug &lt;br/&gt; wholesale&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154,541,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cost of goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,056,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,249,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,126,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,432,529&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22,622,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,608,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,878,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31,108,548&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,680,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,770,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934,223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,385,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,195,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;466,151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,596,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,257,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss&#160;from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,253,531&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,629,006&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,974&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,534,563&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;754,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;36,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;790,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;855,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;856,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Retail &lt;br/&gt; drugstores&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Online &lt;br/&gt; Pharmacy&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug &lt;br/&gt; wholesale&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148,811,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cost of goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,551,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,506,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,473,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,531,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26,800,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,878,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,601,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;34,280,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,644,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,266,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,266,025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,177,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,803,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;439,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,425,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,668,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,360,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,360,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss&#160;from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,007,343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(827,605&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;909,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,925,383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;686,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;718,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;303,312&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;304,016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Retail &lt;br/&gt; drugstores&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Online &lt;br/&gt; Pharmacy&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug &lt;br/&gt; wholesale&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;164,392,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cost of goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,290,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,621,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,961,351&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,873,515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26,937,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,598,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,983,348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;36,519,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,186,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,972,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,718,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,876,959&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,766,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,136,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,187,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Impairment of long-lived assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,795&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,795&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss&#160;from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,163,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(659,477&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,129,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,693,890&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,234,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,256,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;296,562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;299,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company does not have long-lived assets located
outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB&#x2019;s accounting standard, the Company&#x2019;s
net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2024, 2023 and
2022 were as follows:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;For the years ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,269,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,212,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,503,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,542,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,358,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,658,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,890,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,737,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,664,071&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,405,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,719,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,353,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,544,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,440,085&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,241,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,503,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s net revenue from external
customers through online pharmacy by main product category is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;For the years&#160;ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,151,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,606,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,331,652&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,969,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,870,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,473,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,284,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,740,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,448,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,271,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,432,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,603,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,814,284&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s net revenue from external
customers through wholesale by main product category is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;For the years&#160;ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,784,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,617,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,116,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,289,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,903,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;741,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,073,665&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;333,663&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;164,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c326"
      decimals="0"
      id="ixv-24649"
      unitRef="pure">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-24650">The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2024:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Retail &lt;br/&gt; drugstores&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Online &lt;br/&gt; Pharmacy&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug &lt;br/&gt; wholesale&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;154,541,077&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cost of goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,056,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,249,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,126,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123,432,529&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22,622,131&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,608,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,878,417&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31,108,548&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,680,509&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,770,855&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934,223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,385,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,195,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;466,151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,596,220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,257,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss&#160;from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,253,531&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,629,006&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,347,974&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,534,563&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;754,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;36,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;790,449&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;855,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;856,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2023:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Retail &lt;br/&gt; drugstores&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Online &lt;br/&gt; Pharmacy&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug &lt;br/&gt; wholesale&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148,811,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cost of goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,551,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,506,228&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,473,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,531,512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26,800,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,878,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,601,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;34,280,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,644,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,266,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,266,025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,177,163&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,803,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;439,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,425,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,668,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,360,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,360,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss&#160;from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,007,343&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(827,605&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;909,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,925,383&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;686,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;718,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;303,312&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;304,016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The following table presents summarized information
by segment of the continuing operations for the year ended March 31, 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Retail &lt;br/&gt; drugstores&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Online &lt;br/&gt; Pharmacy&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Drug &lt;br/&gt; wholesale&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;164,392,555&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Cost of goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,290,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,621,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,961,351&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,873,515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26,937,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,598,050&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,983,348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;36,519,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,186,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,972,465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,718,236&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,876,959&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,766,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;285,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,136,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,187,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Impairment of long-lived assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,795&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,795&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss&#160;from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,163,433&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(659,477&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,129,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,693,890&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,234,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,256,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total capital expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;296,562&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;299,473&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c327" decimals="0" id="ixv-24651" unitRef="usd">75678470</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c328" decimals="0" id="ixv-24652" unitRef="usd">31857883</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c329" decimals="0" id="ixv-24653" unitRef="usd">47004724</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-24654" unitRef="usd">154541077</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c327" decimals="0" id="ixv-24655" unitRef="usd">53056339</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c328" decimals="0" id="ixv-24656" unitRef="usd">28249883</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c329" decimals="0" id="ixv-24657" unitRef="usd">42126307</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-24658" unitRef="usd">123432529</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c327" decimals="0" id="ixv-24659" unitRef="usd">22622131</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c328" decimals="0" id="ixv-24660" unitRef="usd">3608000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c329" decimals="0" id="ixv-24661" unitRef="usd">4878417</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-24662" unitRef="usd">31108548</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c327" decimals="0" id="ixv-24663" unitRef="usd">21680509</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c328" decimals="0" id="ixv-24664" unitRef="usd">4770855</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c329" decimals="0" id="ixv-24665" unitRef="usd">934223</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c0" decimals="0" id="ixv-24666" unitRef="usd">27385587</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c327" decimals="0" id="ixv-24667" unitRef="usd">5195153</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c328" decimals="0" id="ixv-24668" unitRef="usd">466151</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c329" decimals="0" id="ixv-24669" unitRef="usd">1596220</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-24670" unitRef="usd">7257524</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c327" decimals="0" id="ixv-24671" unitRef="usd">-4253531</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c328" decimals="0" id="ixv-24672" unitRef="usd">-1629006</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c329" decimals="0" id="ixv-24673" unitRef="usd">2347974</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-24674" unitRef="usd">-3534563</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c327" decimals="0" id="ixv-24675" unitRef="usd">754448</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c329" decimals="0" id="ixv-24676" unitRef="usd">36001</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="0" id="ixv-24677" unitRef="usd">790449</us-gaap:DepreciationAndAmortization>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c327" decimals="0" id="ixv-24678" unitRef="usd">855497</cjjd:CapitalExpenditureContinuedOperations>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c329" decimals="0" id="ixv-24679" unitRef="usd">1168</cjjd:CapitalExpenditureContinuedOperations>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c0" decimals="0" id="ixv-24680" unitRef="usd">856665</cjjd:CapitalExpenditureContinuedOperations>
    <us-gaap:Revenues contextRef="c330" decimals="0" id="ixv-24682" unitRef="usd">83351768</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c331" decimals="0" id="ixv-24683" unitRef="usd">32385089</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c332" decimals="0" id="ixv-24684" unitRef="usd">33075119</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" id="ixv-24685" unitRef="usd">148811976</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c330" decimals="0" id="ixv-24686" unitRef="usd">56551607</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c331" decimals="0" id="ixv-24687" unitRef="usd">28506228</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c332" decimals="0" id="ixv-24688" unitRef="usd">29473677</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c6" decimals="0" id="ixv-24689" unitRef="usd">114531512</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c330" decimals="0" id="ixv-24690" unitRef="usd">26800161</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c331" decimals="0" id="ixv-24691" unitRef="usd">3878861</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c332" decimals="0" id="ixv-24692" unitRef="usd">3601442</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" id="ixv-24693" unitRef="usd">34280464</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c330" decimals="0" id="ixv-24694" unitRef="usd">23644339</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c331" decimals="0" id="ixv-24695" unitRef="usd">4266799</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c332" decimals="0" id="ixv-24696" unitRef="usd">1266025</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c6" decimals="0" id="ixv-24697" unitRef="usd">29177163</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c330" decimals="0" id="ixv-24698" unitRef="usd">13803165</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c331" decimals="0" id="ixv-24699" unitRef="usd">439667</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c332" decimals="0" id="ixv-24700" unitRef="usd">1425852</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="0" id="ixv-24701" unitRef="usd">15668684</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensation contextRef="c330" decimals="0" id="ixv-24702" unitRef="usd">10360000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" id="ixv-24703" unitRef="usd">10360000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingIncomeLoss contextRef="c330" decimals="0" id="ixv-24704" unitRef="usd">-21007343</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c331" decimals="0" id="ixv-24705" unitRef="usd">-827605</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c332" decimals="0" id="ixv-24706" unitRef="usd">909565</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" id="ixv-24707" unitRef="usd">-20925383</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c330" decimals="0" id="ixv-24708" unitRef="usd">686777</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c332" decimals="0" id="ixv-24709" unitRef="usd">31225</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="0" id="ixv-24710" unitRef="usd">718002</us-gaap:DepreciationAndAmortization>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c330" decimals="0" id="ixv-24711" unitRef="usd">303312</cjjd:CapitalExpenditureContinuedOperations>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c332" decimals="0" id="ixv-24712" unitRef="usd">704</cjjd:CapitalExpenditureContinuedOperations>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c6" decimals="0" id="ixv-24713" unitRef="usd">304016</cjjd:CapitalExpenditureContinuedOperations>
    <us-gaap:Revenues contextRef="c333" decimals="0" id="ixv-24715" unitRef="usd">84228492</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c334" decimals="0" id="ixv-24716" unitRef="usd">30219364</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c335" decimals="0" id="ixv-24717" unitRef="usd">49944699</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="0" id="ixv-24718" unitRef="usd">164392555</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c333" decimals="0" id="ixv-24719" unitRef="usd">57290850</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c334" decimals="0" id="ixv-24720" unitRef="usd">26621314</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c335" decimals="0" id="ixv-24721" unitRef="usd">43961351</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c7" decimals="0" id="ixv-24722" unitRef="usd">127873515</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c333" decimals="0" id="ixv-24723" unitRef="usd">26937642</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c334" decimals="0" id="ixv-24724" unitRef="usd">3598050</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c335" decimals="0" id="ixv-24725" unitRef="usd">5983348</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="0" id="ixv-24726" unitRef="usd">36519040</us-gaap:GrossProfit>
    <us-gaap:SellingExpense contextRef="c333" decimals="0" id="ixv-24727" unitRef="usd">25186258</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c334" decimals="0" id="ixv-24728" unitRef="usd">3972465</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c335" decimals="0" id="ixv-24729" unitRef="usd">1718236</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="c7" decimals="0" id="ixv-24730" unitRef="usd">30876959</us-gaap:SellingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c333" decimals="0" id="ixv-24731" unitRef="usd">6766022</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c334" decimals="0" id="ixv-24732" unitRef="usd">285062</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c335" decimals="0" id="ixv-24733" unitRef="usd">1136092</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-24734" unitRef="usd">8187176</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c333" decimals="0" id="ixv-24735" unitRef="usd">148795</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c7" decimals="0" id="ixv-24736" unitRef="usd">148795</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingIncomeLoss contextRef="c333" decimals="0" id="ixv-24737" unitRef="usd">-5163433</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c334" decimals="0" id="ixv-24738" unitRef="usd">-659477</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c335" decimals="0" id="ixv-24739" unitRef="usd">3129020</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-24740" unitRef="usd">-2693890</us-gaap:OperatingIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c333" decimals="0" id="ixv-24741" unitRef="usd">1234419</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c335" decimals="0" id="ixv-24742" unitRef="usd">22072</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="0" id="ixv-24743" unitRef="usd">1256491</us-gaap:DepreciationAndAmortization>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c333" decimals="0" id="ixv-24744" unitRef="usd">296562</cjjd:CapitalExpenditureContinuedOperations>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c335" decimals="0" id="ixv-24745" unitRef="usd">2911</cjjd:CapitalExpenditureContinuedOperations>
    <cjjd:CapitalExpenditureContinuedOperations contextRef="c7" decimals="0" id="ixv-24746" unitRef="usd">299473</cjjd:CapitalExpenditureContinuedOperations>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c0" id="ixv-24747">In accordance with the enterprise-wide disclosure requirements of FASB&#x2019;s accounting standard, the Company&#x2019;s
net revenue from external customers through its retail drugstores by main product category for the years ended March 31, 2024, 2023 and
2022 were as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;For the years ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;25,269,177&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,212,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,503,283&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,542,597&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,358,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,658,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,890,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,737,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,664,071&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,405,979&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,719,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,353,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,544,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,440,085&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,241,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,503,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75,678,470&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;83,351,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;84,228,492&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The Company&#x2019;s net revenue from external
customers through online pharmacy by main product category is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;For the years&#160;ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,151,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,606,244&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,331,652&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,969,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,870,953&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,473,177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,284,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,740,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,014,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,769&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;315,231&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,448,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,129,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,271,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,432,296&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,603,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,814,284&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;31,857,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,385,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;30,219,364&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The Company&#x2019;s net revenue from external
customers through wholesale by main product category is as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;For the years&#160;ended&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prescription drugs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,784,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,617,636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,116,991&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;OTC drugs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,323,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,289,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,903,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nutritional supplements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;741,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;310,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;TCM&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,828&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sundry products&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;692,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Medical devices&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,073,665&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;333,663&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;164,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,004,724&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33,075,119&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,944,699&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues contextRef="c92" decimals="0" id="ixv-24748" unitRef="usd">25269177</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c93" decimals="0" id="ixv-24749" unitRef="usd">27212994</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c94" decimals="0" id="ixv-24750" unitRef="usd">28503283</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c95" decimals="0" id="ixv-24751" unitRef="usd">31542597</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c96" decimals="0" id="ixv-24752" unitRef="usd">32358339</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c97" decimals="0" id="ixv-24753" unitRef="usd">35658864</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c98" decimals="0" id="ixv-24754" unitRef="usd">9890985</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c99" decimals="0" id="ixv-24755" unitRef="usd">8737519</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c100" decimals="0" id="ixv-24756" unitRef="usd">9664071</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c101" decimals="0" id="ixv-24757" unitRef="usd">3405979</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c102" decimals="0" id="ixv-24758" unitRef="usd">9719653</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c103" decimals="0" id="ixv-24759" unitRef="usd">5353900</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c104" decimals="0" id="ixv-24760" unitRef="usd">1129647</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c105" decimals="0" id="ixv-24761" unitRef="usd">1082168</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c106" decimals="0" id="ixv-24762" unitRef="usd">1544639</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c107" decimals="0" id="ixv-24763" unitRef="usd">4440085</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c108" decimals="0" id="ixv-24764" unitRef="usd">4241095</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c109" decimals="0" id="ixv-24765" unitRef="usd">3503735</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c327" decimals="0" id="ixv-24766" unitRef="usd">75678470</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c330" decimals="0" id="ixv-24767" unitRef="usd">83351768</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c333" decimals="0" id="ixv-24768" unitRef="usd">84228492</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c113" decimals="0" id="ixv-24770" unitRef="usd">9151412</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c114" decimals="0" id="ixv-24771" unitRef="usd">10606244</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c115" decimals="0" id="ixv-24772" unitRef="usd">10331652</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c116" decimals="0" id="ixv-24773" unitRef="usd">12969313</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c117" decimals="0" id="ixv-24774" unitRef="usd">13870953</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c118" decimals="0" id="ixv-24775" unitRef="usd">11473177</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c119" decimals="0" id="ixv-24776" unitRef="usd">4284556</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c120" decimals="0" id="ixv-24777" unitRef="usd">2740253</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c121" decimals="0" id="ixv-24778" unitRef="usd">2014011</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c122" decimals="0" id="ixv-24779" unitRef="usd">571769</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c123" decimals="0" id="ixv-24780" unitRef="usd">434920</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c124" decimals="0" id="ixv-24781" unitRef="usd">315231</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c125" decimals="0" id="ixv-24782" unitRef="usd">1448537</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c126" decimals="0" id="ixv-24783" unitRef="usd">1129701</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c127" decimals="0" id="ixv-24784" unitRef="usd">2271009</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c128" decimals="0" id="ixv-24785" unitRef="usd">3432296</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c129" decimals="0" id="ixv-24786" unitRef="usd">3603018</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c130" decimals="0" id="ixv-24787" unitRef="usd">3814284</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c328" decimals="0" id="ixv-24788" unitRef="usd">31857883</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c331" decimals="0" id="ixv-24789" unitRef="usd">32385089</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c334" decimals="0" id="ixv-24790" unitRef="usd">30219364</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c336" decimals="0" id="ixv-24792" unitRef="usd">30784949</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c337" decimals="0" id="ixv-24793" unitRef="usd">21617636</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c338" decimals="0" id="ixv-24794" unitRef="usd">41116991</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c339" decimals="0" id="ixv-24795" unitRef="usd">11323730</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c340" decimals="0" id="ixv-24796" unitRef="usd">10289987</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c341" decimals="0" id="ixv-24797" unitRef="usd">7903824</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c342" decimals="0" id="ixv-24798" unitRef="usd">741883</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c343" decimals="0" id="ixv-24799" unitRef="usd">310909</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c344" decimals="0" id="ixv-24800" unitRef="usd">424210</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c345" decimals="0" id="ixv-24801" unitRef="usd">388396</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c346" decimals="0" id="ixv-24802" unitRef="usd">458502</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c347" decimals="0" id="ixv-24803" unitRef="usd">241828</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c348" decimals="0" id="ixv-24804" unitRef="usd">692101</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c349" decimals="0" id="ixv-24805" unitRef="usd">64422</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c350" decimals="0" id="ixv-24806" unitRef="usd">93338</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c351" decimals="0" id="ixv-24807" unitRef="usd">3073665</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c352" decimals="0" id="ixv-24808" unitRef="usd">333663</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c353" decimals="0" id="ixv-24809" unitRef="usd">164508</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c354" decimals="0" id="ixv-24810" unitRef="usd">47004724</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c355" decimals="0" id="ixv-24811" unitRef="usd">33075119</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c356" decimals="0" id="ixv-24812" unitRef="usd">49944699</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-23727">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 23 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 1, 2024, the compensation committee of
our board of directors granted 420,715 ordinary shares (the &#x201c;Shares&#x201d;) of restricted stock awards (with the vesting conditions
waived) to Lei Liu, Chief Executive Officer and Director. The Shares were granted under the Company&#x2019;s Third Amended and Restated
2010 Equity Incentive Plan. The issuance of the Shares is registered under a Registration Statement on Form S-8 filed with the Securities
and Exchange Commission and became effective on March 12, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 29, 2024, the Company entered into certain
Share Purchase Agreements (the &#x201c;Purchase Agreement&#x201d;) with several investors (the &#x201c;Investors&#x201d;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of 900,000 ordinary shares (the&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#x201c;Shares&#x201d;), par value $0.24 per share,
of the Company (&#x201c;Ordinary Shares&#x201d;), at a purchase price of $1.70 per Share (the &#x201c;Purchase Price&#x201d;), for aggregate
gross proceeds to the Company of $1,530,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 10, 2024, the Company entered into certain
Share Purchase Agreements (the &#x201c;Purchase Agreement&#x201d;) with several investors (the &#x201c;Investors&#x201d;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of 1,610,000 ordinary shares (the &#x201c;Shares&#x201d;), par value $0.24 per share, of the Company (&#x201c;Ordinary Shares&#x201d;),
at a purchase price of $1.70 per Share (the &#x201c;Purchase Price&#x201d;), for aggregate gross proceeds to the Company of $2,737,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 11, 2024, the Company entered into certain
Share Purchase Agreements (the &#x201c;Purchase Agreement&#x201d;) with several investors (the &#x201c;Investors&#x201d;) pursuant to which
the Company agreed to sell to the Investors, and the Investors agreed to purchase from the Company, in a registered direct offering, an
aggregate of 1,980,000 ordinary shares (the &#x201c;Shares&#x201d;), par value $0.24 per share, of the Company (&#x201c;Ordinary Shares&#x201d;),
at a purchase price of $1.70 per Share (the &#x201c;Purchase Price&#x201d;), for an aggregate gross proceeds to the Company of $3,366,000.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c357"
      decimals="0"
      id="ixv-24813"
      unitRef="shares">420715</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c358"
      decimals="0"
      id="ixv-24814"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c359"
      decimals="2"
      id="ixv-24815"
      unitRef="usdPershares">0.24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c359"
      decimals="2"
      id="ixv-24816"
      unitRef="usdPershares">1.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c358" decimals="0" id="ixv-24817" unitRef="usd">1530000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c360"
      decimals="0"
      id="ixv-24818"
      unitRef="shares">1610000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c361"
      decimals="2"
      id="ixv-24819"
      unitRef="usdPershares">0.24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c361"
      decimals="2"
      id="ixv-24820"
      unitRef="usdPershares">1.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c360" decimals="0" id="ixv-24821" unitRef="usd">2737000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c362"
      decimals="0"
      id="ixv-24822"
      unitRef="shares">1980000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c363"
      decimals="2"
      id="ixv-24823"
      unitRef="usdPershares">0.24</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c363"
      decimals="2"
      id="ixv-24824"
      unitRef="usdPershares">1.7</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c362" decimals="0" id="ixv-24825" unitRef="usd">3366000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-0">U.S. GAAP</dei:DocumentAccountingStandard>
    <cjjd:DueFromRelatedsParties
      contextRef="c5"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c0"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c7"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c6"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c7"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c15"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c16"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c17"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c19"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c15"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c16"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c17"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c30"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c31"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c32"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c33"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c6"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c31"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c32"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c33"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c30"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c31"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c32"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c33"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c30"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c31"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c32"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c33"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c28"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c29"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c30"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c32"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c28"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c29"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c30"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c31"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c33"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c42"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c43"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c44"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c45"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueForReverseStockSplit
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c42"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c43"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c44"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:StockIssuedDuringPeriodValueSaleOfStockAndWarrants
      contextRef="c45"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c40"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c41"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c42"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c44"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c40"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c41"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c42"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c43"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c45"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c6"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c7"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c6"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c7"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c6"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c0"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c7"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c7"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="c6"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="c7"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c6"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c7"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInterestInJointVenture
      contextRef="c7"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="c6"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="c7"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfOtherShortTermDebt
      contextRef="c6"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c0"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:RepaymentOfOtherPayablesrelatedParties
      contextRef="c0"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:CashlessExerciseOfWarrants
      contextRef="c0"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:CashlessExerciseOfWarrants
      contextRef="c7"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c79"
      id="hidden-fact-92"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c80"
      id="hidden-fact-93"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c82"
      id="hidden-fact-94"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c83"
      id="hidden-fact-95"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c88"
      id="hidden-fact-96"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c89"
      id="hidden-fact-97"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c90"
      id="hidden-fact-98"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c91"
      id="hidden-fact-99"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="c60"
      decimals="0"
      id="hidden-fact-100"
      unitRef="cny">507760</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:CashUninsuredAmount
      contextRef="c2"
      decimals="0"
      id="hidden-fact-101"
      unitRef="usd">79600</us-gaap:CashUninsuredAmount>
    <us-gaap:NotesReceivableNet
      contextRef="c172"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c185"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c194"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c195"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestments
      contextRef="c201"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:LongTermInvestmentImpairmentLoss
      contextRef="c2"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryValuationReserves
      contextRef="c2"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryValuationReserves
      contextRef="c3"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c217"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c220"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c223"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c226"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c229"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c232"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c235"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c238"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c241"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c244"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c247"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c250"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c253"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c256"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c259"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c263"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c266"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c269"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c272"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c275"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c278"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c281"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c284"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c287"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c290"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c293"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c296"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c299"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c308"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivables
      contextRef="c312"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivables
      contextRef="c314"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherReceivables
      contextRef="c5"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants
      contextRef="c0"
      id="hidden-fact-143"
      unitRef="shares"
      xsi:nil="true"/>
    <cjjd:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAndWarrants
      contextRef="c6"
      id="hidden-fact-144"
      unitRef="shares"
      xsi:nil="true"/>
    <cjjd:EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c0"
      id="hidden-fact-145"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cjjd:EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c6"
      id="hidden-fact-146"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cjjd:EarningsPerShareBasicNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c7"
      id="hidden-fact-147"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cjjd:EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c0"
      id="hidden-fact-148"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cjjd:EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c6"
      id="hidden-fact-149"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <cjjd:EarningsPerShareDilutedNetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c7"
      id="hidden-fact-150"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c328"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:CapitalExpenditureContinuedOperations
      contextRef="c328"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c331"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c332"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c331"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:CapitalExpenditureContinuedOperations
      contextRef="c331"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c334"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c335"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c334"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <cjjd:CapitalExpenditureContinuedOperations
      contextRef="c334"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-24989">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-24990">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-24991">0001856084</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-94"
          xlink:label="hidden-fact-94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-93"
          xlink:label="hidden-fact-93"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-92"
          xlink:label="hidden-fact-92"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service had been under the common control of Mr. Lei Liu and Ms. Li Qi, the three shareholders (the &#x201c;Owners&#x201d;) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting rights agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. The Owners have operated these three companies in conjunction with one another since each company&#x2019;s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-93"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-92"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-96"
          xlink:label="hidden-fact-96"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-99"
          xlink:label="hidden-fact-99"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-98"
          xlink:label="hidden-fact-98"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-95"
          xlink:label="hidden-fact-95"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-97"
          xlink:label="hidden-fact-97"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: a consulting services agreement, an operating agreement, an equity pledge agreement, a voting rights agreement and an option agreement. Because such agreements obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for each of the three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (&#x201c;VIE&#x201d;) under the accounting standards of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-96"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-93"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-99"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-98"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-92"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-95"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-97"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance as of March 31, 2024 and March 31, 2023 includes short-term refundable rental security deposits.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The variance of impairment from March 31, 2023 to March 31, 2024 is solely caused by exchange rate variance.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-103"
          xlink:label="hidden-fact-103"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-104"
          xlink:label="hidden-fact-104"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 49% investment in Kahamadi Bio. The investment is recorded using the equity method. Kahamadi Bio suffered loss of $0 and $0 in the year ended March 31, 2024 and 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-103"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-104"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-105"
          xlink:label="hidden-fact-105"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 39% investment in Zhejiang Zhuoli Life Service Co., LTD (&#x201c;Zhuoli Service&#x201d;), formerly known as Zhejiang Zhetong Medical Co., Ltd. Zhuoli Service was established in March 2020 to target potential acquisitions or to cooperate with local pharmacies. By attracting more funds from local investors, the Company expects to continue growing its local network in the future. In the year ended March 31, 2021, Jiuzhou Pharmacy injected funds of approximately $1,443,752 into Zhuoli Service. The investment is recorded using the equity method. Zhuoli Service suffered loss of $2,402,376 in the year ended March 31, 2023. An impairment loss of $1,607,537 was recorded in the year ended March 31, 2024. After the impairment, the carrying amount of Zhuoli Service was <xhtml:span style="-sec-ix-hidden: hidden-fact-107">nil</xhtml:span>.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-105"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 0.37% investment in Inner Mongolia Songlu Pharmaceutical Co. (&#x201c;Songlu Pharmaceutical&#x201d;). The investment is recorded based on cost method.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It represents 25.92% investment in Zhejiang Jiuzhou Digital Medicine Technology Co., LTD. In the year ended March 31, 2023, Jiuzhou Pharmacy injected funds of approximately $4,379 into Jiuzhou Digital. The investment is recorded based on equity method.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-106"
          xlink:label="hidden-fact-106"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">It represents 8% investment in Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. In the year ended March 31, 2024, Jiuzhou Pharmacy injected funds of approximately $1,113,650(RMB 8,000,000) into Guoshu Lianren (Zhejiang) Medical and Health Management Co., Ltd. The investment is recorded based on equity method.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-106"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the years ended March 31, 2024 and 2023, we evaluated the use rights of the forest land, which is currently used to cultivate Ginkgo trees. Based on the evaluation of the forest land use rights, the Company did not record an impairment. In the year ended March 31, 2022, based on the evaluation of the forest land use rights, the Company recorded an impairment of $148,795.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prepayment for lease of forest land use rights is made to a local government in connection with an operating land lease agreement. The land is currently used to cultivate Ginkgo trees. The forest rights certificate from the local village extends the life of the lease to January 31, 2060.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_11_footnote" xlink:label="ix_11_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This represents the fair value of the licenses of insurance applicable drugstores acquired from a variety of drugstores such as Sanhao Pharmacy and several local stores. The licenses allow patients to pay by using insurance cards at stores. The stores are reimbursed from the Human Resource and Social Security Department of Hangzhou City. In 2014, the Company acquired Sanhao Pharmacy, a drugstore chain. In September 2017, the Company acquired several new stores for the purpose of the Municipal Social Medical Reimbursement Qualification Certificates. On January 9, 2020, the Company acquired a local drugstore chain. The acquired drugstores ceased their stores&#x2019; business and liquidate all of the stores&#x2019; accounts after Jiuzhou Pharmacy acquired them. In March 2020, the drugstore chain has dissolved and its certificates were transferred to new stores opened at the same time. In the year ended March 31, 2021, the Company acquired four single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program. In the year ended March 31, 2024, the Company acquired three single drugstores which have been liquidated after the acquisition. Jiuzhou Pharmacy then opened four new stores with the four licenses of local government medical insurance reimbursement program.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_12_footnote" xlink:label="ix_12_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">They are primarily the SAP ERP system, the Internet Clinic Diagnosis Terminal system and the Chronic Disease Management system. In 2017, we have installed a leading ERP system, SAP from Germany. SAP is a well-known management system used by many fortune 500 companies. It is being amortized over three years since its installation. In 2020, we have installed an internet Clinic Diagnosis System used to strengthen our ability to perform online diagnosis which may increase more customer spending and a Chronic Disease Management System used to better manage and monitor our members&#x2019; health.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_13_footnote" xlink:label="ix_13_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2013, the Company purchased the land use rights of a plot of land in Lin&#x2019;an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as the Company&#x2019;s farming business in Lin&#x2019;an has not grown, the Company does not expect completion of the plant in the near future.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_13_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_13_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_14_footnote" xlink:label="ix_14_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In the year ended March 31, 2020, the Company evaluated the licenses of insurance applicable drugstores acquired in the past based on the discounted positive cash value. Due to the stricter government insurance policy in the fourth quarter of fiscal year 2020, the value of these licenses has declined. As a result, the Company recorded an impairment in the fourth quarter of fiscal 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_14_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_14_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_132_fact"
          xlink:label="ix_132_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_56_fact"
          xlink:label="ix_56_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_92_fact"
          xlink:label="ix_92_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-128"
          xlink:label="hidden-fact-128"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_110_fact"
          xlink:label="ix_110_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_76_fact"
          xlink:label="ix_76_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_151_fact"
          xlink:label="ix_151_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_105_fact"
          xlink:label="ix_105_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_85_fact"
          xlink:label="ix_85_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_134_fact"
          xlink:label="ix_134_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-130"
          xlink:label="hidden-fact-130"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_50_fact"
          xlink:label="ix_50_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_118_fact"
          xlink:label="ix_118_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_51_fact"
          xlink:label="ix_51_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-127"
          xlink:label="hidden-fact-127"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_124_fact"
          xlink:label="ix_124_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-129"
          xlink:label="hidden-fact-129"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_55_fact"
          xlink:label="ix_55_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_80_fact"
          xlink:label="ix_80_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_127_fact"
          xlink:label="ix_127_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-111"
          xlink:label="hidden-fact-111"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-115"
          xlink:label="hidden-fact-115"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_114_fact"
          xlink:label="ix_114_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_130_fact"
          xlink:label="ix_130_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_144_fact"
          xlink:label="ix_144_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_143_fact"
          xlink:label="ix_143_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_71_fact"
          xlink:label="ix_71_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_72_fact"
          xlink:label="ix_72_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_95_fact"
          xlink:label="ix_95_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_90_fact"
          xlink:label="ix_90_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_120_fact"
          xlink:label="ix_120_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_137_fact"
          xlink:label="ix_137_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-135"
          xlink:label="hidden-fact-135"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_57_fact"
          xlink:label="ix_57_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_135_fact"
          xlink:label="ix_135_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_83_fact"
          xlink:label="ix_83_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_107_fact"
          xlink:label="ix_107_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_126_fact"
          xlink:label="ix_126_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-133"
          xlink:label="hidden-fact-133"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_133_fact"
          xlink:label="ix_133_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_93_fact"
          xlink:label="ix_93_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_91_fact"
          xlink:label="ix_91_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_149_fact"
          xlink:label="ix_149_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_138_fact"
          xlink:label="ix_138_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_131_fact"
          xlink:label="ix_131_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_100_fact"
          xlink:label="ix_100_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_108_fact"
          xlink:label="ix_108_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_103_fact"
          xlink:label="ix_103_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_98_fact"
          xlink:label="ix_98_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_82_fact"
          xlink:label="ix_82_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_65_fact"
          xlink:label="ix_65_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_106_fact"
          xlink:label="ix_106_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_121_fact"
          xlink:label="ix_121_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_73_fact"
          xlink:label="ix_73_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-131"
          xlink:label="hidden-fact-131"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-124"
          xlink:label="hidden-fact-124"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_96_fact"
          xlink:label="ix_96_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_54_fact"
          xlink:label="ix_54_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-136"
          xlink:label="hidden-fact-136"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-138"
          xlink:label="hidden-fact-138"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_67_fact"
          xlink:label="ix_67_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_109_fact"
          xlink:label="ix_109_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_141_fact"
          xlink:label="ix_141_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_58_fact"
          xlink:label="ix_58_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_119_fact"
          xlink:label="ix_119_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_99_fact"
          xlink:label="ix_99_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_125_fact"
          xlink:label="ix_125_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-116"
          xlink:label="hidden-fact-116"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-139"
          xlink:label="hidden-fact-139"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_74_fact"
          xlink:label="ix_74_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_142_fact"
          xlink:label="ix_142_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-112"
          xlink:label="hidden-fact-112"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_78_fact"
          xlink:label="ix_78_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-134"
          xlink:label="hidden-fact-134"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_86_fact"
          xlink:label="ix_86_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-122"
          xlink:label="hidden-fact-122"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_69_fact"
          xlink:label="ix_69_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_101_fact"
          xlink:label="ix_101_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_147_fact"
          xlink:label="ix_147_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_111_fact"
          xlink:label="ix_111_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-114"
          xlink:label="hidden-fact-114"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_123_fact"
          xlink:label="ix_123_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-120"
          xlink:label="hidden-fact-120"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_136_fact"
          xlink:label="ix_136_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_75_fact"
          xlink:label="ix_75_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_89_fact"
          xlink:label="ix_89_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-113"
          xlink:label="hidden-fact-113"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_88_fact"
          xlink:label="ix_88_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-119"
          xlink:label="hidden-fact-119"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_68_fact"
          xlink:label="ix_68_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-126"
          xlink:label="hidden-fact-126"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_129_fact"
          xlink:label="ix_129_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_146_fact"
          xlink:label="ix_146_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_62_fact"
          xlink:label="ix_62_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_59_fact"
          xlink:label="ix_59_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_139_fact"
          xlink:label="ix_139_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_113_fact"
          xlink:label="ix_113_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_102_fact"
          xlink:label="ix_102_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-132"
          xlink:label="hidden-fact-132"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-123"
          xlink:label="hidden-fact-123"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_70_fact"
          xlink:label="ix_70_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_104_fact"
          xlink:label="ix_104_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_112_fact"
          xlink:label="ix_112_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_52_fact"
          xlink:label="ix_52_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_87_fact"
          xlink:label="ix_87_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_77_fact"
          xlink:label="ix_77_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_115_fact"
          xlink:label="ix_115_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_150_fact"
          xlink:label="ix_150_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_117_fact"
          xlink:label="ix_117_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-121"
          xlink:label="hidden-fact-121"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_128_fact"
          xlink:label="ix_128_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_63_fact"
          xlink:label="ix_63_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_64_fact"
          xlink:label="ix_64_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_81_fact"
          xlink:label="ix_81_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_84_fact"
          xlink:label="ix_84_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_66_fact"
          xlink:label="ix_66_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-117"
          xlink:label="hidden-fact-117"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_61_fact"
          xlink:label="ix_61_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_140_fact"
          xlink:label="ix_140_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_97_fact"
          xlink:label="ix_97_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_145_fact"
          xlink:label="ix_145_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_116_fact"
          xlink:label="ix_116_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_53_fact"
          xlink:label="ix_53_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_60_fact"
          xlink:label="ix_60_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-137"
          xlink:label="hidden-fact-137"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_148_fact"
          xlink:label="ix_148_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_94_fact"
          xlink:label="ix_94_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_122_fact"
          xlink:label="ix_122_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-118"
          xlink:label="hidden-fact-118"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_79_fact"
          xlink:label="ix_79_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-125"
          xlink:label="hidden-fact-125"
          xlink:type="locator"/>
        <link:footnote id="ix_15_footnote" xlink:label="ix_15_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company had $31,676,335 (RMB228,712,642) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,657,839 (RMB 91,393,395 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,501,198 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB. As of March 31, 2023, the Company had $29,255,776 (RMB 200,916,968) of notes payable from HUB. The Company is required to hold restricted cash in the amount of $12,217,616 (RMB 83,905,700 ) with HUB as collateral against these bank notes. Included in the restricted cash is a total of $4,732,366 three-year deposit (RMB32,500,000) deposited into HUB as a collateral for current and future notes payable from HUB.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_132_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_56_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_92_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-128"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_110_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_76_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_151_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_105_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_85_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_134_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-130"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_50_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_118_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_51_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-127"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_124_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-129"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_55_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_80_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_127_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-111"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-115"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_114_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_130_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_144_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_143_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_71_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_72_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_95_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_90_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_120_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_137_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-135"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_57_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_135_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_83_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_107_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_126_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-133"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_133_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_93_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_91_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_149_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_138_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_131_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_100_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_108_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_103_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_98_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_82_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_65_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_106_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_121_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_73_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-131"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-124"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_96_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_54_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-136"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-138"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_67_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_109_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_141_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_58_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_119_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_99_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_125_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-116"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-139"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_74_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_142_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-112"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_78_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-134"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_86_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-122"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_69_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_101_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_147_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_111_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-114"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_123_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-120"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_136_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_75_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_89_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-113"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_88_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-119"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_68_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-126"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_129_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_146_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_62_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_59_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_139_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_113_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_102_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-132"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-123"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_70_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_104_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_112_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_52_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_87_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_77_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_115_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_150_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_117_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-121"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_128_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_63_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_64_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_81_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_84_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_66_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-117"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_61_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_140_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_97_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_145_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_116_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_53_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_60_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-137"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_148_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_94_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_122_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-118"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_79_fact"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-125"
          xlink:to="ix_15_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-141"
          xlink:label="hidden-fact-141"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_153_fact"
          xlink:label="ix_153_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_152_fact"
          xlink:label="ix_152_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-140"
          xlink:label="hidden-fact-140"
          xlink:type="locator"/>
        <link:footnote id="ix_16_footnote" xlink:label="ix_16_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lend to related parties</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-141"
          xlink:to="ix_16_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_153_fact"
          xlink:to="ix_16_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_152_fact"
          xlink:to="ix_16_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-140"
          xlink:to="ix_16_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_154_fact"
          xlink:label="ix_154_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_155_fact"
          xlink:label="ix_155_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_17_footnote" xlink:label="ix_17_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to foreign exchange restrictions, the Company&#x2019;s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. The Company leases a retail space from Mr. Lei Liu. The lease will expire in September 2025. The amounts owed under the lease for the twelve months ended March&#160;31, 2024 were paid to Mr. Liu as of March 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_154_fact"
          xlink:to="ix_17_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_155_fact"
          xlink:to="ix_17_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_156_fact"
          xlink:label="ix_156_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_18_footnote" xlink:label="ix_18_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linjia Medical borrowed from its non-controlling shareholder.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_156_fact"
          xlink:to="ix_18_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
